Difference between revisions of "Gastric cancer"
(407 intermediate revisions by 6 users not shown) | |||
Line 1: | Line 1: | ||
− | + | <span id="BackToTop"></span> | |
− | + | <div class="noprint" style="background-color:LightGray; position:fixed; bottom:2%; right:0.25%; padding-left:5px; padding-right:5px; margin: 15px; opacity:0.8; border-style: solid; border-color:DarkGray; border-width: 1px"> | |
− | + | [[#top|Back to Top]] | |
− | + | </div> | |
− | + | {{#lst:Editorial board transclusions|gi}} | |
− | + | Note: there is significant overlap between regimens for gastric cancer and '''[[esophageal cancer]]''', if you can't find the regimen you're looking for here, please try the esophageal cancer page. If you still can't find it, it is possible that we've moved it to the [[Gastric_cancer_-_historical|historical regimens page]]. For placebo or observational studies in this condition, please visit [[Gastric cancer - null regimens|this page]]. | |
− | + | *'''Note: this page contains regimens which were not tested in biomarker-specific populations. The following links will take you to biomarker-specific subpages:''' | |
− | + | *Regimens for [[Gastric_cancer,_HER2-positive|'''HER2 positive gastric cancer are here''']]. | |
− | | | ||
− | |||
− | |||
{| class="wikitable" style="float:right; margin-right: 5px;" | {| class="wikitable" style="float:right; margin-right: 5px;" | ||
|- | |- | ||
Line 16: | Line 13: | ||
|} | |} | ||
{{TOC limit|limit=3}} | {{TOC limit|limit=3}} | ||
− | |||
=Guidelines= | =Guidelines= | ||
− | == | + | '''Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any guideline published 5+ years ago to be for historical purposes, only.''' |
− | *''' | + | ==[https://www.esmo.org/ ESMO]== |
− | + | *'''2022:''' Lordick et al. [https://doi.org/10.1016/j.annonc.2022.07.004 Gastric cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up] [https://pubmed.ncbi.nlm.nih.gov/35914639/ PubMed] | |
− | + | **'''2016:''' Smyth et al. [https://doi.org/10.1093/annonc/mdw350 Gastric cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up] [https://pubmed.ncbi.nlm.nih.gov/27664260/ PubMed] | |
− | *''' | + | **'''2010:''' Okines et al. [https://doi.org/10.1093/annonc/mdq164 Gastric cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up] [https://pubmed.ncbi.nlm.nih.gov/20555102/ PubMed] |
+ | **'''2009:''' Jackson et al. [https://doi.org/10.1093/annonc/mdp122 Gastric cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up] [https://pubmed.ncbi.nlm.nih.gov/19454457/ PubMed] | ||
+ | **'''2008:''' Cunningham & Oliveira. [https://doi.org/10.1093/annonc/mdn075 Gastric cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up] [https://pubmed.ncbi.nlm.nih.gov/18456755/ PubMed] | ||
+ | **'''2007:''' Cunningham. [https://doi.org/10.1093/annonc/mdm019 Gastric cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up] [https://pubmed.ncbi.nlm.nih.gov/17491028/ PubMed] | ||
+ | **'''2005:''' Cunningham et al. [https://doi.org/10.1093/annonc/mdi812 ESMO Minimum Clinical Recommendations for diagnosis, treatment and follow-up of gastric cancer] [https://pubmed.ncbi.nlm.nih.gov/15888740/ PubMed] | ||
+ | *'''2019:''' Stjepanovic et al. [https://doi.org/10.1093/annonc/mdz233 Hereditary gastrointestinal cancers: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up] [https://pubmed.ncbi.nlm.nih.gov/31378807/ PubMed] | ||
+ | *'''2019:''' Muro et al. [https://doi.org/10.1093/annonc/mdy502 Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with metastatic gastric cancer: a JSMO-ESMO initiative endorsed by CSCO, KSMO, MOS, SSO and TOS] [https://pubmed.ncbi.nlm.nih.gov/30475956/ PubMed] | ||
==ESMO/ESSO/ESTRO== | ==ESMO/ESSO/ESTRO== | ||
− | *'''2013:''' Waddell et al. [https:// | + | *'''2013:''' Waddell et al. [https://doi.org/10.1093/annonc/mdt344 Gastric cancer: ESMO-ESSO-ESTRO Clinical Practice Guidelines for diagnosis, treatment and follow-up] [https://pubmed.ncbi.nlm.nih.gov/24078663/ PubMed] |
+ | ==French Intergroup== | ||
+ | *'''2018:''' Zaanan et al. [https://doi.org/10.1016/j.dld.2018.04.025 Gastric cancer: French intergroup clinical practice guidelines for diagnosis, treatments and follow-up (SNFGE, FFCD, GERCOR, UNICANCER, SFCD, SFED, SFRO)] [https://pubmed.ncbi.nlm.nih.gov/29886081/ PubMed] | ||
+ | ==NCCN== | ||
+ | *[https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1434 NCCN Guidelines - Gastric Cancer] | ||
+ | **'''2022:''' Ajani et al. [https://doi.org/10.6004/Jnccn.2022.0008 Gastric Cancer, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology.] [https://pubmed.ncbi.nlm.nih.gov/35130500/ PubMed] | ||
+ | **'''2016:''' Ajani et al. [https://doi.org/10.6004/Jnccn.2016.0137 Gastric Cancer, Version 3.2016, NCCN Clinical Practice Guidelines in Oncology.] [https://pubmed.ncbi.nlm.nih.gov/27697982/ PubMed] | ||
+ | **'''2013:''' Ajani et al. [https://doi.org/10.6004/Jnccn.2013.0070 Gastric cancer, version 2.2013: featured updates to the NCCN Guidelines.] [https://pubmed.ncbi.nlm.nih.gov/23667204/ PubMed] | ||
+ | **'''2010:''' Ajani et al. [https://doi.org/10.6004/Jnccn.2010.0030 Gastric cancer.] [https://pubmed.ncbi.nlm.nih.gov/20410333/ PubMed] | ||
+ | **'''2006:''' Ajani et al. [https://doi.org/10.6004/Jnccn.2006.0030 Gastric Cancer Clinical Practice Guidelines.] [https://pubmed.ncbi.nlm.nih.gov/16569388/ PubMed] | ||
+ | **'''2003:''' Ajani et al. [https://doi.org/10.6004/Jnccn.2003.0005 Gastric cancer. Clinical practice guidelines in oncology.] [https://pubmed.ncbi.nlm.nih.gov/19764148/ PubMed] | ||
− | ==[https:// | + | =Perioperative therapy= |
− | *[https:// | + | ''This section contains protocols with a pre-planned neoadjuvant (preoperative) and adjuvant (postoperative) component.'' |
+ | ==Capecitabine & Cisplatin (CX) {{#subobject:tr26bc|Regimen=1}}== | ||
+ | CX: '''<u>C</u>'''isplatin, '''<u>X</u>'''eloda (Capecitabine) | ||
+ | <br>XP: '''<u>X</u>'''eloda (Capecitabine), '''<u>P</u>'''latinol (Cisplatin) | ||
+ | <div class="toccolours" style="background-color:#c8a2c8"> | ||
+ | {| class="wikitable sortable" style="width: 100%; text-align:center;" | ||
+ | ! style="width: 20%" |Study | ||
+ | ! style="width: 20%" |Dates of enrollment | ||
+ | ! style="width: 20%" |[[Levels_of_Evidence#Evidence|Evidence]] | ||
+ | ! style="width: 20%" |Comparator | ||
+ | ! style="width: 20%" |[[Levels_of_Evidence#Comparative_efficacy|Comparative Efficacy]] | ||
+ | |- | ||
+ | |rowspan=2|[https://doi.org/10.1016/s1470-2045(23)00541-7 Shitara et al. 2023 (KEYNOTE-585)] | ||
+ | |rowspan=2|2017-10-09 to 2021-01-25 | ||
+ | |rowspan=2 style="background-color:#1a9851" |Phase 3 (C) | ||
+ | |1a. Perioperative [[#Capecitabine_.26_Cisplatin_.28CX.29_.26_Pembrolizumab_888| CX & Pembrolizumab]]<br>1b. Perioperative [[#Cisplatin_.26_Fluorouracil_.28CF.29_.26_Pembrolizumab_888|CF & Pembrolizumab]] | ||
+ | | style="background-color:#d73027" |Inferior pCR rate (co-primary endpoint)<br><br>Might have inferior EFS (co-primary endpoint)<br><br>Did not meet co-primary endpoint of OS | ||
+ | |- | ||
+ | |2. Perioperative [[#FLOT_.26_Pembrolizumab_666|FLOT & Pembrolizumab]] | ||
+ | | style="background-color:#d3d3d3" |Not reported | ||
+ | |- | ||
+ | |} | ||
+ | <div class="toccolours" style="background-color:#eeeeee"> | ||
+ | ===Neoadjuvant {{#subobject:cz7085|Variant=1}}=== | ||
+ | <div class="toccolours" style="background-color:#b3e2cd"> | ||
+ | ====Chemotherapy==== | ||
+ | *[[Cisplatin (Platinol)]] 80 mg/m<sup>2</sup> IV once on day 1 | ||
+ | *[[Capecitabine (Xeloda)]] 1000 mg/m<sup>2</sup> PO twice per day on days 1 to 14 | ||
+ | '''21-day cycle for 3 cycles''' | ||
+ | </div></div><br> | ||
+ | <div class="toccolours" style="background-color:#eeeeee"> | ||
+ | ===Definitive=== | ||
+ | <div class="toccolours" style="background-color:#b3e2cd"> | ||
+ | ====Local therapy==== | ||
+ | *[[Surgery#Gastrectomy|Surgical resection]] | ||
+ | </div></div><br> | ||
+ | <div class="toccolours" style="background-color:#eeeeee"> | ||
+ | ===Adjuvant=== | ||
+ | <div class="toccolours" style="background-color:#b3e2cd"> | ||
+ | ====Chemotherapy==== | ||
+ | *[[Cisplatin (Platinol)]] 80 mg/m<sup>2</sup> IV once on day 1 | ||
+ | *[[Capecitabine (Xeloda)]] 1000 mg/m<sup>2</sup> PO twice per day on days 1 to 14 | ||
+ | '''21-day cycle for 3 cycles''' | ||
+ | </div></div></div> | ||
+ | ===References=== | ||
+ | #'''KEYNOTE-585:''' Shitara K, Rha SY, Wyrwicz LS, Oshima T, Karaseva N, Osipov M, Yasui H, Yabusaki H, Afanasyev S, Park YK, Al-Batran SE, Yoshikawa T, Yanez P, Dib Bartolomeo M, Lonardi S, Tabernero J, Van Cutsem E, Janjigian YY, Oh DY, Xu J, Fang X, Shih CS, Bhagia P, Bang YJ; KEYNOTE-585 investigators. Neoadjuvant and adjuvant pembrolizumab plus chemotherapy in locally advanced gastric or gastro-oesophageal cancer (KEYNOTE-585): an interim analysis of the multicentre, double-blind, randomised phase 3 study. Lancet Oncol. 2024 Feb;25(2):212-224. Epub 2023 Dec 19. [https://doi.org/10.1016/s1470-2045(23)00541-7 link to original article] '''dosing details in manuscript have been reviewed by our editors''' [https://pubmed.ncbi.nlm.nih.gov/38134948/ PubMed] [https://clinicaltrials.gov/study/NCT03221426 NCT03221426] | ||
− | = | + | ==CapeOx {{#subobject:cf9ug1|Regimen=1}}== |
− | + | CapeOX: '''<u>Cape</u>'''citabine & '''<u>OX</u>'''aliplatin | |
− | {| class="wikitable" style=" | + | <div class="toccolours" style="background-color:#c8a2c8"> |
+ | {| class="wikitable sortable" style="width: 100%; text-align:center;" | ||
+ | ! style="width: 20%" |Study | ||
+ | ! style="width: 20%" |Dates of enrollment | ||
+ | ! style="width: 20%" |[[Levels_of_Evidence#Evidence|Evidence]] | ||
+ | ! style="width: 20%" |Comparator | ||
+ | ! style="width: 20%" |[[Levels_of_Evidence#Comparative_efficacy|Comparative Efficacy]] | ||
|- | |- | ||
− | |[ | + | |rowspan=2|[https://www.ncbi.nlm.nih.gov/pmc/articles/pmc8324337/ Tian et al. 2021 (Alien Craft 0004)] |
− | + | |rowspan=2|2014-09 to 2018-06 | |
− | + | |rowspan=2 style="background-color:#1a9851" |Phase 3 (C) | |
− | = | + | |1. Adjuvant [[#CapeOx_2|CapeOx]] |
− | + | | style="background-color:#d3d3d3" |Not reported | |
− | |||
− | |||
− | |||
− | |||
|- | |- | ||
− | |[ | + | |2. Perioperative [[#DOX-CapeOx|DOX-CapeOx]] |
− | | | + | | style="background-color:#d73027" |Inferior pCR rate |
− | |||
− | | style="background-color:# | ||
|- | |- | ||
|} | |} | ||
− | '' | + | <div class="toccolours" style="background-color:#eeeeee"> |
+ | ===Neoadjuvant {{#subobject:cj3085|Variant=1}}=== | ||
+ | <div class="toccolours" style="background-color:#b3e2cd"> | ||
+ | ====Chemotherapy==== | ||
+ | *[[Capecitabine (Xeloda)]] 500 mg/m<sup>2</sup> PO twice per day on days 1 to 14 | ||
+ | *[[Oxaliplatin (Eloxatin)]] 130 mg/m<sup>2</sup> IV once on day 1 | ||
+ | '''21-day cycle for 4 cycles''' | ||
+ | </div></div><br> | ||
+ | <div class="toccolours" style="background-color:#eeeeee"> | ||
− | + | ===Definitive=== | |
+ | <div class="toccolours" style="background-color:#b3e2cd"> | ||
+ | ====Local therapy==== | ||
+ | *[[Surgery#Gastrectomy|Surgical resection]] | ||
+ | </div></div><br> | ||
+ | <div class="toccolours" style="background-color:#eeeeee"> | ||
+ | ===Adjuvant=== | ||
+ | <div class="toccolours" style="background-color:#b3e2cd"> | ||
====Chemotherapy==== | ====Chemotherapy==== | ||
+ | *[[Capecitabine (Xeloda)]] 500 mg/m<sup>2</sup> PO twice per day on days 1 to 14 | ||
+ | *[[Oxaliplatin (Eloxatin)]] 130 mg/m<sup>2</sup> IV over 2 hours once on day 1 | ||
+ | '''21-day cycle for 4 cycles''' | ||
+ | </div></div></div> | ||
+ | ===References=== | ||
+ | #'''Alien Craft 0004:''' Tian Y, Zhao Q, Li Y, Fan L, Zhang Z, Zhao X, Tan B, Wang D, Yang P. Efficacy of Neoadjuvant Chemotherapy DOX and XELOX Regimens for Patients with Resectable Gastric or Gastroesophageal Junction Adenocarcinoma. Gastroenterol Res Pract. 2021 Jul 22;2021:5590626. [https://doi.org/10.1155/2021/5590626 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/pmc8324337/ link to PMC article] '''dosing details in manuscript have been reviewed by our editors''' [https://pubmed.ncbi.nlm.nih.gov/34335737/ PubMed] [https://clinicaltrials.gov/study/NCT02555358 NCT02555358] | ||
+ | ##'''Update:''' Tian Y, Yang P, Guo H, Liu Y, Zhang Z, Ding P, Zheng T, Deng H, Ma W, Li Y, Fan L, Zhang Z, Wang D, Zhao X, Tan B, Liu Y, Zhao Q. Neoadjuvant docetaxel, oxaliplatin plus capecitabine versus oxaliplatin plus capecitabine for patients with locally advanced gastric adenocarcinoma: long-term results of a phase III randomized controlled trial. Int J Surg. 2023 Dec 1;109(12):4000-4008. [https://doi.org/10.1097/js9.0000000000000692 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/pmc10720837/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/37678277/ PubMed] | ||
+ | |||
+ | ==Cisplatin & Fluorouracil (CF) {{#subobject:7b88be|Regimen=1}}== | ||
+ | CF: '''<u>C</u>'''isplatin & '''<u>F</u>'''luorouracil | ||
+ | <br>FP: '''<u>F</u>'''luorouracil & '''<u>P</u>'''latinol (Cisplatin) | ||
+ | <div class="toccolours" style="background-color:#eeeeee"> | ||
+ | ===Protocol variant #1, 80/4000 {{#subobject:c2yy1e|Variant=1}}=== | ||
+ | {| class="wikitable sortable" style="width: 100%; text-align:center;" | ||
+ | ! style="width: 20%" |Study | ||
+ | ! style="width: 20%" |Dates of enrollment | ||
+ | ! style="width: 20%" |[[Levels_of_Evidence#Evidence|Evidence]] | ||
+ | ! style="width: 20%" |Comparator | ||
+ | ! style="width: 20%" |[[Levels_of_Evidence#Comparative_efficacy|Comparative Efficacy]] | ||
+ | |- | ||
+ | |rowspan=2|[https://doi.org/10.1016/s1470-2045(23)00541-7 Shitara et al. 2023 (KEYNOTE-585)] | ||
+ | |rowspan=2|2017-10-09 to 2021-01-25 | ||
+ | |rowspan=2 style="background-color:#1a9851" |Phase 3 (C) | ||
+ | |1a. Perioperative [[#Capecitabine_.26_Cisplatin_.28CX.29_.26_Pembrolizumab_888| CX & Pembrolizumab]]<br>1b. Perioperative [[#Cisplatin_.26_Fluorouracil_.28CF.29_.26_Pembrolizumab_888|CF & Pembrolizumab]] | ||
+ | | style="background-color:#d73027" |Inferior pCR rate (co-primary endpoint)<br><br>Might have inferior EFS (co-primary endpoint)<br><br>Did not meet co-primary endpoint of OS | ||
+ | |- | ||
+ | |2. Perioperative [[#FLOT_.26_Pembrolizumab_666|FLOT & Pembrolizumab]] | ||
+ | | style="background-color:#d3d3d3" |Not reported | ||
+ | |- | ||
+ | |} | ||
+ | <div class="toccolours" style="background-color:#b3e2cd"> | ||
+ | ====Chemotherapy, neoadjuvant CF portion (cycles 1 to 3)==== | ||
+ | *[[Cisplatin (Platinol)]] 80 mg/m<sup>2</sup> IV once on day 1 | ||
+ | *[[Fluorouracil (5-FU)]] 800 mg/m<sup>2</sup>/day IV continuous infusion over 120 hours, started on day 1 (total dose per cycle: 4000 mg/m<sup>2</sup>) | ||
+ | '''21-day cycle for 3 cycles''' | ||
+ | ====Local therapy, definitive portion==== | ||
+ | *[[Surgery#Gastrectomy|Surgical resection]] | ||
+ | ====Chemotherapy, adjuvant CF portion (cycles 4 to 6)==== | ||
+ | *[[Cisplatin (Platinol)]] 80 mg/m<sup>2</sup> IV once on day 1 | ||
+ | *[[Fluorouracil (5-FU)]] 800 mg/m<sup>2</sup>/day IV continuous infusion over 120 hours, started on day 1 (total dose per cycle: 4000 mg/m<sup>2</sup>) | ||
+ | '''21-day cycle for 3 cycles''' | ||
+ | </div></div><br> | ||
+ | <div class="toccolours" style="background-color:#eeeeee"> | ||
+ | ===Protocol variant #2, 100/4000 {{#subobject:c2dc1e|Variant=1}}=== | ||
+ | {| class="wikitable sortable" style="width: 100%; text-align:center;" | ||
+ | ! style="width: 20%" |Study | ||
+ | ! style="width: 20%" |Dates of enrollment | ||
+ | ! style="width: 20%" |[[Levels_of_Evidence#Evidence|Evidence]] | ||
+ | ! style="width: 20%" |Comparator | ||
+ | ! style="width: 20%" |[[Levels_of_Evidence#Comparative_efficacy|Comparative Efficacy]] | ||
+ | |- | ||
+ | |[https://doi.org/10.1200/jco.2010.33.0597 Ychou et al. 2011 (ACCORD 07)] | ||
+ | <!-- {| class="wikitable" style="margin:auto; color:white; background-color:#1B4F26" | ||
+ | |'''[https://www.esmo.org/guidelines/esmo-mcbs/esmo-mcbs-scorecards/scorecard-30-1 <span style="color:white;">ESMO-MCBS (A)</span>]''' | ||
+ | |- | ||
+ | |} --> | ||
+ | |1995-2003 | ||
+ | | style="background-color:#1a9851" |Phase 3 (E-esc) | ||
+ | |[[Surgery#Gastrectomy|Surgery alone]] | ||
+ | | style="background-color:#1a9850" |Superior OS (primary endpoint)<br>OS60: 38% vs 24%<br>(HR 0.69, 95% CI 0.50-0.95) | ||
+ | |- | ||
+ | |} | ||
+ | ''Note: ACCORD 07 included patients with lower esophageal malignancy as well (25% gastric, 11% lower esophagus, and 64% GE junction).'' | ||
+ | <div class="toccolours" style="background-color:#b3e2cd"> | ||
+ | ====Chemotherapy, neoadjuvant CF portion==== | ||
*[[Cisplatin (Platinol)]] 100 mg/m<sup>2</sup> IV over 60 minutes once on day 1 | *[[Cisplatin (Platinol)]] 100 mg/m<sup>2</sup> IV over 60 minutes once on day 1 | ||
*[[Fluorouracil (5-FU)]] 800 mg/m<sup>2</sup>/day IV continuous infusion over 120 hours, started on day 1 (total dose per cycle: 4000 mg/m<sup>2</sup>) | *[[Fluorouracil (5-FU)]] 800 mg/m<sup>2</sup>/day IV continuous infusion over 120 hours, started on day 1 (total dose per cycle: 4000 mg/m<sup>2</sup>) | ||
− | |||
'''28-day cycle for 2 to 3 cycles''' | '''28-day cycle for 2 to 3 cycles''' | ||
− | ==== | + | ====Local therapy, definitive portion==== |
− | *[[Surgery#Gastrectomy|Surgical resection]], | + | *[[Surgery#Gastrectomy|Surgical resection]] |
+ | ====Chemotherapy, adjuvant CF portion==== | ||
+ | *[[Cisplatin (Platinol)]] 100 mg/m<sup>2</sup> IV over 60 minutes once on day 28 | ||
+ | *[[Fluorouracil (5-FU)]] 800 mg/m<sup>2</sup>/day IV continuous infusion over 120 hours, started on day 1 (total dose per cycle: 4000 mg/m<sup>2</sup>) | ||
+ | '''28-day cycle for 3 to 4 cycles, for a total of 6 cycles''' | ||
+ | </div></div> | ||
===References=== | ===References=== | ||
− | # '''ACCORD 07:''' Ychou M, Boige V, Pignon JP, Conroy T, Bouché O, Lebreton G, Ducourtieux M, Bedenne L, Fabre JM, Saint-Aubert B, Genève J, Lasser P, Rougier P. Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase III trial. J Clin Oncol. 2011 May 1;29(13):1715-21. [ | + | #'''ACCORD 07:''' Ychou M, Boige V, Pignon JP, Conroy T, Bouché O, Lebreton G, Ducourtieux M, Bedenne L, Fabre JM, Saint-Aubert B, Genève J, Lasser P, Rougier P; FNCLCC; FFCD. Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase III trial. J Clin Oncol. 2011 May 1;29(13):1715-21. Epub 2011 Mar 28. [https://doi.org/10.1200/jco.2010.33.0597 link to original article] '''dosing details in abstract have been reviewed by our editors''' [https://pubmed.ncbi.nlm.nih.gov/21444866/ PubMed] [https://clinicaltrials.gov/study/NCT00002883 NCT00002883] |
+ | #'''KEYNOTE-585:''' Shitara K, Rha SY, Wyrwicz LS, Oshima T, Karaseva N, Osipov M, Yasui H, Yabusaki H, Afanasyev S, Park YK, Al-Batran SE, Yoshikawa T, Yanez P, Dib Bartolomeo M, Lonardi S, Tabernero J, Van Cutsem E, Janjigian YY, Oh DY, Xu J, Fang X, Shih CS, Bhagia P, Bang YJ; KEYNOTE-585 investigators. Neoadjuvant and adjuvant pembrolizumab plus chemotherapy in locally advanced gastric or gastro-oesophageal cancer (KEYNOTE-585): an interim analysis of the multicentre, double-blind, randomised phase 3 study. Lancet Oncol. 2024 Feb;25(2):212-224. Epub 2023 Dec 19. [https://doi.org/10.1016/s1470-2045(23)00541-7 link to original article] '''dosing details in manuscript have been reviewed by our editors''' [https://pubmed.ncbi.nlm.nih.gov/38134948/ PubMed] [https://clinicaltrials.gov/study/NCT03221426 NCT03221426] | ||
− | == | + | ==DOX-CapeOx {{#subobject:cfdox1|Regimen=1}}== |
− | {| class="wikitable" style=" | + | DOX-CapeOX: neoadjuvant '''<u>D</u>'''ocetaxel, '''<u>O</u>'''xaliplatin, '''<u>X</u>'''eloda (Capecitabine), followed by adjuvant '''<u>Cape</u>'''citabine & '''<u>OX</u>'''aliplatin |
+ | <div class="toccolours" style="background-color:#c8a2c8"> | ||
+ | {| class="wikitable sortable" style="width: 100%; text-align:center;" | ||
+ | ! style="width: 20%" |Study | ||
+ | ! style="width: 20%" |Dates of enrollment | ||
+ | ! style="width: 20%" |[[Levels_of_Evidence#Evidence|Evidence]] | ||
+ | ! style="width: 20%" |Comparator | ||
+ | ! style="width: 20%" |[[Levels_of_Evidence#Comparative_efficacy|Comparative Efficacy]] | ||
+ | |- | ||
+ | |rowspan=2|[https://www.ncbi.nlm.nih.gov/pmc/articles/pmc8324337/ Tian et al. 2021 (Alien Craft 0004)] | ||
+ | |rowspan=2|2014-09 to 2018-06 | ||
+ | |rowspan=2 style="background-color:#1a9851" |Phase 3 (E-esc) | ||
+ | |1. Adjuvant [[#CapeOx_2|CapeOx]] | ||
+ | | style="background-color:#d3d3d3" |Not reported | ||
+ | |- | ||
+ | |2. Perioperative [[#CapeOx|CapeOx]] | ||
+ | | style="background-color:#1a9850" |Superior pCR rate (primary endpoint)<br>pCR rate: 16.1% vs 4.3% | ||
|- | |- | ||
− | |||
|} | |} | ||
+ | <div class="toccolours" style="background-color:#eeeeee"> | ||
+ | ===Neoadjuvant {{#subobject:cj3085|Variant=1}}=== | ||
+ | <div class="toccolours" style="background-color:#b3e2cd"> | ||
+ | ====Chemotherapy==== | ||
+ | *[[Docetaxel (Taxotere)]] 60 mg/m<sup>2</sup> IV once on day 1 | ||
+ | *[[Oxaliplatin (Eloxatin)]] 130 mg/m<sup>2</sup> IV once on day 1 | ||
+ | *[[Capecitabine (Xeloda)]] 500 mg/m<sup>2</sup> PO twice per day on days 1 to 14 | ||
+ | '''21-day cycle for 4 cycles''' | ||
+ | </div></div><br> | ||
+ | <div class="toccolours" style="background-color:#eeeeee"> | ||
+ | ===Definitive=== | ||
+ | <div class="toccolours" style="background-color:#b3e2cd"> | ||
+ | ====Local therapy==== | ||
+ | *[[Surgery#Gastrectomy|Surgical resection]] | ||
+ | </div></div><br> | ||
+ | <div class="toccolours" style="background-color:#eeeeee"> | ||
+ | ===Adjuvant=== | ||
+ | <div class="toccolours" style="background-color:#b3e2cd"> | ||
+ | ====Chemotherapy==== | ||
+ | *[[Capecitabine (Xeloda)]] 500 mg/m<sup>2</sup> PO twice per day on days 1 to 14 | ||
+ | *[[Oxaliplatin (Eloxatin)]] 130 mg/m<sup>2</sup> IV over 2 hours once on day 1 | ||
+ | '''21-day cycle for 4 cycles''' | ||
+ | </div></div></div> | ||
+ | ===References=== | ||
+ | #'''Alien Craft 0004:''' Tian Y, Zhao Q, Li Y, Fan L, Zhang Z, Zhao X, Tan B, Wang D, Yang P. Efficacy of Neoadjuvant Chemotherapy DOX and XELOX Regimens for Patients with Resectable Gastric or Gastroesophageal Junction Adenocarcinoma. Gastroenterol Res Pract. 2021 Jul 22;2021:5590626. [https://doi.org/10.1155/2021/5590626 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/pmc8324337/ link to PMC article] '''dosing details in manuscript have been reviewed by our editors''' [https://pubmed.ncbi.nlm.nih.gov/34335737/ PubMed] [https://clinicaltrials.gov/study/NCT02555358 NCT02555358] | ||
+ | ##'''Update:''' Tian Y, Yang P, Guo H, Liu Y, Zhang Z, Ding P, Zheng T, Deng H, Ma W, Li Y, Fan L, Zhang Z, Wang D, Zhao X, Tan B, Liu Y, Zhao Q. Neoadjuvant docetaxel, oxaliplatin plus capecitabine versus oxaliplatin plus capecitabine for patients with locally advanced gastric adenocarcinoma: long-term results of a phase III randomized controlled trial. Int J Surg. 2023 Dec 1;109(12):4000-4008. [https://doi.org/10.1097/js9.0000000000000692 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/pmc10720837/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/37678277/ PubMed] | ||
+ | |||
+ | ==ECF {{#subobject:f0281c|Regimen=1}}== | ||
ECF: '''<u>E</u>'''pirubicin, '''<u>C</u>'''isplatin, '''<u>F</u>'''luorouracil | ECF: '''<u>E</u>'''pirubicin, '''<u>C</u>'''isplatin, '''<u>F</u>'''luorouracil | ||
− | == | + | <div class="toccolours" style="background-color:#c8a2c8"> |
− | {| class="wikitable" style="width: 100%; text-align:center;" | + | {| class="wikitable sortable" style="width: 100%; text-align:center;" |
− | ! style="width: | + | ! style="width: 20%" |Study |
− | ! style="width: | + | ! style="width: 20%" |Dates of enrollment |
− | ! style="width: | + | ! style="width: 20%" |[[Levels_of_Evidence#Evidence|Evidence]] |
− | ! style="width: | + | ! style="width: 20%" |Comparator |
+ | ! style="width: 20%" |[[Levels_of_Evidence#Comparative_efficacy|Comparative Efficacy]] | ||
+ | |- | ||
+ | |[https://doi.org/10.1056/NEJMoa055531 Cunningham et al. 2006 (MAGIC)] | ||
+ | <!-- {| class="wikitable" style="margin:auto; color:white; background-color:#1B4F26" | ||
+ | |'''[https://www.esmo.org/guidelines/esmo-mcbs/esmo-mcbs-scorecards/scorecard-29-1 <span style="color:white;">ESMO-MCBS (A)</span>]''' | ||
+ | |- | ||
+ | |} --> | ||
+ | |1994-2002 | ||
+ | | style="background-color:#1a9851" |Phase 3 (E-esc) | ||
+ | |[[Surgery#Gastrectomy|Surgery alone]] | ||
+ | | style="background-color:#1a9850" |Superior OS (primary endpoint)<br>OS60: 36% vs 23%<br>(HR 0.75, 95% CI 0.60-0.93) | ||
|- | |- | ||
− | |[https:// | + | |[https://doi.org/10.1016/S1470-2045(18)30132-3 Cats et al. 2018 (CRITICS)] |
− | | style="background-color:#1a9851" |Phase | + | |2007-2015 |
− | |[[# | + | | style="background-color:#1a9851" |Phase 3 (C) |
− | | style="background-color:# | + | |1a. [[#ECF.2FCapecitabine_.26_Cisplatin_.28CX.29_.26_RT_999|ECF/CX & RT]]<br>1b. [[#ECX.2FCapecitabine_.26_Cisplatin_.28CX.29_.26_RT_999|ECX/CX & RT]]<br>1c. [[#EOF.2FCapecitabine_.26_Cisplatin_.28CX.29_.26_RT_999|EOF/CX & RT]]<br>1d. [[#EOX.2FCapecitabine_.26_Cisplatin_.28CX.29_.26_RT_999|EOX/CX & RT]] |
+ | | style="background-color:#ffffbf" |Did not meet primary endpoint of OS<br>Median OS: 43 vs 37 mo<br>(HR 1.01, 95% CI 0.84-1.22) | ||
|- | |- | ||
− | |[https://www. | + | |[https://www.ncbi.nlm.nih.gov/pmc/articles/pmc10567579/ Reynolds et al. 2023 (Neo-AEGIS)] |
− | | style="background-color:# | + | |2013-01-24 to 2020-12-23 |
− | | | + | | style="background-color:#1a9851" |Phase 3 (C) |
− | | style="background-color:# | + | |[[#Carboplatin_.26_Paclitaxel_.28CP.29_.26_RT_999|CP & RT]], then surgery |
+ | | style="background-color:#ffffbf" |Did not meet primary endpoint of OS<br>Median OS: 48 vs 49.2 mo<br>(HR 1.03, 95% CI 0.77-1.38) | ||
|- | |- | ||
|} | |} | ||
− | '' | + | ''Note: MAGIC included patients with lower esophageal malignancy as well (74% gastric, 14.8% lower esophagus, and 11.2% GE junction). CRITICS trial included few patients with GE junction malignancy: 83% gastric, 17% GE junction. In CRITICS, only patients with trouble swallowing pills were assigned to this treatment arm.'' |
− | + | <div class="toccolours" style="background-color:#eeeeee"> | |
− | + | ===Neoadjuvant {{#subobject:66f602|Variant=1}}=== | |
− | + | <div class="toccolours" style="background-color:#b3e2cd"> | |
− | + | ====Chemotherapy==== | |
+ | *[[Epirubicin (Ellence)]] 50 mg/m<sup>2</sup> IV once on day 1 | ||
+ | *[[Cisplatin (Platinol)]] 60 mg/m<sup>2</sup> IV once on day 1 | ||
+ | *[[Fluorouracil (5-FU)]] 200 mg/m<sup>2</sup>/day IV continuous infusion over 21 days, started on day 1 (total dose per cycle: 4200 mg/m<sup>2</sup>) | ||
+ | ====Supportive therapy==== | ||
+ | *MAGIC, suggested as thrombosis prophylaxis: | ||
+ | **[[Warfarin (Coumadin)]] 1 mg PO once per day | ||
+ | '''21-day cycle for 3 cycles, followed by:''' | ||
+ | </div></div><br> | ||
+ | <div class="toccolours" style="background-color:#eeeeee"> | ||
+ | ===Definitive=== | ||
+ | <div class="toccolours" style="background-color:#b3e2cd"> | ||
+ | ====Local therapy==== | ||
+ | *MAGIC: [[Surgery#Gastrectomy|Surgical resection]] is performed 3 to 6 weeks after the completion of cycle 3 | ||
+ | *CRITICS: [[Surgery#Gastrectomy|Surgery]] with a D1+ lymph node resection | ||
+ | '''Followed in 6 to 12 weeks by:''' | ||
+ | </div></div><br> | ||
+ | <div class="toccolours" style="background-color:#eeeeee"> | ||
+ | ===Adjuvant=== | ||
+ | <div class="toccolours" style="background-color:#b3e2cd"> | ||
====Chemotherapy==== | ====Chemotherapy==== | ||
*[[Epirubicin (Ellence)]] 50 mg/m<sup>2</sup> IV once on day 1 | *[[Epirubicin (Ellence)]] 50 mg/m<sup>2</sup> IV once on day 1 | ||
*[[Cisplatin (Platinol)]] 60 mg/m<sup>2</sup> IV once on day 1 | *[[Cisplatin (Platinol)]] 60 mg/m<sup>2</sup> IV once on day 1 | ||
− | *[[Fluorouracil (5-FU)]] 200 mg/m<sup>2</sup>/day IV continuous infusion over 21 days, started on day 1 (total dose per cycle: | + | *[[Fluorouracil (5-FU)]] 200 mg/m<sup>2</sup>/day IV continuous infusion over 21 days, started on day 1 (total dose per cycle: 4200 mg/m<sup>2</sup>) |
− | + | ====Supportive therapy==== | |
− | ====Supportive | ||
*MAGIC, suggested as thrombosis prophylaxis: | *MAGIC, suggested as thrombosis prophylaxis: | ||
**[[Warfarin (Coumadin)]] 1 mg PO once per day | **[[Warfarin (Coumadin)]] 1 mg PO once per day | ||
− | |||
'''21-day cycle for 3 cycles''' | '''21-day cycle for 3 cycles''' | ||
− | + | </div></div></div> | |
− | |||
− | |||
− | |||
===References=== | ===References=== | ||
− | # '''MAGIC:''' Cunningham D, Allum WH, Stenning SP, Thompson JN, Van de Velde CJ, Nicolson M, Scarffe JH, Lofts FJ, Falk SJ, Iveson TJ, Smith DB, Langley RE, Verma M, Weeden S, Chua YJ; MAGIC Trial Participants. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med. 2006 Jul 6;355(1):11-20. [https:// | + | #'''MAGIC:''' Cunningham D, Allum WH, Stenning SP, Thompson JN, Van de Velde CJ, Nicolson M, Scarffe JH, Lofts FJ, Falk SJ, Iveson TJ, Smith DB, Langley RE, Verma M, Weeden S, Chua YJ; MAGIC Trial Participants. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med. 2006 Jul 6;355(1):11-20. [https://doi.org/10.1056/NEJMoa055531 link to original article] '''dosing details in abstract have been reviewed by our editors''' [https://pubmed.ncbi.nlm.nih.gov/16822992/ PubMed] [https://clinicaltrials.gov/study/NCT00002615 NCT00002615] |
− | # '''CRITICS:''' Cats A, Jansen EPM, van Grieken NCT, Sikorska K, Lind P, Nordsmark M, Meershoek-Klein Kranenbarg E, Boot H, Trip AK, Swellengrebel HAM, van Laarhoven HWM, Putter H, van Sandick JW, van Berge Henegouwen MI, Hartgrink HH, van Tinteren H, van de Velde CJH, Verheij M; CRITICS investigators. Chemotherapy versus chemoradiotherapy after surgery and preoperative chemotherapy for resectable gastric cancer (CRITICS): an international, open-label, randomised phase 3 trial. Lancet Oncol. 2018 May;19(5):616-628. Epub 2018 Apr 9. [https:// | + | #'''CRITICS:''' Cats A, Jansen EPM, van Grieken NCT, Sikorska K, Lind P, Nordsmark M, Meershoek-Klein Kranenbarg E, Boot H, Trip AK, Swellengrebel HAM, van Laarhoven HWM, Putter H, van Sandick JW, van Berge Henegouwen MI, Hartgrink HH, van Tinteren H, van de Velde CJH, Verheij M; CRITICS investigators. Chemotherapy versus chemoradiotherapy after surgery and preoperative chemotherapy for resectable gastric cancer (CRITICS): an international, open-label, randomised phase 3 trial. Lancet Oncol. 2018 May;19(5):616-628. Epub 2018 Apr 9. [https://doi.org/10.1016/S1470-2045(18)30132-3 link to original article] '''dosing details in manuscript have been reviewed by our editors''' [https://pubmed.ncbi.nlm.nih.gov/29650363/ PubMed] [https://clinicaltrials.gov/study/NCT00407186 NCT00407186] |
+ | #'''Neo-AEGIS:''' Reynolds JV, Preston SR, O'Neill B, Lowery MA, Baeksgaard L, Crosby T, Cunningham M, Cuffe S, Griffiths GO, Parker I, Risumlund SL, Roy R, Falk S, Hanna GB, Bartlett FR, Alvarez-Iglesias A, Achiam MP, Nilsson M, Piessen G, Ravi N, O'Toole D, Johnston C, McDermott RS, Turkington RC, Wahed S, Sothi S, Ford H, Wadley MS, Power D; Neo-AEGIS Investigators and Trial Group. Trimodality therapy versus perioperative chemotherapy in the management of locally advanced adenocarcinoma of the oesophagus and oesophagogastric junction (Neo-AEGIS): an open-label, randomised, phase 3 trial. Lancet Gastroenterol Hepatol. 2023 Nov;8(11):1015-1027. Epub 2023 Sep 18. [https://doi.org/10.1016/s2468-1253(23)00243-1 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/pmc10567579/ link to PMC article] '''dosing details in manuscript have been reviewed by our editors''' [https://pubmed.ncbi.nlm.nih.gov/37734399/ PubMed] [https://clinicaltrials.gov/study/NCT01726452 NCT01726452] | ||
==ECX {{#subobject:c8ab0e|Regimen=1}}== | ==ECX {{#subobject:c8ab0e|Regimen=1}}== | ||
− | {| class="wikitable" style=" | + | ECX: '''<u>E</u>'''pirubicin, '''<u>C</u>'''isplatin, '''<u>X</u>'''eloda (Capecitabine) |
+ | <div class="toccolours" style="background-color:#c8a2c8"> | ||
+ | {| class="wikitable sortable" style="width: 100%; text-align:center;" | ||
+ | ! style="width: 20%" |Study | ||
+ | ! style="width: 20%" |Dates of enrollment | ||
+ | ! style="width: 20%" |[[Levels_of_Evidence#Evidence|Evidence]] | ||
+ | ! style="width: 20%" |Comparator | ||
+ | ! style="width: 20%" |[[Levels_of_Evidence#Comparative_efficacy|Comparative Efficacy]] | ||
|- | |- | ||
− | |[[# | + | |[https://doi.org/10.1016/S1470-2045(18)30132-3 Cats et al. 2018 (CRITICS)] |
− | | | + | |2007-2015 |
− | ECX | + | | style="background-color:#1a9851" |Phase 3 (C) |
− | + | |1a. [[#ECF.2FCapecitabine_.26_Cisplatin_.28CX.29_.26_RT_999|ECF/CX & RT]]<br>1b. [[#ECX.2FCapecitabine_.26_Cisplatin_.28CX.29_.26_RT_999|ECX/CX & RT]]<br>1c. [[#EOF.2FCapecitabine_.26_Cisplatin_.28CX.29_.26_RT_999|EOF/CX & RT]]<br>1d. [[#EOX.2FCapecitabine_.26_Cisplatin_.28CX.29_.26_RT_999|EOX/CX & RT]] | |
− | + | | style="background-color:#ffffbf" |Did not meet primary endpoint of OS<br>Median OS: 43 vs 37 mo<br>(HR 1.01, 95% CI 0.84-1.22) | |
− | |||
− | |||
|- | |- | ||
− | |[https://www. | + | |[https://www.ncbi.nlm.nih.gov/pmc/articles/pmc10567579/ Reynolds et al. 2023 (Neo-AEGIS)] |
− | | style="background-color:# | + | |2013-01-24 to 2020-12-23 |
+ | | style="background-color:#1a9851" |Phase 3 (C) | ||
+ | |[[#Carboplatin_.26_Paclitaxel_.28CP.29_.26_RT_999|CP & RT]], then surgery | ||
+ | | style="background-color:#ffffbf" |Did not meet primary endpoint of OS<br>Median OS: 48 vs 49.2 mo<br>(HR 1.03, 95% CI 0.77-1.38) | ||
|- | |- | ||
|} | |} | ||
− | ''CRITICS trial included few patients with GE junction malignancy: 83% gastric, 17% GE junction'' | + | ''Note: CRITICS trial included few patients with GE junction malignancy: 83% gastric, 17% GE junction'' |
− | + | <div class="toccolours" style="background-color:#eeeeee"> | |
+ | ===Neoadjuvant {{#subobject:27f848|Variant=1}}=== | ||
+ | <div class="toccolours" style="background-color:#b3e2cd"> | ||
+ | ====Chemotherapy==== | ||
+ | *[[Epirubicin (Ellence)]] 50 mg/m<sup>2</sup> IV once on day 1 | ||
+ | *[[Cisplatin (Platinol)]] 60 mg/m<sup>2</sup> IV once on day 1 | ||
+ | *[[Capecitabine (Xeloda)]] by the following study-specific criteria: | ||
+ | **Neo-AEGIS: 625 mg/m<sup>2</sup> PO twice per day on days 1 to 21 | ||
+ | **CRITICS: 1000 mg/m<sup>2</sup> PO twice per day on days 1 to 14 | ||
+ | '''21-day cycle for 3 cycles, followed by:''' | ||
+ | </div></div><br> | ||
+ | <div class="toccolours" style="background-color:#eeeeee"> | ||
+ | ===Definitive=== | ||
+ | <div class="toccolours" style="background-color:#b3e2cd"> | ||
+ | ====Local therapy==== | ||
+ | *[[Surgery#Gastrectomy|Surgery]] with a D1+ lymph node resection | ||
+ | </div></div><br> | ||
+ | <div class="toccolours" style="background-color:#eeeeee"> | ||
+ | ===Adjuvant=== | ||
+ | <div class="toccolours" style="background-color:#b3e2cd"> | ||
====Chemotherapy==== | ====Chemotherapy==== | ||
*[[Epirubicin (Ellence)]] 50 mg/m<sup>2</sup> IV once on day 1 | *[[Epirubicin (Ellence)]] 50 mg/m<sup>2</sup> IV once on day 1 | ||
*[[Cisplatin (Platinol)]] 60 mg/m<sup>2</sup> IV once on day 1 | *[[Cisplatin (Platinol)]] 60 mg/m<sup>2</sup> IV once on day 1 | ||
− | *[[Capecitabine (Xeloda)]] 1000 mg/m<sup>2</sup> PO twice per day on days 1 to 14 | + | *[[Capecitabine (Xeloda)]] by the following study-specific criteria: |
− | + | **Neo-AEGIS: 625 mg/m<sup>2</sup> PO twice per day on days 1 to 21 | |
+ | **CRITICS: 1000 mg/m<sup>2</sup> PO twice per day on days 1 to 14 | ||
'''21-day cycle for 3 cycles''' | '''21-day cycle for 3 cycles''' | ||
− | + | </div></div></div> | |
− | |||
− | |||
===References=== | ===References=== | ||
− | # '''CRITICS:''' Cats A, Jansen EPM, van Grieken NCT, Sikorska K, Lind P, Nordsmark M, Meershoek-Klein Kranenbarg E, Boot H, Trip AK, Swellengrebel HAM, van Laarhoven HWM, Putter H, van Sandick JW, van Berge Henegouwen MI, Hartgrink HH, van Tinteren H, van de Velde CJH, Verheij M; CRITICS investigators. Chemotherapy versus chemoradiotherapy after surgery and preoperative chemotherapy for resectable gastric cancer (CRITICS): an international, open-label, randomised phase 3 trial. Lancet Oncol. 2018 May;19(5):616-628. Epub 2018 Apr 9. [https:// | + | #'''CRITICS:''' Cats A, Jansen EPM, van Grieken NCT, Sikorska K, Lind P, Nordsmark M, Meershoek-Klein Kranenbarg E, Boot H, Trip AK, Swellengrebel HAM, van Laarhoven HWM, Putter H, van Sandick JW, van Berge Henegouwen MI, Hartgrink HH, van Tinteren H, van de Velde CJH, Verheij M; CRITICS investigators. Chemotherapy versus chemoradiotherapy after surgery and preoperative chemotherapy for resectable gastric cancer (CRITICS): an international, open-label, randomised phase 3 trial. Lancet Oncol. 2018 May;19(5):616-628. Epub 2018 Apr 9. [https://doi.org/10.1016/S1470-2045(18)30132-3 link to original article] '''dosing details in manuscript have been reviewed by our editors''' [https://pubmed.ncbi.nlm.nih.gov/29650363/ PubMed] [https://clinicaltrials.gov/study/NCT00407186 NCT00407186] |
− | + | #'''Neo-AEGIS:''' Reynolds JV, Preston SR, O'Neill B, Lowery MA, Baeksgaard L, Crosby T, Cunningham M, Cuffe S, Griffiths GO, Parker I, Risumlund SL, Roy R, Falk S, Hanna GB, Bartlett FR, Alvarez-Iglesias A, Achiam MP, Nilsson M, Piessen G, Ravi N, O'Toole D, Johnston C, McDermott RS, Turkington RC, Wahed S, Sothi S, Ford H, Wadley MS, Power D; Neo-AEGIS Investigators and Trial Group. Trimodality therapy versus perioperative chemotherapy in the management of locally advanced adenocarcinoma of the oesophagus and oesophagogastric junction (Neo-AEGIS): an open-label, randomised, phase 3 trial. Lancet Gastroenterol Hepatol. 2023 Nov;8(11):1015-1027. Epub 2023 Sep 18. [https://doi.org/10.1016/s2468-1253(23)00243-1 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/pmc10567579/ link to PMC article] '''dosing details in manuscript have been reviewed by our editors''' [https://pubmed.ncbi.nlm.nih.gov/37734399/ PubMed] [https://clinicaltrials.gov/study/NCT01726452 NCT01726452] | |
==EOF {{#subobject:139705|Regimen=1}}== | ==EOF {{#subobject:139705|Regimen=1}}== | ||
− | {| class="wikitable" style=" | + | EOF: '''<u>E</u>'''pirubicin, '''<u>O</u>'''xaliplatin, '''<u>F</u>'''luourouracil |
+ | <div class="toccolours" style="background-color:#c8a2c8"> | ||
+ | {| class="wikitable sortable" style="width: 100%; text-align:center;" | ||
+ | ! style="width: 20%" |Study | ||
+ | ! style="width: 20%" |Dates of enrollment | ||
+ | ! style="width: 20%" |[[Levels_of_Evidence#Evidence|Evidence]] | ||
+ | ! style="width: 20%" |Comparator | ||
+ | ! style="width: 20%" |[[Levels_of_Evidence#Comparative_efficacy|Comparative Efficacy]] | ||
|- | |- | ||
− | |[[# | + | |[https://doi.org/10.1016/S1470-2045(18)30132-3 Cats et al. 2018 (CRITICS)] |
− | + | |2007-2015 | |
− | + | | style="background-color:#1a9851" |Phase 3 (C) | |
− | + | |1a. [[#ECF.2FCapecitabine_.26_Cisplatin_.28CX.29_.26_RT_999|ECF/CX & RT]]<br>1b. [[#ECX.2FCapecitabine_.26_Cisplatin_.28CX.29_.26_RT_999|ECX/CX & RT]]<br>1c. [[#EOF.2FCapecitabine_.26_Cisplatin_.28CX.29_.26_RT_999|EOF/CX & RT]]<br>1d. [[#EOX.2FCapecitabine_.26_Cisplatin_.28CX.29_.26_RT_999|EOX/CX & RT]] | |
− | + | | style="background-color:#ffffbf" |Did not meet primary endpoint of OS<br>Median OS: 43 vs 37 mo<br>(HR 1.01, 95% CI 0.84-1.22) | |
− | |||
− | |||
|- | |- | ||
− | |[https://www. | + | |[https://www.ncbi.nlm.nih.gov/pmc/articles/pmc10567579/ Reynolds et al. 2023 (Neo-AEGIS)] |
− | | style="background-color:# | + | |2013-01-24 to 2020-12-23 |
+ | | style="background-color:#1a9851" |Phase 3 (C) | ||
+ | |[[#Carboplatin_.26_Paclitaxel_.28CP.29_.26_RT_999|CP & RT]], then surgery | ||
+ | | style="background-color:#ffffbf" |Did not meet primary endpoint of OS<br>Median OS: 48 vs 49.2 mo<br>(HR 1.03, 95% CI 0.77-1.38) | ||
|- | |- | ||
|} | |} | ||
− | ''CRITICS trial included few patients with GE junction malignancy: 83% gastric, 17% GE junction'' | + | ''Note: CRITICS trial included few patients with GE junction malignancy: 83% gastric, 17% GE junction. Only patients with trouble swallowing pills were assigned to this treatment arm.'' |
+ | <div class="toccolours" style="background-color:#eeeeee"> | ||
+ | ===Neoadjuvant {{#subobject:bf7464|Variant=1}}=== | ||
+ | <div class="toccolours" style="background-color:#b3e2cd"> | ||
+ | ====Chemotherapy==== | ||
+ | *[[Epirubicin (Ellence)]] 50 mg/m<sup>2</sup> IV once on day 1 | ||
+ | *[[Oxaliplatin (Eloxatin)]] 130 mg/m<sup>2</sup> IV once on day 1 | ||
+ | *[[Fluorouracil (5-FU)]] 200 mg/m<sup>2</sup>/day IV continuous infusion over 21 days, started on day 1 (total dose per cycle: 4000 mg/m<sup>2</sup>) | ||
+ | '''21-day cycle for 3 cycles, followed by:''' | ||
+ | </div></div><br> | ||
+ | <div class="toccolours" style="background-color:#eeeeee"> | ||
+ | ===Definitive=== | ||
+ | <div class="toccolours" style="background-color:#b3e2cd"> | ||
+ | ====Local therapy==== | ||
+ | *[[Surgery#Gastrectomy|Surgery]] with a D1+ lymph node resection | ||
+ | </div></div><br> | ||
+ | <div class="toccolours" style="background-color:#eeeeee"> | ||
+ | ===Adjuvant=== | ||
+ | <div class="toccolours" style="background-color:#b3e2cd"> | ||
====Chemotherapy==== | ====Chemotherapy==== | ||
*[[Epirubicin (Ellence)]] 50 mg/m<sup>2</sup> IV once on day 1 | *[[Epirubicin (Ellence)]] 50 mg/m<sup>2</sup> IV once on day 1 | ||
*[[Oxaliplatin (Eloxatin)]] 130 mg/m<sup>2</sup> IV once on day 1 | *[[Oxaliplatin (Eloxatin)]] 130 mg/m<sup>2</sup> IV once on day 1 | ||
*[[Fluorouracil (5-FU)]] 200 mg/m<sup>2</sup>/day IV continuous infusion over 21 days, started on day 1 (total dose per cycle: 4000 mg/m<sup>2</sup>) | *[[Fluorouracil (5-FU)]] 200 mg/m<sup>2</sup>/day IV continuous infusion over 21 days, started on day 1 (total dose per cycle: 4000 mg/m<sup>2</sup>) | ||
− | |||
'''21-day cycle for 3 cycles''' | '''21-day cycle for 3 cycles''' | ||
− | + | </div></div></div> | |
− | |||
− | |||
===References=== | ===References=== | ||
− | # '''CRITICS:''' Cats A, Jansen EPM, van Grieken NCT, Sikorska K, Lind P, Nordsmark M, Meershoek-Klein Kranenbarg E, Boot H, Trip AK, Swellengrebel HAM, van Laarhoven HWM, Putter H, van Sandick JW, van Berge Henegouwen MI, Hartgrink HH, van Tinteren H, van de Velde CJH, Verheij M; CRITICS investigators. Chemotherapy versus chemoradiotherapy after surgery and preoperative chemotherapy for resectable gastric cancer (CRITICS): an international, open-label, randomised phase 3 trial. Lancet Oncol. 2018 May;19(5):616-628. Epub 2018 Apr 9. [https:// | + | #'''CRITICS:''' Cats A, Jansen EPM, van Grieken NCT, Sikorska K, Lind P, Nordsmark M, Meershoek-Klein Kranenbarg E, Boot H, Trip AK, Swellengrebel HAM, van Laarhoven HWM, Putter H, van Sandick JW, van Berge Henegouwen MI, Hartgrink HH, van Tinteren H, van de Velde CJH, Verheij M; CRITICS investigators. Chemotherapy versus chemoradiotherapy after surgery and preoperative chemotherapy for resectable gastric cancer (CRITICS): an international, open-label, randomised phase 3 trial. Lancet Oncol. 2018 May;19(5):616-628. Epub 2018 Apr 9. [https://doi.org/10.1016/S1470-2045(18)30132-3 link to original article] '''dosing details in manuscript have been reviewed by our editors''' [https://pubmed.ncbi.nlm.nih.gov/29650363/ PubMed] [https://clinicaltrials.gov/study/NCT00407186 NCT00407186] |
− | + | #'''Neo-AEGIS:''' Reynolds JV, Preston SR, O'Neill B, Lowery MA, Baeksgaard L, Crosby T, Cunningham M, Cuffe S, Griffiths GO, Parker I, Risumlund SL, Roy R, Falk S, Hanna GB, Bartlett FR, Alvarez-Iglesias A, Achiam MP, Nilsson M, Piessen G, Ravi N, O'Toole D, Johnston C, McDermott RS, Turkington RC, Wahed S, Sothi S, Ford H, Wadley MS, Power D; Neo-AEGIS Investigators and Trial Group. Trimodality therapy versus perioperative chemotherapy in the management of locally advanced adenocarcinoma of the oesophagus and oesophagogastric junction (Neo-AEGIS): an open-label, randomised, phase 3 trial. Lancet Gastroenterol Hepatol. 2023 Nov;8(11):1015-1027. Epub 2023 Sep 18. [https://doi.org/10.1016/s2468-1253(23)00243-1 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/pmc10567579/ link to PMC article] '''dosing details in manuscript have been reviewed by our editors''' [https://pubmed.ncbi.nlm.nih.gov/37734399/ PubMed] [https://clinicaltrials.gov/study/NCT01726452 NCT01726452] | |
==EOX {{#subobject:86ee8e|Regimen=1}}== | ==EOX {{#subobject:86ee8e|Regimen=1}}== | ||
− | {| class="wikitable" style=" | + | EOX: '''<u>E</u>'''pirubicin, '''<u>O</u>'''xaliplatin, '''<u>X</u>'''eloda (Capecitabine) |
+ | <div class="toccolours" style="background-color:#c8a2c8"> | ||
+ | {| class="wikitable sortable" style="width: 100%; text-align:center;" | ||
+ | ! style="width: 20%" |Study | ||
+ | ! style="width: 20%" |Dates of enrollment | ||
+ | ! style="width: 20%" |[[Levels_of_Evidence#Evidence|Evidence]] | ||
+ | ! style="width: 20%" |Comparator | ||
+ | ! style="width: 20%" |[[Levels_of_Evidence#Comparative_efficacy|Comparative Efficacy]] | ||
|- | |- | ||
− | |[[# | + | |[https://doi.org/10.1016/S1470-2045(18)30132-3 Cats et al. 2018 (CRITICS)] |
− | + | |2007-2015 | |
− | + | | style="background-color:#1a9851" |Phase 3 (C) | |
− | + | |1a. [[#ECF.2FCapecitabine_.26_Cisplatin_.28CX.29_.26_RT_999|ECF/CX & RT]]<br>1b. [[#ECX.2FCapecitabine_.26_Cisplatin_.28CX.29_.26_RT_999|ECX/CX & RT]]<br>1c. [[#EOF.2FCapecitabine_.26_Cisplatin_.28CX.29_.26_RT_999|EOF/CX & RT]]<br>1d. [[#EOX.2FCapecitabine_.26_Cisplatin_.28CX.29_.26_RT_999|EOX/CX & RT]] | |
− | + | | style="background-color:#ffffbf" |Did not meet primary endpoint of OS<br>Median OS: 43 vs 37 mo<br>(HR 1.01, 95% CI 0.84-1.22) | |
− | |||
− | |||
|- | |- | ||
− | |[https://www. | + | |[https://www.ncbi.nlm.nih.gov/pmc/articles/pmc10567579/ Reynolds et al. 2023 (Neo-AEGIS)] |
− | | style="background-color:# | + | |2013-01-24 to 2020-12-23 |
+ | | style="background-color:#1a9851" |Phase 3 (C) | ||
+ | |[[#Carboplatin_.26_Paclitaxel_.28CP.29_.26_RT_999|CP & RT]], then surgery | ||
+ | | style="background-color:#ffffbf" |Did not meet primary endpoint of OS<br>Median OS: 48 vs 49.2 mo<br>(HR 1.03, 95% CI 0.77-1.38) | ||
|- | |- | ||
|} | |} | ||
− | ''CRITICS trial included few patients with GE junction malignancy: 83% gastric, 17% GE junction'' | + | ''Note: CRITICS trial included few patients with GE junction malignancy: 83% gastric, 17% GE junction'' |
− | + | <div class="toccolours" style="background-color:#eeeeee"> | |
+ | ===Neoadjuvant {{#subobject:edae45|Variant=1}}=== | ||
+ | <div class="toccolours" style="background-color:#b3e2cd"> | ||
+ | ====Chemotherapy==== | ||
+ | *[[Epirubicin (Ellence)]] 50 mg/m<sup>2</sup> IV once on day 1 | ||
+ | *[[Oxaliplatin (Eloxatin)]] 130 mg/m<sup>2</sup> IV once on day 1 | ||
+ | *[[Capecitabine (Xeloda)]] 625 mg/m<sup>2</sup> PO twice per day on days 1 to 21 | ||
+ | '''21-day cycle for 3 cycles, followed by:''' | ||
+ | </div></div><br> | ||
+ | <div class="toccolours" style="background-color:#eeeeee"> | ||
+ | ===Definitive=== | ||
+ | <div class="toccolours" style="background-color:#b3e2cd"> | ||
+ | ====Local therapy==== | ||
+ | *[[Surgery#Gastrectomy|Surgery]] with a D1+ lymph node resection | ||
+ | </div></div><br> | ||
+ | <div class="toccolours" style="background-color:#eeeeee"> | ||
+ | ===Adjuvant=== | ||
+ | <div class="toccolours" style="background-color:#b3e2cd"> | ||
====Chemotherapy==== | ====Chemotherapy==== | ||
*[[Epirubicin (Ellence)]] 50 mg/m<sup>2</sup> IV once on day 1 | *[[Epirubicin (Ellence)]] 50 mg/m<sup>2</sup> IV once on day 1 | ||
*[[Oxaliplatin (Eloxatin)]] 130 mg/m<sup>2</sup> IV once on day 1 | *[[Oxaliplatin (Eloxatin)]] 130 mg/m<sup>2</sup> IV once on day 1 | ||
− | *[[Capecitabine (Xeloda)]] 625 mg/m<sup>2</sup> PO twice per day | + | *[[Capecitabine (Xeloda)]] 625 mg/m<sup>2</sup> PO twice per day on days 1 to 21 |
− | |||
'''21-day cycle for 3 cycles''' | '''21-day cycle for 3 cycles''' | ||
− | + | </div></div></div> | |
− | |||
− | |||
===References=== | ===References=== | ||
− | # '''CRITICS:''' Cats A, Jansen EPM, van Grieken NCT, Sikorska K, Lind P, Nordsmark M, Meershoek-Klein Kranenbarg E, Boot H, Trip AK, Swellengrebel HAM, van Laarhoven HWM, Putter H, van Sandick JW, van Berge Henegouwen MI, Hartgrink HH, van Tinteren H, van de Velde CJH, Verheij M; CRITICS investigators. Chemotherapy versus chemoradiotherapy after surgery and preoperative chemotherapy for resectable gastric cancer (CRITICS): an international, open-label, randomised phase 3 trial. Lancet Oncol. 2018 May;19(5):616-628. Epub 2018 Apr 9. [https:// | + | #'''CRITICS:''' Cats A, Jansen EPM, van Grieken NCT, Sikorska K, Lind P, Nordsmark M, Meershoek-Klein Kranenbarg E, Boot H, Trip AK, Swellengrebel HAM, van Laarhoven HWM, Putter H, van Sandick JW, van Berge Henegouwen MI, Hartgrink HH, van Tinteren H, van de Velde CJH, Verheij M; CRITICS investigators. Chemotherapy versus chemoradiotherapy after surgery and preoperative chemotherapy for resectable gastric cancer (CRITICS): an international, open-label, randomised phase 3 trial. Lancet Oncol. 2018 May;19(5):616-628. Epub 2018 Apr 9. [https://doi.org/10.1016/S1470-2045(18)30132-3 link to original article] '''dosing details in manuscript have been reviewed by our editors''' [https://pubmed.ncbi.nlm.nih.gov/29650363/ PubMed] [https://clinicaltrials.gov/study/NCT00407186 NCT00407186] |
− | + | #'''Neo-AEGIS:''' Reynolds JV, Preston SR, O'Neill B, Lowery MA, Baeksgaard L, Crosby T, Cunningham M, Cuffe S, Griffiths GO, Parker I, Risumlund SL, Roy R, Falk S, Hanna GB, Bartlett FR, Alvarez-Iglesias A, Achiam MP, Nilsson M, Piessen G, Ravi N, O'Toole D, Johnston C, McDermott RS, Turkington RC, Wahed S, Sothi S, Ford H, Wadley MS, Power D; Neo-AEGIS Investigators and Trial Group. Trimodality therapy versus perioperative chemotherapy in the management of locally advanced adenocarcinoma of the oesophagus and oesophagogastric junction (Neo-AEGIS): an open-label, randomised, phase 3 trial. Lancet Gastroenterol Hepatol. 2023 Nov;8(11):1015-1027. Epub 2023 Sep 18. [https://doi.org/10.1016/s2468-1253(23)00243-1 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/pmc10567579/ link to PMC article] '''dosing details in manuscript have been reviewed by our editors''' [https://pubmed.ncbi.nlm.nih.gov/37734399/ PubMed] [https://clinicaltrials.gov/study/NCT01726452 NCT01726452] | |
==FLOT {{#subobject:aa7f4f|Regimen=1}}== | ==FLOT {{#subobject:aa7f4f|Regimen=1}}== | ||
− | {| class="wikitable" style=" | + | FLOT: '''<u>F</u>'''luorouracil, '''<u>L</u>'''eucovorin, '''<u>O</u>'''xaliplatin, '''<u>T</u>'''axotere (Docetaxel) |
+ | <div class="toccolours" style="background-color:#c8a2c8"> | ||
+ | {| class="wikitable sortable" style="width: 100%; text-align:center;" | ||
+ | ! style="width: 20%" |Study | ||
+ | ! style="width: 20%" |Dates of enrollment | ||
+ | ! style="width: 20%" |[[Levels_of_Evidence#Evidence|Evidence]] | ||
+ | ! style="width: 20%" |Comparator | ||
+ | ! style="width: 20%" |[[Levels_of_Evidence#Comparative_efficacy|Comparative Efficacy]] | ||
+ | |- | ||
+ | |[https://doi.org/10.1016/S1470-2045(16)30531-9 Al-Batran et al. 2016 (FLOT4-AIO)] | ||
+ | <!-- {| class="wikitable" style="margin:auto; color:white; background-color:#1B4F26" | ||
+ | |'''[https://www.esmo.org/guidelines/esmo-mcbs/esmo-mcbs-scorecards/scorecard-119-1 <span style="color:white;">ESMO-MCBS (A)</span>]''' | ||
|- | |- | ||
− | + | |} --> | |
− | |} | + | |2010-2015 |
− | + | | style="background-color:#1a9851" |Phase 2/3 (E-switch-ic) | |
− | + | |1a. Perioperative [[#ECF|ECF]]<br>1b. Perioperative [[#ECX|ECX]] | |
− | + | | style="background-color:#1a9850" |Superior OS<sup>1</sup> (primary endpoint)<br>Median OS: 50 vs 35 mo<br>(HR 0.77, 95% CI 0.63-0.94) | |
− | |||
− | |||
− | |||
− | |||
|- | |- | ||
− | |[https:// | + | |[https://doi.org/10.1016/s1470-2045(23)00541-7 Shitara et al. 2023 (KEYNOTE-585)] |
− | | style="background-color:#1a9851" |Phase | + | |2017-10-09 to 2021-01-25 |
− | | | + | | style="background-color:#1a9851" |Phase 3 (C) |
− | |style="background-color:# | + | |1a. Perioperative [[#Capecitabine_.26_Cisplatin_.28CX.29_.26_Pembrolizumab| CX & Pembrolizumab]]<br>1b. Perioperative [[#Cisplatin_.26_Fluorouracil_.28CF.29_.26_Pembrolizumab|CF & Pembrolizumab]]<br>2. Perioperative [[#FLOT_.26_Pembrolizumab_666|FLOT & Pembrolizumab]] |
+ | | style="background-color:#d3d3d3" |Not reported<sup>2</sup> | ||
|- | |- | ||
|} | |} | ||
− | '' | + | ''<sup>1</sup>Reported efficacy is based on the 2019 update.''<br> |
− | + | ''<sup>2</sup>In KEYNOTE-585, the FLOT cohort was designated as a safety cohort and efficacy results were not reported in Shitara et al. 2023.'' | |
+ | <div class="toccolours" style="background-color:#eeeeee"> | ||
+ | ===Neoadjuvant {{#subobject:16408e|Variant=1}}=== | ||
+ | <div class="toccolours" style="background-color:#b3e2cd"> | ||
+ | ====Chemotherapy==== | ||
+ | *[[Fluorouracil (5-FU)]] 2600 mg/m<sup>2</sup> IV continuous infusion over 24 hours, started on day 1 | ||
+ | *[[Leucovorin (Folinic acid)]] 200 mg/m<sup>2</sup> IV once on day 1 | ||
+ | *[[Oxaliplatin (Eloxatin)]] 85 mg/m<sup>2</sup> IV once on day 1 | ||
+ | *[[Docetaxel (Taxotere)]] 50 mg/m<sup>2</sup> IV once on day 1 | ||
+ | '''14-day cycle for 4 cycles''' | ||
+ | </div></div><br> | ||
+ | <div class="toccolours" style="background-color:#eeeeee"> | ||
+ | ===Definitive=== | ||
+ | <div class="toccolours" style="background-color:#b3e2cd"> | ||
+ | ====Local therapy==== | ||
+ | *[[Surgery#Gastrectomy|Surgery]] with a D1+ lymph node resection | ||
+ | </div></div><br> | ||
+ | <div class="toccolours" style="background-color:#eeeeee"> | ||
+ | ===Adjuvant=== | ||
+ | <div class="toccolours" style="background-color:#b3e2cd"> | ||
====Chemotherapy==== | ====Chemotherapy==== | ||
− | *[[Fluorouracil (5-FU)]] 2600 mg/m<sup>2</sup> IV continuous infusion over 24 hours on day 1 | + | *[[Fluorouracil (5-FU)]] 2600 mg/m<sup>2</sup> IV continuous infusion over 24 hours, started on day 1 |
− | *[[Folinic acid | + | *[[Leucovorin (Folinic acid)]] 200 mg/m<sup>2</sup> IV once on day 1 |
*[[Oxaliplatin (Eloxatin)]] 85 mg/m<sup>2</sup> IV once on day 1 | *[[Oxaliplatin (Eloxatin)]] 85 mg/m<sup>2</sup> IV once on day 1 | ||
*[[Docetaxel (Taxotere)]] 50 mg/m<sup>2</sup> IV once on day 1 | *[[Docetaxel (Taxotere)]] 50 mg/m<sup>2</sup> IV once on day 1 | ||
− | |||
'''14-day cycle for 4 cycles''' | '''14-day cycle for 4 cycles''' | ||
− | + | </div></div></div> | |
− | |||
===References=== | ===References=== | ||
− | # '''FLOT4-AIO:''' Al-Batran SE, Hofheinz RD, Pauligk C, Kopp HG, Haag GM, Luley KB, Meiler J, Homann N, Lorenzen S, Schmalenberg H, Probst S, Koenigsmann M, Egger M, Prasnikar N, Caca K, Trojan J, Martens UM, Block A, Fischbach W, Mahlberg R, Clemens M, Illerhaus G, Zirlik K, Behringer DM, Schmiegel W, Pohl M, Heike M, Ronellenfitsch U, Schuler M, Bechstein WO, Königsrainer A, Gaiser T, Schirmacher P, Hozaeel W, Reichart A, Goetze TO, Sievert M, Jäger E, Mönig S, Tannapfel A. Histopathological regression after neoadjuvant docetaxel, oxaliplatin, fluorouracil, and leucovorin versus epirubicin, cisplatin, and fluorouracil or capecitabine in patients with resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4-AIO): results from the phase 2 part of a multicentre, open-label, randomised phase 2/3 trial. Lancet Oncol. 2016 Dec;17(12):1697-1708. Epub 2016 Oct 22. [https:// | + | #'''FLOT4-AIO:''' Al-Batran SE, Hofheinz RD, Pauligk C, Kopp HG, Haag GM, Luley KB, Meiler J, Homann N, Lorenzen S, Schmalenberg H, Probst S, Koenigsmann M, Egger M, Prasnikar N, Caca K, Trojan J, Martens UM, Block A, Fischbach W, Mahlberg R, Clemens M, Illerhaus G, Zirlik K, Behringer DM, Schmiegel W, Pohl M, Heike M, Ronellenfitsch U, Schuler M, Bechstein WO, Königsrainer A, Gaiser T, Schirmacher P, Hozaeel W, Reichart A, Goetze TO, Sievert M, Jäger E, Mönig S, Tannapfel A. Histopathological regression after neoadjuvant docetaxel, oxaliplatin, fluorouracil, and leucovorin versus epirubicin, cisplatin, and fluorouracil or capecitabine in patients with resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4-AIO): results from the phase 2 part of a multicentre, open-label, randomised phase 2/3 trial. Lancet Oncol. 2016 Dec;17(12):1697-1708. Epub 2016 Oct 22. [https://doi.org/10.1016/S1470-2045(16)30531-9 link to original article] [https://pubmed.ncbi.nlm.nih.gov/27776843/ PubMed] [https://clinicaltrials.gov/study/NCT01216644 NCT01216644] |
− | ## '''Update:''' Al-Batran SE, Homann N, Pauligk C, Goetze TO, Meiler J, Kasper S, Kopp HG, Mayer F, Haag GM, Luley K, Lindig U, Schmiegel W, Pohl M, Stoehlmacher J, Folprecht G, Probst S, Prasnikar N, Fischbach W, Mahlberg R, Trojan J, Koenigsmann M, Martens UM, Thuss-Patience P, Egger M, Block A, Heinemann V, Illerhaus G, Moehler M, Schenk M, Kullmann F, Behringer DM, Heike M, Pink D, Teschendorf C, Löhr C, Bernhard H, Schuch G, Rethwisch V, | + | ##'''Update:''' Al-Batran SE, Homann N, Pauligk C, Goetze TO, Meiler J, Kasper S, Kopp HG, Mayer F, Haag GM, Luley K, Lindig U, Schmiegel W, Pohl M, Stoehlmacher J, Folprecht G, Probst S, Prasnikar N, Fischbach W, Mahlberg R, Trojan J, Koenigsmann M, Martens UM, Thuss-Patience P, Egger M, Block A, Heinemann V, Illerhaus G, Moehler M, Schenk M, Kullmann F, Behringer DM, Heike M, Pink D, Teschendorf C, Löhr C, Bernhard H, Schuch G, Rethwisch V, von Weikersthal LF, Hartmann JT, Kneba M, Daum S, Schulmann K, Weniger J, Belle S, Gaiser T, Oduncu FS, Güntner M, Hozaeel W, Reichart A, Jäger E, Kraus T, Mönig S, Bechstein WO, Schuler M, Schmalenberg H, Hofheinz RD; FLOT4-AIO Investigators. perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomized, phase 2/3 trial. Lancet. 2019 May 11;393(10184):1948-1957. Epub 2019 Apr 11. [https://doi.org/10.1016/s0140-6736(18)32557-1 link to original article] [https://pubmed.ncbi.nlm.nih.gov/30982686/ PubMed] |
+ | #'''KEYNOTE-585:''' Shitara K, Rha SY, Wyrwicz LS, Oshima T, Karaseva N, Osipov M, Yasui H, Yabusaki H, Afanasyev S, Park YK, Al-Batran SE, Yoshikawa T, Yanez P, Dib Bartolomeo M, Lonardi S, Tabernero J, Van Cutsem E, Janjigian YY, Oh DY, Xu J, Fang X, Shih CS, Bhagia P, Bang YJ; KEYNOTE-585 investigators. Neoadjuvant and adjuvant pembrolizumab plus chemotherapy in locally advanced gastric or gastro-oesophageal cancer (KEYNOTE-585): an interim analysis of the multicentre, double-blind, randomised phase 3 study. Lancet Oncol. 2024 Feb;25(2):212-224. Epub 2023 Dec 19. [https://doi.org/10.1016/s1470-2045(23)00541-7 link to original article] '''dosing details in manuscript have been reviewed by our editors''' [https://pubmed.ncbi.nlm.nih.gov/38134948/ PubMed] [https://clinicaltrials.gov/study/NCT03221426 NCT03221426] | ||
+ | #'''MATTERHORN:''' [https://clinicaltrials.gov/study/NCT04592913 NCT04592913] | ||
+ | #'''RAMSES:''' [https://clinicaltrials.gov/study/NCT02661971 NCT02661971] | ||
− | == | + | ==mFOLFOX6 {{#subobject:nvig8a|Regimen=1}}== |
− | == | + | mFOLFOX6: '''<u>m</u>'''odified '''<u>FOL</u>'''inic acid (Leucovorin), '''<u>F</u>'''luorouracil, '''<u>OX</u>'''aliplatin |
− | {| class="wikitable" style="width: 100%; text-align:center;" | + | <div class="toccolours" style="background-color:#c8a2c8"> |
− | ! style="width: | + | {| class="wikitable sortable" style="width: 100%; text-align:center;" |
− | ! style="width: | + | ! style="width: 20%" |Study |
− | ! style="width: | + | ! style="width: 20%" |Dates of enrollment |
− | ! style="width: | + | ! style="width: 20%" |[[Levels_of_Evidence#Evidence|Evidence]] |
+ | ! style="width: 20%" |Comparator | ||
+ | ! style="width: 20%" |[[Levels_of_Evidence#Comparative_efficacy|Comparative Efficacy]] | ||
|- | |- | ||
− | |[https://www.ncbi.nlm.nih.gov/pmc/articles/ | + | |[https://www.ncbi.nlm.nih.gov/pmc/articles/pmc8886520/ Yu et al. 2022 (FOCUS<sub>gastric</sub>)] |
− | | style="background-color:#1a9851" |Phase | + | |2011-2016 |
− | | | + | |style="background-color:#1a9851" |Phase 3 (C) |
− | | style="background-color:# | + | |Perioperative [[#SOX|SOX]] |
+ | | style="background-color:#eeee01" |Non-inferior OS36 (primary endpoint)<br>OS36: 67.8% vs 75.2% | ||
|- | |- | ||
|} | |} | ||
− | '' | + | <div class="toccolours" style="background-color:#eeeeee"> |
− | ==== | + | ===Neoadjuvant {{#subobject:5h28c3|Variant=1}}=== |
− | *[[Surgery#Gastrectomy| | + | |
+ | <div class="toccolours" style="background-color:#b3e2cd"> | ||
+ | ====Chemotherapy==== | ||
+ | *[[Fluorouracil (5-FU)]] 400 mg/m<sup>2</sup> IV bolus once on day 1, then 2400 mg/m<sup>2</sup> IV continuous infusion over 46 hours (total dose per cycle: 2800 mg/m<sup>2</sup>) | ||
+ | *[[Leucovorin (Folinic acid)]] 400 mg/m<sup>2</sup> IV once on day 1 | ||
+ | *[[Oxaliplatin (Eloxatin)]] 85 mg/m<sup>2</sup> IV over 2 hours once on day 1 | ||
+ | '''21-day cycle for 2 to 4 cycles, followed by:''' | ||
+ | </div></div><br> | ||
+ | <div class="toccolours" style="background-color:#eeeeee"> | ||
+ | ===Definitive=== | ||
+ | <div class="toccolours" style="background-color:#b3e2cd"> | ||
+ | ====Local therapy==== | ||
+ | *[[Surgery#Gastrectomy|Gastrectomy]] with at least D2 dissection | ||
+ | </div></div><br> | ||
+ | <div class="toccolours" style="background-color:#eeeeee"> | ||
+ | ===Adjuvant=== | ||
+ | <div class="toccolours" style="background-color:#b3e2cd"> | ||
+ | ====Chemotherapy==== | ||
+ | *[[Fluorouracil (5-FU)]] 400 mg/m<sup>2</sup> IV bolus once on day 1, then 2400 mg/m<sup>2</sup> IV continuous infusion over 46 hours (total dose per cycle: 2800 mg/m<sup>2</sup>) | ||
+ | *[[Leucovorin (Folinic acid)]] 400 mg/m<sup>2</sup> IV once on day 1 | ||
+ | *[[Oxaliplatin (Eloxatin)]] 85 mg/m<sup>2</sup> IV over 2 hours once on day 1 | ||
+ | '''21-day cycle for 2 to 4 cycles''' | ||
+ | </div></div></div> | ||
===References=== | ===References=== | ||
− | # ''' | + | #'''FOCUS<sub>gastric</sub>:''' Yu J, Gao Y, Chen L, Wu D, Shen Q, Zhao Z, Liu W, Yang H, Zhang Q, Wang X, Hu P, Zheng Z, Wang X, Liu H, Xu Z, Yan Z, Wu Y, Jin M, Zhang Q, Liu X, Zhu K, Shou C. Effect of S-1 Plus Oxaliplatin Compared With Fluorouracil, Leucovorin Plus Oxaliplatin as Perioperative Chemotherapy for Locally Advanced, Resectable Gastric Cancer: A Randomized Clinical Trial. JAMA Netw Open. 2022 Feb 1;5(2):e220426. [https://doi.org/10.1001/jamanetworkopen.2022.0426 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/pmc8886520/ link to PMC article] '''dosing details in manuscript have been reviewed by our editors''' [https://pubmed.ncbi.nlm.nih.gov/35226081/ PubMed] [https://clinicaltrials.gov/study/NCT01364376 NCT01364376] |
+ | ==SOX {{#subobject:ecig8a|Regimen=1}}== | ||
+ | SOX: '''<u>S</u>'''-1 & '''<u>OX</u>'''aliplatin | ||
+ | <div class="toccolours" style="background-color:#c8a2c8"> | ||
+ | {| class="wikitable sortable" style="width: 100%; text-align:center;" | ||
+ | ! style="width: 20%" |Study | ||
+ | ! style="width: 20%" |Dates of enrollment | ||
+ | ! style="width: 20%" |[[Levels_of_Evidence#Evidence|Evidence]] | ||
+ | ! style="width: 20%" |Comparator | ||
+ | ! style="width: 20%" |[[Levels_of_Evidence#Comparative_efficacy|Comparative Efficacy]] | ||
+ | |- | ||
+ | |[https://www.ncbi.nlm.nih.gov/pmc/articles/pmc8886520/ Yu et al. 2022 (FOCUS<sub>gastric</sub>)] | ||
+ | |2011-2016 | ||
+ | |style="background-color:#1a9851" |Phase 3 (E-switch-ic) | ||
+ | |Perioperative [[#mFOLFOX6|mFOLFOX6]] | ||
+ | | style="background-color:#eeee01" |Non-inferior OS36 (primary endpoint)<br>OS36: 75.2% vs 67.8% | ||
+ | |- | ||
+ | |[https://www.ncbi.nlm.nih.gov/pmc/articles/pmc11003079/ Wang et al. 2024 (RESONANCE)] | ||
+ | |2012-09-01 to 2019-07-01 | ||
+ | | style="background-color:#1a9851" |Phase 3 (E-switch-ic) | ||
+ | |Adjuvant [[#SOX_2|SOX]] | ||
+ | | style="background-color:#91cf60" |Seems to have superior DFS36 (primary endpoint)<br>DFS36: 61.7% vs 53.8% | ||
+ | |- | ||
+ | |} | ||
+ | <div class="toccolours" style="background-color:#eeeeee"> | ||
+ | ===Neoadjuvant {{#subobject:5guz13|Variant=1}}=== | ||
− | =Adjuvant | + | <div class="toccolours" style="background-color:#b3e2cd"> |
+ | ====Chemotherapy==== | ||
+ | *[[Tegafur, gimeracil, oteracil (S-1)]] by the following BSA-based criteria: | ||
+ | **Less than 1.25 m<sup>2</sup>: 40 mg PO twice per day on days 1 to 14 | ||
+ | **Between 1.25 m<sup>2</sup> and 1.5 m<sup>2</sup>: 50 mg PO twice per day on days 1 to 14 | ||
+ | **1.5 m<sup>2</sup> or more: 60 mg PO twice per day on days 1 to 14 | ||
+ | *[[Oxaliplatin (Eloxatin)]] 130 mg/m<sup>2</sup> IV over 2 hours once on day 1 | ||
+ | '''21-day cycle for 2 to 4 cycles, followed by:''' | ||
+ | </div></div><br> | ||
+ | <div class="toccolours" style="background-color:#eeeeee"> | ||
+ | ===Definitive=== | ||
+ | <div class="toccolours" style="background-color:#b3e2cd"> | ||
+ | ====Local therapy==== | ||
+ | *[[Surgery#Gastrectomy|Gastrectomy]] with at least D2 dissection | ||
+ | </div></div><br> | ||
+ | <div class="toccolours" style="background-color:#eeeeee"> | ||
+ | ===Adjuvant=== | ||
+ | <div class="toccolours" style="background-color:#b3e2cd"> | ||
+ | ====Chemotherapy==== | ||
+ | *[[Tegafur, gimeracil, oteracil (S-1)]] by the following BSA-based criteria: | ||
+ | **Less than 1.25 m<sup>2</sup>: 40 mg PO twice per day on days 1 to 14 | ||
+ | **Between 1.25 m<sup>2</sup> and 1.5 m<sup>2</sup>: 50 mg PO twice per day on days 1 to 14 | ||
+ | **1.5 m<sup>2</sup> or more: 60 mg PO twice per day on days 1 to 14 | ||
+ | *[[Oxaliplatin (Eloxatin)]] 130 mg/m<sup>2</sup> IV over 2 hours once on day 1 | ||
+ | '''21-day cycle for 2 to 4 cycles''' | ||
+ | </div></div></div> | ||
+ | ===References=== | ||
+ | #'''RESOLVE<sub>gastric</sub>:''' Zhang X, Liang H, Li Z, Xue Y, Wang Y, Zhou Z, Yu J, Bu Z, Chen L, Du Y, Wang X, Wu A, Li G, Su X, Xiao G, Cui M, Wu D, Chen L, Wu X, Zhou Y, Zhang L, Dang C, He Y, Zhang Z, Sun Y, Li Y, Chen H, Bai Y, Qi C, Yu P, Zhu G, Suo J, Jia B, Li L, Huang C, Li F, Ye Y, Xu H, Wang X, Yuan Y, E JY, Ying X, Yao C, Shen L, Ji J; RESOLVE study group. Perioperative or postoperative adjuvant oxaliplatin with S-1 versus adjuvant oxaliplatin with capecitabine in patients with locally advanced gastric or gastro-oesophageal junction adenocarcinoma undergoing D2 gastrectomy (RESOLVE): an open-label, superiority and non-inferiority, phase 3 randomised controlled trial. Lancet Oncol. 2021 Aug;22(8):1081-1092. Epub 2021 Jul 9. Erratum in: Lancet Oncol. 2021 Aug;22(8):e347. [https://doi.org/10.1016/s1470-2045(21)00297-7 link to original article] [https://pubmed.ncbi.nlm.nih.gov/34252374/ PubMed] [https://clinicaltrials.gov/study/NCT01534546 NCT01534546] | ||
+ | #'''FOCUS<sub>gastric</sub>:''' Yu J, Gao Y, Chen L, Wu D, Shen Q, Zhao Z, Liu W, Yang H, Zhang Q, Wang X, Hu P, Zheng Z, Wang X, Liu H, Xu Z, Yan Z, Wu Y, Jin M, Zhang Q, Liu X, Zhu K, Shou C. Effect of S-1 Plus Oxaliplatin Compared With Fluorouracil, Leucovorin Plus Oxaliplatin as Perioperative Chemotherapy for Locally Advanced, Resectable Gastric Cancer: A Randomized Clinical Trial. JAMA Netw Open. 2022 Feb 1;5(2):e220426. [https://doi.org/10.1001/jamanetworkopen.2022.0426 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/pmc8886520/ link to PMC article] '''dosing details in manuscript have been reviewed by our editors''' [https://pubmed.ncbi.nlm.nih.gov/35226081/ PubMed] [https://clinicaltrials.gov/study/NCT01364376 NCT01364376] | ||
+ | #'''RESONANCE:''' Wang X, Lu C, Wei B, Li S, Li Z, Xue Y, Ye Y, Zhang Z, Sun Y, Liang H, Li K, Zhu L, Zheng Z, Zhou Y, He Y, Li F, Wang X, Liang P, Huang H, Li G, Shen X, Ji J, Tang Y, Xu Z, Chen L; RESONANCE study group. Perioperative versus adjuvant S-1 plus oxaliplatin chemotherapy for stage II/III resectable gastric cancer (RESONANCE): a randomized, open-label, phase 3 trial. J Hematol Oncol. 2024 Apr 8;17(1):17. [https://doi.org/10.1186/s13045-024-01536-7 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/pmc11003079/ link to PMC article] '''dosing details in supplement have been reviewed by our editors''' [https://pubmed.ncbi.nlm.nih.gov/38589926/ PubMed] [https://clinicaltrials.gov/study/NCT01583361 NCT01583361] | ||
− | == | + | =Neoadjuvant chemotherapy= |
− | {| class="wikitable" style=" | + | ==DOS {{#subobject:a2ug18|Regimen=1}}== |
+ | DOS: '''<u>D</u>'''ocetaxel, '''<u>O</u>'''xaliplatin, '''<u>S</u>'''-1 | ||
+ | <div class="toccolours" style="background-color:#eeeeee"> | ||
+ | ===Regimen {{#subobject:gu1503|Variant=1}}=== | ||
+ | {| class="wikitable sortable" style="width: 100%; text-align:center;" | ||
+ | ! style="width: 20%" |Study | ||
+ | ! style="width: 20%" |Dates of enrollment | ||
+ | ! style="width: 20%" |[[Levels_of_Evidence#Evidence|Evidence]] | ||
+ | ! style="width: 20%" |Comparator | ||
+ | ! style="width: 20%" |[[Levels_of_Evidence#Comparative_efficacy|Comparative Efficacy]] | ||
+ | |- | ||
+ | |[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8425847/ Kang et al. 2021 (PRODIGY)] | ||
+ | |2012-2017 | ||
+ | | style="background-color:#1a9851" |Phase 3 (E-esc) | ||
+ | |[[Gastric_cancer_-_null_regimens#No_neoadjuvant_therapy|No neoadjuvant therapy]] | ||
+ | | style="background-color:#91cf60" |Seems to have superior PFS (primary endpoint)<br>PFS36: 66% vs 60%<br>(aHR 0.70, 95% CI 0.52-0.95) | ||
|- | |- | ||
− | |||
|} | |} | ||
− | + | <div class="toccolours" style="background-color:#b3e2cd"> | |
− | ===Regimen {{#subobject: | + | ====Chemotherapy==== |
− | {| class="wikitable" style="width: 100%; text-align:center;" | + | *[[Docetaxel (Taxotere)]] 50 mg/m<sup>2</sup> IV once on day 1 |
− | ! style="width: | + | *[[Oxaliplatin (Eloxatin)]] 100 mg/m<sup>2</sup> IV once on day 1 |
− | ! style="width: | + | *[[Tegafur, gimeracil, oteracil (S-1)|S-1]] 40 mg/m<sup>2</sup> PO twice per day on days 1 to 14 |
− | ! style="width: | + | '''21-day cycle for 3 cycles''' |
− | ! style="width: | + | </div> |
− | + | <div class="toccolours" style="background-color:#cbd5e7"> | |
− | + | ====Subsequent treatment==== | |
− | + | *[[Surgery#Gastrectomy|Surgery]], then adjuvant [[#S-1_monotherapy|S-1]] | |
− | + | </div></div> | |
− | + | ===References=== | |
+ | #'''PRODIGY:''' Kang YK, Yook JH, Park YK, Lee JS, Kim YW, Kim JY, Ryu MH, Rha SY, Chung IJ, Kim IH, Oh SC, Park YS, Son T, Jung MR, Heo MH, Kim HK, Park C, Yoo CH, Choi JH, Zang DY, Jang YJ, Sul JY, Kim JG, Kim BS, Beom SH, Cho SH, Ryu SW, Kook MC, Ryoo BY, Kim HK, Yoo MW, Lee NS, Lee SH, Kim G, Lee Y, Lee JH, Noh SH. PRODIGY: A Phase III Study of Neoadjuvant Docetaxel, Oxaliplatin, and S-1 Plus Surgery and Adjuvant S-1 Versus Surgery and Adjuvant S-1 for Resectable Advanced Gastric Cancer. J Clin Oncol. 2021 Sep 10;39(26):2903-2913. Epub 2021 Jun 16. [https://doi.org/10.1200/jco.20.02914 link to original article] '''dosing details in manuscript have been reviewed by our editors''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8425847/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/34133211/ PubMed] [https://clinicaltrials.gov/study/NCT01515748 NCT01515748] | ||
+ | ==ECF {{#subobject:f0281c|Regimen=1}}== | ||
+ | ECF: '''<u>E</u>'''pirubicin, '''<u>C</u>'''isplatin, '''<u>F</u>'''luorouracil | ||
+ | <div class="toccolours" style="background-color:#eeeeee"> | ||
+ | ===Regimen {{#subobject:66f602|Variant=1}}=== | ||
+ | {| class="wikitable sortable" style="width: 100%; text-align:center;" | ||
+ | ! style="width: 20%" |Study | ||
+ | ! style="width: 20%" |Dates of enrollment | ||
+ | ! style="width: 20%" |[[Levels_of_Evidence#Evidence|Evidence]] | ||
+ | ! style="width: 20%" |Comparator | ||
+ | ! style="width: 20%" |[[Levels_of_Evidence#Comparative_efficacy|Comparative Efficacy]] | ||
|- | |- | ||
− | |[https://www. | + | |[https://www.clinicaltrials.gov/study/NCT01924819 Awaiting publication (TOPGEAR)] |
− | | style="background-color:#1a9851" |Phase | + | |2009-ongoing |
− | |ECF | + | | style="background-color:#1a9851" |Phase 3 (C) |
− | | style="background-color:# | + | |1a. [[#ECF.2FFluorouracil_.26_RT_666|ECF/5-FU & RT]]<br>1b. [[#ECX.2FCapecitabine_.26_RT|ECX/Capecitabine & RT]]<br>1c. [[#EOX.2FCapecitabine_.26_RT|EOX/Capecitabine & RT]]<br>1d. [[#FLOT.2FCapecitabine_.26_RT|FLOT/Capecitabine & RT]] |
+ | | style="background-color:#d3d3d3" |TBD if different primary endpoint of OS | ||
|- | |- | ||
|} | |} | ||
− | + | <div class="toccolours" style="background-color:#b3e2cd"> | |
− | + | ====Chemotherapy==== | |
− | + | *[[Epirubicin (Ellence)]] 50 mg/m<sup>2</sup> IV once on day 1 | |
− | == | + | *[[Cisplatin (Platinol)]] 60 mg/m<sup>2</sup> IV once on day 1 |
− | + | *[[Fluorouracil (5-FU)]] 200 mg/m<sup>2</sup>/day IV continuous infusion over 21 days, started on day 1 (total dose per cycle: 4000 mg/m<sup>2</sup>) | |
− | + | '''21-day cycle for 3 cycles''' | |
− | ====Chemotherapy | + | </div></div> |
− | *[[ | ||
− | *[[ | ||
− | |||
− | |||
− | |||
− | |||
− | *[[Fluorouracil (5-FU)]] | ||
− | |||
− | |||
− | |||
− | |||
− | ''' | ||
− | |||
− | |||
− | |||
− | |||
− | |||
===References=== | ===References=== | ||
− | # ''' | + | #'''TOPGEAR:''' [https://clinicaltrials.gov/study/NCT01924819 NCT01924819] |
− | + | =Adjuvant therapy= | |
− | |||
− | |||
==CapeOx {{#subobject:cf9acc|Regimen=1}}== | ==CapeOx {{#subobject:cf9acc|Regimen=1}}== | ||
− | {| class="wikitable" style=" | + | CapeOX: '''<u>Cape</u>'''citabine & '''<u>OX</u>'''aliplatin |
+ | <div class="toccolours" style="background-color:#eeeeee"> | ||
+ | ===Regimen variant #1, 1000/130 {{#subobject:1e5038|Variant=1}}=== | ||
+ | {| class="wikitable sortable" style="width: 100%; text-align:center;" | ||
+ | ! style="width: 20%" |Study | ||
+ | ! style="width: 20%" |Dates of enrollment | ||
+ | ! style="width: 20%" |[[Levels_of_Evidence#Evidence|Evidence]] | ||
+ | ! style="width: 20%" |Comparator | ||
+ | ! style="width: 20%" |[[Levels_of_Evidence#Comparative_efficacy|Comparative Efficacy]] | ||
+ | |- | ||
+ | |[https://www.ncbi.nlm.nih.gov/pmc/articles/pmc8324337/ Tian et al. 2021 (Alien Craft 0004)] | ||
+ | |2014-09 to 2018-06 | ||
+ | | style="background-color:#1a9851" |Phase 3 (C) | ||
+ | |1. Perioperative [[#CapeOx|CapeOx]]<br>2. Perioperative [[#DOX-CapeOx|DOX-CapeOx]] | ||
+ | | style="background-color:#d3d3d3" |Not reported | ||
|- | |- | ||
− | |||
|} | |} | ||
− | + | <div class="toccolours" style="background-color:#cbd5e8"> | |
− | ===Regimen {{#subobject:1ef938|Variant=1}}=== | + | ====Preceding treatment==== |
− | {| class="wikitable" style="width: 100%; text-align:center;" | + | *[[Surgery#Gastrectomy|Gastrectomy]] |
− | ! style="width: | + | </div> |
− | ! style="width: | + | <div class="toccolours" style="background-color:#b3e2cd"> |
− | ! style="width: | + | ====Chemotherapy==== |
− | ! style="width: | + | *[[Capecitabine (Xeloda)]] 500 mg/m<sup>2</sup> PO twice per day on days 1 to 14 |
+ | *[[Oxaliplatin (Eloxatin)]] 130 mg/m<sup>2</sup> IV over 2 hours once on day 1 | ||
+ | '''21-day cycle for 8 cycles''' | ||
+ | </div></div><br> | ||
+ | <div class="toccolours" style="background-color:#eeeeee"> | ||
+ | ===Regimen variant #2, 2000/130 {{#subobject:1ef938|Variant=1}}=== | ||
+ | {| class="wikitable sortable" style="width: 100%; text-align:center;" | ||
+ | ! style="width: 20%" |Study | ||
+ | ! style="width: 20%" |Dates of enrollment | ||
+ | ! style="width: 20%" |[[Levels_of_Evidence#Evidence|Evidence]] | ||
+ | ! style="width: 20%" |Comparator | ||
+ | ! style="width: 20%" |[[Levels_of_Evidence#Comparative_efficacy|Comparative Efficacy]] | ||
+ | |- | ||
+ | |[https://doi.org/10.1016/S0140-6736(11)61873-4 Bang et al. 2012 (CLASSIC)] | ||
+ | |2006-2009 | ||
+ | | style="background-color:#1a9851" |Phase 3 (E-esc) | ||
+ | |[[Gastric_cancer_-_null_regimens#Observation|Surgery alone]] | ||
+ | | style="background-color:#1a9850" |Superior DFS36 (primary endpoint)<br>DFS36: 74% vs 59%<br>(HR 0.56, 95% CI 0.44-0.72)<br><br>Superior OS<sup>1</sup> (secondary endpoint)<br>OS60: 78% vs 69%<br>(HR 0.66, 95% CI 0.51-0.85) | ||
+ | |- | ||
+ | |rowspan=2|[https://doi.org/10.1016/s1470-2045(21)00297-7 Zhang et al. 2021 (RESOLVE<sub>gastric</sub>)] | ||
+ | |rowspan=2|2012-2017 | ||
+ | |rowspan=2 style="background-color:#1a9851" |Phase 3 (C) | ||
+ | |1. Perioperative [[#SOX|SOX]] | ||
+ | | style="background-color:#fc8d59" |Seems to have inferior DFS36 | ||
+ | |- | ||
+ | |2. Adjuvant [[#SOX_2|SOX]] | ||
+ | | style="background-color:#eeee01" |Non-inferior DFS36 | ||
|- | |- | ||
− | |[https:// | + | |[https://doi.org/10.1016/s2468-1253(24)00156-0 Kang et al. 2024 (ATTRACTION-5)] |
− | | style="background-color:#1a9851" |Phase | + | |2017-02-01 to 2019-08-15 |
− | | | + | | style="background-color:#1a9851" |Phase 3 (C) |
− | | style="background-color:# | + | |1a. [[#S-1_.26_Nivolumab_999|S-1 & Nivolumab]]<br>1b. [[#CapeOx_.26_Nivolumab_999|CapeOx & Nivolumab]] |
+ | | style="background-color:#ffffbf" |Did not meet primary endpoint of RFS<br>RFS36: 65.3% vs 68.4%<br>(HR 1.11, 95.72% CI 0.85-1.45) | ||
|- | |- | ||
|} | |} | ||
− | '' | + | ''<sup>1</sup>Reported efficacy for CLASSIC is based on the 2014 update.''<br> |
+ | ''Note: RESOLVE should not be confused for the trial by the same name in pancreatic cancer.'' | ||
+ | <div class="toccolours" style="background-color:#fdcdac"> | ||
+ | ====Eligibility criteria==== | ||
+ | *ATTRACTION-5: Stage IIIA to IIIC gastric or GEJ cancer | ||
+ | </div> | ||
+ | <div class="toccolours" style="background-color:#cbd5e8"> | ||
====Preceding treatment==== | ====Preceding treatment==== | ||
*[[Surgery#Gastrectomy|Gastrectomy]] with D2 dissection | *[[Surgery#Gastrectomy|Gastrectomy]] with D2 dissection | ||
+ | </div> | ||
+ | <div class="toccolours" style="background-color:#b3e2cd"> | ||
====Chemotherapy==== | ====Chemotherapy==== | ||
*[[Capecitabine (Xeloda)]] 1000 mg/m<sup>2</sup> PO twice per day on days 1 to 14 | *[[Capecitabine (Xeloda)]] 1000 mg/m<sup>2</sup> PO twice per day on days 1 to 14 | ||
− | *[[Oxaliplatin (Eloxatin)]] 130 mg/m<sup>2</sup> IV once on day 1 | + | *[[Oxaliplatin (Eloxatin)]] 130 mg/m<sup>2</sup> IV over 2 hours once on day 1 |
− | |||
'''21-day cycle for 8 cycles''' | '''21-day cycle for 8 cycles''' | ||
− | + | </div></div> | |
===References=== | ===References=== | ||
− | # '''CLASSIC:''' Bang YJ, Kim YW, Yang HK, Chung HC, Park YK, Lee KH, Lee KW, Kim YH, Noh SI, Cho JY, Mok YJ, Kim YH, Ji J, Yeh TS, Button P, Sirzén F, Noh SH; CLASSIC trial investigators. Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial. Lancet. 2012 Jan 28;379(9813):315-21. Epub 2012 Jan 7. [https:// | + | #'''CLASSIC:''' Bang YJ, Kim YW, Yang HK, Chung HC, Park YK, Lee KH, Lee KW, Kim YH, Noh SI, Cho JY, Mok YJ, Kim YH, Ji J, Yeh TS, Button P, Sirzén F, Noh SH; CLASSIC trial investigators. Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial. Lancet. 2012 Jan 28;379(9813):315-21. Epub 2012 Jan 7. [https://doi.org/10.1016/S0140-6736(11)61873-4 link to original article] '''dosing details in manuscript have been reviewed by our editors''' [https://pubmed.ncbi.nlm.nih.gov/22226517/ PubMed] [https://clinicaltrials.gov/study/NCT00411229 NCT00411229] |
− | ## '''Update:''' Noh SH, Park SR, Yang HK, Chung HC, Chung IJ, Kim SW, Kim HH, Choi JH, Kim HK, Yu W, Lee JI, Shin DB, Ji J, Chen JS, Lim Y, Ha S, Bang YJ; CLASSIC trial investigators. Adjuvant capecitabine plus oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): 5-year follow-up of an open-label, randomised phase 3 trial. Lancet Oncol. 2014 Nov;15(12):1389-96. Epub 2014 Oct 15. [https://www. | + | ##'''Update:''' Noh SH, Park SR, Yang HK, Chung HC, Chung IJ, Kim SW, Kim HH, Choi JH, Kim HK, Yu W, Lee JI, Shin DB, Ji J, Chen JS, Lim Y, Ha S, Bang YJ; CLASSIC trial investigators. Adjuvant capecitabine plus oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): 5-year follow-up of an open-label, randomised phase 3 trial. Lancet Oncol. 2014 Nov;15(12):1389-96. Epub 2014 Oct 15. [https://doi.org/10.1016/S1470-2045(14)70473-5 link to original article] [https://pubmed.ncbi.nlm.nih.gov/25439693/ PubMed] |
+ | #'''RESOLVE<sub>gastric</sub>:''' Zhang X, Liang H, Li Z, Xue Y, Wang Y, Zhou Z, Yu J, Bu Z, Chen L, Du Y, Wang X, Wu A, Li G, Su X, Xiao G, Cui M, Wu D, Chen L, Wu X, Zhou Y, Zhang L, Dang C, He Y, Zhang Z, Sun Y, Li Y, Chen H, Bai Y, Qi C, Yu P, Zhu G, Suo J, Jia B, Li L, Huang C, Li F, Ye Y, Xu H, Wang X, Yuan Y, E JY, Ying X, Yao C, Shen L, Ji J; RESOLVE study group. Perioperative or postoperative adjuvant oxaliplatin with S-1 versus adjuvant oxaliplatin with capecitabine in patients with locally advanced gastric or gastro-oesophageal junction adenocarcinoma undergoing D2 gastrectomy (RESOLVE): an open-label, superiority and non-inferiority, phase 3 randomised controlled trial. Lancet Oncol. 2021 Aug;22(8):1081-1092. Epub 2021 Jul 9. Erratum in: Lancet Oncol. 2021 Aug;22(8):e347. [https://doi.org/10.1016/s1470-2045(21)00297-7 link to original article] '''dosing details in manuscript have been reviewed by our editors''' [https://pubmed.ncbi.nlm.nih.gov/34252374/ PubMed] [https://clinicaltrials.gov/study/NCT01534546 NCT01534546] | ||
+ | #'''Alien Craft 0004:''' Tian Y, Zhao Q, Li Y, Fan L, Zhang Z, Zhao X, Tan B, Wang D, Yang P. Efficacy of Neoadjuvant Chemotherapy DOX and XELOX Regimens for Patients with Resectable Gastric or Gastroesophageal Junction Adenocarcinoma. Gastroenterol Res Pract. 2021 Jul 22;2021:5590626. [https://doi.org/10.1155/2021/5590626 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/pmc8324337/ link to PMC article] '''dosing details in manuscript have been reviewed by our editors''' [https://pubmed.ncbi.nlm.nih.gov/34335737/ PubMed] [https://clinicaltrials.gov/study/NCT02555358 NCT02555358] | ||
+ | ##'''Update:''' Tian Y, Yang P, Guo H, Liu Y, Zhang Z, Ding P, Zheng T, Deng H, Ma W, Li Y, Fan L, Zhang Z, Wang D, Zhao X, Tan B, Liu Y, Zhao Q. Neoadjuvant docetaxel, oxaliplatin plus capecitabine versus oxaliplatin plus capecitabine for patients with locally advanced gastric adenocarcinoma: long-term results of a phase III randomized controlled trial. Int J Surg. 2023 Dec 1;109(12):4000-4008. [https://doi.org/10.1097/js9.0000000000000692 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/pmc10720837/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/37678277/ PubMed] | ||
+ | #'''ATTRACTION-5:''' Kang YK, Terashima M, Kim YW, Boku N, Chung HC, Chen JS, Ji J, Yeh TS, Chen LT, Ryu MH, Kim JG, Omori T, Rha SY, Kim TY, Ryu KW, Sakuramoto S, Nishida Y, Fukushima N, Yamada T, Bai LY, Hirashima Y, Hagihara S, Nakada T, Sasako M. Adjuvant nivolumab plus chemotherapy versus placebo plus chemotherapy for stage III gastric or gastro-oesophageal junction cancer after gastrectomy with D2 or more extensive lymph-node dissection (ATTRACTION-5): a randomised, multicentre, double-blind, placebo-controlled, phase 3 trial. Lancet Gastroenterol Hepatol. 2024 Aug;9(8):705-717. Epub 2024 Jun 18. [https://doi.org/10.1016/s2468-1253(24)00156-0 link to original article] '''dosing details in manuscript have been reviewed by our editors''' [https://pubmed.ncbi.nlm.nih.gov/38906161/ PubMed] [https://clinicaltrials.gov/study/NCT03006705 NCT03006705] | ||
− | == | + | ==Carboplatin & Docetaxel {{#subobject:7263b8|Regimen=1}}== |
− | + | <div class="toccolours" style="background-color:#eeeeee"> | |
− | + | ===Regimen {{#subobject:cd8hbq|Variant=1}}=== | |
− | + | {| class="wikitable sortable" style="width: 100%; text-align:center;" | |
− | + | ! style="width: 20%" |Study | |
− | ===Regimen {{#subobject: | + | ! style="width: 20%" |Dates of enrollment |
− | {| class="wikitable" style="width: 100%; text-align:center;" | + | ! style="width: 20%" |[[Levels_of_Evidence#Evidence|Evidence]] |
− | ! style="width: | + | ! style="width: 20%" |Comparator |
− | ! style="width: | + | ! style="width: 20%" |[[Levels_of_Evidence#Comparative_efficacy|Comparative Efficacy]] |
− | ! style="width: | ||
− | ! style="width: | ||
|- | |- | ||
− | |[ | + | |[https://doi.org/10.1007/s00280-010-1256-6 Bamias et al. 2010] |
− | | style="background-color:#1a9851" |Phase | + | |2002-2005 |
− | | | + | | style="background-color:#1a9851" |Phase 3 (C) |
− | | style="background-color:# | + | |[[#Carboplatin_.26_Docetaxel_.28DCb.29_.26_RT_999|DCb & RT]] |
+ | | style="background-color:#ffffbf" |Did not meet primary endpoint of OS | ||
|- | |- | ||
|} | |} | ||
− | '' | + | ''Note: the original protocol was for cisplatin & docetaxel but was changed due to excess CINV. To our knowledge, this regimen was not tested as an experimental arm in an RCT prior to becoming a standard comparator arm.'' |
− | + | <div class="toccolours" style="background-color:#cbd5e8"> | |
− | |||
====Preceding treatment==== | ====Preceding treatment==== | ||
− | * | + | *[[Surgery#Gastrectomy|Surgery]] |
+ | </div> | ||
+ | <div class="toccolours" style="background-color:#b3e2cd"> | ||
====Chemotherapy==== | ====Chemotherapy==== | ||
− | *[[ | + | *[[Carboplatin (Paraplatin)]] AUC 5 IV once on day 1 |
− | *[[ | + | *[[Docetaxel (Taxotere)]] 75 mg/m<sup>2</sup> IV once on day 1 |
− | + | '''21-day cycle for 6 cycles''' | |
− | ''' | + | </div></div> |
− | |||
===References=== | ===References=== | ||
− | # | + | #Bamias A, Karina M, Papakostas P, Kostopoulos I, Bobos M, Vourli G, Samantas E, Christodoulou Ch, Pentheroudakis G, Pectasides D, Dimopoulos MA, Fountzilas G. A randomized phase III study of adjuvant platinum/docetaxel chemotherapy with or without radiation therapy in patients with gastric cancer. Cancer Chemother Pharmacol. 2010 May;65(6):1009-21. Epub 2010 Feb 4. [https://doi.org/10.1007/s00280-010-1256-6 link to original article] '''dosing details in abstract have been reviewed by our editors''' [https://pubmed.ncbi.nlm.nih.gov/20130877/ PubMed] |
− | + | ==Capecitabine & Cisplatin (CX) {{#subobject:4896bc|Regimen=1}}== | |
− | ==CX {{#subobject:4896bc|Regimen=1}}== | ||
− | |||
− | |||
− | |||
− | |||
CX: '''<u>C</u>'''isplatin, '''<u>X</u>'''eloda (Capecitabine) | CX: '''<u>C</u>'''isplatin, '''<u>X</u>'''eloda (Capecitabine) | ||
<br>XP: '''<u>X</u>'''eloda (Capecitabine), '''<u>P</u>'''latinol (Cisplatin) | <br>XP: '''<u>X</u>'''eloda (Capecitabine), '''<u>P</u>'''latinol (Cisplatin) | ||
+ | <div class="toccolours" style="background-color:#eeeeee"> | ||
===Regimen {{#subobject:877085|Variant=1}}=== | ===Regimen {{#subobject:877085|Variant=1}}=== | ||
− | {| class="wikitable" style="width: 100%; text-align:center;" | + | {| class="wikitable sortable" style="width: 100%; text-align:center;" |
− | ! style="width: | + | ! style="width: 20%" |Study |
− | ! style="width: | + | ! style="width: 20%" |Dates of enrollment |
− | ! style="width: | + | ! style="width: 20%" |[[Levels_of_Evidence#Evidence|Evidence]] |
− | ! style="width: | + | ! style="width: 20%" |Comparator |
+ | ! style="width: 20%" |[[Levels_of_Evidence#Comparative_efficacy|Comparative Efficacy]] | ||
|- | |- | ||
− | |[ | + | |[https://doi.org/10.1200/jco.2011.39.1953 Lee et al. 2011 (ARTIST<sub>gastric</sub>)] |
− | | style="background-color:#1a9851" |Phase | + | |2004-2008 |
− | |XP | + | | style="background-color:#1a9851" |Phase 3 (C) |
+ | |[[#Capecitabine_.26_Cisplatin_.28CX.29.2FCapecitabine_.26_RT_333|XP/Capecitabine & RT]] | ||
| style="background-color:#fee08b" |Might have inferior DFS | | style="background-color:#fee08b" |Might have inferior DFS | ||
|- | |- | ||
|} | |} | ||
− | ''Note: to our knowledge, this regimen was not tested as an experimental arm in an RCT prior to becoming a standard comparator arm. This trial should not be confused for the one by the same name in colorectal cancer.'' | + | ''Note: to our knowledge, this regimen was not tested as an experimental arm in an RCT in this context, prior to becoming a standard comparator arm. This trial should not be confused for the one by the same name in colorectal cancer.'' |
+ | <div class="toccolours" style="background-color:#cbd5e8"> | ||
====Preceding treatment==== | ====Preceding treatment==== | ||
*R0 [[Surgery#Gastrectomy|gastrectomy]] and at least D2 dissection | *R0 [[Surgery#Gastrectomy|gastrectomy]] and at least D2 dissection | ||
− | + | </div> | |
+ | <div class="toccolours" style="background-color:#b3e2cd"> | ||
====Chemotherapy==== | ====Chemotherapy==== | ||
*[[Cisplatin (Platinol)]] 60 mg/m<sup>2</sup> IV once on day 1 | *[[Cisplatin (Platinol)]] 60 mg/m<sup>2</sup> IV once on day 1 | ||
*[[Capecitabine (Xeloda)]] 1000 mg/m<sup>2</sup> PO twice per day on days 1 to 14 | *[[Capecitabine (Xeloda)]] 1000 mg/m<sup>2</sup> PO twice per day on days 1 to 14 | ||
− | |||
'''21-day cycle for 6 cycles''' | '''21-day cycle for 6 cycles''' | ||
− | + | </div></div> | |
===References=== | ===References=== | ||
− | # '''ARTIST:''' Lee J, Lim DH, Kim S, Park SH, Park JO, Park YS, Lim HY, Choi MG, Sohn TS, Noh JH, Bae JM, Ahn YC, Sohn I, Jung SH, Park CK, Kim KM, Kang WK. Phase III trial comparing capecitabine plus cisplatin versus capecitabine plus cisplatin with concurrent capecitabine radiotherapy in completely resected gastric cancer with D2 lymph node dissection: the ARTIST trial. J Clin Oncol. 2012 Jan 20;30(3):268-73. Epub 2011 Dec 19. [ | + | #'''ARTIST:''' Lee J, Lim DH, Kim S, Park SH, Park JO, Park YS, Lim HY, Choi MG, Sohn TS, Noh JH, Bae JM, Ahn YC, Sohn I, Jung SH, Park CK, Kim KM, Kang WK. Phase III trial comparing capecitabine plus cisplatin versus capecitabine plus cisplatin with concurrent capecitabine radiotherapy in completely resected gastric cancer with D2 lymph node dissection: the ARTIST trial. J Clin Oncol. 2012 Jan 20;30(3):268-73. Epub 2011 Dec 19. [https://doi.org/10.1200/jco.2011.39.1953 link to original article] '''dosing details in manuscript have been reviewed by our editors''' [https://pubmed.ncbi.nlm.nih.gov/22184384/ PubMed] [https://clinicaltrials.gov/study/NCT00323830 NCT00323830] |
− | ## '''Update:''' Park SH, Sohn TS, Lee J, Lim DH, Hong ME, Kim KM, Sohn I, Jung SH, Choi MG, Lee JH, Bae JM, Kim S, Kim ST, Park JO, Park YS, Lim HY, Kang WK. Phase III trial to compare adjuvant chemotherapy with capecitabine and cisplatin versus concurrent chemoradiotherapy in gastric cancer: Final report of the adjuvant chemoradiotherapy in stomach tumors trial, including survival and subset analyses. J Clin Oncol. 2015 Oct 1;33(28):3130-6. Epub 2015 Jan 5. [ | + | ##'''Update:''' Park SH, Sohn TS, Lee J, Lim DH, Hong ME, Kim KM, Sohn I, Jung SH, Choi MG, Lee JH, Bae JM, Kim S, Kim ST, Park JO, Park YS, Lim HY, Kang WK. Phase III trial to compare adjuvant chemotherapy with capecitabine and cisplatin versus concurrent chemoradiotherapy in gastric cancer: Final report of the adjuvant chemoradiotherapy in stomach tumors trial, including survival and subset analyses. J Clin Oncol. 2015 Oct 1;33(28):3130-6. Epub 2015 Jan 5. [https://doi.org/10.1200/jco.2014.58.3930 link to original article] [https://pubmed.ncbi.nlm.nih.gov/25559811/ PubMed] |
− | + | ==Cisplatin & S-1 {{#subobject:s3bc2a|Regimen=1}}== | |
− | == | + | SP: '''<u>S</u>'''-1 & '''<u>P</u>'''latinol (Cisplatin) |
− | {| class="wikitable" style=" | + | <div class="toccolours" style="background-color:#eeeeee"> |
+ | ===Regimen {{#subobject:bc3203|Variant=1}}=== | ||
+ | {| class="wikitable sortable" style="width: 100%; text-align:center;" | ||
+ | ! style="width: 20%" |Study | ||
+ | ! style="width: 20%" |Dates of enrollment | ||
+ | ! style="width: 20%" |[[Levels_of_Evidence#Evidence|Evidence]] | ||
+ | ! style="width: 20%" |Comparator | ||
+ | ! style="width: 20%" |[[Levels_of_Evidence#Comparative_efficacy|Comparative Efficacy]] | ||
|- | |- | ||
− | |[[# | + | |[https://www.ncbi.nlm.nih.gov/pmc/articles/pmc6333977/ Lee et al. 2018 (POST)] |
+ | |2010-2013 | ||
+ | | style="background-color:#1a9851" |Phase 3 (C) | ||
+ | |[[#Docetaxel_.26_S-1|DS]] | ||
+ | | style="background-color:#ffffbf" |Did not meet primary endpoint of DFS36 | ||
|} | |} | ||
− | + | <div class="toccolours" style="background-color:#cbd5e8"> | |
− | ===Regimen {{#subobject: | + | ====Preceding treatment==== |
− | {| class="wikitable" style="width: 100%; text-align:center;" | + | *[[Surgery#Gastrectomy|Surgery]] |
− | ! style="width: | + | </div> |
− | ! style="width: | + | <div class="toccolours" style="background-color:#b3e2cd"> |
− | ! style="width: | + | ====Chemotherapy==== |
− | ! style="width: | + | *[[Cisplatin (Platinol)]] 60 mg/m<sup>2</sup> IV once on day 1 |
+ | *[[Tegafur, gimeracil, oteracil (S-1)|S-1]] 35 mg/m<sup>2</sup> PO twice per day on days 1 to 14 | ||
+ | '''21-day cycle for 8 cycles''' | ||
+ | </div></div> | ||
+ | ===References=== | ||
+ | #'''POST:''' Lee CK, Jung M, Kim HS, Jung I, Shin DB, Kang SY, Zang DY, Kim KH, Lee MH, Kim BS, Lee KH, Cheong JH, Hyung WJ, Noh SH, Chung HC, Rha SY. S-1 Based Doublet as an Adjuvant Chemotherapy for Curatively Resected Stage III Gastric Cancer: Results from the Randomized Phase III POST Trial. Cancer Res Treat. 2019 Jan;51(1):1-11. Epub 2018 Feb 5. [https://doi.org/10.4143/crt.2018.028 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/pmc6333977/ link to PMC article] '''dosing details in manuscript have been reviewed by our editors''' [https://pubmed.ncbi.nlm.nih.gov/29397659/ PubMed] [https://clinicaltrials.gov/study/NCT01283217 NCT01283217] | ||
+ | ==Docetaxel & S-1 {{#subobject:a22c2a|Regimen=1}}== | ||
+ | DS: '''<u>D</u>'''ocetaxel & '''<u>S</u>'''-1 | ||
+ | <div class="toccolours" style="background-color:#eeeeee"> | ||
+ | ===Regimen variant #1 {{#subobject:82ca03|Variant=1}}=== | ||
+ | {| class="wikitable sortable" style="width: 100%; text-align:center;" | ||
+ | ! style="width: 20%" |Study | ||
+ | ! style="width: 20%" |Dates of enrollment | ||
+ | ! style="width: 20%" |[[Levels_of_Evidence#Evidence|Evidence]] | ||
+ | ! style="width: 20%" |Comparator | ||
+ | ! style="width: 20%" |[[Levels_of_Evidence#Comparative_efficacy|Comparative Efficacy]] | ||
|- | |- | ||
− | |[https://www. | + | |[https://www.ncbi.nlm.nih.gov/pmc/articles/pmc6333977/ Lee et al. 2018 (POST)] |
− | | style="background-color:#1a9851" |Phase | + | |2010-2013 |
− | |[[# | + | | style="background-color:#1a9851" |Phase 3 (E-switch-ic) |
− | | style="background-color:# | + | |[[#Cisplatin_.26_S-1|SP]] |
+ | | style="background-color:#ffffbf" |Did not meet primary endpoint of DFS36 | ||
+ | |} | ||
+ | <div class="toccolours" style="background-color:#cbd5e8"> | ||
+ | ====Preceding treatment==== | ||
+ | *[[Surgery#Gastrectomy|Surgery]] | ||
+ | </div> | ||
+ | <div class="toccolours" style="background-color:#b3e2cd"> | ||
+ | ====Chemotherapy==== | ||
+ | *[[Docetaxel (Taxotere)]] 35 mg/m<sup>2</sup> IV once per day on days 1 & 8 | ||
+ | *[[Tegafur, gimeracil, oteracil (S-1)|S-1]] 35 mg/m<sup>2</sup> PO twice per day on days 1 to 14 | ||
+ | '''21-day cycle for 8 cycles''' | ||
+ | </div></div><br> | ||
+ | <div class="toccolours" style="background-color:#eeeeee"> | ||
+ | ===Regimen variant #2, 40/80 {{#subobject:82ca03|Variant=1}}=== | ||
+ | {| class="wikitable sortable" style="width: 100%; text-align:center;" | ||
+ | ! style="width: 20%" |Study | ||
+ | ! style="width: 20%" |Dates of enrollment | ||
+ | ! style="width: 20%" |[[Levels_of_Evidence#Evidence|Evidence]] | ||
+ | ! style="width: 20%" |Comparator | ||
+ | ! style="width: 20%" |[[Levels_of_Evidence#Comparative_efficacy|Comparative Efficacy]] | ||
|- | |- | ||
− | |[https://www. | + | |[https://www.ncbi.nlm.nih.gov/pmc/articles/pmc6524985/ Yoshida et al. 2019 (JACCRO GC-07)] |
− | | style="background-color:#1a9851" |Phase | + | |2013-2017 |
− | | | + | | style="background-color:#1a9851" |Phase 3 (E-esc) |
− | | style="background-color:# | + | |[[#S-1 monotherapy_2|S-1]] |
+ | | style="background-color:#1a9850" |Superior RFS36 (primary endpoint)<br>RFS36: 66% vs 50%<br>(HR 0.632, 99.99% CI 0.40-0.998)<br><br>Superior OS<sup>1</sup> (secondary endpoint)<br>OS36: 77.7% vs 71.2%<br>(HR 0.74, 95% CI 0.60-0.925) | ||
|- | |- | ||
|} | |} | ||
− | '' | + | ''<sup>1</sup>Reported efficacy is based on the 2021 update.''<br> |
− | + | ''Note: this dosing was for BSA less than 1.25 mg/m<sup>2</sup>.'' | |
− | '' | + | <div class="toccolours" style="background-color:#cbd5e8"> |
− | |||
====Preceding treatment==== | ====Preceding treatment==== | ||
− | * | + | *[[Surgery#Gastrectomy|Surgery]] |
+ | </div> | ||
+ | <div class="toccolours" style="background-color:#b3e2cd"> | ||
====Chemotherapy==== | ====Chemotherapy==== | ||
− | *[[ | + | *[[Docetaxel (Taxotere)]] as follows: |
− | * | + | **Cycles 2 to 7: 40 mg/m<sup>2</sup> IV once on day 1 |
− | *[[ | + | *[[Tegafur, gimeracil, oteracil (S-1)|S-1]] as follows: |
− | + | **Cycles 1 to 7: 40 mg/m<sup>2</sup> PO twice per day on days 1 to 14 | |
− | + | **Cycles 8 to 12: 40 mg/m<sup>2</sup> PO twice per day on days 1 to 28 | |
− | + | '''21-day cycle for 7 cycles, then 42-day cycle for up to 5 cycles (1 year total)''' | |
− | + | </div></div><br> | |
− | + | <div class="toccolours" style="background-color:#eeeeee"> | |
− | '''21-day cycle for | + | ===Regimen variant #3, 40/100 {{#subobject:821003|Variant=1}}=== |
− | + | {| class="wikitable sortable" style="width: 100%; text-align:center;" | |
− | === | + | ! style="width: 20%" |Study |
− | + | ! style="width: 20%" |Dates of enrollment | |
− | # | + | ! style="width: 20%" |[[Levels_of_Evidence#Evidence|Evidence]] |
− | + | ! style="width: 20%" |Comparator | |
− | + | ! style="width: 20%" |[[Levels_of_Evidence#Comparative_efficacy|Comparative Efficacy]] | |
− | + | |- | |
+ | |[https://www.ncbi.nlm.nih.gov/pmc/articles/pmc6524985/ Yoshida et al. 2019 (JACCRO GC-07)] | ||
+ | |2013-2017 | ||
+ | | style="background-color:#1a9851" |Phase 3 (E-esc) | ||
+ | |[[#S-1 monotherapy_2|S-1]] | ||
+ | | style="background-color:#1a9850" |Superior RFS36 (primary endpoint)<br>RFS36: 66% vs 50%<br>(HR 0.632, 99.99% CI 0.40-0.998)<br><br>Superior OS<sup>1</sup> (secondary endpoint)<br>OS36: 77.7% vs 71.2%<br>(HR 0.74, 95% CI 0.60-0.925) | ||
|- | |- | ||
− | |||
|} | |} | ||
− | + | ''<sup>1</sup>Reported efficacy is based on the 2021 update.''<br> | |
− | ===Regimen {{#subobject: | + | ''Note: this dosing was for BSA between 1.25 to 1.5 mg/m<sup>2</sup>.'' |
− | {| class="wikitable" style="width: 100%; text-align:center;" | + | <div class="toccolours" style="background-color:#cbd5e8"> |
− | ! style="width: | + | ====Preceding treatment==== |
− | ! style="width: | + | *[[Surgery#Gastrectomy|Surgery]] |
− | ! style="width: | + | </div> |
− | ! style="width: | + | <div class="toccolours" style="background-color:#b3e2cd"> |
+ | ====Chemotherapy==== | ||
+ | *[[Docetaxel (Taxotere)]] as follows: | ||
+ | **Cycles 2 to 7: 40 mg/m<sup>2</sup> IV once on day 1 | ||
+ | *[[Tegafur, gimeracil, oteracil (S-1)|S-1]] as follows: | ||
+ | **Cycles 1 to 7: 50 mg/m<sup>2</sup> PO twice per day on days 1 to 14 | ||
+ | **Cycles 8 to 12: 50 mg/m<sup>2</sup> PO twice per day on days 1 to 28 | ||
+ | '''21-day cycle for 7 cycles, then 42-day cycle for up to 5 cycles (1 year total)''' | ||
+ | </div></div><br> | ||
+ | <div class="toccolours" style="background-color:#eeeeee"> | ||
+ | ===Regimen variant #4, 40/120 {{#subobject:82ca2b|Variant=1}}=== | ||
+ | {| class="wikitable sortable" style="width: 100%; text-align:center;" | ||
+ | ! style="width: 20%" |Study | ||
+ | ! style="width: 20%" |Dates of enrollment | ||
+ | ! style="width: 20%" |[[Levels_of_Evidence#Evidence|Evidence]] | ||
+ | ! style="width: 20%" |Comparator | ||
+ | ! style="width: 20%" |[[Levels_of_Evidence#Comparative_efficacy|Comparative Efficacy]] | ||
|- | |- | ||
− | |[https://www. | + | |[https://www.ncbi.nlm.nih.gov/pmc/articles/pmc6524985/ Yoshida et al. 2019 (JACCRO GC-07)] |
− | | style="background-color:#1a9851" |Phase | + | |2013-2017 |
− | | | + | | style="background-color:#1a9851" |Phase 3 (E-esc) |
− | | style="background-color:# | + | |[[#S-1 monotherapy_2|S-1]] |
+ | | style="background-color:#1a9850" |Superior RFS36 (primary endpoint)<br>RFS36: 66% vs 50%<br>(HR 0.632, 99.99% CI 0.40-0.998)<br><br>Superior OS<sup>1</sup> (secondary endpoint)<br>OS36: 77.7% vs 71.2%<br>(HR 0.74, 95% CI 0.60-0.925) | ||
|- | |- | ||
|} | |} | ||
+ | ''<sup>1</sup>Reported efficacy is based on the 2021 update.''<br> | ||
+ | ''Note: this dosing was for BSA greater than 1.5 mg/m<sup>2</sup>.'' | ||
+ | <div class="toccolours" style="background-color:#cbd5e8"> | ||
====Preceding treatment==== | ====Preceding treatment==== | ||
− | * | + | *[[Surgery#Gastrectomy|Surgery]] |
+ | </div> | ||
+ | <div class="toccolours" style="background-color:#b3e2cd"> | ||
====Chemotherapy==== | ====Chemotherapy==== | ||
− | *[[ | + | *[[Docetaxel (Taxotere)]] as follows: |
− | *[[ | + | **Cycles 2 to 7: 40 mg/m<sup>2</sup> IV once on day 1 |
− | * | + | *[[Tegafur, gimeracil, oteracil (S-1)|S-1]] as follows: |
− | + | **Cycles 1 to 7: 60 mg/m<sup>2</sup> PO twice per day on days 1 to 14 | |
− | '''21-day cycle for | + | **Cycles 8 to 12: 60 mg/m<sup>2</sup> PO twice per day on days 1 to 28 |
− | + | '''21-day cycle for 7 cycles, then 42-day cycle for up to 5 cycles (1 year total)''' | |
+ | </div></div> | ||
===References=== | ===References=== | ||
− | # ''' | + | #'''POST:''' Lee CK, Jung M, Kim HS, Jung I, Shin DB, Kang SY, Zang DY, Kim KH, Lee MH, Kim BS, Lee KH, Cheong JH, Hyung WJ, Noh SH, Chung HC, Rha SY. S-1 Based Doublet as an Adjuvant Chemotherapy for Curatively Resected Stage III Gastric Cancer: Results from the Randomized Phase III POST Trial. Cancer Res Treat. 2019 Jan;51(1):1-11. Epub 2018 Feb 5. [https://doi.org/10.4143/crt.2018.028 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/pmc6333977/ link to PMC article] '''dosing details in manuscript have been reviewed by our editors''' [https://pubmed.ncbi.nlm.nih.gov/29397659/ PubMed] [https://clinicaltrials.gov/study/NCT01283217 NCT01283217] |
+ | <!-- #'''Abstract:''' Kodera Y, Yoshida K, Kochi M, Ichikawa W, Kakeji Y, Sano T, Nagao N, Takahashi M, Takagane A, Nakamura M, Kaji M, Okitsu H, Nomura T, Matsui T, Yoshikawa T, Matssuyama J, Yamada M, Ito Y, Takeuchi M, Fujii M; JACCRO. A randomized phase III study comparing S-1 plus docetaxel with S-1 alone as a postoperative adjuvant chemotherapy for curatively resected stage III gastric cancer (JACCRO GC-07 trial). 2019 American Society of Clinical Oncology annual meeting. DOI: 10.1200/JCO.2018.36.15_suppl.4007 36, no. 15_suppl (May 20, 2018) 4007-4007. [https://doi.org/10.1200/JCO.2018.36.15_suppl.4007 link to abstract] --> | ||
+ | #'''JACCRO GC-07:''' Yoshida K, Kodera Y, Kochi M, Ichikawa W, Kakeji Y, Sano T, Nagao N, Takahashi M, Takagane A, Watanabe T, Kaji M, Okitsu H, Nomura T, Matsui T, Yoshikawa T, Matsuyama J, Yamada M, Ito S, Takeuchi M, Fujii M. Addition of Docetaxel to Oral Fluoropyrimidine Improves Efficacy in Patients With Stage III Gastric Cancer: Interim Analysis of JACCRO GC-07, a Randomized Controlled Trial. J Clin Oncol. 2019 May 20;37(15):1296-1304. Epub 2019 Mar 29. [https://doi.org/10.1200/jco.18.01138 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/pmc6524985/ link to PMC article] '''dosing details in manuscript have been reviewed by our editors''' [https://pubmed.ncbi.nlm.nih.gov/30925125/ PubMed] UMIN000010337 | ||
+ | ##'''Update:''' Kakeji Y, Yoshida K, Kodera Y, Kochi M, Sano T, Ichikawa W, Lee SW, Shibahara K, Shikano T, Kataoka M, Ishiguro A, Ojima H, Sakai Y, Musha N, Takase T, Kimura T, Takeuchi M, Fujii M. Three-year outcomes of a randomized phase III trial comparing adjuvant chemotherapy with S-1 plus docetaxel versus S-1 alone in stage III gastric cancer: JACCRO GC-07. Gastric Cancer. 2022 Jan;25(1):188-196. Epub 2021 Aug 5. [https://doi.org/10.1007/s10120-021-01224-2 link to original article] [https://pubmed.ncbi.nlm.nih.gov/34351555/ PubMed] | ||
− | == | + | ==FP/Capecitabine & RT {{#subobject:778727|Regimen=1}}== |
− | {| class="wikitable" style=" | + | FP/Capecitabine & RT: '''<u>F</u>'''luorouracil & '''<u>P</u>'''latinol (Cisplatin) alternating with Capecitabine & '''<u>R</u>'''adiation '''<u>T</u>'''herapy |
+ | <div class="toccolours" style="background-color:#eeeeee"> | ||
+ | ===Regimen {{#subobject:20ea7f|Variant=1}}=== | ||
+ | {| class="wikitable sortable" style="width: 60%; text-align:center;" | ||
+ | !style="width: 33%"|Study | ||
+ | !style="width: 33%"|Dates of enrollment | ||
+ | !style="width: 33%"|[[Levels_of_Evidence#Evidence|Evidence]] | ||
+ | |- | ||
+ | |[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4066094/ Lee et al. 2006] | ||
+ | |Not reported | ||
+ | | style="background-color:#91cf61" |Phase 2 | ||
|- | |- | ||
− | |||
|} | |} | ||
− | + | ''Note: In contrast to the primary reference, some guidelines list this regimen without FP cycles 1, 3, 4, 5. Dosage of [[Capecitabine (Xeloda)]] was listed as 625 to 825 mg/m<sup>2</sup> PO twice per day on days 1 to 5 or 1 to 7 while radiation is being given.'' | |
− | ===Regimen {{#subobject: | + | <div class="toccolours" style="background-color:#cbd5e8"> |
− | {| class="wikitable" style="width: 100%; text-align:center;" | + | ====Preceding treatment==== |
− | ! style="width: | + | *[[Surgery#Gastrectomy|Surgery]], 3 weeks prior |
− | ! style="width: | + | </div> |
− | ! style="width: | + | <div class="toccolours" style="background-color:#b3e2cd"> |
− | ! style="width: | + | ====Chemotherapy==== |
+ | *[[Cisplatin (Platinol)]] as follows: | ||
+ | **Cycles 1, 3, 4, 5: 60 mg/m<sup>2</sup> IV once on day 1 | ||
+ | *[[Fluorouracil (5-FU)]] as follows: | ||
+ | **Cycles 1, 3, 4, 5: 1000 mg/m<sup>2</sup>/day IV continuous infusion over 120 hours, started on day 1 (total dose per cycle: 5000 mg/m<sup>2</sup>) | ||
+ | *[[Capecitabine (Xeloda)]] as follows: | ||
+ | **Cycle 2 (chemoradiation): 825 mg/m<sup>2</sup> PO twice per day on days 1 to 35 | ||
+ | ====Radiotherapy==== | ||
+ | *Concurrent [[External_beam_radiotherapy|radiation therapy]] during cycle 2: 180 cGy fractions x 25 fractions (total dose of 4500 cGy) | ||
+ | '''21-day course, then 9-week course, then 21-day cycle for 3 cycles''' | ||
+ | </div></div> | ||
+ | ===References=== | ||
+ | #Lee HS, Choi Y, Hur WJ, Kim HJ, Kwon HC, Kim SH, Kim JS, Lee JH, Jung GJ, Kim MC. Pilot study of postoperative adjuvant chemoradiation for advanced gastric cancer: adjuvant 5-FU/cisplatin and chemoradiation with capecitabine. World J Gastroenterol. 2006 Jan 28;12(4):603-7. [https://doi.org/10.3748/wjg.v12.i4.603 link to original article] '''dosing details in manuscript have been reviewed by our editors''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4066094/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/16489675/ PubMed] | ||
+ | ==FULV {{#subobject:5bbh1e|Regimen=1}}== | ||
+ | FULV: 5-'''<u>FU</u>''' & '''<u>L</u>'''euco'''<u>V</u>'''orin | ||
+ | <div class="toccolours" style="background-color:#eeeeee"> | ||
+ | ===Regimen {{#subobject:1tzi01|Variant=1}}=== | ||
+ | {| class="wikitable sortable" style="width: 100%; text-align:center;" | ||
+ | ! style="width: 20%" |Study | ||
+ | ! style="width: 20%" |Dates of enrollment | ||
+ | ! style="width: 20%" |[[Levels_of_Evidence#Evidence|Evidence]] | ||
+ | ! style="width: 20%" |Comparator | ||
+ | ! style="width: 20%" |[[Levels_of_Evidence#Comparative_efficacy|Comparative Efficacy]] | ||
|- | |- | ||
− | |[https:// | + | |[https://doi.org/10.1093/annonc/mdu146 Bajetta et al. 2014 (ITACA-S)] |
− | | style="background-color:#1a9851" |Phase | + | |2005-2009 |
− | | | + | | style="background-color:#1a9851" |Phase 3 (C) |
− | | style="background-color:#ffffbf" | | + | |[[#FOLFIRI_999|FOLFIRI]], then [[#Cisplatin_.26_Docetaxel_.28DC.29_999|Cisplatin & Docetaxel]] |
+ | | style="background-color:#ffffbf" |Did not meet primary endpoint of DFS | ||
|- | |- | ||
|} | |} | ||
− | + | <div class="toccolours" style="background-color:#cbd5e8"> | |
====Preceding treatment==== | ====Preceding treatment==== | ||
− | * | + | *[[Surgery#Gastrectomy|Surgery]] |
+ | </div> | ||
+ | <div class="toccolours" style="background-color:#b3e2cd"> | ||
====Chemotherapy==== | ====Chemotherapy==== | ||
− | *[[ | + | *[[Fluorouracil (5-FU)]] 400 mg/m<sup>2</sup> IV bolus once per day on days 1 & 2, then 600 mg/m<sup>2</sup> IV continuous infusion over 22 hours after each bolus (total dose per cycle: 2000 mg/m<sup>2</sup>) |
− | + | *[[Leucovorin (Folinic acid)]] 100 mg/m<sup>2</sup> IV over 2 hours once per day on days 1 & 2 | |
− | *[[ | + | '''14-day cycle for 9 cycles''' |
− | + | </div></div> | |
− | ''' | ||
− | |||
===References=== | ===References=== | ||
− | # ''' | + | #'''ITACA-S:''' Bajetta E, Floriani I, Di Bartolomeo M, Labianca R, Falcone A, Di Costanzo F, Comella G, Amadori D, Pinto C, Carlomagno C, Nitti D, Daniele B, Mini E, Poli D, Santoro A, Mosconi S, Casaretti R, Boni C, Pinotti G, Bidoli P, Landi L, Rosati G, Ravaioli A, Cantore M, Di Fabio F, Aitini E, Marchet A; ITACA-S (Intergroup Trial of Adjuvant Chemotherapy in Adenocarcinoma of the Stomach Trial) Study Group. Randomized trial on adjuvant treatment with FOLFIRI followed by docetaxel and cisplatin versus 5-fluorouracil and folinic acid for radically resected gastric cancer. Ann Oncol. 2014 Jul;25(7):1373-1378. Epub 2014 Apr 12. [https://doi.org/10.1093/annonc/mdu146 link to original article] '''dosing details in manuscript have been reviewed by our editors''' [https://pubmed.ncbi.nlm.nih.gov/24728035/ PubMed] [https://clinicaltrials.gov/study/NCT01640782 NCT01640782] |
− | + | ==FULV/FULV & RT {{#subobject:2cd29|Regimen=1}}== | |
− | == | + | FULV/FULV & RT: '''<u>F</u>'''luoro'''<u>U</u>'''racil & '''<u>L</u>'''euco'''<u>V</u>'''orin alternating with '''<u>F</u>'''luoro'''<u>U</u>'''racil, '''<u>L</u>'''euco'''<u>V</u>'''orin, '''<u>R</u>'''adiation '''<u>T</u>'''herapy |
− | {| class="wikitable" style=" | + | <div class="toccolours" style="background-color:#eeeeee"> |
+ | ===Regimen {{#subobject:dfd3ec|Variant=1}}=== | ||
+ | {| class="wikitable sortable" style="width: 100%; text-align:center;" | ||
+ | ! style="width: 20%" |Study | ||
+ | ! style="width: 20%" |Dates of enrollment | ||
+ | ! style="width: 20%" |[[Levels_of_Evidence#Evidence|Evidence]] | ||
+ | ! style="width: 20%" |Comparator | ||
+ | ! style="width: 20%" |[[Levels_of_Evidence#Comparative_efficacy|Comparative Efficacy]] | ||
|- | |- | ||
− | |[ | + | |[https://doi.org/10.1056/NEJMoa010187 Macdonald et al. 2001 (INT-0116)] |
− | + | |1991-1998 | |
− | + | | style="background-color:#1a9851" |Phase 3 (E-esc) | |
− | + | |[[Gastric_cancer_-_null_regimens#Observation|Surgery alone]] | |
− | + | | style="background-color:#1a9850" |Superior OS (primary endpoint) | |
− | |||
− | |||
− | |||
− | |||
|- | |- | ||
− | |[https://www. | + | |[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5678342/ Fuchs et al. 2017 (CALGB 80101)] |
− | | style="background-color:#1a9851" |Phase | + | |2002-2009 |
− | | | + | | style="background-color:#1a9851" |Phase 3 (C) |
− | | style="background-color:#ffffbf" | | + | |[[#ECF.2FFULV_.26_RT_999|ECF/FULV & RT]] |
+ | | style="background-color:#ffffbf" |Did not meet primary endpoint of OS | ||
|- | |- | ||
|} | |} | ||
+ | ''Treatment is to start 20 to 40 days after surgery.'' | ||
+ | ''Note: Study included patients with GE junction malignancy as well (20% GE junction) and included patients with a performance status of 2.'' | ||
+ | <div class="toccolours" style="background-color:#cbd5e8"> | ||
====Preceding treatment==== | ====Preceding treatment==== | ||
− | *[[# | + | *INT-0116: [[Surgery#Gastrectomy|Surgery]] with R0 resection (10% underwent D2 dissection, 36% underwent D1 dissection and 54% underwent D0 dissection) |
+ | *CALGB 80101: [[Surgery#Gastrectomy|Surgery]] | ||
+ | </div> | ||
+ | <div class="toccolours" style="background-color:#b3e2cd"> | ||
====Chemotherapy==== | ====Chemotherapy==== | ||
− | *[[ | + | *[[Fluorouracil (5-FU)]] as follows: |
− | *[[ | + | **Cycles 1, 3, 4: 425 mg/m<sup>2</sup> IV bolus once per day on days 1 to 5 |
− | * | + | **Cycle 2 (chemoradiation): 400 mg/m<sup>2</sup> IV bolus once per day on days 1 to 4 and the last 3 days of radiation therapy |
− | + | *[[Leucovorin (Folinic acid)]] as follows: | |
− | ''' | + | **Cycles 1, 3, 4: 20 mg/m<sup>2</sup> IV bolus once per day on days 1 to 5 |
− | + | **Cycle 2 (chemoradiation): 20 mg/m<sup>2</sup> IV bolus once per day on days 1 to 4 and the last 3 days of radiation therapy | |
+ | ====Radiotherapy==== | ||
+ | *Concurrent [[External_beam_radiotherapy|radiation therapy]] during cycle 2: 180 cGy x 25 fractions (total of 4500 cGy) | ||
+ | '''28-day course, then 9-week course, then 28-day cycle for 2 cycles''' | ||
+ | </div></div> | ||
===References=== | ===References=== | ||
− | # ''' | + | #'''INT-0116:''' Macdonald JS, Smalley SR, Benedetti J, Hundahl SA, Estes NC, Stemmermann GN, Haller DG, Ajani JA, Gunderson LL, Jessup JM, Martenson JA. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med. 2001 Sep 6;345(10):725-30. [https://doi.org/10.1056/NEJMoa010187 link to original article] '''dosing details in abstract have been reviewed by our editors''' [https://pubmed.ncbi.nlm.nih.gov/11547741/ PubMed] |
+ | ##'''Update:''' Smalley SR, Benedetti JK, Haller DG, Hundahl SA, Estes NC, Ajani JA, Gunderson LL, Goldman B, Martenson JA, Jessup JM, Stemmermann GN, Blanke CD, Macdonald JS. Updated analysis of SWOG-directed intergroup study 0116: a phase III trial of adjuvant radiochemotherapy versus observation after curative gastric cancer resection. J Clin Oncol. 2012 Jul 1;30(19):2327-33. Epub 2012 May 14. [https://doi.org/10.1200/JCO.2011.36.7136 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4517071/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/22585691/ PubMed] | ||
+ | #'''CALGB 80101:''' Fuchs CS, Niedzwiecki D, Mamon HJ, Tepper JE, Ye X, Swanson RS, Enzinger PC, Haller DG, Dragovich T, Alberts SR, Bjarnason GA, Willett CG, Gunderson LL, Goldberg RM, Venook AP, Ilson D, O'Reilly E, Ciombor K, Berg DJ, Meyerhardt J, Mayer RJ. Adjuvant chemoradiotherapy with epirubicin, cisplatin, and fluorouracil compared with adjuvant chemoradiotherapy with fluorouracil and leucovorin after curative resection of gastric cancer: results from CALGB 80101 (Alliance). J Clin Oncol. 2017 Nov 10;35(32):3671-3677. Epub 2017 Oct 4. [https://doi.org/10.1200/JCO.2017.74.2130 link to original article] '''dosing details in manuscript have been reviewed by our editors''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5678342/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/28976791/ PubMed] [https://clinicaltrials.gov/study/NCT00052910 NCT00052910] | ||
− | == | + | ==S-1 monotherapy {{#subobject:ec10ef|Regimen=1}}== |
− | {| class="wikitable" style=" | + | <div class="toccolours" style="background-color:#eeeeee"> |
+ | ===Regimen variant #1, 21-day cycles {{#subobject:5dbc53|Variant=1}}=== | ||
+ | {| class="wikitable sortable" style="width: 100%; text-align:center;" | ||
+ | ! style="width: 20%" |Study | ||
+ | ! style="width: 20%" |Dates of enrollment | ||
+ | ! style="width: 20%" |[[Levels_of_Evidence#Evidence|Evidence]] | ||
+ | ! style="width: 20%" |Comparator | ||
+ | ! style="width: 20%" |[[Levels_of_Evidence#Comparative_efficacy|Comparative Efficacy]] | ||
+ | |- | ||
+ | | rowspan="2" |[https://doi.org/10.1016/S1470-2045(14)70025-7 Tsuburaya et al. 2014 (SAMIT)] | ||
+ | | rowspan="2" |2004-2009 | ||
+ | | rowspan="2" style="background-color:#1a9851" |Phase 3 (C) | ||
+ | |1. [[#Paclitaxel_monotherapy_999|Paclitaxel]], then [[#S-1_monotherapy|S-1]]<br>2. [[#Paclitaxel_monotherapy_999|Paclitaxel]], then [[#UFT_monotherapy|UFT]] | ||
+ | | style="background-color:#ffffbf" |Did not meet primary endpoint of DFS | ||
+ | |- | ||
+ | |3. [[#UFT_monotherapy|UFT]] | ||
+ | | style="background-color:#1a9850" |Superior DFS<br>DFS36: 58.2% vs 53%<br>(HR 0.81, 95% CI 0.70-0.93) | ||
|- | |- | ||
− | |||
|} | |} | ||
− | + | <div class="toccolours" style="background-color:#cbd5e8"> | |
− | ===Regimen {{#subobject: | + | ====Preceding treatment==== |
− | {| class="wikitable" style="width: 100%; text-align:center;" | + | *R0 or R1 [[Surgery#Gastrectomy|gastrectomy]] with at least D2 dissection, within 2 to 8 weeks |
− | ! style="width: | + | </div> |
− | ! style="width: | + | <div class="toccolours" style="background-color:#b3e2cd"> |
− | ! style="width: | + | ====Chemotherapy==== |
− | ! style="width: | + | *[[Tegafur, gimeracil, oteracil (S-1)]] 80 mg/m<sup>2</sup> PO twice per day on days 1 to 14 |
+ | '''21-day cycle for 16 cycles (1 year)''' | ||
+ | </div></div><br> | ||
+ | <div class="toccolours" style="background-color:#eeeeee"> | ||
+ | ===Regimen variant #2, 42-day cycles {{#subobject:0ee98c|Variant=1}}=== | ||
+ | {| class="wikitable sortable" style="width: 100%; text-align:center;" | ||
+ | ! style="width: 20%" |Study | ||
+ | ! style="width: 20%" |Dates of enrollment | ||
+ | ! style="width: 20%" |[[Levels_of_Evidence#Evidence|Evidence]] | ||
+ | ! style="width: 20%" |Comparator | ||
+ | ! style="width: 20%" |[[Levels_of_Evidence#Comparative_efficacy|Comparative Efficacy]] | ||
+ | |- | ||
+ | |[https://doi.org/10.1056/NEJMoa072252 Sakuramoto et al. 2007 (ACTS-GC)] | ||
+ | |2001-2004 | ||
+ | | style="background-color:#1a9851" |Phase 3 (E-esc) | ||
+ | |[[Gastric_cancer_-_null_regimens#Observation|Observation]] | ||
+ | | style="background-color:#1a9850" |Superior OS<sup>1</sup> (primary endpoint)<br>OS60: 72% vs 61%<br>(HR 0.67, 95% CI 0.54-0.83) | ||
+ | |- | ||
+ | |[https://doi.org/10.1016/S2468-1253(18)30383-2 Yoshikawa et al. 2019 (OPAS-1)] | ||
+ | |2012-2017 | ||
+ | | style="background-color:#1a9851" |Phase 3 (C) | ||
+ | |[[#S-1_monotherapy|S-1]] x 6 mo | ||
+ | | style="background-color:#ffffbf" |Inconclusive whether non-inferior RFS | ||
+ | |- | ||
+ | |[https://www.ncbi.nlm.nih.gov/pmc/articles/pmc6524985/ Yoshida et al. 2019 (JACCRO GC-07)] | ||
+ | |2013-2017 | ||
+ | | style="background-color:#1a9851" |Phase 3 (C) | ||
+ | |[[#Docetaxel_.26_S-1|Docetaxel & S-1]] | ||
+ | | style="background-color:#d73027" |Inferior RFS36 | ||
+ | |- | ||
+ | |rowspan=2|[https://doi.org/10.1016/j.annonc.2020.11.017 Park et al. 2020 (ARTIST 2)] | ||
+ | |rowspan=2|2013-2018 | ||
+ | |rowspan=2 style="background-color:#1a9851" |Phase 3 (C) | ||
+ | |1. [[#SOX|SOX]] | ||
+ | | style="background-color:#fc8d59" |Seems to have inferior DFS | ||
+ | |- | ||
+ | |2. [[#SOX_.26_RT_333|SOXRT]] | ||
+ | | style="background-color:#fee08b" |Might have inferior DFS | ||
|- | |- | ||
− | |[https:// | + | |[https://doi.org/10.1016/s2468-1253(24)00156-0 Kang et al. 2024 (ATTRACTION-5)] |
− | | style="background-color:#1a9851" |Phase | + | |2017-02-01 to 2019-08-15 |
− | | | + | | style="background-color:#1a9851" |Phase 3 (C) |
− | |style="background-color:# | + | |1a. [[#S-1_.26_Nivolumab_999|S-1 & Nivolumab]]<br>1b. [[#CapeOx_.26_Nivolumab_999|CapeOx & Nivolumab]] |
+ | | style="background-color:#ffffbf" |Did not meet primary endpoint of RFS<br>RFS36: 65.3% vs 68.4%<br>(HR 1.11, 95.72% CI 0.85-1.45) | ||
|- | |- | ||
|} | |} | ||
− | '' | + | ''<sup>1</sup>Reported efficacy for ACTS-GC is based on the 2011 update.'' |
+ | <div class="toccolours" style="background-color:#fdcdac"> | ||
+ | ====Eligibility criteria==== | ||
+ | *ACTS-GC, ARTIST 2, JACCRO GC-07: Stage II or III gastric cancer | ||
+ | *OPAS-1: Stage II gastric cancer | ||
+ | *ATTRACTION-5: Stage IIIA to IIIC gastric or GEJ cancer | ||
+ | </div> | ||
+ | <div class="toccolours" style="background-color:#cbd5e8"> | ||
====Preceding treatment==== | ====Preceding treatment==== | ||
− | *[[# | + | *R0 [[Surgery#Gastrectomy|gastrectomy]] with at least D2 dissection, within 6 weeks |
+ | </div> | ||
+ | <div class="toccolours" style="background-color:#b3e2cd"> | ||
====Chemotherapy==== | ====Chemotherapy==== | ||
− | *[[ | + | *[[Tegafur, gimeracil, oteracil (S-1)]] by the following BSA-based criteria: |
− | * | + | **Less than 1.25 m<sup>2</sup>: 40 mg PO twice per day on days 1 to 28 |
− | * | + | **Between 1.25 and 1.5 m<sup>2</sup>: 50 mg PO twice per day on days 1 to 28 |
− | * | + | **1.5 m<sup>2</sup> or more: 60 mg PO twice per day on days 1 to 28 |
− | + | '''42-day cycle for 8 cycles (1 year)''' | |
− | ''' | + | </div></div> |
===References=== | ===References=== | ||
− | # ''' | + | #'''ACTS-GC:''' Sakuramoto S, Sasako M, Yamaguchi T, Kinoshita T, Fujii M, Nashimoto A, Furukawa H, Nakajima T, Ohashi Y, Imamura H, Higashino M, Yamamura Y, Kurita A, Arai K; ACTS-GC Group. Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. N Engl J Med. 2007 Nov 1;357(18):1810-20. Erratum in: N Engl J Med. 2008 May 1;358(18):1977. [https://doi.org/10.1056/NEJMoa072252 link to original article] '''dosing details in manuscript have been reviewed by our editors''' [https://pubmed.ncbi.nlm.nih.gov/17978289/ PubMed] [https://clinicaltrials.gov/study/NCT00152217 NCT00152217] |
− | ## '''Update:''' | + | ##'''Update:''' Sasako M, Sakuramoto S, Katai H, Kinoshita T, Furukawa H, Yamaguchi T, Nashimoto A, Fujii M, Nakajima T, Ohashi Y. Five-year outcomes of a randomized phase III trial comparing adjuvant chemotherapy with S-1 versus surgery alone in stage II or III gastric cancer. J Clin Oncol. 2011 Nov 20;29(33):4387-93. Epub 2011 Oct 17. [https://doi.org/10.1200/JCO.2011.36.5908 link to original article] [https://pubmed.ncbi.nlm.nih.gov/22010012/ PubMed] |
+ | #'''SAMIT:''' Tsuburaya A, Yoshida K, Kobayashi M, Yoshino S, Takahashi M, Takiguchi N, Tanabe K, Takahashi N, Imamura H, Tatsumoto N, Hara A, Nishikawa K, Fukushima R, Nozaki I, Kojima H, Miyashita Y, Oba K, Buyse M, Morita S, Sakamoto J. Sequential paclitaxel followed by tegafur and uracil (UFT) or S-1 versus UFT or S-1 monotherapy as adjuvant chemotherapy for T4a/b gastric cancer (SAMIT): a phase 3 factorial randomised controlled trial. Lancet Oncol. 2014 Jul;15(8):886-93. Epub 2014 Jun 18. [https://doi.org/10.1016/S1470-2045(14)70025-7 link to original article] '''dosing details in manuscript have been reviewed by our editors''' [https://pubmed.ncbi.nlm.nih.gov/24954805/ PubMed] UMIN C000000082 | ||
+ | #'''OPAS-1:''' Yoshikawa T, Terashima M, Mizusawa J, Nunobe S, Nishida Y, Yamada T, Kaji M, Fukushima N, Hato S, Choda Y, Yabusaki H, Yoshida K, Ito S, Takeno A, Yasuda T, Kawachi Y, Katayama H, Fukuda H, Boku N, Sano T, Sasako M. Four courses versus eight courses of adjuvant S-1 for patients with stage II gastric cancer (JCOG1104[OPAS-1]): an open-label, phase 3, non-inferiority, randomised trial. Lancet Gastroenterol Hepatol. 2019 Mar;4(3):208-216. Epub 2019 Jan 22. Erratum in: Lancet Gastroenterol Hepatol. 2019 Apr;4(4):e3. [https://doi.org/10.1016/S2468-1253(18)30383-2 link to original article] [https://pubmed.ncbi.nlm.nih.gov/30679107/ PubMed] UMIN000007306 | ||
+ | ##'''Update:''' Yoshikawa T, Terashima M, Mizusawa J, Nunobe S, Nishida Y, Yamada T, Kaji M, Nomura T, Hato S, Choda Y, Yabusaki H, Yoshida K, Misawa K, Masuzawa T, Tsuda M, Kawachi Y, Katayama H, Fukuda H, Kurokawa Y, Boku N, Sano T, Sasako M. 5-year follow-up results of a JCOG1104 (OPAS-1) phase III non-inferiority trial to compare 4 courses and 8 courses of S-1 adjuvant chemotherapy for pathological stage II gastric cancer. Gastric Cancer. 2024 Jan;27(1):155-163. Epub 2023 Nov 21. [https://doi.org/10.1007/s10120-023-01447-5 link to original article] [https://pubmed.ncbi.nlm.nih.gov/37989806/ PubMed] | ||
+ | #'''JACCRO GC-07:''' Yoshida K, Kodera Y, Kochi M, Ichikawa W, Kakeji Y, Sano T, Nagao N, Takahashi M, Takagane A, Watanabe T, Kaji M, Okitsu H, Nomura T, Matsui T, Yoshikawa T, Matsuyama J, Yamada M, Ito S, Takeuchi M, Fujii M. Addition of Docetaxel to Oral Fluoropyrimidine Improves Efficacy in Patients With Stage III Gastric Cancer: Interim Analysis of JACCRO GC-07, a Randomized Controlled Trial. J Clin Oncol. 2019 May 20;37(15):1296-1304. Epub 2019 Mar 29. [https://doi.org/10.1200/jco.18.01138 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/pmc6524985/ link to PMC article] '''dosing details in manuscript have been reviewed by our editors''' [https://pubmed.ncbi.nlm.nih.gov/30925125/ PubMed] UMIN000010337 | ||
+ | ##'''Update:''' Kakeji Y, Yoshida K, Kodera Y, Kochi M, Sano T, Ichikawa W, Lee SW, Shibahara K, Shikano T, Kataoka M, Ishiguro A, Ojima H, Sakai Y, Musha N, Takase T, Kimura T, Takeuchi M, Fujii M. Three-year outcomes of a randomized phase III trial comparing adjuvant chemotherapy with S-1 plus docetaxel versus S-1 alone in stage III gastric cancer: JACCRO GC-07. Gastric Cancer. 2022 Jan;25(1):188-196. Epub 2021 Aug 5. [https://doi.org/10.1007/s10120-021-01224-2 link to original article] [https://pubmed.ncbi.nlm.nih.gov/34351555/ PubMed] | ||
+ | #'''ARTIST 2:''' Park SH, Lim DH, Sohn TS, Lee J, Zang DY, Kim ST, Kang JH, Oh SY, Hwang IG, Ji JH, Shin DB, Yu JI, Kim KM, An JY, Choi MG, Lee JH, Kim S, Hong JY, Park JO, Park YS, Lim HY, Bae JM, Kang WK; ARTIST 2 investigators. A randomized phase III trial comparing adjuvant single-agent S1, S-1 with oxaliplatin, and postoperative chemoradiation with S-1 and oxaliplatin in patients with node-positive gastric cancer after D2 resection: the ARTIST 2 trial. Ann Oncol. 2021 Mar;32(3):368-374. Epub 2020 Dec 3. [https://doi.org/10.1016/j.annonc.2020.11.017 link to original article] '''dosing details in manuscript have been reviewed by our editors''' [https://pubmed.ncbi.nlm.nih.gov/33278599/ PubMed] [https://clinicaltrials.gov/study/NCT01761461 NCT01761461] | ||
+ | #'''ATTRACTION-5:''' Kang YK, Terashima M, Kim YW, Boku N, Chung HC, Chen JS, Ji J, Yeh TS, Chen LT, Ryu MH, Kim JG, Omori T, Rha SY, Kim TY, Ryu KW, Sakuramoto S, Nishida Y, Fukushima N, Yamada T, Bai LY, Hirashima Y, Hagihara S, Nakada T, Sasako M. Adjuvant nivolumab plus chemotherapy versus placebo plus chemotherapy for stage III gastric or gastro-oesophageal junction cancer after gastrectomy with D2 or more extensive lymph-node dissection (ATTRACTION-5): a randomised, multicentre, double-blind, placebo-controlled, phase 3 trial. Lancet Gastroenterol Hepatol. 2024 Aug;9(8):705-717. Epub 2024 Jun 18. [https://doi.org/10.1016/s2468-1253(24)00156-0 link to original article] '''dosing details in manuscript have been reviewed by our editors''' [https://pubmed.ncbi.nlm.nih.gov/38906161/ PubMed] [https://clinicaltrials.gov/study/NCT03006705 NCT03006705] | ||
+ | #'''HKIT-GC:''' [https://clinicaltrials.gov/study/NCT00216034 NCT00216034] | ||
− | == | + | ==SOX {{#subobject:ecig8a|Regimen=1}}== |
− | {| class="wikitable" style=" | + | <div class="toccolours" style="background-color:#eeeeee"> |
+ | ===Regimen {{#subobject:5guz13|Variant=1}}=== | ||
+ | {| class="wikitable sortable" style="width: 100%; text-align:center;" | ||
+ | ! style="width: 20%" |Study | ||
+ | ! style="width: 20%" |Dates of enrollment | ||
+ | ! style="width: 20%" |[[Levels_of_Evidence#Evidence|Evidence]] | ||
+ | ! style="width: 20%" |Comparator | ||
+ | ! style="width: 20%" |[[Levels_of_Evidence#Comparative_efficacy|Comparative Efficacy]] | ||
+ | |- | ||
+ | |[https://www.ncbi.nlm.nih.gov/pmc/articles/pmc11003079/ Wang et al. 2024 (RESONANCE)] | ||
+ | |2012-09-01 to 2019-07-01 | ||
+ | | style="background-color:#1a9851" |Phase 3 (C) | ||
+ | |Perioperative [[#SOX|SOX]] | ||
+ | | style="background-color:#fc8d59" |Seems to have inferior DFS36 | ||
|- | |- | ||
− | |[ | + | |rowspan=2|[https://doi.org/10.1016/j.annonc.2020.11.017 Park et al. 2020 (ARTIST 2)] |
− | + | |rowspan=2|2013-2018 | |
− | + | |rowspan=2 style="background-color:#1a9851" |Phase 3 (E-esc) | |
− | = | + | |1. [[#S-1_monotherapy|S-1]] |
− | + | | style="background-color:#91cf60" |Seems to have superior DFS (primary endpoint)<br>DFS36: 74.3% vs 64.8%<br>(HR 0.69, 95% CI 0.41-0.99) | |
− | |||
− | |||
|- | |- | ||
− | |[ | + | |2. [[#SOX_.26_RT_888|SOXRT]] |
− | | style="background-color:# | + | | style="background-color:#ffffbf" |Did not meet primary endpoint of DFS |
|- | |- | ||
|} | |} | ||
− | + | <div class="toccolours" style="background-color:#cbd5e8"> | |
====Preceding treatment==== | ====Preceding treatment==== | ||
− | *[[Surgery#Gastrectomy| | + | *R0 or R1 [[Surgery#Gastrectomy|gastrectomy]] with at least D2 dissection |
− | ====Chemotherapy | + | </div> |
− | *[[ | + | <div class="toccolours" style="background-color:#b3e2cd"> |
− | * | + | ====Chemotherapy==== |
− | + | *[[Tegafur, gimeracil, oteracil (S-1)]] by the following BSA-based criteria: | |
− | + | **Less than 1.25 m<sup>2</sup>: 40 mg PO twice per day on days 1 to 14 | |
− | + | **Between 1.25 and 1.5 m<sup>2</sup>: 50 mg PO twice per day on days 1 to 14 | |
− | + | **1.5 m<sup>2</sup> or more: 60 mg PO twice per day on days 1 to 14 | |
− | + | *[[Oxaliplatin (Eloxatin)]] 130 mg/m<sup>2</sup> IV over 2 hours once on day 1 | |
− | + | '''21-day cycle for up to 8 cycles (6 months)''' | |
− | * | + | </div></div> |
− | |||
− | |||
− | |||
− | |||
− | |||
− | *[[ | ||
− | |||
− | '''21-day cycle for | ||
− | |||
===References=== | ===References=== | ||
− | # Lee | + | #'''ARTIST 2:''' Park SH, Lim DH, Sohn TS, Lee J, Zang DY, Kim ST, Kang JH, Oh SY, Hwang IG, Ji JH, Shin DB, Yu JI, Kim KM, An JY, Choi MG, Lee JH, Kim S, Hong JY, Park JO, Park YS, Lim HY, Bae JM, Kang WK; ARTIST 2 investigators. A randomized phase III trial comparing adjuvant single-agent S1, S-1 with oxaliplatin, and postoperative chemoradiation with S-1 and oxaliplatin in patients with node-positive gastric cancer after D2 resection: the ARTIST 2 trial. Ann Oncol. 2021 Mar;32(3):368-374. Epub 2020 Dec 3. [https://doi.org/10.1016/j.annonc.2020.11.017 link to original article] '''dosing details in manuscript have been reviewed by our editors''' [https://pubmed.ncbi.nlm.nih.gov/33278599/ PubMed] [https://clinicaltrials.gov/study/NCT01761461 NCT01761461] |
+ | #'''TOTTG030103:''' Zhao Q, Lian C, Huo Z, Li M, Liu Y, Fan L, Tan B, Zhao X, Zhang Z, Wang D, Liu Y, Guo H, Yang P, Tian Y, Li Y. The efficacy and safety of neoadjuvant chemotherapy on patients with advanced gastric cancer: A multicenter randomized clinical trial. Cancer Med. 2020 Aug;9(16):5731-5745. Epub 2020 Jun 24. [https://doi.org/10.1002/cam4.3224 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/pmc7433829/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/32583567/ PubMed] [https://clinicaltrials.gov/study/NCT01516944 NCT01516944] | ||
+ | #'''RESONANCE:''' Wang X, Lu C, Wei B, Li S, Li Z, Xue Y, Ye Y, Zhang Z, Sun Y, Liang H, Li K, Zhu L, Zheng Z, Zhou Y, He Y, Li F, Wang X, Liang P, Huang H, Li G, Shen X, Ji J, Tang Y, Xu Z, Chen L; RESONANCE study group. Perioperative versus adjuvant S-1 plus oxaliplatin chemotherapy for stage II/III resectable gastric cancer (RESONANCE): a randomized, open-label, phase 3 trial. J Hematol Oncol. 2024 Apr 8;17(1):17. [https://doi.org/10.1186/s13045-024-01536-7 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/pmc11003079/ link to PMC article] '''dosing details in supplement have been reviewed by our editors''' [https://pubmed.ncbi.nlm.nih.gov/38589926/ PubMed] [https://clinicaltrials.gov/study/NCT01583361 NCT01583361] | ||
− | == | + | ==UFT monotherapy {{#subobject:ecufef|Regimen=1}}== |
− | {| class="wikitable" style=" | + | <div class="toccolours" style="background-color:#eeeeee"> |
+ | ===Regimen {{#subobject:5dufuf|Variant=1}}=== | ||
+ | {| class="wikitable sortable" style="width: 100%; text-align:center;" | ||
+ | ! style="width: 20%" |Study | ||
+ | ! style="width: 20%" |Dates of enrollment | ||
+ | ! style="width: 20%" |[[Levels_of_Evidence#Evidence|Evidence]] | ||
+ | ! style="width: 20%" |Comparator | ||
+ | ! style="width: 20%" |[[Levels_of_Evidence#Comparative_efficacy|Comparative Efficacy]] | ||
+ | |- | ||
+ | |[https://doi.org/10.1002/bjs.5996 Nakajima et al. 2007 (NSAS-GC)] | ||
+ | |1997-2001 | ||
+ | | style="background-color:#1a9851" |Phase 3 (E-esc) | ||
+ | |[[Gastric_cancer_-_null_regimens#Observation|Observation]] | ||
+ | | style="background-color:#1a9850" |Superior OS (primary endpoint)<br>OS60: 86% vs 73%<br>(HR 0.48, 95% CI 0.26-0.89) | ||
|- | |- | ||
− | |||
|} | |} | ||
− | ===Regimen=== | + | <div class="toccolours" style="background-color:#cbd5e8"> |
− | {| class="wikitable" style="width: 100%; text-align:center;" | + | ====Preceding treatment==== |
− | ! style="width: | + | *[[Surgery#Gastrectomy|Gastrectomy]], with complete (R0) D2 dissection |
− | ! style="width: | + | </div> |
− | ! style="width: | + | <div class="toccolours" style="background-color:#b3e2cd"> |
− | ! style="width: | + | ====Chemotherapy==== |
+ | *[[Tegafur and uracil (UFT)]] 360 mg/m<sup>2</sup> PO once per day | ||
+ | '''16-month course''' | ||
+ | </div></div> | ||
+ | ===References=== | ||
+ | #'''NSAS-GC:''' Nakajima T, Kinoshita T, Nashimoto A, Sairenji M, Yamaguchi T, Sakamoto J, Fujiya T, Inada T, Sasako M, Ohashi Y; National Surgical Adjuvant Study of Gastric Cancer Group. Randomized controlled trial of adjuvant uracil-tegafur versus surgery alone for serosa-negative, locally advanced gastric cancer. Br J Surg. 2007 Dec;94(12):1468-76. [https://doi.org/10.1002/bjs.5996 link to original article] '''dosing details in abstract have been reviewed by our editors''' [https://pubmed.ncbi.nlm.nih.gov/17948223/ PubMed] [https://clinicaltrials.gov/study/NCT00152243 NCT00152243] | ||
+ | #'''SAMIT:''' Tsuburaya A, Yoshida K, Kobayashi M, Yoshino S, Takahashi M, Takiguchi N, Tanabe K, Takahashi N, Imamura H, Tatsumoto N, Hara A, Nishikawa K, Fukushima R, Nozaki I, Kojima H, Miyashita Y, Oba K, Buyse M, Morita S, Sakamoto J. Sequential paclitaxel followed by tegafur and uracil (UFT) or S-1 versus UFT or S-1 monotherapy as adjuvant chemotherapy for T4a/b gastric cancer (SAMIT): a phase 3 factorial randomised controlled trial. Lancet Oncol. 2014 Jul;15(8):886-93. Epub 2014 Jun 18. [https://doi.org/10.1016/S1470-2045(14)70025-7 link to original article] [https://pubmed.ncbi.nlm.nih.gov/24954805/ PubMed] UMIN C000000082 | ||
+ | |||
+ | =Metastatic or locally advanced disease, first-line= | ||
+ | ==Capecitabine monotherapy {{#subobject:a9eb0b|Regimen=1}}== | ||
+ | X: '''<u>X</u>'''eloda (Capecitabine) | ||
+ | <div class="toccolours" style="background-color:#eeeeee"> | ||
+ | ===Regimen variant #1, 2000 mg/m<sup>2</sup>/day {{#subobject:b6ba4c|Variant=1}}=== | ||
+ | {| class="wikitable sortable" style="width: 100%; text-align:center;" | ||
+ | ! style="width: 20%" |Study | ||
+ | ! style="width: 20%" |Dates of enrollment | ||
+ | ! style="width: 20%" |[[Levels_of_Evidence#Evidence|Evidence]] | ||
+ | ! style="width: 20%" |Comparator | ||
+ | ! style="width: 20%" |[[Levels_of_Evidence#Comparative_efficacy|Comparative Efficacy]] | ||
|- | |- | ||
− | |[https:// | + | |[https://doi.org/10.1016/j.jgo.2017.01.002 Hwang et al. 2017 (SMC 2010-04-118)] |
− | | style="background-color:#1a9851" |Phase | + | |2010-2014 |
− | |[[ | + | | style="background-color:#1a9851" |Phase 3 (C) |
− | | style="background-color:#ffffbf" | | + | |[[#CapeOx_3|XELOX]] |
+ | | style="background-color:#ffffbf" |Did not meet primary endpoint of OS | ||
|- | |- | ||
− | |[https:// | + | |[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10645518/ Lee et al. 2023 (KCSG ST13-10)] |
− | | style="background-color:#1a9851" |Phase | + | |2014-02 to 2019-01 |
− | | | + | |style="background-color:#1a9851" |Phase 3 (C) |
− | | style="background-color:#ffffbf" | | + | |1a. [[#mFOLFOX6_2|mFOLFOX6]]<br>1b. [[#CapeOx_3|CapeOx]]<br>1c. [[#Cisplatin_.26_S-1|Cisplatin & S-1]]<br>1d. [[#Capecitabine_.26_Cisplatin_.28CX.29_3|CX]] |
+ | | style="background-color:#ffffbf" |Did not meet primary endpoint of OS<br>Median OS: 7.5 vs 11.5 mo<br>(HR 1.16, 95% CI 0.77-1.79) | ||
|- | |- | ||
− | | | + | |} |
− | + | ''Note: to our knowledge, this regimen variant was not tested as an experimental arm in an RCT in this context, prior to becoming a standard comparator arm.'' | |
− | + | <div class="toccolours" style="background-color:#fdcdac"> | |
− | | style=" | + | ====Eligibility criteria==== |
+ | *KCSG ST13-10: CrCl at least 60 mL/min | ||
+ | </div> | ||
+ | <div class="toccolours" style="background-color:#b3e2cd"> | ||
+ | ====Chemotherapy==== | ||
+ | *[[Capecitabine (Xeloda)]] 1000 mg/m<sup>2</sup> PO twice per day on days 1 to 14 | ||
+ | '''21-day cycles''' | ||
+ | </div></div><br> | ||
+ | <div class="toccolours" style="background-color:#eeeeee"> | ||
+ | ===Regimen variant #2, 2500 mg/m<sup>2</sup>/day {{#subobject:b6ba4c|Variant=1}}=== | ||
+ | {| class="wikitable sortable" style="width: 60%; text-align:center;" | ||
+ | !style="width: 33%"|Study | ||
+ | !style="width: 33%"|Dates of enrollment | ||
+ | !style="width: 33%"|[[Levels_of_Evidence#Evidence|Evidence]] | ||
|- | |- | ||
− | |[https:// | + | |[https://doi.org/10.1093/annonc/mdh343 Hong et al. 2004] |
− | | | + | |Not reported |
− | + | | style="background-color:#91cf61" |Phase 2 | |
− | | style="background-color:# | ||
|- | |- | ||
− | |[https://link. | + | |} |
− | | style="background-color:# | + | <div class="toccolours" style="background-color:#fdcdac"> |
− | | | + | ====Eligibility criteria==== |
− | | style=" | + | *Karnofsky status of at least 70% |
+ | </div> | ||
+ | <div class="toccolours" style="background-color:#b3e2cd"> | ||
+ | ====Chemotherapy==== | ||
+ | *[[Capecitabine (Xeloda)]] 1250 mg/m<sup>2</sup> PO twice per day on days 1 to 14 | ||
+ | '''21-day cycle for up to 6 cycles''' | ||
+ | </div></div> | ||
+ | ===References=== | ||
+ | #Hong YS, Song SY, Lee SI, Chung HC, Choi SH, Noh SH, Park JN, Han JY, Kang JH, Lee KS, Cho JY. A phase II trial of capecitabine in previously untreated patients with advanced and/or metastatic gastric cancer. Ann Oncol. 2004 Sep;15(9):1344-7. [https://doi.org/10.1093/annonc/mdh343 link to original article] '''dosing details in manuscript have been reviewed by our editors''' [https://pubmed.ncbi.nlm.nih.gov/15319239/ PubMed] | ||
+ | #'''SMC 2010-04-118:''' Hwang IG, Ji JH, Kang JH, Lee HR, Lee HY, Chi KC, Park SW, Lee SJ, Kim ST, Lee J, Park SH, Park JO, Park YS, Lim HY, Kang WK. A multi-center, open-label, randomized phase III trial of first-line chemotherapy with capecitabine monotherapy versus capecitabine plus oxaliplatin in elderly patients with advanced gastric cancer. J Geriatr Oncol. 2017 May;8(3):170-175. Epub 2017 Jan 21. [https://doi.org/10.1016/j.jgo.2017.01.002 link to original article] '''dosing details in abstract have been reviewed by our editors''' [https://pubmed.ncbi.nlm.nih.gov/28119041/ PubMed] [https://clinicaltrials.gov/study/NCT01470742 NCT01470742] | ||
+ | #'''KCSG ST13-10:''' Lee KW, Zang DY, Ryu MH, Han HS, Kim KH, Kim MJ, Koh SA, Lee SS, Koo DH, Ko YH, Sohn BS, Kim JW, Park JH, Nam BH, Choi IS. A Phase 3 Randomized Clinical Trial to Compare Efficacy and Safety between Combination Therapy and Monotherapy in Elderly Patients with Advanced Gastric Cancer (KCSG ST13-10). Cancer Res Treat. 2022 Oct;55(4):1250-1260. Epub 2023 May 25. [https://doi.org/10.4143/crt.2023.333 link to original article] '''dosing details in manuscript have been reviewed by our editors''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10645518/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/37232070/ PubMed] [https://clinicaltrials.gov/study/NCT02114359 NCT02114359] | ||
+ | ==Capecitabine & Cisplatin (CX) {{#subobject:2bd34d|Regimen=1}}== | ||
+ | CX: '''<u>C</u>'''isplatin, '''<u>X</u>'''eloda (Capecitabine) | ||
+ | <br>XP: '''<u>X</u>'''eloda (Capecitabine), '''<u>P</u>'''latinol (Cisplatin) | ||
+ | <div class="toccolours" style="background-color:#eeeeee"> | ||
+ | ===Regimen variant #1, 6 cycles {{#subobject:62b184|Variant=1}}=== | ||
+ | {| class="wikitable sortable" style="width: 100%; text-align:center;" | ||
+ | ! style="width: 20%" |Study | ||
+ | ! style="width: 20%" |Dates of enrollment | ||
+ | ! style="width: 20%" |[[Levels_of_Evidence#Evidence|Evidence]] | ||
+ | ! style="width: 20%" |Comparator | ||
+ | ! style="width: 20%" |[[Levels_of_Evidence#Comparative_efficacy|Comparative Efficacy]] | ||
|- | |- | ||
− | |[https:// | + | |[https://doi.org/10.1200/JCO.2011.36.2236 Ohtsu et al. 2011 (AVAGAST)] |
− | | style="background-color:#1a9851" |Phase | + | |2007-09 to 2008-12 |
− | | | + | | style="background-color:#1a9851" |Phase 3 (C) |
− | | style="background-color:#ffffbf" | | + | |[[Stub#Capecitabine_.26_Cisplatin_.28CX.29_.26_Bevacizumab|CX & Bevacizumab]] |
+ | | style="background-color:#ffffbf" |Did not meet primary endpoint of OS | ||
|- | |- | ||
− | |[https:// | + | |[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4544634/ Shen et al. 2014 (AVATAR)] |
− | | style="background-color:#1a9851" |Phase | + | |2009-03-25 to 2010-07-12 |
− | | | + | | style="background-color:#1a9851" |Phase 3 (C) |
− | | style="background-color:# | + | |[[Stub#Capecitabine_.26_Cisplatin_.28CX.29_.26_Bevacizumab|CX & Bevacizumab]] |
+ | | style="background-color:#ffffbf" |Did not meet primary endpoint of OS | ||
|- | |- | ||
− | |[https://www. | + | |[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6097104/ Lu et al. 2018 (PAC-C)] |
− | | style="background-color:#1a9851" |Phase | + | |2009-2014 |
− | |[[# | + | | style="background-color:#1a9851" |Phase 3 (C) |
− | | style="background-color:# | + | |[[#Capecitabine_.26_Paclitaxel_999|Capecitabine & Paclitaxel]] |
+ | | style="background-color:#ffffbf" |Did not meet primary endpoint of PFS | ||
|- | |- | ||
− | | | + | |} |
− | | style="background-color:# | + | ''Note: The following studies included patients with GE junction malignancy as well: |
− | + | *''AVAGAST patients: 86% gastric and 14% GE junction. 5.4% of patients had an ECOG PS of 2.'' | |
− | | style=" | + | <div class="toccolours" style="background-color:#b3e2cd"> |
+ | ====Chemotherapy==== | ||
+ | *[[Cisplatin (Platinol)]] 80 mg/m<sup>2</sup> IV over 2 hours once on day 1 | ||
+ | *[[Capecitabine (Xeloda)]] 1000 mg/m<sup>2</sup> PO twice per day on days 1 to 14 | ||
+ | ====Supportive therapy==== | ||
+ | *Some protocols: [[:Category:Hydration|"Hyperhydration"]] for cisplatin | ||
+ | '''21-day cycle for 6 cycles''' | ||
+ | </div> | ||
+ | <div class="toccolours" style="background-color:#cbd5e7"> | ||
+ | ====Subsequent treatment==== | ||
+ | *AVAGAST & AVATAR: [[#Capecitabine_monotherapy_2|Capecitabine]] maintenance | ||
+ | </div></div><br> | ||
+ | <div class="toccolours" style="background-color:#eeeeee"> | ||
+ | ===Regimen variant #2, 8 cycles {{#subobject:628184|Variant=1}}=== | ||
+ | {| class="wikitable sortable" style="width: 100%; text-align:center;" | ||
+ | ! style="width: 20%" |Study | ||
+ | ! style="width: 20%" |Dates of enrollment | ||
+ | ! style="width: 20%" |[[Levels_of_Evidence#Evidence|Evidence]] | ||
+ | ! style="width: 20%" |Comparator | ||
+ | ! style="width: 20%" |[[Levels_of_Evidence#Comparative_efficacy|Comparative Efficacy]] | ||
|- | |- | ||
− | |[https:// | + | |[https://doi.org/10.1016/j.ejca.2014.08.005 Kim et al. 2014 (SMC 2008-12-019)] |
− | | style="background-color:#1a9851" |Phase | + | |2009-2012 |
− | |[[# | + | | style="background-color:#1a9851" |Phase 3 (C) |
− | | style="background-color:#ffffbf" | | + | |[[#Capecitabine_.26_Cisplatin_.28CX.29_.26_Simvastatin_999|CX & Simvastatin]] |
+ | | style="background-color:#ffffbf" |Did not meet primary endpoint of PFS | ||
|- | |- | ||
− | | | + | |} |
− | + | ''Note: The following studies included patients with GE junction malignancy as well: | |
− | + | *''SMC 2008-12-019 patients: 79% gastric, 16% GE junction and 5% unknown'' | |
− | + | <div class="toccolours" style="background-color:#b3e2cd"> | |
− | + | ====Chemotherapy==== | |
− | + | *[[Cisplatin (Platinol)]] 80 mg/m<sup>2</sup> IV once on day 1 | |
− | + | *[[Capecitabine (Xeloda)]] 1000 mg/m<sup>2</sup> PO twice per day on days 1 to 14 | |
− | + | '''21-day cycle for 8 cycles''' | |
− | + | </div> | |
− | |- | + | <div class="toccolours" style="background-color:#cbd5e7"> |
− | + | ====Subsequent treatment==== | |
− | + | *[[#Capecitabine_monotherapy_2|Capecitabine]] maintenance | |
− | + | </div></div><br> | |
− | + | <div class="toccolours" style="background-color:#eeeeee"> | |
− | + | ===Regimen variant #3, indefinite {{#subobject:82b184|Variant=1}}=== | |
− | + | {| class="wikitable sortable" style="width: 100%; text-align:center;" | |
− | + | ! style="width: 20%" |Study | |
− | |[[# | + | ! style="width: 20%" |Dates of enrollment |
− | | style=" | + | ! style="width: 20%" |[[Levels_of_Evidence#Evidence|Evidence]] |
+ | ! style="width: 20%" |Comparator | ||
+ | ! style="width: 20%" |[[Levels_of_Evidence#Comparative_efficacy|Comparative Efficacy]] | ||
|- | |- | ||
− | |[https:// | + | |[https://doi.org/10.1093/annonc/mdn717 Kang et al. 2009 (ML17032)] |
− | | style="background-color:#1a9851" |Phase | + | |2003-2005 |
− | | | + | | style="background-color:#1a9851" |Phase 3 (E-switch-ic) |
− | | style="background-color:# | + | |[[#Cisplatin_.26_Fluorouracil_.28CF.29_3|CF]] |
+ | | style="background-color:#eeee01" |Non-inferior PFS (primary endpoint)<br>Median PFS: 5.6 vs 5 mo<br>(HR 0.81, 95% CI 0.63-1.04) | ||
|- | |- | ||
− | |[https:// | + | |[https://doi.org/10.1016/S1470-2045(13)70102-5 Lordick et al. 2013 (EXPAND)] |
− | | style="background-color:#1a9851" |Phase | + | |2008-2010 |
− | | | + | | style="background-color:#1a9851" |Phase 3 (C) |
− | | style="background-color:#ffffbf" | | + | |[[#Capecitabine_.26_Cisplatin_.28CX.29_.26_Cetuximab_999|CX & Cetuximab]] |
+ | | style="background-color:#ffffbf" |Did not meet primary endpoint of PFS | ||
|- | |- | ||
− | |[https:// | + | |[https://doi.org/10.1016/S1470-2045(18)30791-5 Fuchs et al. 2019 (RAINFALL)] |
− | | style="background-color:#1a9851" |Phase | + | |2015-01-28 to 2016-09-16 |
− | | | + | | style="background-color:#1a9851" |Phase 3 (C) |
− | | style="background-color:#ffffbf" | | + | |[[Stub#Capecitabine_.26_Cisplatin_.28CX.29_.26_Ramucirumab|CX & Ramucirumab]] |
+ | | style="background-color:#ffffbf" |Did not meet primary endpoint of PFS<sup>1</sup> | ||
|- | |- | ||
|} | |} | ||
− | '' | + | ''<sup>1</sup>while the primary analysis of RAINFALL showed that this arm seemed to have inferior PFS, independent central review did not confirm this finding.''<br> |
− | ==== | + | The following studies included patients with GE junction malignancy as well: |
− | *[[ | + | *''EXPAND patients: 83% gastric, 5% GE junction and 16% unknown'' |
− | + | <div class="toccolours" style="background-color:#b3e2cd"> | |
+ | ====Chemotherapy==== | ||
+ | *[[Cisplatin (Platinol)]] 80 mg/m<sup>2</sup> IV over 2 hours once on day 1 | ||
+ | *[[Capecitabine (Xeloda)]] 1000 mg/m<sup>2</sup> PO twice per day on days 1 to 14 | ||
+ | **Alternate dosing in EXPAND: 1000 mg/m<sup>2</sup> PO twice per day from the evening of day 1 to the morning of day 15 (28 doses per cycle) | ||
+ | ====Supportive therapy==== | ||
+ | *Some protocols: [[:Category:Hydration|"Hyperhydration"]] for cisplatin | ||
+ | '''21-day cycles''' | ||
+ | </div></div> | ||
===References=== | ===References=== | ||
− | # | + | #'''ML17032:''' Kang YK, Kang WK, Shin DB, Chen J, Xiong J, Wang J, Lichinitser M, Guan Z, Khasanov R, Zheng L, Philco-Salas M, Suarez T, Santamaria J, Forster G, McCloud PI. Capecitabine/cisplatin versus 5-fluorouracil/cisplatin as first-line therapy in patients with advanced gastric cancer: a randomised phase III noninferiority trial. Ann Oncol. 2009 Apr;20(4):666-73. Epub 2009 Jan 19. [https://doi.org/10.1093/annonc/mdn717 link to original article] '''dosing details in manuscript have been reviewed by our editors''' [https://pubmed.ncbi.nlm.nih.gov/19153121/ PubMed] content property of [https://hemonc.org HemOnc.org] [https://clinicaltrials.gov/study/NCT02563054 NCT02563054] |
− | + | #'''AVAGAST:''' Ohtsu A, Shah MA, Van Cutsem E, Rha SY, Sawaki A, Park SR, Lim HY, Yamada Y, Wu J, Langer B, Starnawski M, Kang YK. Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a randomized, double-blind, placebo-controlled phase III study. J Clin Oncol. 2011 Oct 20;29(30):3968-76. Epub 2011 Aug 15. [https://doi.org/10.1200/JCO.2011.36.2236 link to original article] '''dosing details in manuscript have been reviewed by our editors''' [https://pubmed.ncbi.nlm.nih.gov/21844504/ PubMed] [https://clinicaltrials.gov/study/NCT00548548 NCT00548548] | |
− | + | #'''EXPAND:''' Lordick F, Kang YK, Chung HC, Salman P, Oh SC, Bodoky G, Kurteva G, Volovat C, Moiseyenko VM, Gorbunova V, Park JO, Sawaki A, Celik I, Götte H, Melezínková H, Moehler M; Arbeitsgemeinschaft Internistische Onkologie. Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND): a randomised, open-label phase 3 trial. Lancet Oncol. 2013 May;14(6):490-9. Epub 2013 Apr 15. [https://doi.org/10.1016/S1470-2045(13)70102-5 link to original article] '''dosing details in manuscript have been reviewed by our editors''' [https://pubmed.ncbi.nlm.nih.gov/23594786/ PubMed] [https://clinicaltrials.gov/study/NCT00678535 NCT00678535] | |
− | # ''' | + | #'''AVATAR:''' Shen L, Li J, Xu J, Pan H, Dai G, Qin S, Wang L, Wang J, Yang Z, Shu Y, Xu R, Chen L, Liu Y, Yu S, Bu L, Piao Y. Bevacizumab plus capecitabine and cisplatin in Chinese patients with inoperable locally advanced or metastatic gastric or gastroesophageal junction cancer: randomized, double-blind, phase III study (AVATAR study). Gastric Cancer. 2015 Jan;18(1):168-76. Epub 2014 Feb 21. [https://doi.org/10.1007/s10120-014-0351-5 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4544634/ link to PMC article] '''dosing details in manuscript have been reviewed by our editors''' [https://pubmed.ncbi.nlm.nih.gov/24557418/ PubMed] [https://clinicaltrials.gov/study/NCT00887822 NCT00887822] |
− | + | #'''SMC 2008-12-019:''' Kim ST, Kang JH, Lee J, Park SH, Park JO, Park YS, Lim HY, Hwang IG, Lee SC, Park KW, Lee HR, Kang WK. Simvastatin plus capecitabine-cisplatin versus placebo plus capecitabine-cisplatin in patients with previously untreated advanced gastric cancer: a double-blind randomised phase 3 study. Eur J Cancer. 2014 Nov;50(16):2822-30. Epub 2014 Sep 15. [https://doi.org/10.1016/j.ejca.2014.08.005 link to original article] '''dosing details in manuscript have been reviewed by our editors''' [https://pubmed.ncbi.nlm.nih.gov/25218337/ PubMed] [https://clinicaltrials.gov/study/NCT01099085 NCT01099085] | |
− | # ''' | + | #'''PAC-C:''' Lu Z, Zhang X, Liu W, Liu T, Hu B, Li W, Fan Q, Xu J, Xu N, Bai Y, Pan Y, Xu Q, Bai W, Xia L, Gao Y, Wang W, Shu Y, Shen L. A multicenter, randomized trial comparing efficacy and safety of paclitaxel/capecitabine and cisplatin/capecitabine in advanced gastric cancer. Gastric Cancer. 2018 Sep;21(5):782-791. Epub 2018 Feb 27. [https://doi.org/10.1007/s10120-018-0809-y link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6097104/ link to PMC article] '''dosing details in manuscript have been reviewed by our editors''' [https://pubmed.ncbi.nlm.nih.gov/29488121/ PubMed] [https://clinicaltrials.gov/study/NCT01015339 NCT01015339] |
− | + | #'''RAINFALL:''' Fuchs CS, Shitara K, Di Bartolomeo M, Lonardi S, Al-Batran SE, Van Cutsem E, Ilson DH, Alsina M, Chau I, Lacy J, Ducreux M, Mendez GA, Alavez AM, Takahari D, Mansoor W, Enzinger PC, Gorbounova V, Wainberg ZA, Hegewisch-Becker S, Ferry D, Lin J, Carlesi R, Das M, Shah MA; RAINFALL Study Group. Ramucirumab with cisplatin and fluoropyrimidine as first-line therapy in patients with metastatic gastric or junctional adenocarcinoma (RAINFALL): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncol. 2019 Mar;20(3):420-435. Epub 2019 Feb 1. Erratum in: Lancet Oncol. 2019 May;20(5):e242. [https://doi.org/10.1016/S1470-2045(18)30791-5 link to original article] '''dosing details in abstract have been reviewed by our editors''' [https://pubmed.ncbi.nlm.nih.gov/30718072/ PubMed] [https://clinicaltrials.gov/study/NCT02314117 NCT02314117] | |
− | # ''' | ||
− | |||
− | |||
− | # ''' | ||
− | |||
− | # ''' | ||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | == | + | ==Capecitabine & Cisplatin (CX) & Pembrolizumab {{#subobject:ahg7ab|Regimen=1}}== |
− | {| class="wikitable" style=" | + | CX & Pembrolizumab: '''<u>C</u>'''isplatin, '''<u>X</u>'''eloda (Capecitabine), Pembrolizumab |
+ | <div class="toccolours" style="background-color:#eeeeee"> | ||
+ | ===Regimen {{#subobject:1yt34c|Variant=1}}=== | ||
+ | {| class="wikitable sortable" style="width: 100%; text-align:center;" | ||
+ | ! style="width: 20%" |Study | ||
+ | ! style="width: 20%" |Dates of enrollment | ||
+ | ! style="width: 20%" |[[Levels_of_Evidence#Evidence|Evidence]] | ||
+ | ! style="width: 20%" |Comparator | ||
+ | ! style="width: 20%" |[[Levels_of_Evidence#Comparative_efficacy|Comparative Efficacy]] | ||
+ | |- | ||
+ | |rowspan=2|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7489405/ Shitara et al. 2020 (KEYNOTE-062)] | ||
+ | |rowspan=2|2015-2017 | ||
+ | |rowspan=2 style="background-color:#1a9851" |Phase 3 (E-esc) | ||
+ | |1a. [[#Cisplatin_.26_Fluorouracil_.28CF.29_3|CF]]<br>1b. [[#Capecitabine_.26_Cisplatin_.28CX.29_3|CX]] | ||
+ | | style="background-color:#d9ef8b" |Might have superior OS<sup>1</sup> (co-primary endpoint)<br>Median OS: 12.5 vs 11.1 mo<br>(HR 0.85, 95% CI 0.70-1.03) | ||
|- | |- | ||
− | |[[# | + | |2. [[#Pembrolizumab_monotherapy|Pembrolizumab]] |
+ | | style="background-color:#d3d3d3" |Not reported | ||
|} | |} | ||
− | === | + | ''<sup>1</sup>Reported efficacy is for patients with CPS of 1 or greater.''<br> |
− | {| class="wikitable" style="width: 100%; text-align:center;" | + | ''Note: KEYNOTE-062 included patients with GEJ malignancy.'' |
− | ! style="width: | + | <div class="toccolours" style="background-color:#fdcdac"> |
− | ! style="width: | + | ====Biomarker eligibility criteria==== |
− | ! style="width: | + | PD-L1 Combined Positive Score (CPS) of 1 or more as determined by an FDA-approved test |
− | ! style="width: | + | </div> |
+ | <div class="toccolours" style="background-color:#b3e2cd"> | ||
+ | ====Chemotherapy==== | ||
+ | *[[Capecitabine (Xeloda)]] 1000 mg/m<sup>2</sup> PO twice per day on days 1 to 14 | ||
+ | *[[Cisplatin (Platinol)]] 80 mg/m<sup>2</sup> IV once on day 1 | ||
+ | ====Immunotherapy==== | ||
+ | *[[Pembrolizumab (Keytruda)]] 200 mg IV once on day 1 | ||
+ | '''21-day cycles''' | ||
+ | </div></div> | ||
+ | ===References=== | ||
+ | <!-- #'''Abstract:''' Tabernero J, Van Cutsem E, Yung-Jue B, Fuchs CS, Wyrwicz L, Lee KW, Kudaba I, Garrido M, Chung HC, Salguero HR, Mansoor W, Freitas MI, Brachiroli M, Goekkurt E, Chao J, Wainberg ZA, Kher U, Shah S, Kang SP, Shitara K. Pembrolizumab with or without chemotherapy versus chemotherapy for advanced gastric or gastroesophgeal junction (G/GEJ) adenocarcinoma: The phase III KEYNOTE-062 study. 2019 American Society of Clinical Oncology annual meeting. [https://doi.org/10.1200/JCO.2019.37.18_suppl.LBA4007 link to abstract] --> | ||
+ | #'''KEYNOTE-062:''' Shitara K, Van Cutsem E, Bang YJ, Fuchs C, Wyrwicz L, Lee KW, Kudaba I, Garrido M, Chung HC, Lee J, Castro HR, Mansoor W, Braghiroli MI, Karaseva N, Caglevic C, Villanueva L, Goekkurt E, Satake H, Enzinger P, Alsina M, Benson A, Chao J, Ko AH, Wainberg ZA, Kher U, Shah S, Kang SP, Tabernero J. Efficacy and Safety of Pembrolizumab or Pembrolizumab Plus Chemotherapy vs Chemotherapy Alone for Patients With First-line, Advanced Gastric Cancer: The KEYNOTE-062 Phase 3 Randomized Clinical Trial. JAMA Oncol. 2020 Oct 1;6(10):1571-1580. Epub 2020 Sep 3. [https://doi.org/10.1001/jamaoncol.2020.3370 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7489405/ link to PMC article] '''dosing details in manuscript have been reviewed by our editors''' [https://pubmed.ncbi.nlm.nih.gov/32880601/ PubMed] [https://clinicaltrials.gov/study/NCT02494583 NCT02494583] | ||
+ | ==CapeOx {{#subobject:4e3bb4|Regimen=1}}== | ||
+ | CapeOX: '''<u>Cape</u>'''citabine & '''<u>OX</u>'''aliplatin | ||
+ | <div class="toccolours" style="background-color:#eeeeee"> | ||
+ | ===Regimen variant #1, 750/78 {{#subobject:4faj81|Variant=1}}=== | ||
+ | {| class="wikitable sortable" style="width: 100%; text-align:center;" | ||
+ | !style="width: 20%"|Study | ||
+ | !style="width: 20%"|Dates of enrollment | ||
+ | !style="width: 20%"|[[Levels_of_Evidence#Evidence|Evidence]] | ||
+ | !style="width: 20%"|Comparator | ||
+ | !style="width: 20%"|[[Levels_of_Evidence#Comparative_efficacy|Comparative Efficacy]] | ||
|- | |- | ||
− | | rowspan= | + | |rowspan=2|[https://www.ncbi.nlm.nih.gov/pmc/articles/pmc8120440/ Hall et al. 2021 (GO2)] |
− | | rowspan= | + | |rowspan=2|2014-2017 |
− | |1. | + | |rowspan=2 style="background-color:#1a9851" |Phase 3 (E-de-esc) |
− | | style="background-color:# | + | |1. [[#CapeOx_3|CapeOx]]; 1000/104 |
+ | | style="background-color:#d3d3d3" |Not reported | ||
|- | |- | ||
− | | | + | |2. [[#CapeOx_3|CapeOx]]; 1250/130 |
− | | style="background-color:# | + | | style="background-color:#eeee01" |Non-inferior PFS (primary endpoint)<br>(HR 1.10, 95% CI 0.90-1.33) |
|- | |- | ||
|} | |} | ||
− | == | + | <div class="toccolours" style="background-color:#b3e2cd"> |
− | |||
====Chemotherapy==== | ====Chemotherapy==== | ||
− | *[[ | + | *[[Capecitabine (Xeloda)]] 375 mg/m<sup>2</sup> PO twice per day |
+ | *[[Oxaliplatin (Eloxatin)]] 78 mg/m<sup>2</sup> IV once on day 1 | ||
+ | '''21-day cycles''' | ||
+ | </div></div><br> | ||
+ | <div class="toccolours" style="background-color:#eeeeee"> | ||
− | + | ===Regimen variant #2, 1000/104 {{#subobject:4faj65|Variant=1}}=== | |
− | + | {| class="wikitable sortable" style="width: 100%; text-align:center;" | |
− | === | + | !style="width: 20%"|Study |
− | {| class="wikitable" style="width: 100%; text-align:center;" | + | !style="width: 20%"|Dates of enrollment |
− | ! style="width: | + | !style="width: 20%"|[[Levels_of_Evidence#Evidence|Evidence]] |
− | ! style="width: | + | !style="width: 20%"|Comparator |
− | ! style="width: | + | !style="width: 20%"|[[Levels_of_Evidence#Comparative_efficacy|Comparative Efficacy]] |
− | ! style="width: | + | |- |
+ | |rowspan=2|[https://www.ncbi.nlm.nih.gov/pmc/articles/pmc8120440/ Hall et al. 2021 (GO2)] | ||
+ | |rowspan=2|2014-2017 | ||
+ | |rowspan=2 style="background-color:#1a9851" |Phase 3 (E-de-esc) | ||
+ | |1. [[#CapeOx_3|CapeOx]]; 750/78 | ||
+ | | style="background-color:#d3d3d3" |Not reported | ||
+ | |- | ||
+ | |2. [[#CapeOx_3|CapeOx]]; 1250/130 | ||
+ | | style="background-color:#eeee01" |Non-inferior PFS (primary endpoint)<br>(HR 1.09, 95% CI 0.89-1.32) | ||
|- | |- | ||
− | |[ | + | |} |
− | + | <div class="toccolours" style="background-color:#b3e2cd"> | |
− | |[[# | + | ====Chemotherapy==== |
− | | style=" | + | *[[Capecitabine (Xeloda)]] 500 mg/m<sup>2</sup> PO twice per day |
+ | *[[Oxaliplatin (Eloxatin)]] 104 mg/m<sup>2</sup> IV once on day 1 | ||
+ | '''21-day cycles''' | ||
+ | </div></div><br> | ||
+ | <div class="toccolours" style="background-color:#eeeeee"> | ||
+ | ===Regimen variant #3, 1250/130 {{#subobject:guzj65|Variant=1}}=== | ||
+ | {| class="wikitable sortable" style="width: 100%; text-align:center;" | ||
+ | !style="width: 20%"|Study | ||
+ | !style="width: 20%"|Dates of enrollment | ||
+ | !style="width: 20%"|[[Levels_of_Evidence#Evidence|Evidence]] | ||
+ | !style="width: 20%"|Comparator | ||
+ | !style="width: 20%"|[[Levels_of_Evidence#Comparative_efficacy|Comparative Efficacy]] | ||
|- | |- | ||
− | |[https://www. | + | |[https://www.ncbi.nlm.nih.gov/pmc/articles/pmc8120440/ Hall et al. 2021 (GO2)] |
− | | style="background-color:#1a9851" |Phase | + | |2014-2017 |
− | | | + | | style="background-color:#1a9851" |Phase 3 (C) |
− | | style="background-color:# | + | |1. [[#CapeOx_3|CapeOx]]; 750/78<br>2. [[#CapeOx_3|CapeOx]]; 1000/104 |
+ | | style="background-color:#eeee01" |Non-inferior PFS | ||
|- | |- | ||
|} | |} | ||
− | == | + | <div class="toccolours" style="background-color:#b3e2cd"> |
− | |||
====Chemotherapy==== | ====Chemotherapy==== | ||
− | *[[ | + | *[[Capecitabine (Xeloda)]] 625 mg/m<sup>2</sup> PO twice per day |
− | + | *[[Oxaliplatin (Eloxatin)]] 130 mg/m<sup>2</sup> IV once on day 1 | |
− | * | + | '''21-day cycles''' |
− | + | </div></div><br> | |
− | + | <div class="toccolours" style="background-color:#eeeeee"> | |
− | ''' | + | ===Regimen variant #4, 1700/130 {{#subobject:4faee3|Variant=1}}=== |
− | === | + | {| class="wikitable sortable" style="width: 60%; text-align:center;" |
− | + | !style="width: 33%"|Study | |
− | + | !style="width: 33%"|Dates of enrollment | |
− | # | + | !style="width: 33%"|[[Levels_of_Evidence#Evidence|Evidence]] |
− | + | |- | |
− | + | |[https://doi.org/10.1093/annonc/mdj063 Jatoi et al. 2006] | |
− | + | |2002-2004 | |
− | + | | style="background-color:#91cf61" |Phase 2 | |
− | |||
|- | |- | ||
− | |||
|} | |} | ||
− | + | <div class="toccolours" style="background-color:#b3e2cd"> | |
− | + | ====Chemotherapy==== | |
− | {| class="wikitable" style="width: 100%; text-align:center;" | + | *[[Capecitabine (Xeloda)]] 850 mg/m<sup>2</sup> PO twice per day on days 1 to 14 |
− | ! style="width: | + | *[[Oxaliplatin (Eloxatin)]] 130 mg/m<sup>2</sup> IV once on day 1 |
− | ! style="width: | + | '''21-day cycles''' |
− | ! style="width: | + | </div></div><br> |
− | ! style="width: | + | <div class="toccolours" style="background-color:#eeeeee"> |
+ | ===Regimen variant #5, 2000/130 {{#subobject:4fagg3|Variant=1}}=== | ||
+ | {| class="wikitable sortable" style="width: 100%; text-align:center;" | ||
+ | !style="width: 20%"|Study | ||
+ | !style="width: 20%"|Dates of enrollment | ||
+ | !style="width: 20%"|[[Levels_of_Evidence#Evidence|Evidence]] | ||
+ | !style="width: 20%"|Comparator | ||
+ | !style="width: 20%"|[[Levels_of_Evidence#Comparative_efficacy|Comparative Efficacy]] | ||
+ | |- | ||
+ | |[https://www.ncbi.nlm.nih.gov/pmc/articles/pmc8078426/ Moehler et al. 2020 (JAVELIN Gastric 100)] | ||
+ | |2015-2017 | ||
+ | | style="background-color:#1a9851" |Phase 3 (C) | ||
+ | |1a. [[#CapeOx-Avelumab_999|CapeOx-Avelumab]]<br>1b. [[#FOLFOX6-Avelumab_999|FOLFOX6-Avelumab]]<br>1c. [[#mFOLFOX6-Avelumab_999|mFOLFOX6-Avelumab]] | ||
+ | | style="background-color:#ffffbf" |Did not meet primary endpoint of OS | ||
+ | |- | ||
+ | |[https://www.clinicaltrials.gov/study/NCT02934464 Awaiting publication (ARMANI)] | ||
+ | |2016-2019 | ||
+ | | style="background-color:#1a9851" |Phase 3 (C) | ||
+ | |1a. [[#CapeOx_3|CapeOx]] x 3 mo, then [[#Paclitaxel_.26_Ramucirumab_888|Paclitaxel & Ramucirumab]]<br>1b. [[#FOLFOX4_888|FOLFOX4]] x 3 mo, then [[#Paclitaxel_.26_Ramucirumab_888|Paclitaxel & Ramucirumab]]<br>1c. [[#mFOLFOX6_2|mFOLFOX6]] x 3 mo, then [[#Paclitaxel_.26_Ramucirumab_888|Paclitaxel & Ramucirumab]] | ||
+ | | style="background-color:#d3d3d3" |TBD if different primary endpoint of PFS | ||
+ | |- | ||
+ | |[https://doi.org/10.1016/s1470-2045(21)00692-6 Kang et al. 2022 (ATTRACTION-4)] | ||
+ | |2017-03-23 to 2018-05-10 | ||
+ | | style="background-color:#1a9851" |Phase 3 (C) | ||
+ | |1a. [[#CapeOx_.26_Nivolumab|CapeOx & Nivolumab]]<br>1b. [[#SOX_.26_Nivolumab_888|SOX & Nivolumab]] | ||
+ | | style="background-color:#d73027" |Inferior PFS | ||
+ | |- | ||
+ | |rowspan=2|[https://www.ncbi.nlm.nih.gov/pmc/articles/pmc8436782/ Janjigian et al. 2021 (CheckMate 649)] | ||
+ | |rowspan=2|2017-03 to 2019-04 | ||
+ | |rowspan=2 style="background-color:#1a9851" |Phase 3 (C) | ||
+ | |1a. [[#CapeOx_.26_Nivolumab|CapeOx & Nivolumab]]<br>1b. [[#mFOLFOX6_.26_Nivolumab|mFOLFOX6 & Nivolumab]] | ||
+ | | style="background-color:#d73027" |Inferior OS | ||
+ | |- | ||
+ | |2. [[#Ipilimumab_.26_Nivolumab_999|Ipilimumab & Nivolumab]] | ||
+ | | style="background-color:#d3d3d3" |Not reported | ||
+ | |- | ||
+ | |[https://doi.org/10.1136/bmj-2023-078876 Qiu et al. 2024 (RATIONALE-305)] | ||
+ | |2018-12-13 to 2021-02-09 | ||
+ | | style="background-color:#1a9851" |Phase 3 (C) | ||
+ | |1a. [[#CapeOx_.26_Tislelizumab|CapeOx & Tislelizumab]]<br>1b. [[#Cisplatin_.26_Fluorouracil_.28CF.29_.26_Tislelizumab|CF & Tislelizumab]] | ||
+ | | style="background-color:#d73027" |Inferior OS | ||
|- | |- | ||
− | |[https:// | + | |[https://doi.org/10.1016/s1470-2045(23)00515-6 Rha et al. 2023 (KEYNOTE-859)] |
− | | style="background-color:#1a9851" |Phase | + | |2018-11-08 to 2021-06-11 |
− | |[[# | + | | style="background-color:#1a9851" |Phase 3 (C) |
− | | style="background-color:# | + | |1a. [[#CapeOx_.26_Pembrolizumab|CapeOx & Pembrolizumab]]<br>1b. [[#Cisplatin_.26_Fluorouracil_.28CF.29_.26_Pembrolizumab|CF & Pembrolizumab]] |
+ | | style="background-color:#d73027" |Inferior OS | ||
|- | |- | ||
|} | |} | ||
+ | <div class="toccolours" style="background-color:#b3e2cd"> | ||
====Chemotherapy==== | ====Chemotherapy==== | ||
*[[Capecitabine (Xeloda)]] 1000 mg/m<sup>2</sup> PO twice per day on days 1 to 14 | *[[Capecitabine (Xeloda)]] 1000 mg/m<sup>2</sup> PO twice per day on days 1 to 14 | ||
− | + | *[[Oxaliplatin (Eloxatin)]] 130 mg/m<sup>2</sup> IV once on day 1 | |
'''21-day cycles''' | '''21-day cycles''' | ||
+ | </div></div><br> | ||
+ | <div class="toccolours" style="background-color:#eeeeee"> | ||
− | === | + | ===Regimen variant #6, 2000/130, limited oxaliplatin {{#subobject:4hazb3|Variant=1}}=== |
− | {| class="wikitable" style="width: | + | {| class="wikitable sortable" style="width: 100%; text-align:center;" |
− | ! style="width: | + | !style="width: 20%"|Study |
− | ! style="width: | + | !style="width: 20%"|Dates of enrollment |
+ | !style="width: 20%"|[[Levels_of_Evidence#Evidence|Evidence]] | ||
+ | !style="width: 20%"|Comparator | ||
+ | !style="width: 20%"|[[Levels_of_Evidence#Comparative_efficacy|Comparative Efficacy]] | ||
+ | |- | ||
+ | |[https://www.ncbi.nlm.nih.gov/pmc/articles/pmc9017757/ Zhu et al. 2022 (EXELOX)] | ||
+ | |2015-2020 | ||
+ | | style="background-color:#1a9851" |Phase 3 (E-de-esc) | ||
+ | |[[#EOX_2|EOX]] | ||
+ | | style="background-color:#eeee01" |Non-inferior PFS (primary endpoint)<br>Median PFS: 5 vs 5.5 mo<br>(HR 0.989, 95% CI 0.81-1.20) | ||
|- | |- | ||
− | |[ | + | |[https://www.ncbi.nlm.nih.gov/pmc/articles/pmc10427418/ Shah et al. 2023 (GLOW<sub>gastric</sub>)] |
− | | style="background-color:# | + | |2018-11-28 to 2022-02-18 |
+ | | style="background-color:#1a9851" |Phase 3 (C) | ||
+ | |[[#Capectiabine_.26_Oxaliplatin_.28CapeOx.29_.26_Zolbetuximab_777|CapeOx & Zolbetuximab]] | ||
+ | | style="background-color:#fc8d59" |Seems to have inferior OS (secondary endpoint)<br><br>Inferior PFS (primary endpoint) | ||
|- | |- | ||
|} | |} | ||
− | '' | + | ''Note: GLOW should not be confused by the trial of the same name in CLL. In GLOW, continuation of capecitabine past cycle 8 was at the investigator's discretion.'' |
+ | <div class="toccolours" style="background-color:#fdcdac"> | ||
+ | ====Biomarker eligibility criteria==== | ||
+ | *GLOW<sub>gastric</sub>: CLDN18.2 positive | ||
+ | </div> | ||
+ | <div class="toccolours" style="background-color:#b3e2cd"> | ||
====Chemotherapy==== | ====Chemotherapy==== | ||
− | *[[Capecitabine (Xeloda)]] | + | *[[Capecitabine (Xeloda)]] 1000 mg/m<sup>2</sup> PO twice per day on days 1 to 14 |
− | + | *[[Oxaliplatin (Eloxatin)]] as follows: | |
− | '''21-day | + | **Cycles 1 up to 8: 130 mg/m<sup>2</sup> IV once on day 1 |
− | + | '''21-day cycles''' | |
+ | </div></div> | ||
===References=== | ===References=== | ||
− | # | + | #Jatoi A, Murphy BR, Foster NR, Nikcevich DA, Alberts SR, Knost JA, Fitch TR, Rowland KM Jr; North Central Cancer Treatment Group. Oxaliplatin and capecitabine in patients with metastatic adenocarcinoma of the esophagus, gastroesophageal junction and gastric cardia: a phase II study from the North Central Cancer Treatment Group. Ann Oncol. 2006 Jan;17(1):29-34. Epub 2005 Nov 22. [https://doi.org/10.1093/annonc/mdj063 link to original article] '''dosing details in abstract have been reviewed by our editors''' [https://pubmed.ncbi.nlm.nih.gov/16303863/ PubMed] |
− | # | + | #'''JAVELIN Gastric 100:''' Moehler M, Dvorkin M, Boku N, Özgüroğlu M, Ryu MH, Muntean AS, Lonardi S, Nechaeva M, Bragagnoli AC, Coşkun HS, Cubillo Gracian A, Takano T, Wong R, Safran H, Vaccaro GM, Wainberg ZA, Silver MR, Xiong H, Hong J, Taieb J, Bang YJ. Phase III Trial of Avelumab Maintenance After First-Line Induction Chemotherapy Versus Continuation of Chemotherapy in Patients With Gastric Cancers: Results From JAVELIN Gastric 100. J Clin Oncol. 2021 Mar 20;39(9):966-977. Epub 2020 Nov 16. [https://doi.org/10.1200/jco.20.00892 link to original article] '''dosing details in manuscript have been reviewed by our editors''' [https://www.ncbi.nlm.nih.gov/pmc/articles/pmc8078426/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/33197226/ PubMed] [https://clinicaltrials.gov/study/NCT02625610 NCT02625610] |
+ | #'''CheckMate 649:''' Janjigian YY, Shitara K, Moehler M, Garrido M, Salman P, Shen L, Wyrwicz L, Yamaguchi K, Skoczylas T, Campos Bragagnoli A, Liu T, Schenker M, Yanez P, Tehfe M, Kowalyszyn R, Karamouzis MV, Bruges R, Zander T, Pazo-Cid R, Hitre E, Feeney K, Cleary JM, Poulart V, Cullen D, Lei M, Xiao H, Kondo K, Li M, Ajani JA. First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial. Lancet. 2021 Jul 3;398(10294):27-40. Epub 2021 Jun 5. [https://doi.org/10.1016/s0140-6736(21)00797-2 link to original article] '''dosing details in manuscript have been reviewed by our editors''' [https://www.ncbi.nlm.nih.gov/pmc/articles/pmc8436782/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/34102137/ PubMed] [https://clinicaltrials.gov/study/NCT02872116 NCT02872116] | ||
+ | ##'''Update:''' Shitara K, Ajani JA, Moehler M, Garrido M, Gallardo C, Shen L, Yamaguchi K, Wyrwicz L, Skoczylas T, Bragagnoli AC, Liu T, Tehfe M, Elimova E, Bruges R, Zander T, de Azevedo S, Kowalyszyn R, Pazo-Cid R, Schenker M, Cleary JM, Yanez P, Feeney K, Karamouzis MV, Poulart V, Lei M, Xiao H, Kondo K, Li M, Janjigian YY. Nivolumab plus chemotherapy or ipilimumab in gastro-oesophageal cancer. Nature. 2022 Mar;603(7903):942-948. Epub 2022 Mar 23. [https://doi.org/10.1038/s41586-022-04508-4 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8967713/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/35322232/ PubMed] | ||
+ | ##'''HRQoL analysis:''' Moehler M, Xiao H, Blum SI, Elimova E, Cella D, Shitara K, Ajani JA, Janjigian YY, Garrido M, Shen L, Yamaguchi K, Liu T, Schenker M, Kowalyszyn R, Bragagnoli AC, Bruges R, Montesarchio V, Pazo-Cid R, Hunter S, Davenport E, Wang J, Kondo K, Li M, Wyrwicz L. Health-Related Quality of Life With Nivolumab Plus Chemotherapy Versus Chemotherapy in Patients With Advanced Gastric/Gastroesophageal Junction Cancer or Esophageal Adenocarcinoma From CheckMate 649. J Clin Oncol. 2023 Dec 10;41(35):5388-5399. Epub 2023 Sep 15. [https://doi.org/10.1200/jco.23.00170 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/pmc10713185/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/37713657/ PubMed] | ||
+ | ##'''Update:''' Janjigian YY, Ajani JA, Moehler M, Shen L, Garrido M, Gallardo C, Wyrwicz L, Yamaguchi K, Cleary JM, Elimova E, Karamouzis M, Bruges R, Skoczylas T, Bragagnoli A, Liu T, Tehfe M, Zander T, Kowalyszyn R, Pazo-Cid R, Schenker M, Feeny K, Wang R, Lei M, Chen C, Nathani R, Shitara K. First-Line Nivolumab Plus Chemotherapy for Advanced Gastric, Gastroesophageal Junction, and Esophageal Adenocarcinoma: 3-Year Follow-Up of the Phase III CheckMate 649 Trial. J Clin Oncol. 2024 Jun 10;42(17):2012-2020. Epub 2024 Feb 21. [https://doi.org/10.1200/jco.23.01601 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/pmc11185916/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/38382001/ PubMed] | ||
+ | #'''GO2:''' Hall PS, Swinson D, Cairns DA, Waters JS, Petty R, Allmark C, Ruddock S, Falk S, Wadsley J, Roy R, Tillett T, Nicoll J, Cummins S, Mano J, Grumett S, Stokes Z, Kamposioras KV, Chatterjee A, Garcia A, Waddell T, Guptal K, Maisey N, Khan M, Dent J, Lord S, Crossley A, Katona E, Marshall H, Grabsch HI, Velikova G, Ow PL, Handforth C, Howard H, Seymour MT; GO2 Trial Investigators. Efficacy of Reduced-Intensity Chemotherapy With Oxaliplatin and Capecitabine on Quality of Life and Cancer Control Among Older and Frail Patients With Advanced Gastroesophageal Cancer: The GO2 Phase 3 Randomized Clinical Trial. JAMA Oncol. 2021 Jun 1;7(6):869-877. Erratum in: JAMA Oncol. 2021 Aug 1;7(8):1249. [https://doi.org/10.1001/jamaoncol.2021.0848 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/pmc8120440/ link to PMC article] '''dosing details in manuscript have been reviewed by our editors''' [https://pubmed.ncbi.nlm.nih.gov/33983395/ PubMed] ISRCTN44687907 | ||
+ | #'''ATTRACTION-4:''' Kang YK, Chen LT, Ryu MH, Oh DY, Oh SC, Chung HC, Lee KW, Omori T, Shitara K, Sakuramoto S, Chung IJ, Yamaguchi K, Kato K, Sym SJ, Kadowaki S, Tsuji K, Chen JS, Bai LY, Oh SY, Choda Y, Yasui H, Takeuchi K, Hirashima Y, Hagihara S, Boku N. Nivolumab plus chemotherapy versus placebo plus chemotherapy in patients with HER2-negative, untreated, unresectable advanced or recurrent gastric or gastro-oesophageal junction cancer (ATTRACTION-4): a randomised, multicentre, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2022 Feb;23(2):234-247. Epub 2022 Jan 11. [https://doi.org/10.1016/s1470-2045(21)00692-6 link to original article] '''dosing details in abstract have been reviewed by our editors''' [https://pubmed.ncbi.nlm.nih.gov/35030335/ PubMed] [https://clinicaltrials.gov/study/NCT02746796 NCT02746796] | ||
+ | #'''EXELOX:''' Zhu XD, Huang MZ, Wang YS, Feng WJ, Chen ZY, He YF, Zhang XW, Liu X, Wang CC, Zhang W, Ying JE, Wu J, Yang L, Qin YR, Luo JF, Zhao XY, Li WH, Zhang Z, Qiu LX, Geng QR, Zou JL, Zhang JY, Zheng H, Song XF, Wu SS, Zhang CY, Gong Z, Liu QQ, Wang XF, Xu Q, Wang Q, Ji JM, Zhao J, Guo WJ. XELOX doublet regimen versus EOX triplet regimen as first-line treatment for advanced gastric cancer: An open-labeled, multicenter, randomized, prospective phase III trial (EXELOX). Cancer Commun (Lond). 2022 Apr;42(4):314-326. Epub 2022 Feb 25. [https://doi.org/10.1002/cac2.12278 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/pmc9017757/ link to PMC article] '''dosing details in manuscript have been reviewed by our editors''' [https://pubmed.ncbi.nlm.nih.gov/35212487/ PubMed] [https://clinicaltrials.gov/study/NCT02395640 NCT02395640] | ||
+ | #'''GLOW<sub>gastric</sub>:''' Shah MA, Shitara K, Ajani JA, Bang YJ, Enzinger P, Ilson D, Lordick F, Van Cutsem E, Gallego Plazas J, Huang J, Shen L, Oh SC, Sunpaweravong P, Soo Hoo HF, Turk HM, Oh M, Park JW, Moran D, Bhattacharya P, Arozullah A, Xu RH. Zolbetuximab plus CAPOX in CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma: the randomized, phase 3 GLOW trial. Nat Med. 2023 Aug;29(8):2133-2141. Epub 2023 Jul 31. [https://doi.org/10.1038/s41591-023-02465-7 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/pmc10427418/ link to PMC article] '''dosing details in manuscript have been reviewed by our editors''' [https://pubmed.ncbi.nlm.nih.gov/37524953/ PubMed] [https://clinicaltrials.gov/study/NCT03653507 NCT03653507] | ||
+ | #'''KEYNOTE-859:''' Rha SY, Oh DY, Yañez P, Bai Y, Ryu MH, Lee J, Rivera F, Alves GV, Garrido M, Shiu KK, Fernández MG, Li J, Lowery MA, Çil T, Cruz FM, Qin S, Luo S, Pan H, Wainberg ZA, Yin L, Bordia S, Bhagia P, Wyrwicz LS; KEYNOTE-859 investigators. Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): a multicentre, randomised, double-blind, phase 3 trial. Lancet Oncol. 2023 Nov;24(11):1181-1195. Epub 2023 Oct 21. [https://doi.org/10.1016/s1470-2045(23)00515-6 link to original article] '''dosing details in abstract have been reviewed by our editors''' [https://pubmed.ncbi.nlm.nih.gov/37875143/ PubMed] [https://clinicaltrials.gov/study/NCT03675737 NCT03675737] | ||
+ | #'''RATIONALE-305:''' Qiu MZ, Oh DY, Kato K, Arkenau T, Tabernero J, Correa MC, Zimina AV, Bai Y, Shi J, Lee KW, Wang J, Poddubskaya E, Pan H, Rha SY, Zhang R, Hirano H, Spigel D, Yamaguchi K, Chao Y, Wyrwicz L, Disel U, Cid RP, Fornaro L, Evesque L, Wang H, Xu Y, Li J, Sheng T, Yang S, Li L, Moehler M, Xu RH; RATIONALE-305 Investigators. Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first line treatment for advanced gastric or gastro-oesophageal junction adenocarcinoma: RATIONALE-305 randomised, double blind, phase 3 trial. BMJ. 2024 May 28;385:e078876. [https://doi.org/10.1136/bmj-2023-078876 link to original article] '''contains dosing details on CT.gov''' [https://pubmed.ncbi.nlm.nih.gov/38806195/ PubMed] [https://clinicaltrials.gov/study/NCT03777657 NCT03777657] | ||
+ | #'''ARMANI:''' [https://clinicaltrials.gov/study/NCT02934464 NCT02934464] | ||
+ | #'''ORIENT-16:''' [https://clinicaltrials.gov/study/NCT03745170 NCT03745170] | ||
− | ==CapeOx {{#subobject: | + | ==CapeOx & Nivolumab {{#subobject:1ybz18|Regimen=1}}== |
− | {| class="wikitable" style=" | + | CapeOx & Nivolumab: '''<u>Cape</u>'''citabine, '''<u>OX</u>'''aliplatin, Nivolumab |
+ | <div class="toccolours" style="background-color:#eeeeee"> | ||
+ | ===Regimen {{#subobject:1bja1f|Variant=1}}=== | ||
+ | {| class="wikitable sortable" style="width: 100%; text-align:center;" | ||
+ | !style="width: 20%"|Study | ||
+ | !style="width: 20%"|Dates of enrollment | ||
+ | !style="width: 20%"|[[Levels_of_Evidence#Evidence|Evidence]] | ||
+ | !style="width: 20%"|Comparator | ||
+ | !style="width: 20%"|[[Levels_of_Evidence#Comparative_efficacy|Comparative Efficacy]] | ||
+ | |- | ||
+ | |[https://doi.org/10.1016/s1470-2045(21)00692-6 Kang et al. 2022 (ATTRACTION-4)] | ||
+ | |2017-03-23 to 2018-05-10 | ||
+ | | style="background-color:#1a9851" |Phase 3 (E-esc) | ||
+ | |1a. [[#CapeOx_3|CapeOx]]<br>1b. [[#SOX_888|SOX]] | ||
+ | | style="background-color:#1a9850" |Superior PFS (co-primary endpoint)<br>Median PFS: 10.45 vs 8.3 mo<br>(HR 0.68, 98.51% CI 0.51-0.90)<br><br>Did not meet co-primary endpoint of OS<br>Median OS: 17.45 vs 17.15 mo<br>(HR 0.90, 95% CI 0.75-1.08) | ||
+ | |- | ||
+ | |rowspan=2|[https://www.ncbi.nlm.nih.gov/pmc/articles/pmc8436782/ Janjigian et al. 2021 (CheckMate 649)] | ||
+ | <!-- {| class="wikitable" style="margin:auto; color:white; background-color:#1B4F26" | ||
+ | |'''[https://www.esmo.org/guidelines/esmo-mcbs/esmo-mcbs-scorecards/scorecard-290-1 <span style="color:white;">ESMO-MCBS (4)</span>]''' | ||
|- | |- | ||
− | + | |} --> | |
− | |} | + | |rowspan=2|2017-03 to 2019-04 |
− | + | |rowspan=2 style="background-color:#1a9851" |Phase 3 (E-RT-esc) | |
− | = | + | |1a. [[#CapeOx_3|CapeOx]]<br>1b. [[#mFOLFOX6_2|mFOLFOX6]] |
− | + | | style="background-color:#1a9850" |Superior OS<sup>1</sup> (co-primary endpoint)<br>Median OS: 14.4 vs 11.1 mo<br>(HR 0.70, 95% CI 0.61-0.81) | |
− | |||
− | |||
|- | |- | ||
− | |[ | + | |2. [[#Ipilimumab_.26_Nivolumab_999|Ipilimumab & Nivolumab]] |
− | | style="background-color:# | + | | style="background-color:#d3d3d3" |Not reported |
|- | |- | ||
|} | |} | ||
+ | ''<sup>1</sup>Reported efficacy and MCBS score are for the group with PD-L1 CPS of 5 or more; reported efficacy is based on the 2022 update.'' | ||
+ | <div class="toccolours" style="background-color:#b3e2cd"> | ||
====Chemotherapy==== | ====Chemotherapy==== | ||
− | *[[Capecitabine (Xeloda)]] | + | *[[Capecitabine (Xeloda)]] 1000 mg/m<sup>2</sup> PO twice per day on days 1 to 14 |
*[[Oxaliplatin (Eloxatin)]] 130 mg/m<sup>2</sup> IV once on day 1 | *[[Oxaliplatin (Eloxatin)]] 130 mg/m<sup>2</sup> IV once on day 1 | ||
− | + | ====Immunotherapy==== | |
+ | *[[Nivolumab (Opdivo)]] 360 mg IV once on day 1 | ||
'''21-day cycles''' | '''21-day cycles''' | ||
− | + | </div></div> | |
+ | ===References=== | ||
+ | #'''CheckMate 649:''' Janjigian YY, Shitara K, Moehler M, Garrido M, Salman P, Shen L, Wyrwicz L, Yamaguchi K, Skoczylas T, Campos Bragagnoli A, Liu T, Schenker M, Yanez P, Tehfe M, Kowalyszyn R, Karamouzis MV, Bruges R, Zander T, Pazo-Cid R, Hitre E, Feeney K, Cleary JM, Poulart V, Cullen D, Lei M, Xiao H, Kondo K, Li M, Ajani JA. First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial. Lancet. 2021 Jul 3;398(10294):27-40. Epub 2021 Jun 5. [https://doi.org/10.1016/s0140-6736(21)00797-2 link to original article] '''dosing details in manuscript have been reviewed by our editors''' [https://www.ncbi.nlm.nih.gov/pmc/articles/pmc8436782/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/34102137/ PubMed] [https://clinicaltrials.gov/study/NCT02872116 NCT02872116] | ||
+ | ##'''Update:''' Shitara K, Ajani JA, Moehler M, Garrido M, Gallardo C, Shen L, Yamaguchi K, Wyrwicz L, Skoczylas T, Bragagnoli AC, Liu T, Tehfe M, Elimova E, Bruges R, Zander T, de Azevedo S, Kowalyszyn R, Pazo-Cid R, Schenker M, Cleary JM, Yanez P, Feeney K, Karamouzis MV, Poulart V, Lei M, Xiao H, Kondo K, Li M, Janjigian YY. Nivolumab plus chemotherapy or ipilimumab in gastro-oesophageal cancer. Nature. 2022 Mar;603(7903):942-948. Epub 2022 Mar 23. [https://doi.org/10.1038/s41586-022-04508-4 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8967713/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/35322232/ PubMed] | ||
+ | ##'''HRQoL analysis:''' Moehler M, Xiao H, Blum SI, Elimova E, Cella D, Shitara K, Ajani JA, Janjigian YY, Garrido M, Shen L, Yamaguchi K, Liu T, Schenker M, Kowalyszyn R, Bragagnoli AC, Bruges R, Montesarchio V, Pazo-Cid R, Hunter S, Davenport E, Wang J, Kondo K, Li M, Wyrwicz L. Health-Related Quality of Life With Nivolumab Plus Chemotherapy Versus Chemotherapy in Patients With Advanced Gastric/Gastroesophageal Junction Cancer or Esophageal Adenocarcinoma From CheckMate 649. J Clin Oncol. 2023 Dec 10;41(35):5388-5399. Epub 2023 Sep 15. [https://doi.org/10.1200/jco.23.00170 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/pmc10713185/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/37713657/ PubMed] | ||
+ | ##'''Update:''' Janjigian YY, Ajani JA, Moehler M, Shen L, Garrido M, Gallardo C, Wyrwicz L, Yamaguchi K, Cleary JM, Elimova E, Karamouzis M, Bruges R, Skoczylas T, Bragagnoli A, Liu T, Tehfe M, Zander T, Kowalyszyn R, Pazo-Cid R, Schenker M, Feeny K, Wang R, Lei M, Chen C, Nathani R, Shitara K. First-Line Nivolumab Plus Chemotherapy for Advanced Gastric, Gastroesophageal Junction, and Esophageal Adenocarcinoma: 3-Year Follow-Up of the Phase III CheckMate 649 Trial. J Clin Oncol. 2024 Jun 10;42(17):2012-2020. Epub 2024 Feb 21. [https://doi.org/10.1200/jco.23.01601 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/pmc11185916/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/38382001/ PubMed] | ||
+ | #'''ATTRACTION-4:''' Kang YK, Chen LT, Ryu MH, Oh DY, Oh SC, Chung HC, Lee KW, Omori T, Shitara K, Sakuramoto S, Chung IJ, Yamaguchi K, Kato K, Sym SJ, Kadowaki S, Tsuji K, Chen JS, Bai LY, Oh SY, Choda Y, Yasui H, Takeuchi K, Hirashima Y, Hagihara S, Boku N. Nivolumab plus chemotherapy versus placebo plus chemotherapy in patients with HER2-negative, untreated, unresectable advanced or recurrent gastric or gastro-oesophageal junction cancer (ATTRACTION-4): a randomised, multicentre, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2022 Feb;23(2):234-247. Epub 2022 Jan 11. [https://doi.org/10.1016/s1470-2045(21)00692-6 link to original article] '''dosing details in abstract have been reviewed by our editors''' [https://pubmed.ncbi.nlm.nih.gov/35030335/ PubMed] [https://clinicaltrials.gov/study/NCT02746796 NCT02746796] | ||
+ | ==CapeOx & Pembrolizumab {{#subobject:1yhy28|Regimen=1}}== | ||
+ | CapeOx & Pembrolizumab: '''<u>Cape</u>'''citabine, '''<u>OX</u>'''aliplatin, Pembrolizumab | ||
+ | <div class="toccolours" style="background-color:#eeeeee"> | ||
+ | ===Regimen {{#subobject:acb31f|Variant=1}}=== | ||
+ | {| class="wikitable sortable" style="width: 100%; text-align:center;" | ||
+ | ! style="width: 20%" |Study | ||
+ | ! style="width: 20%" |Dates of enrollment | ||
+ | ! style="width: 20%" |[[Levels_of_Evidence#Evidence|Evidence]] | ||
+ | ! style="width: 20%" |Comparator | ||
+ | ! style="width: 20%" |[[Levels_of_Evidence#Comparative_efficacy|Comparative Efficacy]] | ||
+ | |- | ||
+ | |[https://doi.org/10.1016/s1470-2045(23)00515-6 Rha et al. 2023 (KEYNOTE-859)] | ||
+ | |2018-11-08 to 2021-06-11 | ||
+ | | style="background-color:#1a9851" |Phase 3 (E-RT-esc) | ||
+ | |1a. [[#Cisplatin_.26_Fluorouracil_.28CF.29_2|CF]]<br>1b. [[#CapeOx_3|CapeOx]] | ||
+ | | style="background-color:#1a9850" |Superior OS (primary endpoint)<br>Median OS: 12.9 vs 11.5 mo<br>(HR 0.78, 95% CI 0.70-0.87) | ||
+ | |} | ||
+ | ''KEYNOTE-859 included patients with GEJ malignancy'' | ||
+ | <div class="toccolours" style="background-color:#fdcdac"> | ||
+ | ====Biomarker eligibility criteria==== | ||
+ | *PD-L1 Combined Positive Score (CPS) of 1 or more as determined by an FDA-approved test | ||
+ | </div> | ||
+ | <div class="toccolours" style="background-color:#b3e2cd"> | ||
+ | ====Chemotherapy==== | ||
+ | *[[Capecitabine (Xeloda)]] 1000 mg/m<sup>2</sup> PO twice per day on days 1 to 14 | ||
+ | *[[Oxaliplatin (Eloxatin)]] 130 mg/m<sup>2</sup> IV once on day 1 | ||
+ | ====Immunotherapy==== | ||
+ | *[[Pembrolizumab (Keytruda)]] 200 mg IV once on day 1 | ||
+ | '''21-day cycle for up to 35 cycles''' | ||
+ | </div></div> | ||
===References=== | ===References=== | ||
− | # | + | #'''KEYNOTE-859:''' Rha SY, Oh DY, Yañez P, Bai Y, Ryu MH, Lee J, Rivera F, Alves GV, Garrido M, Shiu KK, Fernández MG, Li J, Lowery MA, Çil T, Cruz FM, Qin S, Luo S, Pan H, Wainberg ZA, Yin L, Bordia S, Bhagia P, Wyrwicz LS; KEYNOTE-859 investigators. Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): a multicentre, randomised, double-blind, phase 3 trial. Lancet Oncol. 2023 Nov;24(11):1181-1195. Epub 2023 Oct 21. [https://doi.org/10.1016/s1470-2045(23)00515-6 link to original article] '''dosing details in abstract have been reviewed by our editors''' [https://pubmed.ncbi.nlm.nih.gov/37875143/ PubMed] [https://clinicaltrials.gov/study/NCT03675737 NCT03675737] |
− | == | + | ==CapeOx & Tislelizumab {{#subobject:4dcxw6|Regimen=1}}== |
− | {| class="wikitable" style=" | + | CapeOX & Tislelizumab: '''<u>Cape</u>'''citabine, '''<u>OX</u>'''aliplatin, Tislelizumab |
+ | <div class="toccolours" style="background-color:#eeeeee"> | ||
+ | ===Regimen {{#subobject:capis5|Variant=1}}=== | ||
+ | {| class="wikitable sortable" style="width: 100%; text-align:center;" | ||
+ | ! style="width: 20%" |Study | ||
+ | ! style="width: 20%" |Dates of enrollment | ||
+ | ! style="width: 20%" |[[Levels_of_Evidence#Evidence|Evidence]] | ||
+ | ! style="width: 20%" |Comparator | ||
+ | ! style="width: 20%" |[[Levels_of_Evidence#Comparative_efficacy|Comparative Efficacy]] | ||
+ | |- | ||
+ | |[https://doi.org/10.1136/bmj-2023-078876 Qiu et al. 2024 (RATIONALE-305)] | ||
+ | |2018-12-13 to 2021-02-09 | ||
+ | | style="background-color:#1a9851" |Phase 3 (E-esc) | ||
+ | |1a. [[#CapeOx_3|CapeOx]]<br>1b. [[#Cisplatin_.26_Fluorouracil_.28CF.29_2|CF]] | ||
+ | | style="background-color:#1a9850" |Superior OS (primary endpoint)<br>Median OS: 15 vs 12.9 mo<br>(HR 0.80, 95% CI 0.70-0.92) | ||
|- | |- | ||
− | |||
|} | |} | ||
+ | <div class="toccolours" style="background-color:#b3e2cd"> | ||
+ | ====Chemotherapy==== | ||
+ | *[[Capecitabine (Xeloda)]] 1000 mg/m<sup>2</sup> PO twice per day on days 1 to 14 | ||
+ | *[[Oxaliplatin (Eloxatin)]] 130 mg/m<sup>2</sup> IV once on day 1 | ||
+ | ====Immunotherapy==== | ||
+ | *[[Tislelizumab (Baizean)]] 200 mg IV once on day 1 | ||
+ | '''21-day cycles''' | ||
+ | </div></div> | ||
+ | ===References=== | ||
+ | #'''RATIONALE-305:''' Qiu MZ, Oh DY, Kato K, Arkenau T, Tabernero J, Correa MC, Zimina AV, Bai Y, Shi J, Lee KW, Wang J, Poddubskaya E, Pan H, Rha SY, Zhang R, Hirano H, Spigel D, Yamaguchi K, Chao Y, Wyrwicz L, Disel U, Cid RP, Fornaro L, Evesque L, Wang H, Xu Y, Li J, Sheng T, Yang S, Li L, Moehler M, Xu RH; RATIONALE-305 Investigators. Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first line treatment for advanced gastric or gastro-oesophageal junction adenocarcinoma: RATIONALE-305 randomised, double blind, phase 3 trial. BMJ. 2024 May 28;385:e078876. [https://doi.org/10.1136/bmj-2023-078876 link to original article] '''contains dosing details on CT.gov''' [https://pubmed.ncbi.nlm.nih.gov/38806195/ PubMed] [https://clinicaltrials.gov/study/NCT03777657 NCT03777657] | ||
+ | |||
+ | ==Carboplatin & Paclitaxel (CP) {{#subobject:4df570|Regimen=1}}== | ||
+ | <div class="toccolours" style="background-color:#eeeeee"> | ||
===Regimen {{#subobject:9725d8|Variant=1}}=== | ===Regimen {{#subobject:9725d8|Variant=1}}=== | ||
− | {| class="wikitable" style="width: | + | {| class="wikitable sortable" style="width: 60%; text-align:center;" |
− | ! style="width: | + | !style="width: 33%"|Study |
− | ! style="width: | + | !style="width: 33%"|Dates of enrollment |
+ | !style="width: 33%"|[[Levels_of_Evidence#Evidence|Evidence]] | ||
|- | |- | ||
− | |[https:// | + | |[https://pubmed.ncbi.nlm.nih.gov/9427274 Philip et al. 1997] |
− | | style="background-color:#91cf61" |Phase | + | |Not reported in abstract |
+ | | style="background-color:#91cf61" |Phase 2 | ||
|- | |- | ||
− | |[ | + | |[https://doi.org/10.1097/00000421-200302000-00008 Gadgeel et al. 2003] |
− | | style="background-color:#91cf61" |Phase | + | |1996-2000 |
+ | | style="background-color:#91cf61" |Phase 2 | ||
|- | |- | ||
|} | |} | ||
− | ''Note: In contrast to the original reference, some guidelines list the dosage of carboplatin as AUC 6. | + | ''Note: In contrast to the original reference, some guidelines list the dosage of carboplatin as AUC 6. Philip et al. included patients with locally advanced metastatic or recurrent esophageal or gastric cancer. Gadgeel et al. study showed an ORR of 35%.'' |
− | + | <div class="toccolours" style="background-color:#b3e2cd"> | |
− | |||
− | |||
− | |||
====Chemotherapy==== | ====Chemotherapy==== | ||
*[[Carboplatin (Paraplatin)]] AUC 5 IV once on day 1, '''given second''' | *[[Carboplatin (Paraplatin)]] AUC 5 IV once on day 1, '''given second''' | ||
*[[Paclitaxel (Taxol)]] 200 mg/m<sup>2</sup> IV over 3 hours once on day 1, '''given first''' | *[[Paclitaxel (Taxol)]] 200 mg/m<sup>2</sup> IV over 3 hours once on day 1, '''given first''' | ||
− | |||
'''21-day cycles''' | '''21-day cycles''' | ||
− | + | </div></div> | |
===References=== | ===References=== | ||
− | # Philip PA, Zalupski MM, Gadgeel S, Hussain M, Shields A. A phase II study of carboplatin and paclitaxel in the treatment of patients with advanced esophageal and gastric cancer. Semin Oncol. 1997 Dec;24(6 Suppl 19):S19-86-S19-88. ''' | + | #Philip PA, Zalupski MM, Gadgeel S, Hussain M, Shields A. A phase II study of carboplatin and paclitaxel in the treatment of patients with advanced esophageal and gastric cancer. Semin Oncol. 1997 Dec;24(6 Suppl 19):S19-86-S19-88. '''dosing details in abstract have been reviewed by our editors''' [https://pubmed.ncbi.nlm.nih.gov/9427274/ PubMed] |
− | # Gadgeel SM, Shields AF, Heilbrun LK, Labadidi S, Zalupski M, Chaplen R, Philip PA. Phase II study of paclitaxel and carboplatin in patients with advanced gastric cancer. Am J Clin Oncol. 2003 Feb;26(1):37-41. [ | + | #Gadgeel SM, Shields AF, Heilbrun LK, Labadidi S, Zalupski M, Chaplen R, Philip PA. Phase II study of paclitaxel and carboplatin in patients with advanced gastric cancer. Am J Clin Oncol. 2003 Feb;26(1):37-41. [https://doi.org/10.1097/00000421-200302000-00008 link to original article] '''dosing details in abstract have been reviewed by our editors''' [https://pubmed.ncbi.nlm.nih.gov/12576922/ PubMed] |
− | + | ==Cisplatin & Docetaxel (DC) {{#subobject:724868|Regimen=1}}== | |
− | ==Cisplatin & Docetaxel {{#subobject:724868|Regimen=1}}== | ||
− | |||
− | |||
− | |||
− | |||
DC: '''<u>D</u>'''ocetaxel, '''<u>C</u>'''isplatin | DC: '''<u>D</u>'''ocetaxel, '''<u>C</u>'''isplatin | ||
<br>TC: '''<u>T</u>'''axotere (Docetaxel), '''<u>C</u>'''isplatin | <br>TC: '''<u>T</u>'''axotere (Docetaxel), '''<u>C</u>'''isplatin | ||
− | + | <div class="toccolours" style="background-color:#eeeeee"> | |
− | === | + | ===Regimen variant #1, 75/75 {{#subobject:cd0910|Variant=1}}=== |
− | {| class="wikitable" style="width: 100%; text-align:center;" | + | {| class="wikitable sortable" style="width: 100%; text-align:center;" |
− | ! style="width: | + | ! style="width: 20%" |Study |
− | ! style="width: | + | ! style="width: 20%" |Dates of enrollment |
− | ! style="width: | + | ! style="width: 20%" |[[Levels_of_Evidence#Evidence|Evidence]] |
− | ! style="width: | + | ! style="width: 20%" |Comparator |
+ | ! style="width: 20%" |[[Levels_of_Evidence#Comparative_efficacy|Comparative Efficacy]] | ||
|- | |- | ||
− | | rowspan="2" |[ | + | | rowspan="2" |[https://doi.org/10.1200/jco.2006.08.0135 Roth et al. 2007] |
− | | rowspan="2" style="background-color:#1a9851" |Randomized Phase | + | | rowspan="2" |1999-2003 |
+ | | rowspan="2" style="background-color:#1a9851" |Randomized Phase 2 (E-de-esc) | ||
|1. [[#ECF_3|ECF]] | |1. [[#ECF_3|ECF]] | ||
| style="background-color:#d3d3d3" |Not reported | | style="background-color:#d3d3d3" |Not reported | ||
Line 928: | Line 1,872: | ||
|} | |} | ||
''Note: the protocol was amended to change the original dose of docetaxel from 85 mg/m<sup>2</sup> to 75 mg/m<sup>2</sup> based on high incidence of febrile neutropenia.'' | ''Note: the protocol was amended to change the original dose of docetaxel from 85 mg/m<sup>2</sup> to 75 mg/m<sup>2</sup> based on high incidence of febrile neutropenia.'' | ||
+ | <div class="toccolours" style="background-color:#b3e2cd"> | ||
====Chemotherapy==== | ====Chemotherapy==== | ||
+ | *[[Cisplatin (Platinol)]] 75 mg/m<sup>2</sup> IV over 4 hours once on day 1 | ||
*[[Docetaxel (Taxotere)]] 75 mg/m<sup>2</sup> IV over 60 minutes once on day 1 | *[[Docetaxel (Taxotere)]] 75 mg/m<sup>2</sup> IV over 60 minutes once on day 1 | ||
− | + | ====Supportive therapy==== | |
− | + | *3 liters per day [[:Category:Hydration|"hyperhydration"]] | |
− | ====Supportive | + | *[[Dexamethasone (Decadron)]] 8 mg PO given 12 hours & 6 hours prior to docetaxel, then 8 mg PO twice per day for 4 days after docetaxel |
− | *3 liters per day "hyperhydration" | ||
− | *[[Dexamethasone (Decadron)]] 8 mg PO given 12 hours & 6 hours | ||
*[[:Category:Serotonin_5-HT3_antagonists|5-HT3 antagonist]] for emesis prophylaxis | *[[:Category:Serotonin_5-HT3_antagonists|5-HT3 antagonist]] for emesis prophylaxis | ||
*Growth factor support allowed, such as with [[Filgrastim (Neupogen)]] | *Growth factor support allowed, such as with [[Filgrastim (Neupogen)]] | ||
− | |||
'''21-day cycle for up to 8 cycles''' | '''21-day cycle for up to 8 cycles''' | ||
− | + | </div></div><br> | |
− | === | + | <div class="toccolours" style="background-color:#eeeeee"> |
− | {| class="wikitable" style="width: 100%; text-align:center;" | + | ===Regimen variant #2, 75/85 {{#subobject:f1913d|Variant=1}}=== |
− | ! style="width: | + | {| class="wikitable sortable" style="width: 100%; text-align:center;" |
− | ! style="width: | + | ! style="width: 20%" |Study |
− | ! style="width: | + | ! style="width: 20%" |Dates of enrollment |
− | ! style="width: | + | ! style="width: 20%" |[[Levels_of_Evidence#Evidence|Evidence]] |
+ | ! style="width: 20%" |Comparator | ||
+ | ! style="width: 20%" |[[Levels_of_Evidence#Comparative_efficacy|Comparative Efficacy]] | ||
|- | |- | ||
− | |[ | + | |[https://doi.org/10.1200/jco.2005.17.376 Ajani et al. 2005 (V-325)] |
− | | style="background-color:#1a9851" |Randomized Phase | + | |1998-1999 |
+ | | style="background-color:#1a9851" |Randomized Phase 2 (C) | ||
|[[#DCF|DCF]] | |[[#DCF|DCF]] | ||
| style="background-color:#fc8d59" |Seems to have inferior ORR | | style="background-color:#fc8d59" |Seems to have inferior ORR | ||
|- | |- | ||
|} | |} | ||
− | '' | + | ''Note: patients had 100% adenocarcinoma histology (32% esophagogastric junction/fundus and 68% gastric antrum/body). 95% were metastatic. 1% with Karnofsky PS score of 70.'' |
− | + | <div class="toccolours" style="background-color:#b3e2cd"> | |
====Chemotherapy==== | ====Chemotherapy==== | ||
+ | *[[Cisplatin (Platinol)]] 75 mg/m<sup>2</sup> IV over 1 to 3 hours once on day 1 | ||
*[[Docetaxel (Taxotere)]] 85 mg/m<sup>2</sup> IV over 60 minutes once on day 1 | *[[Docetaxel (Taxotere)]] 85 mg/m<sup>2</sup> IV over 60 minutes once on day 1 | ||
− | + | ====Supportive therapy==== | |
− | |||
− | ====Supportive | ||
*[[Dexamethasone (Decadron)]] 8 mg PO the night before chemotherapy, the morning of day 1, 1 hour before chemotherapy, the night of day 1, the morning of day 2, and the evening of day 2 (total dose per cycle: 48 mg) | *[[Dexamethasone (Decadron)]] 8 mg PO the night before chemotherapy, the morning of day 1, 1 hour before chemotherapy, the night of day 1, the morning of day 2, and the evening of day 2 (total dose per cycle: 48 mg) | ||
− | *[[Dexamethasone (Decadron)]] 20 mg IV | + | *[[Dexamethasone (Decadron)]] 20 mg IV prior to cisplatin and 8 hours after cisplatin |
− | *[[Ondansetron (Zofran)]] 8 mg IV | + | *[[Ondansetron (Zofran)]] 8 mg IV prior to cisplatin, 4 hours after cisplatin, and 8 hours after cisplatin |
− | + | *"[[:Category:Hydration|Hydration]] was administered in a standard manner" | |
− | |||
'''21-day cycles''' | '''21-day cycles''' | ||
− | + | </div></div> | |
===References=== | ===References=== | ||
− | # '''V-325:''' Ajani JA, Fodor MB, Tjulandin SA, Moiseyenko VM, Chao Y, Cabral Filho S, Majlis A, Assadourian S, Van Cutsem E. Phase II multi-institutional randomized trial of docetaxel plus cisplatin with or without fluorouracil in patients with untreated, advanced gastric, or gastroesophageal adenocarcinoma. J Clin Oncol. 2005 Aug 20;23(24):5660-7. [ | + | #'''V-325:''' Ajani JA, Fodor MB, Tjulandin SA, Moiseyenko VM, Chao Y, Cabral Filho S, Majlis A, Assadourian S, Van Cutsem E. Phase II multi-institutional randomized trial of docetaxel plus cisplatin with or without fluorouracil in patients with untreated, advanced gastric, or gastroesophageal adenocarcinoma. J Clin Oncol. 2005 Aug 20;23(24):5660-7. [https://doi.org/10.1200/jco.2005.17.376 link to original article] '''dosing details in manuscript have been reviewed by our editors''' [https://pubmed.ncbi.nlm.nih.gov/16110025/ PubMed] |
− | # Roth AD, Fazio N, Stupp R, Falk S, Bernhard J, Saletti P, Köberle D, Borner MM, Rufibach K, Maibach R, Wernli M, Leslie M, Glynne-Jones R, Widmer L, Seymour M, de Braud F; Swiss Group for Clinical Cancer Research. Docetaxel, cisplatin, and fluorouracil; docetaxel and cisplatin; and epirubicin, cisplatin, and fluorouracil as systemic treatment for advanced gastric carcinoma: a randomized phase II trial of the Swiss Group for Clinical Cancer Research. J Clin Oncol. 2007 Aug 1;25(22):3217-23. [ | + | #Roth AD, Fazio N, Stupp R, Falk S, Bernhard J, Saletti P, Köberle D, Borner MM, Rufibach K, Maibach R, Wernli M, Leslie M, Glynne-Jones R, Widmer L, Seymour M, de Braud F; Swiss Group for Clinical Cancer Research. Docetaxel, cisplatin, and fluorouracil; docetaxel and cisplatin; and epirubicin, cisplatin, and fluorouracil as systemic treatment for advanced gastric carcinoma: a randomized phase II trial of the Swiss Group for Clinical Cancer Research. J Clin Oncol. 2007 Aug 1;25(22):3217-23. [https://doi.org/10.1200/jco.2006.08.0135 link to original article] '''dosing details in manuscript have been reviewed by our editors''' [https://pubmed.ncbi.nlm.nih.gov/17664469/ PubMed] |
− | + | ==Cisplatin & Fluorouracil (CF) {{#subobject:4d9936|Regimen=1}}== | |
− | ==Cisplatin & Fluorouracil {{#subobject:4d9936|Regimen=1}}== | ||
− | |||
− | |||
− | |||
− | |||
CF: '''<u>C</u>'''isplatin, '''<u>F</u>'''luorouracil | CF: '''<u>C</u>'''isplatin, '''<u>F</u>'''luorouracil | ||
<br>FP: '''<u>F</u>'''luorouracil, '''<u>P</u>'''latinol (Cisplatin) | <br>FP: '''<u>F</u>'''luorouracil, '''<u>P</u>'''latinol (Cisplatin) | ||
− | === | + | <div class="toccolours" style="background-color:#eeeeee"> |
− | {| class="wikitable" style="width: 100%; text-align:center;" | + | ===Regimen variant #1, 60/5000 {{#subobject:9yt155|Variant=1}}=== |
− | ! style="width: | + | {| class="wikitable sortable" style="width: 100%; text-align:center;" |
− | ! style="width: | + | ! style="width: 20%" |Study |
− | ! style="width: | + | ! style="width: 20%" |Dates of enrollment |
− | ! style="width: | + | ! style="width: 20%" |[[Levels_of_Evidence#Evidence|Evidence]] |
+ | ! style="width: 20%" |Comparator | ||
+ | ! style="width: 20%" |[[Levels_of_Evidence#Comparative_efficacy|Comparative Efficacy]] | ||
|- | |- | ||
− | |[https://www. | + | |[https://www.ncbi.nlm.nih.gov/pmc/articles/pmc2699097/ Lee et al. 2009a] |
− | | style="background-color:#1a9851" |Phase | + | |2000-2004 |
− | |[[# | + | | style="background-color:#1a9851" |Phase 3 (C) |
− | | style="background-color:# | + | |[[#Fluorouracil_.26_Heptaplatin_.28FH.29|Fluorouracil & Heptaplatin (FH)]] |
+ | | style="background-color:#eeee01" |Equivalent OS | ||
|- | |- | ||
|} | |} | ||
− | '' | + | ''Note: this is reported to be an equivalence study but the statistical analysis does not provide details on the definition of equivalence.'' |
− | + | <div class="toccolours" style="background-color:#b3e2cd"> | |
− | |||
− | |||
====Chemotherapy==== | ====Chemotherapy==== | ||
− | *[[Cisplatin (Platinol)]] | + | *[[Cisplatin (Platinol)]] 60 mg/m<sup>2</sup> IV over 60 minutes once on day 1, '''given first''' |
− | *[[Fluorouracil (5-FU)]] | + | *[[Fluorouracil (5-FU)]] 1000 mg/m<sup>2</sup> IV over 12 hours once per day on days 1 to 5, '''given second''' |
− | + | '''28-day cycles''' | |
− | + | </div></div><br> | |
− | + | <div class="toccolours" style="background-color:#eeeeee"> | |
− | + | ===Regimen variant #2, 80/4000 x 8 {{#subobject:9abe95|Variant=1}}=== | |
− | ''' | + | {| class="wikitable sortable" style="width: 100%; text-align:center;" |
− | + | ! style="width: 20%" |Study | |
− | === | + | ! style="width: 20%" |Dates of enrollment |
− | {| class="wikitable" style="width: 100%; text-align:center;" | + | ! style="width: 20%" |[[Levels_of_Evidence#Evidence|Evidence]] |
− | ! style="width: | + | ! style="width: 20%" |Comparator |
− | ! style="width: | + | ! style="width: 20%" |[[Levels_of_Evidence#Comparative_efficacy|Comparative Efficacy]] |
− | ! style="width: | ||
− | ! style="width: | ||
|- | |- | ||
− | |[https:// | + | |[https://doi.org/10.1093/annonc/mdx275 Ajani et al. 2017 (DIGEST)] |
− | | style="background-color:#1a9851" |Phase | + | |2011-2014 |
+ | | style="background-color:#1a9851" |Phase 3 (C) | ||
|[[#Cisplatin_.26_S-1|CS]] | |[[#Cisplatin_.26_S-1|CS]] | ||
− | | style="background-color:#ffffbf" | | + | | style="background-color:#ffffbf" |Did not meet primary endpoint of OS |
|- | |- | ||
|} | |} | ||
+ | <div class="toccolours" style="background-color:#b3e2cd"> | ||
====Chemotherapy==== | ====Chemotherapy==== | ||
*[[Cisplatin (Platinol)]] 80 mg/m<sup>2</sup> IV over 1 to 3 hours once on day 1, '''given first''' | *[[Cisplatin (Platinol)]] 80 mg/m<sup>2</sup> IV over 1 to 3 hours once on day 1, '''given first''' | ||
*[[Fluorouracil (5-FU)]] 800 mg/m<sup>2</sup>/day IV continuous infusion over 120 hours, started on day 1, '''given second''' (total dose per cycle: 4000 mg/m<sup>2</sup>) | *[[Fluorouracil (5-FU)]] 800 mg/m<sup>2</sup>/day IV continuous infusion over 120 hours, started on day 1, '''given second''' (total dose per cycle: 4000 mg/m<sup>2</sup>) | ||
− | + | ====Supportive therapy==== | |
− | ====Supportive | + | *Some protocols: [[:Category:Hydration|"Hyperhydration"]] for cisplatin |
− | *Some protocols: "Hyperhydration" | ||
− | |||
'''21-day cycle for 8 cycles''' | '''21-day cycle for 8 cycles''' | ||
− | + | </div></div><br> | |
− | === | + | <div class="toccolours" style="background-color:#eeeeee"> |
− | {| class="wikitable" style="width: 100%; text-align:center;" | + | ===Regimen variant #3, 80/4000, indefinite {{#subobject:69c795|Variant=1}}=== |
− | ! style="width: | + | {| class="wikitable sortable" style="width: 100%; text-align:center;" |
− | ! style="width: | + | ! style="width: 20%" |Study |
− | ! style="width: | + | ! style="width: 20%" |Dates of enrollment |
− | ! style="width: | + | ! style="width: 20%" |[[Levels_of_Evidence#Evidence|Evidence]] |
+ | ! style="width: 20%" |Comparator | ||
+ | ! style="width: 20%" |[[Levels_of_Evidence#Comparative_efficacy|Comparative Efficacy]] | ||
|- | |- | ||
− | |[ | + | |[https://doi.org/10.1093/annonc/mdn717 Kang et al. 2009 (ML17032)] |
− | | style="background-color:#1a9851" |Phase | + | |2003-2005 |
− | |[[# | + | | style="background-color:#1a9851" |Phase 3 (C) |
+ | |[[#Capecitabine_.26_Cisplatin_.28CX.29_3|CX]] | ||
| style="background-color:#eeee01" |Non-inferior PFS | | style="background-color:#eeee01" |Non-inferior PFS | ||
+ | |- | ||
+ | |rowspan=2|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7489405/ Shitara et al. 2020 (KEYNOTE-062)] | ||
+ | |rowspan=2|2015-2017 | ||
+ | |rowspan=2 style="background-color:#1a9851" |Phase 3 (C) | ||
+ | |1a. [[#Cisplatin_.26_Fluorouracil_.28CF.29_.26_Pembrolizumab|CF & Pembrolizumab]]<br>1b. [[#Capecitabine_.26_Cisplatin_.28CX.29_.26_Pembrolizumab|CX & Pembrolizumab]] | ||
+ | | style="background-color:#fee08b" |Might have inferior OS | ||
+ | |- | ||
+ | |2. [[#Pembrolizumab_monotherapy|Pembrolizumab]] | ||
+ | | style="background-color:#eeee01" |Non-inferior OS | ||
+ | |- | ||
+ | |[https://doi.org/10.1136/bmj-2023-078876 Qiu et al. 2024 (RATIONALE-305)] | ||
+ | |2018-12-13 to 2021-02-09 | ||
+ | | style="background-color:#1a9851" |Phase 3 (C) | ||
+ | |1a. [[#CapeOx_.26_Tislelizumab|CapeOx & Tislelizumab]]<br>1b. [[#Cisplatin_.26_Fluorouracil_.28CF.29_.26_Tislelizumab|CF & Tislelizumab]] | ||
+ | | style="background-color:#d73027" |Inferior OS | ||
+ | |- | ||
+ | |[https://doi.org/10.1016/s1470-2045(23)00515-6 Rha et al. 2023 (KEYNOTE-859)] | ||
+ | |2018-11-08 to 2021-06-11 | ||
+ | | style="background-color:#1a9851" |Phase 3 (C) | ||
+ | |1a. [[#CapeOx_.26_Pembrolizumab|CapeOx & Pembrolizumab]]<br>1b. [[#Cisplatin_.26_Fluorouracil_.28CF.29_.26_Pembrolizumab|CF & Pembrolizumab]] | ||
+ | | style="background-color:#d73027" |Inferior OS | ||
|- | |- | ||
|} | |} | ||
+ | <div class="toccolours" style="background-color:#b3e2cd"> | ||
====Chemotherapy==== | ====Chemotherapy==== | ||
*[[Cisplatin (Platinol)]] 80 mg/m<sup>2</sup> IV over 1 to 3 hours once on day 1, '''given first''' | *[[Cisplatin (Platinol)]] 80 mg/m<sup>2</sup> IV over 1 to 3 hours once on day 1, '''given first''' | ||
*[[Fluorouracil (5-FU)]] 800 mg/m<sup>2</sup>/day IV continuous infusion over 120 hours, started on day 1, '''given second''' (total dose per cycle: 4000 mg/m<sup>2</sup>) | *[[Fluorouracil (5-FU)]] 800 mg/m<sup>2</sup>/day IV continuous infusion over 120 hours, started on day 1, '''given second''' (total dose per cycle: 4000 mg/m<sup>2</sup>) | ||
− | + | ====Supportive therapy==== | |
− | ====Supportive | + | *Some protocols: [[:Category:Hydration|"Hyperhydration"]] for cisplatin |
− | *Some protocols: "Hyperhydration" | ||
− | |||
'''21-day cycles''' | '''21-day cycles''' | ||
− | + | </div></div><br> | |
− | === | + | <div class="toccolours" style="background-color:#eeeeee"> |
− | {| class="wikitable" style="width: 100%; text-align:center;" | + | ===Regimen variant #4, 100/4000 {{#subobject:16f88f|Variant=1}}=== |
− | ! style="width: | + | {| class="wikitable sortable" style="width: 100%; text-align:center;" |
− | ! style="width: | + | ! style="width: 20%" |Study |
− | ! style="width: | + | ! style="width: 20%" |Dates of enrollment |
− | ! style="width: | + | ! style="width: 20%" |[[Levels_of_Evidence#Evidence|Evidence]] |
+ | ! style="width: 20%" |Comparator | ||
+ | ! style="width: 20%" |[[Levels_of_Evidence#Comparative_efficacy|Comparative Efficacy]] | ||
|- | |- | ||
− | |[ | + | |[https://ar.iiarjournals.org/content/26/5B/3877.long Duffour et al. 2006 (FFCD 9404)] |
− | | style="background-color:#1a9851" |Phase | + | |1995-1998 |
+ | | style="background-color:#1a9851" |Phase 3 (C) | ||
|[[#CLF|FLP]] | |[[#CLF|FLP]] | ||
− | | style="background-color:#ffffbf" | | + | | style="background-color:#ffffbf" |Inconclusive whether non-inferior ORR |
|- | |- | ||
|} | |} | ||
+ | <div class="toccolours" style="background-color:#b3e2cd"> | ||
====Chemotherapy==== | ====Chemotherapy==== | ||
*[[Cisplatin (Platinol)]] 100 mg/m<sup>2</sup> IV over 60 minutes once on either day 1 or 2 | *[[Cisplatin (Platinol)]] 100 mg/m<sup>2</sup> IV over 60 minutes once on either day 1 or 2 | ||
*[[Fluorouracil (5-FU)]] 800 mg/m<sup>2</sup>/day IV continuous infusion over 120 hours, started on day 1 (total dose per cycle: 4000 mg/m<sup>2</sup>) | *[[Fluorouracil (5-FU)]] 800 mg/m<sup>2</sup>/day IV continuous infusion over 120 hours, started on day 1 (total dose per cycle: 4000 mg/m<sup>2</sup>) | ||
− | |||
'''28-day cycles''' | '''28-day cycles''' | ||
− | + | </div></div><br> | |
− | === | + | <div class="toccolours" style="background-color:#eeeeee"> |
− | {| class="wikitable" style="width: 100%; text-align:center;" | + | ===Regimen variant #5, 100/4000, split-dose cisplatin {{#subobject:16f18e|Variant=1}}=== |
− | ! style="width: | + | {| class="wikitable sortable" style="width: 100%; text-align:center;" |
− | ! style="width: | + | ! style="width: 20%" |Study |
− | ! style="width: | + | ! style="width: 20%" |Dates of enrollment |
− | ! style="width: | + | ! style="width: 20%" |[[Levels_of_Evidence#Evidence|Evidence]] |
+ | ! style="width: 20%" |Comparator | ||
+ | ! style="width: 20%" |[[Levels_of_Evidence#Comparative_efficacy|Comparative Efficacy]] | ||
|- | |- | ||
− | | rowspan="2" |[ | + | | rowspan="2" |[https://doi.org/10.1200/jco.2003.04.130 Ohtsu et al. 2003 (JCOG 9205)] |
− | | rowspan="2" style="background-color:#1a9851" |Phase | + | | rowspan="2" |1992-1997 |
+ | | rowspan="2" style="background-color:#1a9851" |Phase 3 (E-esc) | ||
|1. [[#Fluorouracil_monotherapy|Fluorouracil]] | |1. [[#Fluorouracil_monotherapy|Fluorouracil]] | ||
− | | style="background-color:# | + | | style="background-color:#ffffbf" |Did not meet primary endpoint of OS |
|- | |- | ||
|2. [[#UFTM|UFTM]] | |2. [[#UFTM|UFTM]] | ||
− | | style="background-color:#ffffbf" | | + | | style="background-color:#ffffbf" |Did not meet primary endpoint of OS |
|- | |- | ||
|} | |} | ||
− | '' | + | ''Note: this study included patients with ECOG PS of 2 (9.6%)'' |
− | + | <div class="toccolours" style="background-color:#b3e2cd"> | |
====Chemotherapy==== | ====Chemotherapy==== | ||
*[[Cisplatin (Platinol)]] 20 mg/m<sup>2</sup> IV over 30 minutes once per day on days 1 to 5 | *[[Cisplatin (Platinol)]] 20 mg/m<sup>2</sup> IV over 30 minutes once per day on days 1 to 5 | ||
*[[Fluorouracil (5-FU)]] 800 mg/m<sup>2</sup>/day IV continuous infusion over 120 hours, started on day 1 (total dose per cycle: 4000 mg/m<sup>2</sup>) | *[[Fluorouracil (5-FU)]] 800 mg/m<sup>2</sup>/day IV continuous infusion over 120 hours, started on day 1 (total dose per cycle: 4000 mg/m<sup>2</sup>) | ||
− | |||
'''28-day cycle for up to 6 cycles''' | '''28-day cycle for up to 6 cycles''' | ||
− | + | </div></div><br> | |
− | === | + | <div class="toccolours" style="background-color:#eeeeee"> |
− | {| class="wikitable" style="width: 100%; text-align:center;" | + | ===Regimen variant #6, 100/5000 {{#subobject:10f0c6|Variant=1}}=== |
− | ! style="width: | + | {| class="wikitable sortable" style="width: 100%; text-align:center;" |
− | ! style="width: | + | ! style="width: 20%" |Study |
− | ! style="width: | + | ! style="width: 20%" |Dates of enrollment |
− | ! style="width: | + | ! style="width: 20%" |[[Levels_of_Evidence#Evidence|Evidence]] |
+ | ! style="width: 20%" |Comparator | ||
+ | ! style="width: 20%" |[[Levels_of_Evidence#Comparative_efficacy|Comparative Efficacy]] | ||
|- | |- | ||
− | |[ | + | |[https://doi.org/10.1200/jco.2006.06.8429 Van Cutsem et al. 2006 (TAX 325)] |
− | | style="background-color:#1a9851" |Phase | + | |1999-2003 |
+ | | style="background-color:#1a9851" |Phase 3 (C) | ||
|[[#DCF|DCF]] | |[[#DCF|DCF]] | ||
| style="background-color:#fc8d59" |Seems to have inferior OS | | style="background-color:#fc8d59" |Seems to have inferior OS | ||
|- | |- | ||
− | |[ | + | |[https://doi.org/10.1093/annonc/mdn166 Dank et al. 2008] |
− | | style="background-color:#1a9851" |Phase | + | |2000-2002 |
+ | | style="background-color:#1a9851" |Phase 3 (C) | ||
|[[#FOLFIRI|IF]] | |[[#FOLFIRI|IF]] | ||
− | | style="background-color:# | + | | style="background-color:#fee08b" |Might have inferior TTP |
|- | |- | ||
− | |[https:// | + | |[https://doi.org/10.1200/JCO.2009.25.4706 Ajani et al. 2010 (FLAGS)] |
− | | style="background-color:#1a9851" |Phase | + | |2005-2007 |
+ | | style="background-color:#1a9851" |Phase 3 (C) | ||
|[[#Cisplatin_.26_S-1|CS]] | |[[#Cisplatin_.26_S-1|CS]] | ||
− | | style="background-color:#ffffbf" | | + | | style="background-color:#ffffbf" |Did not meet primary endpoint of OS |
|- | |- | ||
|} | |} | ||
− | '' | + | ''Note: TAX 325 patients had 100% adenocarcinoma histology (22% Esophagogastric junction, 88% gastric origin). 97% with metastatic disease. 1% with Karnosky PS of 70. Dank et al patients had 100% adenocarcinoma histology (20% Esophagogastric junction, 80% gastric origin). 96% with metastatic disease. 1% with Karnofsky PS of 70.'' |
− | + | <div class="toccolours" style="background-color:#b3e2cd"> | |
− | |||
− | |||
====Chemotherapy==== | ====Chemotherapy==== | ||
*[[Cisplatin (Platinol)]] 100 mg/m<sup>2</sup> IV over 1 to 3 hours once on day 1, '''given first''' | *[[Cisplatin (Platinol)]] 100 mg/m<sup>2</sup> IV over 1 to 3 hours once on day 1, '''given first''' | ||
− | *[[Fluorouracil (5-FU)]] 1000 mg/m<sup>2</sup>/day IV continuous infusion over 120 hours, started on day 1, '''given second''' (total dose per cycle: 5000 mg/m<sup>2</sup> ) | + | *[[Fluorouracil (5-FU)]] 1000 mg/m<sup>2</sup>/day IV continuous infusion over 120 hours, started on day 1, '''given second''' (total dose per cycle: 5000 mg/m<sup>2</sup>) |
− | + | ====Supportive therapy==== | |
− | ====Supportive | ||
*As described in Dank et al. 2008: | *As described in Dank et al. 2008: | ||
− | *"Hyperhydration" for 2 to 3 days with each infusion | + | *[[:Category:Hydration|"Hyperhydration"]] for 2 to 3 days with each infusion |
*[[Ondansetron (Zofran)]] IV for antiemetic prophylaxis | *[[Ondansetron (Zofran)]] IV for antiemetic prophylaxis | ||
*[[Dexamethasone (Decadron)]] IV for antiemetic prophylaxis, then PO for 2 to 3 days | *[[Dexamethasone (Decadron)]] IV for antiemetic prophylaxis, then PO for 2 to 3 days | ||
*[[Metoclopramide (Reglan)]] for antiemetic prophylaxis | *[[Metoclopramide (Reglan)]] for antiemetic prophylaxis | ||
− | *[[Filgrastim (Neupogen)]] (dose not specified) SC once per day, starting on day 4, to be continued until ANC greater than 1000/ | + | *[[Filgrastim (Neupogen)]] (dose not specified) SC once per day, starting on day 4, to be continued until ANC greater than 1000/μL for grade 3 to 4 neutropenia, febrile neutropenia, or neutropenic infection |
− | *[[Atropine (Atropen)]] prn cholinergic symptoms | + | *[[Atropine (Atropen)]] prn cholinergic symptoms |
*[[Loperamide (Imodium)]] prn delayed diarrhea | *[[Loperamide (Imodium)]] prn delayed diarrhea | ||
+ | '''28-day cycles''' | ||
+ | </div></div> | ||
+ | ===References=== | ||
+ | #'''JCOG 9205:''' Ohtsu A, Shimada Y, Shirao K, Boku N, Hyodo I, Saito H, Yamamichi N, Miyata Y, Ikeda N, Yamamoto S, Fukuda H, Yoshida S; [[Study_Groups#JCOG|JCOG]]. Randomized phase III trial of fluorouracil alone versus fluorouracil plus cisplatin versus uracil and tegafur plus mitomycin in patients with unresectable, advanced gastric cancer: the Japan Clinical Oncology Group study (JCOG9205). J Clin Oncol. 2003 Jan 1;21(1):54-9. [https://doi.org/10.1200/jco.2003.04.130 link to original article] '''dosing details in manuscript have been reviewed by our editors''' [https://pubmed.ncbi.nlm.nih.gov/12506170/ PubMed] | ||
+ | #'''FFCD 9404:''' Duffour J, Bouché O, Rougier P, Milan C, Bedenne L, Seitz JF, Buecher B, Legoux JL, Ducreux M, Vetter D, Raoul JL, François E, Ychou M. Safety of cisplatin combined with continuous 5-FU versus bolus 5-FU and leucovorin, in metastatic gastrointestinal cancer (FFCD 9404 randomised trial). Anticancer Res. 2006 Sep-Oct;26(5B):3877-83. [https://ar.iiarjournals.org/content/26/5B/3877.long link to original article] '''dosing details in manuscript have been reviewed by our editors''' [https://pubmed.ncbi.nlm.nih.gov/17094417/ PubMed] | ||
+ | #'''TAX 325:''' Van Cutsem E, Moiseyenko VM, Tjulandin S, Majlis A, Constenla M, Boni C, Rodrigues A, Fodor M, Chao Y, Voznyi E, Risse ML, Ajani JA; V325 Study Group. Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group. J Clin Oncol. 2006 Nov 1;24(31):4991-7. [https://doi.org/10.1200/jco.2006.06.8429 link to original article] '''dosing details in manuscript have been reviewed by our editors''' [https://pubmed.ncbi.nlm.nih.gov/17075117/ PubMed] | ||
+ | #Dank M, Zaluski J, Barone C, Valvere V, Yalcin S, Peschel C, Wenczl M, Goker E, Cisar L, Wang K, Bugat R. Randomized phase III study comparing irinotecan combined with 5-fluorouracil and folinic acid to cisplatin combined with 5-fluorouracil in chemotherapy naive patients with advanced adenocarcinoma of the stomach or esophagogastric junction. Ann Oncol. 2008 Aug;19(8):1450-7. Epub 2008 Jun 16. [https://doi.org/10.1093/annonc/mdn166 link to original article] '''dosing details in manuscript have been reviewed by our editors''' [https://pubmed.ncbi.nlm.nih.gov/18558665/ PubMed] | ||
+ | #'''ML17032:''' Kang YK, Kang WK, Shin DB, Chen J, Xiong J, Wang J, Lichinitser M, Guan Z, Khasanov R, Zheng L, Philco-Salas M, Suarez T, Santamaria J, Forster G, McCloud PI. Capecitabine/cisplatin versus 5-fluorouracil/cisplatin as first-line therapy in patients with advanced gastric cancer: a randomised phase III noninferiority trial. Ann Oncol. 2009 Apr;20(4):666-73. Epub 2009 Jan 19. [https://doi.org/10.1093/annonc/mdn717 link to original article] '''dosing details in manuscript have been reviewed by our editors''' [https://pubmed.ncbi.nlm.nih.gov/19153121/ PubMed] [https://clinicaltrials.gov/study/NCT02563054 NCT02563054] | ||
+ | #Lee KH, Hyun MS, Kim HK, Jin HM, Yang J, Song HS, Do YR, Ryoo HM, Chung JS, Zang DY, Lim HY, Jin JY, Yim CY, Park HS, Kim JS, Sohn CH, Lee SN. Randomized, multicenter, phase III trial of heptaplatin 1-hour infusion and 5-fluorouracil combination chemotherapy comparing with cisplatin and 5-fluorouracil combination chemotherapy in patients with advanced gastric cancer. Cancer Res Treat. 2009 Mar;41(1):12-8. Epub 2009 Mar 31. [https://doi.org/10.4143/crt.2009.41.1.12 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/pmc2699097/ link to PMC article] '''dosing details in manuscript have been reviewed by our editors''' [https://pubmed.ncbi.nlm.nih.gov/19688066/ PubMed] | ||
+ | #'''FLAGS:''' Ajani JA, Rodriguez W, Bodoky G, Moiseyenko V, Lichinitser M, Gorbunova V, Vynnychenko I, Garin A, Lang I, Falcon S. Multicenter phase III comparison of cisplatin/S-1 with cisplatin/infusional fluorouracil in advanced gastric or gastroesophageal adenocarcinoma study: the FLAGS trial. J Clin Oncol. 2010 Mar 20;28(9):1547-53. Epub 2010 Feb 16. [https://doi.org/10.1200/JCO.2009.25.4706 link to original article] '''dosing details in abstract have been reviewed by our editors''' [https://pubmed.ncbi.nlm.nih.gov/20159816/ PubMed] [https://clinicaltrials.gov/study/NCT00400179 NCT00400179] | ||
+ | #'''AVAGAST:''' Ohtsu A, Shah MA, Van Cutsem E, Rha SY, Sawaki A, Park SR, Lim HY, Yamada Y, Wu J, Langer B, Starnawski M, Kang YK. Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a randomized, double-blind, placebo-controlled phase III study. J Clin Oncol. 2011 Oct 20;29(30):3968-76. Epub 2011 Aug 15. [https://doi.org/10.1200/JCO.2011.36.2236 link to original article] '''dosing details in manuscript have been reviewed by our editors''' [https://pubmed.ncbi.nlm.nih.gov/21844504/ PubMed] [https://clinicaltrials.gov/study/NCT00548548 NCT00548548] | ||
+ | #'''DIGEST:''' Ajani JA, Abramov M, Bondarenko I, Shparyk Y, Gorbunova V, Hontsa A, Otchenash N, Alsina M, Lazarev S, Feliu J, Elme A, Esko V, Abdalla K, Verma U, Benedetti F, Aoyama T, Mizuguchi H, Makris L, Rosati G; DIGEST Study Group. A phase III trial comparing oral S-1/cisplatin and intravenous 5-fluorouracil/cisplatin in patients with untreated diffuse gastric cancer. Ann Oncol. 2017 Sep 1;28(9):2142-2148. [https://doi.org/10.1093/annonc/mdx275 link to original article] '''dosing details in manuscript have been reviewed by our editors''' [https://pubmed.ncbi.nlm.nih.gov/28911091/ PubMed] [https://clinicaltrials.gov/study/NCT01285557 NCT01285557] | ||
+ | <!-- #'''Abstract:''' Tabernero J, Van Cutsem E, Yung-Jue B, Fuchs CS, Wyrwicz L, Lee KW, Kudaba I, Garrido M, Chung HC, Salguero HR, Mansoor W, Freitas MI, Brachiroli M, Goekkurt E, Chao J, Wainberg ZA, Kher U, Shah S, Kang SP, Shitara K. Pembrolizumab with or without chemotherapy versus chemotherapy for advanced gastric or gastroesophgeal junction (G/GEJ) adenocarcinoma: The phase III KEYNOTE-062 study. 2019 American Society of Clinical Oncology annual meeting. [https://doi.org/10.1200/JCO.2019.37.18_suppl.LBA4007 link to abstract] --> | ||
+ | #'''KEYNOTE-062:''' Shitara K, Van Cutsem E, Bang YJ, Fuchs C, Wyrwicz L, Lee KW, Kudaba I, Garrido M, Chung HC, Lee J, Castro HR, Mansoor W, Braghiroli MI, Karaseva N, Caglevic C, Villanueva L, Goekkurt E, Satake H, Enzinger P, Alsina M, Benson A, Chao J, Ko AH, Wainberg ZA, Kher U, Shah S, Kang SP, Tabernero J. Efficacy and Safety of Pembrolizumab or Pembrolizumab Plus Chemotherapy vs Chemotherapy Alone for Patients With First-line, Advanced Gastric Cancer: The KEYNOTE-062 Phase 3 Randomized Clinical Trial. JAMA Oncol. 2020 Oct 1;6(10):1571-1580. Epub 2020 Sep 3. [https://doi.org/10.1001/jamaoncol.2020.3370 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7489405/ link to PMC article] '''dosing details in manuscript have been reviewed by our editors''' [https://pubmed.ncbi.nlm.nih.gov/32880601/ PubMed] [https://clinicaltrials.gov/study/NCT02494583 NCT02494583] | ||
+ | #'''KEYNOTE-859:''' Rha SY, Oh DY, Yañez P, Bai Y, Ryu MH, Lee J, Rivera F, Alves GV, Garrido M, Shiu KK, Fernández MG, Li J, Lowery MA, Çil T, Cruz FM, Qin S, Luo S, Pan H, Wainberg ZA, Yin L, Bordia S, Bhagia P, Wyrwicz LS; KEYNOTE-859 investigators. Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): a multicentre, randomised, double-blind, phase 3 trial. Lancet Oncol. 2023 Nov;24(11):1181-1195. Epub 2023 Oct 21. [https://doi.org/10.1016/s1470-2045(23)00515-6 link to original article] '''dosing details in abstract have been reviewed by our editors''' [https://pubmed.ncbi.nlm.nih.gov/37875143/ PubMed] [https://clinicaltrials.gov/study/NCT03675737 NCT03675737] | ||
+ | #'''RATIONALE-305:''' Qiu MZ, Oh DY, Kato K, Arkenau T, Tabernero J, Correa MC, Zimina AV, Bai Y, Shi J, Lee KW, Wang J, Poddubskaya E, Pan H, Rha SY, Zhang R, Hirano H, Spigel D, Yamaguchi K, Chao Y, Wyrwicz L, Disel U, Cid RP, Fornaro L, Evesque L, Wang H, Xu Y, Li J, Sheng T, Yang S, Li L, Moehler M, Xu RH; RATIONALE-305 Investigators. Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first line treatment for advanced gastric or gastro-oesophageal junction adenocarcinoma: RATIONALE-305 randomised, double blind, phase 3 trial. BMJ. 2024 May 28;385:e078876. [https://doi.org/10.1136/bmj-2023-078876 link to original article] '''contains dosing details on CT.gov''' [https://pubmed.ncbi.nlm.nih.gov/38806195/ PubMed] [https://clinicaltrials.gov/study/NCT03777657 NCT03777657] | ||
− | ''' | + | ==Cisplatin & Fluorouracil (CF) & Pembrolizumab {{#subobject:25ncw1|Regimen=1}}== |
+ | CF & Pembrolizumab: '''<u>C</u>'''isplatin, '''<u>F</u>'''luorouracil, Pembrolizumab | ||
+ | <div class="toccolours" style="background-color:#eeeeee"> | ||
+ | ===Regimen {{#subobject:4fewd7|Variant=1}}=== | ||
+ | {| class="wikitable sortable" style="width: 100%; text-align:center;" | ||
+ | ! style="width: 20%" |Study | ||
+ | ! style="width: 20%" |Dates of enrollment | ||
+ | ! style="width: 20%" |[[Levels_of_Evidence#Evidence|Evidence]] | ||
+ | ! style="width: 20%" |Comparator | ||
+ | ! style="width: 20%" |[[Levels_of_Evidence#Comparative_efficacy|Comparative Efficacy]] | ||
+ | |- | ||
+ | |rowspan=2|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7489405/ Shitara et al. 2020 (KEYNOTE-062)] | ||
+ | |rowspan=2|2015-2017 | ||
+ | |rowspan=2 style="background-color:#1a9851" |Phase 3 (E-esc) | ||
+ | |1a. [[#Cisplatin_.26_Fluorouracil_.28CF.29_3|CF]]<br>1b. [[#Capecitabine_.26_Cisplatin_.28CX.29_3|CX]] | ||
+ | | style="background-color:#d9ef8b" |Might have superior OS (co-primary endpoint)<br>Median OS: 12.5 vs 11.1 mo<br>(HR 0.85, 95% CI 0.70-1.03) | ||
+ | |- | ||
+ | |2. [[#Pembrolizumab_monotherapy|Pembrolizumab]] | ||
+ | | style="background-color:#d3d3d3" |Not reported | ||
+ | |- | ||
+ | |[https://doi.org/10.1016/s1470-2045(23)00515-6 Rha et al. 2023 (KEYNOTE-859)] | ||
+ | |2018-11-08 to 2021-06-11 | ||
+ | | style="background-color:#1a9851" |Phase 3 (E-RT-esc) | ||
+ | |1a. [[#Cisplatin_.26_Fluorouracil_.28CF.29_2|CF]]<br>1b. [[#CapeOx_3|CapeOx]] | ||
+ | | style="background-color:#1a9850" |Superior OS (primary endpoint)<br>Median OS: 12.9 vs 11.5 mo<br>(HR 0.78, 95% CI 0.70-0.87) | ||
+ | |} | ||
+ | ''KEYNOTE-062 & KEYNOTE-859 included patients with GEJ malignancy'' | ||
+ | <div class="toccolours" style="background-color:#fdcdac"> | ||
+ | ====Biomarker eligibility criteria==== | ||
+ | PD-L1 Combined Positive Score (CPS) of 1 or more as determined by an FDA-approved test | ||
+ | </div> | ||
+ | <div class="toccolours" style="background-color:#b3e2cd"> | ||
+ | ====Chemotherapy==== | ||
+ | *[[Cisplatin (Platinol)]] 80 mg/m<sup>2</sup> IV once on day 1 | ||
+ | *[[Fluorouracil (5-FU)]] 800 mg/m<sup>2</sup>/day IV continuous infusion over 120 hours, started on day 1 (total dose per cycle: 4000 mg/m<sup>2</sup>) | ||
+ | ====Immunotherapy==== | ||
+ | *[[Pembrolizumab (Keytruda)]] 200 mg IV once on day 1 | ||
+ | '''21-day cycle for up to 35 cycles''' | ||
+ | </div></div> | ||
===References=== | ===References=== | ||
− | # ''' | + | <!-- #'''Abstract:''' Tabernero J, Van Cutsem E, Yung-Jue B, Fuchs CS, Wyrwicz L, Lee KW, Kudaba I, Garrido M, Chung HC, Salguero HR, Mansoor W, Freitas MI, Brachiroli M, Goekkurt E, Chao J, Wainberg ZA, Kher U, Shah S, Kang SP, Shitara K. Pembrolizumab with or without chemotherapy versus chemotherapy for advanced gastric or gastroesophgeal junction (G/GEJ) adenocarcinoma: The phase III KEYNOTE-062 study. 2019 American Society of Clinical Oncology annual meeting. [https://doi.org/10.1200/JCO.2019.37.18_suppl.LBA4007 link to abstract] --> |
− | # ''' | + | #'''KEYNOTE-062:''' Shitara K, Van Cutsem E, Bang YJ, Fuchs C, Wyrwicz L, Lee KW, Kudaba I, Garrido M, Chung HC, Lee J, Castro HR, Mansoor W, Braghiroli MI, Karaseva N, Caglevic C, Villanueva L, Goekkurt E, Satake H, Enzinger P, Alsina M, Benson A, Chao J, Ko AH, Wainberg ZA, Kher U, Shah S, Kang SP, Tabernero J. Efficacy and Safety of Pembrolizumab or Pembrolizumab Plus Chemotherapy vs Chemotherapy Alone for Patients With First-line, Advanced Gastric Cancer: The KEYNOTE-062 Phase 3 Randomized Clinical Trial. JAMA Oncol. 2020 Oct 1;6(10):1571-1580. Epub 2020 Sep 3. [https://doi.org/10.1001/jamaoncol.2020.3370 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7489405/ link to PMC article] '''dosing details in manuscript have been reviewed by our editors''' [https://pubmed.ncbi.nlm.nih.gov/32880601/ PubMed] [https://clinicaltrials.gov/study/NCT02494583 NCT02494583] |
− | + | #'''KEYNOTE-859:''' Rha SY, Oh DY, Yañez P, Bai Y, Ryu MH, Lee J, Rivera F, Alves GV, Garrido M, Shiu KK, Fernández MG, Li J, Lowery MA, Çil T, Cruz FM, Qin S, Luo S, Pan H, Wainberg ZA, Yin L, Bordia S, Bhagia P, Wyrwicz LS; KEYNOTE-859 investigators. Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): a multicentre, randomised, double-blind, phase 3 trial. Lancet Oncol. 2023 Nov;24(11):1181-1195. Epub 2023 Oct 21. [https://doi.org/10.1016/s1470-2045(23)00515-6 link to original article] '''dosing details in abstract have been reviewed by our editors''' [https://pubmed.ncbi.nlm.nih.gov/37875143/ PubMed] [https://clinicaltrials.gov/study/NCT03675737 NCT03675737] | |
− | |||
− | |||
− | # ''' | ||
− | |||
− | |||
− | |||
− | ==Cisplatin & | + | ==Cisplatin & Fluorouracil (CF) & Tislelizumab {{#subobject:4dtis6|Regimen=1}}== |
− | {| class="wikitable" style=" | + | CF & Tislelizumab: '''<u>C</u>'''isplatin, '''<u>F</u>'''luorouracil, Tislelizumab |
+ | <div class="toccolours" style="background-color:#eeeeee"> | ||
+ | ===Regimen {{#subobject:69tis5|Variant=1}}=== | ||
+ | {| class="wikitable sortable" style="width: 100%; text-align:center;" | ||
+ | ! style="width: 20%" |Study | ||
+ | ! style="width: 20%" |Dates of enrollment | ||
+ | ! style="width: 20%" |[[Levels_of_Evidence#Evidence|Evidence]] | ||
+ | ! style="width: 20%" |Comparator | ||
+ | ! style="width: 20%" |[[Levels_of_Evidence#Comparative_efficacy|Comparative Efficacy]] | ||
+ | |- | ||
+ | |[https://doi.org/10.1136/bmj-2023-078876 Qiu et al. 2024 (RATIONALE-305)] | ||
+ | |2018-12-13 to 2021-02-09 | ||
+ | | style="background-color:#1a9851" |Phase 3 (E-esc) | ||
+ | |1a. [[#CapeOx_3|CapeOx]]<br>1b. [[#Cisplatin_.26_Fluorouracil_.28CF.29_2|CF]] | ||
+ | | style="background-color:#1a9850" |Superior OS (primary endpoint)<br>Median OS: 15 vs 12.9 mo<br>(HR 0.80, 95% CI 0.70-0.92) | ||
|- | |- | ||
− | |||
|} | |} | ||
+ | <div class="toccolours" style="background-color:#b3e2cd"> | ||
+ | ====Chemotherapy==== | ||
+ | *[[Cisplatin (Platinol)]] 80 mg/m<sup>2</sup> IV once on day 1 | ||
+ | *[[Fluorouracil (5-FU)]] 800 mg/m<sup>2</sup>/day IV continuous infusion over 120 hours, started on day 1 (total dose per cycle: 4000 mg/m<sup>2</sup>) | ||
+ | ====Immunotherapy==== | ||
+ | *[[Tislelizumab (Baizean)]] 200 mg IV once on day 1 | ||
+ | '''21-day cycles''' | ||
+ | </div></div> | ||
+ | ===References=== | ||
+ | #'''RATIONALE-305:''' Qiu MZ, Oh DY, Kato K, Arkenau T, Tabernero J, Correa MC, Zimina AV, Bai Y, Shi J, Lee KW, Wang J, Poddubskaya E, Pan H, Rha SY, Zhang R, Hirano H, Spigel D, Yamaguchi K, Chao Y, Wyrwicz L, Disel U, Cid RP, Fornaro L, Evesque L, Wang H, Xu Y, Li J, Sheng T, Yang S, Li L, Moehler M, Xu RH; RATIONALE-305 Investigators. Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first line treatment for advanced gastric or gastro-oesophageal junction adenocarcinoma: RATIONALE-305 randomised, double blind, phase 3 trial. BMJ. 2024 May 28;385:e078876. [https://doi.org/10.1136/bmj-2023-078876 link to original article] '''contains dosing details on CT.gov''' [https://pubmed.ncbi.nlm.nih.gov/38806195/ PubMed] [https://clinicaltrials.gov/study/NCT03777657 NCT03777657] | ||
+ | |||
+ | ==Cisplatin & S-1 {{#subobject:252c51|Regimen=1}}== | ||
CS: '''<u>C</u>'''isplatin & '''<u>S</u>'''-1 | CS: '''<u>C</u>'''isplatin & '''<u>S</u>'''-1 | ||
<br>SP: '''<u>S</u>'''-1 & '''<u>P</u>'''latinol (Cisplatin) | <br>SP: '''<u>S</u>'''-1 & '''<u>P</u>'''latinol (Cisplatin) | ||
− | === | + | <div class="toccolours" style="background-color:#eeeeee"> |
− | {| class="wikitable" style="width: 100%; text-align:center;" | + | ===Regimen variant #1, q3wk ("SP3") {{#subobject:4ff7cf|Variant=1}}=== |
− | ! style="width: | + | {| class="wikitable sortable" style="width: 100%; text-align:center;" |
− | ! style="width: | + | ! style="width: 20%" |Study |
− | ! style="width: | + | ! style="width: 20%" |Dates of enrollment |
− | ! style="width: | + | ! style="width: 20%" |[[Levels_of_Evidence#Evidence|Evidence]] |
+ | ! style="width: 20%" |Comparator | ||
+ | ! style="width: 20%" |[[Levels_of_Evidence#Comparative_efficacy|Comparative Efficacy]] | ||
+ | |- | ||
+ | |[https://doi.org/10.1093/annonc/mdv316 Ryu et al. 2015 (SOS)] | ||
+ | |2009-2012 | ||
+ | | style="background-color:#1a9851" |Phase 3 (E-switch-ic) | ||
+ | |[[#Cisplatin_.26_S-1|Cisplatin & S-1]]; SP5 | ||
+ | | style="background-color:#91cf60" |Seems to have superior PFS (primary endpoint)<br>Median PFS: 5.5 vs 4.9 mo<br>(HR 0.82, 95% CI 0.68-0.99) | ||
|- | |- | ||
− | |[https:// | + | |[https://doi.org/10.1007/s10120-020-01101-4 Lee et al. 2020 (SOPP)] |
− | | style="background-color:#1a9851" |Phase | + | |2012-2014 |
− | | | + | | style="background-color:#1a9851" |Phase 3 (C) |
− | | style="background-color:# | + | |[[#SOX_888|SOX]] |
+ | | style="background-color:#eeee01" |Non-inferior PFS | ||
|- | |- | ||
|} | |} | ||
+ | <div class="toccolours" style="background-color:#b3e2cd"> | ||
====Chemotherapy==== | ====Chemotherapy==== | ||
*[[Cisplatin (Platinol)]] 60 mg/m<sup>2</sup> IV once on day 1 | *[[Cisplatin (Platinol)]] 60 mg/m<sup>2</sup> IV once on day 1 | ||
*[[Tegafur, gimeracil, oteracil (S-1)]] 40 mg/m<sup>2</sup> PO twice per day on days 1 to 14 | *[[Tegafur, gimeracil, oteracil (S-1)]] 40 mg/m<sup>2</sup> PO twice per day on days 1 to 14 | ||
− | |||
'''21-day cycles''' | '''21-day cycles''' | ||
− | + | </div></div><br> | |
− | === | + | <div class="toccolours" style="background-color:#eeeeee"> |
− | {| class="wikitable" style="width: 100%; text-align:center;" | + | ===Regimen variant #2, q4wk {{#subobject:03b3c4|Variant=1}}=== |
− | ! style="width: | + | {| class="wikitable sortable" style="width: 100%; text-align:center;" |
− | ! style="width: | + | ! style="width: 20%" |Study |
− | ! style="width: | + | ! style="width: 20%" |Dates of enrollment |
− | ! style="width: | + | ! style="width: 20%" |[[Levels_of_Evidence#Evidence|Evidence]] |
+ | ! style="width: 20%" |Comparator | ||
+ | ! style="width: 20%" |[[Levels_of_Evidence#Comparative_efficacy|Comparative Efficacy]] | ||
+ | |- | ||
+ | |[https://doi.org/10.1200/JCO.2009.25.4706 Ajani et al. 2010 (FLAGS)] | ||
+ | |2005-2007 | ||
+ | | style="background-color:#1a9851" |Phase 3 (E-switch-ic) | ||
+ | |[[#Cisplatin_.26_Fluorouracil_.28CF.29_3|CF]] | ||
+ | | style="background-color:#ffffbf" |Did not meet primary endpoint of OS | ||
|- | |- | ||
− | |[https:// | + | |[https://doi.org/10.1093/annonc/mdx275 Ajani et al. 2017 (DIGEST)] |
− | | style="background-color:#1a9851" |Phase | + | |2011-2014 |
− | |[[#Cisplatin_. | + | | style="background-color:#1a9851" |Phase 3 (E-switch-ic) |
− | | style="background-color:#ffffbf" | | + | |[[#Cisplatin_.26_Fluorouracil_.28CF.29_3|CF]] |
+ | | style="background-color:#ffffbf" |Did not meet primary endpoint of OS | ||
|- | |- | ||
|} | |} | ||
− | ''Note: | + | ''Note: This was an experimental arm of a study where the primary endpoint was not met. Included because CS has been shown to be superior in comparison to other regimens (see above).'' |
+ | <div class="toccolours" style="background-color:#b3e2cd"> | ||
====Chemotherapy==== | ====Chemotherapy==== | ||
*[[Cisplatin (Platinol)]] 75 mg/m<sup>2</sup> IV over 1 to 3 hours once on day 1 | *[[Cisplatin (Platinol)]] 75 mg/m<sup>2</sup> IV over 1 to 3 hours once on day 1 | ||
*[[Tegafur, gimeracil, oteracil (S-1)]] 25 mg/m<sup>2</sup> PO twice per day on days 1 to 21 | *[[Tegafur, gimeracil, oteracil (S-1)]] 25 mg/m<sup>2</sup> PO twice per day on days 1 to 21 | ||
− | |||
'''28-day cycles''' | '''28-day cycles''' | ||
− | + | </div></div><br> | |
− | === | + | <div class="toccolours" style="background-color:#eeeeee"> |
− | {| class="wikitable" style="width: 100%; text-align:center;" | + | ===Regimen variant #3, q5wk ("SP5") {{#subobject:cdcc15|Variant=1}}=== |
− | ! style="width: | + | {| class="wikitable sortable" style="width: 100%; text-align:center;" |
− | ! style="width: | + | ! style="width: 20%" |Study |
− | ! style="width: | + | ! style="width: 20%" |Dates of enrollment |
− | ! style="width: | + | ! style="width: 20%" |[[Levels_of_Evidence#Evidence|Evidence]] |
+ | ! style="width: 20%" |Comparator | ||
+ | ! style="width: 20%" |[[Levels_of_Evidence#Comparative_efficacy|Comparative Efficacy]] | ||
|- | |- | ||
− | |[https:// | + | |[https://doi.org/10.1016/S1470-2045(08)70035-4 Koizumi et al. 2008 (SPIRITS)] |
− | | style="background-color:#1a9851" |Phase | + | |2002-2004 |
+ | | style="background-color:#1a9851" |Phase 3 (E-esc) | ||
|[[#S-1_monotherapy_2|S-1]] | |[[#S-1_monotherapy_2|S-1]] | ||
− | | style="background-color:#91cf60" |Seems to have superior OS | + | | style="background-color:#91cf60" |Seems to have superior OS (primary endpoint)<br>Median OS: 13 vs 11 mo<br>(HR 0.77, 95% CI 0.61-0.98) |
|- | |- | ||
− | |[https:// | + | |[https://doi.org/10.1016/S1470-2045(15)00553-7 Fujitani et al. 2016 (REGATTA)] |
− | | style="background-color:# | + | |2008-2013 |
− | | | + | | style="background-color:#91cf61" |Non-randomized part of phase 3 RCT |
− | | style="background-color:# | + | | style="background-color:#d3d3d3" | |
+ | | style="background-color:#d3d3d3" | | ||
|- | |- | ||
− | |[https:// | + | |[https://doi.org/10.1093/annonc/mdv316 Ryu et al. 2015 (SOS)] |
− | | style="background-color:#1a9851" |Phase | + | |2009-2012 |
− | |SP3 | + | | style="background-color:#1a9851" |Phase 3 (C) |
+ | |[[#Cisplatin_.26_S-1|Cisplatin & S-1]]; SP3 | ||
| style="background-color:#fc8d59" |Seems to have inferior PFS | | style="background-color:#fc8d59" |Seems to have inferior PFS | ||
|- | |- | ||
− | |[https:// | + | |[https://doi.org/10.1093/annonc/mdu472 Yamada et al. 2014 (G-SOX)] |
− | | style="background-color:# | + | |2010-01 to 2011-10 |
− | | | + | | style="background-color:#1a9851" |Phase 3 (C) |
− | | style="background-color:# | + | |[[#SOX_888|SOX]] |
+ | | style="background-color:#eeee01" |Non-inferior PFS | ||
|- | |- | ||
− | |[https:// | + | |[https://doi.org/10.1200/JCO.2018.77.8613 Ishigami et al. 2018 (PHOENIX-GC)] |
− | | style="background-color:#1a9851" |Phase | + | |2011-2013 |
+ | | style="background-color:#1a9851" |Phase 3 (C) | ||
|[[#Paclitaxel_.26_S-1|IV/IP Paclitaxel & S-1]] | |[[#Paclitaxel_.26_S-1|IV/IP Paclitaxel & S-1]] | ||
| style="background-color:#fee08b" |Might have inferior OS | | style="background-color:#fee08b" |Might have inferior OS | ||
|- | |- | ||
− | |[https:// | + | |[https://doi.org/10.1016/s2468-1253(19)30083-4 Yamada et al. 2019 (JCOG1013)] |
− | | style="background-color:#1a9851" |Phase | + | |2012-2016 |
− | |Cisplatin, Docetaxel, S-1 | + | | style="background-color:#1a9851" |Phase 3 (C) |
− | | style="background-color:#ffffbf" |Seems | + | |[[#Cisplatin_.26_Docetaxel_.28DC.29_.26_S-1_999|Cisplatin, Docetaxel, S-1]] |
+ | | style="background-color:#ffffbf" |Did not meet primary endpoint of OS | ||
+ | |- | ||
+ | |[https://doi.org/10.1016/s1470-2045(20)30315-6 Kang et al. 2020 (SOLAR)] | ||
+ | |2015-01-28 to 2016-12-05 | ||
+ | | style="background-color:#1a9851" |Phase 3 (C) | ||
+ | |[[#Oxaliplatin_.26_TAS-118_777|Oxaliplatin & TAS-118]] | ||
+ | | style="background-color:#fc8d59" |Seems to have inferior PFS | ||
|- | |- | ||
|} | |} | ||
− | ''Note: in REGATTA, there was no difference in outcome amongst patients who did or did not undergo surgery.'' | + | ''Note: in REGATTA, there was no difference in outcome amongst patients who did or did not undergo surgery. SPIRITS trial included patients with ECOG PS of 2 (3% of patients).'' |
− | + | <div class="toccolours" style="background-color:#fdcdac"> | |
− | + | ====Eligibility criteria==== | |
− | + | *REGATTA: presence of a single non-curable factor (ex: hepatic, peritoneal, and para-aortic mets), see link for further details | |
− | + | *PHEONIX-GC: patients with peritoneal metastasis who had received less than or equal to 2 months of prior chemotherapy without disease progression, see link for further details | |
− | + | </div> | |
− | + | <div class="toccolours" style="background-color:#cbd5e8"> | |
====Preceding treatment==== | ====Preceding treatment==== | ||
− | *REGATTA: Non-laparoscopic [[Surgery#Gastrectomy|gastrectomy]] with D1 [[Surgery#Lymphadenectomy|lymphadenectomy]] versus no surgery; chemotherapy began within 8 weeks of surgery | + | *REGATTA: Non-laparoscopic [[Surgery#Gastrectomy|gastrectomy]] with D1 [[Surgery#Lymphadenectomy|lymphadenectomy]] versus [[Surgery#No_surgery|no surgery]]; chemotherapy began within 8 weeks of surgery |
− | + | </div> | |
+ | <div class="toccolours" style="background-color:#b3e2cd"> | ||
====Chemotherapy==== | ====Chemotherapy==== | ||
*[[Cisplatin (Platinol)]] 60 mg/m<sup>2</sup> IV once on day 8 | *[[Cisplatin (Platinol)]] 60 mg/m<sup>2</sup> IV once on day 8 | ||
− | *[[Tegafur, gimeracil, oteracil (S-1)]] | + | *[[Tegafur, gimeracil, oteracil (S-1)]] by the following BSA-based criteria: |
− | ** | + | **Less than 1.25 m<sup>2</sup>: 40 mg PO twice per day on days 1 to 21 |
− | ** | + | **Between 1.25 m<sup>2</sup> and 1.5 m<sup>2</sup>: 50 mg PO twice per day on days 1 to 21 |
− | ** | + | **1.5 m<sup>2</sup> or more: 60 mg PO twice per day on days 1 to 21 |
− | |||
'''35-day cycles''' | '''35-day cycles''' | ||
+ | </div></div> | ||
===References=== | ===References=== | ||
− | # '''SPIRITS:''' Koizumi W, Narahara H, Hara T, Takagane A, Akiya T, Takagi M, Miyashita K, Nishizaki T, Kobayashi O, Takiyama W, Toh Y, Nagaie T, Takagi S, Yamamura Y, Yanaoka K, Orita H, Takeuchi M. S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial. Lancet Oncol. 2008 Mar;9(3):215-21. Epub 2008 Feb 20. [https:// | + | #'''SPIRITS:''' Koizumi W, Narahara H, Hara T, Takagane A, Akiya T, Takagi M, Miyashita K, Nishizaki T, Kobayashi O, Takiyama W, Toh Y, Nagaie T, Takagi S, Yamamura Y, Yanaoka K, Orita H, Takeuchi M. S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial. Lancet Oncol. 2008 Mar;9(3):215-21. Epub 2008 Feb 20. [https://doi.org/10.1016/S1470-2045(08)70035-4 link to original article] '''dosing details in manuscript have been reviewed by our editors''' [https://pubmed.ncbi.nlm.nih.gov/18282805/ PubMed] [https://clinicaltrials.gov/study/NCT00150670 NCT00150670] |
− | # '''G-SOX:''' Yamada Y, Higuchi K, Nishikawa K, Gotoh M, Fuse N, Sugimoto N, Nishina T, Amagai K, Chin K, Niwa Y, Tsuji A, Imamura H, Tsuda M, Yasui H, Fujii H, Yamaguchi K, Yasui H, Hironaka S, Shimada K, Miwa H, Hamada C, Hyodo I. Phase III study comparing oxaliplatin plus S-1 with cisplatin plus S-1 in chemotherapy-naïve patients with advanced gastric cancer. Ann Oncol. 2015 Jan;26(1):141-8. Epub 2014 Oct 14. [https:// | + | #'''FLAGS:''' Ajani JA, Rodriguez W, Bodoky G, Moiseyenko V, Lichinitser M, Gorbunova V, Vynnychenko I, Garin A, Lang I, Falcon S. Multicenter phase III comparison of cisplatin/S-1 with cisplatin/infusional fluorouracil in advanced gastric or gastroesophageal adenocarcinoma study: the FLAGS trial. J Clin Oncol. 2010 Mar 20;28(9):1547-53. Epub 2010 Feb 16. [https://doi.org/10.1200/JCO.2009.25.4706 link to original article] '''dosing details in abstract have been reviewed by our editors''' [https://pubmed.ncbi.nlm.nih.gov/20159816/ PubMed] [https://clinicaltrials.gov/study/NCT00400179 NCT00400179] |
− | # '''SOS:''' Ryu MH, Baba E, Lee KH, Park YI, Boku N, Hyodo I, Nam BH, Esaki T, Yoo C, Ryoo BY, Song EK, Cho SH, Kang WK, Yang SH, Zang DY, Shin DB, Park SR, Shinozaki K, Takano T, Kang YK; SOS study investigators. Comparison of two different S-1 plus cisplatin dosing schedules as first-line chemotherapy for metastatic and/or recurrent gastric cancer: a multicenter, randomized phase III trial (SOS). Ann Oncol. 2015 Oct;26(10):2097-101. Epub 2015 Jul 27. [https:// | + | #'''G-SOX:''' Yamada Y, Higuchi K, Nishikawa K, Gotoh M, Fuse N, Sugimoto N, Nishina T, Amagai K, Chin K, Niwa Y, Tsuji A, Imamura H, Tsuda M, Yasui H, Fujii H, Yamaguchi K, Yasui H, Hironaka S, Shimada K, Miwa H, Hamada C, Hyodo I. Phase III study comparing oxaliplatin plus S-1 with cisplatin plus S-1 in chemotherapy-naïve patients with advanced gastric cancer. Ann Oncol. 2015 Jan;26(1):141-8. Epub 2014 Oct 14. [https://doi.org/10.1093/annonc/mdu472 link to original article] '''dosing details in abstract have been reviewed by our editors''' [https://pubmed.ncbi.nlm.nih.gov/25316259/ PubMed] JapicCTI-101021 |
− | # '''REGATTA:''' Fujitani K, Yang HK, Mizusawa J, Kim YW, Terashima M, Han SU, Iwasaki Y, Hyung WJ, Takagane A, Park DJ, Yoshikawa T, Hahn S, Nakamura K, Park CH, Kurokawa Y, Bang YJ, Park BJ, Sasako M, Tsujinaka T; REGATTA study investigators. Gastrectomy plus chemotherapy versus chemotherapy alone for advanced gastric cancer with a single non-curable factor (REGATTA): a phase 3, randomised controlled trial. Lancet Oncol. 2016 Mar;17(3):309-18. Epub 2016 Jan 26. [https:// | + | #'''SOS:''' Ryu MH, Baba E, Lee KH, Park YI, Boku N, Hyodo I, Nam BH, Esaki T, Yoo C, Ryoo BY, Song EK, Cho SH, Kang WK, Yang SH, Zang DY, Shin DB, Park SR, Shinozaki K, Takano T, Kang YK; SOS study investigators. Comparison of two different S-1 plus cisplatin dosing schedules as first-line chemotherapy for metastatic and/or recurrent gastric cancer: a multicenter, randomized phase III trial (SOS). Ann Oncol. 2015 Oct;26(10):2097-101. Epub 2015 Jul 27. [https://doi.org/10.1093/annonc/mdv316 link to original article] '''dosing details in abstract have been reviewed by our editors''' [https://pubmed.ncbi.nlm.nih.gov/26216386/ PubMed] [https://clinicaltrials.gov/study/NCT00915382 NCT00915382] |
− | # '''DIGEST:''' Ajani JA, Abramov M, Bondarenko I, Shparyk Y, Gorbunova V, Hontsa A, Otchenash N, Alsina M, Lazarev S, Feliu J, Elme A, Esko V, Abdalla K, Verma U, Benedetti F, Aoyama T, Mizuguchi H, Makris L, Rosati G; DIGEST Study Group. A phase III trial comparing oral S-1/cisplatin and intravenous 5-fluorouracil/cisplatin in patients with untreated diffuse gastric cancer. Ann Oncol. 2017 Sep 1;28(9):2142-2148. [https:// | + | #'''REGATTA:''' Fujitani K, Yang HK, Mizusawa J, Kim YW, Terashima M, Han SU, Iwasaki Y, Hyung WJ, Takagane A, Park DJ, Yoshikawa T, Hahn S, Nakamura K, Park CH, Kurokawa Y, Bang YJ, Park BJ, Sasako M, Tsujinaka T; REGATTA study investigators. Gastrectomy plus chemotherapy versus chemotherapy alone for advanced gastric cancer with a single non-curable factor (REGATTA): a phase 3, randomised controlled trial. Lancet Oncol. 2016 Mar;17(3):309-18. Epub 2016 Jan 26. [https://doi.org/10.1016/S1470-2045(15)00553-7 link to original article] '''dosing details in manuscript have been reviewed by our editors''' [https://pubmed.ncbi.nlm.nih.gov/26822397/ PubMed] UMIN000001012 |
− | # '''PHOENIX-GC:''' Ishigami H, Fujiwara Y, Fukushima R, Nashimoto A, Yabusaki H, Imano M, Imamoto H, Kodera Y, Uenosono Y, Amagai K, Kadowaki S, Miwa H, Yamaguchi H, Yamaguchi T, Miyaji T, Kitayama J. Phase III trial comparing intraperitoneal and intravenous paclitaxel plus S-1 versus cisplatin plus S-1 in patients with gastric cancer with peritoneal metastasis: PHOENIX-GC trial. J Clin Oncol. 2018 Jul 1;36(19):1922-1929. Epub 2018 May 10. [https:// | + | #'''DIGEST:''' Ajani JA, Abramov M, Bondarenko I, Shparyk Y, Gorbunova V, Hontsa A, Otchenash N, Alsina M, Lazarev S, Feliu J, Elme A, Esko V, Abdalla K, Verma U, Benedetti F, Aoyama T, Mizuguchi H, Makris L, Rosati G; DIGEST Study Group. A phase III trial comparing oral S-1/cisplatin and intravenous 5-fluorouracil/cisplatin in patients with untreated diffuse gastric cancer. Ann Oncol. 2017 Sep 1;28(9):2142-2148. [https://doi.org/10.1093/annonc/mdx275 link to original article] '''dosing details in manuscript have been reviewed by our editors''' [https://pubmed.ncbi.nlm.nih.gov/28911091/ PubMed] [https://clinicaltrials.gov/study/NCT01285557 NCT01285557] |
− | # '''JCOG1013:''' Yamada Y, Boku N, Mizusawa J, Iwasa S, Kadowaki S, Nakayama N, Azuma M, Sakamoto T, Shitara K, Tamura T, Chin K, Hata H, Nakamori M, Hara H, Yasui H, Katayama H, Fukuda H, Yoshikawa T, Sasako M, Terashima M. Docetaxel plus cisplatin and S-1 versus cisplatin and S-1 in patients with advanced gastric cancer (JCOG1013): an open-label, phase 3, randomised controlled trial. Lancet Gastroenterol Hepatol. 2019 May 14. [Epub | + | #'''PHOENIX-GC:''' Ishigami H, Fujiwara Y, Fukushima R, Nashimoto A, Yabusaki H, Imano M, Imamoto H, Kodera Y, Uenosono Y, Amagai K, Kadowaki S, Miwa H, Yamaguchi H, Yamaguchi T, Miyaji T, Kitayama J. Phase III trial comparing intraperitoneal and intravenous paclitaxel plus S-1 versus cisplatin plus S-1 in patients with gastric cancer with peritoneal metastasis: PHOENIX-GC trial. J Clin Oncol. 2018 Jul 1;36(19):1922-1929. Epub 2018 May 10. [https://doi.org/10.1200/JCO.2018.77.8613 link to original article] '''dosing details in manuscript have been reviewed by our editors''' [https://pubmed.ncbi.nlm.nih.gov/29746229/ PubMed] UMIN000005930 |
− | + | #'''JCOG1013:''' Yamada Y, Boku N, Mizusawa J, Iwasa S, Kadowaki S, Nakayama N, Azuma M, Sakamoto T, Shitara K, Tamura T, Chin K, Hata H, Nakamori M, Hara H, Yasui H, Katayama H, Fukuda H, Yoshikawa T, Sasako M, Terashima M. Docetaxel plus cisplatin and S-1 versus cisplatin and S-1 in patients with advanced gastric cancer (JCOG1013): an open-label, phase 3, randomised controlled trial. Lancet Gastroenterol Hepatol. 2019 Jul;4(7):501-510. Epub 2019 May 14. [https://doi.org/10.1016/s2468-1253(19)30083-4 link to original article] '''dosing details in abstract have been reviewed by our editors''' [https://pubmed.ncbi.nlm.nih.gov/31101534/ PubMed] UMIN000007652 | |
+ | #'''SOPP:''' Lee KW, Chung IJ, Ryu MH, Park YI, Nam BH, Oh HS, Lee KH, Han HS, Seo BG, Jo JC, Lee HR, Kim JW, Park SR, Cho SH, Kang YK; SOPP study investigators. Multicenter phase III trial of S-1 and cisplatin versus S-1 and oxaliplatin combination chemotherapy for first-line treatment of advanced gastric cancer (SOPP trial). Gastric Cancer. 2021 Jan;24(1):156-167. Epub 2020 Jun 28. [https://doi.org/10.1007/s10120-020-01101-4 link to original article] '''dosing details in abstract have been reviewed by our editors''' [https://pubmed.ncbi.nlm.nih.gov/32596783/ PubMed] [https://clinicaltrials.gov/study/NCT01671449 NCT01671449] | ||
+ | #'''SOLAR:''' Kang YK, Chin K, Chung HC, Kadowaki S, Oh SC, Nakayama N, Lee KW, Hara H, Chung IJ, Tsuda M, Park SH, Hosaka H, Hironaka S, Miyata Y, Ryu MH, Baba H, Hyodo I, Bang YJ, Boku N. S-1 plus leucovorin and oxaliplatin versus S-1 plus cisplatin as first-line therapy in patients with advanced gastric cancer (SOLAR): a randomised, open-label, phase 3 trial. Lancet Oncol. 2020 Aug;21(8):1045-1056. Epub 2020 Jul 16. [https://doi.org/10.1016/s1470-2045(20)30315-6 link to original article] '''dosing details in abstract have been reviewed by our editors''' [https://pubmed.ncbi.nlm.nih.gov/32682457/ PubMed] [https://clinicaltrials.gov/study/NCT02322593 NCT02322593] | ||
==CLF {{#subobject:b913d6|Regimen=1}}== | ==CLF {{#subobject:b913d6|Regimen=1}}== | ||
− | |||
− | |||
− | |||
− | |||
CLF: '''<u>C</u>'''isplatin, '''<u>L</u>'''eucovorin, '''<u>F</u>'''luorouracil | CLF: '''<u>C</u>'''isplatin, '''<u>L</u>'''eucovorin, '''<u>F</u>'''luorouracil | ||
<br>FLP: '''<u>F</u>'''luorouracil, '''<u>L</u>'''eucovorin, '''<u>P</u>'''latinol (Cisplatin) | <br>FLP: '''<u>F</u>'''luorouracil, '''<u>L</u>'''eucovorin, '''<u>P</u>'''latinol (Cisplatin) | ||
− | === | + | <div class="toccolours" style="background-color:#eeeeee"> |
− | {| class="wikitable" style="width: 100%; text-align:center;" | + | ===Regimen variant #1 {{#subobject:beef19|Variant=1}}=== |
− | ! style="width: | + | {| class="wikitable sortable" style="width: 100%; text-align:center;" |
− | ! style="width: | + | ! style="width: 20%" |Study |
− | ! style="width: | + | ! style="width: 20%" |Dates of enrollment |
− | ! style="width: | + | ! style="width: 20%" |[[Levels_of_Evidence#Evidence|Evidence]] |
+ | ! style="width: 20%" |Comparator | ||
+ | ! style="width: 20%" |[[Levels_of_Evidence#Comparative_efficacy|Comparative Efficacy]] | ||
|- | |- | ||
− | |[ | + | |[https://doi.org/10.1200/jco.2007.13.9378 Al-Batran et al. 2008] |
− | | style="background-color:#1a9851" |Phase | + | |2003-2006 |
+ | | style="background-color:#1a9851" |Phase 3 (C) | ||
|[[#OLF|FLO]] | |[[#OLF|FLO]] | ||
| style="background-color:#fee08b" |Might have inferior PFS | | style="background-color:#fee08b" |Might have inferior PFS | ||
|- | |- | ||
|} | |} | ||
− | ''Note: In contrast to the original reference, some guidelines list 5-FU as being given every 2 weeks rather than the schedule below. | + | ''Note: In contrast to the original reference, some guidelines list 5-FU as being given every 2 weeks rather than the schedule below. Patients had 100% adenocarcinoma histology (20% gastroesophageal junction, 80% gastric).'' |
− | + | <div class="toccolours" style="background-color:#b3e2cd"> | |
− | |||
====Chemotherapy==== | ====Chemotherapy==== | ||
*[[Cisplatin (Platinol)]] 50 mg/m<sup>2</sup> IV over 2 hours once per day on days 1, 15, 29, 43 | *[[Cisplatin (Platinol)]] 50 mg/m<sup>2</sup> IV over 2 hours once per day on days 1, 15, 29, 43 | ||
− | *[[Folinic acid | + | *[[Leucovorin (Folinic acid)]] 200 mg/m<sup>2</sup> IV over 2 hours once per day on days 1, 15, 29, 43 |
*[[Fluorouracil (5-FU)]] 2000 mg/m<sup>2</sup> IV continuous infusion over 24 hours, started on days 1, 8, 15, 22, 29, 36 (total dose per cycle: 12,000 mg/m<sup>2</sup>) | *[[Fluorouracil (5-FU)]] 2000 mg/m<sup>2</sup> IV continuous infusion over 24 hours, started on days 1, 8, 15, 22, 29, 36 (total dose per cycle: 12,000 mg/m<sup>2</sup>) | ||
− | + | ====Supportive therapy==== | |
− | ====Supportive | + | *Up to 3 liters [[normal saline]] as hydration with cisplatin |
− | *Up to 3 liters normal saline as hydration with [[ | + | *[[:Category:Emesis prevention|Antiemetic medications]] per "local protocols" |
− | |||
− | |||
'''8-week cycles''' | '''8-week cycles''' | ||
− | + | </div></div><br> | |
− | === | + | <div class="toccolours" style="background-color:#eeeeee"> |
− | {| class="wikitable" style="width: 100%; text-align:center;" | + | ===Regimen variant #2 {{#subobject:34890|Variant=1}}=== |
− | ! style="width: | + | {| class="wikitable sortable" style="width: 100%; text-align:center;" |
− | ! style="width: | + | ! style="width: 20%" |Study |
− | ! style="width: | + | ! style="width: 20%" |Dates of enrollment |
− | ! style="width: | + | ! style="width: 20%" |[[Levels_of_Evidence#Evidence|Evidence]] |
+ | ! style="width: 20%" |Comparator | ||
+ | ! style="width: 20%" |[[Levels_of_Evidence#Comparative_efficacy|Comparative Efficacy]] | ||
|- | |- | ||
− | |[ | + | |[https://doi.org/10.1200/jco.2004.01.140 Bouché et al. 2004 (FFCD 9803)] |
− | | style="background-color:#1a9851" |Randomized Phase | + | |1999-2001 |
− | |1. [[ | + | | style="background-color:#1a9851" |Randomized Phase 2 (E-esc) |
+ | |1. [[#FULV_2|LV5FU2]]<br>2. [[#FOLFIRI|LV5FU2 & Irinotecan]] | ||
| style="background-color:#d3d3d3" |Not powered to draw conclusions | | style="background-color:#d3d3d3" |Not powered to draw conclusions | ||
|- | |- | ||
|} | |} | ||
''Note: the primary reference said every cycle was 15 days, but also said that medications were given every 14 days, so the assumption was made that this more regular schedule was used.'' | ''Note: the primary reference said every cycle was 15 days, but also said that medications were given every 14 days, so the assumption was made that this more regular schedule was used.'' | ||
+ | <div class="toccolours" style="background-color:#b3e2cd"> | ||
====Chemotherapy==== | ====Chemotherapy==== | ||
*[[Cisplatin (Platinol)]] 50 mg/m<sup>2</sup> IV over 60 minutes once on either day 1 or 2 | *[[Cisplatin (Platinol)]] 50 mg/m<sup>2</sup> IV over 60 minutes once on either day 1 or 2 | ||
− | *[[Folinic acid | + | *[[Leucovorin (Folinic acid)]] 200 mg/m<sup>2</sup> IV over 2 hours once on day 1 |
*[[Fluorouracil (5-FU)]] 400 mg/m<sup>2</sup> IV bolus once on day 1, then 1200 mg/m<sup>2</sup> IV continuous infusion over 22 hours (total dose per cycle: 1600 mg/m<sup>2</sup>) | *[[Fluorouracil (5-FU)]] 400 mg/m<sup>2</sup> IV bolus once on day 1, then 1200 mg/m<sup>2</sup> IV continuous infusion over 22 hours (total dose per cycle: 1600 mg/m<sup>2</sup>) | ||
− | + | ====Supportive therapy==== | |
− | ====Supportive | + | *1 liter [[:Category:Hydration|hydration]] over 3 hours before and after cisplatin |
− | *1 liter hydration over 3 hours before and after | + | *[[:Category:Serotonin_5-HT3_antagonists|5-HT3 antagonist]] IV prior to cisplatin |
− | *[[:Category:Serotonin_5-HT3_antagonists|5-HT3 antagonist]] IV | + | *[[Methylprednisolone (Solumedrol)]] 120 mg IV 10 minutes prior to cisplatin |
− | *[[Methylprednisolone (Solumedrol)]] 120 mg IV 10 minutes | + | *Oral [[:Category:Emesis prevention|antiemetics]] and [[:Category:Steroids|corticosteroids]] from days 2 to 5 |
− | |||
− | |||
'''14-day cycle for at least 4 cycles''' | '''14-day cycle for at least 4 cycles''' | ||
− | + | </div></div> | |
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
===References=== | ===References=== | ||
− | # ''' | + | #'''FFCD 9803:''' Bouché O, Raoul JL, Bonnetain F, Giovannini M, Etienne PL, Lledo G, Arsène D, Paitel JF, Guérin-Meyer V, Mitry E, Buecher B, Kaminsky MC, Seitz JF, Rougier P, Bedenne L, Milan C; Fédération Francophone de Cancérologie Digestive. Randomized multicenter phase II trial of a biweekly regimen of fluorouracil and leucovorin (LV5FU2), LV5FU2 plus cisplatin, or LV5FU2 plus irinotecan in patients with previously untreated metastatic gastric cancer: a Federation Francophone de Cancerologie Digestive Group Study--FFCD 9803. J Clin Oncol. 2004 Nov 1;22(21):4319-28. [https://doi.org/10.1200/jco.2004.01.140 link to original article] '''dosing details in manuscript have been reviewed by our editors''' [https://pubmed.ncbi.nlm.nih.gov/15514373/ PubMed] |
− | + | #Al-Batran SE, Hartmann JT, Probst S, Schmalenberg H, Hollerbach S, Hofheinz R, Rethwisch V, Seipelt G, Homann N, Wilhelm G, Schuch G, Stoehlmacher J, Derigs HG, Hegewisch-Becker S, Grossmann J, Pauligk C, Atmaca A, Bokemeyer C, Knuth A, Jäger E; Arbeitsgemeinschaft Internistische Onkologie. Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie. J Clin Oncol. 2008 Mar 20;26(9):1435-42. [https://doi.org/10.1200/jco.2007.13.9378 link to original article] '''dosing details in manuscript have been reviewed by our editors''' [https://pubmed.ncbi.nlm.nih.gov/18349393/ PubMed] | |
− | # | ||
− | |||
==DCF {{#subobject:efbdc5|Regimen=1}}== | ==DCF {{#subobject:efbdc5|Regimen=1}}== | ||
− | |||
− | |||
− | |||
− | |||
DCF: '''<u>D</u>'''ocetaxel, '''<u>C</u>'''isplatin, '''<u>F</u>'''luorouracil | DCF: '''<u>D</u>'''ocetaxel, '''<u>C</u>'''isplatin, '''<u>F</u>'''luorouracil | ||
<br>TCF: '''<u>T</u>'''axotere (Docetaxel), '''<u>C</u>'''isplatin, '''<u>F</u>'''luorouracil | <br>TCF: '''<u>T</u>'''axotere (Docetaxel), '''<u>C</u>'''isplatin, '''<u>F</u>'''luorouracil | ||
− | + | <div class="toccolours" style="background-color:#eeeeee"> | |
− | === | + | ===Regimen variant #1 {{#subobject:5aba07|Variant=1}}=== |
− | {| class="wikitable" style="width: 100%; text-align:center;" | + | {| class="wikitable sortable" style="width: 100%; text-align:center;" |
− | ! style="width: | + | ! style="width: 20%" |Study |
− | ! style="width: | + | ! style="width: 20%" |Dates of enrollment |
− | ! style="width: | + | ! style="width: 20%" |[[Levels_of_Evidence#Evidence|Evidence]] |
− | ! style="width: | + | ! style="width: 20%" |Comparator |
+ | ! style="width: 20%" |[[Levels_of_Evidence#Comparative_efficacy|Comparative Efficacy]] | ||
|- | |- | ||
− | |[ | + | |[https://doi.org/10.1200/jco.2005.17.376 Ajani et al. 2005 (V-325)] |
− | | style="background-color:#1a9851" |Randomized Phase | + | |1998-1999 |
− | |[[#Cisplatin_. | + | | style="background-color:#1a9851" |Randomized Phase 2 (E-esc) |
+ | |[[#Cisplatin_.26_Docetaxel_.28DC.29|DC]] | ||
| style="background-color:#91cf60" |Seems to have superior ORR | | style="background-color:#91cf60" |Seems to have superior ORR | ||
|- | |- | ||
− | |[ | + | |[https://doi.org/10.1200/jco.2006.06.8429 Van Cutsem et al. 2006 (TAX 325)] |
− | | style="background-color:#1a9851" |Phase | + | |1999-2003 |
− | |[[#Cisplatin_. | + | | style="background-color:#1a9851" |Phase 3 (E-RT-esc) |
− | | style="background-color:#91cf60" |Seems to have superior OS | + | |[[#Cisplatin_.26_Fluorouracil_.28CF.29_3|CF]] |
+ | | style="background-color:#91cf60" |Seems to have superior OS (secondary endpoint)<br><br>Superior TTP (primary endpoint) | ||
|- | |- | ||
|} | |} | ||
− | + | ''Note: In contrast to the original references, some guidelines list each cycle as lasting 28 days. V-325 patients had 100% adenocarcinoma histology (32% gastroesophageal junction/fundus and 68% gastric antrum/body). 95% were metastatic. 1% with Karnofsky PS score of 70. TAX 325 patients had 100% adenocarcinoma histology (22% gastroesophageal junction, 88% gastric origin). 97% with metastatic disease. 1% with Karnosky PS score of 70.'' | |
− | ''Note: In contrast to the original references, some guidelines list each cycle as lasting 28 days. | + | <div class="toccolours" style="background-color:#b3e2cd"> |
− | |||
− | |||
− | |||
− | |||
====Chemotherapy==== | ====Chemotherapy==== | ||
*[[Docetaxel (Taxotere)]] 75 mg/m<sup>2</sup> IV over 60 minutes once on day 1 | *[[Docetaxel (Taxotere)]] 75 mg/m<sup>2</sup> IV over 60 minutes once on day 1 | ||
*[[Cisplatin (Platinol)]] 75 mg/m<sup>2</sup> IV over 1 to 3 hours once on day 1 | *[[Cisplatin (Platinol)]] 75 mg/m<sup>2</sup> IV over 1 to 3 hours once on day 1 | ||
*[[Fluorouracil (5-FU)]] 750 mg/m<sup>2</sup>/day IV continuous infusion over 120 hours, started on day 1 (total dose per cycle: 3750 mg/m<sup>2</sup>) | *[[Fluorouracil (5-FU)]] 750 mg/m<sup>2</sup>/day IV continuous infusion over 120 hours, started on day 1 (total dose per cycle: 3750 mg/m<sup>2</sup>) | ||
− | + | ====Supportive therapy==== | |
− | ====Supportive | ||
*(varied depending on reference): | *(varied depending on reference): | ||
*[[Dexamethasone (Decadron)]] 8 mg PO once the night before chemotherapy, then 8 mg PO once on day 1; 1 hour prior to chemotherapy, then 8 mg PO twice per day until day 2 (total dose per cycle: 48 mg) | *[[Dexamethasone (Decadron)]] 8 mg PO once the night before chemotherapy, then 8 mg PO once on day 1; 1 hour prior to chemotherapy, then 8 mg PO twice per day until day 2 (total dose per cycle: 48 mg) | ||
− | *[[Dexamethasone (Decadron)]] 20 mg IV | + | *[[Dexamethasone (Decadron)]] 20 mg IV prior to cisplatin and 8 hours after cisplatin |
− | *[[Ondansetron (Zofran)]] 8 mg IV | + | *[[Ondansetron (Zofran)]] 8 mg IV prior to cisplatin, 4 hours after cisplatin, and 8 hours after cisplatin |
− | + | *"[[:Category:Hydration|Hydration]] (was) administered in a standard manner" | |
− | |||
'''21-day cycles''' | '''21-day cycles''' | ||
+ | </div></div><br> | ||
+ | <div class="toccolours" style="background-color:#eeeeee"> | ||
− | === | + | ===Regimen variant #2 {{#subobject:baa015|Variant=1}}=== |
− | {| class="wikitable" style="width: 100%; text-align:center;" | + | {| class="wikitable sortable" style="width: 100%; text-align:center;" |
− | ! style="width: | + | ! style="width: 20%" |Study |
− | ! style="width: | + | ! style="width: 20%" |Dates of enrollment |
− | ! style="width: | + | ! style="width: 20%" |[[Levels_of_Evidence#Evidence|Evidence]] |
− | ! style="width: | + | ! style="width: 20%" |Comparator |
+ | ! style="width: 20%" |[[Levels_of_Evidence#Comparative_efficacy|Comparative Efficacy]] | ||
|- | |- | ||
− | | rowspan="2" |[ | + | | rowspan="2" |[https://doi.org/10.1200/jco.2006.08.0135 Roth et al. 2007] |
− | | style="background-color:#1a9851 | + | | rowspan="2" |1999-2003 |
+ | | rowspan="2" style="background-color:#1a9851" |Randomized Phase 2 (E-esc) | ||
|1. [[#ECF_3|ECF]] | |1. [[#ECF_3|ECF]] | ||
| style="background-color:#d3d3d3" |Not reported | | style="background-color:#d3d3d3" |Not reported | ||
|- | |- | ||
− | |2. [[#Cisplatin_. | + | |2. [[#Cisplatin_.26_Docetaxel_.28DC.29|TC]] |
− | | style="background-color:#d9ef8b" |Might have superior ORR | + | | style="background-color:#d9ef8b" |Might have superior ORR (primary endpoint) |
|- | |- | ||
|} | |} | ||
''Note: the protocol was amended to change the original dose of ''docetaxel from'' 85 mg/m<sup>2</sup> to 75 mg/m<sup>2</sup> based on high incidence of febrile neutropenia.'' | ''Note: the protocol was amended to change the original dose of ''docetaxel from'' 85 mg/m<sup>2</sup> to 75 mg/m<sup>2</sup> based on high incidence of febrile neutropenia.'' | ||
+ | <div class="toccolours" style="background-color:#b3e2cd"> | ||
====Chemotherapy==== | ====Chemotherapy==== | ||
*[[Docetaxel (Taxotere)]] 75 mg/m<sup>2</sup> IV over 60 minutes once on day 1 | *[[Docetaxel (Taxotere)]] 75 mg/m<sup>2</sup> IV over 60 minutes once on day 1 | ||
*[[Cisplatin (Platinol)]] 75 mg/m<sup>2</sup> IV over 4 hours once on day 1 | *[[Cisplatin (Platinol)]] 75 mg/m<sup>2</sup> IV over 4 hours once on day 1 | ||
*[[Fluorouracil (5-FU)]] 300 mg/m<sup>2</sup>/day IV continuous infusion over 14 days, started on day 1 (total dose per cycle: 4200 mg/m<sup>2</sup>) | *[[Fluorouracil (5-FU)]] 300 mg/m<sup>2</sup>/day IV continuous infusion over 14 days, started on day 1 (total dose per cycle: 4200 mg/m<sup>2</sup>) | ||
− | + | ====Supportive therapy==== | |
− | ====Supportive | + | *3 liters per day [[:Category:Hydration|"hyperhydration"]] |
− | *3 liters per day "hyperhydration" | + | *[[Dexamethasone (Decadron)]] 8 mg PO given 12 hours & 6 hours prior to docetaxel, then 8 mg PO twice per day for 4 days after docetaxel |
− | *[[Dexamethasone (Decadron)]] 8 mg PO given 12 hours & 6 hours | ||
*[[:Category:Serotonin_5-HT3_antagonists|5-HT3 antagonist]] for emesis prophylaxis | *[[:Category:Serotonin_5-HT3_antagonists|5-HT3 antagonist]] for emesis prophylaxis | ||
*Growth factor support allowed, such as with [[Filgrastim (Neupogen)]] | *Growth factor support allowed, such as with [[Filgrastim (Neupogen)]] | ||
− | |||
'''21-day cycle for up to 8 cycles''' | '''21-day cycle for up to 8 cycles''' | ||
− | + | </div></div> | |
===References=== | ===References=== | ||
− | # '''V-325:''' Ajani JA, Fodor MB, Tjulandin SA, Moiseyenko VM, Chao Y, Cabral Filho S, Majlis A, Assadourian S, Van Cutsem E. Phase II multi-institutional randomized trial of docetaxel plus cisplatin with or without fluorouracil in patients with untreated, advanced gastric, or gastroesophageal adenocarcinoma. J Clin Oncol. 2005 Aug 20;23(24):5660-7. [ | + | #'''V-325:''' Ajani JA, Fodor MB, Tjulandin SA, Moiseyenko VM, Chao Y, Cabral Filho S, Majlis A, Assadourian S, Van Cutsem E. Phase II multi-institutional randomized trial of docetaxel plus cisplatin with or without fluorouracil in patients with untreated, advanced gastric, or gastroesophageal adenocarcinoma. J Clin Oncol. 2005 Aug 20;23(24):5660-7. [https://doi.org/10.1200/jco.2005.17.376 link to original article] '''dosing details in manuscript have been reviewed by our editors''' [https://pubmed.ncbi.nlm.nih.gov/16110025/ PubMed] |
− | # ''' | + | #'''TAX 325:''' Van Cutsem E, Moiseyenko VM, Tjulandin S, Majlis A, Constenla M, Boni C, Rodrigues A, Fodor M, Chao Y, Voznyi E, Risse ML, Ajani JA; V325 Study Group. Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group. J Clin Oncol. 2006 Nov 1;24(31):4991-7. [https://doi.org/10.1200/jco.2006.06.8429 link to original article] '''dosing details in manuscript have been reviewed by our editors''' [https://pubmed.ncbi.nlm.nih.gov/17075117/ PubMed] |
− | # Roth AD, Fazio N, Stupp R, Falk S, Bernhard J, Saletti P, Köberle D, Borner MM, Rufibach K, Maibach R, Wernli M, Leslie M, Glynne-Jones R, Widmer L, Seymour M, de Braud F; Swiss Group for Clinical Cancer Research. Docetaxel, cisplatin, and fluorouracil; docetaxel and cisplatin; and epirubicin, cisplatin, and fluorouracil as systemic treatment for advanced gastric carcinoma: a randomized phase II trial of the Swiss Group for Clinical Cancer Research. J Clin Oncol. 2007 Aug 1;25(22):3217-23. [ | + | #Roth AD, Fazio N, Stupp R, Falk S, Bernhard J, Saletti P, Köberle D, Borner MM, Rufibach K, Maibach R, Wernli M, Leslie M, Glynne-Jones R, Widmer L, Seymour M, de Braud F; Swiss Group for Clinical Cancer Research. Docetaxel, cisplatin, and fluorouracil; docetaxel and cisplatin; and epirubicin, cisplatin, and fluorouracil as systemic treatment for advanced gastric carcinoma: a randomized phase II trial of the Swiss Group for Clinical Cancer Research. J Clin Oncol. 2007 Aug 1;25(22):3217-23. [https://doi.org/10.1200/jco.2006.08.0135 link to original article] '''dosing details in manuscript have been reviewed by our editors''' [https://pubmed.ncbi.nlm.nih.gov/17664469/ PubMed] |
− | |||
==mDCF {{#subobject:70e20f|Regimen=1}}== | ==mDCF {{#subobject:70e20f|Regimen=1}}== | ||
− | |||
− | |||
− | |||
− | |||
mDCF: '''<u>m</u>'''odified '''<u>D</u>'''ocetaxel, '''<u>C</u>'''isplatin, '''<u>F</u>'''luorouracil | mDCF: '''<u>m</u>'''odified '''<u>D</u>'''ocetaxel, '''<u>C</u>'''isplatin, '''<u>F</u>'''luorouracil | ||
− | === | + | <div class="toccolours" style="background-color:#eeeeee"> |
− | {| class="wikitable" style="width: | + | ===Regimen variant #1, 60/60/3000, 4-day 5-FU infusion {{#subobject:323b13|Variant=1}}=== |
− | ! style="width: | + | {| class="wikitable sortable" style="width: 100%; text-align:center;" |
− | ! style="width: | + | ! style="width: 20%" |Study |
+ | ! style="width: 20%" |Dates of enrollment | ||
+ | ! style="width: 20%" |[[Levels_of_Evidence#Evidence|Evidence]] | ||
+ | ! style="width: 20%" |Comparator | ||
+ | ! style="width: 20%" |[[Levels_of_Evidence#Comparative_efficacy|Comparative Efficacy]] | ||
|- | |- | ||
− | |[https://www.ncbi.nlm.nih.gov/pmc/articles/ | + | |[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4688303/ Wang et al. 2015 (DOCET L 02195)] |
− | | style="background-color:# | + | |2008-2010 |
+ | | style="background-color:#1a9851" |Phase 3 (E-esc) | ||
+ | |[[#Cisplatin_.26_Fluorouracil_.28CF.29_3|CF]] | ||
+ | | style="background-color:#91cf60" |Seems to have superior OS (secondary endpoint)<br>Median OS: 10.2 vs 8.5 mo<br>(HR 0.71, 95% CI 0.52-0.97) | ||
|- | |- | ||
|} | |} | ||
− | + | <div class="toccolours" style="background-color:#b3e2cd"> | |
− | |||
− | |||
====Chemotherapy==== | ====Chemotherapy==== | ||
− | *[[Docetaxel (Taxotere)]] | + | *[[Docetaxel (Taxotere)]] 60 mg/m<sup>2</sup> IV once on day 1 |
− | *[[Cisplatin (Platinol)]] | + | *[[Cisplatin (Platinol)]] 60 mg/m<sup>2</sup> IV once on day 1 |
− | + | *[[Fluorouracil (5-FU)]] 750 mg/m<sup>2</sup>/day IV continuous infusion over 96 hours, started on day 1 (total dose per cycle: 3000 mg/m<sup>2</sup>) | |
− | *[[Fluorouracil (5-FU)]] | + | '''21-day cycles''' |
− | + | </div></div><br> | |
− | + | <div class="toccolours" style="background-color:#eeeeee"> | |
− | + | ===Regimen variant #2, 60/60/3000, 5-day 5-FU infusion {{#subobject:323bug|Variant=1}}=== | |
− | + | {| class="wikitable sortable" style="width: 100%; text-align:center;" | |
− | ''' | + | ! style="width: 20%" |Study |
− | + | ! style="width: 20%" |Dates of enrollment | |
− | === | + | ! style="width: 20%" |[[Levels_of_Evidence#Evidence|Evidence]] |
− | {| class="wikitable" style="width: 100%; text-align:center;" | + | ! style="width: 20%" |Comparator |
− | !style="width: | + | ! style="width: 20%" |[[Levels_of_Evidence#Comparative_efficacy|Comparative Efficacy]] |
− | !style="width: | ||
− | !style="width: | ||
− | !style="width: | ||
− | |||
− | |||
− | |||
− | |||
− | |||
|- | |- | ||
− | |[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4688303/ Wang et al. 2015 ( | + | |[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4688303/ Wang et al. 2015 (DOCET L 02195)] |
− | | style="background-color:#1a9851" |Phase | + | |2008-2010 |
− | |[[#Cisplatin_. | + | | style="background-color:#1a9851" |Phase 3 (E-esc) |
− | | style="background-color:#91cf60" |Seems to have superior OS | + | |[[#Cisplatin_.26_Fluorouracil_.28CF.29_3|CF]] |
+ | | style="background-color:#91cf60" |Seems to have superior OS (secondary endpoint)<br>Median OS: 10.2 vs 8.5 mo<br>(HR 0.71, 95% CI 0.52-0.97) | ||
|- | |- | ||
|} | |} | ||
+ | <div class="toccolours" style="background-color:#b3e2cd"> | ||
====Chemotherapy==== | ====Chemotherapy==== | ||
*[[Docetaxel (Taxotere)]] 60 mg/m<sup>2</sup> IV once on day 1 | *[[Docetaxel (Taxotere)]] 60 mg/m<sup>2</sup> IV once on day 1 | ||
*[[Cisplatin (Platinol)]] 60 mg/m<sup>2</sup> IV once on day 1 | *[[Cisplatin (Platinol)]] 60 mg/m<sup>2</sup> IV once on day 1 | ||
− | *[[Fluorouracil (5-FU)]] | + | *[[Fluorouracil (5-FU)]] 600 mg/m<sup>2</sup>/day IV continuous infusion over 120 hours, started on day 1 (total dose per cycle: 3000 mg/m<sup>2</sup>) |
− | |||
− | |||
− | |||
'''21-day cycles''' | '''21-day cycles''' | ||
+ | </div></div> | ||
===References=== | ===References=== | ||
− | # ''' | + | #'''DOCET L 02195:''' Wang J, Xu R, Li J, Bai Y, Liu T, Jiao S, Dai G, Xu J, Liu Y, Fan N, Shu Y, Ba Y, Ma D, Qin S, Zheng L, Chen W, Shen L. Randomized multicenter phase III study of a modified docetaxel and cisplatin plus fluorouracil regimen compared with cisplatin and fluorouracil as first-line therapy for advanced or locally recurrent gastric cancer. Gastric Cancer. 2016 Jan;19(1):234-44. Epub 2015 Jan 21. [https://doi.org/10.1007/s10120-015-0457-4 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4688303/ link to PMC article] '''dosing details in manuscript have been reviewed by our editors''' [https://pubmed.ncbi.nlm.nih.gov/25604851/ PubMed] [https://clinicaltrials.gov/study/NCT00811447 NCT00811447] |
− | |||
− | |||
==mDCF & Bevacizumab {{#subobject:30ea9e|Regimen=1}}== | ==mDCF & Bevacizumab {{#subobject:30ea9e|Regimen=1}}== | ||
− | |||
− | |||
− | |||
− | |||
mDCF & Bevacizumab: '''<u>m</u>'''odified '''<u>D</u>'''ocetaxel, '''<u>C</u>'''isplatin, '''<u>F</u>'''luorouracil & Bevacizumab | mDCF & Bevacizumab: '''<u>m</u>'''odified '''<u>D</u>'''ocetaxel, '''<u>C</u>'''isplatin, '''<u>F</u>'''luorouracil & Bevacizumab | ||
+ | <div class="toccolours" style="background-color:#eeeeee"> | ||
===Regimen {{#subobject:5485f9|Variant=1}}=== | ===Regimen {{#subobject:5485f9|Variant=1}}=== | ||
− | {| class="wikitable" style="width: | + | {| class="wikitable sortable" style="width: 60%; text-align:center;" |
− | ! style="width: | + | !style="width: 33%"|Study |
− | ! style="width: | + | !style="width: 33%"|Dates of enrollment |
+ | !style="width: 33%"|[[Levels_of_Evidence#Evidence|Evidence]] | ||
|- | |- | ||
− | |[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3646322/ Shah et al. 2010] | + | |[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3646322/ Shah et al. 2010 (MSK 06-096)] |
− | | style="background-color:#91cf61" |Phase | + | |2006-2008 |
+ | | style="background-color:#91cf61" |Phase 2 | ||
|- | |- | ||
|} | |} | ||
− | '' | + | ''Note: patients had 100% adenocarcinoma (50% gastric, 45% gastroesophageal junction, 5% esophagus). 93% received no prior therapy. Unlike most DCF regimens that we are aware of, this one includes leucovorin.'' |
− | + | <div class="toccolours" style="background-color:#b3e2cd"> | |
====Chemotherapy==== | ====Chemotherapy==== | ||
*[[Docetaxel (Taxotere)]] 40 mg/m<sup>2</sup> IV over 60 minutes once on day 1 | *[[Docetaxel (Taxotere)]] 40 mg/m<sup>2</sup> IV over 60 minutes once on day 1 | ||
*[[Cisplatin (Platinol)]] 40 mg/m<sup>2</sup> IV over 1 to 3 hours once on day 3 | *[[Cisplatin (Platinol)]] 40 mg/m<sup>2</sup> IV over 1 to 3 hours once on day 3 | ||
− | *[[Folinic acid | + | *[[Leucovorin (Folinic acid)]] 400 mg/m<sup>2</sup> IV once on day 1 |
*[[Fluorouracil (5-FU)]] 400 mg/m<sup>2</sup> IV bolus once on day 1, then 1200 mg/m<sup>2</sup>/day IV continuous infusion over 48 hours (total dose per cycle: 2800 mg/m<sup>2</sup>) | *[[Fluorouracil (5-FU)]] 400 mg/m<sup>2</sup> IV bolus once on day 1, then 1200 mg/m<sup>2</sup>/day IV continuous infusion over 48 hours (total dose per cycle: 2800 mg/m<sup>2</sup>) | ||
+ | ====Targeted therapy==== | ||
*[[Bevacizumab (Avastin)]] 10 mg/kg IV once on day 1 | *[[Bevacizumab (Avastin)]] 10 mg/kg IV once on day 1 | ||
− | ====Supportive | + | ====Supportive therapy==== |
*"Standard premedication and delayed emesis regimens" | *"Standard premedication and delayed emesis regimens" | ||
− | |||
'''14-day cycles''' | '''14-day cycles''' | ||
− | + | </div></div> | |
===References=== | ===References=== | ||
− | # Shah MA, Jhawer M, Ilson DH, Lefkowitz RA, Robinson E, Capanu M, Kelsen DP. Phase II study of modified docetaxel, cisplatin, and fluorouracil with bevacizumab in patients with metastatic gastroesophageal adenocarcinoma. J Clin Oncol. 2011 Mar 1;29(7):868-74. Epub 2010 Dec 28. [ | + | #'''MSK 06-096:''' Shah MA, Jhawer M, Ilson DH, Lefkowitz RA, Robinson E, Capanu M, Kelsen DP. Phase II study of modified docetaxel, cisplatin, and fluorouracil with bevacizumab in patients with metastatic gastroesophageal adenocarcinoma. J Clin Oncol. 2011 Mar 1;29(7):868-74. Epub 2010 Dec 28. [https://doi.org/10.1200/jco.2010.32.0770 link to original article] '''dosing details in manuscript have been reviewed by our editors''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3646322/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/21189380/ PubMed] [https://clinicaltrials.gov/study/NCT00390416 NCT00390416] |
==Docetaxel & S-1 {{#subobject:a22c2a|Regimen=1}}== | ==Docetaxel & S-1 {{#subobject:a22c2a|Regimen=1}}== | ||
− | + | <div class="toccolours" style="background-color:#eeeeee"> | |
− | |||
− | |||
− | |||
===Regimen {{#subobject:82ca03|Variant=1}}=== | ===Regimen {{#subobject:82ca03|Variant=1}}=== | ||
− | {| class="wikitable" style="width: 100%; text-align:center;" | + | {| class="wikitable sortable" style="width: 100%; text-align:center;" |
− | ! style="width: | + | ! style="width: 20%" |Study |
− | ! style="width: | + | ! style="width: 20%" |Dates of enrollment |
− | ! style="width: | + | ! style="width: 20%" |[[Levels_of_Evidence#Evidence|Evidence]] |
− | ! style="width: | + | ! style="width: 20%" |Comparator |
+ | ! style="width: 20%" |[[Levels_of_Evidence#Comparative_efficacy|Comparative Efficacy]] | ||
|- | |- | ||
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3895196/ Koizumi et al. 2013 (START<sub>gastric</sub>)] | |[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3895196/ Koizumi et al. 2013 (START<sub>gastric</sub>)] | ||
− | | style="background-color:#1a9851" |Phase | + | |2005-2008 |
+ | | style="background-color:#1a9851" |Phase 3 (E-esc) | ||
|[[#S-1_monotherapy_2|S-1]] | |[[#S-1_monotherapy_2|S-1]] | ||
− | | style="background-color:#91cf60" |Seems to have superior OS | + | | style="background-color:#91cf60" |Seems to have superior OS (primary endpoint)<br>Median OS: 12.5 vs 10.8 mo<br>(HR 0.84, 95% CI 0.71-0.99) |
|} | |} | ||
+ | <div class="toccolours" style="background-color:#b3e2cd"> | ||
====Chemotherapy==== | ====Chemotherapy==== | ||
*[[Docetaxel (Taxotere)]] 40 mg/m<sup>2</sup> IV once on day 1 | *[[Docetaxel (Taxotere)]] 40 mg/m<sup>2</sup> IV once on day 1 | ||
− | *[[Tegafur, gimeracil, oteracil (S-1)]] | + | *[[Tegafur, gimeracil, oteracil (S-1)]] by the following BSA-based criteria: |
− | ** | + | **Less than 1.25 m<sup>2</sup>: 40 mg PO twice per day on days 1 to 14 |
− | ** | + | **Between 1.25 m<sup>2</sup> and 1.5 m<sup>2</sup>: 50 mg PO twice per day on days 1 to 14 |
− | ** | + | **1.5 m<sup>2</sup> or more: 60 mg PO twice per day on days 1 to 14 |
− | |||
'''21-day cycles''' | '''21-day cycles''' | ||
+ | </div></div> | ||
===References=== | ===References=== | ||
− | # '''START:''' Koizumi W, Kim YH, Fujii M, Kim HK, Imamura H, Lee KH, Hara T, Chung HC, Satoh T, Cho JY, Hosaka H, Tsuji A, Takagane A, Inokuchi M, Tanabe K, Okuno T, Ogura M, Yoshida K, Takeuchi M, Nakajima T; JACCRO | + | #'''START:''' Koizumi W, Kim YH, Fujii M, Kim HK, Imamura H, Lee KH, Hara T, Chung HC, Satoh T, Cho JY, Hosaka H, Tsuji A, Takagane A, Inokuchi M, Tanabe K, Okuno T, Ogura M, Yoshida K, Takeuchi M, Nakajima T; JACCRO; KCSG. Addition of docetaxel to S-1 without platinum prolongs survival of patients with advanced gastric cancer: a randomized study (START). J Cancer Res Clin Oncol. 2014 Feb;140(2):319-28. Epub 2013 Dec 24. [https://doi.org/10.1007/s00432-013-1563-5 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3895196/ link to PMC article] '''dosing details in manuscript have been reviewed by our editors''' [https://pubmed.ncbi.nlm.nih.gov/24366758/ PubMed] [https://clinicaltrials.gov/study/NCT00287768 NCT00287768] |
− | |||
==ECF {{#subobject:6325cb|Regimen=1}}== | ==ECF {{#subobject:6325cb|Regimen=1}}== | ||
− | |||
− | |||
− | |||
− | |||
ECF: '''<u>E</u>'''pirubicin, '''<u>C</u>'''isplatin, '''<u>F</u>'''luorouracil | ECF: '''<u>E</u>'''pirubicin, '''<u>C</u>'''isplatin, '''<u>F</u>'''luorouracil | ||
+ | <div class="toccolours" style="background-color:#eeeeee"> | ||
===Regimen {{#subobject:e5ede0|Variant=1}}=== | ===Regimen {{#subobject:e5ede0|Variant=1}}=== | ||
− | {| class="wikitable" style="width: 100%; text-align:center;" | + | {| class="wikitable sortable" style="width: 100%; text-align:center;" |
− | ! style="width: | + | ! style="width: 20%" |Study |
− | ! style="width: | + | ! style="width: 20%" |Dates of enrollment |
− | ! style="width: | + | ! style="width: 20%" |[[Levels_of_Evidence#Evidence|Evidence]] |
− | ! style="width: | + | ! style="width: 20%" |Comparator |
+ | ! style="width: 20%" |[[Levels_of_Evidence#Comparative_efficacy|Comparative Efficacy]] | ||
|- | |- | ||
− | |[ | + | |[https://doi.org/10.1093/oxfordjournals.annonc.a058932 Findlay et al. 1994] |
− | | style="background-color:#91cf61" |Phase | + | |1988-1992 |
+ | | style="background-color:#91cf61" |Phase 2 | ||
| style="background-color:#d3d3d3" | | | style="background-color:#d3d3d3" | | ||
| style="background-color:#d3d3d3" | | | style="background-color:#d3d3d3" | | ||
|- | |- | ||
− | |[https:// | + | |[https://doi.org/10.1200/JCO.1997.15.1.261 Webb et al. 1997] |
− | | style="background-color:#1a9851" | | + | |1992-1995 |
+ | | style="background-color:#1a9851" |Randomized (E-switch-ic) | ||
|[[Gastric_cancer_-_historical#FAMTX|FAMTX]] | |[[Gastric_cancer_-_historical#FAMTX|FAMTX]] | ||
| style="background-color:#1a9850" |Superior OS | | style="background-color:#1a9850" |Superior OS | ||
|- | |- | ||
− | |[ | + | |[https://doi.org/10.1200/jco.2002.08.105 Ross et al. 2002] |
− | | style="background-color:#1a9851" |Phase | + | |1995-1998 |
+ | | style="background-color:#1a9851" |Phase 3 (C) | ||
|[[#MCF|MCF]] | |[[#MCF|MCF]] | ||
− | | style="background-color:#eeee01" |Seems to have | + | | style="background-color:#eeee01" |Seems to have non-inferior OS |
|- | |- | ||
− | |[ | + | |[https://doi.org/10.1200/jco.2006.08.0135 Roth et al. 2007] |
− | | style="background-color:#1a9851" |Randomized Phase | + | |1999-2003 |
− | |1. [[#Cisplatin_. | + | | style="background-color:#1a9851" |Randomized Phase 2 (C) |
+ | |1. [[#Cisplatin_.26_Docetaxel_.28DC.29|TC]]<br>2. [[#DCF|TCF]] | ||
| style="background-color:#d3d3d3" |Not reported | | style="background-color:#d3d3d3" |Not reported | ||
|- | |- | ||
− | | rowspan="3" |[https:// | + | | rowspan="3" |[https://doi.org/10.1056/NEJMoa073149 Cunningham et al. 2008 (REAL-2)] |
− | | rowspan="3" style="background-color:#1a9851" |Phase | + | | rowspan="3" |2000-2005 |
+ | | rowspan="3" style="background-color:#1a9851" |Phase 3 (C) | ||
|1. [[#ECX_2|ECX]] | |1. [[#ECX_2|ECX]] | ||
| style="background-color:#eeee01" |Non-inferior OS | | style="background-color:#eeee01" |Non-inferior OS | ||
Line 1,713: | Line 2,627: | ||
|- | |- | ||
|} | |} | ||
− | ''Findlay et al. | + | ''Note: Findlay et al. patients all had metastatic gastric cancer. Ross et al. patients had adenocarcinoma, squamous carcinoma, or undifferentiated carcinoma histology, all advanced esophagogastric cancer. Roth et al. patients all had metastatic gastric cancer. REAL-2 patients had 35% esophageal, 25% gastroesophageal junction, 40% gastric. 11% ECOG PS of 2.'' |
− | + | <div class="toccolours" style="background-color:#b3e2cd"> | |
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
====Chemotherapy==== | ====Chemotherapy==== | ||
*[[Epirubicin (Ellence)]] 50 mg/m<sup>2</sup> IV bolus once on day 1 | *[[Epirubicin (Ellence)]] 50 mg/m<sup>2</sup> IV bolus once on day 1 | ||
*[[Cisplatin (Platinol)]] 60 mg/m<sup>2</sup> IV over 4 hours once on day 1 | *[[Cisplatin (Platinol)]] 60 mg/m<sup>2</sup> IV over 4 hours once on day 1 | ||
*[[Fluorouracil (5-FU)]] 200 mg/m<sup>2</sup>/day IV continuous infusion over 21 days, started on day 1 (total dose per cycle: 4200 mg/m<sup>2</sup>) | *[[Fluorouracil (5-FU)]] 200 mg/m<sup>2</sup>/day IV continuous infusion over 21 days, started on day 1 (total dose per cycle: 4200 mg/m<sup>2</sup>) | ||
− | + | ====Supportive therapy==== | |
− | ====Supportive | ||
*(varied depending on reference): | *(varied depending on reference): | ||
− | *3 liters per day "hyperhydration" | + | *3 liters per day [[:Category:Hydration|"hyperhydration"]] |
*[[:Category:Serotonin_5-HT3_antagonists|5-HT3 antagonist]] for emesis prophylaxis | *[[:Category:Serotonin_5-HT3_antagonists|5-HT3 antagonist]] for emesis prophylaxis | ||
*Growth factor support allowed, such as with [[Filgrastim (Neupogen)]] | *Growth factor support allowed, such as with [[Filgrastim (Neupogen)]] | ||
*Ross et al. 2002 & Cunningham et al. 2008 used [[Warfarin (Coumadin)]] 1 mg PO once per day for catheter thrombosis prophylaxis | *Ross et al. 2002 & Cunningham et al. 2008 used [[Warfarin (Coumadin)]] 1 mg PO once per day for catheter thrombosis prophylaxis | ||
− | |||
'''21-day cycle for up to 8 cycles''' | '''21-day cycle for up to 8 cycles''' | ||
− | + | </div></div> | |
===References=== | ===References=== | ||
− | # Findlay M, Cunningham D, Norman A, Mansi J, Nicolson M, Hickish T, Nicolson V, Nash A, Sacks N, Ford H, Carter R, Hill A. A phase II study in advanced gastro-esophageal cancer using epirubicin and cisplatin in combination with continuous infusion 5-fluorouracil (ECF). Ann Oncol. 1994 Sep;5(7):609-16. [ | + | #Findlay M, Cunningham D, Norman A, Mansi J, Nicolson M, Hickish T, Nicolson V, Nash A, Sacks N, Ford H, Carter R, Hill A. A phase II study in advanced gastro-esophageal cancer using epirubicin and cisplatin in combination with continuous infusion 5-fluorouracil (ECF). Ann Oncol. 1994 Sep;5(7):609-16. [https://doi.org/10.1093/oxfordjournals.annonc.a058932 link to original article] '''dosing details in manuscript have been reviewed by our editors''' [https://pubmed.ncbi.nlm.nih.gov/7993836/ PubMed] |
− | # Webb A, Cunningham D, Scarffe JH, Harper P, Norman A, Joffe JK, Hughes M, Mansi J, Findlay M, Hill A, Oates J, Nicolson M, Hickish T, O'Brien M, Iveson T, Watson M, Underhill C, Wardley A, Meehan M. Randomized trial comparing epirubicin, cisplatin, and fluorouracil versus fluorouracil, doxorubicin, and methotrexate in advanced esophagogastric cancer. J Clin Oncol. 1997 Jan;15(1):261-7. [https:// | + | #Webb A, Cunningham D, Scarffe JH, Harper P, Norman A, Joffe JK, Hughes M, Mansi J, Findlay M, Hill A, Oates J, Nicolson M, Hickish T, O'Brien M, Iveson T, Watson M, Underhill C, Wardley A, Meehan M. Randomized trial comparing epirubicin, cisplatin, and fluorouracil versus fluorouracil, doxorubicin, and methotrexate in advanced esophagogastric cancer. J Clin Oncol. 1997 Jan;15(1):261-7. [https://doi.org/10.1200/JCO.1997.15.1.261 link to original article] '''dosing details in manuscript have been reviewed by our editors''' [https://pubmed.ncbi.nlm.nih.gov/8996151/ PubMed] |
− | ## '''Update:''' Waters JS, Norman A, Cunningham D, Scarffe JH, Webb A, Harper P, Joffe JK, Mackean M, Mansi J, Leahy M, Hill A, Oates J, Rao S, Nicolson M, Hickish T. Long-term survival after epirubicin, cisplatin and fluorouracil for gastric cancer: results of a randomized trial. Br J Cancer. 1999 Apr;80(1-2):269-72. [https:// | + | ##'''Update:''' Waters JS, Norman A, Cunningham D, Scarffe JH, Webb A, Harper P, Joffe JK, Mackean M, Mansi J, Leahy M, Hill A, Oates J, Rao S, Nicolson M, Hickish T. Long-term survival after epirubicin, cisplatin and fluorouracil for gastric cancer: results of a randomized trial. Br J Cancer. 1999 Apr;80(1-2):269-72. [https://doi.org/10.1038/sj.bjc.6690350 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2363002/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/10390007/ PubMed] |
− | # Ross P, Nicolson M, Cunningham D, Valle J, Seymour M, Harper P, Price T, Anderson H, Iveson T, Hickish T, Lofts F, Norman A. Prospective randomized trial comparing mitomycin, cisplatin, and protracted venous-infusion fluorouracil (PVI 5-FU) With epirubicin, cisplatin, and PVI 5-FU in advanced esophagogastric cancer. J Clin Oncol. 2002 Apr 15;20(8):1996-2004. [ | + | #Ross P, Nicolson M, Cunningham D, Valle J, Seymour M, Harper P, Price T, Anderson H, Iveson T, Hickish T, Lofts F, Norman A. Prospective randomized trial comparing mitomycin, cisplatin, and protracted venous-infusion fluorouracil (PVI 5-FU) With epirubicin, cisplatin, and PVI 5-FU in advanced esophagogastric cancer. J Clin Oncol. 2002 Apr 15;20(8):1996-2004. [https://doi.org/10.1200/jco.2002.08.105 link to original article] '''dosing details in manuscript have been reviewed by our editors''' [https://pubmed.ncbi.nlm.nih.gov/11956258/ PubMed] |
− | # Roth AD, Fazio N, Stupp R, Falk S, Bernhard J, Saletti P, Köberle D, Borner MM, Rufibach K, Maibach R, Wernli M, Leslie M, Glynne-Jones R, Widmer L, Seymour M, de Braud F; Swiss Group for Clinical Cancer Research. Docetaxel, cisplatin, and fluorouracil; docetaxel and cisplatin; and epirubicin, cisplatin, and fluorouracil as systemic treatment for advanced gastric carcinoma: a randomized phase II trial of the Swiss Group for Clinical Cancer Research. J Clin Oncol. 2007 Aug 1;25(22):3217-23. [ | + | #Roth AD, Fazio N, Stupp R, Falk S, Bernhard J, Saletti P, Köberle D, Borner MM, Rufibach K, Maibach R, Wernli M, Leslie M, Glynne-Jones R, Widmer L, Seymour M, de Braud F; Swiss Group for Clinical Cancer Research. Docetaxel, cisplatin, and fluorouracil; docetaxel and cisplatin; and epirubicin, cisplatin, and fluorouracil as systemic treatment for advanced gastric carcinoma: a randomized phase II trial of the Swiss Group for Clinical Cancer Research. J Clin Oncol. 2007 Aug 1;25(22):3217-23. [https://doi.org/10.1200/jco.2006.08.0135 link to original article] '''dosing details in manuscript have been reviewed by our editors''' [https://pubmed.ncbi.nlm.nih.gov/17664469/ PubMed] |
− | # '''REAL-2:''' Cunningham D, Starling N, Rao S, Iveson T, Nicolson M, Coxon F, Middleton G, Daniel F, Oates J, Norman AR; Upper Gastrointestinal Clinical Studies Group of the National Cancer Research Institute of the United Kingdom. Capecitabine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med. 2008 Jan 3;358(1):36-46. [https:// | + | #'''REAL-2:''' Cunningham D, Starling N, Rao S, Iveson T, Nicolson M, Coxon F, Middleton G, Daniel F, Oates J, Norman AR; Upper Gastrointestinal Clinical Studies Group of the National Cancer Research Institute of the United Kingdom. Capecitabine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med. 2008 Jan 3;358(1):36-46. [https://doi.org/10.1056/NEJMoa073149 link to original article] '''dosing details in manuscript have been reviewed by our editors''' [https://pubmed.ncbi.nlm.nih.gov/18172173/ PubMed] ISRCTN51678883 |
− | |||
==ECX {{#subobject:36cac7|Regimen=1}}== | ==ECX {{#subobject:36cac7|Regimen=1}}== | ||
− | |||
− | |||
− | |||
− | |||
ECX: '''<u>E</u>'''pirubicin, '''<u>C</u>'''isplatin, '''<u>X</u>'''eloda (Capecitabine) | ECX: '''<u>E</u>'''pirubicin, '''<u>C</u>'''isplatin, '''<u>X</u>'''eloda (Capecitabine) | ||
<br>ECC: '''<u>E</u>'''pirubicin, '''<u>C</u>'''isplatin, '''<u>C</u>'''apecitabine | <br>ECC: '''<u>E</u>'''pirubicin, '''<u>C</u>'''isplatin, '''<u>C</u>'''apecitabine | ||
− | === | + | <div class="toccolours" style="background-color:#eeeeee"> |
− | {| class="wikitable" style="width: 100%; text-align:center;" | + | ===Regimen variant #1, continuous capecitabine {{#subobject:f0efc0|Variant=1}}=== |
− | ! style="width: | + | {| class="wikitable sortable" style="width: 100%; text-align:center;" |
− | ! style="width: | + | ! style="width: 20%" |Study |
− | ! style="width: | + | ! style="width: 20%" |Dates of enrollment |
− | ! style="width: | + | ! style="width: 20%" |[[Levels_of_Evidence#Evidence|Evidence]] |
+ | ! style="width: 20%" |Comparator | ||
+ | ! style="width: 20%" |[[Levels_of_Evidence#Comparative_efficacy|Comparative Efficacy]] | ||
+ | |- | ||
+ | | rowspan="2" |[https://doi.org/10.1056/NEJMoa073149 Cunningham et al. 2008 (REAL-2)] | ||
+ | |rowspan=2|2000-2005 | ||
+ | | rowspan="2" style="background-color:#1a9851" |Phase 3 (E-RT-switch-ic) | ||
+ | |1. [[#ECF_2|ECF]] | ||
+ | | style="background-color:#eeee01" |Non-inferior OS (primary endpoint) | ||
+ | |- | ||
+ | |2. [[#EOF_2|EOF]]<br> 3. [[#EOX_2|EOX]] | ||
+ | | style="background-color:#eeee01" |Non-inferior OS (primary endpoint) | ||
|- | |- | ||
− | |[https://www. | + | |[https://www.ncbi.nlm.nih.gov/pmc/articles/pmc5898242/ Catenacci et al. 2017 (RILOMET-1)] |
− | | style="background-color:#1a9851" |Randomized Phase | + | |2012-2014 |
− | |ECX & Rilotumumab | + | | style="background-color:#1a9851" |Randomized Phase 2 (C) |
− | | style="background-color:#1a9850" |Superior OS | + | |[[#ECX_.26_Rilotumumab_999|ECX & Rilotumumab]] |
+ | | style="background-color:#1a9850" |Superior OS (primary endpoint)<br>Median OS: 10.7 vs 8.8 mo<br>(HR 0.75, 95% CI 0.61-0.91) | ||
|- | |- | ||
|} | |} | ||
− | '' | + | ''Note: REAL-2 patients had 35% esophageal, 25% gastroesophageal junction, 40% gastric. 11% ECOG PS of 2. RILOMET-1 patients had unresectable or metastatic MET-positive gastric or gastro-esophageal junction cancer. ~80% gastric, 20% GE junction and 10% distal esophageal.'' |
− | + | <div class="toccolours" style="background-color:#b3e2cd"> | |
− | |||
====Chemotherapy==== | ====Chemotherapy==== | ||
*[[Epirubicin (Ellence)]] 50 mg/m<sup>2</sup> IV once on day 1 | *[[Epirubicin (Ellence)]] 50 mg/m<sup>2</sup> IV once on day 1 | ||
*[[Cisplatin (Platinol)]] 60 mg/m<sup>2</sup> IV once on day 1 | *[[Cisplatin (Platinol)]] 60 mg/m<sup>2</sup> IV once on day 1 | ||
*[[Capecitabine (Xeloda)]] 625 mg/m<sup>2</sup> PO twice per day | *[[Capecitabine (Xeloda)]] 625 mg/m<sup>2</sup> PO twice per day | ||
− | + | '''21-day cycle for up to 8 cycles (REAL-2) or 10 cycles (RILOMET-1)''' | |
− | '''21-day cycle for up to 10 cycles''' | + | </div></div><br> |
− | + | <div class="toccolours" style="background-color:#eeeeee"> | |
− | === | + | ===Regimen variant #2, intermittent capecitabine {{#subobject:f0efc0|Variant=1}}=== |
− | {| class="wikitable" style="width: 100%; text-align:center;" | + | {| class="wikitable sortable" style="width: 100%; text-align:center;" |
− | ! style="width: | + | ! style="width: 20%" |Study |
− | ! style="width: | + | ! style="width: 20%" |Dates of enrollment |
− | ! style="width: | + | ! style="width: 20%" |[[Levels_of_Evidence#Evidence|Evidence]] |
− | ! style="width: | + | ! style="width: 20%" |Comparator |
+ | ! style="width: 20%" |[[Levels_of_Evidence#Comparative_efficacy|Comparative Efficacy]] | ||
|- | |- | ||
− | |[https:// | + | |[https://doi.org/10.1016/j.ejca.2010.07.036 Konings et al. 2010] |
− | | style="background-color:#1a9851" |Randomized Phase | + | |2005-2009 |
− | |ECC & Pravastatin | + | | style="background-color:#1a9851" |Randomized Phase 2 (C) |
− | | style="background-color:#ffffbf" | | + | |[[#ECX_.26_Pravastatin_999|ECC & Pravastatin]] |
+ | | style="background-color:#ffffbf" |Did not meet primary endpoint of PFS6 | ||
|- | |- | ||
|} | |} | ||
− | '' | + | ''Note: 6.6% of patients had an ECOG PS of 2'' |
− | + | <div class="toccolours" style="background-color:#b3e2cd"> | |
====Chemotherapy==== | ====Chemotherapy==== | ||
*[[Epirubicin (Ellence)]] 50 mg/m<sup>2</sup> IV bolus once on day 1, '''given first''' | *[[Epirubicin (Ellence)]] 50 mg/m<sup>2</sup> IV bolus once on day 1, '''given first''' | ||
*[[Cisplatin (Platinol)]] 60 mg/m<sup>2</sup> IV over 3 hours once on day 1, '''given second''' | *[[Cisplatin (Platinol)]] 60 mg/m<sup>2</sup> IV over 3 hours once on day 1, '''given second''' | ||
*[[Capecitabine (Xeloda)]] 1000 mg/m<sup>2</sup> PO twice per day on days 1 to 14 | *[[Capecitabine (Xeloda)]] 1000 mg/m<sup>2</sup> PO twice per day on days 1 to 14 | ||
− | |||
'''21-day cycle for up to 6 cycles''' | '''21-day cycle for up to 6 cycles''' | ||
+ | </div></div> | ||
+ | ===References=== | ||
+ | #'''REAL-2:''' Cunningham D, Starling N, Rao S, Iveson T, Nicolson M, Coxon F, Middleton G, Daniel F, Oates J, Norman AR; Upper Gastrointestinal Clinical Studies Group of the National Cancer Research Institute of the United Kingdom. Capecitabine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med. 2008 Jan 3;358(1):36-46. [https://doi.org/10.1056/NEJMoa073149 link to original article] '''dosing details in manuscript have been reviewed by our editors''' [https://pubmed.ncbi.nlm.nih.gov/18172173/ PubMed] ISRCTN51678883 | ||
+ | #Konings IR, van der Gaast A, van der Wijk LJ, de Jongh FE, Eskens FA, Sleijfer S. The addition of pravastatin to chemotherapy in advanced gastric carcinoma: a randomised phase II trial. Eur J Cancer. 2010 Dec;46(18):3200-4. Epub 2010 Aug 18. [https://doi.org/10.1016/j.ejca.2010.07.036 link to original article] '''dosing details in manuscript have been reviewed by our editors''' [https://pubmed.ncbi.nlm.nih.gov/20727735/ PubMed] | ||
+ | #'''RILOMET-1:''' Catenacci DVT, Tebbutt NC, Davidenko I, Murad AM, Al-Batran SE, Ilson DH, Tjulandin S, Gotovkin E, Karaszewska B, Bondarenko I, Tejani MA, Udrea AA, Tehfe M, De Vita F, Turkington C, Tang R, Ang A, Zhang Y, Hoang T, Sidhu R, Cunningham D. Rilotumumab plus epirubicin, cisplatin, and capecitabine as first-line therapy in advanced MET-positive gastric or gastro-oesophageal junction cancer (RILOMET-1): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2017 Nov;18(11):1467-1482. Epub 2017 Sep 25. [https://doi.org/10.1016/S1470-2045(17)30566-1 link to original article] '''dosing details in manuscript have been reviewed by our editors''' [https://www.ncbi.nlm.nih.gov/pmc/articles/pmc5898242/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/28958504/ PubMed] [https://clinicaltrials.gov/study/NCT01697072 NCT01697072] | ||
+ | ==EOF {{#subobject:a6390c|Regimen=1}}== | ||
+ | EOF: '''<u>E</u>'''pirubicin, '''<u>O</u>'''xaliplatin, '''<u>F</u>'''luorouracil | ||
+ | <div class="toccolours" style="background-color:#eeeeee"> | ||
+ | ===Regimen {{#subobject:abf19f|Variant=1}}=== | ||
+ | {| class="wikitable sortable" style="width: 100%; text-align:center;" | ||
+ | !style="width: 20%"|Study | ||
+ | !style="width: 20%"|Dates of enrollment | ||
+ | !style="width: 20%"|[[Levels_of_Evidence#Evidence|Evidence]] | ||
+ | !style="width: 20%"|Comparator | ||
+ | !style="width: 20%"|[[Levels_of_Evidence#Comparative_efficacy|Comparative Efficacy]] | ||
+ | |- | ||
+ | | rowspan="2" |[https://doi.org/10.1056/NEJMoa073149 Cunningham et al. 2008 (REAL-2)] | ||
+ | |rowspan=2|2000-2005 | ||
+ | | rowspan="2" style="background-color:#1a9851" |Phase 3 (E-switch-ic) | ||
+ | |1. [[#ECF_2|ECF]]<br>2. [[#ECX_2|ECX]] | ||
+ | | style="background-color:#eeee01" |Non-inferior OS (primary endpoint) | ||
+ | |- | ||
+ | |3. [[#EOX_2|EOX]] | ||
+ | | style="background-color:#eeee01" |Non-inferior OS (primary endpoint) | ||
+ | |- | ||
+ | |} | ||
+ | ''Note: patients had 35% esophageal, 25% gastroesophageal junction, 40% gastric. 11% ECOG PS of 2.'' | ||
+ | <div class="toccolours" style="background-color:#b3e2cd"> | ||
+ | ====Chemotherapy==== | ||
+ | *[[Epirubicin (Ellence)]] 50 mg/m<sup>2</sup> IV bolus once on day 1 | ||
+ | *[[Oxaliplatin (Eloxatin)]] 130 mg/m<sup>2</sup> IV over 2 hours once on day 1 | ||
+ | *[[Fluorouracil (5-FU)]] 200 mg/m<sup>2</sup>/day IV continuous infusion, started on day 1 (total dose per cycle: 4200 mg/m<sup>2</sup>) | ||
+ | ====Supportive therapy==== | ||
+ | *[[Warfarin (Coumadin)]] 1 mg PO once per day for catheter thrombosis prophylaxis | ||
+ | '''21-day cycle for up to 8 cycles''' | ||
+ | </div></div> | ||
===References=== | ===References=== | ||
− | # | + | #'''REAL-2:''' Cunningham D, Starling N, Rao S, Iveson T, Nicolson M, Coxon F, Middleton G, Daniel F, Oates J, Norman AR; Upper Gastrointestinal Clinical Studies Group of the National Cancer Research Institute of the United Kingdom. Capecitabine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med. 2008 Jan 3;358(1):36-46. [https://doi.org/10.1056/NEJMoa073149 link to original article] '''dosing details in manuscript have been reviewed by our editors''' [https://pubmed.ncbi.nlm.nih.gov/18172173/ PubMed] ISRCTN51678883 |
− | # ''' | + | ==EOX {{#subobject:438182|Regimen=1}}== |
− | + | EOX: '''<u>E</u>'''pirubicin, '''<u>O</u>'''xaliplatin, '''<u>X</u>'''eloda (Capecitabine) | |
− | == | + | <br>EOC: '''<u>E</u>'''pirubicin, '''<u>O</u>'''xaliplatin, '''<u>C</u>'''apecitabine |
− | {| class="wikitable" style=" | + | <div class="toccolours" style="background-color:#eeeeee"> |
+ | ===Regimen variant #1 {{#subobject:339609|Variant=1}}=== | ||
+ | {| class="wikitable sortable" style="width: 100%; text-align:center;" | ||
+ | !style="width: 20%"|Study | ||
+ | !style="width: 20%"|Dates of enrollment | ||
+ | !style="width: 20%"|[[Levels_of_Evidence#Evidence|Evidence]] | ||
+ | !style="width: 20%"|Comparator | ||
+ | !style="width: 20%"|[[Levels_of_Evidence#Comparative_efficacy|Comparative Efficacy]] | ||
+ | |- | ||
+ | | rowspan="3" |[https://doi.org/10.1056/NEJMoa073149 Cunningham et al. 2008 (REAL-2)] | ||
+ | |rowspan=3|2000-2005 | ||
+ | | rowspan="3" style="background-color:#1a9851" |Phase 3 (E-RT-switch-ic) | ||
+ | |1. [[#ECF_2|ECF]] | ||
+ | | style="background-color:#91cf60" |Seems to have superior OS (secondary endpoint)<br>Median OS: 11.2 vs 9.9 mo<br>(HR 0.80, 95% CI 0.66-0.97) | ||
+ | |- | ||
+ | |2. [[#ECX_2|ECX]] | ||
+ | | style="background-color:#eeee01" |Non-inferior OS (primary endpoint) | ||
+ | |- | ||
+ | |3. [[#EOF_2|EOF]] | ||
+ | | style="background-color:#eeee01" |Non-inferior OS (primary endpoint) | ||
+ | |- | ||
+ | |[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3669518/ Waddell et al. 2013 (REAL3)] | ||
+ | |2008-2011 | ||
+ | | style="background-color:#1a9851" |Phase 3 (C) | ||
+ | |[[#mEOC.2BP_999|mEOC+P]] | ||
+ | | style="background-color:#1a9850" |Superior OS<br>Median OS: 11.3 vs 8.3 mo<br>(HR 0.73, 95% CI 0.57-0.93) | ||
+ | |- | ||
+ | |} | ||
+ | ''Note: REAL-2 patients had 35% esophageal, 25% gastroesophageal junction, 40% gastric. 11% ECOG PS of 2. REAL3 patients had 99% adenocarcinoma, 1% undifferentiated histology. 39% esophagus, 31% ''gastroesophageal'' junction, 30% gastric. 6% ECOF PS of 2. 89% metastatic disease.'' | ||
+ | <div class="toccolours" style="background-color:#b3e2cd"> | ||
+ | ====Chemotherapy==== | ||
+ | *[[Epirubicin (Ellence)]] 50 mg/m<sup>2</sup> IV once on day 1 | ||
+ | *[[Oxaliplatin (Eloxatin)]] 130 mg/m<sup>2</sup> IV over 2 hours once on day 1 | ||
+ | *[[Capecitabine (Xeloda)]] 625 mg/m<sup>2</sup> PO twice per day on days 1 to 21 | ||
+ | '''21-day cycle for up to 8 cycles''' | ||
+ | </div></div><br> | ||
+ | <div class="toccolours" style="background-color:#eeeeee"> | ||
+ | ===Regimen variant #2, with maintenance capecitabine {{#subobject:3gacn9|Variant=1}}=== | ||
+ | {| class="wikitable sortable" style="width: 100%; text-align:center;" | ||
+ | !style="width: 20%"|Study | ||
+ | !style="width: 20%"|Dates of enrollment | ||
+ | !style="width: 20%"|[[Levels_of_Evidence#Evidence|Evidence]] | ||
+ | !style="width: 20%"|Comparator | ||
+ | !style="width: 20%"|[[Levels_of_Evidence#Comparative_efficacy|Comparative Efficacy]] | ||
+ | |- | ||
+ | |[https://www.ncbi.nlm.nih.gov/pmc/articles/pmc9017757/ Zhu et al. 2022 (EXELOX)] | ||
+ | |2015-2020 | ||
+ | | style="background-color:#1a9851" |Phase 3 (C) | ||
+ | |[[#CapeOx_3|CapeOx]] | ||
+ | | style="background-color:#eeee01" |Non-inferior PFS | ||
|- | |- | ||
− | |||
|} | |} | ||
− | === | + | <div class="toccolours" style="background-color:#b3e2cd"> |
− | {| class="wikitable" style="width: 100%; text-align:center;" | + | ====Chemotherapy==== |
− | ! style="width: | + | *[[Epirubicin (Ellence)]] as follows: |
− | ! style="width: | + | **Cycles 1 up to 8: 50 mg/m<sup>2</sup> IV once on day 1 |
− | ! style="width: | + | *[[Oxaliplatin (Eloxatin)]] as follows: |
− | ! style="width: | + | **Cycles 1 up to 8: 130 mg/m<sup>2</sup> IV over 2 hours once on day 1 |
+ | *[[Capecitabine (Xeloda)]] 1000 mg/m<sup>2</sup> PO twice per day on days 1 to 14 | ||
+ | '''21-day cycles''' | ||
+ | </div></div> | ||
+ | ===References=== | ||
+ | #'''REAL-2:''' Cunningham D, Starling N, Rao S, Iveson T, Nicolson M, Coxon F, Middleton G, Daniel F, Oates J, Norman AR; Upper Gastrointestinal Clinical Studies Group of the National Cancer Research Institute of the United Kingdom. Capecitabine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med. 2008 Jan 3;358(1):36-46. [https://doi.org/10.1056/NEJMoa073149 link to original article] '''dosing details in manuscript have been reviewed by our editors''' [https://pubmed.ncbi.nlm.nih.gov/18172173/ PubMed] content property of [https://hemonc.org HemOnc.org] ISRCTN51678883 | ||
+ | #'''REAL3:''' Waddell T, Chau I, Cunningham D, Gonzalez D, Okines AF, Okines C, Wotherspoon A, Saffery C, Middleton G, Wadsley J, Ferry D, Mansoor W, Crosby T, Coxon F, Smith D, Waters J, Iveson T, Falk S, Slater S, Peckitt C, Barbachano Y. Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for patients with previously untreated advanced oesophagogastric cancer (REAL3): a randomised, open-label phase 3 trial. Lancet Oncol. 2013 May;14(6):481-9. Epub 2013 Apr 15. [https://doi.org/10.1016/s1470-2045(13)70096-2 link to original article] '''dosing details in manuscript have been reviewed by our editors''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3669518/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/23594787/ PubMed] [https://clinicaltrials.gov/study/NCT00824785 NCT00824785] | ||
+ | #'''EXELOX:''' Zhu XD, Huang MZ, Wang YS, Feng WJ, Chen ZY, He YF, Zhang XW, Liu X, Wang CC, Zhang W, Ying JE, Wu J, Yang L, Qin YR, Luo JF, Zhao XY, Li WH, Zhang Z, Qiu LX, Geng QR, Zou JL, Zhang JY, Zheng H, Song XF, Wu SS, Zhang CY, Gong Z, Liu QQ, Wang XF, Xu Q, Wang Q, Ji JM, Zhao J, Guo WJ. XELOX doublet regimen versus EOX triplet regimen as first-line treatment for advanced gastric cancer: An open-labeled, multicenter, randomized, prospective phase III trial (EXELOX). Cancer Commun (Lond). 2022 Apr;42(4):314-326. Epub 2022 Feb 25. [https://doi.org/10.1002/cac2.12278 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/pmc9017757/ link to PMC article] '''dosing details in manuscript have been reviewed by our editors''' [https://pubmed.ncbi.nlm.nih.gov/35212487/ PubMed] [https://clinicaltrials.gov/study/NCT02395640 NCT02395640] | ||
+ | ==Fluorouracil monotherapy {{#subobject:588907|Regimen=1}}== | ||
+ | <div class="toccolours" style="background-color:#eeeeee"> | ||
+ | ===Regimen variant #1, CI {{#subobject:3289d8|Variant=1}}=== | ||
+ | {| class="wikitable sortable" style="width: 100%; text-align:center;" | ||
+ | ! style="width: 20%" |Study | ||
+ | ! style="width: 20%" |Dates of enrollment | ||
+ | ! style="width: 20%" |[[Levels_of_Evidence#Evidence|Evidence]] | ||
+ | ! style="width: 20%" |Comparator | ||
+ | ! style="width: 20%" |[[Levels_of_Evidence#Comparative_efficacy|Comparative Efficacy]] | ||
|- | |- | ||
− | | rowspan="2" |[ | + | | rowspan="2" |[https://doi.org/10.1200/jco.2003.04.130 Ohtsu et al. 2003 (JCOG 9205)] |
− | | rowspan="2" style="background-color:#1a9851" |Phase | + | | rowspan="2" |1992-1997 |
− | |1. [[#Cisplatin_. | + | | rowspan="2" style="background-color:#1a9851" |Phase 3 (C) |
− | | style="background-color:# | + | |1. [[#Cisplatin_.26_Fluorouracil_.28CF.29_3|FP]] |
+ | | style="background-color:#ffffbf" |Did not meet primary endpoint of OS | ||
|- | |- | ||
|2. [[#UFTM|UFTM]] | |2. [[#UFTM|UFTM]] | ||
− | | style="background-color:#ffffbf" | | + | | style="background-color:#ffffbf" |Did not meet primary endpoint of OS |
|- | |- | ||
− | | rowspan="2" |[https:// | + | | rowspan="2" |[https://doi.org/10.1016/S1470-2045(09)70259-1 Boku et al. 2009 (JCOG 9912)] |
− | | rowspan="2" style="background-color:#1a9851" |Phase | + | | rowspan="2" |2000-2006 |
− | |1. Cisplatin & Irinotecan | + | | rowspan="2" style="background-color:#1a9851" |Phase 3 (C) |
+ | |1. [[#Cisplatin_.26_Irinotecan_333|Cisplatin & Irinotecan]] | ||
| style="background-color:#fee08b" |Might have inferior OS | | style="background-color:#fee08b" |Might have inferior OS | ||
|- | |- | ||
Line 1,827: | Line 2,842: | ||
| style="background-color:#eeee01" |Non-inferior OS | | style="background-color:#eeee01" |Non-inferior OS | ||
|- | |- | ||
− | |[https:// | + | |[https://doi.org/10.1093/jjco/hyt114 Shirao et al. 2013 (JCOG 0106)] |
− | | style="background-color:#1a9851" |Phase | + | |2002-2007 |
− | |MF | + | | style="background-color:#1a9851" |Phase 3 (C) |
− | | style="background-color:#ffffbf" | | + | |[[#Fluorouracil_.26_Methotrexate_.28MF.29_999|MF]] |
+ | | style="background-color:#ffffbf" |Did not meet primary endpoint of OS50% | ||
|- | |- | ||
|} | |} | ||
− | ''JCOG 9205 included patients with PFS of 2 (9.6%)'' | + | ''Note: JCOG 9205 included patients with PFS of 2 (9.6%)'' |
− | + | <div class="toccolours" style="background-color:#b3e2cd"> | |
====Chemotherapy==== | ====Chemotherapy==== | ||
*[[Fluorouracil (5-FU)]] 800 mg/m<sup>2</sup>/day IV continuous infusion over 120 hours, started on day 1 (total dose per cycle: 4000 mg/m<sup>2</sup>) | *[[Fluorouracil (5-FU)]] 800 mg/m<sup>2</sup>/day IV continuous infusion over 120 hours, started on day 1 (total dose per cycle: 4000 mg/m<sup>2</sup>) | ||
− | |||
'''28-day cycles''' | '''28-day cycles''' | ||
− | + | </div></div><br> | |
− | === | + | <div class="toccolours" style="background-color:#eeeeee"> |
− | {| class="wikitable" style="width: 100%; text-align:center;" | + | ===Regimen variant #2, intermittent, BSA-based {{#subobject:27a992|Variant=1}}=== |
− | ! style="width: | + | {| class="wikitable sortable" style="width: 100%; text-align:center;" |
− | ! style="width: | + | ! style="width: 20%" |Study |
− | ! style="width: | + | ! style="width: 20%" |Dates of enrollment |
− | ! style="width: | + | ! style="width: 20%" |[[Levels_of_Evidence#Evidence|Evidence]] |
+ | ! style="width: 20%" |Comparator | ||
+ | ! style="width: 20%" |[[Levels_of_Evidence#Comparative_efficacy|Comparative Efficacy]] | ||
|- | |- | ||
− | |[https:// | + | |[https://doi.org/10.1001/jama.1985.03350380077025 Cullinan et al. 1985] |
− | | style="background-color:#1a9851" |Phase | + | |Not reported |
− | |1. FA<br> 2. [[Gastric_cancer_-_historical# | + | | style="background-color:#1a9851" |Phase 3 (E-de-esc) |
− | | style="background-color:#ffffbf" | | + | |1. [[#Doxorubicin_.26_Fluorouracil_.28FA.29_888|FA]]<br>2. [[Gastric_cancer_-_historical#FAM_2|FAM]] |
+ | | style="background-color:#ffffbf" |Did not meet primary endpoint of OS | ||
|- | |- | ||
|} | |} | ||
− | ''Note: | + | ''Note: This was an experimental arm that did not meet its primary endpoint; included here because it represents a de-escalation strategy.'' |
+ | <div class="toccolours" style="background-color:#b3e2cd"> | ||
====Chemotherapy==== | ====Chemotherapy==== | ||
*[[Fluorouracil (5-FU)]] 500 mg/m<sup>2</sup> IV once per day on days 1 to 5 | *[[Fluorouracil (5-FU)]] 500 mg/m<sup>2</sup> IV once per day on days 1 to 5 | ||
− | |||
'''28-day cycle for 2 cycles, then 35-day cycles''' | '''28-day cycle for 2 cycles, then 35-day cycles''' | ||
− | + | </div></div><br> | |
− | ===Variant #3, PVI {{#subobject:d98c9f|Variant=1}}=== | + | <div class="toccolours" style="background-color:#eeeeee"> |
− | {| class="wikitable" style="width: 100%; text-align:center;" | + | ===Regimen variant #3, intermittent, weight-based {{#subobject:27jb82|Variant=1}}=== |
− | ! style="width: | + | {| class="wikitable sortable" style="width: 100%; text-align:center;" |
− | ! style="width: | + | ! style="width: 20%" |Study |
− | ! style="width: | + | ! style="width: 20%" |Dates of enrollment |
− | ! style="width: | + | ! style="width: 20%" |[[Levels_of_Evidence#Evidence|Evidence]] |
+ | ! style="width: 20%" |Comparator | ||
+ | ! style="width: 20%" |[[Levels_of_Evidence#Comparative_efficacy|Comparative Efficacy]] | ||
+ | |- | ||
+ | |[https://doi.org/10.1159/000226337 Kolarić et al. 1986] | ||
+ | |Not reported | ||
+ | | style="background-color:#1a9851" |Phase 3 (C) | ||
+ | |[[#Epirubicin_.26_Fluorouracil_888|Epirubicin & Fluorouracil]] | ||
+ | | style="background-color:#fc8d59" |Seems to have inferior DOR | ||
+ | |- | ||
+ | |} | ||
+ | <div class="toccolours" style="background-color:#b3e2cd"> | ||
+ | ====Chemotherapy==== | ||
+ | *[[Fluorouracil (5-FU)]] 12 mg/kg IV once per day on days 1 to 5 | ||
+ | '''21- to 28-day cycles''' | ||
+ | </div></div><br> | ||
+ | <div class="toccolours" style="background-color:#eeeeee"> | ||
+ | ===Regimen variant #4, PVI {{#subobject:d98c9f|Variant=1}}=== | ||
+ | {| class="wikitable sortable" style="width: 100%; text-align:center;" | ||
+ | ! style="width: 20%" |Study | ||
+ | ! style="width: 20%" |Dates of enrollment | ||
+ | ! style="width: 20%" |[[Levels_of_Evidence#Evidence|Evidence]] | ||
+ | ! style="width: 20%" |Comparator | ||
+ | ! style="width: 20%" |[[Levels_of_Evidence#Comparative_efficacy|Comparative Efficacy]] | ||
|- | |- | ||
− | |[https:// | + | |[https://doi.org/10.1093/annonc/mdf273 Tebbutt et al. 2002] |
− | | style="background-color:#1a9851" |Phase | + | |1994-2001 |
− | |5-FU & Mitomycin | + | | style="background-color:#1a9851" |Phase 3 (C) |
− | | style="background-color:#ffffbf" | | + | |[[#Fluorouracil_.26_Mitomycin_999|5-FU & Mitomycin]] |
+ | | style="background-color:#ffffbf" |Did not meet primary endpoint of ORR | ||
|- | |- | ||
|} | |} | ||
+ | <div class="toccolours" style="background-color:#b3e2cd"> | ||
====Chemotherapy==== | ====Chemotherapy==== | ||
*[[Fluorouracil (5-FU)]] 300 mg/m<sup>2</sup>/day IV continuous infusion | *[[Fluorouracil (5-FU)]] 300 mg/m<sup>2</sup>/day IV continuous infusion | ||
− | |||
'''Up to 24-week course''' | '''Up to 24-week course''' | ||
− | + | </div></div> | |
+ | ===References=== | ||
+ | #Cullinan SA, Moertel CG, Fleming TR, Rubin JR, Krook JE, Everson LK, Windschitl HE, Twito DI, Marschke RF, Foley JF, Pfeifle DM, Barlow JF. A comparison of three chemotherapeutic regimens in the treatment of advanced pancreatic and gastric carcinoma: fluorouracil vs fluorouracil and doxorubicin vs fluorouracil, doxorubicin, and mitomycin. JAMA. 1985 Apr 12;253(14):2061-7. [https://doi.org/10.1001/jama.1985.03350380077025 link to original article] [https://pubmed.ncbi.nlm.nih.gov/2579257/ PubMed] | ||
+ | #Kolarić K, Potrebica V, Stanovnik M. Controlled phase III clinical study of 4-epi-doxorubicin + 5-fluorouracil versus 5-fluorouracil alone in metastatic gastric and rectosigmoid cancer. Oncology. 1986;43(2):73-7. [https://doi.org/10.1159/000226337 link to original article] '''dosing details in abstract have been reviewed by our editors''' [https://pubmed.ncbi.nlm.nih.gov/3513075/ PubMed] | ||
+ | #Tebbutt NC, Norman A, Cunningham D, Iveson T, Seymour M, Hickish T, Harper P, Maisey N, Mochlinski K, Prior Y, Hill M. A multicentre, randomised phase III trial comparing protracted venous infusion (PVI) 5-fluorouracil (5-FU) with PVI 5-FU plus mitomycin C in patients with inoperable oesophago-gastric cancer. Ann Oncol. 2002 Oct;13(10):1568-75. [https://doi.org/10.1093/annonc/mdf273 link to original article] '''dosing details in manuscript have been reviewed by our editors''' [https://pubmed.ncbi.nlm.nih.gov/12377644/ PubMed] | ||
+ | #'''JCOG 9205:''' Ohtsu A, Shimada Y, Shirao K, Boku N, Hyodo I, Saito H, Yamamichi N, Miyata Y, Ikeda N, Yamamoto S, Fukuda H, Yoshida S; [[Study_Groups#JCOG|JCOG]]. Randomized phase III trial of fluorouracil alone versus fluorouracil plus cisplatin versus uracil and tegafur plus mitomycin in patients with unresectable, advanced gastric cancer: the Japan Clinical Oncology Group study (JCOG9205). J Clin Oncol. 2003 Jan 1;21(1):54-9. [https://doi.org/10.1200/jco.2003.04.130 link to original article] '''dosing details in manuscript have been reviewed by our editors''' [https://pubmed.ncbi.nlm.nih.gov/12506170/ PubMed] | ||
+ | #'''JCOG 9912:''' Boku N, Yamamoto S, Fukuda H, Shirao K, Doi T, Sawaki A, Koizumi W, Saito H, Yamaguchi K, Takiuchi H, Nasu J, Ohtsu A; Gastrointestinal Oncology Study Group of the Japan Clinical Oncology Group. Fluorouracil versus combination of irinotecan plus cisplatin versus S-1 in metastatic gastric cancer: a randomised phase 3 study. Lancet Oncol. 2009 Nov;10(11):1063-9. Epub 2009 Oct 7. [https://doi.org/10.1016/S1470-2045(09)70259-1 link to original article] '''dosing details in abstract have been reviewed by our editors''' [https://pubmed.ncbi.nlm.nih.gov/19818685/ PubMed] [https://clinicaltrials.gov/study/NCT00142350 NCT00142350] | ||
+ | #'''JCOG 0106:''' Shirao K, Boku N, Yamada Y, Yamaguchi K, Doi T, Goto M, Nasu J, Denda T, Hamamoto Y, Takashima A, Fukuda H, Ohtsu A; Gastrointestinal Oncology Study Group of the Japan Clinical Oncology Group. Randomized Phase III study of 5-fluorouracil continuous infusion vs sequential methotrexate and 5-fluorouracil therapy in far advanced gastric cancer with peritoneal metastasis (JCOG0106). Jpn J Clin Oncol. 2013 Oct;43(10):972-80. Epub 2013 Sep 7. [https://doi.org/10.1093/jjco/hyt114 link to original article] '''dosing details in manuscript have been reviewed by our editors''' [https://pubmed.ncbi.nlm.nih.gov/24014884/ PubMed] [https://clinicaltrials.gov/study/NCT00149201 NCT00149201] | ||
+ | ==Fluorouracil & Heptaplatin (FH) {{#subobject:4ihe36|Regimen=1}}== | ||
+ | FH: '''<u>F</u>'''luorouracil & '''<u>H</u>'''eptaplatin | ||
+ | <div class="toccolours" style="background-color:#eeeeee"> | ||
+ | ===Regimen {{#subobject:9se43z|Variant=1}}=== | ||
+ | {| class="wikitable sortable" style="width: 100%; text-align:center;" | ||
+ | ! style="width: 20%" |Study | ||
+ | ! style="width: 20%" |Dates of enrollment | ||
+ | ! style="width: 20%" |[[Levels_of_Evidence#Evidence|Evidence]] | ||
+ | ! style="width: 20%" |Comparator | ||
+ | ! style="width: 20%" |[[Levels_of_Evidence#Comparative_efficacy|Comparative Efficacy]] | ||
+ | |- | ||
+ | |[https://www.ncbi.nlm.nih.gov/pmc/articles/pmc2699097/ Lee et al. 2009a] | ||
+ | |2000-2004 | ||
+ | | style="background-color:#1a9851" |Phase 3 (E-switch-ic) | ||
+ | |[[#Cisplatin_.26_Fluorouracil_.28CF.29_2|CF]] | ||
+ | | style="background-color:#eeee01" |Equivalent OS (primary endpoint)<br>Median OS: 7.3 vs 7.9 mo | ||
+ | |- | ||
+ | |} | ||
+ | ''Note: this is reported to be an equivalence study but the statistical analysis does not provide details on the definition of equivalence.'' | ||
+ | <div class="toccolours" style="background-color:#b3e2cd"> | ||
+ | ====Chemotherapy==== | ||
+ | *[[Fluorouracil (5-FU)]] 1000 mg/m<sup>2</sup> IV over 12 hours once per day on days 1 to 5, '''given second''' | ||
+ | *[[Heptaplatin (SunPla)]] 400 mg/m<sup>2</sup> IV over 60 minutes once on day 1, '''given first''' | ||
+ | '''28-day cycles''' | ||
+ | </div></div> | ||
===References=== | ===References=== | ||
− | # | + | #Lee KH, Hyun MS, Kim HK, Jin HM, Yang J, Song HS, Do YR, Ryoo HM, Chung JS, Zang DY, Lim HY, Jin JY, Yim CY, Park HS, Kim JS, Sohn CH, Lee SN. Randomized, multicenter, phase III trial of heptaplatin 1-hour infusion and 5-fluorouracil combination chemotherapy comparing with cisplatin and 5-fluorouracil combination chemotherapy in patients with advanced gastric cancer. Cancer Res Treat. 2009 Mar;41(1):12-8. Epub 2009 Mar 31. [https://doi.org/10.4143/crt.2009.41.1.12 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/pmc2699097/ link to PMC article] '''dosing details in manuscript have been reviewed by our editors''' [https://pubmed.ncbi.nlm.nih.gov/19688066/ PubMed] |
− | |||
− | |||
− | |||
− | |||
==Fluorouracil, Folinic acid, Mitomycin {{#subobject:a4ca9d|Regimen=1}}== | ==Fluorouracil, Folinic acid, Mitomycin {{#subobject:a4ca9d|Regimen=1}}== | ||
− | + | <div class="toccolours" style="background-color:#eeeeee"> | |
− | |||
− | |||
− | |||
===Regimen {{#subobject:672a28|Variant=1}}=== | ===Regimen {{#subobject:672a28|Variant=1}}=== | ||
− | {| class="wikitable" style="width: | + | {| class="wikitable sortable" style="width: 60%; text-align:center;" |
− | ! style="width: | + | !style="width: 33%"|Study |
− | ! style="width: | + | !style="width: 33%"|Dates of enrollment |
+ | !style="width: 33%"|[[Levels_of_Evidence#Evidence|Evidence]] | ||
|- | |- | ||
− | |[ | + | |[https://doi.org/10.1159/000064319 Hofheinz et al. 2002] |
− | | style="background-color:#ffffbe" |Phase | + | |1998-2000 |
+ | | style="background-color:#ffffbe" |Phase 2, fewer than 20 pts in this subgroup | ||
|- | |- | ||
|} | |} | ||
+ | <div class="toccolours" style="background-color:#b3e2cd"> | ||
====Chemotherapy==== | ====Chemotherapy==== | ||
− | *[[Fluorouracil (5-FU)]] 2600 mg/m<sup>2</sup> IV continuous infusion over 24 hours | + | *[[Fluorouracil (5-FU)]] 2600 mg/m<sup>2</sup> IV continuous infusion over 24 hours, started on days 1, 8, 15, 22, 29, 36 (total dose per cycle: 15,600 mg/m<sup>2</sup>) |
− | *[[Folinic acid | + | *[[Leucovorin (Folinic acid)]] 500 mg/m<sup>2</sup> IV over 2 hours once per day on days 1, 8, 15, 22, 29, 36 |
*[[Mitomycin (Mutamycin)]] 10 mg/m<sup>2</sup> IV once per day on days 1 & 22 | *[[Mitomycin (Mutamycin)]] 10 mg/m<sup>2</sup> IV once per day on days 1 & 22 | ||
− | |||
'''56-day cycle for 2 cycles''' | '''56-day cycle for 2 cycles''' | ||
+ | </div></div> | ||
+ | ===References=== | ||
+ | #Hofheinz RD, Hartung G, Samel S, Hochhaus A, Pichlmeier U, Post S, Hehlmann R, Queisser W. High-dose 5-fluorouracil / folinic acid in combination with three-weekly mitomycin C in the treatment of advanced gastric cancer: a phase II study. Onkologie. 2002 Jun;25(3):255-60. [https://doi.org/10.1159/000064319 link to original article] '''dosing details in abstract have been reviewed by our editors''' [https://pubmed.ncbi.nlm.nih.gov/12119460/ PubMed] | ||
+ | ==FOLFIRI {{#subobject:ba35aa|Regimen=1}}== | ||
+ | FOLFIRI: '''<u>FOL</u>'''inic acid (Leucovorin), '''<u>F</u>'''luorouracil, '''<u>IRI</u>'''notecan | ||
+ | <br>IF: '''<u>I</u>'''rinotecan & 5-'''<u>F</u>'''luorouracil | ||
+ | <div class="toccolours" style="background-color:#eeeeee"> | ||
+ | ===Regimen variant #1, 6 out of 7 weeks ("AIO regimen") {{#subobject:cec083|Variant=1}}=== | ||
+ | {| class="wikitable sortable" style="width: 100%; text-align:center;" | ||
+ | ! style="width: 20%" |Study | ||
+ | ! style="width: 20%" |Dates of enrollment | ||
+ | ! style="width: 20%" |[[Levels_of_Evidence#Evidence|Evidence]] | ||
+ | ! style="width: 20%" |Comparator | ||
+ | ! style="width: 20%" |[[Levels_of_Evidence#Comparative_efficacy|Comparative Efficacy]] | ||
+ | |- | ||
+ | |[https://doi.org/10.1093/annonc/mdn166 Dank et al. 2008] | ||
+ | |2000-2002 | ||
+ | | style="background-color:#1a9851" |Phase 3 (E-switch-ic) | ||
+ | |[[#Cisplatin_.26_Fluorouracil_.28CF.29_4|CF]] | ||
+ | | style="background-color:#d9ef8b" |Might have superior TTP (primary endpoint) | ||
+ | |- | ||
+ | |} | ||
+ | ''Note: patients had 100% adenocarcinoma histology (20% gastroesophageal junction, 80% gastric origin). 96% with metastatic disease.'' | ||
+ | <div class="toccolours" style="background-color:#b3e2cd"> | ||
+ | ====Chemotherapy==== | ||
+ | *[[Fluorouracil (5-FU)]] 2000 mg/m<sup>2</sup> IV continuous infusion over 22 hours, started on days 1, 8, 15, 22, 29, 36, '''given third''' (total dose per cycle: 12,000 mg/m<sup>2</sup>) | ||
+ | *[[Leucovorin (Folinic acid)]] 500 mg/m<sup>2</sup> IV over 2 hours once per day on days 1, 8, 15, 22, 29, 36, '''given second''' | ||
+ | *[[Irinotecan (Camptosar)]] 80 mg/m<sup>2</sup> IV over 30 minutes once per day on days 1, 8, 15, 22, 29, 36, '''given first''' | ||
+ | ====Supportive therapy==== | ||
+ | *[[Ondansetron (Zofran)]] for antiemetic prophylaxis | ||
+ | *[[Dexamethasone (Decadron)]] for antiemetic prophylaxis | ||
+ | *[[Filgrastim (Neupogen)]] (dose not specified) SC once per day, starting on day 4, to be continued until ANC greater than 1000/μL for grade 3 to 4 neutropenia, febrile neutropenia, or neutropenic infection | ||
+ | *[[Atropine (Atropen)]] prn cholinergic symptoms | ||
+ | *[[Loperamide (Imodium)]] prn delayed diarrhea | ||
+ | '''7-week cycles''' | ||
+ | </div></div><br> | ||
+ | <div class="toccolours" style="background-color:#eeeeee"> | ||
+ | ===Regimen variant #2, LV5FU2 & Irinotecan (200/1600/180) {{#subobject:56018a|Variant=1}}=== | ||
+ | {| class="wikitable sortable" style="width: 100%; text-align:center;" | ||
+ | ! style="width: 20%" |Study | ||
+ | ! style="width: 20%" |Dates of enrollment | ||
+ | ! style="width: 20%" |[[Levels_of_Evidence#Evidence|Evidence]] | ||
+ | ! style="width: 20%" |Comparator | ||
+ | ! style="width: 20%" |[[Levels_of_Evidence#Comparative_efficacy|Comparative Efficacy]] | ||
+ | |- | ||
+ | |[https://doi.org/10.1200/jco.2004.01.140 Bouché et al. 2004 (FFCD 9803)] | ||
+ | |1999-2001 | ||
+ | | style="background-color:#1a9851" |Randomized Phase 2 (E-esc) | ||
+ | |1. [[#FULV_2|LV5FU2]]<br>2. [[#CLF|LV5FU2 & Cisplatin]] | ||
+ | | style="background-color:#d3d3d3" |Not powered to draw conclusions | ||
+ | |- | ||
+ | |} | ||
+ | ''Note: patients had 100% adenocarcinoma (70% gastric origin, 30% cardia). The primary reference said every cycle was 15 days, but also said that medications were given every 14 days, so the assumption was made that this more typical schedule was used.'' | ||
+ | <div class="toccolours" style="background-color:#b3e2cd"> | ||
+ | ====Chemotherapy==== | ||
+ | *[[Leucovorin (Folinic acid)]] 200 mg/m<sup>2</sup> IV over 2 hours once on day 1 | ||
+ | *[[Fluorouracil (5-FU)]] 400 mg/m<sup>2</sup> IV bolus once on day 1, then 1200 mg/m<sup>2</sup> IV continuous infusion over 22 hours (total dose per cycle: 1600 mg/m<sup>2</sup>) | ||
+ | *[[Irinotecan (Camptosar)]] 180 mg/m<sup>2</sup> IV over 90 minutes once on day 1 | ||
+ | '''14-day cycle for at least 4 cycles''' | ||
+ | </div></div><br> | ||
+ | <div class="toccolours" style="background-color:#eeeeee"> | ||
+ | ===Regimen variant #3, 400/2800/180 {{#subobject:6526d0|Variant=1}}=== | ||
+ | {| class="wikitable sortable" style="width: 100%; text-align:center;" | ||
+ | ! style="width: 20%" |Study | ||
+ | ! style="width: 20%" |Dates of enrollment | ||
+ | ! style="width: 20%" |[[Levels_of_Evidence#Evidence|Evidence]] | ||
+ | ! style="width: 20%" |Comparator | ||
+ | ! style="width: 20%" |[[Levels_of_Evidence#Comparative_efficacy|Comparative Efficacy]] | ||
+ | |- | ||
+ | |[https://doi.org/10.1200/JCO.2013.54.1011 Guimbaud et al. 2014 (FFCD 03-07)] | ||
+ | |2005-2008 | ||
+ | | style="background-color:#1a9851" |Phase 3 (E-switch-ic) | ||
+ | |[[#ECX_2|ECX]] | ||
+ | | style="background-color:#1a9850" |Superior TTF (primary endpoint)<br>Median TTF: 5.08 vs 4.24 mo<br>(HR 0.77, 95% CI 0.63-0.93) | ||
+ | |- | ||
+ | |} | ||
+ | <div class="toccolours" style="background-color:#b3e2cd"> | ||
+ | ====Chemotherapy==== | ||
+ | *[[Leucovorin (Folinic acid)]] 400 mg/m<sup>2</sup> IV over 2 hours once on day 1 | ||
+ | *[[Fluorouracil (5-FU)]] 400 mg/m<sup>2</sup> IV bolus once on day 1, then 2400 mg/m<sup>2</sup> IV continuous infusion over 46 hours, '''given third''' (total dose per cycle: 2800 mg/m<sup>2</sup>) | ||
+ | *[[Irinotecan (Camptosar)]] 180 mg/m<sup>2</sup> IV over 90 minutes once on day 1 | ||
+ | '''14-day cycles''' | ||
+ | </div></div> | ||
+ | ===References=== | ||
+ | #'''FFCD 9803:''' Bouché O, Raoul JL, Bonnetain F, Giovannini M, Etienne PL, Lledo G, Arsène D, Paitel JF, Guérin-Meyer V, Mitry E, Buecher B, Kaminsky MC, Seitz JF, Rougier P, Bedenne L, Milan C; Fédération Francophone de Cancérologie Digestive. Randomized multicenter phase II trial of a biweekly regimen of fluorouracil and leucovorin (LV5FU2), LV5FU2 plus cisplatin, or LV5FU2 plus irinotecan in patients with previously untreated metastatic gastric cancer: a Federation Francophone de Cancerologie Digestive Group Study--FFCD 9803. J Clin Oncol. 2004 Nov 1;22(21):4319-28. [https://doi.org/10.1200/jco.2004.01.140 link to original article] '''dosing details in manuscript have been reviewed by our editors''' [https://pubmed.ncbi.nlm.nih.gov/15514373/ PubMed] | ||
+ | #Dank M, Zaluski J, Barone C, Valvere V, Yalcin S, Peschel C, Wenczl M, Goker E, Cisar L, Wang K, Bugat R. Randomized phase III study comparing irinotecan combined with 5-fluorouracil and folinic acid to cisplatin combined with 5-fluorouracil in chemotherapy naive patients with advanced adenocarcinoma of the stomach or esophagogastric junction. Ann Oncol. 2008 Aug;19(8):1450-7. Epub 2008 Jun 16. [https://doi.org/10.1093/annonc/mdn166 link to original article] '''dosing details in manuscript have been reviewed by our editors''' [https://pubmed.ncbi.nlm.nih.gov/18558665/ PubMed] | ||
+ | #'''FFCD 03-07:''' Guimbaud R, Louvet C, Ries P, Ychou M, Maillard E, André T, Gornet JM, Aparicio T, Nguyen S, Azzedine A, Etienne PL, Boucher E, Rebischung C, Hammel P, Rougier P, Bedenne L, Bouché O. Prospective, randomized, multicenter, phase III study of fluorouracil, leucovorin, and irinotecan versus epirubicin, cisplatin, and capecitabine in advanced gastric adenocarcinoma: a French intergroup (Fédération Francophone de Cancérologie Digestive, Fédération Nationale des Centres de Lutte Contre le Cancer, and Groupe Coopérateur Multidisciplinaire en Oncologie) study. J Clin Oncol. 2014 Nov 1;32(31):3520-6. Epub 2014 Oct 6. Erratum in: J Clin Oncol. 2015 Apr 20;33(12):1416. [https://doi.org/10.1200/JCO.2013.54.1011 link to original article] '''dosing details in manuscript have been reviewed by our editors''' [https://pubmed.ncbi.nlm.nih.gov/25287828/ PubMed] [https://clinicaltrials.gov/study/NCT00374036 NCT00374036] | ||
+ | ==mFOLFOX6 {{#subobject:328g5a|Regimen=1}}== | ||
+ | mFOLFOX6: '''<u>m</u>'''odified '''<u>FOL</u>'''inic acid (Leucovorin), '''<u>F</u>'''luorouracil, '''<u>OX</u>'''aliplatin | ||
+ | <div class="toccolours" style="background-color:#eeeeee"> | ||
+ | ===Regimen variant #1, limited duration {{#subobject:2057uf|Variant=1}}=== | ||
+ | {| class="wikitable sortable" style="width: 100%; text-align:center;" | ||
+ | !style="width: 20%"|Study | ||
+ | !style="width: 20%"|Dates of enrollment | ||
+ | !style="width: 20%"|[[Levels_of_Evidence#Evidence|Evidence]] | ||
+ | !style="width: 20%"|Comparator | ||
+ | !style="width: 20%"|[[Levels_of_Evidence#Comparative_efficacy|Comparative Efficacy]] | ||
+ | |- | ||
+ | |[https://www.ncbi.nlm.nih.gov/pmc/articles/pmc8078292/ Shah et al. 2021 (GAMMA-1)] | ||
+ | |2015-2019 | ||
+ | | style="background-color:#1a9851" |Phase 3 (C) | ||
+ | |[[#mFOLFOX6_.26_Andecaliximab_999|mFOLFOX6 & Andecaliximab]] | ||
+ | | style="background-color:#ffffbf" |Did not meet primary endpoint of OS | ||
+ | |- | ||
+ | |} | ||
+ | ''Note: to our knowledge, this regimen was not tested as an experimental arm in an RCT in this context, prior to becoming a standard comparator arm.'' | ||
+ | <div class="toccolours" style="background-color:#b3e2cd"> | ||
+ | ====Chemotherapy==== | ||
+ | *[[Fluorouracil (5-FU)]] 400 mg/m<sup>2</sup> IV bolus once on day 1, then 2400 mg/m<sup>2</sup> IV continuous infusion over 46 hours (total dose per cycle: 2800 mg/m<sup>2</sup>) | ||
+ | *[[Leucovorin (Folinic acid)]] 400 mg/m<sup>2</sup> IV once on day 1 | ||
+ | *[[Oxaliplatin (Eloxatin)]] 85 mg/m<sup>2</sup> IV once on day 1 | ||
+ | '''14-day cycle for 12 cycles''' | ||
+ | </div> | ||
+ | <div class="toccolours" style="background-color:#cbd5e7"> | ||
+ | ====Subsequent treatment==== | ||
+ | *[[#FULV_2|FULV]] maintenance | ||
+ | </div></div><br> | ||
+ | <div class="toccolours" style="background-color:#eeeeee"> | ||
+ | ===Regimen variant #2, indefinite {{#subobject:2057uf|Variant=1}}=== | ||
+ | {| class="wikitable sortable" style="width: 100%; text-align:center;" | ||
+ | !style="width: 20%"|Study | ||
+ | !style="width: 20%"|Dates of enrollment | ||
+ | !style="width: 20%"|[[Levels_of_Evidence#Evidence|Evidence]] | ||
+ | !style="width: 20%"|Comparator | ||
+ | !style="width: 20%"|[[Levels_of_Evidence#Comparative_efficacy|Comparative Efficacy]] | ||
+ | |- | ||
+ | |rowspan=2|[https://www.ncbi.nlm.nih.gov/pmc/articles/pmc8436782/ Janjigian et al. 2021 (CheckMate 649)] | ||
+ | |rowspan=2|2017-03 to 2019-04 | ||
+ | |rowspan=2 style="background-color:#1a9851" |Phase 3 (C) | ||
+ | |1a. [[#CapeOx_.26_Nivolumab|CapeOx & Nivolumab]]<br>1b. [[#mFOLFOX6_.26_Nivolumab|mFOLFOX6 & Nivolumab]] | ||
+ | | style="background-color:#d73027" |Inferior OS | ||
+ | |- | ||
+ | |2. [[#Ipilimumab_.26_Nivolumab_999|Ipilimumab & Nivolumab]] | ||
+ | | style="background-color:#d3d3d3" |Not reported | ||
+ | |- | ||
+ | |[https://doi.org/10.1016/s0140-6736(23)00620-7 Shitara et al. 2023 (SPOTLIGHT)] | ||
+ | |2018-06-21 to 2022-04-01 | ||
+ | |style="background-color:#1a9851" |Phase 3 (C) | ||
+ | |[[#mFOLFOX6_.26_Zolbetuximab_777|mFOLFOX6 & Zolbetuximab]] | ||
+ | | style="background-color:#d73027" |Inferior PFS (primary endpoint)<br><br>Inferior OS (secondary endpoint) | ||
+ | |- | ||
+ | |} | ||
+ | ''Note: to our knowledge, this regimen was not tested as an experimental arm in an RCT in this context, prior to becoming a standard comparator arm.'' | ||
+ | <div class="toccolours" style="background-color:#fdcdac"> | ||
+ | ====Biomarker eligibility criteria==== | ||
+ | *SPOTLIGHT: CLDN18.2 positive | ||
+ | </div> | ||
+ | <div class="toccolours" style="background-color:#b3e2cd"> | ||
+ | ====Chemotherapy==== | ||
+ | *[[Fluorouracil (5-FU)]] 400 mg/m<sup>2</sup> IV bolus once on day 1, then 2400 mg/m<sup>2</sup> IV continuous infusion over 46 hours (total dose per cycle: 2800 mg/m<sup>2</sup>) | ||
+ | *[[Leucovorin (Folinic acid)]] 400 mg/m<sup>2</sup> IV once on day 1 | ||
+ | *[[Oxaliplatin (Eloxatin)]] 85 mg/m<sup>2</sup> IV once on day 1 | ||
+ | '''14-day cycles''' | ||
+ | </div></div> | ||
+ | ===References=== | ||
+ | #'''GAMMA-1:''' Shah MA, Bodoky G, Starodub A, Cunningham D, Yip D, Wainberg ZA, Bendell J, Thai D, He J, Bhargava P, Ajani JA. Phase III Study to Evaluate Efficacy and Safety of Andecaliximab With mFOLFOX6 as First-Line Treatment in Patients With Advanced Gastric or GEJ Adenocarcinoma (GAMMA-1). J Clin Oncol. 2021 Mar 20;39(9):990-1000. Epub 2021 Feb 12. [https://doi.org/10.1200/jco.20.02755 link to original article] '''dosing details in manuscript have been reviewed by our editors''' [https://www.ncbi.nlm.nih.gov/pmc/articles/pmc8078292/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/33577358/ PubMed] [https://clinicaltrials.gov/study/NCT02545504 NCT02545504] | ||
+ | #'''CheckMate 649:''' Janjigian YY, Shitara K, Moehler M, Garrido M, Salman P, Shen L, Wyrwicz L, Yamaguchi K, Skoczylas T, Campos Bragagnoli A, Liu T, Schenker M, Yanez P, Tehfe M, Kowalyszyn R, Karamouzis MV, Bruges R, Zander T, Pazo-Cid R, Hitre E, Feeney K, Cleary JM, Poulart V, Cullen D, Lei M, Xiao H, Kondo K, Li M, Ajani JA. First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial. Lancet. 2021 Jul 3;398(10294):27-40. Epub 2021 Jun 5. [https://doi.org/10.1016/s0140-6736(21)00797-2 link to original article] '''dosing details in manuscript have been reviewed by our editors''' [https://www.ncbi.nlm.nih.gov/pmc/articles/pmc8436782/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/34102137/ PubMed] [https://clinicaltrials.gov/study/NCT02872116 NCT02872116] | ||
+ | ##'''Update:''' Shitara K, Ajani JA, Moehler M, Garrido M, Gallardo C, Shen L, Yamaguchi K, Wyrwicz L, Skoczylas T, Bragagnoli AC, Liu T, Tehfe M, Elimova E, Bruges R, Zander T, de Azevedo S, Kowalyszyn R, Pazo-Cid R, Schenker M, Cleary JM, Yanez P, Feeney K, Karamouzis MV, Poulart V, Lei M, Xiao H, Kondo K, Li M, Janjigian YY. Nivolumab plus chemotherapy or ipilimumab in gastro-oesophageal cancer. Nature. 2022 Mar;603(7903):942-948. Epub 2022 Mar 23. [https://doi.org/10.1038/s41586-022-04508-4 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8967713/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/35322232/ PubMed] | ||
+ | ##'''HRQoL analysis:''' Moehler M, Xiao H, Blum SI, Elimova E, Cella D, Shitara K, Ajani JA, Janjigian YY, Garrido M, Shen L, Yamaguchi K, Liu T, Schenker M, Kowalyszyn R, Bragagnoli AC, Bruges R, Montesarchio V, Pazo-Cid R, Hunter S, Davenport E, Wang J, Kondo K, Li M, Wyrwicz L. Health-Related Quality of Life With Nivolumab Plus Chemotherapy Versus Chemotherapy in Patients With Advanced Gastric/Gastroesophageal Junction Cancer or Esophageal Adenocarcinoma From CheckMate 649. J Clin Oncol. 2023 Dec 10;41(35):5388-5399. Epub 2023 Sep 15. [https://doi.org/10.1200/jco.23.00170 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/pmc10713185/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/37713657/ PubMed] | ||
+ | ##'''Update:''' Janjigian YY, Ajani JA, Moehler M, Shen L, Garrido M, Gallardo C, Wyrwicz L, Yamaguchi K, Cleary JM, Elimova E, Karamouzis M, Bruges R, Skoczylas T, Bragagnoli A, Liu T, Tehfe M, Zander T, Kowalyszyn R, Pazo-Cid R, Schenker M, Feeny K, Wang R, Lei M, Chen C, Nathani R, Shitara K. First-Line Nivolumab Plus Chemotherapy for Advanced Gastric, Gastroesophageal Junction, and Esophageal Adenocarcinoma: 3-Year Follow-Up of the Phase III CheckMate 649 Trial. J Clin Oncol. 2024 Jun 10;42(17):2012-2020. Epub 2024 Feb 21. [https://doi.org/10.1200/jco.23.01601 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/pmc11185916/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/38382001/ PubMed] | ||
+ | #'''SPOTLIGHT:''' Shitara K, Lordick F, Bang YJ, Enzinger P, Ilson D, Shah MA, Van Cutsem E, Xu RH, Aprile G, Xu J, Chao J, Pazo-Cid R, Kang YK, Yang J, Moran D, Bhattacharya P, Arozullah A, Park JW, Oh M, Ajani JA. Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): a multicentre, randomised, double-blind, phase 3 trial. Lancet. 2023 May 20;401(10389):1655-1668. Epub 2023 Apr 15. Erratum in: Lancet. 2023 Jul 22;402(10398):290. [https://doi.org/10.1016/s0140-6736(23)00620-7 link to original article] [https://pubmed.ncbi.nlm.nih.gov/37068504/ PubMed] [https://clinicaltrials.gov/study/NCT03504397 NCT03504397] | ||
+ | ==mFOLFOX6 (L-Leucovorin) {{#subobject:32hyaa|Regimen=1}}== | ||
+ | mFOLFOX6: '''<u>m</u>'''odified L-'''<u>FOL</u>'''inic acid (Leucovorin), '''<u>F</u>'''luorouracil, '''<u>OX</u>'''aliplatin | ||
+ | <div class="toccolours" style="background-color:#eeeeee"> | ||
+ | ===Regimen {{#subobject:21jxuf|Variant=1}}=== | ||
+ | {| class="wikitable sortable" style="width: 100%; text-align:center;" | ||
+ | !style="width: 20%"|Study | ||
+ | !style="width: 20%"|Dates of enrollment | ||
+ | !style="width: 20%"|[[Levels_of_Evidence#Evidence|Evidence]] | ||
+ | !style="width: 20%"|Comparator | ||
+ | !style="width: 20%"|[[Levels_of_Evidence#Comparative_efficacy|Comparative Efficacy]] | ||
+ | |- | ||
+ | |[https://www.ncbi.nlm.nih.gov/pmc/articles/pmc8078292/ Shah et al. 2021 (GAMMA-1)] | ||
+ | |2015-2019 | ||
+ | | style="background-color:#1a9851" |Phase 3 (C) | ||
+ | |[[#mFOLFOX6_.26_Andecaliximab_999|mFOLFOX6 & Andecaliximab]] | ||
+ | | style="background-color:#ffffbf" |Did not meet primary endpoint of OS | ||
+ | |- | ||
+ | |} | ||
+ | ''Note: to our knowledge, this regimen was not tested as an experimental arm in an RCT in this context, prior to becoming a standard comparator arm.'' | ||
+ | <div class="toccolours" style="background-color:#b3e2cd"> | ||
+ | ====Chemotherapy==== | ||
+ | *[[Fluorouracil (5-FU)]] 400 mg/m<sup>2</sup> IV bolus once on day 1, then 2400 mg/m<sup>2</sup> IV continuous infusion over 46 hours (total dose per cycle: 2800 mg/m<sup>2</sup>) | ||
+ | *[[Levoleucovorin (Fusilev)]] 200 mg/m<sup>2</sup> IV once on day 1 | ||
+ | *[[Oxaliplatin (Eloxatin)]] 85 mg/m<sup>2</sup> IV once on day 1 | ||
+ | '''14-day cycle for 12 cycles''' | ||
+ | </div> | ||
+ | <div class="toccolours" style="background-color:#cbd5e7"> | ||
+ | ====Subsequent treatment==== | ||
+ | *[[#FULV_2|FULV]] maintenance | ||
+ | </div></div> | ||
===References=== | ===References=== | ||
− | # | + | #'''GAMMA-1:''' Shah MA, Bodoky G, Starodub A, Cunningham D, Yip D, Wainberg ZA, Bendell J, Thai D, He J, Bhargava P, Ajani JA. Phase III Study to Evaluate Efficacy and Safety of Andecaliximab With mFOLFOX6 as First-Line Treatment in Patients With Advanced Gastric or GEJ Adenocarcinoma (GAMMA-1). J Clin Oncol. 2021 Mar 20;39(9):990-1000. Epub 2021 Feb 12. [https://doi.org/10.1200/jco.20.02755 link to original article] '''dosing details in manuscript have been reviewed by our editors''' [https://www.ncbi.nlm.nih.gov/pmc/articles/pmc8078292/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/33577358/ PubMed] [https://clinicaltrials.gov/study/NCT02545504 NCT02545504] |
− | + | #'''ARMANI:''' [https://clinicaltrials.gov/study/NCT02934464 NCT02934464] | |
− | == | + | ==mFOLFOX6 & Nivolumab {{#subobject:32ug18|Regimen=1}}== |
− | {| class="wikitable" style=" | + | mFOLFOX6 & Nivolumab: '''<u>m</u>'''odified '''<u>FOL</u>'''inic acid (Leucovorin), '''<u>F</u>'''luorouracil, '''<u>OX</u>'''aliplatin, Nivolumab |
+ | <div class="toccolours" style="background-color:#eeeeee"> | ||
+ | ===Regimen {{#subobject:1gh7uf|Variant=1}}=== | ||
+ | {| class="wikitable sortable" style="width: 100%; text-align:center;" | ||
+ | !style="width: 20%"|Study | ||
+ | !style="width: 20%"|Dates of enrollment | ||
+ | !style="width: 20%"|[[Levels_of_Evidence#Evidence|Evidence]] | ||
+ | !style="width: 20%"|Comparator | ||
+ | !style="width: 20%"|[[Levels_of_Evidence#Comparative_efficacy|Comparative Efficacy]] | ||
+ | |- | ||
+ | |rowspan=2|[https://www.ncbi.nlm.nih.gov/pmc/articles/pmc8436782/ Janjigian et al. 2021 (CheckMate 649)] | ||
+ | <!-- {| class="wikitable" style="margin:auto; color:white; background-color:#1B4F26" | ||
+ | |'''[https://www.esmo.org/guidelines/esmo-mcbs/esmo-mcbs-scorecards/scorecard-290-1 <span style="color:white;">ESMO-MCBS (4)</span>]''' | ||
+ | |- | ||
+ | |} --> | ||
+ | |rowspan=2|2017-03 to 2019-04 | ||
+ | |rowspan=2 style="background-color:#1a9851" |Phase 3 (E-RT-esc) | ||
+ | |1a. [[#CapeOx_3|CapeOx]]<br>1b. [[#mFOLFOX6_2|mFOLFOX6]] | ||
+ | | style="background-color:#1a9850" |Superior OS<sup>1</sup> (co-primary endpoint)<br>Median OS: 14.4 vs 11.1 mo<br>(HR 0.70, 95% CI 0.61-0.81) | ||
+ | |- | ||
+ | |2. [[#Ipilimumab_.26_Nivolumab_999|Ipilimumab & Nivolumab]] | ||
+ | | style="background-color:#d3d3d3" |Not reported | ||
+ | |- | ||
+ | |} | ||
+ | ''<sup>1</sup>Reported efficacy and MCBS score are for the group with PD-L1 CPS of 5 or more; reported efficacy is based on the 2022 update.'' | ||
+ | <div class="toccolours" style="background-color:#b3e2cd"> | ||
+ | ====Chemotherapy==== | ||
+ | *[[Fluorouracil (5-FU)]] 400 mg/m<sup>2</sup> IV bolus once on day 1, then 2400 mg/m<sup>2</sup> IV continuous infusion over 46 hours (total dose per cycle: 2800 mg/m<sup>2</sup>) | ||
+ | *[[Leucovorin (Folinic acid)]] 400 mg/m<sup>2</sup> IV once on day 1 | ||
+ | *[[Oxaliplatin (Eloxatin)]] 85 mg/m<sup>2</sup> IV once on day 1 | ||
+ | ====Immunotherapy==== | ||
+ | *[[Nivolumab (Opdivo)]] 240 mg IV once on day 1 | ||
+ | '''14-day cycles''' | ||
+ | </div></div> | ||
+ | ===References=== | ||
+ | #'''CheckMate 649:''' Janjigian YY, Shitara K, Moehler M, Garrido M, Salman P, Shen L, Wyrwicz L, Yamaguchi K, Skoczylas T, Campos Bragagnoli A, Liu T, Schenker M, Yanez P, Tehfe M, Kowalyszyn R, Karamouzis MV, Bruges R, Zander T, Pazo-Cid R, Hitre E, Feeney K, Cleary JM, Poulart V, Cullen D, Lei M, Xiao H, Kondo K, Li M, Ajani JA. First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial. Lancet. 2021 Jul 3;398(10294):27-40. Epub 2021 Jun 5. [https://doi.org/10.1016/s0140-6736(21)00797-2 link to original article] '''dosing details in manuscript have been reviewed by our editors''' [https://www.ncbi.nlm.nih.gov/pmc/articles/pmc8436782/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/34102137/ PubMed] [https://clinicaltrials.gov/study/NCT02872116 NCT02872116] | ||
+ | ##'''Update:''' Shitara K, Ajani JA, Moehler M, Garrido M, Gallardo C, Shen L, Yamaguchi K, Wyrwicz L, Skoczylas T, Bragagnoli AC, Liu T, Tehfe M, Elimova E, Bruges R, Zander T, de Azevedo S, Kowalyszyn R, Pazo-Cid R, Schenker M, Cleary JM, Yanez P, Feeney K, Karamouzis MV, Poulart V, Lei M, Xiao H, Kondo K, Li M, Janjigian YY. Nivolumab plus chemotherapy or ipilimumab in gastro-oesophageal cancer. Nature. 2022 Mar;603(7903):942-948. Epub 2022 Mar 23. [https://doi.org/10.1038/s41586-022-04508-4 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8967713/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/35322232/ PubMed] | ||
+ | ##'''HRQoL analysis:''' Moehler M, Xiao H, Blum SI, Elimova E, Cella D, Shitara K, Ajani JA, Janjigian YY, Garrido M, Shen L, Yamaguchi K, Liu T, Schenker M, Kowalyszyn R, Bragagnoli AC, Bruges R, Montesarchio V, Pazo-Cid R, Hunter S, Davenport E, Wang J, Kondo K, Li M, Wyrwicz L. Health-Related Quality of Life With Nivolumab Plus Chemotherapy Versus Chemotherapy in Patients With Advanced Gastric/Gastroesophageal Junction Cancer or Esophageal Adenocarcinoma From CheckMate 649. J Clin Oncol. 2023 Dec 10;41(35):5388-5399. Epub 2023 Sep 15. [https://doi.org/10.1200/jco.23.00170 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/pmc10713185/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/37713657/ PubMed] | ||
+ | ##'''Update:''' Janjigian YY, Ajani JA, Moehler M, Shen L, Garrido M, Gallardo C, Wyrwicz L, Yamaguchi K, Cleary JM, Elimova E, Karamouzis M, Bruges R, Skoczylas T, Bragagnoli A, Liu T, Tehfe M, Zander T, Kowalyszyn R, Pazo-Cid R, Schenker M, Feeny K, Wang R, Lei M, Chen C, Nathani R, Shitara K. First-Line Nivolumab Plus Chemotherapy for Advanced Gastric, Gastroesophageal Junction, and Esophageal Adenocarcinoma: 3-Year Follow-Up of the Phase III CheckMate 649 Trial. J Clin Oncol. 2024 Jun 10;42(17):2012-2020. Epub 2024 Feb 21. [https://doi.org/10.1200/jco.23.01601 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/pmc11185916/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/38382001/ PubMed] | ||
+ | ==FULV {{#subobject:5aad1e|Regimen=1}}== | ||
+ | FULV: 5-'''<u>FU</u>''' & '''<u>L</u>'''euco'''<u>V</u>'''orin | ||
+ | <div class="toccolours" style="background-color:#eeeeee"> | ||
+ | ===Regimen variant #1 {{#subobject:2d601|Variant=1}}=== | ||
+ | {| class="wikitable sortable" style="width: 100%; text-align:center;" | ||
+ | ! style="width: 20%" |Study | ||
+ | ! style="width: 20%" |Dates of enrollment | ||
+ | ! style="width: 20%" |[[Levels_of_Evidence#Evidence|Evidence]] | ||
+ | ! style="width: 20%" |Comparator | ||
+ | ! style="width: 20%" |[[Levels_of_Evidence#Comparative_efficacy|Comparative Efficacy]] | ||
+ | |- | ||
+ | |[https://doi.org/10.1200/jco.2004.01.140 Bouché et al. 2004 (FFCD 9803)] | ||
+ | |1999-2001 | ||
+ | | style="background-color:#1a9851" |Randomized Phase 2 (E-de-esc) | ||
+ | |1. [[#CLF_2|LV5FU2 & Cisplatin]]<br>2. [[#FOLFIRI|LV5FU2 & Irinotecan]] | ||
+ | | style="background-color:#d3d3d3" |Not powered to draw conclusions | ||
+ | |- | ||
+ | |} | ||
+ | ''Note: the primary reference said every cycle was 15 days, but also said that medications were given every 14 days, so the assumption was made that this more typical schedule was used. Patients had 100% adenocarcinoma histology (70% gastric origin, 30% cardia).'' | ||
+ | <div class="toccolours" style="background-color:#b3e2cd"> | ||
+ | ====Chemotherapy==== | ||
+ | *[[Fluorouracil (5-FU)]] 400 mg/m<sup>2</sup> IV bolus once on day 1, then 1200 mg/m<sup>2</sup> IV continuous infusion over 22 hours (total dose per cycle: 1600 mg/m<sup>2</sup>) | ||
+ | *[[Leucovorin (Folinic acid)]] 200 mg/m<sup>2</sup> IV over 2 hours once on day 1 | ||
+ | '''14-day cycle for at least 4 cycles''' | ||
+ | </div></div><br> | ||
+ | <div class="toccolours" style="background-color:#eeeeee"> | ||
+ | ===Regimen variant #2 {{#subobject:2d601x|Variant=1}}=== | ||
+ | {| class="wikitable sortable" style="width: 100%; text-align:center;" | ||
+ | ! style="width: 20%" |Study | ||
+ | ! style="width: 20%" |Dates of enrollment | ||
+ | ! style="width: 20%" |[[Levels_of_Evidence#Evidence|Evidence]] | ||
+ | ! style="width: 20%" |Comparator | ||
+ | ! style="width: 20%" |[[Levels_of_Evidence#Comparative_efficacy|Comparative Efficacy]] | ||
+ | |- | ||
+ | |[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10645518/ Lee et al. 2023 (KCSG ST13-10)] | ||
+ | |2014-02 to 2019-01 | ||
+ | |style="background-color:#1a9851" |Phase 3 (C) | ||
+ | |1a. [[#mFOLFOX6_2|mFOLFOX6]]<br>1b. [[#CapeOx_3|CapeOx]]<br>1c. [[#Cisplatin_.26_S-1|Cisplatin & S-1]]<br>1d. [[#Capecitabine_.26_Cisplatin_.28CX.29_3|CX]] | ||
+ | | style="background-color:#ffffbf" |Did not meet primary endpoint of OS<br>Median OS: 7.5 vs 11.5 mo<br>(HR 1.16, 95% CI 0.77-1.79) | ||
+ | |- | ||
+ | |} | ||
+ | ''Note: to our knowledge, this regimen variant was not tested as an experimental arm in an RCT in this context, prior to becoming a standard comparator arm.'' | ||
+ | <div class="toccolours" style="background-color:#b3e2cd"> | ||
+ | ====Chemotherapy==== | ||
+ | *[[Fluorouracil (5-FU)]] 2400 mg/m<sup>2</sup> IV continuous infusion over 46 hours, started on day 1 | ||
+ | *[[Leucovorin (Folinic acid)]] 100 mg/m<sup>2</sup> IV once on day 1 | ||
+ | '''14-day cycles''' | ||
+ | </div></div> | ||
+ | ===References=== | ||
+ | #'''FFCD 9803:''' Bouché O, Raoul JL, Bonnetain F, Giovannini M, Etienne PL, Lledo G, Arsène D, Paitel JF, Guérin-Meyer V, Mitry E, Buecher B, Kaminsky MC, Seitz JF, Rougier P, Bedenne L, Milan C; Fédération Francophone de Cancérologie Digestive. Randomized multicenter phase II trial of a biweekly regimen of fluorouracil and leucovorin (LV5FU2), LV5FU2 plus cisplatin, or LV5FU2 plus irinotecan in patients with previously untreated metastatic gastric cancer: a Federation Francophone de Cancerologie Digestive Group Study--FFCD 9803. J Clin Oncol. 2004 Nov 1;22(21):4319-28. [https://doi.org/10.1200/jco.2004.01.140 link to original article] '''dosing details in manuscript have been reviewed by our editors''' [https://pubmed.ncbi.nlm.nih.gov/15514373/ PubMed] | ||
+ | #'''KCSG ST13-10:''' Lee KW, Zang DY, Ryu MH, Han HS, Kim KH, Kim MJ, Koh SA, Lee SS, Koo DH, Ko YH, Sohn BS, Kim JW, Park JH, Nam BH, Choi IS. A Phase 3 Randomized Clinical Trial to Compare Efficacy and Safety between Combination Therapy and Monotherapy in Elderly Patients with Advanced Gastric Cancer (KCSG ST13-10). Cancer Res Treat. 2022 Oct;55(4):1250-1260. Epub 2023 May 25. [https://doi.org/10.4143/crt.2023.333 link to original article] '''dosing details in manuscript have been reviewed by our editors''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10645518/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/37232070/ PubMed] [https://clinicaltrials.gov/study/NCT02114359 NCT02114359] | ||
+ | ==FULV (L-Leucovorin) {{#subobject:5ga11e|Regimen=1}}== | ||
+ | FULV: 5-'''<u>FU</u>''' & Levo-'''<u>L</u>'''euco'''<u>V</u>'''orin | ||
+ | <div class="toccolours" style="background-color:#eeeeee"> | ||
+ | ===Regimen {{#subobject:2gahc1|Variant=1}}=== | ||
+ | {| class="wikitable sortable" style="width: 100%; text-align:center;" | ||
+ | ! style="width: 20%" |Study | ||
+ | ! style="width: 20%" |Dates of enrollment | ||
+ | ! style="width: 20%" |[[Levels_of_Evidence#Evidence|Evidence]] | ||
+ | ! style="width: 20%" |Comparator | ||
+ | ! style="width: 20%" |[[Levels_of_Evidence#Comparative_efficacy|Comparative Efficacy]] | ||
+ | |- | ||
+ | |[https://doi.org/10.1007/s10120-020-01043-x Nakajima et al. 2020 (JCOG1108)] | ||
+ | |2013-2017 | ||
+ | | style="background-color:#1a9851" |Phase 2/3 (C) | ||
+ | |[[#CLF|FLTAX]] | ||
+ | | style="background-color:#ffffbf" |Did not meet primary endpoint of OS | ||
|- | |- | ||
− | |||
|} | |} | ||
+ | <div class="toccolours" style="background-color:#b3e2cd"> | ||
+ | ====Chemotherapy==== | ||
+ | *[[Fluorouracil (5-FU)]] 600 mg/m<sup>2</sup> IV bolus once per day on days 1, 8, 15, 22, 29, 36, '''given second, 60 minutes after levoleucovorin''' | ||
+ | *[[Levoleucovorin (Fusilev)]] 250 mg/m<sup>2</sup> IV over 2 hours once per day on days 1, 8, 15, 22, 29, 36, '''given first''' | ||
+ | '''8-week cycles''' | ||
+ | </div></div> | ||
+ | ===References=== | ||
+ | #'''JCOG1108:''' Nakajima TE, Yamaguchi K, Boku N, Hyodo I, Mizusawa J, Hara H, Nishina T, Sakamoto T, Shitara K, Shinozaki K, Katayama H, Nakamura S, Muro K, Terashima M. Randomized phase II/III study of 5-fluorouracil/l-leucovorin versus 5-fluorouracil/l-leucovorin plus paclitaxel administered to patients with severe peritoneal metastases of gastric cancer (JCOG1108/WJOG7312G). Gastric Cancer. 2020 Jul;23(4):677-688. Epub 2020 Feb 8. [https://doi.org/10.1007/s10120-020-01043-x link to original article] '''dosing details in manuscript have been reviewed by our editors''' [https://pubmed.ncbi.nlm.nih.gov/32036492/ PubMed] UMIN000010949 | ||
+ | ==Irinotecan monotherapy {{#subobject:41e063|Regimen=1}}== | ||
+ | <div class="toccolours" style="background-color:#eeeeee"> | ||
===Regimen {{#subobject:9fb427|Variant=1}}=== | ===Regimen {{#subobject:9fb427|Variant=1}}=== | ||
− | {| class="wikitable" style="width: | + | {| class="wikitable sortable" style="width: 60%; text-align:center;" |
− | ! style="width: | + | !style="width: 33%"|Study |
− | ! style="width: | + | !style="width: 33%"|Dates of enrollment |
+ | !style="width: 33%"|[[Levels_of_Evidence#Evidence|Evidence]] | ||
|- | |- | ||
− | |[ | + | |[https://doi.org/10.1007/s10620-005-3038-2 Enzinger et al. 2005] |
− | | style="background-color:#91cf61" |Phase | + | |1997-12 to 2000-08 |
+ | | style="background-color:#91cf61" |Phase 2 | ||
|- | |- | ||
|} | |} | ||
− | ''Note: In contrast to the primary references, some guidelines list a dosing schedule of 125 mg/m<sup>2</sup> IV once per day on days 1 & 8, with 21-day cycles. Enzinger et al. 2005 comment that "when irinotecan is used as a single-agent, a tri-weekly schedule may be preferable." | + | ''Note: In contrast to the primary references, some guidelines list a dosing schedule of 125 mg/m<sup>2</sup> IV once per day on days 1 & 8, with 21-day cycles. Enzinger et al. 2005 comment that "when irinotecan is used as a single-agent, a tri-weekly schedule may be preferable." This study included patients with GE junction and distal esophageal malignancy as well (~59% gastric, 9% GEJ and 33% distal esophagus). The results showed a 14% response rate and 53% disease control rate.'' |
− | + | <div class="toccolours" style="background-color:#b3e2cd"> | |
− | |||
− | |||
− | |||
====Chemotherapy==== | ====Chemotherapy==== | ||
*[[Irinotecan (Camptosar)]] 125 mg/m<sup>2</sup> IV over 90 minutes once per day on days 1, 8, 15, 22 | *[[Irinotecan (Camptosar)]] 125 mg/m<sup>2</sup> IV over 90 minutes once per day on days 1, 8, 15, 22 | ||
− | |||
'''42-day cycles''' | '''42-day cycles''' | ||
− | + | </div></div> | |
===References=== | ===References=== | ||
− | # Enzinger PC, Kulke MH, Clark JW, Ryan DP, Kim H, Earle CC, Vincitore MM, Michelini AL, Mayer RJ, Fuchs CS. A phase II trial of irinotecan in patients with previously untreated advanced esophageal and gastric adenocarcinoma. Dig Dis Sci. 2005 Dec;50(12):2218-23. [ | + | #Enzinger PC, Kulke MH, Clark JW, Ryan DP, Kim H, Earle CC, Vincitore MM, Michelini AL, Mayer RJ, Fuchs CS. A phase II trial of irinotecan in patients with previously untreated advanced esophageal and gastric adenocarcinoma. Dig Dis Sci. 2005 Dec;50(12):2218-23. [https://doi.org/10.1007/s10620-005-3038-2 link to original article] [https://pubmed.ncbi.nlm.nih.gov/16416165/ PubMed] |
− | |||
==OLF {{#subobject:98b4fa|Regimen=1}}== | ==OLF {{#subobject:98b4fa|Regimen=1}}== | ||
− | |||
− | |||
− | |||
− | |||
OLF: '''<u>O</u>'''xaliplatin, '''<u>L</u>'''eucovorin, '''<u>F</u>'''luorouracil | OLF: '''<u>O</u>'''xaliplatin, '''<u>L</u>'''eucovorin, '''<u>F</u>'''luorouracil | ||
<br>FLO: '''<u>F</u>'''luorouracil, '''<u>L</u>'''eucovorin, '''<u>O</u>'''xaliplatin | <br>FLO: '''<u>F</u>'''luorouracil, '''<u>L</u>'''eucovorin, '''<u>O</u>'''xaliplatin | ||
+ | <div class="toccolours" style="background-color:#eeeeee"> | ||
===Regimen {{#subobject:3d7273|Variant=1}}=== | ===Regimen {{#subobject:3d7273|Variant=1}}=== | ||
− | {| class="wikitable" style="width: 100%; text-align:center;" | + | {| class="wikitable sortable" style="width: 100%; text-align:center;" |
− | ! style="width: | + | ! style="width: 20%" |Study |
− | ! style="width: | + | ! style="width: 20%" |Dates of enrollment |
− | ! style="width: | + | ! style="width: 20%" |[[Levels_of_Evidence#Evidence|Evidence]] |
− | ! style="width: | + | ! style="width: 20%" |Comparator |
+ | ! style="width: 20%" |[[Levels_of_Evidence#Comparative_efficacy|Comparative Efficacy]] | ||
|- | |- | ||
− | |[ | + | |[https://doi.org/10.1200/jco.2007.13.9378 Al-Batran et al. 2008] |
− | | style="background-color:#1a9851" |Phase | + | |2003-2006 |
+ | | style="background-color:#1a9851" |Phase 3 (E-switch-ic) | ||
|[[#CLF|FLP]] | |[[#CLF|FLP]] | ||
− | | style="background-color:#d9ef8b" |Might have superior PFS | + | | style="background-color:#d9ef8b" |Might have superior PFS (primary endpoint)<br>Median PFS: 5.8 vs 3.9 mo |
|- | |- | ||
|} | |} | ||
− | ''Patients | + | ''Note: Patients had 100% adenocarcinoma histology (20% esophagogastric junction, 80% gastric).'' |
− | + | <div class="toccolours" style="background-color:#b3e2cd"> | |
====Chemotherapy==== | ====Chemotherapy==== | ||
*[[Oxaliplatin (Eloxatin)]] 85 mg/m<sup>2</sup> IV over 2 hours once per day on days 1, 15, 29, 43 | *[[Oxaliplatin (Eloxatin)]] 85 mg/m<sup>2</sup> IV over 2 hours once per day on days 1, 15, 29, 43 | ||
− | *[[Folinic acid | + | *[[Leucovorin (Folinic acid)]] 200 mg/m<sup>2</sup> IV over 2 hours once per day on days 1, 15, 29, 43 |
*[[Fluorouracil (5-FU)]] 2600 mg/m<sup>2</sup> IV continuous infusion over 24 hours, started on days 1, 15, 29, 43 (total dose per cycle: 10,400 mg/m<sup>2</sup>) | *[[Fluorouracil (5-FU)]] 2600 mg/m<sup>2</sup> IV continuous infusion over 24 hours, started on days 1, 15, 29, 43 (total dose per cycle: 10,400 mg/m<sup>2</sup>) | ||
− | + | ====Supportive therapy==== | |
− | ====Supportive | + | *[[:Category:Emesis prevention|Antiemetic medications]] per "local protocols" |
− | *Antiemetic medications per "local protocols" | ||
− | |||
'''8-week cycles''' | '''8-week cycles''' | ||
− | + | </div></div> | |
===References=== | ===References=== | ||
− | # Al-Batran SE, Hartmann JT, Probst S, Schmalenberg H, Hollerbach S, Hofheinz R, Rethwisch V, Seipelt G, Homann N, Wilhelm G, Schuch G, Stoehlmacher J, Derigs HG, Hegewisch-Becker S, Grossmann J, Pauligk C, Atmaca A, Bokemeyer C, Knuth A, Jäger E; Arbeitsgemeinschaft Internistische Onkologie. Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie. J Clin Oncol. 2008 Mar 20;26(9):1435-42. [ | + | #Al-Batran SE, Hartmann JT, Probst S, Schmalenberg H, Hollerbach S, Hofheinz R, Rethwisch V, Seipelt G, Homann N, Wilhelm G, Schuch G, Stoehlmacher J, Derigs HG, Hegewisch-Becker S, Grossmann J, Pauligk C, Atmaca A, Bokemeyer C, Knuth A, Jäger E; Arbeitsgemeinschaft Internistische Onkologie. Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie. J Clin Oncol. 2008 Mar 20;26(9):1435-42. [https://doi.org/10.1200/jco.2007.13.9378 link to original article] '''dosing details in manuscript have been reviewed by our editors''' [https://pubmed.ncbi.nlm.nih.gov/18349393/ PubMed] |
− | |||
==Paclitaxel & S-1 {{#subobject:a88c2a|Regimen=1}}== | ==Paclitaxel & S-1 {{#subobject:a88c2a|Regimen=1}}== | ||
− | + | <div class="toccolours" style="background-color:#eeeeee"> | |
− | |||
− | |||
− | |||
===Regimen {{#subobject:82ca09|Variant=1}}=== | ===Regimen {{#subobject:82ca09|Variant=1}}=== | ||
− | {| class="wikitable" style="width: 100%; text-align:center;" | + | {| class="wikitable sortable" style="width: 100%; text-align:center;" |
− | ! style="width: | + | ! style="width: 20%" |Study |
− | ! style="width: | + | ! style="width: 20%" |Dates of enrollment |
− | ! style="width: | + | ! style="width: 20%" |[[Levels_of_Evidence#Evidence|Evidence]] |
− | ! style="width: | + | ! style="width: 20%" |Comparator |
+ | ! style="width: 20%" |[[Levels_of_Evidence#Comparative_efficacy|Comparative Efficacy]] | ||
|- | |- | ||
− | |[https:// | + | |[https://doi.org/10.1200/JCO.2018.77.8613 Ishigami et al. 2018 (PHOENIX-GC)] |
− | | style="background-color:#1a9851" |Phase | + | |2011-2013 |
+ | | style="background-color:#1a9851" |Phase 3 (E-switch-ooc) | ||
|[[#Cisplatin_.26_S-1|Cisplatin & S-1]] | |[[#Cisplatin_.26_S-1|Cisplatin & S-1]] | ||
− | | style="background-color:#d9ef8b" |Might have superior OS | + | | style="background-color:#d9ef8b" |Might have superior OS<br>Median OS: 17.7 vs 15.2 mo<br>(HR 0.72, 95% CI 0.49-1.04) |
|} | |} | ||
''Note: Inclusion criteria for PHOENIX-GC included patients with peritoneal metastasis who had received less than or equal to 2 months of prior chemotherapy without disease progression, see link for further details'' | ''Note: Inclusion criteria for PHOENIX-GC included patients with peritoneal metastasis who had received less than or equal to 2 months of prior chemotherapy without disease progression, see link for further details'' | ||
− | ==== Chemotherapy ==== | + | <div class="toccolours" style="background-color:#b3e2cd"> |
+ | ====Chemotherapy==== | ||
*[[Paclitaxel (Taxol)]] 50 mg/m<sup>2</sup> IV once per day on days 1 and 8 | *[[Paclitaxel (Taxol)]] 50 mg/m<sup>2</sup> IV once per day on days 1 and 8 | ||
− | *[[Tegafur, gimeracil, oteracil (S-1)]] | + | *[[Tegafur, gimeracil, oteracil (S-1)]] by the following BSA-based criteria: |
− | ** | + | **Less than 1.25 m<sup>2</sup>: 40 mg PO twice per day on days 1 to 14 |
− | + | **Between 1.25 to 1.5 m<sup>2</sup>: 50 mg PO twice per day on days 1 to 14 | |
− | ** | + | **More than 1.5 m<sup>2</sup>: 60 mg PO twice per day on days 1 to 14 |
− | ** | ||
*[[Paclitaxel (Taxol)]] 20 mg/m<sup>2</sup> IP once per day over 1 hour on days 1 and 8 | *[[Paclitaxel (Taxol)]] 20 mg/m<sup>2</sup> IP once per day over 1 hour on days 1 and 8 | ||
− | + | ====Supportive therapy==== | |
− | ====Supportive | + | *500 mL of [[normal saline]] was given prior to intraperitoneal paclitaxel |
− | * 500 mL of normal saline was given prior to intraperitoneal | ||
− | |||
'''35-day cycles''' | '''35-day cycles''' | ||
− | + | </div></div> | |
===References=== | ===References=== | ||
− | # '''PHOENIX-GC:''' Ishigami H, Fujiwara Y, Fukushima R, Nashimoto A, Yabusaki H, Imano M, Imamoto H, Kodera Y, Uenosono Y, Amagai K, Kadowaki S, Miwa H, Yamaguchi H, Yamaguchi T, Miyaji T, Kitayama J. Phase III trial comparing intraperitoneal and intravenous paclitaxel plus S-1 versus cisplatin plus S-1 in patients with gastric cancer with peritoneal metastasis: PHOENIX-GC trial. J Clin Oncol. 2018 Jul 1;36(19):1922-1929. Epub 2018 May 10. [https:// | + | #'''PHOENIX-GC:''' Ishigami H, Fujiwara Y, Fukushima R, Nashimoto A, Yabusaki H, Imano M, Imamoto H, Kodera Y, Uenosono Y, Amagai K, Kadowaki S, Miwa H, Yamaguchi H, Yamaguchi T, Miyaji T, Kitayama J. Phase III trial comparing intraperitoneal and intravenous paclitaxel plus S-1 versus cisplatin plus S-1 in patients with gastric cancer with peritoneal metastasis: PHOENIX-GC trial. J Clin Oncol. 2018 Jul 1;36(19):1922-1929. Epub 2018 May 10. [https://doi.org/10.1200/JCO.2018.77.8613 link to original article] '''dosing details in manuscript have been reviewed by our editors''' [https://pubmed.ncbi.nlm.nih.gov/29746229/ PubMed] UMIN000005930 |
− | == | + | ==Pembrolizumab monotherapy== |
− | {| class="wikitable" style=" | + | <div class="toccolours" style="background-color:#eeeeee"> |
+ | ===Regimen=== | ||
+ | {| class="wikitable sortable" style="width: 100%; text-align:center;" | ||
+ | ! style="width: 20%" |Study | ||
+ | ! style="width: 20%" |Dates of enrollment | ||
+ | ! style="width: 20%" |[[Levels_of_Evidence#Evidence|Evidence]] | ||
+ | ! style="width: 20%" |Comparator | ||
+ | ! style="width: 20%" |[[Levels_of_Evidence#Comparative_efficacy|Comparative Efficacy]] | ||
+ | |- | ||
+ | |rowspan=2|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7489405/ Shitara et al. 2020 (KEYNOTE-062)] | ||
+ | |rowspan=2|2015-2017 | ||
+ | |rowspan=2 style="background-color:#1a9851" |Phase 3 (E-switch-ooc) | ||
+ | |1a. [[#Cisplatin_.26_Fluorouracil_.28CF.29_3|CF]]<br>1b. [[#Capecitabine_.26_Cisplatin_.28CX.29_3|CX]] | ||
+ | | style="background-color:#eeee01" |Non-inferior OS<sup>1</sup> (co-primary endpoint) | ||
+ | |- | ||
+ | |2a. [[#Cisplatin_.26_Fluorouracil_.28CF.29_.26_Pembrolizumab|CF & Pembrolizumab]]<br>2b. [[#Capecitabine_.26_Cisplatin_.28CX.29_.26_Pembrolizumab_999|CX & Pembrolizumab]] | ||
+ | | style="background-color:#d3d3d3" |Not reported | ||
|- | |- | ||
− | |||
|} | |} | ||
− | === | + | ''<sup>1</sup>Reported efficacy is for patients with PD-L1 CPS score of 1 or more. Improved OS was seen in patients with PD-L1 CPS score of 10 or more (HR: 0.62) but was not tested per analysis plan.''<br> |
− | {| class="wikitable" style="width: 100%; text-align:center;" | + | ''KEYNOTE-062 included patients with GEJ malignancy.'' |
− | ! style="width: | + | <div class="toccolours" style="background-color:#fdcdac"> |
− | ! style="width: | + | ====Biomarker eligibility criteria==== |
− | ! style="width: | + | *PD-L1 CPS score of 1 or more |
− | ! style="width: | + | </div> |
+ | <div class="toccolours" style="background-color:#b3e2cd"> | ||
+ | ====Immunotherapy==== | ||
+ | *[[Pembrolizumab (Keytruda)]] 200 mg IV once on day 1 | ||
+ | '''21-day cycle for up to 35 cycles''' | ||
+ | </div></div> | ||
+ | ===References=== | ||
+ | <!-- #'''Abstract:''' Tabernero J, Van Cutsem E, Yung-Jue B, Fuchs CS, Wyrwicz L, Lee KW, Kudaba I, Garrido M, Chung HC, Salguero HR, Mansoor W, Freitas MI, Brachiroli M, Goekkurt E, Chao J, Wainberg ZA, Kher U, Shah S, Kang SP, Shitara K. Pembrolizumab with or without chemotherapy versus chemotherapy for advanced gastric or gastroesophgeal junction (G/GEJ) adenocarcinoma: The phase III KEYNOTE-062 study. 2019 American Society of Clinical Oncology annual meeting. [https://doi.org/10.1200/JCO.2019.37.18_suppl.LBA4007 link to abstract] --> | ||
+ | #'''KEYNOTE-062:''' Shitara K, Van Cutsem E, Bang YJ, Fuchs C, Wyrwicz L, Lee KW, Kudaba I, Garrido M, Chung HC, Lee J, Castro HR, Mansoor W, Braghiroli MI, Karaseva N, Caglevic C, Villanueva L, Goekkurt E, Satake H, Enzinger P, Alsina M, Benson A, Chao J, Ko AH, Wainberg ZA, Kher U, Shah S, Kang SP, Tabernero J. Efficacy and Safety of Pembrolizumab or Pembrolizumab Plus Chemotherapy vs Chemotherapy Alone for Patients With First-line, Advanced Gastric Cancer: The KEYNOTE-062 Phase 3 Randomized Clinical Trial. JAMA Oncol. 2020 Oct 1;6(10):1571-1580. Epub 2020 Sep 3. [https://doi.org/10.1001/jamaoncol.2020.3370 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7489405/ link to PMC article] '''dosing details in manuscript have been reviewed by our editors''' [https://pubmed.ncbi.nlm.nih.gov/32880601/ PubMed] [https://clinicaltrials.gov/study/NCT02494583 NCT02494583] | ||
+ | ==S-1 monotherapy {{#subobject:a12a2a|Regimen=1}}== | ||
+ | <div class="toccolours" style="background-color:#eeeeee"> | ||
+ | ===Regimen variant #1, BSA-based {{#subobject:86c009|Variant=1}}=== | ||
+ | {| class="wikitable sortable" style="width: 100%; text-align:center;" | ||
+ | ! style="width: 20%" |Study | ||
+ | ! style="width: 20%" |Dates of enrollment | ||
+ | ! style="width: 20%" |[[Levels_of_Evidence#Evidence|Evidence]] | ||
+ | ! style="width: 20%" |Comparator | ||
+ | ! style="width: 20%" |[[Levels_of_Evidence#Comparative_efficacy|Comparative Efficacy]] | ||
|- | |- | ||
− | | rowspan="2" |[https:// | + | | rowspan="2" |[https://doi.org/10.1016/S1470-2045(09)70259-1 Boku et al. 2009 (JCOG 9912)] |
− | | rowspan="2" style="background-color:#1a9851" |Phase | + | | rowspan="2" |2000-2006 |
− | |1. Cisplatin & Irinotecan | + | | rowspan="2" style="background-color:#1a9851" |Phase 3 (E-switch-ic) |
+ | |1. [[#Cisplatin_.26_Irinotecan_888|Cisplatin & Irinotecan]] | ||
| style="background-color:#d3d3d3" |Not reported | | style="background-color:#d3d3d3" |Not reported | ||
|- | |- | ||
|2. [[#Fluorouracil_monotherapy|5-FU]] | |2. [[#Fluorouracil_monotherapy|5-FU]] | ||
− | | style="background-color:#eeee01" |Non-inferior OS | + | | style="background-color:#eeee01" |Non-inferior OS (primary endpoint) |
|- | |- | ||
|} | |} | ||
+ | <div class="toccolours" style="background-color:#b3e2cd"> | ||
====Chemotherapy==== | ====Chemotherapy==== | ||
*[[Tegafur, gimeracil, oteracil (S-1)]] 40 mg/m<sup>2</sup> PO twice per day on days 1 to 28 | *[[Tegafur, gimeracil, oteracil (S-1)]] 40 mg/m<sup>2</sup> PO twice per day on days 1 to 28 | ||
− | |||
'''42-day cycles''' | '''42-day cycles''' | ||
− | + | </div></div><br> | |
− | === | + | <div class="toccolours" style="background-color:#eeeeee"> |
− | {| class="wikitable" style="width: 100%; text-align:center;" | + | ===Regimen variant #2, weight-based {{#subobject:f90b1b|Variant=1}}=== |
− | ! style="width: | + | {| class="wikitable sortable" style="width: 100%; text-align:center;" |
− | ! style="width: | + | ! style="width: 20%" |Study |
− | ! style="width: | + | ! style="width: 20%" |Dates of enrollment |
− | ! style="width: | + | ! style="width: 20%" |[[Levels_of_Evidence#Evidence|Evidence]] |
+ | ! style="width: 20%" |Comparator | ||
+ | ! style="width: 20%" |[[Levels_of_Evidence#Comparative_efficacy|Comparative Efficacy]] | ||
|- | |- | ||
− | |[https:// | + | |[https://doi.org/10.1016/S1470-2045(08)70035-4 Koizumi et al. 2008 (SPIRITS)] |
− | | style="background-color:#1a9851" |Phase | + | |2002-2004 |
+ | | style="background-color:#1a9851" |Phase 3 (C) | ||
|[[#Cisplatin_.26_S-1|Cisplatin & S-1]] | |[[#Cisplatin_.26_S-1|Cisplatin & S-1]] | ||
| style="background-color:#fc8d59" |Seems to have inferior OS | | style="background-color:#fc8d59" |Seems to have inferior OS | ||
|- | |- | ||
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3056989/ Narahara et al. 2011 (TOP-002)] | |[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3056989/ Narahara et al. 2011 (TOP-002)] | ||
− | | style="background-color:#1a9851" |Phase | + | |2004-06 to 2005-11 |
− | |IRIS | + | | style="background-color:#1a9851" |Phase 3 (C) |
− | | style="background-color:#ffffbf" | | + | |[[#IRIS_999|IRIS]] |
+ | | style="background-color:#ffffbf" |Did not meet primary endpoint of OS | ||
|- | |- | ||
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3895196/ Koizumi et al. 2013 (START<sub>gastric</sub>)] | |[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3895196/ Koizumi et al. 2013 (START<sub>gastric</sub>)] | ||
− | | style="background-color:#1a9851" |Phase | + | |2005-2008 |
+ | | style="background-color:#1a9851" |Phase 3 (C) | ||
|[[#Docetaxel_.26_S-1|Docetaxel & S-1]] | |[[#Docetaxel_.26_S-1|Docetaxel & S-1]] | ||
| style="background-color:#fc8d59" |Seems to have inferior OS | | style="background-color:#fc8d59" |Seems to have inferior OS | ||
|- | |- | ||
− | |[https:// | + | |[https://doi.org/10.1016/j.ejca.2016.06.012 Yoshino et al. 2016 (JFMC36-0701)] |
− | | style="background-color:#1a9851" |Phase | + | |2007-2010 |
− | |Lentinan & S-1 | + | | style="background-color:#1a9851" |Phase 3 (C) |
− | | style="background-color:#ffffbf" | | + | |[[#Lentinan_.26_S-1_999|Lentinan & S-1]] |
+ | | style="background-color:#ffffbf" |Did not meet primary endpoint of OS | ||
|- | |- | ||
|} | |} | ||
''Note: there is another trial named START in NSCLC.'' | ''Note: there is another trial named START in NSCLC.'' | ||
+ | <div class="toccolours" style="background-color:#b3e2cd"> | ||
====Chemotherapy==== | ====Chemotherapy==== | ||
− | *[[Tegafur, gimeracil, oteracil (S-1)]] | + | *[[Tegafur, gimeracil, oteracil (S-1)]] by the following BSA-based criteria: |
− | ** | + | **Less than 1.25 m<sup>2</sup>: 40 mg PO twice per day on days 1 to 28 |
− | ** | + | **Between 1.25 and 1.5 m<sup>2</sup>: 50 mg PO twice per day on days 1 to 28 |
− | ** | + | **1.5 m<sup>2</sup> or more: 60 mg PO twice per day on days 1 to 28 |
− | |||
'''42-day cycles''' | '''42-day cycles''' | ||
+ | </div></div><br> | ||
+ | <div class="toccolours" style="background-color:#eeeeee"> | ||
+ | ===Regimen variant #3, 14 of 21 days {{#subobject:fjkq1b|Variant=1}}=== | ||
+ | {| class="wikitable sortable" style="width: 100%; text-align:center;" | ||
+ | ! style="width: 20%" |Study | ||
+ | ! style="width: 20%" |Dates of enrollment | ||
+ | ! style="width: 20%" |[[Levels_of_Evidence#Evidence|Evidence]] | ||
+ | ! style="width: 20%" |Comparator | ||
+ | ! style="width: 20%" |[[Levels_of_Evidence#Comparative_efficacy|Comparative Efficacy]] | ||
+ | |- | ||
+ | |[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10645518/ Lee et al. 2023 (KCSG ST13-10)] | ||
+ | |2014-02 to 2019-01 | ||
+ | |style="background-color:#1a9851" |Phase 3 (C) | ||
+ | |1a. [[#mFOLFOX6_2|mFOLFOX6]]<br>1b. [[#CapeOx_3|CapeOx]]<br>1c. [[#Cisplatin_.26_S-1|Cisplatin & S-1]]<br>1d. [[#Capecitabine_.26_Cisplatin_.28CX.29_3|CX]] | ||
+ | | style="background-color:#ffffbf" |Did not meet primary endpoint of OS<br>Median OS: 7.5 vs 11.5 mo<br>(HR 1.16, 95% CI 0.77-1.79) | ||
+ | |- | ||
+ | |} | ||
+ | ''Note: to our knowledge, this regimen variant was not tested as an experimental arm in an RCT in this context, prior to becoming a standard comparator arm.'' | ||
+ | <div class="toccolours" style="background-color:#b3e2cd"> | ||
+ | ====Chemotherapy==== | ||
+ | *[[Tegafur, gimeracil, oteracil (S-1)]] by the following renal function-based criteria: | ||
+ | **CrCl 60 mL/min or more: 40 mg/m<sup>2</sup> PO twice per day on days 1 to 14 | ||
+ | **CrCl less than 60 mL/min: 30 mg/m<sup>2</sup> PO twice per day on days 1 to 14 | ||
+ | '''21-day cycles''' | ||
+ | </div></div> | ||
===References=== | ===References=== | ||
− | # '''SPIRITS:''' Koizumi W, Narahara H, Hara T, Takagane A, Akiya T, Takagi M, Miyashita K, Nishizaki T, Kobayashi O, Takiyama W, Toh Y, Nagaie T, Takagi S, Yamamura Y, Yanaoka K, Orita H, Takeuchi M. S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial. Lancet Oncol. 2008 Mar;9(3):215-21. Epub 2008 Feb 20. [https:// | + | #'''SPIRITS:''' Koizumi W, Narahara H, Hara T, Takagane A, Akiya T, Takagi M, Miyashita K, Nishizaki T, Kobayashi O, Takiyama W, Toh Y, Nagaie T, Takagi S, Yamamura Y, Yanaoka K, Orita H, Takeuchi M. S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial. Lancet Oncol. 2008 Mar;9(3):215-21. Epub 2008 Feb 20. [https://doi.org/10.1016/S1470-2045(08)70035-4 link to original article] '''dosing details in manuscript have been reviewed by our editors''' [https://pubmed.ncbi.nlm.nih.gov/18282805/ PubMed] [https://clinicaltrials.gov/study/NCT00150670 NCT00150670] |
− | # '''JCOG 9912:''' Boku N, Yamamoto S, Fukuda H, Shirao K, Doi T, Sawaki A, Koizumi W, Saito H, Yamaguchi K, Takiuchi H, Nasu J, Ohtsu A; Gastrointestinal Oncology Study Group of the Japan Clinical Oncology Group. Fluorouracil versus combination of irinotecan plus cisplatin versus S-1 in metastatic gastric cancer: a randomised phase 3 study. Lancet Oncol. 2009 Nov;10(11):1063-9. Epub 2009 Oct 7. [https:// | + | #'''JCOG 9912:''' Boku N, Yamamoto S, Fukuda H, Shirao K, Doi T, Sawaki A, Koizumi W, Saito H, Yamaguchi K, Takiuchi H, Nasu J, Ohtsu A; Gastrointestinal Oncology Study Group of the Japan Clinical Oncology Group. Fluorouracil versus combination of irinotecan plus cisplatin versus S-1 in metastatic gastric cancer: a randomised phase 3 study. Lancet Oncol. 2009 Nov;10(11):1063-9. Epub 2009 Oct 7. [https://doi.org/10.1016/S1470-2045(09)70259-1 link to original article] '''dosing details in abstract have been reviewed by our editors''' [https://pubmed.ncbi.nlm.nih.gov/19818685/ PubMed] [https://clinicaltrials.gov/study/NCT00142350 NCT00142350] |
− | # '''TOP-002:''' Narahara H, Iishi H, Imamura H, Tsuburaya A, Chin K, Imamoto H, Esaki T, Furukawa H, Hamada C, Sakata Y. Randomized phase III study comparing the efficacy and safety of irinotecan plus S-1 with S-1 alone as first-line treatment for advanced gastric cancer (study GC0301/TOP-002). Gastric Cancer. 2011 Mar;14(1):72-80. Epub 2011 Feb 23. [https:// | + | #'''TOP-002:''' Narahara H, Iishi H, Imamura H, Tsuburaya A, Chin K, Imamoto H, Esaki T, Furukawa H, Hamada C, Sakata Y. Randomized phase III study comparing the efficacy and safety of irinotecan plus S-1 with S-1 alone as first-line treatment for advanced gastric cancer (study GC0301/TOP-002). Gastric Cancer. 2011 Mar;14(1):72-80. Epub 2011 Feb 23. [https://doi.org/10.1007/s10120-011-0009-5 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3056989/ link to PMC article] '''dosing details in manuscript have been reviewed by our editors''' [https://pubmed.ncbi.nlm.nih.gov/21340666/ PubMed] JapicCTI-050083 |
− | # '''START:''' Koizumi W, Kim YH, Fujii M, Kim HK, Imamura H, Lee KH, Hara T, Chung HC, Satoh T, Cho JY, Hosaka H, Tsuji A, Takagane A, Inokuchi M, Tanabe K, Okuno T, Ogura M, Yoshida K, Takeuchi M, Nakajima T; JACCRO | + | #'''START:''' Koizumi W, Kim YH, Fujii M, Kim HK, Imamura H, Lee KH, Hara T, Chung HC, Satoh T, Cho JY, Hosaka H, Tsuji A, Takagane A, Inokuchi M, Tanabe K, Okuno T, Ogura M, Yoshida K, Takeuchi M, Nakajima T; JACCRO; KCSG. Addition of docetaxel to S-1 without platinum prolongs survival of patients with advanced gastric cancer: a randomized study (START). J Cancer Res Clin Oncol. 2014 Feb;140(2):319-28. Epub 2013 Dec 24. [https://doi.org/10.1007/s00432-013-1563-5 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3895196/ link to PMC article] '''dosing details in manuscript have been reviewed by our editors''' [https://pubmed.ncbi.nlm.nih.gov/24366758/ PubMed] [https://clinicaltrials.gov/study/NCT00287768 NCT00287768] |
− | # '''JFMC36-0701:''' Yoshino S, Nishikawa K, Morita S, Takahashi T, Sakata K, Nagao J, Nemoto H, Murakami N, Matsuda T, Hasegawa H, Shimizu R, Yoshikawa T, Osanai H, Imano M, Naitoh H, Tanaka A, Tajiri T, Gochi A, Suzuki M, Sakamoto J, Saji S, Oka M. Randomised phase III study of S-1 alone versus S-1 plus lentinan for unresectable or recurrent gastric cancer (JFMC36-0701). Eur J Cancer. 2016 Sep;65:164-71. Epub 2016 Aug 5. [https:// | + | #'''JFMC36-0701:''' Yoshino S, Nishikawa K, Morita S, Takahashi T, Sakata K, Nagao J, Nemoto H, Murakami N, Matsuda T, Hasegawa H, Shimizu R, Yoshikawa T, Osanai H, Imano M, Naitoh H, Tanaka A, Tajiri T, Gochi A, Suzuki M, Sakamoto J, Saji S, Oka M. Randomised phase III study of S-1 alone versus S-1 plus lentinan for unresectable or recurrent gastric cancer (JFMC36-0701). Eur J Cancer. 2016 Sep;65:164-71. Epub 2016 Aug 5. [https://doi.org/10.1016/j.ejca.2016.06.012 link to original article] [https://pubmed.ncbi.nlm.nih.gov/27501505/ PubMed] UMIN000000574 |
− | + | #'''KCSG ST13-10:''' Lee KW, Zang DY, Ryu MH, Han HS, Kim KH, Kim MJ, Koh SA, Lee SS, Koo DH, Ko YH, Sohn BS, Kim JW, Park JH, Nam BH, Choi IS. A Phase 3 Randomized Clinical Trial to Compare Efficacy and Safety between Combination Therapy and Monotherapy in Elderly Patients with Advanced Gastric Cancer (KCSG ST13-10). Cancer Res Treat. 2022 Oct;55(4):1250-1260. Epub 2023 May 25. [https://doi.org/10.4143/crt.2023.333 link to original article] '''dosing details in manuscript have been reviewed by our editors''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10645518/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/37232070/ PubMed] [https://clinicaltrials.gov/study/NCT02114359 NCT02114359] | |
+ | #'''RESCUE-GC:''' [https://clinicaltrials.gov/study/NCT02867839 NCT02867839] | ||
==UFTM {{#subobject:96e8bf|Regimen=1}}== | ==UFTM {{#subobject:96e8bf|Regimen=1}}== | ||
− | |||
− | |||
− | |||
− | |||
UFTM: '''<u>UFT</u>''' (Tegafur and uracil) & '''<u>M</u>'''itomycin | UFTM: '''<u>UFT</u>''' (Tegafur and uracil) & '''<u>M</u>'''itomycin | ||
− | + | <div class="toccolours" style="background-color:#eeeeee"> | |
===Regimen {{#subobject:3a603b|Variant=1}}=== | ===Regimen {{#subobject:3a603b|Variant=1}}=== | ||
− | {| class="wikitable" style="width: 100%; text-align:center;" | + | {| class="wikitable sortable" style="width: 100%; text-align:center;" |
− | ! style="width: | + | ! style="width: 20%" |Study |
− | ! style="width: | + | ! style="width: 20%" |Dates of enrollment |
− | ! style="width: | + | ! style="width: 20%" |[[Levels_of_Evidence#Evidence|Evidence]] |
− | ! style="width: | + | ! style="width: 20%" |Comparator |
+ | ! style="width: 20%" |[[Levels_of_Evidence#Comparative_efficacy|Comparative Efficacy]] | ||
|- | |- | ||
− | | rowspan="2" |[ | + | | rowspan="2" |[https://doi.org/10.1200/jco.2003.04.130 Ohtsu et al. 2003 (JCOG 9205)] |
− | | rowspan="2" style="background-color:#1a9851" |Phase | + | | rowspan="2" |1992-1997 |
+ | | rowspan="2" style="background-color:#1a9851" |Phase 3 (E-esc) | ||
|1. [[#Fluorouracil_monotherapy|Fluorouracil]] | |1. [[#Fluorouracil_monotherapy|Fluorouracil]] | ||
− | | style="background-color:#ffffbf" | | + | | style="background-color:#ffffbf" |Did not meet primary endpoint of OS |
|- | |- | ||
− | |2. [[#Cisplatin_. | + | |2. [[#Cisplatin_.26_Fluorouracil_.28CF.29_3|FP]] |
− | | style="background-color:#ffffbf" | | + | | style="background-color:#ffffbf" |Did not meet primary endpoint of OS |
|- | |- | ||
|} | |} | ||
− | ''Study included patients with PFS of 2 (9.6%)'' | + | ''Note: this arm of the study was terminated early, in 1995. Study included patients with PFS of 2 (9.6%). Mitomycin was interrupted for 1 month after patients received a total cumulative dose of 60 mg.'' |
− | + | <div class="toccolours" style="background-color:#b3e2cd"> | |
====Chemotherapy==== | ====Chemotherapy==== | ||
*[[Tegafur and uracil (UFT)]] 187.5 mg/m<sup>2</sup> PO twice per day | *[[Tegafur and uracil (UFT)]] 187.5 mg/m<sup>2</sup> PO twice per day | ||
− | *[[Mitomycin (Mutamycin)]] 5 mg/m<sup>2</sup> IV once | + | *[[Mitomycin (Mutamycin)]] 5 mg/m<sup>2</sup> IV once on day 1 |
− | + | '''7-day cycles (see note)''' | |
− | + | </div></div> | |
− | ''' | ||
− | |||
===References=== | ===References=== | ||
− | # '''JCOG 9205:''' Ohtsu A, Shimada Y, Shirao K, Boku N, Hyodo I, Saito H, Yamamichi N, Miyata Y, Ikeda N, Yamamoto S, Fukuda H, Yoshida S; | + | #'''JCOG 9205:''' Ohtsu A, Shimada Y, Shirao K, Boku N, Hyodo I, Saito H, Yamamichi N, Miyata Y, Ikeda N, Yamamoto S, Fukuda H, Yoshida S; [[Study_Groups#JCOG|JCOG]]. Randomized phase III trial of fluorouracil alone versus fluorouracil plus cisplatin versus uracil and tegafur plus mitomycin in patients with unresectable, advanced gastric cancer: the Japan Clinical Oncology Group study (JCOG9205). J Clin Oncol. 2003 Jan 1;21(1):54-9. [https://doi.org/10.1200/jco.2003.04.130 link to original article] '''dosing details in manuscript have been reviewed by our editors''' [https://pubmed.ncbi.nlm.nih.gov/12506170/ PubMed] |
=Maintenance after first-line therapy= | =Maintenance after first-line therapy= | ||
==Capecitabine monotherapy {{#subobject:c6df5d|Regimen=1}}== | ==Capecitabine monotherapy {{#subobject:c6df5d|Regimen=1}}== | ||
− | + | <div class="toccolours" style="background-color:#eeeeee"> | |
− | |||
− | |||
− | |||
===Regimen {{#subobject:878a56|Variant=1}}=== | ===Regimen {{#subobject:878a56|Variant=1}}=== | ||
− | {| class="wikitable" style="width: | + | {| class="wikitable sortable" style="width: 60%; text-align:center;" |
− | ! style="width: | + | !style="width: 33%"|Study |
− | ! style="width: | + | !style="width: 33%"|Dates of enrollment |
+ | !style="width: 33%"|[[Levels_of_Evidence#Evidence|Evidence]] | ||
|- | |- | ||
− | |[https:// | + | |[https://doi.org/10.1200/JCO.2011.36.2236 Ohtsu et al. 2011 (AVAGAST)] |
− | | style="background-color:#91cf61" |Non-randomized | + | |2007-09 to 2008-12 |
+ | | style="background-color:#91cf61" |Non-randomized part of phase 3 RCT | ||
|- | |- | ||
− | |[https:// | + | |[https://doi.org/10.1016/j.ejca.2014.08.005 Kim et al. 2014 (SMC 2008-12-019)] |
− | | style="background-color:#91cf61" |Non-randomized | + | |2009-2012 |
+ | | style="background-color:#91cf61" |Non-randomized part of phase 3 RCT | ||
|- | |- | ||
|} | |} | ||
− | '' | + | ''Note: AVAGAST patients had 86% gastric and 14% GEJ. 5.4% of patients had an ECOG PS of 2. SMC 2008-12-019 patients had 79% gastric, 5% GEJ, and 16% unknown. 2% of patients had an ECOG PS of 2.'' |
− | + | <div class="toccolours" style="background-color:#cbd5e8"> | |
− | |||
====Preceding treatment==== | ====Preceding treatment==== | ||
− | *AVAGAST: [[# | + | *AVAGAST: First-line [[#Capecitabine_.26_Cisplatin_.28CX.29_3|CX]] x 6 |
− | * | + | *SMC 2008-12-019: First-line [[#Capecitabine_.26_Cisplatin_.28CX.29_3|CX]] x 8 |
+ | </div> | ||
+ | <div class="toccolours" style="background-color:#b3e2cd"> | ||
====Chemotherapy==== | ====Chemotherapy==== | ||
*[[Capecitabine (Xeloda)]] 1000 mg/m<sup>2</sup> PO twice per day on days 1 to 14 | *[[Capecitabine (Xeloda)]] 1000 mg/m<sup>2</sup> PO twice per day on days 1 to 14 | ||
− | |||
'''21-day cycles''' | '''21-day cycles''' | ||
+ | </div></div> | ||
===References=== | ===References=== | ||
− | # Ohtsu A, Shah MA, Van Cutsem E, Rha SY, Sawaki A, Park SR, Lim HY, Yamada Y, Wu J, Langer B, Starnawski M, Kang YK. Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a randomized, double-blind, placebo-controlled phase III study. J Clin Oncol. 2011 Oct 20;29(30):3968-76. Epub 2011 Aug 15. [https:// | + | #'''AVAGAST:''' Ohtsu A, Shah MA, Van Cutsem E, Rha SY, Sawaki A, Park SR, Lim HY, Yamada Y, Wu J, Langer B, Starnawski M, Kang YK. Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a randomized, double-blind, placebo-controlled phase III study. J Clin Oncol. 2011 Oct 20;29(30):3968-76. Epub 2011 Aug 15. [https://doi.org/10.1200/JCO.2011.36.2236 link to original article] '''dosing details in manuscript have been reviewed by our editors''' [https://pubmed.ncbi.nlm.nih.gov/21844504/ PubMed] [https://clinicaltrials.gov/study/NCT00548548 NCT00548548] |
− | # Kim ST, Kang JH, Lee J, Park SH, Park JO, Park YS, Lim HY, Hwang IG, Lee SC, Park KW, Lee HR, Kang WK. Simvastatin plus capecitabine-cisplatin versus placebo plus capecitabine-cisplatin in patients with previously untreated advanced gastric cancer: a double-blind randomised phase 3 study. Eur J Cancer. 2014 Nov;50(16):2822-30. Epub 2014 Sep 15. [https:// | + | #'''SMC 2008-12-019:''' Kim ST, Kang JH, Lee J, Park SH, Park JO, Park YS, Lim HY, Hwang IG, Lee SC, Park KW, Lee HR, Kang WK. Simvastatin plus capecitabine-cisplatin versus placebo plus capecitabine-cisplatin in patients with previously untreated advanced gastric cancer: a double-blind randomised phase 3 study. Eur J Cancer. 2014 Nov;50(16):2822-30. Epub 2014 Sep 15. [https://doi.org/10.1016/j.ejca.2014.08.005 link to original article] '''dosing details in manuscript have been reviewed by our editors''' [https://pubmed.ncbi.nlm.nih.gov/25218337/ PubMed] [https://clinicaltrials.gov/study/NCT01099085 NCT01099085] |
=Metastatic or locally advanced disease, subsequent lines of therapy= | =Metastatic or locally advanced disease, subsequent lines of therapy= | ||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
==Docetaxel monotherapy {{#subobject:4f3230|Regimen=1}}== | ==Docetaxel monotherapy {{#subobject:4f3230|Regimen=1}}== | ||
− | + | <div class="toccolours" style="background-color:#eeeeee"> | |
− | + | ===Regimen variant #1, 60 mg/m<sup>2</sup> {{#subobject:577cd6|Variant=1}}=== | |
− | + | {| class="wikitable sortable" style="width: 100%; text-align:center;" | |
− | + | ! style="width: 20%" |Study | |
− | === | + | ! style="width: 20%" |Dates of enrollment |
− | {| class="wikitable" style="width: 100%; text-align:center;" | + | ! style="width: 20%" |[[Levels_of_Evidence#Evidence|Evidence]] |
− | ! style="width: | + | ! style="width: 20%" |Comparator |
− | ! style="width: | + | ! style="width: 20%" |[[Levels_of_Evidence#Comparative_efficacy|Comparative Efficacy]] |
− | ! style="width: | ||
− | ! style="width: | ||
|- | |- | ||
− | |[ | + | |[https://doi.org/10.1200/jco.2011.39.4585 Kang et al. 2012 (SMC 2008-08-055)] |
− | | style="background-color:#1a9851" |Phase | + | |2008-2010 |
− | |[[# | + | | style="background-color:#1a9851" |Phase 3 (E-esc) |
− | | style="background-color:#1a9850" |Superior OS | + | |[[Gastric_cancer_-_null_regimens#Best_supportive_care_2|Best supportive care]] |
+ | | style="background-color:#1a9850" |Superior OS (primary endpoint)<br>Median OS: 5.3 vs 3.8 mo<br>(HR 0.66, 95% CI 0.485-0.89) | ||
|- | |- | ||
|} | |} | ||
+ | <div class="toccolours" style="background-color:#b3e2cd"> | ||
====Chemotherapy==== | ====Chemotherapy==== | ||
*[[Docetaxel (Taxotere)]] 60 mg/m<sup>2</sup> IV once on day 1 | *[[Docetaxel (Taxotere)]] 60 mg/m<sup>2</sup> IV once on day 1 | ||
− | |||
'''21-day cycles''' | '''21-day cycles''' | ||
− | + | </div></div><br> | |
− | === | + | <div class="toccolours" style="background-color:#eeeeee"> |
− | {| class="wikitable" style="width: 100%; text-align:center;" | + | ===Regimen variant #2, 75 mg/m<sup>2</sup> x 6 {{#subobject:3b4816|Variant=1}}=== |
− | ! style="width: | + | {| class="wikitable sortable" style="width: 100%; text-align:center;" |
− | ! style="width: | + | ! style="width: 20%" |Study |
− | ! style="width: | + | ! style="width: 20%" |Dates of enrollment |
− | ! style="width: | + | ! style="width: 20%" |[[Levels_of_Evidence#Evidence|Evidence]] |
+ | ! style="width: 20%" |Comparator | ||
+ | ! style="width: 20%" |[[Levels_of_Evidence#Comparative_efficacy|Comparative Efficacy]] | ||
|- | |- | ||
− | |[https:// | + | |[https://doi.org/10.1016/S1470-2045(13)70549-7 Ford et al. 2013 (COUGAR-02)] |
− | | style="background-color:#1a9851" |Phase | + | |2008-2012 |
− | |[[# | + | | style="background-color:#1a9851" |Phase 3 (E-esc) |
− | | style="background-color:#1a9850" |Superior OS | + | |[[Gastric_cancer_-_null_regimens#Best_supportive_care_2|Best supportive care]] |
+ | | style="background-color:#1a9850" |Superior OS (primary endpoint)<br>Median OS: 5.2 vs 3.6 mo<br>(HR 0.67, 95% CI 0.49-0.92) | ||
|- | |- | ||
|} | |} | ||
+ | <div class="toccolours" style="background-color:#b3e2cd"> | ||
====Chemotherapy==== | ====Chemotherapy==== | ||
− | *[[Docetaxel (Taxotere)]] 75 mg/m<sup>2</sup> IV once on day 1 | + | *[[Docetaxel (Taxotere)]] 75 mg/m<sup>2</sup> IV over 60 minutes once on day 1 |
− | |||
'''21-day cycle for up to 6 cycles''' | '''21-day cycle for up to 6 cycles''' | ||
− | + | </div></div> | |
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
===References=== | ===References=== | ||
− | # Kang JH, Lee SI, Lim DH, Park KW, Oh SY, Kwon HC, Hwang IG, Lee SC, Nam E, Shin DB, Lee J, Park JO, Park YS, Lim HY, Kang WK, Park SH. Salvage chemotherapy for pretreated gastric cancer: a randomized phase III trial comparing chemotherapy plus best supportive care with best supportive care alone. J Clin Oncol. 2012 May 1;30(13):1513-8. Epub 2012 Mar 12. Erratum in: J Clin Oncol. 2012 Aug 20;30(24):3035. [ | + | #'''SMC 2008-08-055:''' Kang JH, Lee SI, Lim DH, Park KW, Oh SY, Kwon HC, Hwang IG, Lee SC, Nam E, Shin DB, Lee J, Park JO, Park YS, Lim HY, Kang WK, Park SH. Salvage chemotherapy for pretreated gastric cancer: a randomized phase III trial comparing chemotherapy plus best supportive care with best supportive care alone. J Clin Oncol. 2012 May 1;30(13):1513-8. Epub 2012 Mar 12. Erratum in: J Clin Oncol. 2012 Aug 20;30(24):3035. [https://doi.org/10.1200/jco.2011.39.4585 link to original article] '''dosing details in abstract have been reviewed by our editors''' [https://pubmed.ncbi.nlm.nih.gov/22412140/ PubMed] [https://clinicaltrials.gov/study/NCT00821990 NCT00821990] |
− | # '''COUGAR-02:''' Ford HE, Marshall A, Bridgewater JA, Janowitz T, Coxon FY, Wadsley J, Mansoor W, Fyfe D, Madhusudan S, Middleton GW, Swinson D, Falk S, Chau I, Cunningham D, Kareclas P, Cook N, Blazeby JM, Dunn JA; COUGAR-02 Investigators. Docetaxel versus active symptom control for refractory oesophagogastric adenocarcinoma (COUGAR-02): an open-label, phase 3 randomised controlled trial. Lancet Oncol. 2014 Jan;15(1):78-86. Epub 2013 Dec 10. [https:// | + | #'''PEP0206:''' Roy AC, Park SR, Cunningham D, Kang YK, Chao Y, Chen LT, Rees C, Lim HY, Tabernero J, Ramos FJ, Kujundzic M, Cardic MB, Yeh CG, de Gramont A. A randomized phase II study of PEP02 (MM-398), irinotecan or docetaxel as a second-line therapy in patients with locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma. Ann Oncol. 2013 Jun;24(6):1567-73. Epub 2013 Feb 13. [https://doi.org/10.1093/annonc/mdt002 link to original article] [https://pubmed.ncbi.nlm.nih.gov/23406728/ PubMed] [https://clinicaltrials.gov/study/NCT00813072 NCT00813072] |
− | + | #'''COUGAR-02:''' Ford HE, Marshall A, Bridgewater JA, Janowitz T, Coxon FY, Wadsley J, Mansoor W, Fyfe D, Madhusudan S, Middleton GW, Swinson D, Falk S, Chau I, Cunningham D, Kareclas P, Cook N, Blazeby JM, Dunn JA; COUGAR-02 Investigators. Docetaxel versus active symptom control for refractory oesophagogastric adenocarcinoma (COUGAR-02): an open-label, phase 3 randomised controlled trial. Lancet Oncol. 2014 Jan;15(1):78-86. Epub 2013 Dec 10. [https://doi.org/10.1016/S1470-2045(13)70549-7 link to original article] '''dosing details in abstract have been reviewed by our editors''' [https://pubmed.ncbi.nlm.nih.gov/24332238/ PubMed] [https://clinicaltrials.gov/study/NCT00978549 NCT00978549] | |
+ | #'''INTEGRATEIIb:''' [https://clinicaltrials.gov/study/NCT04879368 NCT04879368] | ||
==Fluorouracil, Folinic acid, Mitomycin {{#subobject:b4ca9d|Regimen=1}}== | ==Fluorouracil, Folinic acid, Mitomycin {{#subobject:b4ca9d|Regimen=1}}== | ||
− | + | <div class="toccolours" style="background-color:#eeeeee"> | |
− | |||
− | |||
− | |||
===Regimen {{#subobject:672b28|Variant=1}}=== | ===Regimen {{#subobject:672b28|Variant=1}}=== | ||
− | {| class="wikitable" style="width: | + | {| class="wikitable sortable" style="width: 60%; text-align:center;" |
− | ! style="width: | + | !style="width: 33%"|Study |
− | ! style="width: | + | !style="width: 33%"|Dates of enrollment |
+ | !style="width: 33%"|[[Levels_of_Evidence#Evidence|Evidence]] | ||
|- | |- | ||
− | |[ | + | |[https://doi.org/10.1159/000064319 Hofheinz et al. 2002] |
− | | style="background-color:#ffffbe" |Phase | + | |1998-2000 |
+ | | style="background-color:#ffffbe" |Phase 2, fewer than 20 pts in this subgroup | ||
|- | |- | ||
|} | |} | ||
+ | <div class="toccolours" style="background-color:#b3e2cd"> | ||
====Chemotherapy==== | ====Chemotherapy==== | ||
− | *[[Fluorouracil (5-FU)]] 2600 mg/m<sup>2</sup> IV continuous infusion over 24 hours | + | *[[Fluorouracil (5-FU)]] 2600 mg/m<sup>2</sup> IV continuous infusion over 24 hours, started on days 1, 8, 15, 22, 29, 36 (total dose per cycle: 15,600 mg/m<sup>2</sup>) |
− | *[[Folinic acid | + | *[[Leucovorin (Folinic acid)]] 500 mg/m<sup>2</sup> IV over 2 hours once per day on days 1, 8, 15, 22, 29, 36 |
*[[Mitomycin (Mutamycin)]] 10 mg/m<sup>2</sup> IV once per day on days 1 & 22 | *[[Mitomycin (Mutamycin)]] 10 mg/m<sup>2</sup> IV once per day on days 1 & 22 | ||
− | |||
'''56-day cycle for 2 cycles''' | '''56-day cycle for 2 cycles''' | ||
− | + | </div></div> | |
===References=== | ===References=== | ||
− | # Hofheinz RD, Hartung G, Samel S, Hochhaus A, Pichlmeier U, Post S, Hehlmann R, Queisser W. High-dose 5-fluorouracil / folinic acid in combination with three-weekly mitomycin C in the treatment of advanced gastric cancer: a phase II study. Onkologie. 2002 Jun;25(3):255-60. [ | + | #Hofheinz RD, Hartung G, Samel S, Hochhaus A, Pichlmeier U, Post S, Hehlmann R, Queisser W. High-dose 5-fluorouracil / folinic acid in combination with three-weekly mitomycin C in the treatment of advanced gastric cancer: a phase II study. Onkologie. 2002 Jun;25(3):255-60. [https://doi.org/10.1159/000064319 link to original article] '''dosing details in abstract have been reviewed by our editors''' [https://pubmed.ncbi.nlm.nih.gov/12119460/ PubMed] |
− | |||
==Irinotecan monotherapy {{#subobject:6df2c0|Regimen=1}}== | ==Irinotecan monotherapy {{#subobject:6df2c0|Regimen=1}}== | ||
− | + | <div class="toccolours" style="background-color:#eeeeee"> | |
− | + | ===Regimen variant #1, 125 mg/m<sup>2</sup>, 4 weeks out of 6 {{#subobject:9fb427|Variant=1}}=== | |
− | + | {| class="wikitable sortable" style="width: 60%; text-align:center;" | |
− | + | !style="width: 33%"|Study | |
− | === | + | !style="width: 33%"|Dates of enrollment |
− | {| class="wikitable" style="width: | + | !style="width: 33%"|[[Levels_of_Evidence#Evidence|Evidence]] |
− | ! style="width: | ||
− | ! style="width: | ||
|- | |- | ||
− | |[ | + | |[https://doi.org/10.1007/s10620-005-3038-2 Enzinger et al. 2005] |
− | | style="background-color:#91cf61" |Phase | + | |1997-12 to 2000-08 |
+ | | style="background-color:#91cf61" |Phase 2 | ||
|- | |- | ||
|} | |} | ||
− | ''Note: In contrast to the primary references, some guidelines list a dosing schedule of 125 mg/m<sup>2</sup> IV once per day on days 1 & 8, with 21-day cycles. Enzinger et al. 2005 comment that "when irinotecan is used as a single-agent, a tri-weekly schedule may be preferable." | + | ''Note: In contrast to the primary references, some guidelines list a dosing schedule of 125 mg/m<sup>2</sup> IV once per day on days 1 & 8, with 21-day cycles. Enzinger et al. 2005 comment that "when irinotecan is used as a single-agent, a tri-weekly schedule may be preferable." This study included patients with GE junction and distal esophageal malignancy as well (~59% gastric, 9% GE junction and 33% distal esophagus), and showed a 14% response rate and 53% disease control rate.'' |
− | + | <div class="toccolours" style="background-color:#b3e2cd"> | |
− | |||
− | |||
− | |||
− | |||
====Chemotherapy==== | ====Chemotherapy==== | ||
*[[Irinotecan (Camptosar)]] 125 mg/m<sup>2</sup> IV over 90 minutes once per day on days 1, 8, 15, 22 | *[[Irinotecan (Camptosar)]] 125 mg/m<sup>2</sup> IV over 90 minutes once per day on days 1, 8, 15, 22 | ||
− | |||
'''42-day cycles''' | '''42-day cycles''' | ||
− | + | </div></div><br> | |
− | === | + | <div class="toccolours" style="background-color:#eeeeee"> |
− | {| class="wikitable" style="width: 100%; text-align:center;" | + | ===Regimen variant #2, 150 mg/m<sup>2</sup> q2wk {{#subobject:fa1ef9|Variant=1}}=== |
− | ! style="width: | + | {| class="wikitable sortable" style="width: 100%; text-align:center;" |
− | ! style="width: | + | ! style="width: 20%" |Study |
− | ! style="width: | + | ! style="width: 20%" |Dates of enrollment |
− | ! style="width: | + | ! style="width: 20%" |[[Levels_of_Evidence#Evidence|Evidence]] |
+ | ! style="width: 20%" |Comparator | ||
+ | ! style="width: 20%" |[[Levels_of_Evidence#Comparative_efficacy|Comparative Efficacy]] | ||
+ | |- | ||
+ | |[https://doi.org/10.1200/JCO.2012.48.5805 Hironaka et al. 2013 (WJOG 4007)] | ||
+ | |2007-2010 | ||
+ | | style="background-color:#1a9851" |Phase 3 (E-switch-ic) | ||
+ | |[[#Paclitaxel_monotherapy|Paclitaxel]] | ||
+ | | style="background-color:#ffffbf" |Did not meet primary endpoint of OS | ||
|- | |- | ||
− | |[ | + | |[https://doi.org/10.1016/j.ejca.2015.02.009 Nishikawa et al. 2015 (TRICS)] |
− | | style="background-color:#1a9851" |Phase | + | |2007-2011 |
− | |[[# | + | | style="background-color:#1a9851" |Phase 3 (C) |
− | | style="background-color:# | + | |[[#Cisplatin_.26_Irinotecan_.28IC.29|Cisplatin & Irinotecan]] |
+ | | style="background-color:#ffffbf" |Did not meet primary endpoint of OS | ||
|- | |- | ||
− | |[https:// | + | |[https://doi.org/10.1200/jco.2011.39.4585 Kang et al. 2012 (SMC 2008-08-055)] |
− | | style="background-color:#1a9851" |Phase | + | |2008-2010 |
− | |[[# | + | | style="background-color:#1a9851" |Phase 3 (E-esc) |
− | | style="background-color:# | + | |[[Gastric_cancer_-_null_regimens#Best_supportive_care_2|Best supportive care]] |
+ | | style="background-color:#1a9850" |Superior OS (primary endpoint)<br>Median OS: 5.3 vs 3.8 mo<br>(HR 0.66, 95% CI 0.485-0.89) | ||
|- | |- | ||
− | |[https:// | + | |[https://doi.org/10.1016/j.ejca.2014.01.020 Higuchi et al. 2014 (BIRIP)] |
− | | style="background-color:#1a9851" |Phase | + | |2008-2011 |
− | |[[#Cisplatin_. | + | | style="background-color:#1a9851" |Phase 3 (C) |
+ | |[[#Cisplatin_.26_Irinotecan_.28IC.29|Cisplatin & Irinotecan]] | ||
| style="background-color:#fc8d59" |Seems to have inferior PFS | | style="background-color:#fc8d59" |Seems to have inferior PFS | ||
|- | |- | ||
− | |[https:// | + | |[https://doi.org/10.1093/annonc/mdv265 Tanabe et al. 2015 (JACCRO GC-05)] |
− | + | |2008-2011 | |
− | + | | style="background-color:#1a9851" |Phase 3 (C) | |
− | + | |[[#Irinotecan_.26_S-1_999|Irinotecan & S-1]] | |
− | + | | style="background-color:#ffffbf" |Did not meet primary endpoint of OS | |
− | |||
− | | style="background-color:#1a9851" |Phase | ||
− | |Irinotecan & S-1 | ||
− | | style="background-color:#ffffbf" | | ||
|- | |- | ||
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6225815/ Bang et al. 2018 (JAVELIN Gastric 300)] | |[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6225815/ Bang et al. 2018 (JAVELIN Gastric 300)] | ||
− | | style="background-color:#1a9851" |Phase | + | |2015-2017 |
− | |Avelumab | + | | style="background-color:#1a9851" |Phase 3 (C) |
− | | style="background-color:#ffffbf" | | + | |[[#Avelumab_monotherapy_999|Avelumab]] |
+ | | style="background-color:#ffffbf" |Did not meet primary endpoint of OS | ||
|- | |- | ||
|} | |} | ||
− | '' | + | ''Note: WJOG 4007 had 3.7% patients with an ECOG PS of 2'' |
− | + | <div class="toccolours" style="background-color:#b3e2cd"> | |
====Chemotherapy==== | ====Chemotherapy==== | ||
*[[Irinotecan (Camptosar)]] 150 mg/m<sup>2</sup> IV once on day 1 | *[[Irinotecan (Camptosar)]] 150 mg/m<sup>2</sup> IV once on day 1 | ||
− | |||
'''14-day cycles''' | '''14-day cycles''' | ||
− | + | </div></div><br> | |
− | === | + | <div class="toccolours" style="background-color:#eeeeee"> |
− | {| class="wikitable" style="width: 100%; text-align:center;" | + | ===Regimen variant #3, 300 mg/m<sup>2</sup> q3wk {{#subobject:c410d|Variant=1}}=== |
− | !Study | + | {| class="wikitable sortable" style="width: 100%; text-align:center;" |
− | ![[Levels_of_Evidence#Evidence|Evidence]] | + | ! style="width: 20%" |Study |
− | !Comparator | + | ! style="width: 20%" |Dates of enrollment |
+ | ! style="width: 20%" |[[Levels_of_Evidence#Evidence|Evidence]] | ||
+ | ! style="width: 20%" |Comparator | ||
+ | ! style="width: 20%" |[[Levels_of_Evidence#Comparative_efficacy|Comparative Efficacy]] | ||
|- | |- | ||
− | |[ | + | |[https://doi.org/10.1093/annonc/mdt002 Roy et al. 2013 (PEP0206)] |
− | | style="background-color:#1a9851" |Randomized Phase | + | |2008-2010 |
− | |1. [[#Docetaxel_monotherapy|Docetaxel]]<br> 2. Irinotecan | + | | style="background-color:#1a9851" |Randomized Phase 2 (C) |
+ | |1. [[#Docetaxel_monotherapy|Docetaxel]]<br>2. [[#Irinotecan_liposomal_monotherapy|Irinotecan liposomal]] | ||
+ | | style="background-color:#ffffbf" |Did not meet primary endpoint of ORR | ||
|- | |- | ||
|} | |} | ||
− | '' | + | ''Note: this study included patients with GE junction malignancy (77% gastric, 23% GE junction) and included patients with ECOG PS of 2'' |
− | + | <div class="toccolours" style="background-color:#b3e2cd"> | |
====Chemotherapy==== | ====Chemotherapy==== | ||
*[[Irinotecan (Camptosar)]] 300 mg/m<sup>2</sup> IV over 90 minutes once on day 1 | *[[Irinotecan (Camptosar)]] 300 mg/m<sup>2</sup> IV over 90 minutes once on day 1 | ||
− | |||
'''21-day cycles''' | '''21-day cycles''' | ||
− | + | </div></div><br> | |
− | === | + | <div class="toccolours" style="background-color:#eeeeee"> |
− | {| class="wikitable" style="width: 100%; text-align:center;" | + | ===Regimen variant #4, 350 mg/m<sup>2</sup> q3wk {{#subobject:160f2f|Variant=1}}=== |
− | ! style="width: | + | {| class="wikitable sortable" style="width: 100%; text-align:center;" |
− | ! style="width: | + | ! style="width: 20%" |Study |
− | ! style="width: | + | ! style="width: 20%" |Dates of enrollment |
− | ! style="width: | + | ! style="width: 20%" |[[Levels_of_Evidence#Evidence|Evidence]] |
+ | ! style="width: 20%" |Comparator | ||
+ | ! style="width: 20%" |[[Levels_of_Evidence#Comparative_efficacy|Comparative Efficacy]] | ||
|- | |- | ||
− | |[https:// | + | |[https://doi.org/10.1016/j.ejca.2011.06.002 Thuss-Patience et al. 2011] |
− | | style="background-color:#1a9851" |Phase | + | |2002-2006 |
− | |[[# | + | | style="background-color:#1a9851" |Phase 3 (E-esc) |
− | | style="background-color:#91cf60" |Seems to have superior OS | + | |[[Gastric_cancer_-_null_regimens#Best_supportive_care_2|Best supportive care]] |
+ | | style="background-color:#91cf60" |Seems to have superior OS<br>Median OS: 4 vs 2.4 mo<br>(HR 0.48, 95% CI 0.25-0.92) | ||
|- | |- | ||
|} | |} | ||
− | ''Thuss-Patience et al. included patients with GE junction malignancy (~58% gastric, 43% GE junction) and included patients with ECOG of 2'' | + | ''Note: Thuss-Patience et al. 2011 included patients with GE junction malignancy (~58% gastric, 43% GE junction) and included patients with ECOG PS of 2.'' |
− | + | <div class="toccolours" style="background-color:#b3e2cd"> | |
====Chemotherapy==== | ====Chemotherapy==== | ||
*[[Irinotecan (Camptosar)]] as follows: | *[[Irinotecan (Camptosar)]] as follows: | ||
**Cycle 1: 250 mg/m<sup>2</sup> (maximum dose of 500 mg) IV over 30 minutes once on day 1 | **Cycle 1: 250 mg/m<sup>2</sup> (maximum dose of 500 mg) IV over 30 minutes once on day 1 | ||
**Cycles 2 to 10 (depending on toxicity): 350 mg/m<sup>2</sup> IV over 30 minutes once on day 1 | **Cycles 2 to 10 (depending on toxicity): 350 mg/m<sup>2</sup> IV over 30 minutes once on day 1 | ||
− | + | ====Supportive therapy==== | |
− | ====Supportive | + | *[[Atropine (Atropen)]] 0.25 mg SC once on day 1, given prior to irinotecan |
− | *[[Atropine (Atropen)]] 0.25 mg SC once on day 1, given prior to | + | *[[:Category:Serotonin_5-HT3_antagonists|5-HT3 antagonist]] |
− | *[[:Category:Serotonin_5-HT3_antagonists|5-HT3 antagonist]] | ||
*[[Dexamethasone (Decadron)]] | *[[Dexamethasone (Decadron)]] | ||
− | |||
'''21-day cycle for up to 10 cycles''' | '''21-day cycle for up to 10 cycles''' | ||
− | + | </div></div> | |
===References=== | ===References=== | ||
− | # Enzinger PC, Kulke MH, Clark JW, Ryan DP, Kim H, Earle CC, Vincitore MM, Michelini AL, Mayer RJ, Fuchs CS. A phase II trial of irinotecan in patients with previously untreated advanced esophageal and gastric adenocarcinoma. Dig Dis Sci. 2005 Dec;50(12):2218-23. [ | + | #Enzinger PC, Kulke MH, Clark JW, Ryan DP, Kim H, Earle CC, Vincitore MM, Michelini AL, Mayer RJ, Fuchs CS. A phase II trial of irinotecan in patients with previously untreated advanced esophageal and gastric adenocarcinoma. Dig Dis Sci. 2005 Dec;50(12):2218-23. [https://doi.org/10.1007/s10620-005-3038-2 link to original article] [https://pubmed.ncbi.nlm.nih.gov/16416165/ PubMed] |
− | # Thuss-Patience PC, Kretzschmar A, Bichev D, Deist T, Hinke A, Breithaupt K, Dogan Y, Gebauer B, Schumacher G, Reichardt P. Survival advantage for irinotecan versus best supportive care as second-line chemotherapy in gastric cancer--a randomised phase III study of the Arbeitsgemeinschaft Internistische Onkologie (AIO). Eur J Cancer. 2011 Oct;47(15):2306-14. [https:// | + | #Thuss-Patience PC, Kretzschmar A, Bichev D, Deist T, Hinke A, Breithaupt K, Dogan Y, Gebauer B, Schumacher G, Reichardt P. Survival advantage for irinotecan versus best supportive care as second-line chemotherapy in gastric cancer--a randomised phase III study of the Arbeitsgemeinschaft Internistische Onkologie (AIO). Eur J Cancer. 2011 Oct;47(15):2306-14. [https://doi.org/10.1016/j.ejca.2011.06.002 link to original article] '''dosing details in manuscript have been reviewed by our editors''' [https://pubmed.ncbi.nlm.nih.gov/21742485/ PubMed] [https://clinicaltrials.gov/study/NCT00144378 NCT00144378] |
− | # Kang JH, Lee SI, Lim DH, Park KW, Oh SY, Kwon HC, Hwang IG, Lee SC, Nam E, Shin DB, Lee J, Park JO, Park YS, Lim HY, Kang WK, Park SH. Salvage chemotherapy for pretreated gastric cancer: a randomized phase III trial comparing chemotherapy plus best supportive care with best supportive care alone. J Clin Oncol. 2012 May 1;30(13):1513-8. Epub 2012 Mar 12. Erratum in: J Clin Oncol. 2012 Aug 20;30(24):3035. [ | + | #'''SMC 2008-08-055:''' Kang JH, Lee SI, Lim DH, Park KW, Oh SY, Kwon HC, Hwang IG, Lee SC, Nam E, Shin DB, Lee J, Park JO, Park YS, Lim HY, Kang WK, Park SH. Salvage chemotherapy for pretreated gastric cancer: a randomized phase III trial comparing chemotherapy plus best supportive care with best supportive care alone. J Clin Oncol. 2012 May 1;30(13):1513-8. Epub 2012 Mar 12. Erratum in: J Clin Oncol. 2012 Aug 20;30(24):3035. [https://doi.org/10.1200/jco.2011.39.4585 link to original article] [https://pubmed.ncbi.nlm.nih.gov/22412140/ PubMed] [https://clinicaltrials.gov/study/NCT00821990 NCT00821990] |
− | # '''PEP0206:''' Roy AC, Park SR, Cunningham D, Kang YK, Chao Y, Chen LT, Rees C, Lim HY, Tabernero J, Ramos FJ, Kujundzic M, Cardic MB, Yeh CG, de Gramont A. A randomized phase II study of PEP02 (MM-398), irinotecan or docetaxel as a second-line therapy in patients with locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma. Ann Oncol. 2013 Jun;24(6):1567-73. Epub 2013 Feb 13. [ | + | #'''PEP0206:''' Roy AC, Park SR, Cunningham D, Kang YK, Chao Y, Chen LT, Rees C, Lim HY, Tabernero J, Ramos FJ, Kujundzic M, Cardic MB, Yeh CG, de Gramont A. A randomized phase II study of PEP02 (MM-398), irinotecan or docetaxel as a second-line therapy in patients with locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma. Ann Oncol. 2013 Jun;24(6):1567-73. Epub 2013 Feb 13. [https://doi.org/10.1093/annonc/mdt002 link to original article] [https://pubmed.ncbi.nlm.nih.gov/23406728/ PubMed] [https://clinicaltrials.gov/study/NCT00813072 NCT00813072] |
− | # '''WJOG 4007:''' Hironaka S, Ueda S, Yasui H, Nishina T, Tsuda M, Tsumura T, Sugimoto N, Shimodaira H, Tokunaga S, Moriwaki T, Esaki T, Nagase M, Fujitani K, Yamaguchi K, Ura T, Hamamoto Y, Morita S, Okamoto I, Boku N, Hyodo I. Randomized, open-label, phase III study comparing irinotecan with paclitaxel in patients with advanced gastric cancer without severe peritoneal metastasis after failure of prior combination chemotherapy using fluoropyrimidine plus platinum: WJOG 4007 trial. J Clin Oncol. 2013 Dec 10;31(35):4438-44. Epub 2013 Nov 4. [https:// | + | #'''WJOG 4007:''' Hironaka S, Ueda S, Yasui H, Nishina T, Tsuda M, Tsumura T, Sugimoto N, Shimodaira H, Tokunaga S, Moriwaki T, Esaki T, Nagase M, Fujitani K, Yamaguchi K, Ura T, Hamamoto Y, Morita S, Okamoto I, Boku N, Hyodo I. Randomized, open-label, phase III study comparing irinotecan with paclitaxel in patients with advanced gastric cancer without severe peritoneal metastasis after failure of prior combination chemotherapy using fluoropyrimidine plus platinum: WJOG 4007 trial. J Clin Oncol. 2013 Dec 10;31(35):4438-44. Epub 2013 Nov 4. [https://doi.org/10.1200/JCO.2012.48.5805 link to original artile] '''dosing details in abstract have been reviewed by our editors''' [https://pubmed.ncbi.nlm.nih.gov/24190112/ PubMed] UMIN000001252 |
− | # '''BIRIP:''' Higuchi K, Tanabe S, Shimada K, Hosaka H, Sasaki E, Nakayama N, Takeda Y, Moriwaki T, Amagai K, Sekikawa T, Sakuyama T, Kanda T, Sasaki T, Azuma M, Takahashi F, Takeuchi M, Koizumi W; Tokyo Cooperative Oncology Group | + | #'''BIRIP:''' Higuchi K, Tanabe S, Shimada K, Hosaka H, Sasaki E, Nakayama N, Takeda Y, Moriwaki T, Amagai K, Sekikawa T, Sakuyama T, Kanda T, Sasaki T, Azuma M, Takahashi F, Takeuchi M, Koizumi W; Tokyo Cooperative Oncology Group. Biweekly irinotecan plus cisplatin versus irinotecan alone as second-line treatment for advanced gastric cancer: a randomised phase III trial (TCOG GI-0801/BIRIP trial). Eur J Cancer. 2014 May;50(8):1437-45. Epub 2014 Feb 20. [https://doi.org/10.1016/j.ejca.2014.01.020 link to original article] '''dosing details in abstract have been reviewed by our editors''' [https://pubmed.ncbi.nlm.nih.gov/24560487/ PubMed] UMIN000001028 |
− | # '''TRICS:''' Nishikawa K, Fujitani K, Inagaki H, Akamaru Y, Tokunaga S, Takagi M, Tamura S, Sugimoto N, Shigematsu T, Yoshikawa T, Ishiguro T, Nakamura M, Morita S, Miyashita Y, Tsuburaya A, Sakamoto J, Tsujinaka T. Randomised phase III trial of second-line irinotecan plus cisplatin versus irinotecan alone in patients with advanced gastric cancer refractory to S-1 monotherapy: TRICS trial. Eur J Cancer. 2015 May;51(7):808-16. Epub 2015 Mar 18. [https:// | + | #'''TRICS:''' Nishikawa K, Fujitani K, Inagaki H, Akamaru Y, Tokunaga S, Takagi M, Tamura S, Sugimoto N, Shigematsu T, Yoshikawa T, Ishiguro T, Nakamura M, Morita S, Miyashita Y, Tsuburaya A, Sakamoto J, Tsujinaka T. Randomised phase III trial of second-line irinotecan plus cisplatin versus irinotecan alone in patients with advanced gastric cancer refractory to S-1 monotherapy: TRICS trial. Eur J Cancer. 2015 May;51(7):808-16. Epub 2015 Mar 18. [https://doi.org/10.1016/j.ejca.2015.02.009 link to original article] '''dosing details in abstract have been reviewed by our editors''' [https://pubmed.ncbi.nlm.nih.gov/25797356/ PubMed] UMIN000002571 |
− | # '''JACCRO GC-05:''' Tanabe K, Fujii M, Nishikawa K, Kunisaki C, Tsuji A, Matsuhashi N, Takagane A, Ohno T, Kawase T, Kochi M, Yoshida K, Kakeji Y, Ichikawa W, Chin K, Terashima M, Takeuchi M, Nakajima T; JACCRO | + | #'''JACCRO GC-05:''' Tanabe K, Fujii M, Nishikawa K, Kunisaki C, Tsuji A, Matsuhashi N, Takagane A, Ohno T, Kawase T, Kochi M, Yoshida K, Kakeji Y, Ichikawa W, Chin K, Terashima M, Takeuchi M, Nakajima T; JACCRO. Phase II/III study of second-line chemotherapy comparing irinotecan-alone with S-1 plus irinotecan in advanced gastric cancer refractory to first-line treatment with S-1 (JACCRO GC-05). Ann Oncol. 2015 Sep;26(9):1916-22. Epub 2015 Jun 24. [https://doi.org/10.1093/annonc/mdv265 link to original article] [https://pubmed.ncbi.nlm.nih.gov/26109630/ PubMed] [https://clinicaltrials.gov/study/NCT00639327 NCT00639327] |
− | # '''JAVELIN Gastric 300:''' Bang YJ, Ruiz | + | #'''JAVELIN Gastric 300:''' Bang YJ, Yanez Ruiz E, Van Cutsem E, Lee KW, Wyrwicz L, Schenker M, Alsina M, Ryu MH, Chung HC, Evesque L, Al-Batran SE, Park SH, Lichinitser M, Boku N, Moehler MH, Hong J, Xiong H, Hallwachs R, Conti I, Taieb J. Phase III, randomised trial of avelumab versus physician's choice of chemotherapy as third-line treatment of patients with advanced gastric or gastro-oesophageal junction cancer: primary analysis of JAVELIN Gastric 300. Ann Oncol. 2018 Oct 1;29(10):2052-2060. [https://doi.org/10.1093/annonc/mdy264 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6225815/ link to PMC article] '''dosing details in abstract have been reviewed by our editors''' [https://pubmed.ncbi.nlm.nih.gov/30052729/ PubMed] [https://clinicaltrials.gov/study/NCT02625623 NCT02625623] |
− | + | #'''INTEGRATEIIb:''' [https://clinicaltrials.gov/study/NCT04879368 NCT04879368] | |
==Irinotecan liposomal monotherapy {{#subobject:9a99c8|Regimen=1}}== | ==Irinotecan liposomal monotherapy {{#subobject:9a99c8|Regimen=1}}== | ||
− | {| class="wikitable" style=" | + | <div class="toccolours" style="background-color:#eeeeee"> |
+ | ===Regimen {{#subobject:c50e15|Variant=1}}=== | ||
+ | {| class="wikitable sortable" style="width: 100%; text-align:center;" | ||
+ | ! style="width: 20%" |Study | ||
+ | ! style="width: 20%" |Dates of enrollment | ||
+ | ! style="width: 20%" |[[Levels_of_Evidence#Evidence|Evidence]] | ||
+ | ! style="width: 20%" |Comparator | ||
+ | ! style="width: 20%" |[[Levels_of_Evidence#Comparative_efficacy|Comparative Efficacy]] | ||
+ | |- | ||
+ | |[https://doi.org/10.1093/annonc/mdt002 Roy et al. 2013 (PEP0206)] | ||
+ | |2008-2010 | ||
+ | | style="background-color:#1a9851" |Randomized Phase 2 (E-switch-ic) | ||
+ | |1. [[#Docetaxel_monotherapy|Docetaxel]]<br>2. [[#Irinotecan_monotherapy|Irinotecan]] | ||
+ | | style="background-color:#ffffbf" |Did not meet primary endpoint of ORR | ||
|- | |- | ||
− | |||
|} | |} | ||
− | ===Regimen {{#subobject: | + | <div class="toccolours" style="background-color:#b3e2cd"> |
− | {| class="wikitable" style="width: | + | ====Chemotherapy==== |
− | !Study | + | *[[Irinotecan liposome (Onivyde)]] 120 mg/m<sup>2</sup> IV over 90 minutes once on day 1 |
− | ![[Levels_of_Evidence#Evidence|Evidence]] | + | '''21-day cycles''' |
− | + | </div></div> | |
+ | ===References=== | ||
+ | #'''PEP0206:''' Roy AC, Park SR, Cunningham D, Kang YK, Chao Y, Chen LT, Rees C, Lim HY, Tabernero J, Ramos FJ, Kujundzic M, Cardic MB, Yeh CG, de Gramont A. A randomized phase II study of PEP02 (MM-398), irinotecan or docetaxel as a second-line therapy in patients with locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma. Ann Oncol. 2013 Jun;24(6):1567-73. Epub 2013 Feb 13. [https://doi.org/10.1093/annonc/mdt002 link to original article] '''dosing details in manuscript have been reviewed by our editors''' [https://pubmed.ncbi.nlm.nih.gov/23406728/ PubMed] [https://clinicaltrials.gov/study/NCT00813072 NCT00813072] | ||
+ | |||
+ | ==Irinotecan & Mitomycin {{#subobject:dfc95f|Regimen=1}}== | ||
+ | <div class="toccolours" style="background-color:#eeeeee"> | ||
+ | ===Regimen {{#subobject:3213a7|Variant=1}}=== | ||
+ | {| class="wikitable sortable" style="width: 60%; text-align:center;" | ||
+ | !style="width: 33%"|Study | ||
+ | !style="width: 33%"|Dates of enrollment | ||
+ | !style="width: 33%"|[[Levels_of_Evidence#Evidence|Evidence]] | ||
|- | |- | ||
− | |[https:// | + | |[https://doi.org/10.1179/joc.2003.15.3.275 Bamias et al. 2003a] |
− | | style="background-color:# | + | |1999-07 to 2001-02 |
− | + | | style="background-color:#91cf61" |Phase 2 | |
|- | |- | ||
|} | |} | ||
+ | ''Note: Patients had advanced gastric and colorectal cancers.'' | ||
+ | <div class="toccolours" style="background-color:#cbd5e8"> | ||
+ | ====Prior treatment criteria==== | ||
+ | *5-fluorouracil-based chemotherapy | ||
+ | </div> | ||
+ | <div class="toccolours" style="background-color:#b3e2cd"> | ||
====Chemotherapy==== | ====Chemotherapy==== | ||
− | |||
− | + | *[[Irinotecan (Camptosar)]] 125 mg/m<sup>2</sup> IV once on day 1 | |
+ | *[[Mitomycin (Mutamycin)]] 5 mg/m<sup>2</sup> IV once on day 1 | ||
+ | '''14-day cycles''' | ||
+ | </div></div> | ||
===References=== | ===References=== | ||
− | # | + | |
+ | #Bamias A, Papamichael D, Syrigos K, Pavlidis N. Phase II study of irinotecan and mitomycin C in 5-fluorouracil-pretreated patients with advanced colorectal and gastric cancer. J Chemother. 2003 Jun;15(3):275-81. [https://doi.org/10.1179/joc.2003.15.3.275 link to original article] '''dosing details in abstract have been reviewed by our editors''' [https://pubmed.ncbi.nlm.nih.gov/12868555/ PubMed] | ||
==Nivolumab monotherapy {{#subobject:7011e1|Regimen=1}}== | ==Nivolumab monotherapy {{#subobject:7011e1|Regimen=1}}== | ||
− | + | <div class="toccolours" style="background-color:#eeeeee"> | |
− | |||
− | |||
− | |||
===Regimen {{#subobject:#f2fd8e|Variant=1}}=== | ===Regimen {{#subobject:#f2fd8e|Variant=1}}=== | ||
− | {| class="wikitable" style="width: 100%; text-align:center;" | + | {| class="wikitable sortable" style="width: 100%; text-align:center;" |
− | ! style="width: | + | ! style="width: 20%" |Study |
− | ! style="width: | + | ! style="width: 20%" |Dates of enrollment |
− | ! style="width: | + | ! style="width: 20%" |[[Levels_of_Evidence#Evidence|Evidence]] |
− | ! style="width: | + | ! style="width: 20%" |Comparator |
− | + | ! style="width: 20%" |[[Levels_of_Evidence#Comparative_efficacy|Comparative Efficacy]] | |
− | |||
− | |||
− | |||
− | |||
|- | |- | ||
− | |[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6161834/ Janjigian et al. 2018 (CheckMate | + | |[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6161834/ Janjigian et al. 2018 (CheckMate 032<sub>UGI</sub>)] |
− | | style="background-color:#91cf61" |Phase | + | |2013-2015 |
+ | | style="background-color:#91cf61" |Phase 1/2 | ||
| style="background-color:#d3d3d3" | | | style="background-color:#d3d3d3" | | ||
| style="background-color:#d3d3d3" | | | style="background-color:#d3d3d3" | | ||
+ | |- | ||
+ | |[https://doi.org/10.1016/S0140-6736(17)31827-5 Kang et al. 2017 (ATTRACTION-2)] | ||
+ | |2014-2016 | ||
+ | | style="background-color:#1a9851" |Phase 3 (E-esc) | ||
+ | |[[Gastric_cancer_-_null_regimens#Placebo|Placebo]] | ||
+ | | style="background-color:#1a9850" |Superior OS<sup>1</sup> (primary endpoint)<br>Median OS: 5.3 vs 4.1 mo<br>(HR 0.62, 95% CI 0.50-0.75) | ||
|- | |- | ||
|} | |} | ||
− | ''ATTRACTION-2 included patients with GE junction malignancy (82.6% gastric, 8.5% GE junction) and 12.3% of patients had a PD-L1 CPS score of at least 1'' | + | ''<sup>1</sup>Reported efficacy for ATTRACTION-2 is based on the 2021 update.''<br> |
− | + | ''Note: ATTRACTION-2 included patients with GE junction malignancy (82.6% gastric, 8.5% GE junction) and 12.3% of patients had a PD-L1 CPS score of at least 1'' | |
+ | <div class="toccolours" style="background-color:#b3e2cd"> | ||
====Immunotherapy==== | ====Immunotherapy==== | ||
*[[Nivolumab (Opdivo)]] 3 mg/kg IV once on day 1 | *[[Nivolumab (Opdivo)]] 3 mg/kg IV once on day 1 | ||
− | |||
'''14-day cycles''' | '''14-day cycles''' | ||
− | + | </div></div> | |
===References=== | ===References=== | ||
− | # '''ATTRACTION-2:''' Kang YK, Boku N, Satoh T, Ryu MH, Chao Y, Kato K, Chung HC, Chen JS, Muro K, Kang WK, Yeh KH, Yoshikawa T, Oh SC, Bai LY, Tamura T, Lee KW, Hamamoto Y, Kim JG, Chin K, Oh DY, Minashi K, Cho JY, Tsuda M, Chen LT. Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2017 Dec 2;390(10111):2461-2471. Epub 2017 Oct 6. [https:// | + | #'''ATTRACTION-2:''' Kang YK, Boku N, Satoh T, Ryu MH, Chao Y, Kato K, Chung HC, Chen JS, Muro K, Kang WK, Yeh KH, Yoshikawa T, Oh SC, Bai LY, Tamura T, Lee KW, Hamamoto Y, Kim JG, Chin K, Oh DY, Minashi K, Cho JY, Tsuda M, Chen LT. Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2017 Dec 2;390(10111):2461-2471. Epub 2017 Oct 6. [https://doi.org/10.1016/S0140-6736(17)31827-5 link to original article] '''dosing details in manuscript have been reviewed by our editors''' [https://pubmed.ncbi.nlm.nih.gov/28993052/ PubMed] [https://clinicaltrials.gov/study/NCT02267343 NCT02267343] |
− | ## '''Subgroup analysis:''' Kato K, Satoh T, Muro K, Yoshikawa T, Tamura T, Hamamoto Y, Chin K, Minashi K, Tsuda M, Yamaguchi K, Machida N, Esaki T, Goto M, Komatsu Y, Nakajima TE, Sugimoto N, Yoshida K, Oki E, Nishina T, Tsuji A, Fujii H, Kunieda K, Saitoh S, Omuro Y, Azuma M, Iwamoto Y, Taku K, Fushida S, Chen LT, Kang YK, Boku N. A subanalysis of Japanese patients in a randomized, double-blind, placebo-controlled, phase 3 trial of nivolumab for patients with advanced gastric or gastro-esophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2). Gastric Cancer. 2019 Mar;22(2):344-354. Epub 2018 Dec 1. [https://link. | + | ##'''Subgroup analysis:''' Kato K, Satoh T, Muro K, Yoshikawa T, Tamura T, Hamamoto Y, Chin K, Minashi K, Tsuda M, Yamaguchi K, Machida N, Esaki T, Goto M, Komatsu Y, Nakajima TE, Sugimoto N, Yoshida K, Oki E, Nishina T, Tsuji A, Fujii H, Kunieda K, Saitoh S, Omuro Y, Azuma M, Iwamoto Y, Taku K, Fushida S, Chen LT, Kang YK, Boku N. A subanalysis of Japanese patients in a randomized, double-blind, placebo-controlled, phase 3 trial of nivolumab for patients with advanced gastric or gastro-esophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2). Gastric Cancer. 2019 Mar;22(2):344-354. Epub 2018 Dec 1. [https://doi.org/10.1007/s10120-018-0899-6 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6394726/ link to original article] [https://pubmed.ncbi.nlm.nih.gov/30506519/ PubMed] |
− | # '''CheckMate | + | ##'''Update:''' Chen LT, Satoh T, Ryu MH, Chao Y, Kato K, Chung HC, Chen JS, Muro K, Kang WK, Yeh KH, Yoshikawa T, Oh SC, Bai LY, Tamura T, Lee KW, Hamamoto Y, Kim JG, Chin K, Oh DY, Minashi K, Cho JY, Tsuda M, Sameshima H, Kang YK, Boku N. A phase 3 study of nivolumab in previously treated advanced gastric or gastroesophageal junction cancer (ATTRACTION-2): 2-year update data. Gastric Cancer. 2020 May;23(3):510-519. Epub 2019 Dec 20. [https://doi.org/10.1007/s10120-019-01034-7 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/pmc7165140/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/31863227/ PubMed] |
+ | ##'''Update:''' Boku N, Satoh T, Ryu MH, Chao Y, Kato K, Chung HC, Chen JS, Muro K, Kang WK, Yeh KH, Yoshikawa T, Oh SC, Bai LY, Tamura T, Lee KW, Hamamoto Y, Kim JG, Chin K, Oh DY, Minashi K, Cho JY, Tsuda M, Nishiyama T, Chen LT, Kang YK. Nivolumab in previously treated advanced gastric cancer (ATTRACTION-2): 3-year update and outcome of treatment beyond progression with nivolumab. Gastric Cancer. 2021 Jul;24(4):946-958. Epub 2021 Mar 20. [https://doi.org/10.1007/s10120-021-01173-w link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/pmc8205916/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/33743112/ PubMed] | ||
+ | #'''CheckMate 032<sub>UGI</sub>:''' Janjigian YY, Bendell J, Calvo E, Kim JW, Ascierto PA, Sharma P, Ott PA, Peltola K, Jaeger D, Evans J, de Braud F, Chau I, Harbison CT, Dorange C, Tschaika M, Le DT. CheckMate 032 Study: Efficacy and Safety of Nivolumab and Nivolumab Plus Ipilimumab in Patients With Metastatic Esophagogastric Cancer. J Clin Oncol. 2018 Oct 1;36(28):2836-2844. Epub 2018 Aug 15. [https://doi.org/10.1200/JCO.2017.76.6212 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6161834/ link to PMC article] '''dosing details in manuscript have been reviewed by our editors''' [https://pubmed.ncbi.nlm.nih.gov/30110194/ PubMed] [https://clinicaltrials.gov/study/NCT01928394 NCT01928394] | ||
==Paclitaxel monotherapy {{#subobject:2dcad9|Regimen=1}}== | ==Paclitaxel monotherapy {{#subobject:2dcad9|Regimen=1}}== | ||
− | + | <div class="toccolours" style="background-color:#eeeeee"> | |
− | + | ===Regimen variant #1, 70 mg/m<sup>2</sup>, 3 out of 4 weeks {{#subobject:gg21e8|Variant=1}}=== | |
− | + | {| class="wikitable sortable" style="width: 100%; text-align:center;" | |
− | + | ! style="width: 20%" |Study | |
− | === | + | ! style="width: 20%" |Dates of enrollment |
− | {| class="wikitable" style="width: 100%; text-align:center;" | + | ! style="width: 20%" |[[Levels_of_Evidence#Evidence|Evidence]] |
− | ! style="width: | + | ! style="width: 20%" |Comparator |
− | ! style="width: | + | ! style="width: 20%" |[[Levels_of_Evidence#Comparative_efficacy|Comparative Efficacy]] |
− | ! style="width: | ||
− | ! style="width: | ||
|- | |- | ||
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6324622/ Lee et al. 2018 (KCSG ST10-01)] | |[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6324622/ Lee et al. 2018 (KCSG ST10-01)] | ||
− | | style="background-color:#1a9851" |Phase | + | |2011-2015 |
+ | | style="background-color:#1a9851" |Phase 3 (C) | ||
|[[#Irinotecan_monotherapy_2|Irinotecan]] | |[[#Irinotecan_monotherapy_2|Irinotecan]] | ||
− | | style="background-color:#ffffbf" |Inconclusive whether non-inferior | + | | style="background-color:#ffffbf" |Inconclusive whether non-inferior PFS |
|- | |- | ||
|} | |} | ||
+ | <div class="toccolours" style="background-color:#b3e2cd"> | ||
====Chemotherapy==== | ====Chemotherapy==== | ||
*[[Paclitaxel (Taxol)]] 70 mg/m<sup>2</sup> IV once per day on days 1, 8, 15 | *[[Paclitaxel (Taxol)]] 70 mg/m<sup>2</sup> IV once per day on days 1, 8, 15 | ||
− | |||
'''28-day cycles''' | '''28-day cycles''' | ||
− | + | </div></div><br> | |
− | === | + | <div class="toccolours" style="background-color:#eeeeee"> |
− | {| class="wikitable" style="width: | + | ===Regimen variant #2, 80 mg/m<sup>2</sup> weekly {{#subobject:0e8f41|Variant=1}}=== |
− | ! style="width: | + | {| class="wikitable sortable" style="width: 60%; text-align:center;" |
− | ! style="width: | + | !style="width: 33%"|Study |
− | + | !style="width: 33%"|Dates of enrollment | |
− | ! style="width: | + | !style="width: 33%"|[[Levels_of_Evidence#Evidence|Evidence]] |
− | |||
− | |||
− | |||
− | |||
− | |||
|- | |- | ||
− | |[https:// | + | |[https://ar.iiarjournals.org/content/27/4C/2667.long Kodera et al. 2007 (CCOG0302)] |
− | | | + | |2003-2006 |
− | + | | style="background-color:#91cf61" |Phase 2 | |
− | | style="background-color:# | ||
|- | |- | ||
|} | |} | ||
− | + | <div class="toccolours" style="background-color:#b3e2cd"> | |
− | |||
− | |||
====Chemotherapy==== | ====Chemotherapy==== | ||
− | *[[Paclitaxel (Taxol)]] 80 mg/m<sup>2</sup> IV once | + | *[[Paclitaxel (Taxol)]] 80 mg/m<sup>2</sup> IV once on day 1 |
− | + | '''7-day cycles''' | |
− | ''' | + | </div></div><br> |
− | + | <div class="toccolours" style="background-color:#eeeeee"> | |
− | === | + | ===Regimen variant #3, 80 mg/m<sup>2</sup>, 3 out of 4 weeks {{#subobject:dd21e8|Variant=1}}=== |
− | {| class="wikitable" style="width: 100%; text-align:center;" | + | {| class="wikitable sortable" style="width: 100%; text-align:center;" |
− | ! style="width: | + | ! style="width: 20%" |Study |
− | ! style="width: | + | ! style="width: 20%" |Dates of enrollment |
− | ! style="width: | + | ! style="width: 20%" |[[Levels_of_Evidence#Evidence|Evidence]] |
− | ! style="width: | + | ! style="width: 20%" |Comparator |
+ | ! style="width: 20%" |[[Levels_of_Evidence#Comparative_efficacy|Comparative Efficacy]] | ||
|- | |- | ||
− | |[https:// | + | |[https://doi.org/10.1007/s10120-005-0351-6 Hironaka et al. 2006] |
+ | |2002-2004 | ||
| style="background-color:#91cf61" |Non-randomized | | style="background-color:#91cf61" |Non-randomized | ||
| style="background-color:#d3d3d3" | | | style="background-color:#d3d3d3" | | ||
| style="background-color:#d3d3d3" | | | style="background-color:#d3d3d3" | | ||
|- | |- | ||
− | |[https:// | + | |[https://doi.org/10.1200/JCO.2012.48.5805 Hironaka et al. 2013 (WJOG 4007)] |
− | | style="background-color:#1a9851" |Phase | + | |2007-2010 |
+ | | style="background-color:#1a9851" |Phase 3 (E-switch-ic) | ||
|[[#Irinotecan_monotherapy_2|Irinotecan]] | |[[#Irinotecan_monotherapy_2|Irinotecan]] | ||
− | | style="background-color:#ffffbf" | | + | | style="background-color:#ffffbf" |Did not meet primary endpoint of OS<br>Median OS: 9.5 vs 8.4 mo<br>(HR 0.88, 95% CI 0.67-1.16) |
− | |||
− | |||
− | |||
− | |||
− | |||
|- | |- | ||
− | |[https:// | + | |[https://doi.org/10.1016/S1470-2045%2814%2970420-6 Wilke et al. 2014 (RAINBOW)] |
− | | style="background-color:#1a9851" |Phase | + | |2010-2012 |
+ | | style="background-color:#1a9851" |Phase 3 (C) | ||
|[[#Paclitaxel_.26_Ramucirumab|Paclitaxel & Ramucirumab]] | |[[#Paclitaxel_.26_Ramucirumab|Paclitaxel & Ramucirumab]] | ||
| style="background-color:#fc8d59" |Seems to have inferior OS | | style="background-color:#fc8d59" |Seems to have inferior OS | ||
|- | |- | ||
− | | rowspan="2" |[https:// | + | |[https://doi.org/10.1002/ijc.33025 Lorenzen et al. 2020 (RADPAC)] |
− | | rowspan="2" style="background-color:#1a9851" |Phase | + | |2011-2015 |
+ | | style="background-color:#1a9851" |Phase 3 (C) | ||
+ | |[[#Everolimus_.26_Paclitaxel_999|Everolimus & Paclitaxel]] | ||
+ | | style="background-color:#ffffbf" |Did not meet primary endpoint of OS | ||
+ | |- | ||
+ | | rowspan="2" |[https://doi.org/10.1016/S2468-1253(16)30219-9 Shitara et al. 2017 (ABSOLUTE)] | ||
+ | | rowspan="2" |2013-2015 | ||
+ | | rowspan="2" style="background-color:#1a9851" |Phase 3 (C) | ||
|1. [[#nab-Paclitaxel_monotherapy|nab-Paclitaxel]] weekly | |1. [[#nab-Paclitaxel_monotherapy|nab-Paclitaxel]] weekly | ||
| style="background-color:#eeee01" |Non-inferior OS | | style="background-color:#eeee01" |Non-inferior OS | ||
Line 2,546: | Line 3,944: | ||
| style="background-color:#d9ef8b" |Might have superior OS | | style="background-color:#d9ef8b" |Might have superior OS | ||
|- | |- | ||
− | |[https:// | + | |[https://doi.org/10.1016/S1470-2045(17)30682-4 Bang et al. 2017 (GOLD)] |
− | | style="background-color:#1a9851" |Phase | + | |2013-2016 |
− | |Olaparib & Paclitaxel | + | | style="background-color:#1a9851" |Phase 3 (C) |
+ | |[[#Olaparib_.26_Paclitaxel_333|Olaparib & Paclitaxel]] | ||
| style="background-color:#fee08b" |Might have inferior OS | | style="background-color:#fee08b" |Might have inferior OS | ||
|- | |- | ||
− | |[https://www. | + | |[https://www.ncbi.nlm.nih.gov/pmc/articles/pmc9433958/ Shah et al. 2022 (BRIGHTER)] |
− | | style="background-color:#1a9851" |Phase | + | |2014-10-02 to 2016-12-12 |
+ | | style="background-color:#1a9851" |Phase 3 (C) | ||
+ | |[[#Napabucasin_.26_Paclitaxel_777|Napabucasin & Paclitaxel]] | ||
+ | | style="background-color:#ffffbf" |Did not meet primary endpoint of OS | ||
+ | |- | ||
+ | |[https://doi.org/10.1016/S0140-6736(18)31257-1 Shitara et al. 2018 (KEYNOTE-061)] | ||
+ | |2015-06-04 to 2016-07-26 | ||
+ | | style="background-color:#1a9851" |Phase 3 (C) | ||
|[[#Pembrolizumab_monotherapy|Pembrolizumab]] | |[[#Pembrolizumab_monotherapy|Pembrolizumab]] | ||
− | | style="background-color:# | + | | style="background-color:#fc8d59" |Seems to have inferior OS<sup>1</sup> |
|- | |- | ||
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6225815/ Bang et al. 2018 (JAVELIN Gastric 300)] | |[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6225815/ Bang et al. 2018 (JAVELIN Gastric 300)] | ||
− | | style="background-color:#1a9851" |Phase | + | |2015-2017 |
− | |Avelumab | + | | style="background-color:#1a9851" |Phase 3 (C) |
− | | style="background-color:#ffffbf" |Seems not | + | |[[#Avelumab_monotherapy_999|Avelumab]] |
+ | | style="background-color:#ffffbf" |Did not meet primary endpoint of OS | ||
+ | |- | ||
+ | |[https://www.ncbi.nlm.nih.gov/pmc/articles/pmc9299889/ Chung et al. 2021 (KEYNOTE-063)] | ||
+ | |2017-02-16 to 2018-03-12 | ||
+ | | style="background-color:#1a9851" |Phase 3 (C) | ||
+ | |[[#Pembrolizumab_monotherapy|Pembrolizumab]] | ||
+ | | style="background-color:#91cf60" |Seems to have superior PFS (co-primary endpoint)<br>Median PFS: 4 vs 2 mo<br>(HR 0.62, 95% CI 0.40-0.96)<br><br>Did not meet co-primary endpoint of OS | ||
+ | |- | ||
+ | |[https://doi.org/10.1016/s2468-1253(21)00313-7 Xu et al. 2021 (RAINBOW-Asia)] | ||
+ | |2017-2020 | ||
+ | | style="background-color:#1a9851" |Phase 3 (C) | ||
+ | |[[#Paclitaxel_.26_Ramucirumab|Paclitaxel & Ramucirumab]] | ||
+ | | style="background-color:#fc8d59" |Seems to have inferior PFS | ||
|- | |- | ||
|} | |} | ||
− | '' | + | ''<sup>1</sup>Reported efficacy is based on the 2021 update, for the CPS at least 1 group.''<br> |
− | + | ''Note: RAINBOW included patients with GE junction malignancy (79% gastric, 21% GE junction). Satoh et al. patients had 98.5% gastric, 1.5% other. WJOG 4007 had 3.7% patients with a PFS of 2.'' | |
− | ''RAINBOW included patients with GE junction malignancy (79% gastric, 21% GE junction) | + | <div class="toccolours" style="background-color:#fdcdac"> |
− | + | ====Prior treatment criteria==== | |
− | + | *RAINBOW: documented objective radiological or clinical disease progression during or within 4 months of the last dose of first-line platinum and fluoropyrimidine doublet with or without anthracycline | |
− | + | </div> | |
− | + | <div class="toccolours" style="background-color:#b3e2cd"> | |
− | |||
====Chemotherapy==== | ====Chemotherapy==== | ||
*[[Paclitaxel (Taxol)]] 80 mg/m<sup>2</sup> IV over 60 minutes once per day on days 1, 8, 15 | *[[Paclitaxel (Taxol)]] 80 mg/m<sup>2</sup> IV over 60 minutes once per day on days 1, 8, 15 | ||
− | |||
'''28-day cycles''' | '''28-day cycles''' | ||
− | + | </div></div><br> | |
− | === | + | <div class="toccolours" style="background-color:#eeeeee"> |
− | {| class="wikitable" style="width: 100%; text-align:center;" | + | ===Regimen variant #4, 175 mg/m<sup>2</sup> q3wk {{#subobject:a4bdf6|Variant=1}}=== |
− | ! style="width: | + | {| class="wikitable sortable" style="width: 100%; text-align:center;" |
− | ! style="width: | + | ! style="width: 20%" |Study |
− | ! style="width: | + | ! style="width: 20%" |Dates of enrollment |
− | ! style="width: | + | ! style="width: 20%" |[[Levels_of_Evidence#Evidence|Evidence]] |
+ | ! style="width: 20%" |Comparator | ||
+ | ! style="width: 20%" |[[Levels_of_Evidence#Comparative_efficacy|Comparative Efficacy]] | ||
|- | |- | ||
− | |[https:// | + | |[https://doi.org/10.1093/annonc/mdy055 Kang et al. 2018 (DREAM)] |
− | | style="background-color:#1a9851" |Phase | + | |2013-2015 |
− | | | + | | style="background-color:#1a9851" |Phase 3 (C) |
+ | |[[#DHP-107_monotherapy_777|DHP-107]] | ||
| style="background-color:#eeee01" |Non-inferior PFS | | style="background-color:#eeee01" |Non-inferior PFS | ||
|- | |- | ||
|} | |} | ||
+ | <div class="toccolours" style="background-color:#b3e2cd"> | ||
====Chemotherapy==== | ====Chemotherapy==== | ||
*[[Paclitaxel (Taxol)]] 175 mg/m<sup>2</sup> IV once on day 1 | *[[Paclitaxel (Taxol)]] 175 mg/m<sup>2</sup> IV once on day 1 | ||
− | |||
'''21-day cycles''' | '''21-day cycles''' | ||
− | + | </div></div> | |
===References=== | ===References=== | ||
− | # Hironaka S, Zenda S, Boku N, Fukutomi A, Yoshino T, Onozawa Y. Weekly paclitaxel as second-line chemotherapy for advanced or recurrent gastric cancer. Gastric Cancer. 2006;9(1):14-8. [https:// | + | #Hironaka S, Zenda S, Boku N, Fukutomi A, Yoshino T, Onozawa Y. Weekly paclitaxel as second-line chemotherapy for advanced or recurrent gastric cancer. Gastric Cancer. 2006;9(1):14-8. [https://doi.org/10.1007/s10120-005-0351-6 link to original article] '''dosing details in manuscript have been reviewed by our editors''' [https://pubmed.ncbi.nlm.nih.gov/16557431/ PubMed] |
− | # '''CCOG0302:''' Kodera Y, Ito S, Mochizuki Y, Fujitake S, Koshikawa K, Kanyama Y, Matsui T, Kojima H, Takase T, Ohashi N, Fujiwara M, Sakamoto J, Akimasa N; Chubu Clinical Cancer Group. A phase II study of weekly paclitaxel as second-line chemotherapy for advanced gastric cancer (CCOG0302 study). Anticancer Res. 2007 Jul-Aug;27(4C):2667-71. [ | + | #'''CCOG0302:''' Kodera Y, Ito S, Mochizuki Y, Fujitake S, Koshikawa K, Kanyama Y, Matsui T, Kojima H, Takase T, Ohashi N, Fujiwara M, Sakamoto J, Akimasa N; Chubu Clinical Cancer Group. A phase II study of weekly paclitaxel as second-line chemotherapy for advanced gastric cancer (CCOG0302 study). Anticancer Res. 2007 Jul-Aug;27(4C):2667-71. [https://ar.iiarjournals.org/content/27/4C/2667.long link to original article] '''dosing details in abstract have been reviewed by our editors''' [https://pubmed.ncbi.nlm.nih.gov/17695430/ PubMed] |
− | # '''WJOG 4007:''' Hironaka S, Ueda S, Yasui H, Nishina T, Tsuda M, Tsumura T, Sugimoto N, Shimodaira H, Tokunaga S, Moriwaki T, Esaki T, Nagase M, Fujitani K, Yamaguchi K, Ura T, Hamamoto Y, Morita S, Okamoto I, Boku N, Hyodo I. Randomized, open-label, phase III study comparing irinotecan with paclitaxel in patients with advanced gastric cancer without severe peritoneal metastasis after failure of prior combination chemotherapy using fluoropyrimidine plus platinum: WJOG 4007 trial. J Clin Oncol. 2013 Dec 10;31(35):4438-44. Epub 2013 Nov 4. [https:// | + | #'''WJOG 4007:''' Hironaka S, Ueda S, Yasui H, Nishina T, Tsuda M, Tsumura T, Sugimoto N, Shimodaira H, Tokunaga S, Moriwaki T, Esaki T, Nagase M, Fujitani K, Yamaguchi K, Ura T, Hamamoto Y, Morita S, Okamoto I, Boku N, Hyodo I. Randomized, open-label, phase III study comparing irinotecan with paclitaxel in patients with advanced gastric cancer without severe peritoneal metastasis after failure of prior combination chemotherapy using fluoropyrimidine plus platinum: WJOG 4007 trial. J Clin Oncol. 2013 Dec 10;31(35):4438-44. Epub 2013 Nov 4. [https://doi.org/10.1200/JCO.2012.48.5805 link to original artile] '''dosing details in abstract have been reviewed by our editors''' [https://pubmed.ncbi.nlm.nih.gov/24190112/ PubMed] UMIN000001252 |
− | # ''' | + | #'''RAINBOW:''' Wilke H, Muro K, Van Cutsem E, Oh SC, Bodoky G, Shimada Y, Hironaka S, Sugimoto N, Lipatov O, Kim TY, Cunningham D, Rougier P, Komatsu Y, Ajani J, Emig M, Carlesi R, Ferry D, Chandrawansa K, Schwartz JD, Ohtsu A; RAINBOW Study Group. Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial. Lancet Oncol. 2014 Oct;15(11):1224-35. Epub 2014 Sep 17. [https://doi.org/10.1016/S1470-2045%2814%2970420-6 link to original article] '''dosing details in manuscript have been reviewed by our editors''' [https://pubmed.ncbi.nlm.nih.gov/25240821/ PubMed] [https://clinicaltrials.gov/study/NCT01170663 NCT01170663] |
− | + | ##'''PRO analysis:''' Al-Batran SE, Van Cutsem E, Oh SC, Bodoky G, Shimada Y, Hironaka S, Sugimoto N, Lipatov ON, Kim TY, Cunningham D, Rougier P, Muro K, Liepa AM, Chandrawansa K, Emig M, Ohtsu A, Wilke H. Quality-of-life and performance status results from the phase III RAINBOW study of ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated gastric or gastroesophageal junction adenocarcinoma. Ann Oncol. 2016 Apr;27(4):673-9. Epub 2016 Jan 7. [https://doi.org/10.1093/annonc/mdv625 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/pmc4803452/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/26747859/ PubMed] | |
− | # '''ABSOLUTE:''' Shitara K, Takashima A, Fujitani K, Koeda K, Hara H, Nakayama N, Hironaka S, Nishikawa K, Makari Y, Amagai K, Ueda S, Yoshida K, Shimodaira H, Nishina T, Tsuda M, Kurokawa Y, Tamura T, Sasaki Y, Morita S, Koizumi W. Nab-paclitaxel versus solvent-based paclitaxel in patients with previously treated advanced gastric cancer (ABSOLUTE): an open-label, randomised, non-inferiority, phase 3 trial. Lancet Gastroenterol Hepatol. 2017 Apr;2(4):277-287. Epub 2017 Jan 19. [https:// | + | #'''ABSOLUTE:''' Shitara K, Takashima A, Fujitani K, Koeda K, Hara H, Nakayama N, Hironaka S, Nishikawa K, Makari Y, Amagai K, Ueda S, Yoshida K, Shimodaira H, Nishina T, Tsuda M, Kurokawa Y, Tamura T, Sasaki Y, Morita S, Koizumi W. Nab-paclitaxel versus solvent-based paclitaxel in patients with previously treated advanced gastric cancer (ABSOLUTE): an open-label, randomised, non-inferiority, phase 3 trial. Lancet Gastroenterol Hepatol. 2017 Apr;2(4):277-287. Epub 2017 Jan 19. [https://doi.org/10.1016/S2468-1253(16)30219-9 link to original article] '''dosing details in abstract have been reviewed by our editors''' [https://pubmed.ncbi.nlm.nih.gov/28404157/ PubMed] JapicCTI-132059 |
− | # ''' | + | #'''GOLD:''' Bang YJ, Xu RH, Chin K, Lee KW, Park SH, Rha SY, Shen L, Qin S, Xu N, Im SA, Locker G, Rowe P, Shi X, Hodgson D, Liu YZ, Boku N. Olaparib in combination with paclitaxel in patients with advanced gastric cancer who have progressed following first-line therapy (GOLD): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncol. 2017 Dec;18(12):1637-1651. Epub 2017 Nov 2. [https://doi.org/10.1016/S1470-2045(17)30682-4 link to original article] [https://pubmed.ncbi.nlm.nih.gov/29103871/ PubMed] [https://clinicaltrials.gov/study/NCT01924533 NCT01924533] |
− | # ''' | + | #'''DREAM:''' Kang YK, Ryu MH, Park SH, Kim JG, Kim JW, Cho SH, Park YI, Park SR, Rha SY, Kang MJ, Cho JY, Kang SY, Roh SY, Ryoo BY, Nam BH, Jo YW, Yoon KE, Oh SC. Efficacy and safety findings from DREAM: a phase III study of DHP107 (oral paclitaxel) versus IV paclitaxel in patients with advanced gastric cancer after failure of first-line chemotherapy. Ann Oncol. 2018 May 1;29(5):1220-1226. [https://doi.org/10.1093/annonc/mdy055 link to original article] '''dosing details in abstract have been reviewed by our editors''' [https://pubmed.ncbi.nlm.nih.gov/29438463/ PubMed] [https://clinicaltrials.gov/study/NCT01839773 NCT01839773] |
− | # ''' | + | #'''KEYNOTE-061:''' Shitara K, Özgüroğlu M, Bang YJ, Di Bartolomeo MD, Mandalà M, Ryu MH, Fornaro L, Olesiński T, Caglevic C, Chung HC, Muro K, Goekkurt E, Mansoor W, McDermott RS, Shacham-Shmueli E, Chen X, Mayo C, Kang SP, Ohtsu A, Fuchs CS; KEYNOTE-061 investigators. Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial. Lancet. 2018 Jul 14;392(10142):123-133. Epub 2018 Jun 4. [https://doi.org/10.1016/S0140-6736(18)31257-1 link to original article] '''dosing details in manuscript have been reviewed by our editors''' [https://pubmed.ncbi.nlm.nih.gov/29880231/ PubMed] [https://clinicaltrials.gov/study/NCT02370498 NCT02370498] |
− | # ''' | + | ##'''Update:''' Fuchs CS, Özgüroğlu M, Bang YJ, Di Bartolomeo M, Mandala M, Ryu MH, Fornaro L, Olesinski T, Caglevic C, Chung HC, Muro K, Van Cutsem E, Elme A, Thuss-Patience P, Chau I, Ohtsu A, Bhagia P, Wang A, Shih CS, Shitara K. Pembrolizumab versus paclitaxel for previously treated PD-L1-positive advanced gastric or gastroesophageal junction cancer: 2-year update of the randomized phase 3 KEYNOTE-061 trial. Gastric Cancer. 2022 Jan;25(1):197-206. Epub 2021 Sep 1. [https://doi.org/10.1007/s10120-021-01227-z link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/pmc8732941/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/34468869/ PubMed] |
− | # '''KCSG ST10-01:''' Lee KW, Maeng CH, Kim TY, Zang DY, Kim YH, Hwang IG, Oh SC, Chung JS, Song HS, Kim JW, Jeong SJ, Cho JY. A phase III study to compare the efficacy and safety of paclitaxel versus irinotecan in patients with metastatic or recurrent gastric cancer who failed in first-line therapy (KCSG ST10-01). Oncologist. 2019 Jan;24(1):18-e24. Epub 2018 Aug 20. [ | + | #'''KCSG ST10-01:''' Lee KW, Maeng CH, Kim TY, Zang DY, Kim YH, Hwang IG, Oh SC, Chung JS, Song HS, Kim JW, Jeong SJ, Cho JY. A phase III study to compare the efficacy and safety of paclitaxel versus irinotecan in patients with metastatic or recurrent gastric cancer who failed in first-line therapy (KCSG ST10-01). Oncologist. 2019 Jan;24(1):18-e24. Epub 2018 Aug 20. [https://doi.org/10.1634/theoncologist.2018-0142 link to original article] '''dosing details in abstract have been reviewed by our editors''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6324622/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/30126861/ PubMed] [https://clinicaltrials.gov/study/NCT01224652 NCT01224652] |
− | + | #'''JAVELIN Gastric 300:''' Bang YJ, Yanez Ruiz E, Van Cutsem E, Lee KW, Wyrwicz L, Schenker M, Alsina M, Ryu MH, Chung HC, Evesque L, Al-Batran SE, Park SH, Lichinitser M, Boku N, Moehler MH, Hong J, Xiong H, Hallwachs R, Conti I, Taieb J. Phase III, randomised trial of avelumab versus physician's choice of chemotherapy as third-line treatment of patients with advanced gastric or gastro-oesophageal junction cancer: primary analysis of JAVELIN Gastric 300. Ann Oncol. 2018 Oct 1;29(10):2052-2060. [https://doi.org/10.1093/annonc/mdy264 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6225815/ link to PMC article] '''dosing details in abstract have been reviewed by our editors''' [https://pubmed.ncbi.nlm.nih.gov/30052729/ PubMed] [https://clinicaltrials.gov/study/NCT02625623 NCT02625623] | |
+ | #'''RADPAC:''' Lorenzen S, Knorrenschild JR, Pauligk C, Hegewisch-Becker S, Seraphin J, Thuss-Patience P, Kopp HG, Dechow T, Vogel A, Luley KB, Pink D, Stahl M, Kullmann F, Hebart H, Siveke J, Egger M, Homann N, Probst S, Goetze TO, Al-Batran SE. Phase III randomized, double-blind study of paclitaxel with and without everolimus in patients with advanced gastric or esophagogastric junction carcinoma who have progressed after therapy with a fluoropyrimidine/platinum-containing regimen (RADPAC). Int J Cancer. 2020 Nov 1;147(9):2493-2502. Epub 2020 May 7. [https://doi.org/10.1002/ijc.33025 link to original article] '''dosing details in abstract have been reviewed by our editors''' [https://pubmed.ncbi.nlm.nih.gov/32339253/ PubMed] [https://clinicaltrials.gov/study/NCT01248403 NCT01248403] | ||
+ | #'''RAINBOW-Asia:''' Xu RH, Zhang Y, Pan H, Feng J, Zhang T, Liu T, Qin Y, Qin S, Yin X, Liu B, Ba Y, Yang N, Voon PJ, Tanasanvimon S, Zhou C, Zhang WL, Shen L. Efficacy and safety of weekly paclitaxel with or without ramucirumab as second-line therapy for the treatment of advanced gastric or gastroesophageal junction adenocarcinoma (RAINBOW-Asia): a randomised, multicentre, double-blind, phase 3 trial. Lancet Gastroenterol Hepatol. 2021 Dec;6(12):1015-1024. Epub 2021 Oct 6. [https://doi.org/10.1016/s2468-1253(21)00313-7 link to original article] '''dosing details in abstract have been reviewed by our editors''' [https://pubmed.ncbi.nlm.nih.gov/34626550/ PubMed] [https://clinicaltrials.gov/study/NCT02898077 NCT02898077] | ||
+ | #'''KEYNOTE-063:''' Chung HC, Kang YK, Chen Z, Bai Y, Wan Ishak WZ, Shim BY, Park YL, Koo DH, Lu J, Xu J, Chon HJ, Bai LY, Zeng S, Yuan Y, Chen YY, Gu K, Zhong WY, Kuang S, Shih CS, Qin SK. Pembrolizumab versus paclitaxel for previously treated advanced gastric or gastroesophageal junction cancer (KEYNOTE-063): A randomized, open-label, phase 3 trial in Asian patients. Cancer. 2022 Mar 1;128(5):995-1003. Epub 2021 Dec 8. [https://doi.org/10.1002/cncr.34019 link to original article] '''dosing details in manuscript have been reviewed by our editors''' [https://www.ncbi.nlm.nih.gov/pmc/articles/pmc9299889/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/34878659/ PubMed] [https://clinicaltrials.gov/study/NCT03019588 NCT03019588] | ||
+ | #'''BRIGHTER:''' Shah MA, Shitara K, Lordick F, Bang YJ, Tebbutt NC, Metges JP, Muro K, Lee KW, Shen L, Tjulandin S, Hays JL, Starling N, Xu RH, Sturtz K, Fontaine M, Oh C, Brooks EM, Xu B, Li W, Li CJ, Borodyansky L, Van Cutsem E. Randomized, Double-Blind, Placebo-Controlled Phase III Study of Paclitaxel ± Napabucasin in Pretreated Advanced Gastric or Gastroesophageal Junction Adenocarcinoma. Clin Cancer Res. 2022 Sep 2;28(17):3686–3694. Epub 2022 Jul 14. [https://doi.org/10.1158/1078-0432.ccr-21-4021 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/pmc9433958/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/35833783/ PubMed] [https://clinicaltrials.gov/study/NCT02178956 NCT02178956] | ||
+ | #'''INTEGRATEIIb:''' [https://clinicaltrials.gov/study/NCT04879368 NCT04879368] | ||
==nab-Paclitaxel monotherapy {{#subobject:8f6227|Regimen=1}}== | ==nab-Paclitaxel monotherapy {{#subobject:8f6227|Regimen=1}}== | ||
− | + | <div class="toccolours" style="background-color:#eeeeee"> | |
− | |||
− | |||
− | |||
===Regimen {{#subobject:fe2978|Variant=1}}=== | ===Regimen {{#subobject:fe2978|Variant=1}}=== | ||
− | {| class="wikitable" style="width: 100%; text-align:center;" | + | {| class="wikitable sortable" style="width: 100%; text-align:center;" |
− | ! style="width: | + | ! style="width: 20%" |Study |
− | ! style="width: | + | ! style="width: 20%" |Dates of enrollment |
− | ! style="width: | + | ! style="width: 20%" |[[Levels_of_Evidence#Evidence|Evidence]] |
− | ! style="width: | + | ! style="width: 20%" |Comparator |
+ | ! style="width: 20%" |[[Levels_of_Evidence#Comparative_efficacy|Comparative Efficacy]] | ||
|- | |- | ||
− | | rowspan="2" |[https:// | + | | rowspan="2" |[https://doi.org/10.1016/S2468-1253(16)30219-9 Shitara et al. 2017 (ABSOLUTE)] |
− | | rowspan="2" style="background-color:#1a9851" |Phase | + | | rowspan="2" |2013-2015 |
− | |1. [[#Paclitaxel_monotherapy| | + | | rowspan="2" style="background-color:#1a9851" |Phase 3 (E-switch-ic) |
− | | style="background-color:#eeee01" |Non-inferior OS | + | |1. [[#Paclitaxel_monotherapy|Paclitaxel]]; weekly |
+ | | style="background-color:#eeee01" |Non-inferior OS (primary endpoint)<br>Median OS: 11.1 vs 10.9 mo<br>(HR 0.97, 97.5% CI 0.76-1.23) | ||
|- | |- | ||
− | |2. [[#nab-Paclitaxel_monotherapy|nab-Paclitaxel]] q3wk | + | |2. [[#nab-Paclitaxel_monotherapy|nab-Paclitaxel]]; q3wk |
| style="background-color:#d3d3d3" |Not reported | | style="background-color:#d3d3d3" |Not reported | ||
|- | |- | ||
|} | |} | ||
+ | <div class="toccolours" style="background-color:#b3e2cd"> | ||
====Chemotherapy==== | ====Chemotherapy==== | ||
*[[Paclitaxel, nanoparticle albumin-bound (Abraxane)]] 100 mg/m<sup>2</sup> IV once per day on days 1, 8, 15 | *[[Paclitaxel, nanoparticle albumin-bound (Abraxane)]] 100 mg/m<sup>2</sup> IV once per day on days 1, 8, 15 | ||
− | |||
'''28-day cycles''' | '''28-day cycles''' | ||
− | + | </div></div> | |
===References=== | ===References=== | ||
− | # '''ABSOLUTE:''' Shitara K, Takashima A, Fujitani K, Koeda K, Hara H, Nakayama N, Hironaka S, Nishikawa K, Makari Y, Amagai K, Ueda S, Yoshida K, Shimodaira H, Nishina T, Tsuda M, Kurokawa Y, Tamura T, Sasaki Y, Morita S, Koizumi W. Nab-paclitaxel versus solvent-based paclitaxel in patients with previously treated advanced gastric cancer (ABSOLUTE): an open-label, randomised, non-inferiority, phase 3 trial. Lancet Gastroenterol Hepatol. 2017 Apr;2(4):277-287. Epub 2017 Jan 19. [https:// | + | #'''ABSOLUTE:''' Shitara K, Takashima A, Fujitani K, Koeda K, Hara H, Nakayama N, Hironaka S, Nishikawa K, Makari Y, Amagai K, Ueda S, Yoshida K, Shimodaira H, Nishina T, Tsuda M, Kurokawa Y, Tamura T, Sasaki Y, Morita S, Koizumi W. Nab-paclitaxel versus solvent-based paclitaxel in patients with previously treated advanced gastric cancer (ABSOLUTE): an open-label, randomised, non-inferiority, phase 3 trial. Lancet Gastroenterol Hepatol. 2017 Apr;2(4):277-287. Epub 2017 Jan 19. [https://doi.org/10.1016/S2468-1253(16)30219-9 link to original article] '''dosing details in abstract have been reviewed by our editors''' [https://pubmed.ncbi.nlm.nih.gov/28404157/ PubMed] JapicCTI-132059 |
− | |||
==Paclitaxel & Ramucirumab {{#subobject:fdd93f|Regimen=1}}== | ==Paclitaxel & Ramucirumab {{#subobject:fdd93f|Regimen=1}}== | ||
− | + | <div class="toccolours" style="background-color:#eeeeee"> | |
− | |||
− | |||
− | |||
===Regimen {{#subobject:f66446|Variant=1}}=== | ===Regimen {{#subobject:f66446|Variant=1}}=== | ||
{| class="wikitable" style="color:white; background-color:#404040" | {| class="wikitable" style="color:white; background-color:#404040" | ||
Line 2,646: | Line 4,066: | ||
|- | |- | ||
|} | |} | ||
− | {| class="wikitable" style="width: 100%; text-align:center;" | + | {| class="wikitable sortable" style="width: 100%; text-align:center;" |
− | !Study | + | ! style="width: 20%" |Study |
− | ![[Levels_of_Evidence#Evidence|Evidence]] | + | ! style="width: 20%" |Dates of enrollment |
− | ![[ | + | ! style="width: 20%" |[[Levels_of_Evidence#Evidence|Evidence]] |
− | ! | + | ! style="width: 20%" |Comparator |
− | + | ! style="width: 20%" |[[Levels_of_Evidence#Comparative_efficacy|Comparative Efficacy]] | |
− | + | |- | |
+ | |[https://doi.org/10.1016/S1470-2045%2814%2970420-6 Wilke et al. 2014 (RAINBOW)] | ||
+ | <!-- {| class="wikitable" style="margin:auto; color:white; background-color:#1B4F26" | ||
+ | |'''[https://www.esmo.org/guidelines/esmo-mcbs/esmo-mcbs-scorecards/scorecard-31-1 <span style="color:white;">ESMO-MCBS (2)</span>]''' | ||
+ | |- | ||
+ | |} --> | ||
+ | |2010-2012 | ||
+ | | style="background-color:#1a9851" |Phase 3 (E-RT-esc) | ||
+ | |[[#Paclitaxel_monotherapy|Paclitaxel]] | ||
+ | | style="background-color:#91cf60" |Seems to have superior OS (primary endpoint)<br>Median OS: 9.6 vs 7.4 mo<br>(HR 0.81, 95% CI 0.68-0.96) | ||
|- | |- | ||
− | |[https:// | + | |[https://doi.org/10.1016/s2468-1253(21)00313-7 Xu et al. 2021 (RAINBOW-Asia)] |
− | | style="background-color:#1a9851" |Phase | + | |2017-2020 |
− | + | | style="background-color:#1a9851" |Phase 3 (E-esc) | |
|[[#Paclitaxel_monotherapy|Paclitaxel]] | |[[#Paclitaxel_monotherapy|Paclitaxel]] | ||
− | | style="background-color:# | + | | style="background-color:#91cf60" |Seems to have superior PFS (co-primary endpoint)<br>Median PFS: 4.1 vs 3.15 mo <br>(HR 0.77, 95% CI 0.61-0.955) |
− | |||
|- | |- | ||
|} | |} | ||
− | '' | + | ''Note: RAINBOW included patients with GE junction malignancy (79% gastric, 21% GE junction).'' |
− | + | <div class="toccolours" style="background-color:#fdcdac"> | |
− | '' | + | ====Prior treatment criteria==== |
− | + | *RAINBOW: documented objective radiological or clinical disease progression during or within 4 months of the last dose of first-line platinum and fluoropyrimidine doublet with or without anthracycline | |
+ | </div> | ||
+ | <div class="toccolours" style="background-color:#b3e2cd"> | ||
+ | ====Targeted therapy==== | ||
+ | *[[Ramucirumab (Cyramza)]] 8 mg/kg IV over 60 minutes once per day on days 1 & 15, '''given first''' | ||
====Chemotherapy==== | ====Chemotherapy==== | ||
− | |||
*[[Paclitaxel (Taxol)]] 80 mg/m<sup>2</sup> IV once per day on days 1, 8, 15, '''given second''' | *[[Paclitaxel (Taxol)]] 80 mg/m<sup>2</sup> IV once per day on days 1, 8, 15, '''given second''' | ||
− | |||
'''28-day cycles''' | '''28-day cycles''' | ||
− | + | </div></div> | |
===References=== | ===References=== | ||
− | # '''RAINBOW:''' Wilke H, Muro K, Van Cutsem E, Oh SC, Bodoky G, Shimada Y, Hironaka S, Sugimoto N, Lipatov O, Kim TY, Cunningham D, Rougier P, Komatsu Y, Ajani J, Emig M, Carlesi R, Ferry D, Chandrawansa K, Schwartz JD, Ohtsu A; RAINBOW Study Group. Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial. Lancet Oncol. 2014 Oct;15(11):1224-35. [https:// | + | #'''RAINBOW:''' Wilke H, Muro K, Van Cutsem E, Oh SC, Bodoky G, Shimada Y, Hironaka S, Sugimoto N, Lipatov O, Kim TY, Cunningham D, Rougier P, Komatsu Y, Ajani J, Emig M, Carlesi R, Ferry D, Chandrawansa K, Schwartz JD, Ohtsu A; RAINBOW Study Group. Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial. Lancet Oncol. 2014 Oct;15(11):1224-35. Epub 2014 Sep 17. [https://doi.org/10.1016/S1470-2045%2814%2970420-6 link to original article] '''dosing details in manuscript have been reviewed by our editors''' [https://pubmed.ncbi.nlm.nih.gov/25240821/ PubMed] [https://clinicaltrials.gov/study/NCT01170663 NCT01170663] |
− | + | ##'''PRO analysis:''' Al-Batran SE, Van Cutsem E, Oh SC, Bodoky G, Shimada Y, Hironaka S, Sugimoto N, Lipatov ON, Kim TY, Cunningham D, Rougier P, Muro K, Liepa AM, Chandrawansa K, Emig M, Ohtsu A, Wilke H. Quality-of-life and performance status results from the phase III RAINBOW study of ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated gastric or gastroesophageal junction adenocarcinoma. Ann Oncol. 2016 Apr;27(4):673-9. Epub 2016 Jan 7. [https://doi.org/10.1093/annonc/mdv625 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/pmc4803452/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/26747859/ PubMed] | |
+ | #'''RAINBOW-Asia:''' Xu RH, Zhang Y, Pan H, Feng J, Zhang T, Liu T, Qin Y, Qin S, Yin X, Liu B, Ba Y, Yang N, Voon PJ, Tanasanvimon S, Zhou C, Zhang WL, Shen L. Efficacy and safety of weekly paclitaxel with or without ramucirumab as second-line therapy for the treatment of advanced gastric or gastroesophageal junction adenocarcinoma (RAINBOW-Asia): a randomised, multicentre, double-blind, phase 3 trial. Lancet Gastroenterol Hepatol. 2021 Dec;6(12):1015-1024. Epub 2021 Oct 6. [https://doi.org/10.1016/s2468-1253(21)00313-7 link to original article] '''dosing details in abstract have been reviewed by our editors''' [https://pubmed.ncbi.nlm.nih.gov/34626550/ PubMed] [https://clinicaltrials.gov/study/NCT02898077 NCT02898077] | ||
+ | #'''RAMIRIS:''' [https://clinicaltrials.gov/study/NCT03081143 NCT03081143] | ||
==Pembrolizumab monotherapy {{#subobject:88c665|Regimen=1}}== | ==Pembrolizumab monotherapy {{#subobject:88c665|Regimen=1}}== | ||
− | + | <div class="toccolours" style="background-color:#eeeeee"> | |
− | |||
− | |||
− | |||
− | |||
===Regimen {{#subobject:ac7d94|Variant=1}}=== | ===Regimen {{#subobject:ac7d94|Variant=1}}=== | ||
− | {| class="wikitable" style="width: 100%; text-align:center;" | + | {| class="wikitable sortable" style="width: 100%; text-align:center;" |
− | ! style="width: | + | ! style="width: 20%" |Study |
− | ! style="width: | + | ! style="width: 20%" |Dates of enrollment |
− | ! style="width: | + | ! style="width: 20%" |[[Levels_of_Evidence#Evidence|Evidence]] |
− | ! style="width: | + | ! style="width: 20%" |Comparator |
+ | ! style="width: 20%" |[[Levels_of_Evidence#Comparative_efficacy|Comparative Efficacy]] | ||
|- | |- | ||
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5885175/ Fuchs et al. 2018 (KEYNOTE-059)] | |[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5885175/ Fuchs et al. 2018 (KEYNOTE-059)] | ||
− | | style="background-color:#91cf61" |Phase | + | |2015-03-02 to 2016-05-26 |
− | | | + | | style="background-color:#91cf61" |Phase 2 (RT) |
+ | | style="background-color:#d3d3d3" | | ||
|ORR: 12% (95% CI 8-16) | |ORR: 12% (95% CI 8-16) | ||
|- | |- | ||
− | |[https:// | + | |[https://doi.org/10.1016/S0140-6736(18)31257-1 Shitara et al. 2018 (KEYNOTE-061)] |
− | | style="background-color:#1a9851" |Phase | + | |2015-06-04 to 2016-07-26 |
+ | | style="background-color:#1a9851" |Phase 3 (E-switch-ooc) | ||
|[[#Paclitaxel_monotherapy|Paclitaxel]] | |[[#Paclitaxel_monotherapy|Paclitaxel]] | ||
− | | style="background-color:# | + | | style="background-color:#91cf60" |Seems to have superior OS<sup>1</sup> (co-primary endpoint)<br>Median OS: 9.1 vs 8.3 mo<br>(HR 0.81, 95% CI 0.66-1.00) |
|- | |- | ||
|} | |} | ||
− | ''Both studies included patients with GE junction malignancy:'' | + | ''<sup>1</sup>Reported efficacy is based on the 2021 update, for the CPS at least 1 group.''<br> |
− | * ''KEYNOTE-059: 48.3% gastric, 51.4% GE junction and 57.1% of patients had a PD-L1 CPS score of at least 1'' | + | <br> |
− | + | ''Note: Both studies included patients with GE junction malignancy:'' | |
− | * ''KEYNOTE-061: 68.8% gastric, 31.2% GE junction and 66% of all patients receiving pembrolizumab had a PD-L1 CPS score of at least 1'' | + | *''KEYNOTE-059: 48.3% gastric, 51.4% GE junction and 57.1% of patients had a PD-L1 CPS score of at least 1'' |
− | + | *''KEYNOTE-061: 68.8% gastric, 31.2% GE junction and 66% of all patients receiving pembrolizumab had a PD-L1 CPS score of at least 1'' | |
+ | <div class="toccolours" style="background-color:#fdcdac"> | ||
+ | ====Biomarker eligibility criteria==== | ||
+ | PD-L1 (combined positive score > 1%) as determined by an FDA-approved test. | ||
+ | </div> | ||
+ | <div class="toccolours" style="background-color:#b3e2cd"> | ||
====Immunotherapy==== | ====Immunotherapy==== | ||
*[[Pembrolizumab (Keytruda)]] 200 mg IV once on day 1 | *[[Pembrolizumab (Keytruda)]] 200 mg IV once on day 1 | ||
− | |||
'''21-day cycle for up to 35 cycles (2 years)''' | '''21-day cycle for up to 35 cycles (2 years)''' | ||
− | + | </div></div> | |
===References=== | ===References=== | ||
− | <!-- # '''Abstract:''' Charles S. Fuchs, Toshihiko Doi, Raymond Woo-Jun Jang, Kei Muro, Taroh Satoh, Manuela Machado, ...Weijing Sun, Shadia Ibrahim Jalal, Manish A. Shah, Jean-Philippe Metges, Marcelo Garrido, Talia Golan, Mario Mandala, Zev A. Wainberg, Daniel V.T. Catenacci, Yung-Jue Bang, Jiangdian Wang, Minori Koshiji, Rita P. Dalal, Harry H. Yoon (2017). KEYNOTE-059 cohort 1: Efficacy and safety of pembrolizumab (pembro) monotherapy in patients with previously treated advanced gastric cancer. Journal of Clinical Oncology 35, no. 15_suppl (May 2017) 4003-4003. [https:// | + | <!-- # '''Abstract:''' Charles S. Fuchs, Toshihiko Doi, Raymond Woo-Jun Jang, Kei Muro, Taroh Satoh, Manuela Machado, ...Weijing Sun, Shadia Ibrahim Jalal, Manish A. Shah, Jean-Philippe Metges, Marcelo Garrido, Talia Golan, Mario Mandala, Zev A. Wainberg, Daniel V.T. Catenacci, Yung-Jue Bang, Jiangdian Wang, Minori Koshiji, Rita P. Dalal, Harry H. Yoon (2017). KEYNOTE-059 cohort 1: Efficacy and safety of pembrolizumab (pembro) monotherapy in patients with previously treated advanced gastric cancer. Journal of Clinical Oncology 35, no. 15_suppl (May 2017) 4003-4003. [https://doi.org/10.1200/JCO.2017.35.15_suppl.4003 link to abstract] --> |
− | # '''KEYNOTE-059:''' Fuchs CS, Doi T, Jang RW, Muro K, Satoh T, Machado M, Sun W, Jalal SI, Shah MA, Metges JP, Garrido M, Golan T, Mandala M, Wainberg ZA, Catenacci DV, Ohtsu A, Shitara K, Geva R, Bleeker J, Ko AH, Ku G, Philip P, Enzinger PC, Bang YJ, Levitan D, Wang J, Rosales M, Dalal RP, Yoon HH. Safety and efficacy of pembrolizumab monotherapy in patients with previously treated advanced gastric and gastroesophageal junction cancer: phase 2 clinical KEYNOTE-059 trial. JAMA Oncol. 2018 May 10;4(5):e180013. Epub 2018 May 10. [https:// | + | #'''KEYNOTE-059:''' Fuchs CS, Doi T, Jang RW, Muro K, Satoh T, Machado M, Sun W, Jalal SI, Shah MA, Metges JP, Garrido M, Golan T, Mandala M, Wainberg ZA, Catenacci DV, Ohtsu A, Shitara K, Geva R, Bleeker J, Ko AH, Ku G, Philip P, Enzinger PC, Bang YJ, Levitan D, Wang J, Rosales M, Dalal RP, Yoon HH. Safety and efficacy of pembrolizumab monotherapy in patients with previously treated advanced gastric and gastroesophageal junction cancer: phase 2 clinical KEYNOTE-059 trial. JAMA Oncol. 2018 May 10;4(5):e180013. Epub 2018 May 10. [https://doi.org/10.1001/jamaoncol.2018.0013 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5885175/ link to PMC article] '''dosing details in manuscript have been reviewed by our editors''' [https://pubmed.ncbi.nlm.nih.gov/29543932/ PubMed] [https://clinicaltrials.gov/study/NCT02335411 NCT02335411] |
− | # '''KEYNOTE-061:''' Shitara K, Özgüroğlu M, Bang YJ, Di Bartolomeo MD, Mandalà M, Ryu MH, Fornaro L, Olesiński T, Caglevic C, Chung HC, Muro K, Goekkurt E, Mansoor W, McDermott RS, Shacham-Shmueli E, Chen X, Mayo C, Kang SP, Ohtsu A, Fuchs CS; KEYNOTE-061 investigators. Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial. Lancet. 2018 Jul 14;392(10142):123-133. Epub 2018 Jun 4. [https:// | + | #'''KEYNOTE-061:''' Shitara K, Özgüroğlu M, Bang YJ, Di Bartolomeo MD, Mandalà M, Ryu MH, Fornaro L, Olesiński T, Caglevic C, Chung HC, Muro K, Goekkurt E, Mansoor W, McDermott RS, Shacham-Shmueli E, Chen X, Mayo C, Kang SP, Ohtsu A, Fuchs CS; KEYNOTE-061 investigators. Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial. Lancet. 2018 Jul 14;392(10142):123-133. Epub 2018 Jun 4. [https://doi.org/10.1016/S0140-6736(18)31257-1 link to original article] '''dosing details in manuscript have been reviewed by our editors''' [https://pubmed.ncbi.nlm.nih.gov/29880231/ PubMed] [https://clinicaltrials.gov/study/NCT02370498 NCT02370498] |
− | + | ##'''Update:''' Fuchs CS, Özgüroğlu M, Bang YJ, Di Bartolomeo M, Mandala M, Ryu MH, Fornaro L, Olesinski T, Caglevic C, Chung HC, Muro K, Van Cutsem E, Elme A, Thuss-Patience P, Chau I, Ohtsu A, Bhagia P, Wang A, Shih CS, Shitara K. Pembrolizumab versus paclitaxel for previously treated PD-L1-positive advanced gastric or gastroesophageal junction cancer: 2-year update of the randomized phase 3 KEYNOTE-061 trial. Gastric Cancer. 2022 Jan;25(1):197-206. Epub 2021 Sep 1. [https://doi.org/10.1007/s10120-021-01227-z link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/pmc8732941/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/34468869/ PubMed] | |
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
==Ramucirumab monotherapy {{#subobject:425b15|Regimen=1}}== | ==Ramucirumab monotherapy {{#subobject:425b15|Regimen=1}}== | ||
− | + | <div class="toccolours" style="background-color:#eeeeee"> | |
− | |||
− | |||
− | |||
===Regimen {{#subobject:813cff|Variant=1}}=== | ===Regimen {{#subobject:813cff|Variant=1}}=== | ||
{| class="wikitable" style="color:white; background-color:#404040" | {| class="wikitable" style="color:white; background-color:#404040" | ||
Line 2,771: | Line 4,157: | ||
|- | |- | ||
|} | |} | ||
− | {| class="wikitable" style="width: 100%; text-align:center;" | + | {| class="wikitable sortable" style="width: 100%; text-align:center;" |
− | !Study | + | ! style="width: 20%" |Study |
− | ![[Levels_of_Evidence#Evidence|Evidence]] | + | ! style="width: 20%" |Dates of enrollment |
− | ![[ | + | ! style="width: 20%" |[[Levels_of_Evidence#Evidence|Evidence]] |
− | ! | + | ! style="width: 20%" |Comparator |
− | + | ! style="width: 20%" |[[Levels_of_Evidence#Comparative_efficacy|Comparative Efficacy]] | |
− | + | |- | |
+ | |[https://doi.org/10.1016/S0140-6736(13)61719-5 Fuchs et al. 2013 (REGARD)] | ||
+ | <!-- {| class="wikitable" style="margin:auto; color:white; background-color:#1B4F26" | ||
+ | |'''[https://www.esmo.org/guidelines/esmo-mcbs/esmo-mcbs-scorecards/scorecard-32-1 <span style="color:white;">ESMO-MCBS (1)</span>]''' | ||
|- | |- | ||
− | | | + | |} --> |
− | | style="background-color:#1a9851" |Phase | + | |2009-2012 |
− | + | | style="background-color:#1a9851" |Phase 3 (E-RT-esc) | |
− | |[[#Placebo|Placebo]] | + | |[[Gastric_cancer_-_null_regimens#Placebo|Placebo]] |
− | + | | style="background-color:#91cf60" |Seems to have superior OS (primary endpoint)<br>Median OS: 5.2 vs 3.8 mo<br>(HR 0.78, 95% CI 0.60-0.998) | |
− | | style="background-color:#91cf60" |Seems to have superior OS | ||
|- | |- | ||
|} | |} | ||
− | '' | + | ''Note: this study included patients with GE junction malignancy (75% gastric, 25% GE junction).'' |
− | + | <div class="toccolours" style="background-color:#fdcdac"> | |
− | + | ====Prior treatment criteria==== | |
− | ==== | + | *REGARD: Disease progression within 4 months of the last dose of first-line platinum-containing or fluoropyrimidine-containing chemotherapy for metastatic disease, or within 6 months of the last dose of platinum-containing or fluoropyrimidine-containing adjuvant treatment |
+ | </div> | ||
+ | <div class="toccolours" style="background-color:#b3e2cd"> | ||
+ | ====Targeted therapy==== | ||
*[[Ramucirumab (Cyramza)]] 8 mg/kg IV over 60 minutes once on day 1 | *[[Ramucirumab (Cyramza)]] 8 mg/kg IV over 60 minutes once on day 1 | ||
− | |||
'''14-day cycles''' | '''14-day cycles''' | ||
− | + | </div></div> | |
===References=== | ===References=== | ||
− | # '''REGARD:''' Fuchs CS, Tomasek J, Yong CJ, Dumitru F, Passalacqua R, Goswami C, Safran H, dos Santos LV, Aprile G, Ferry DR, Melichar B, Tehfe M, Topuzov E, Zalcberg JR, Chau I, Campbell W, Sivanandan C, Pikiel J, Koshiji M, Hsu Y, Liepa AM, Gao L, Schwartz JD, Tabernero J; REGARD Trial Investigators. Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet. 2014 Jan 4;383(9911):31-9. Epub 2013 Oct 3. [https:// | + | #'''REGARD:''' Fuchs CS, Tomasek J, Yong CJ, Dumitru F, Passalacqua R, Goswami C, Safran H, dos Santos LV, Aprile G, Ferry DR, Melichar B, Tehfe M, Topuzov E, Zalcberg JR, Chau I, Campbell W, Sivanandan C, Pikiel J, Koshiji M, Hsu Y, Liepa AM, Gao L, Schwartz JD, Tabernero J; REGARD Trial Investigators. Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet. 2014 Jan 4;383(9911):31-9. Epub 2013 Oct 3. [https://doi.org/10.1016/S0140-6736(13)61719-5 link to original article] '''dosing details in manuscript have been reviewed by our editors''' [https://pubmed.ncbi.nlm.nih.gov/24094768/ PubMed] [https://clinicaltrials.gov/study/NCT00917384 NCT00917384] |
==Regorafenib monotherapy {{#subobject:022ef0|Regimen=1}}== | ==Regorafenib monotherapy {{#subobject:022ef0|Regimen=1}}== | ||
− | + | <div class="toccolours" style="background-color:#eeeeee"> | |
− | |||
− | |||
− | |||
===Regimen {{#subobject:5f203f|Variant=1}}=== | ===Regimen {{#subobject:5f203f|Variant=1}}=== | ||
− | {| class="wikitable" style="width: 100%; text-align:center;" | + | {| class="wikitable sortable" style="width: 100%; text-align:center;" |
− | ! style="width: | + | ! style="width: 20%" |Study |
− | ! style="width: | + | ! style="width: 20%" |Dates of enrollment |
− | ! style="width: | + | ! style="width: 20%" |[[Levels_of_Evidence#Evidence|Evidence]] |
− | ! style="width: | + | ! style="width: 20%" |Comparator |
+ | ! style="width: 20%" |[[Levels_of_Evidence#Comparative_efficacy|Comparative Efficacy]] | ||
|- | |- | ||
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5019744/ Pavlakis et al. 2016 (INTEGRATE)] | |[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5019744/ Pavlakis et al. 2016 (INTEGRATE)] | ||
− | | style="background-color:#1a9851" |Randomized Phase | + | |2012-2014 |
− | |[[#Placebo|Placebo]] | + | | style="background-color:#1a9851" |Randomized Phase 2 (E-esc) |
− | | style="background-color:#1a9850" |Superior PFS | + | |[[Gastric_cancer_-_null_regimens#Placebo|Placebo]] |
+ | | style="background-color:#1a9850" |Superior PFS (primary endpoint)<br>Median PFS: 2.6 vs 0.9 mo<br>(HR 0.40, 95% CI 0.28-0.59) | ||
|- | |- | ||
|} | |} | ||
− | ''INTEGRATE included patients with GEJ malignancy: 62% stomach or other, 38% GEJ'' | + | ''Note: INTEGRATE included patients with GEJ malignancy: 62% stomach or other, 38% GEJ'' |
− | + | <div class="toccolours" style="background-color:#b3e2cd"> | |
− | ==== | + | ====Targeted therapy==== |
*[[Regorafenib (Stivarga)]] 160 mg PO once per day on days 1 to 21 | *[[Regorafenib (Stivarga)]] 160 mg PO once per day on days 1 to 21 | ||
− | |||
'''28-day cycles''' | '''28-day cycles''' | ||
− | + | </div></div> | |
===References=== | ===References=== | ||
− | # '''INTEGRATE:''' Pavlakis N, Sjoquist KM, Martin AJ, Tsobanis E, Yip S, Kang YK, Bang YJ, Alcindor T, O'Callaghan CJ, Burnell MJ, Tebbutt NC, Rha SY, Lee J, Cho JY, Lipton LR, Wong M, Strickland A, Kim JW, Zalcberg JR, Simes J, Goldstein D. Regorafenib for the treatment of advanced gastric cancer (INTEGRATE): A multinational placebo-controlled phase II trial. J Clin Oncol. 2016 Aug 10;34(23):2728-35. Epub 2016 Jun 20. [https:// | + | #'''INTEGRATE:''' Pavlakis N, Sjoquist KM, Martin AJ, Tsobanis E, Yip S, Kang YK, Bang YJ, Alcindor T, O'Callaghan CJ, Burnell MJ, Tebbutt NC, Rha SY, Lee J, Cho JY, Lipton LR, Wong M, Strickland A, Kim JW, Zalcberg JR, Simes J, Goldstein D. Regorafenib for the treatment of advanced gastric cancer (INTEGRATE): A multinational placebo-controlled phase II trial. J Clin Oncol. 2016 Aug 10;34(23):2728-35. Epub 2016 Jun 20. [https://doi.org/10.1200/JCO.2015.65.1901 link to original article] '''dosing details in manuscript have been reviewed by our editors''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5019744/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/27325864/ PubMed] ANZCTR12612000239864 |
− | |||
==Trifluridine and tipiracil monotherapy {{#subobject:938bf3|Regimen=1}}== | ==Trifluridine and tipiracil monotherapy {{#subobject:938bf3|Regimen=1}}== | ||
− | {| class="wikitable" style=" | + | <div class="toccolours" style="background-color:#eeeeee"> |
+ | ===Regimen {{#subobject:cfc20c|Variant=1}}=== | ||
+ | {| class="wikitable sortable" style="width: 100%; text-align:center;" | ||
+ | ! style="width: 20%" |Study | ||
+ | ! style="width: 20%" |Dates of enrollment | ||
+ | ! style="width: 20%" |[[Levels_of_Evidence#Evidence|Evidence]] | ||
+ | ! style="width: 20%" |Comparator | ||
+ | ! style="width: 20%" |[[Levels_of_Evidence#Comparative_efficacy|Comparative Efficacy]] | ||
|- | |- | ||
− | |[ | + | |[https://doi.org/10.1016/S1470-2045(18)30739-3 Shitara et al. 2018 (TAGS)] |
− | + | <!-- {| class="wikitable" style="margin:auto; color:white; background-color:#1B4F26" | |
− | + | |'''[https://www.esmo.org/guidelines/esmo-mcbs/esmo-mcbs-scorecards/scorecard-138-1 <span style="color:white;">ESMO-MCBS (3)</span>]''' | |
− | {| class="wikitable" style=" | ||
− | |||
− | |||
− | |||
− | |||
|- | |- | ||
− | | | + | |} --> |
− | | style="background-color:#1a9851" |Phase | + | |2016-2018 |
− | |[[#Placebo|Placebo]] | + | | style="background-color:#1a9851" |Phase 3 (E-RT-esc) |
− | | style="background-color:#1a9850" |Superior OS | + | |[[Gastric_cancer_-_null_regimens#Placebo|Placebo]] |
+ | | style="background-color:#1a9850" |Superior OS (primary endpoint)<br>Median OS: 5.7 vs 3.6 mo<br>(HR 0.69, 95% CI 0.56-0.85) | ||
|- | |- | ||
|} | |} | ||
+ | <div class="toccolours" style="background-color:#b3e2cd"> | ||
====Chemotherapy==== | ====Chemotherapy==== | ||
*[[Trifluridine and tipiracil (Lonsurf)]] 35 mg/m<sup>2</sup> PO twice per day on days 1 to 5, 8 to 12 | *[[Trifluridine and tipiracil (Lonsurf)]] 35 mg/m<sup>2</sup> PO twice per day on days 1 to 5, 8 to 12 | ||
− | |||
'''28-day cycles''' | '''28-day cycles''' | ||
− | + | </div></div> | |
===References=== | ===References=== | ||
− | # '''TAGS:''' Shitara K, Doi T, Dvorkin M, Mansoor W, Arkenau HT, Prokharau A, Alsina M, Ghidini M, Faustino C, Gorbunova V, Zhavrid E, Nishikawa K, Hosokawa A, Yalçın Ş, Fujitani K, Beretta GD, Van Cutsem E, Winkler RE, Makris L, Ilson DH, Tabernero J. Trifluridine/tipiracil versus placebo in patients with heavily pretreated metastatic gastric cancer (TAGS): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2018 Nov 1;19(11):1437-48. Epub 2018 Oct 18. [https:// | + | #'''TAGS:''' Shitara K, Doi T, Dvorkin M, Mansoor W, Arkenau HT, Prokharau A, Alsina M, Ghidini M, Faustino C, Gorbunova V, Zhavrid E, Nishikawa K, Hosokawa A, Yalçın Ş, Fujitani K, Beretta GD, Van Cutsem E, Winkler RE, Makris L, Ilson DH, Tabernero J. Trifluridine/tipiracil versus placebo in patients with heavily pretreated metastatic gastric cancer (TAGS): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2018 Nov 1;19(11):1437-48. Epub 2018 Oct 18. [https://doi.org/10.1016/S1470-2045(18)30739-3 link to original article] '''dosing details in abstract have been reviewed by our editors''' [https://pubmed.ncbi.nlm.nih.gov/30355453/ PubMed] [https://clinicaltrials.gov/study/NCT02500043 NCT02500043] |
− | + | #'''INTEGRATEIIb:''' [https://clinicaltrials.gov/study/NCT04879368 NCT04879368] | |
[[Category:Gastric cancer regimens]] | [[Category:Gastric cancer regimens]] | ||
[[Category:Disease-specific pages]] | [[Category:Disease-specific pages]] | ||
− | [[Category: | + | [[Category:Gastroesophageal cancers]] |
Latest revision as of 02:14, 20 July 2024
Section editor | |
---|---|
Travis Zack, MD, PhD University of California San Francisco San Francisco, CA, USA |
Note: there is significant overlap between regimens for gastric cancer and esophageal cancer, if you can't find the regimen you're looking for here, please try the esophageal cancer page. If you still can't find it, it is possible that we've moved it to the historical regimens page. For placebo or observational studies in this condition, please visit this page.
- Note: this page contains regimens which were not tested in biomarker-specific populations. The following links will take you to biomarker-specific subpages:
- Regimens for HER2 positive gastric cancer are here.
71 regimens on this page
108 variants on this page
|
Guidelines
Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any guideline published 5+ years ago to be for historical purposes, only.
ESMO
- 2022: Lordick et al. Gastric cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up PubMed
- 2016: Smyth et al. Gastric cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up PubMed
- 2010: Okines et al. Gastric cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up PubMed
- 2009: Jackson et al. Gastric cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up PubMed
- 2008: Cunningham & Oliveira. Gastric cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up PubMed
- 2007: Cunningham. Gastric cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up PubMed
- 2005: Cunningham et al. ESMO Minimum Clinical Recommendations for diagnosis, treatment and follow-up of gastric cancer PubMed
- 2019: Stjepanovic et al. Hereditary gastrointestinal cancers: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up PubMed
- 2019: Muro et al. Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with metastatic gastric cancer: a JSMO-ESMO initiative endorsed by CSCO, KSMO, MOS, SSO and TOS PubMed
ESMO/ESSO/ESTRO
- 2013: Waddell et al. Gastric cancer: ESMO-ESSO-ESTRO Clinical Practice Guidelines for diagnosis, treatment and follow-up PubMed
French Intergroup
- 2018: Zaanan et al. Gastric cancer: French intergroup clinical practice guidelines for diagnosis, treatments and follow-up (SNFGE, FFCD, GERCOR, UNICANCER, SFCD, SFED, SFRO) PubMed
NCCN
- NCCN Guidelines - Gastric Cancer
- 2022: Ajani et al. Gastric Cancer, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology. PubMed
- 2016: Ajani et al. Gastric Cancer, Version 3.2016, NCCN Clinical Practice Guidelines in Oncology. PubMed
- 2013: Ajani et al. Gastric cancer, version 2.2013: featured updates to the NCCN Guidelines. PubMed
- 2010: Ajani et al. Gastric cancer. PubMed
- 2006: Ajani et al. Gastric Cancer Clinical Practice Guidelines. PubMed
- 2003: Ajani et al. Gastric cancer. Clinical practice guidelines in oncology. PubMed
Perioperative therapy
This section contains protocols with a pre-planned neoadjuvant (preoperative) and adjuvant (postoperative) component.
Capecitabine & Cisplatin (CX)
CX: Cisplatin, Xeloda (Capecitabine)
XP: Xeloda (Capecitabine), Platinol (Cisplatin)
Study | Dates of enrollment | Evidence | Comparator | Comparative Efficacy |
---|---|---|---|---|
Shitara et al. 2023 (KEYNOTE-585) | 2017-10-09 to 2021-01-25 | Phase 3 (C) | 1a. Perioperative CX & Pembrolizumab 1b. Perioperative CF & Pembrolizumab |
Inferior pCR rate (co-primary endpoint) Might have inferior EFS (co-primary endpoint) Did not meet co-primary endpoint of OS |
2. Perioperative FLOT & Pembrolizumab | Not reported |
Neoadjuvant
Chemotherapy
- Cisplatin (Platinol) 80 mg/m2 IV once on day 1
- Capecitabine (Xeloda) 1000 mg/m2 PO twice per day on days 1 to 14
21-day cycle for 3 cycles
Definitive
Local therapy
Adjuvant
Chemotherapy
- Cisplatin (Platinol) 80 mg/m2 IV once on day 1
- Capecitabine (Xeloda) 1000 mg/m2 PO twice per day on days 1 to 14
21-day cycle for 3 cycles
References
- KEYNOTE-585: Shitara K, Rha SY, Wyrwicz LS, Oshima T, Karaseva N, Osipov M, Yasui H, Yabusaki H, Afanasyev S, Park YK, Al-Batran SE, Yoshikawa T, Yanez P, Dib Bartolomeo M, Lonardi S, Tabernero J, Van Cutsem E, Janjigian YY, Oh DY, Xu J, Fang X, Shih CS, Bhagia P, Bang YJ; KEYNOTE-585 investigators. Neoadjuvant and adjuvant pembrolizumab plus chemotherapy in locally advanced gastric or gastro-oesophageal cancer (KEYNOTE-585): an interim analysis of the multicentre, double-blind, randomised phase 3 study. Lancet Oncol. 2024 Feb;25(2):212-224. Epub 2023 Dec 19. link to original article dosing details in manuscript have been reviewed by our editors PubMed NCT03221426
CapeOx
CapeOX: Capecitabine & OXaliplatin
Study | Dates of enrollment | Evidence | Comparator | Comparative Efficacy |
---|---|---|---|---|
Tian et al. 2021 (Alien Craft 0004) | 2014-09 to 2018-06 | Phase 3 (C) | 1. Adjuvant CapeOx | Not reported |
2. Perioperative DOX-CapeOx | Inferior pCR rate |
Neoadjuvant
Chemotherapy
- Capecitabine (Xeloda) 500 mg/m2 PO twice per day on days 1 to 14
- Oxaliplatin (Eloxatin) 130 mg/m2 IV once on day 1
21-day cycle for 4 cycles
Definitive
Local therapy
Adjuvant
Chemotherapy
- Capecitabine (Xeloda) 500 mg/m2 PO twice per day on days 1 to 14
- Oxaliplatin (Eloxatin) 130 mg/m2 IV over 2 hours once on day 1
21-day cycle for 4 cycles
References
- Alien Craft 0004: Tian Y, Zhao Q, Li Y, Fan L, Zhang Z, Zhao X, Tan B, Wang D, Yang P. Efficacy of Neoadjuvant Chemotherapy DOX and XELOX Regimens for Patients with Resectable Gastric or Gastroesophageal Junction Adenocarcinoma. Gastroenterol Res Pract. 2021 Jul 22;2021:5590626. link to original article link to PMC article dosing details in manuscript have been reviewed by our editors PubMed NCT02555358
- Update: Tian Y, Yang P, Guo H, Liu Y, Zhang Z, Ding P, Zheng T, Deng H, Ma W, Li Y, Fan L, Zhang Z, Wang D, Zhao X, Tan B, Liu Y, Zhao Q. Neoadjuvant docetaxel, oxaliplatin plus capecitabine versus oxaliplatin plus capecitabine for patients with locally advanced gastric adenocarcinoma: long-term results of a phase III randomized controlled trial. Int J Surg. 2023 Dec 1;109(12):4000-4008. link to original article link to PMC article PubMed
Cisplatin & Fluorouracil (CF)
CF: Cisplatin & Fluorouracil
FP: Fluorouracil & Platinol (Cisplatin)
Protocol variant #1, 80/4000
Study | Dates of enrollment | Evidence | Comparator | Comparative Efficacy |
---|---|---|---|---|
Shitara et al. 2023 (KEYNOTE-585) | 2017-10-09 to 2021-01-25 | Phase 3 (C) | 1a. Perioperative CX & Pembrolizumab 1b. Perioperative CF & Pembrolizumab |
Inferior pCR rate (co-primary endpoint) Might have inferior EFS (co-primary endpoint) Did not meet co-primary endpoint of OS |
2. Perioperative FLOT & Pembrolizumab | Not reported |
Chemotherapy, neoadjuvant CF portion (cycles 1 to 3)
- Cisplatin (Platinol) 80 mg/m2 IV once on day 1
- Fluorouracil (5-FU) 800 mg/m2/day IV continuous infusion over 120 hours, started on day 1 (total dose per cycle: 4000 mg/m2)
21-day cycle for 3 cycles
Local therapy, definitive portion
Chemotherapy, adjuvant CF portion (cycles 4 to 6)
- Cisplatin (Platinol) 80 mg/m2 IV once on day 1
- Fluorouracil (5-FU) 800 mg/m2/day IV continuous infusion over 120 hours, started on day 1 (total dose per cycle: 4000 mg/m2)
21-day cycle for 3 cycles
Protocol variant #2, 100/4000
Study | Dates of enrollment | Evidence | Comparator | Comparative Efficacy |
---|---|---|---|---|
Ychou et al. 2011 (ACCORD 07) | 1995-2003 | Phase 3 (E-esc) | Surgery alone | Superior OS (primary endpoint) OS60: 38% vs 24% (HR 0.69, 95% CI 0.50-0.95) |
Note: ACCORD 07 included patients with lower esophageal malignancy as well (25% gastric, 11% lower esophagus, and 64% GE junction).
Chemotherapy, neoadjuvant CF portion
- Cisplatin (Platinol) 100 mg/m2 IV over 60 minutes once on day 1
- Fluorouracil (5-FU) 800 mg/m2/day IV continuous infusion over 120 hours, started on day 1 (total dose per cycle: 4000 mg/m2)
28-day cycle for 2 to 3 cycles
Local therapy, definitive portion
Chemotherapy, adjuvant CF portion
- Cisplatin (Platinol) 100 mg/m2 IV over 60 minutes once on day 28
- Fluorouracil (5-FU) 800 mg/m2/day IV continuous infusion over 120 hours, started on day 1 (total dose per cycle: 4000 mg/m2)
28-day cycle for 3 to 4 cycles, for a total of 6 cycles
References
- ACCORD 07: Ychou M, Boige V, Pignon JP, Conroy T, Bouché O, Lebreton G, Ducourtieux M, Bedenne L, Fabre JM, Saint-Aubert B, Genève J, Lasser P, Rougier P; FNCLCC; FFCD. Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase III trial. J Clin Oncol. 2011 May 1;29(13):1715-21. Epub 2011 Mar 28. link to original article dosing details in abstract have been reviewed by our editors PubMed NCT00002883
- KEYNOTE-585: Shitara K, Rha SY, Wyrwicz LS, Oshima T, Karaseva N, Osipov M, Yasui H, Yabusaki H, Afanasyev S, Park YK, Al-Batran SE, Yoshikawa T, Yanez P, Dib Bartolomeo M, Lonardi S, Tabernero J, Van Cutsem E, Janjigian YY, Oh DY, Xu J, Fang X, Shih CS, Bhagia P, Bang YJ; KEYNOTE-585 investigators. Neoadjuvant and adjuvant pembrolizumab plus chemotherapy in locally advanced gastric or gastro-oesophageal cancer (KEYNOTE-585): an interim analysis of the multicentre, double-blind, randomised phase 3 study. Lancet Oncol. 2024 Feb;25(2):212-224. Epub 2023 Dec 19. link to original article dosing details in manuscript have been reviewed by our editors PubMed NCT03221426
DOX-CapeOx
DOX-CapeOX: neoadjuvant Docetaxel, Oxaliplatin, Xeloda (Capecitabine), followed by adjuvant Capecitabine & OXaliplatin
Study | Dates of enrollment | Evidence | Comparator | Comparative Efficacy |
---|---|---|---|---|
Tian et al. 2021 (Alien Craft 0004) | 2014-09 to 2018-06 | Phase 3 (E-esc) | 1. Adjuvant CapeOx | Not reported |
2. Perioperative CapeOx | Superior pCR rate (primary endpoint) pCR rate: 16.1% vs 4.3% |
Neoadjuvant
Chemotherapy
- Docetaxel (Taxotere) 60 mg/m2 IV once on day 1
- Oxaliplatin (Eloxatin) 130 mg/m2 IV once on day 1
- Capecitabine (Xeloda) 500 mg/m2 PO twice per day on days 1 to 14
21-day cycle for 4 cycles
Definitive
Local therapy
Adjuvant
Chemotherapy
- Capecitabine (Xeloda) 500 mg/m2 PO twice per day on days 1 to 14
- Oxaliplatin (Eloxatin) 130 mg/m2 IV over 2 hours once on day 1
21-day cycle for 4 cycles
References
- Alien Craft 0004: Tian Y, Zhao Q, Li Y, Fan L, Zhang Z, Zhao X, Tan B, Wang D, Yang P. Efficacy of Neoadjuvant Chemotherapy DOX and XELOX Regimens for Patients with Resectable Gastric or Gastroesophageal Junction Adenocarcinoma. Gastroenterol Res Pract. 2021 Jul 22;2021:5590626. link to original article link to PMC article dosing details in manuscript have been reviewed by our editors PubMed NCT02555358
- Update: Tian Y, Yang P, Guo H, Liu Y, Zhang Z, Ding P, Zheng T, Deng H, Ma W, Li Y, Fan L, Zhang Z, Wang D, Zhao X, Tan B, Liu Y, Zhao Q. Neoadjuvant docetaxel, oxaliplatin plus capecitabine versus oxaliplatin plus capecitabine for patients with locally advanced gastric adenocarcinoma: long-term results of a phase III randomized controlled trial. Int J Surg. 2023 Dec 1;109(12):4000-4008. link to original article link to PMC article PubMed
ECF
ECF: Epirubicin, Cisplatin, Fluorouracil
Study | Dates of enrollment | Evidence | Comparator | Comparative Efficacy |
---|---|---|---|---|
Cunningham et al. 2006 (MAGIC) | 1994-2002 | Phase 3 (E-esc) | Surgery alone | Superior OS (primary endpoint) OS60: 36% vs 23% (HR 0.75, 95% CI 0.60-0.93) |
Cats et al. 2018 (CRITICS) | 2007-2015 | Phase 3 (C) | 1a. ECF/CX & RT 1b. ECX/CX & RT 1c. EOF/CX & RT 1d. EOX/CX & RT |
Did not meet primary endpoint of OS Median OS: 43 vs 37 mo (HR 1.01, 95% CI 0.84-1.22) |
Reynolds et al. 2023 (Neo-AEGIS) | 2013-01-24 to 2020-12-23 | Phase 3 (C) | CP & RT, then surgery | Did not meet primary endpoint of OS Median OS: 48 vs 49.2 mo (HR 1.03, 95% CI 0.77-1.38) |
Note: MAGIC included patients with lower esophageal malignancy as well (74% gastric, 14.8% lower esophagus, and 11.2% GE junction). CRITICS trial included few patients with GE junction malignancy: 83% gastric, 17% GE junction. In CRITICS, only patients with trouble swallowing pills were assigned to this treatment arm.
Neoadjuvant
Chemotherapy
- Epirubicin (Ellence) 50 mg/m2 IV once on day 1
- Cisplatin (Platinol) 60 mg/m2 IV once on day 1
- Fluorouracil (5-FU) 200 mg/m2/day IV continuous infusion over 21 days, started on day 1 (total dose per cycle: 4200 mg/m2)
Supportive therapy
- MAGIC, suggested as thrombosis prophylaxis:
- Warfarin (Coumadin) 1 mg PO once per day
21-day cycle for 3 cycles, followed by:
Definitive
Local therapy
- MAGIC: Surgical resection is performed 3 to 6 weeks after the completion of cycle 3
- CRITICS: Surgery with a D1+ lymph node resection
Followed in 6 to 12 weeks by:
Adjuvant
Chemotherapy
- Epirubicin (Ellence) 50 mg/m2 IV once on day 1
- Cisplatin (Platinol) 60 mg/m2 IV once on day 1
- Fluorouracil (5-FU) 200 mg/m2/day IV continuous infusion over 21 days, started on day 1 (total dose per cycle: 4200 mg/m2)
Supportive therapy
- MAGIC, suggested as thrombosis prophylaxis:
- Warfarin (Coumadin) 1 mg PO once per day
21-day cycle for 3 cycles
References
- MAGIC: Cunningham D, Allum WH, Stenning SP, Thompson JN, Van de Velde CJ, Nicolson M, Scarffe JH, Lofts FJ, Falk SJ, Iveson TJ, Smith DB, Langley RE, Verma M, Weeden S, Chua YJ; MAGIC Trial Participants. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med. 2006 Jul 6;355(1):11-20. link to original article dosing details in abstract have been reviewed by our editors PubMed NCT00002615
- CRITICS: Cats A, Jansen EPM, van Grieken NCT, Sikorska K, Lind P, Nordsmark M, Meershoek-Klein Kranenbarg E, Boot H, Trip AK, Swellengrebel HAM, van Laarhoven HWM, Putter H, van Sandick JW, van Berge Henegouwen MI, Hartgrink HH, van Tinteren H, van de Velde CJH, Verheij M; CRITICS investigators. Chemotherapy versus chemoradiotherapy after surgery and preoperative chemotherapy for resectable gastric cancer (CRITICS): an international, open-label, randomised phase 3 trial. Lancet Oncol. 2018 May;19(5):616-628. Epub 2018 Apr 9. link to original article dosing details in manuscript have been reviewed by our editors PubMed NCT00407186
- Neo-AEGIS: Reynolds JV, Preston SR, O'Neill B, Lowery MA, Baeksgaard L, Crosby T, Cunningham M, Cuffe S, Griffiths GO, Parker I, Risumlund SL, Roy R, Falk S, Hanna GB, Bartlett FR, Alvarez-Iglesias A, Achiam MP, Nilsson M, Piessen G, Ravi N, O'Toole D, Johnston C, McDermott RS, Turkington RC, Wahed S, Sothi S, Ford H, Wadley MS, Power D; Neo-AEGIS Investigators and Trial Group. Trimodality therapy versus perioperative chemotherapy in the management of locally advanced adenocarcinoma of the oesophagus and oesophagogastric junction (Neo-AEGIS): an open-label, randomised, phase 3 trial. Lancet Gastroenterol Hepatol. 2023 Nov;8(11):1015-1027. Epub 2023 Sep 18. link to original article link to PMC article dosing details in manuscript have been reviewed by our editors PubMed NCT01726452
ECX
ECX: Epirubicin, Cisplatin, Xeloda (Capecitabine)
Study | Dates of enrollment | Evidence | Comparator | Comparative Efficacy |
---|---|---|---|---|
Cats et al. 2018 (CRITICS) | 2007-2015 | Phase 3 (C) | 1a. ECF/CX & RT 1b. ECX/CX & RT 1c. EOF/CX & RT 1d. EOX/CX & RT |
Did not meet primary endpoint of OS Median OS: 43 vs 37 mo (HR 1.01, 95% CI 0.84-1.22) |
Reynolds et al. 2023 (Neo-AEGIS) | 2013-01-24 to 2020-12-23 | Phase 3 (C) | CP & RT, then surgery | Did not meet primary endpoint of OS Median OS: 48 vs 49.2 mo (HR 1.03, 95% CI 0.77-1.38) |
Note: CRITICS trial included few patients with GE junction malignancy: 83% gastric, 17% GE junction
Neoadjuvant
Chemotherapy
- Epirubicin (Ellence) 50 mg/m2 IV once on day 1
- Cisplatin (Platinol) 60 mg/m2 IV once on day 1
- Capecitabine (Xeloda) by the following study-specific criteria:
- Neo-AEGIS: 625 mg/m2 PO twice per day on days 1 to 21
- CRITICS: 1000 mg/m2 PO twice per day on days 1 to 14
21-day cycle for 3 cycles, followed by:
Definitive
Local therapy
- Surgery with a D1+ lymph node resection
Adjuvant
Chemotherapy
- Epirubicin (Ellence) 50 mg/m2 IV once on day 1
- Cisplatin (Platinol) 60 mg/m2 IV once on day 1
- Capecitabine (Xeloda) by the following study-specific criteria:
- Neo-AEGIS: 625 mg/m2 PO twice per day on days 1 to 21
- CRITICS: 1000 mg/m2 PO twice per day on days 1 to 14
21-day cycle for 3 cycles
References
- CRITICS: Cats A, Jansen EPM, van Grieken NCT, Sikorska K, Lind P, Nordsmark M, Meershoek-Klein Kranenbarg E, Boot H, Trip AK, Swellengrebel HAM, van Laarhoven HWM, Putter H, van Sandick JW, van Berge Henegouwen MI, Hartgrink HH, van Tinteren H, van de Velde CJH, Verheij M; CRITICS investigators. Chemotherapy versus chemoradiotherapy after surgery and preoperative chemotherapy for resectable gastric cancer (CRITICS): an international, open-label, randomised phase 3 trial. Lancet Oncol. 2018 May;19(5):616-628. Epub 2018 Apr 9. link to original article dosing details in manuscript have been reviewed by our editors PubMed NCT00407186
- Neo-AEGIS: Reynolds JV, Preston SR, O'Neill B, Lowery MA, Baeksgaard L, Crosby T, Cunningham M, Cuffe S, Griffiths GO, Parker I, Risumlund SL, Roy R, Falk S, Hanna GB, Bartlett FR, Alvarez-Iglesias A, Achiam MP, Nilsson M, Piessen G, Ravi N, O'Toole D, Johnston C, McDermott RS, Turkington RC, Wahed S, Sothi S, Ford H, Wadley MS, Power D; Neo-AEGIS Investigators and Trial Group. Trimodality therapy versus perioperative chemotherapy in the management of locally advanced adenocarcinoma of the oesophagus and oesophagogastric junction (Neo-AEGIS): an open-label, randomised, phase 3 trial. Lancet Gastroenterol Hepatol. 2023 Nov;8(11):1015-1027. Epub 2023 Sep 18. link to original article link to PMC article dosing details in manuscript have been reviewed by our editors PubMed NCT01726452
EOF
EOF: Epirubicin, Oxaliplatin, Fluourouracil
Study | Dates of enrollment | Evidence | Comparator | Comparative Efficacy |
---|---|---|---|---|
Cats et al. 2018 (CRITICS) | 2007-2015 | Phase 3 (C) | 1a. ECF/CX & RT 1b. ECX/CX & RT 1c. EOF/CX & RT 1d. EOX/CX & RT |
Did not meet primary endpoint of OS Median OS: 43 vs 37 mo (HR 1.01, 95% CI 0.84-1.22) |
Reynolds et al. 2023 (Neo-AEGIS) | 2013-01-24 to 2020-12-23 | Phase 3 (C) | CP & RT, then surgery | Did not meet primary endpoint of OS Median OS: 48 vs 49.2 mo (HR 1.03, 95% CI 0.77-1.38) |
Note: CRITICS trial included few patients with GE junction malignancy: 83% gastric, 17% GE junction. Only patients with trouble swallowing pills were assigned to this treatment arm.
Neoadjuvant
Chemotherapy
- Epirubicin (Ellence) 50 mg/m2 IV once on day 1
- Oxaliplatin (Eloxatin) 130 mg/m2 IV once on day 1
- Fluorouracil (5-FU) 200 mg/m2/day IV continuous infusion over 21 days, started on day 1 (total dose per cycle: 4000 mg/m2)
21-day cycle for 3 cycles, followed by:
Definitive
Local therapy
- Surgery with a D1+ lymph node resection
Adjuvant
Chemotherapy
- Epirubicin (Ellence) 50 mg/m2 IV once on day 1
- Oxaliplatin (Eloxatin) 130 mg/m2 IV once on day 1
- Fluorouracil (5-FU) 200 mg/m2/day IV continuous infusion over 21 days, started on day 1 (total dose per cycle: 4000 mg/m2)
21-day cycle for 3 cycles
References
- CRITICS: Cats A, Jansen EPM, van Grieken NCT, Sikorska K, Lind P, Nordsmark M, Meershoek-Klein Kranenbarg E, Boot H, Trip AK, Swellengrebel HAM, van Laarhoven HWM, Putter H, van Sandick JW, van Berge Henegouwen MI, Hartgrink HH, van Tinteren H, van de Velde CJH, Verheij M; CRITICS investigators. Chemotherapy versus chemoradiotherapy after surgery and preoperative chemotherapy for resectable gastric cancer (CRITICS): an international, open-label, randomised phase 3 trial. Lancet Oncol. 2018 May;19(5):616-628. Epub 2018 Apr 9. link to original article dosing details in manuscript have been reviewed by our editors PubMed NCT00407186
- Neo-AEGIS: Reynolds JV, Preston SR, O'Neill B, Lowery MA, Baeksgaard L, Crosby T, Cunningham M, Cuffe S, Griffiths GO, Parker I, Risumlund SL, Roy R, Falk S, Hanna GB, Bartlett FR, Alvarez-Iglesias A, Achiam MP, Nilsson M, Piessen G, Ravi N, O'Toole D, Johnston C, McDermott RS, Turkington RC, Wahed S, Sothi S, Ford H, Wadley MS, Power D; Neo-AEGIS Investigators and Trial Group. Trimodality therapy versus perioperative chemotherapy in the management of locally advanced adenocarcinoma of the oesophagus and oesophagogastric junction (Neo-AEGIS): an open-label, randomised, phase 3 trial. Lancet Gastroenterol Hepatol. 2023 Nov;8(11):1015-1027. Epub 2023 Sep 18. link to original article link to PMC article dosing details in manuscript have been reviewed by our editors PubMed NCT01726452
EOX
EOX: Epirubicin, Oxaliplatin, Xeloda (Capecitabine)
Study | Dates of enrollment | Evidence | Comparator | Comparative Efficacy |
---|---|---|---|---|
Cats et al. 2018 (CRITICS) | 2007-2015 | Phase 3 (C) | 1a. ECF/CX & RT 1b. ECX/CX & RT 1c. EOF/CX & RT 1d. EOX/CX & RT |
Did not meet primary endpoint of OS Median OS: 43 vs 37 mo (HR 1.01, 95% CI 0.84-1.22) |
Reynolds et al. 2023 (Neo-AEGIS) | 2013-01-24 to 2020-12-23 | Phase 3 (C) | CP & RT, then surgery | Did not meet primary endpoint of OS Median OS: 48 vs 49.2 mo (HR 1.03, 95% CI 0.77-1.38) |
Note: CRITICS trial included few patients with GE junction malignancy: 83% gastric, 17% GE junction
Neoadjuvant
Chemotherapy
- Epirubicin (Ellence) 50 mg/m2 IV once on day 1
- Oxaliplatin (Eloxatin) 130 mg/m2 IV once on day 1
- Capecitabine (Xeloda) 625 mg/m2 PO twice per day on days 1 to 21
21-day cycle for 3 cycles, followed by:
Definitive
Local therapy
- Surgery with a D1+ lymph node resection
Adjuvant
Chemotherapy
- Epirubicin (Ellence) 50 mg/m2 IV once on day 1
- Oxaliplatin (Eloxatin) 130 mg/m2 IV once on day 1
- Capecitabine (Xeloda) 625 mg/m2 PO twice per day on days 1 to 21
21-day cycle for 3 cycles
References
- CRITICS: Cats A, Jansen EPM, van Grieken NCT, Sikorska K, Lind P, Nordsmark M, Meershoek-Klein Kranenbarg E, Boot H, Trip AK, Swellengrebel HAM, van Laarhoven HWM, Putter H, van Sandick JW, van Berge Henegouwen MI, Hartgrink HH, van Tinteren H, van de Velde CJH, Verheij M; CRITICS investigators. Chemotherapy versus chemoradiotherapy after surgery and preoperative chemotherapy for resectable gastric cancer (CRITICS): an international, open-label, randomised phase 3 trial. Lancet Oncol. 2018 May;19(5):616-628. Epub 2018 Apr 9. link to original article dosing details in manuscript have been reviewed by our editors PubMed NCT00407186
- Neo-AEGIS: Reynolds JV, Preston SR, O'Neill B, Lowery MA, Baeksgaard L, Crosby T, Cunningham M, Cuffe S, Griffiths GO, Parker I, Risumlund SL, Roy R, Falk S, Hanna GB, Bartlett FR, Alvarez-Iglesias A, Achiam MP, Nilsson M, Piessen G, Ravi N, O'Toole D, Johnston C, McDermott RS, Turkington RC, Wahed S, Sothi S, Ford H, Wadley MS, Power D; Neo-AEGIS Investigators and Trial Group. Trimodality therapy versus perioperative chemotherapy in the management of locally advanced adenocarcinoma of the oesophagus and oesophagogastric junction (Neo-AEGIS): an open-label, randomised, phase 3 trial. Lancet Gastroenterol Hepatol. 2023 Nov;8(11):1015-1027. Epub 2023 Sep 18. link to original article link to PMC article dosing details in manuscript have been reviewed by our editors PubMed NCT01726452
FLOT
FLOT: Fluorouracil, Leucovorin, Oxaliplatin, Taxotere (Docetaxel)
Study | Dates of enrollment | Evidence | Comparator | Comparative Efficacy |
---|---|---|---|---|
Al-Batran et al. 2016 (FLOT4-AIO) | 2010-2015 | Phase 2/3 (E-switch-ic) | 1a. Perioperative ECF 1b. Perioperative ECX |
Superior OS1 (primary endpoint) Median OS: 50 vs 35 mo (HR 0.77, 95% CI 0.63-0.94) |
Shitara et al. 2023 (KEYNOTE-585) | 2017-10-09 to 2021-01-25 | Phase 3 (C) | 1a. Perioperative CX & Pembrolizumab 1b. Perioperative CF & Pembrolizumab 2. Perioperative FLOT & Pembrolizumab |
Not reported2 |
1Reported efficacy is based on the 2019 update.
2In KEYNOTE-585, the FLOT cohort was designated as a safety cohort and efficacy results were not reported in Shitara et al. 2023.
Neoadjuvant
Chemotherapy
- Fluorouracil (5-FU) 2600 mg/m2 IV continuous infusion over 24 hours, started on day 1
- Leucovorin (Folinic acid) 200 mg/m2 IV once on day 1
- Oxaliplatin (Eloxatin) 85 mg/m2 IV once on day 1
- Docetaxel (Taxotere) 50 mg/m2 IV once on day 1
14-day cycle for 4 cycles
Definitive
Local therapy
- Surgery with a D1+ lymph node resection
Adjuvant
Chemotherapy
- Fluorouracil (5-FU) 2600 mg/m2 IV continuous infusion over 24 hours, started on day 1
- Leucovorin (Folinic acid) 200 mg/m2 IV once on day 1
- Oxaliplatin (Eloxatin) 85 mg/m2 IV once on day 1
- Docetaxel (Taxotere) 50 mg/m2 IV once on day 1
14-day cycle for 4 cycles
References
- FLOT4-AIO: Al-Batran SE, Hofheinz RD, Pauligk C, Kopp HG, Haag GM, Luley KB, Meiler J, Homann N, Lorenzen S, Schmalenberg H, Probst S, Koenigsmann M, Egger M, Prasnikar N, Caca K, Trojan J, Martens UM, Block A, Fischbach W, Mahlberg R, Clemens M, Illerhaus G, Zirlik K, Behringer DM, Schmiegel W, Pohl M, Heike M, Ronellenfitsch U, Schuler M, Bechstein WO, Königsrainer A, Gaiser T, Schirmacher P, Hozaeel W, Reichart A, Goetze TO, Sievert M, Jäger E, Mönig S, Tannapfel A. Histopathological regression after neoadjuvant docetaxel, oxaliplatin, fluorouracil, and leucovorin versus epirubicin, cisplatin, and fluorouracil or capecitabine in patients with resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4-AIO): results from the phase 2 part of a multicentre, open-label, randomised phase 2/3 trial. Lancet Oncol. 2016 Dec;17(12):1697-1708. Epub 2016 Oct 22. link to original article PubMed NCT01216644
- Update: Al-Batran SE, Homann N, Pauligk C, Goetze TO, Meiler J, Kasper S, Kopp HG, Mayer F, Haag GM, Luley K, Lindig U, Schmiegel W, Pohl M, Stoehlmacher J, Folprecht G, Probst S, Prasnikar N, Fischbach W, Mahlberg R, Trojan J, Koenigsmann M, Martens UM, Thuss-Patience P, Egger M, Block A, Heinemann V, Illerhaus G, Moehler M, Schenk M, Kullmann F, Behringer DM, Heike M, Pink D, Teschendorf C, Löhr C, Bernhard H, Schuch G, Rethwisch V, von Weikersthal LF, Hartmann JT, Kneba M, Daum S, Schulmann K, Weniger J, Belle S, Gaiser T, Oduncu FS, Güntner M, Hozaeel W, Reichart A, Jäger E, Kraus T, Mönig S, Bechstein WO, Schuler M, Schmalenberg H, Hofheinz RD; FLOT4-AIO Investigators. perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomized, phase 2/3 trial. Lancet. 2019 May 11;393(10184):1948-1957. Epub 2019 Apr 11. link to original article PubMed
- KEYNOTE-585: Shitara K, Rha SY, Wyrwicz LS, Oshima T, Karaseva N, Osipov M, Yasui H, Yabusaki H, Afanasyev S, Park YK, Al-Batran SE, Yoshikawa T, Yanez P, Dib Bartolomeo M, Lonardi S, Tabernero J, Van Cutsem E, Janjigian YY, Oh DY, Xu J, Fang X, Shih CS, Bhagia P, Bang YJ; KEYNOTE-585 investigators. Neoadjuvant and adjuvant pembrolizumab plus chemotherapy in locally advanced gastric or gastro-oesophageal cancer (KEYNOTE-585): an interim analysis of the multicentre, double-blind, randomised phase 3 study. Lancet Oncol. 2024 Feb;25(2):212-224. Epub 2023 Dec 19. link to original article dosing details in manuscript have been reviewed by our editors PubMed NCT03221426
- MATTERHORN: NCT04592913
- RAMSES: NCT02661971
mFOLFOX6
mFOLFOX6: modified FOLinic acid (Leucovorin), Fluorouracil, OXaliplatin
Study | Dates of enrollment | Evidence | Comparator | Comparative Efficacy |
---|---|---|---|---|
Yu et al. 2022 (FOCUSgastric) | 2011-2016 | Phase 3 (C) | Perioperative SOX | Non-inferior OS36 (primary endpoint) OS36: 67.8% vs 75.2% |
Neoadjuvant
Chemotherapy
- Fluorouracil (5-FU) 400 mg/m2 IV bolus once on day 1, then 2400 mg/m2 IV continuous infusion over 46 hours (total dose per cycle: 2800 mg/m2)
- Leucovorin (Folinic acid) 400 mg/m2 IV once on day 1
- Oxaliplatin (Eloxatin) 85 mg/m2 IV over 2 hours once on day 1
21-day cycle for 2 to 4 cycles, followed by:
Definitive
Local therapy
- Gastrectomy with at least D2 dissection
Adjuvant
Chemotherapy
- Fluorouracil (5-FU) 400 mg/m2 IV bolus once on day 1, then 2400 mg/m2 IV continuous infusion over 46 hours (total dose per cycle: 2800 mg/m2)
- Leucovorin (Folinic acid) 400 mg/m2 IV once on day 1
- Oxaliplatin (Eloxatin) 85 mg/m2 IV over 2 hours once on day 1
21-day cycle for 2 to 4 cycles
References
- FOCUSgastric: Yu J, Gao Y, Chen L, Wu D, Shen Q, Zhao Z, Liu W, Yang H, Zhang Q, Wang X, Hu P, Zheng Z, Wang X, Liu H, Xu Z, Yan Z, Wu Y, Jin M, Zhang Q, Liu X, Zhu K, Shou C. Effect of S-1 Plus Oxaliplatin Compared With Fluorouracil, Leucovorin Plus Oxaliplatin as Perioperative Chemotherapy for Locally Advanced, Resectable Gastric Cancer: A Randomized Clinical Trial. JAMA Netw Open. 2022 Feb 1;5(2):e220426. link to original article link to PMC article dosing details in manuscript have been reviewed by our editors PubMed NCT01364376
SOX
SOX: S-1 & OXaliplatin
Study | Dates of enrollment | Evidence | Comparator | Comparative Efficacy |
---|---|---|---|---|
Yu et al. 2022 (FOCUSgastric) | 2011-2016 | Phase 3 (E-switch-ic) | Perioperative mFOLFOX6 | Non-inferior OS36 (primary endpoint) OS36: 75.2% vs 67.8% |
Wang et al. 2024 (RESONANCE) | 2012-09-01 to 2019-07-01 | Phase 3 (E-switch-ic) | Adjuvant SOX | Seems to have superior DFS36 (primary endpoint) DFS36: 61.7% vs 53.8% |
Neoadjuvant
Chemotherapy
- Tegafur, gimeracil, oteracil (S-1) by the following BSA-based criteria:
- Less than 1.25 m2: 40 mg PO twice per day on days 1 to 14
- Between 1.25 m2 and 1.5 m2: 50 mg PO twice per day on days 1 to 14
- 1.5 m2 or more: 60 mg PO twice per day on days 1 to 14
- Oxaliplatin (Eloxatin) 130 mg/m2 IV over 2 hours once on day 1
21-day cycle for 2 to 4 cycles, followed by:
Definitive
Local therapy
- Gastrectomy with at least D2 dissection
Adjuvant
Chemotherapy
- Tegafur, gimeracil, oteracil (S-1) by the following BSA-based criteria:
- Less than 1.25 m2: 40 mg PO twice per day on days 1 to 14
- Between 1.25 m2 and 1.5 m2: 50 mg PO twice per day on days 1 to 14
- 1.5 m2 or more: 60 mg PO twice per day on days 1 to 14
- Oxaliplatin (Eloxatin) 130 mg/m2 IV over 2 hours once on day 1
21-day cycle for 2 to 4 cycles
References
- RESOLVEgastric: Zhang X, Liang H, Li Z, Xue Y, Wang Y, Zhou Z, Yu J, Bu Z, Chen L, Du Y, Wang X, Wu A, Li G, Su X, Xiao G, Cui M, Wu D, Chen L, Wu X, Zhou Y, Zhang L, Dang C, He Y, Zhang Z, Sun Y, Li Y, Chen H, Bai Y, Qi C, Yu P, Zhu G, Suo J, Jia B, Li L, Huang C, Li F, Ye Y, Xu H, Wang X, Yuan Y, E JY, Ying X, Yao C, Shen L, Ji J; RESOLVE study group. Perioperative or postoperative adjuvant oxaliplatin with S-1 versus adjuvant oxaliplatin with capecitabine in patients with locally advanced gastric or gastro-oesophageal junction adenocarcinoma undergoing D2 gastrectomy (RESOLVE): an open-label, superiority and non-inferiority, phase 3 randomised controlled trial. Lancet Oncol. 2021 Aug;22(8):1081-1092. Epub 2021 Jul 9. Erratum in: Lancet Oncol. 2021 Aug;22(8):e347. link to original article PubMed NCT01534546
- FOCUSgastric: Yu J, Gao Y, Chen L, Wu D, Shen Q, Zhao Z, Liu W, Yang H, Zhang Q, Wang X, Hu P, Zheng Z, Wang X, Liu H, Xu Z, Yan Z, Wu Y, Jin M, Zhang Q, Liu X, Zhu K, Shou C. Effect of S-1 Plus Oxaliplatin Compared With Fluorouracil, Leucovorin Plus Oxaliplatin as Perioperative Chemotherapy for Locally Advanced, Resectable Gastric Cancer: A Randomized Clinical Trial. JAMA Netw Open. 2022 Feb 1;5(2):e220426. link to original article link to PMC article dosing details in manuscript have been reviewed by our editors PubMed NCT01364376
- RESONANCE: Wang X, Lu C, Wei B, Li S, Li Z, Xue Y, Ye Y, Zhang Z, Sun Y, Liang H, Li K, Zhu L, Zheng Z, Zhou Y, He Y, Li F, Wang X, Liang P, Huang H, Li G, Shen X, Ji J, Tang Y, Xu Z, Chen L; RESONANCE study group. Perioperative versus adjuvant S-1 plus oxaliplatin chemotherapy for stage II/III resectable gastric cancer (RESONANCE): a randomized, open-label, phase 3 trial. J Hematol Oncol. 2024 Apr 8;17(1):17. link to original article link to PMC article dosing details in supplement have been reviewed by our editors PubMed NCT01583361
Neoadjuvant chemotherapy
DOS
DOS: Docetaxel, Oxaliplatin, S-1
Regimen
Study | Dates of enrollment | Evidence | Comparator | Comparative Efficacy |
---|---|---|---|---|
Kang et al. 2021 (PRODIGY) | 2012-2017 | Phase 3 (E-esc) | No neoadjuvant therapy | Seems to have superior PFS (primary endpoint) PFS36: 66% vs 60% (aHR 0.70, 95% CI 0.52-0.95) |
Chemotherapy
- Docetaxel (Taxotere) 50 mg/m2 IV once on day 1
- Oxaliplatin (Eloxatin) 100 mg/m2 IV once on day 1
- S-1 40 mg/m2 PO twice per day on days 1 to 14
21-day cycle for 3 cycles
References
- PRODIGY: Kang YK, Yook JH, Park YK, Lee JS, Kim YW, Kim JY, Ryu MH, Rha SY, Chung IJ, Kim IH, Oh SC, Park YS, Son T, Jung MR, Heo MH, Kim HK, Park C, Yoo CH, Choi JH, Zang DY, Jang YJ, Sul JY, Kim JG, Kim BS, Beom SH, Cho SH, Ryu SW, Kook MC, Ryoo BY, Kim HK, Yoo MW, Lee NS, Lee SH, Kim G, Lee Y, Lee JH, Noh SH. PRODIGY: A Phase III Study of Neoadjuvant Docetaxel, Oxaliplatin, and S-1 Plus Surgery and Adjuvant S-1 Versus Surgery and Adjuvant S-1 for Resectable Advanced Gastric Cancer. J Clin Oncol. 2021 Sep 10;39(26):2903-2913. Epub 2021 Jun 16. link to original article dosing details in manuscript have been reviewed by our editors link to PMC article PubMed NCT01515748
ECF
ECF: Epirubicin, Cisplatin, Fluorouracil
Regimen
Study | Dates of enrollment | Evidence | Comparator | Comparative Efficacy |
---|---|---|---|---|
Awaiting publication (TOPGEAR) | 2009-ongoing | Phase 3 (C) | 1a. ECF/5-FU & RT 1b. ECX/Capecitabine & RT 1c. EOX/Capecitabine & RT 1d. FLOT/Capecitabine & RT |
TBD if different primary endpoint of OS |
Chemotherapy
- Epirubicin (Ellence) 50 mg/m2 IV once on day 1
- Cisplatin (Platinol) 60 mg/m2 IV once on day 1
- Fluorouracil (5-FU) 200 mg/m2/day IV continuous infusion over 21 days, started on day 1 (total dose per cycle: 4000 mg/m2)
21-day cycle for 3 cycles
References
- TOPGEAR: NCT01924819
Adjuvant therapy
CapeOx
CapeOX: Capecitabine & OXaliplatin
Regimen variant #1, 1000/130
Study | Dates of enrollment | Evidence | Comparator | Comparative Efficacy |
---|---|---|---|---|
Tian et al. 2021 (Alien Craft 0004) | 2014-09 to 2018-06 | Phase 3 (C) | 1. Perioperative CapeOx 2. Perioperative DOX-CapeOx |
Not reported |
Preceding treatment
Chemotherapy
- Capecitabine (Xeloda) 500 mg/m2 PO twice per day on days 1 to 14
- Oxaliplatin (Eloxatin) 130 mg/m2 IV over 2 hours once on day 1
21-day cycle for 8 cycles
Regimen variant #2, 2000/130
Study | Dates of enrollment | Evidence | Comparator | Comparative Efficacy |
---|---|---|---|---|
Bang et al. 2012 (CLASSIC) | 2006-2009 | Phase 3 (E-esc) | Surgery alone | Superior DFS36 (primary endpoint) DFS36: 74% vs 59% (HR 0.56, 95% CI 0.44-0.72) Superior OS1 (secondary endpoint) OS60: 78% vs 69% (HR 0.66, 95% CI 0.51-0.85) |
Zhang et al. 2021 (RESOLVEgastric) | 2012-2017 | Phase 3 (C) | 1. Perioperative SOX | Seems to have inferior DFS36 |
2. Adjuvant SOX | Non-inferior DFS36 | |||
Kang et al. 2024 (ATTRACTION-5) | 2017-02-01 to 2019-08-15 | Phase 3 (C) | 1a. S-1 & Nivolumab 1b. CapeOx & Nivolumab |
Did not meet primary endpoint of RFS RFS36: 65.3% vs 68.4% (HR 1.11, 95.72% CI 0.85-1.45) |
1Reported efficacy for CLASSIC is based on the 2014 update.
Note: RESOLVE should not be confused for the trial by the same name in pancreatic cancer.
Eligibility criteria
- ATTRACTION-5: Stage IIIA to IIIC gastric or GEJ cancer
Preceding treatment
- Gastrectomy with D2 dissection
Chemotherapy
- Capecitabine (Xeloda) 1000 mg/m2 PO twice per day on days 1 to 14
- Oxaliplatin (Eloxatin) 130 mg/m2 IV over 2 hours once on day 1
21-day cycle for 8 cycles
References
- CLASSIC: Bang YJ, Kim YW, Yang HK, Chung HC, Park YK, Lee KH, Lee KW, Kim YH, Noh SI, Cho JY, Mok YJ, Kim YH, Ji J, Yeh TS, Button P, Sirzén F, Noh SH; CLASSIC trial investigators. Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial. Lancet. 2012 Jan 28;379(9813):315-21. Epub 2012 Jan 7. link to original article dosing details in manuscript have been reviewed by our editors PubMed NCT00411229
- Update: Noh SH, Park SR, Yang HK, Chung HC, Chung IJ, Kim SW, Kim HH, Choi JH, Kim HK, Yu W, Lee JI, Shin DB, Ji J, Chen JS, Lim Y, Ha S, Bang YJ; CLASSIC trial investigators. Adjuvant capecitabine plus oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): 5-year follow-up of an open-label, randomised phase 3 trial. Lancet Oncol. 2014 Nov;15(12):1389-96. Epub 2014 Oct 15. link to original article PubMed
- RESOLVEgastric: Zhang X, Liang H, Li Z, Xue Y, Wang Y, Zhou Z, Yu J, Bu Z, Chen L, Du Y, Wang X, Wu A, Li G, Su X, Xiao G, Cui M, Wu D, Chen L, Wu X, Zhou Y, Zhang L, Dang C, He Y, Zhang Z, Sun Y, Li Y, Chen H, Bai Y, Qi C, Yu P, Zhu G, Suo J, Jia B, Li L, Huang C, Li F, Ye Y, Xu H, Wang X, Yuan Y, E JY, Ying X, Yao C, Shen L, Ji J; RESOLVE study group. Perioperative or postoperative adjuvant oxaliplatin with S-1 versus adjuvant oxaliplatin with capecitabine in patients with locally advanced gastric or gastro-oesophageal junction adenocarcinoma undergoing D2 gastrectomy (RESOLVE): an open-label, superiority and non-inferiority, phase 3 randomised controlled trial. Lancet Oncol. 2021 Aug;22(8):1081-1092. Epub 2021 Jul 9. Erratum in: Lancet Oncol. 2021 Aug;22(8):e347. link to original article dosing details in manuscript have been reviewed by our editors PubMed NCT01534546
- Alien Craft 0004: Tian Y, Zhao Q, Li Y, Fan L, Zhang Z, Zhao X, Tan B, Wang D, Yang P. Efficacy of Neoadjuvant Chemotherapy DOX and XELOX Regimens for Patients with Resectable Gastric or Gastroesophageal Junction Adenocarcinoma. Gastroenterol Res Pract. 2021 Jul 22;2021:5590626. link to original article link to PMC article dosing details in manuscript have been reviewed by our editors PubMed NCT02555358
- Update: Tian Y, Yang P, Guo H, Liu Y, Zhang Z, Ding P, Zheng T, Deng H, Ma W, Li Y, Fan L, Zhang Z, Wang D, Zhao X, Tan B, Liu Y, Zhao Q. Neoadjuvant docetaxel, oxaliplatin plus capecitabine versus oxaliplatin plus capecitabine for patients with locally advanced gastric adenocarcinoma: long-term results of a phase III randomized controlled trial. Int J Surg. 2023 Dec 1;109(12):4000-4008. link to original article link to PMC article PubMed
- ATTRACTION-5: Kang YK, Terashima M, Kim YW, Boku N, Chung HC, Chen JS, Ji J, Yeh TS, Chen LT, Ryu MH, Kim JG, Omori T, Rha SY, Kim TY, Ryu KW, Sakuramoto S, Nishida Y, Fukushima N, Yamada T, Bai LY, Hirashima Y, Hagihara S, Nakada T, Sasako M. Adjuvant nivolumab plus chemotherapy versus placebo plus chemotherapy for stage III gastric or gastro-oesophageal junction cancer after gastrectomy with D2 or more extensive lymph-node dissection (ATTRACTION-5): a randomised, multicentre, double-blind, placebo-controlled, phase 3 trial. Lancet Gastroenterol Hepatol. 2024 Aug;9(8):705-717. Epub 2024 Jun 18. link to original article dosing details in manuscript have been reviewed by our editors PubMed NCT03006705
Carboplatin & Docetaxel
Regimen
Study | Dates of enrollment | Evidence | Comparator | Comparative Efficacy |
---|---|---|---|---|
Bamias et al. 2010 | 2002-2005 | Phase 3 (C) | DCb & RT | Did not meet primary endpoint of OS |
Note: the original protocol was for cisplatin & docetaxel but was changed due to excess CINV. To our knowledge, this regimen was not tested as an experimental arm in an RCT prior to becoming a standard comparator arm.
Preceding treatment
Chemotherapy
- Carboplatin (Paraplatin) AUC 5 IV once on day 1
- Docetaxel (Taxotere) 75 mg/m2 IV once on day 1
21-day cycle for 6 cycles
References
- Bamias A, Karina M, Papakostas P, Kostopoulos I, Bobos M, Vourli G, Samantas E, Christodoulou Ch, Pentheroudakis G, Pectasides D, Dimopoulos MA, Fountzilas G. A randomized phase III study of adjuvant platinum/docetaxel chemotherapy with or without radiation therapy in patients with gastric cancer. Cancer Chemother Pharmacol. 2010 May;65(6):1009-21. Epub 2010 Feb 4. link to original article dosing details in abstract have been reviewed by our editors PubMed
Capecitabine & Cisplatin (CX)
CX: Cisplatin, Xeloda (Capecitabine)
XP: Xeloda (Capecitabine), Platinol (Cisplatin)
Regimen
Study | Dates of enrollment | Evidence | Comparator | Comparative Efficacy |
---|---|---|---|---|
Lee et al. 2011 (ARTISTgastric) | 2004-2008 | Phase 3 (C) | XP/Capecitabine & RT | Might have inferior DFS |
Note: to our knowledge, this regimen was not tested as an experimental arm in an RCT in this context, prior to becoming a standard comparator arm. This trial should not be confused for the one by the same name in colorectal cancer.
Preceding treatment
- R0 gastrectomy and at least D2 dissection
Chemotherapy
- Cisplatin (Platinol) 60 mg/m2 IV once on day 1
- Capecitabine (Xeloda) 1000 mg/m2 PO twice per day on days 1 to 14
21-day cycle for 6 cycles
References
- ARTIST: Lee J, Lim DH, Kim S, Park SH, Park JO, Park YS, Lim HY, Choi MG, Sohn TS, Noh JH, Bae JM, Ahn YC, Sohn I, Jung SH, Park CK, Kim KM, Kang WK. Phase III trial comparing capecitabine plus cisplatin versus capecitabine plus cisplatin with concurrent capecitabine radiotherapy in completely resected gastric cancer with D2 lymph node dissection: the ARTIST trial. J Clin Oncol. 2012 Jan 20;30(3):268-73. Epub 2011 Dec 19. link to original article dosing details in manuscript have been reviewed by our editors PubMed NCT00323830
- Update: Park SH, Sohn TS, Lee J, Lim DH, Hong ME, Kim KM, Sohn I, Jung SH, Choi MG, Lee JH, Bae JM, Kim S, Kim ST, Park JO, Park YS, Lim HY, Kang WK. Phase III trial to compare adjuvant chemotherapy with capecitabine and cisplatin versus concurrent chemoradiotherapy in gastric cancer: Final report of the adjuvant chemoradiotherapy in stomach tumors trial, including survival and subset analyses. J Clin Oncol. 2015 Oct 1;33(28):3130-6. Epub 2015 Jan 5. link to original article PubMed
Cisplatin & S-1
SP: S-1 & Platinol (Cisplatin)
Regimen
Study | Dates of enrollment | Evidence | Comparator | Comparative Efficacy |
---|---|---|---|---|
Lee et al. 2018 (POST) | 2010-2013 | Phase 3 (C) | DS | Did not meet primary endpoint of DFS36 |
Preceding treatment
Chemotherapy
- Cisplatin (Platinol) 60 mg/m2 IV once on day 1
- S-1 35 mg/m2 PO twice per day on days 1 to 14
21-day cycle for 8 cycles
References
- POST: Lee CK, Jung M, Kim HS, Jung I, Shin DB, Kang SY, Zang DY, Kim KH, Lee MH, Kim BS, Lee KH, Cheong JH, Hyung WJ, Noh SH, Chung HC, Rha SY. S-1 Based Doublet as an Adjuvant Chemotherapy for Curatively Resected Stage III Gastric Cancer: Results from the Randomized Phase III POST Trial. Cancer Res Treat. 2019 Jan;51(1):1-11. Epub 2018 Feb 5. link to original article link to PMC article dosing details in manuscript have been reviewed by our editors PubMed NCT01283217
Docetaxel & S-1
DS: Docetaxel & S-1
Regimen variant #1
Study | Dates of enrollment | Evidence | Comparator | Comparative Efficacy |
---|---|---|---|---|
Lee et al. 2018 (POST) | 2010-2013 | Phase 3 (E-switch-ic) | SP | Did not meet primary endpoint of DFS36 |
Preceding treatment
Chemotherapy
- Docetaxel (Taxotere) 35 mg/m2 IV once per day on days 1 & 8
- S-1 35 mg/m2 PO twice per day on days 1 to 14
21-day cycle for 8 cycles
Regimen variant #2, 40/80
Study | Dates of enrollment | Evidence | Comparator | Comparative Efficacy |
---|---|---|---|---|
Yoshida et al. 2019 (JACCRO GC-07) | 2013-2017 | Phase 3 (E-esc) | S-1 | Superior RFS36 (primary endpoint) RFS36: 66% vs 50% (HR 0.632, 99.99% CI 0.40-0.998) Superior OS1 (secondary endpoint) OS36: 77.7% vs 71.2% (HR 0.74, 95% CI 0.60-0.925) |
1Reported efficacy is based on the 2021 update.
Note: this dosing was for BSA less than 1.25 mg/m2.
Preceding treatment
Chemotherapy
- Docetaxel (Taxotere) as follows:
- Cycles 2 to 7: 40 mg/m2 IV once on day 1
- S-1 as follows:
- Cycles 1 to 7: 40 mg/m2 PO twice per day on days 1 to 14
- Cycles 8 to 12: 40 mg/m2 PO twice per day on days 1 to 28
21-day cycle for 7 cycles, then 42-day cycle for up to 5 cycles (1 year total)
Regimen variant #3, 40/100
Study | Dates of enrollment | Evidence | Comparator | Comparative Efficacy |
---|---|---|---|---|
Yoshida et al. 2019 (JACCRO GC-07) | 2013-2017 | Phase 3 (E-esc) | S-1 | Superior RFS36 (primary endpoint) RFS36: 66% vs 50% (HR 0.632, 99.99% CI 0.40-0.998) Superior OS1 (secondary endpoint) OS36: 77.7% vs 71.2% (HR 0.74, 95% CI 0.60-0.925) |
1Reported efficacy is based on the 2021 update.
Note: this dosing was for BSA between 1.25 to 1.5 mg/m2.
Preceding treatment
Chemotherapy
- Docetaxel (Taxotere) as follows:
- Cycles 2 to 7: 40 mg/m2 IV once on day 1
- S-1 as follows:
- Cycles 1 to 7: 50 mg/m2 PO twice per day on days 1 to 14
- Cycles 8 to 12: 50 mg/m2 PO twice per day on days 1 to 28
21-day cycle for 7 cycles, then 42-day cycle for up to 5 cycles (1 year total)
Regimen variant #4, 40/120
Study | Dates of enrollment | Evidence | Comparator | Comparative Efficacy |
---|---|---|---|---|
Yoshida et al. 2019 (JACCRO GC-07) | 2013-2017 | Phase 3 (E-esc) | S-1 | Superior RFS36 (primary endpoint) RFS36: 66% vs 50% (HR 0.632, 99.99% CI 0.40-0.998) Superior OS1 (secondary endpoint) OS36: 77.7% vs 71.2% (HR 0.74, 95% CI 0.60-0.925) |
1Reported efficacy is based on the 2021 update.
Note: this dosing was for BSA greater than 1.5 mg/m2.
Preceding treatment
Chemotherapy
- Docetaxel (Taxotere) as follows:
- Cycles 2 to 7: 40 mg/m2 IV once on day 1
- S-1 as follows:
- Cycles 1 to 7: 60 mg/m2 PO twice per day on days 1 to 14
- Cycles 8 to 12: 60 mg/m2 PO twice per day on days 1 to 28
21-day cycle for 7 cycles, then 42-day cycle for up to 5 cycles (1 year total)
References
- POST: Lee CK, Jung M, Kim HS, Jung I, Shin DB, Kang SY, Zang DY, Kim KH, Lee MH, Kim BS, Lee KH, Cheong JH, Hyung WJ, Noh SH, Chung HC, Rha SY. S-1 Based Doublet as an Adjuvant Chemotherapy for Curatively Resected Stage III Gastric Cancer: Results from the Randomized Phase III POST Trial. Cancer Res Treat. 2019 Jan;51(1):1-11. Epub 2018 Feb 5. link to original article link to PMC article dosing details in manuscript have been reviewed by our editors PubMed NCT01283217
- JACCRO GC-07: Yoshida K, Kodera Y, Kochi M, Ichikawa W, Kakeji Y, Sano T, Nagao N, Takahashi M, Takagane A, Watanabe T, Kaji M, Okitsu H, Nomura T, Matsui T, Yoshikawa T, Matsuyama J, Yamada M, Ito S, Takeuchi M, Fujii M. Addition of Docetaxel to Oral Fluoropyrimidine Improves Efficacy in Patients With Stage III Gastric Cancer: Interim Analysis of JACCRO GC-07, a Randomized Controlled Trial. J Clin Oncol. 2019 May 20;37(15):1296-1304. Epub 2019 Mar 29. link to original article link to PMC article dosing details in manuscript have been reviewed by our editors PubMed UMIN000010337
- Update: Kakeji Y, Yoshida K, Kodera Y, Kochi M, Sano T, Ichikawa W, Lee SW, Shibahara K, Shikano T, Kataoka M, Ishiguro A, Ojima H, Sakai Y, Musha N, Takase T, Kimura T, Takeuchi M, Fujii M. Three-year outcomes of a randomized phase III trial comparing adjuvant chemotherapy with S-1 plus docetaxel versus S-1 alone in stage III gastric cancer: JACCRO GC-07. Gastric Cancer. 2022 Jan;25(1):188-196. Epub 2021 Aug 5. link to original article PubMed
FP/Capecitabine & RT
FP/Capecitabine & RT: Fluorouracil & Platinol (Cisplatin) alternating with Capecitabine & Radiation Therapy
Regimen
Study | Dates of enrollment | Evidence |
---|---|---|
Lee et al. 2006 | Not reported | Phase 2 |
Note: In contrast to the primary reference, some guidelines list this regimen without FP cycles 1, 3, 4, 5. Dosage of Capecitabine (Xeloda) was listed as 625 to 825 mg/m2 PO twice per day on days 1 to 5 or 1 to 7 while radiation is being given.
Preceding treatment
- Surgery, 3 weeks prior
Chemotherapy
- Cisplatin (Platinol) as follows:
- Cycles 1, 3, 4, 5: 60 mg/m2 IV once on day 1
- Fluorouracil (5-FU) as follows:
- Cycles 1, 3, 4, 5: 1000 mg/m2/day IV continuous infusion over 120 hours, started on day 1 (total dose per cycle: 5000 mg/m2)
- Capecitabine (Xeloda) as follows:
- Cycle 2 (chemoradiation): 825 mg/m2 PO twice per day on days 1 to 35
Radiotherapy
- Concurrent radiation therapy during cycle 2: 180 cGy fractions x 25 fractions (total dose of 4500 cGy)
21-day course, then 9-week course, then 21-day cycle for 3 cycles
References
- Lee HS, Choi Y, Hur WJ, Kim HJ, Kwon HC, Kim SH, Kim JS, Lee JH, Jung GJ, Kim MC. Pilot study of postoperative adjuvant chemoradiation for advanced gastric cancer: adjuvant 5-FU/cisplatin and chemoradiation with capecitabine. World J Gastroenterol. 2006 Jan 28;12(4):603-7. link to original article dosing details in manuscript have been reviewed by our editors link to PMC article PubMed
FULV
FULV: 5-FU & LeucoVorin
Regimen
Study | Dates of enrollment | Evidence | Comparator | Comparative Efficacy |
---|---|---|---|---|
Bajetta et al. 2014 (ITACA-S) | 2005-2009 | Phase 3 (C) | FOLFIRI, then Cisplatin & Docetaxel | Did not meet primary endpoint of DFS |
Preceding treatment
Chemotherapy
- Fluorouracil (5-FU) 400 mg/m2 IV bolus once per day on days 1 & 2, then 600 mg/m2 IV continuous infusion over 22 hours after each bolus (total dose per cycle: 2000 mg/m2)
- Leucovorin (Folinic acid) 100 mg/m2 IV over 2 hours once per day on days 1 & 2
14-day cycle for 9 cycles
References
- ITACA-S: Bajetta E, Floriani I, Di Bartolomeo M, Labianca R, Falcone A, Di Costanzo F, Comella G, Amadori D, Pinto C, Carlomagno C, Nitti D, Daniele B, Mini E, Poli D, Santoro A, Mosconi S, Casaretti R, Boni C, Pinotti G, Bidoli P, Landi L, Rosati G, Ravaioli A, Cantore M, Di Fabio F, Aitini E, Marchet A; ITACA-S (Intergroup Trial of Adjuvant Chemotherapy in Adenocarcinoma of the Stomach Trial) Study Group. Randomized trial on adjuvant treatment with FOLFIRI followed by docetaxel and cisplatin versus 5-fluorouracil and folinic acid for radically resected gastric cancer. Ann Oncol. 2014 Jul;25(7):1373-1378. Epub 2014 Apr 12. link to original article dosing details in manuscript have been reviewed by our editors PubMed NCT01640782
FULV/FULV & RT
FULV/FULV & RT: FluoroUracil & LeucoVorin alternating with FluoroUracil, LeucoVorin, Radiation Therapy
Regimen
Study | Dates of enrollment | Evidence | Comparator | Comparative Efficacy |
---|---|---|---|---|
Macdonald et al. 2001 (INT-0116) | 1991-1998 | Phase 3 (E-esc) | Surgery alone | Superior OS (primary endpoint) |
Fuchs et al. 2017 (CALGB 80101) | 2002-2009 | Phase 3 (C) | ECF/FULV & RT | Did not meet primary endpoint of OS |
Treatment is to start 20 to 40 days after surgery. Note: Study included patients with GE junction malignancy as well (20% GE junction) and included patients with a performance status of 2.
Preceding treatment
Chemotherapy
- Fluorouracil (5-FU) as follows:
- Cycles 1, 3, 4: 425 mg/m2 IV bolus once per day on days 1 to 5
- Cycle 2 (chemoradiation): 400 mg/m2 IV bolus once per day on days 1 to 4 and the last 3 days of radiation therapy
- Leucovorin (Folinic acid) as follows:
- Cycles 1, 3, 4: 20 mg/m2 IV bolus once per day on days 1 to 5
- Cycle 2 (chemoradiation): 20 mg/m2 IV bolus once per day on days 1 to 4 and the last 3 days of radiation therapy
Radiotherapy
- Concurrent radiation therapy during cycle 2: 180 cGy x 25 fractions (total of 4500 cGy)
28-day course, then 9-week course, then 28-day cycle for 2 cycles
References
- INT-0116: Macdonald JS, Smalley SR, Benedetti J, Hundahl SA, Estes NC, Stemmermann GN, Haller DG, Ajani JA, Gunderson LL, Jessup JM, Martenson JA. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med. 2001 Sep 6;345(10):725-30. link to original article dosing details in abstract have been reviewed by our editors PubMed
- Update: Smalley SR, Benedetti JK, Haller DG, Hundahl SA, Estes NC, Ajani JA, Gunderson LL, Goldman B, Martenson JA, Jessup JM, Stemmermann GN, Blanke CD, Macdonald JS. Updated analysis of SWOG-directed intergroup study 0116: a phase III trial of adjuvant radiochemotherapy versus observation after curative gastric cancer resection. J Clin Oncol. 2012 Jul 1;30(19):2327-33. Epub 2012 May 14. link to original article link to PMC article PubMed
- CALGB 80101: Fuchs CS, Niedzwiecki D, Mamon HJ, Tepper JE, Ye X, Swanson RS, Enzinger PC, Haller DG, Dragovich T, Alberts SR, Bjarnason GA, Willett CG, Gunderson LL, Goldberg RM, Venook AP, Ilson D, O'Reilly E, Ciombor K, Berg DJ, Meyerhardt J, Mayer RJ. Adjuvant chemoradiotherapy with epirubicin, cisplatin, and fluorouracil compared with adjuvant chemoradiotherapy with fluorouracil and leucovorin after curative resection of gastric cancer: results from CALGB 80101 (Alliance). J Clin Oncol. 2017 Nov 10;35(32):3671-3677. Epub 2017 Oct 4. link to original article dosing details in manuscript have been reviewed by our editors link to PMC article PubMed NCT00052910
S-1 monotherapy
Regimen variant #1, 21-day cycles
Study | Dates of enrollment | Evidence | Comparator | Comparative Efficacy |
---|---|---|---|---|
Tsuburaya et al. 2014 (SAMIT) | 2004-2009 | Phase 3 (C) | 1. Paclitaxel, then S-1 2. Paclitaxel, then UFT |
Did not meet primary endpoint of DFS |
3. UFT | Superior DFS DFS36: 58.2% vs 53% (HR 0.81, 95% CI 0.70-0.93) |
Preceding treatment
- R0 or R1 gastrectomy with at least D2 dissection, within 2 to 8 weeks
Chemotherapy
- Tegafur, gimeracil, oteracil (S-1) 80 mg/m2 PO twice per day on days 1 to 14
21-day cycle for 16 cycles (1 year)
Regimen variant #2, 42-day cycles
Study | Dates of enrollment | Evidence | Comparator | Comparative Efficacy |
---|---|---|---|---|
Sakuramoto et al. 2007 (ACTS-GC) | 2001-2004 | Phase 3 (E-esc) | Observation | Superior OS1 (primary endpoint) OS60: 72% vs 61% (HR 0.67, 95% CI 0.54-0.83) |
Yoshikawa et al. 2019 (OPAS-1) | 2012-2017 | Phase 3 (C) | S-1 x 6 mo | Inconclusive whether non-inferior RFS |
Yoshida et al. 2019 (JACCRO GC-07) | 2013-2017 | Phase 3 (C) | Docetaxel & S-1 | Inferior RFS36 |
Park et al. 2020 (ARTIST 2) | 2013-2018 | Phase 3 (C) | 1. SOX | Seems to have inferior DFS |
2. SOXRT | Might have inferior DFS | |||
Kang et al. 2024 (ATTRACTION-5) | 2017-02-01 to 2019-08-15 | Phase 3 (C) | 1a. S-1 & Nivolumab 1b. CapeOx & Nivolumab |
Did not meet primary endpoint of RFS RFS36: 65.3% vs 68.4% (HR 1.11, 95.72% CI 0.85-1.45) |
1Reported efficacy for ACTS-GC is based on the 2011 update.
Eligibility criteria
- ACTS-GC, ARTIST 2, JACCRO GC-07: Stage II or III gastric cancer
- OPAS-1: Stage II gastric cancer
- ATTRACTION-5: Stage IIIA to IIIC gastric or GEJ cancer
Preceding treatment
- R0 gastrectomy with at least D2 dissection, within 6 weeks
Chemotherapy
- Tegafur, gimeracil, oteracil (S-1) by the following BSA-based criteria:
- Less than 1.25 m2: 40 mg PO twice per day on days 1 to 28
- Between 1.25 and 1.5 m2: 50 mg PO twice per day on days 1 to 28
- 1.5 m2 or more: 60 mg PO twice per day on days 1 to 28
42-day cycle for 8 cycles (1 year)
References
- ACTS-GC: Sakuramoto S, Sasako M, Yamaguchi T, Kinoshita T, Fujii M, Nashimoto A, Furukawa H, Nakajima T, Ohashi Y, Imamura H, Higashino M, Yamamura Y, Kurita A, Arai K; ACTS-GC Group. Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. N Engl J Med. 2007 Nov 1;357(18):1810-20. Erratum in: N Engl J Med. 2008 May 1;358(18):1977. link to original article dosing details in manuscript have been reviewed by our editors PubMed NCT00152217
- Update: Sasako M, Sakuramoto S, Katai H, Kinoshita T, Furukawa H, Yamaguchi T, Nashimoto A, Fujii M, Nakajima T, Ohashi Y. Five-year outcomes of a randomized phase III trial comparing adjuvant chemotherapy with S-1 versus surgery alone in stage II or III gastric cancer. J Clin Oncol. 2011 Nov 20;29(33):4387-93. Epub 2011 Oct 17. link to original article PubMed
- SAMIT: Tsuburaya A, Yoshida K, Kobayashi M, Yoshino S, Takahashi M, Takiguchi N, Tanabe K, Takahashi N, Imamura H, Tatsumoto N, Hara A, Nishikawa K, Fukushima R, Nozaki I, Kojima H, Miyashita Y, Oba K, Buyse M, Morita S, Sakamoto J. Sequential paclitaxel followed by tegafur and uracil (UFT) or S-1 versus UFT or S-1 monotherapy as adjuvant chemotherapy for T4a/b gastric cancer (SAMIT): a phase 3 factorial randomised controlled trial. Lancet Oncol. 2014 Jul;15(8):886-93. Epub 2014 Jun 18. link to original article dosing details in manuscript have been reviewed by our editors PubMed UMIN C000000082
- OPAS-1: Yoshikawa T, Terashima M, Mizusawa J, Nunobe S, Nishida Y, Yamada T, Kaji M, Fukushima N, Hato S, Choda Y, Yabusaki H, Yoshida K, Ito S, Takeno A, Yasuda T, Kawachi Y, Katayama H, Fukuda H, Boku N, Sano T, Sasako M. Four courses versus eight courses of adjuvant S-1 for patients with stage II gastric cancer (JCOG1104[OPAS-1]): an open-label, phase 3, non-inferiority, randomised trial. Lancet Gastroenterol Hepatol. 2019 Mar;4(3):208-216. Epub 2019 Jan 22. Erratum in: Lancet Gastroenterol Hepatol. 2019 Apr;4(4):e3. link to original article PubMed UMIN000007306
- Update: Yoshikawa T, Terashima M, Mizusawa J, Nunobe S, Nishida Y, Yamada T, Kaji M, Nomura T, Hato S, Choda Y, Yabusaki H, Yoshida K, Misawa K, Masuzawa T, Tsuda M, Kawachi Y, Katayama H, Fukuda H, Kurokawa Y, Boku N, Sano T, Sasako M. 5-year follow-up results of a JCOG1104 (OPAS-1) phase III non-inferiority trial to compare 4 courses and 8 courses of S-1 adjuvant chemotherapy for pathological stage II gastric cancer. Gastric Cancer. 2024 Jan;27(1):155-163. Epub 2023 Nov 21. link to original article PubMed
- JACCRO GC-07: Yoshida K, Kodera Y, Kochi M, Ichikawa W, Kakeji Y, Sano T, Nagao N, Takahashi M, Takagane A, Watanabe T, Kaji M, Okitsu H, Nomura T, Matsui T, Yoshikawa T, Matsuyama J, Yamada M, Ito S, Takeuchi M, Fujii M. Addition of Docetaxel to Oral Fluoropyrimidine Improves Efficacy in Patients With Stage III Gastric Cancer: Interim Analysis of JACCRO GC-07, a Randomized Controlled Trial. J Clin Oncol. 2019 May 20;37(15):1296-1304. Epub 2019 Mar 29. link to original article link to PMC article dosing details in manuscript have been reviewed by our editors PubMed UMIN000010337
- Update: Kakeji Y, Yoshida K, Kodera Y, Kochi M, Sano T, Ichikawa W, Lee SW, Shibahara K, Shikano T, Kataoka M, Ishiguro A, Ojima H, Sakai Y, Musha N, Takase T, Kimura T, Takeuchi M, Fujii M. Three-year outcomes of a randomized phase III trial comparing adjuvant chemotherapy with S-1 plus docetaxel versus S-1 alone in stage III gastric cancer: JACCRO GC-07. Gastric Cancer. 2022 Jan;25(1):188-196. Epub 2021 Aug 5. link to original article PubMed
- ARTIST 2: Park SH, Lim DH, Sohn TS, Lee J, Zang DY, Kim ST, Kang JH, Oh SY, Hwang IG, Ji JH, Shin DB, Yu JI, Kim KM, An JY, Choi MG, Lee JH, Kim S, Hong JY, Park JO, Park YS, Lim HY, Bae JM, Kang WK; ARTIST 2 investigators. A randomized phase III trial comparing adjuvant single-agent S1, S-1 with oxaliplatin, and postoperative chemoradiation with S-1 and oxaliplatin in patients with node-positive gastric cancer after D2 resection: the ARTIST 2 trial. Ann Oncol. 2021 Mar;32(3):368-374. Epub 2020 Dec 3. link to original article dosing details in manuscript have been reviewed by our editors PubMed NCT01761461
- ATTRACTION-5: Kang YK, Terashima M, Kim YW, Boku N, Chung HC, Chen JS, Ji J, Yeh TS, Chen LT, Ryu MH, Kim JG, Omori T, Rha SY, Kim TY, Ryu KW, Sakuramoto S, Nishida Y, Fukushima N, Yamada T, Bai LY, Hirashima Y, Hagihara S, Nakada T, Sasako M. Adjuvant nivolumab plus chemotherapy versus placebo plus chemotherapy for stage III gastric or gastro-oesophageal junction cancer after gastrectomy with D2 or more extensive lymph-node dissection (ATTRACTION-5): a randomised, multicentre, double-blind, placebo-controlled, phase 3 trial. Lancet Gastroenterol Hepatol. 2024 Aug;9(8):705-717. Epub 2024 Jun 18. link to original article dosing details in manuscript have been reviewed by our editors PubMed NCT03006705
- HKIT-GC: NCT00216034
SOX
Regimen
Study | Dates of enrollment | Evidence | Comparator | Comparative Efficacy |
---|---|---|---|---|
Wang et al. 2024 (RESONANCE) | 2012-09-01 to 2019-07-01 | Phase 3 (C) | Perioperative SOX | Seems to have inferior DFS36 |
Park et al. 2020 (ARTIST 2) | 2013-2018 | Phase 3 (E-esc) | 1. S-1 | Seems to have superior DFS (primary endpoint) DFS36: 74.3% vs 64.8% (HR 0.69, 95% CI 0.41-0.99) |
2. SOXRT | Did not meet primary endpoint of DFS |
Preceding treatment
- R0 or R1 gastrectomy with at least D2 dissection
Chemotherapy
- Tegafur, gimeracil, oteracil (S-1) by the following BSA-based criteria:
- Less than 1.25 m2: 40 mg PO twice per day on days 1 to 14
- Between 1.25 and 1.5 m2: 50 mg PO twice per day on days 1 to 14
- 1.5 m2 or more: 60 mg PO twice per day on days 1 to 14
- Oxaliplatin (Eloxatin) 130 mg/m2 IV over 2 hours once on day 1
21-day cycle for up to 8 cycles (6 months)
References
- ARTIST 2: Park SH, Lim DH, Sohn TS, Lee J, Zang DY, Kim ST, Kang JH, Oh SY, Hwang IG, Ji JH, Shin DB, Yu JI, Kim KM, An JY, Choi MG, Lee JH, Kim S, Hong JY, Park JO, Park YS, Lim HY, Bae JM, Kang WK; ARTIST 2 investigators. A randomized phase III trial comparing adjuvant single-agent S1, S-1 with oxaliplatin, and postoperative chemoradiation with S-1 and oxaliplatin in patients with node-positive gastric cancer after D2 resection: the ARTIST 2 trial. Ann Oncol. 2021 Mar;32(3):368-374. Epub 2020 Dec 3. link to original article dosing details in manuscript have been reviewed by our editors PubMed NCT01761461
- TOTTG030103: Zhao Q, Lian C, Huo Z, Li M, Liu Y, Fan L, Tan B, Zhao X, Zhang Z, Wang D, Liu Y, Guo H, Yang P, Tian Y, Li Y. The efficacy and safety of neoadjuvant chemotherapy on patients with advanced gastric cancer: A multicenter randomized clinical trial. Cancer Med. 2020 Aug;9(16):5731-5745. Epub 2020 Jun 24. link to original article link to PMC article PubMed NCT01516944
- RESONANCE: Wang X, Lu C, Wei B, Li S, Li Z, Xue Y, Ye Y, Zhang Z, Sun Y, Liang H, Li K, Zhu L, Zheng Z, Zhou Y, He Y, Li F, Wang X, Liang P, Huang H, Li G, Shen X, Ji J, Tang Y, Xu Z, Chen L; RESONANCE study group. Perioperative versus adjuvant S-1 plus oxaliplatin chemotherapy for stage II/III resectable gastric cancer (RESONANCE): a randomized, open-label, phase 3 trial. J Hematol Oncol. 2024 Apr 8;17(1):17. link to original article link to PMC article dosing details in supplement have been reviewed by our editors PubMed NCT01583361
UFT monotherapy
Regimen
Study | Dates of enrollment | Evidence | Comparator | Comparative Efficacy |
---|---|---|---|---|
Nakajima et al. 2007 (NSAS-GC) | 1997-2001 | Phase 3 (E-esc) | Observation | Superior OS (primary endpoint) OS60: 86% vs 73% (HR 0.48, 95% CI 0.26-0.89) |
Preceding treatment
- Gastrectomy, with complete (R0) D2 dissection
References
- NSAS-GC: Nakajima T, Kinoshita T, Nashimoto A, Sairenji M, Yamaguchi T, Sakamoto J, Fujiya T, Inada T, Sasako M, Ohashi Y; National Surgical Adjuvant Study of Gastric Cancer Group. Randomized controlled trial of adjuvant uracil-tegafur versus surgery alone for serosa-negative, locally advanced gastric cancer. Br J Surg. 2007 Dec;94(12):1468-76. link to original article dosing details in abstract have been reviewed by our editors PubMed NCT00152243
- SAMIT: Tsuburaya A, Yoshida K, Kobayashi M, Yoshino S, Takahashi M, Takiguchi N, Tanabe K, Takahashi N, Imamura H, Tatsumoto N, Hara A, Nishikawa K, Fukushima R, Nozaki I, Kojima H, Miyashita Y, Oba K, Buyse M, Morita S, Sakamoto J. Sequential paclitaxel followed by tegafur and uracil (UFT) or S-1 versus UFT or S-1 monotherapy as adjuvant chemotherapy for T4a/b gastric cancer (SAMIT): a phase 3 factorial randomised controlled trial. Lancet Oncol. 2014 Jul;15(8):886-93. Epub 2014 Jun 18. link to original article PubMed UMIN C000000082
Metastatic or locally advanced disease, first-line
Capecitabine monotherapy
X: Xeloda (Capecitabine)
Regimen variant #1, 2000 mg/m2/day
Study | Dates of enrollment | Evidence | Comparator | Comparative Efficacy |
---|---|---|---|---|
Hwang et al. 2017 (SMC 2010-04-118) | 2010-2014 | Phase 3 (C) | XELOX | Did not meet primary endpoint of OS |
Lee et al. 2023 (KCSG ST13-10) | 2014-02 to 2019-01 | Phase 3 (C) | 1a. mFOLFOX6 1b. CapeOx 1c. Cisplatin & S-1 1d. CX |
Did not meet primary endpoint of OS Median OS: 7.5 vs 11.5 mo (HR 1.16, 95% CI 0.77-1.79) |
Note: to our knowledge, this regimen variant was not tested as an experimental arm in an RCT in this context, prior to becoming a standard comparator arm.
Eligibility criteria
- KCSG ST13-10: CrCl at least 60 mL/min
Regimen variant #2, 2500 mg/m2/day
Study | Dates of enrollment | Evidence |
---|---|---|
Hong et al. 2004 | Not reported | Phase 2 |
Eligibility criteria
- Karnofsky status of at least 70%
Chemotherapy
- Capecitabine (Xeloda) 1250 mg/m2 PO twice per day on days 1 to 14
21-day cycle for up to 6 cycles
References
- Hong YS, Song SY, Lee SI, Chung HC, Choi SH, Noh SH, Park JN, Han JY, Kang JH, Lee KS, Cho JY. A phase II trial of capecitabine in previously untreated patients with advanced and/or metastatic gastric cancer. Ann Oncol. 2004 Sep;15(9):1344-7. link to original article dosing details in manuscript have been reviewed by our editors PubMed
- SMC 2010-04-118: Hwang IG, Ji JH, Kang JH, Lee HR, Lee HY, Chi KC, Park SW, Lee SJ, Kim ST, Lee J, Park SH, Park JO, Park YS, Lim HY, Kang WK. A multi-center, open-label, randomized phase III trial of first-line chemotherapy with capecitabine monotherapy versus capecitabine plus oxaliplatin in elderly patients with advanced gastric cancer. J Geriatr Oncol. 2017 May;8(3):170-175. Epub 2017 Jan 21. link to original article dosing details in abstract have been reviewed by our editors PubMed NCT01470742
- KCSG ST13-10: Lee KW, Zang DY, Ryu MH, Han HS, Kim KH, Kim MJ, Koh SA, Lee SS, Koo DH, Ko YH, Sohn BS, Kim JW, Park JH, Nam BH, Choi IS. A Phase 3 Randomized Clinical Trial to Compare Efficacy and Safety between Combination Therapy and Monotherapy in Elderly Patients with Advanced Gastric Cancer (KCSG ST13-10). Cancer Res Treat. 2022 Oct;55(4):1250-1260. Epub 2023 May 25. link to original article dosing details in manuscript have been reviewed by our editors link to PMC article PubMed NCT02114359
Capecitabine & Cisplatin (CX)
CX: Cisplatin, Xeloda (Capecitabine)
XP: Xeloda (Capecitabine), Platinol (Cisplatin)
Regimen variant #1, 6 cycles
Study | Dates of enrollment | Evidence | Comparator | Comparative Efficacy |
---|---|---|---|---|
Ohtsu et al. 2011 (AVAGAST) | 2007-09 to 2008-12 | Phase 3 (C) | CX & Bevacizumab | Did not meet primary endpoint of OS |
Shen et al. 2014 (AVATAR) | 2009-03-25 to 2010-07-12 | Phase 3 (C) | CX & Bevacizumab | Did not meet primary endpoint of OS |
Lu et al. 2018 (PAC-C) | 2009-2014 | Phase 3 (C) | Capecitabine & Paclitaxel | Did not meet primary endpoint of PFS |
Note: The following studies included patients with GE junction malignancy as well:
- AVAGAST patients: 86% gastric and 14% GE junction. 5.4% of patients had an ECOG PS of 2.
Chemotherapy
- Cisplatin (Platinol) 80 mg/m2 IV over 2 hours once on day 1
- Capecitabine (Xeloda) 1000 mg/m2 PO twice per day on days 1 to 14
Supportive therapy
- Some protocols: "Hyperhydration" for cisplatin
21-day cycle for 6 cycles
Subsequent treatment
- AVAGAST & AVATAR: Capecitabine maintenance
Regimen variant #2, 8 cycles
Study | Dates of enrollment | Evidence | Comparator | Comparative Efficacy |
---|---|---|---|---|
Kim et al. 2014 (SMC 2008-12-019) | 2009-2012 | Phase 3 (C) | CX & Simvastatin | Did not meet primary endpoint of PFS |
Note: The following studies included patients with GE junction malignancy as well:
- SMC 2008-12-019 patients: 79% gastric, 16% GE junction and 5% unknown
Chemotherapy
- Cisplatin (Platinol) 80 mg/m2 IV once on day 1
- Capecitabine (Xeloda) 1000 mg/m2 PO twice per day on days 1 to 14
21-day cycle for 8 cycles
Subsequent treatment
- Capecitabine maintenance
Regimen variant #3, indefinite
Study | Dates of enrollment | Evidence | Comparator | Comparative Efficacy |
---|---|---|---|---|
Kang et al. 2009 (ML17032) | 2003-2005 | Phase 3 (E-switch-ic) | CF | Non-inferior PFS (primary endpoint) Median PFS: 5.6 vs 5 mo (HR 0.81, 95% CI 0.63-1.04) |
Lordick et al. 2013 (EXPAND) | 2008-2010 | Phase 3 (C) | CX & Cetuximab | Did not meet primary endpoint of PFS |
Fuchs et al. 2019 (RAINFALL) | 2015-01-28 to 2016-09-16 | Phase 3 (C) | CX & Ramucirumab | Did not meet primary endpoint of PFS1 |
1while the primary analysis of RAINFALL showed that this arm seemed to have inferior PFS, independent central review did not confirm this finding.
The following studies included patients with GE junction malignancy as well:
- EXPAND patients: 83% gastric, 5% GE junction and 16% unknown
Chemotherapy
- Cisplatin (Platinol) 80 mg/m2 IV over 2 hours once on day 1
- Capecitabine (Xeloda) 1000 mg/m2 PO twice per day on days 1 to 14
- Alternate dosing in EXPAND: 1000 mg/m2 PO twice per day from the evening of day 1 to the morning of day 15 (28 doses per cycle)
Supportive therapy
- Some protocols: "Hyperhydration" for cisplatin
21-day cycles
References
- ML17032: Kang YK, Kang WK, Shin DB, Chen J, Xiong J, Wang J, Lichinitser M, Guan Z, Khasanov R, Zheng L, Philco-Salas M, Suarez T, Santamaria J, Forster G, McCloud PI. Capecitabine/cisplatin versus 5-fluorouracil/cisplatin as first-line therapy in patients with advanced gastric cancer: a randomised phase III noninferiority trial. Ann Oncol. 2009 Apr;20(4):666-73. Epub 2009 Jan 19. link to original article dosing details in manuscript have been reviewed by our editors PubMed content property of HemOnc.org NCT02563054
- AVAGAST: Ohtsu A, Shah MA, Van Cutsem E, Rha SY, Sawaki A, Park SR, Lim HY, Yamada Y, Wu J, Langer B, Starnawski M, Kang YK. Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a randomized, double-blind, placebo-controlled phase III study. J Clin Oncol. 2011 Oct 20;29(30):3968-76. Epub 2011 Aug 15. link to original article dosing details in manuscript have been reviewed by our editors PubMed NCT00548548
- EXPAND: Lordick F, Kang YK, Chung HC, Salman P, Oh SC, Bodoky G, Kurteva G, Volovat C, Moiseyenko VM, Gorbunova V, Park JO, Sawaki A, Celik I, Götte H, Melezínková H, Moehler M; Arbeitsgemeinschaft Internistische Onkologie. Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND): a randomised, open-label phase 3 trial. Lancet Oncol. 2013 May;14(6):490-9. Epub 2013 Apr 15. link to original article dosing details in manuscript have been reviewed by our editors PubMed NCT00678535
- AVATAR: Shen L, Li J, Xu J, Pan H, Dai G, Qin S, Wang L, Wang J, Yang Z, Shu Y, Xu R, Chen L, Liu Y, Yu S, Bu L, Piao Y. Bevacizumab plus capecitabine and cisplatin in Chinese patients with inoperable locally advanced or metastatic gastric or gastroesophageal junction cancer: randomized, double-blind, phase III study (AVATAR study). Gastric Cancer. 2015 Jan;18(1):168-76. Epub 2014 Feb 21. link to original article link to PMC article dosing details in manuscript have been reviewed by our editors PubMed NCT00887822
- SMC 2008-12-019: Kim ST, Kang JH, Lee J, Park SH, Park JO, Park YS, Lim HY, Hwang IG, Lee SC, Park KW, Lee HR, Kang WK. Simvastatin plus capecitabine-cisplatin versus placebo plus capecitabine-cisplatin in patients with previously untreated advanced gastric cancer: a double-blind randomised phase 3 study. Eur J Cancer. 2014 Nov;50(16):2822-30. Epub 2014 Sep 15. link to original article dosing details in manuscript have been reviewed by our editors PubMed NCT01099085
- PAC-C: Lu Z, Zhang X, Liu W, Liu T, Hu B, Li W, Fan Q, Xu J, Xu N, Bai Y, Pan Y, Xu Q, Bai W, Xia L, Gao Y, Wang W, Shu Y, Shen L. A multicenter, randomized trial comparing efficacy and safety of paclitaxel/capecitabine and cisplatin/capecitabine in advanced gastric cancer. Gastric Cancer. 2018 Sep;21(5):782-791. Epub 2018 Feb 27. link to original article link to PMC article dosing details in manuscript have been reviewed by our editors PubMed NCT01015339
- RAINFALL: Fuchs CS, Shitara K, Di Bartolomeo M, Lonardi S, Al-Batran SE, Van Cutsem E, Ilson DH, Alsina M, Chau I, Lacy J, Ducreux M, Mendez GA, Alavez AM, Takahari D, Mansoor W, Enzinger PC, Gorbounova V, Wainberg ZA, Hegewisch-Becker S, Ferry D, Lin J, Carlesi R, Das M, Shah MA; RAINFALL Study Group. Ramucirumab with cisplatin and fluoropyrimidine as first-line therapy in patients with metastatic gastric or junctional adenocarcinoma (RAINFALL): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncol. 2019 Mar;20(3):420-435. Epub 2019 Feb 1. Erratum in: Lancet Oncol. 2019 May;20(5):e242. link to original article dosing details in abstract have been reviewed by our editors PubMed NCT02314117
Capecitabine & Cisplatin (CX) & Pembrolizumab
CX & Pembrolizumab: Cisplatin, Xeloda (Capecitabine), Pembrolizumab
Regimen
Study | Dates of enrollment | Evidence | Comparator | Comparative Efficacy |
---|---|---|---|---|
Shitara et al. 2020 (KEYNOTE-062) | 2015-2017 | Phase 3 (E-esc) | 1a. CF 1b. CX |
Might have superior OS1 (co-primary endpoint) Median OS: 12.5 vs 11.1 mo (HR 0.85, 95% CI 0.70-1.03) |
2. Pembrolizumab | Not reported |
1Reported efficacy is for patients with CPS of 1 or greater.
Note: KEYNOTE-062 included patients with GEJ malignancy.
Biomarker eligibility criteria
PD-L1 Combined Positive Score (CPS) of 1 or more as determined by an FDA-approved test
Chemotherapy
- Capecitabine (Xeloda) 1000 mg/m2 PO twice per day on days 1 to 14
- Cisplatin (Platinol) 80 mg/m2 IV once on day 1
Immunotherapy
- Pembrolizumab (Keytruda) 200 mg IV once on day 1
21-day cycles
References
- KEYNOTE-062: Shitara K, Van Cutsem E, Bang YJ, Fuchs C, Wyrwicz L, Lee KW, Kudaba I, Garrido M, Chung HC, Lee J, Castro HR, Mansoor W, Braghiroli MI, Karaseva N, Caglevic C, Villanueva L, Goekkurt E, Satake H, Enzinger P, Alsina M, Benson A, Chao J, Ko AH, Wainberg ZA, Kher U, Shah S, Kang SP, Tabernero J. Efficacy and Safety of Pembrolizumab or Pembrolizumab Plus Chemotherapy vs Chemotherapy Alone for Patients With First-line, Advanced Gastric Cancer: The KEYNOTE-062 Phase 3 Randomized Clinical Trial. JAMA Oncol. 2020 Oct 1;6(10):1571-1580. Epub 2020 Sep 3. link to original article link to PMC article dosing details in manuscript have been reviewed by our editors PubMed NCT02494583
CapeOx
CapeOX: Capecitabine & OXaliplatin
Regimen variant #1, 750/78
Study | Dates of enrollment | Evidence | Comparator | Comparative Efficacy |
---|---|---|---|---|
Hall et al. 2021 (GO2) | 2014-2017 | Phase 3 (E-de-esc) | 1. CapeOx; 1000/104 | Not reported |
2. CapeOx; 1250/130 | Non-inferior PFS (primary endpoint) (HR 1.10, 95% CI 0.90-1.33) |
Chemotherapy
- Capecitabine (Xeloda) 375 mg/m2 PO twice per day
- Oxaliplatin (Eloxatin) 78 mg/m2 IV once on day 1
21-day cycles
Regimen variant #2, 1000/104
Study | Dates of enrollment | Evidence | Comparator | Comparative Efficacy |
---|---|---|---|---|
Hall et al. 2021 (GO2) | 2014-2017 | Phase 3 (E-de-esc) | 1. CapeOx; 750/78 | Not reported |
2. CapeOx; 1250/130 | Non-inferior PFS (primary endpoint) (HR 1.09, 95% CI 0.89-1.32) |
Chemotherapy
- Capecitabine (Xeloda) 500 mg/m2 PO twice per day
- Oxaliplatin (Eloxatin) 104 mg/m2 IV once on day 1
21-day cycles
Regimen variant #3, 1250/130
Study | Dates of enrollment | Evidence | Comparator | Comparative Efficacy |
---|---|---|---|---|
Hall et al. 2021 (GO2) | 2014-2017 | Phase 3 (C) | 1. CapeOx; 750/78 2. CapeOx; 1000/104 |
Non-inferior PFS |
Chemotherapy
- Capecitabine (Xeloda) 625 mg/m2 PO twice per day
- Oxaliplatin (Eloxatin) 130 mg/m2 IV once on day 1
21-day cycles
Regimen variant #4, 1700/130
Study | Dates of enrollment | Evidence |
---|---|---|
Jatoi et al. 2006 | 2002-2004 | Phase 2 |
Chemotherapy
- Capecitabine (Xeloda) 850 mg/m2 PO twice per day on days 1 to 14
- Oxaliplatin (Eloxatin) 130 mg/m2 IV once on day 1
21-day cycles
Regimen variant #5, 2000/130
Chemotherapy
- Capecitabine (Xeloda) 1000 mg/m2 PO twice per day on days 1 to 14
- Oxaliplatin (Eloxatin) 130 mg/m2 IV once on day 1
21-day cycles
Regimen variant #6, 2000/130, limited oxaliplatin
Study | Dates of enrollment | Evidence | Comparator | Comparative Efficacy |
---|---|---|---|---|
Zhu et al. 2022 (EXELOX) | 2015-2020 | Phase 3 (E-de-esc) | EOX | Non-inferior PFS (primary endpoint) Median PFS: 5 vs 5.5 mo (HR 0.989, 95% CI 0.81-1.20) |
Shah et al. 2023 (GLOWgastric) | 2018-11-28 to 2022-02-18 | Phase 3 (C) | CapeOx & Zolbetuximab | Seems to have inferior OS (secondary endpoint) Inferior PFS (primary endpoint) |
Note: GLOW should not be confused by the trial of the same name in CLL. In GLOW, continuation of capecitabine past cycle 8 was at the investigator's discretion.
Biomarker eligibility criteria
- GLOWgastric: CLDN18.2 positive
Chemotherapy
- Capecitabine (Xeloda) 1000 mg/m2 PO twice per day on days 1 to 14
- Oxaliplatin (Eloxatin) as follows:
- Cycles 1 up to 8: 130 mg/m2 IV once on day 1
21-day cycles
References
- Jatoi A, Murphy BR, Foster NR, Nikcevich DA, Alberts SR, Knost JA, Fitch TR, Rowland KM Jr; North Central Cancer Treatment Group. Oxaliplatin and capecitabine in patients with metastatic adenocarcinoma of the esophagus, gastroesophageal junction and gastric cardia: a phase II study from the North Central Cancer Treatment Group. Ann Oncol. 2006 Jan;17(1):29-34. Epub 2005 Nov 22. link to original article dosing details in abstract have been reviewed by our editors PubMed
- JAVELIN Gastric 100: Moehler M, Dvorkin M, Boku N, Özgüroğlu M, Ryu MH, Muntean AS, Lonardi S, Nechaeva M, Bragagnoli AC, Coşkun HS, Cubillo Gracian A, Takano T, Wong R, Safran H, Vaccaro GM, Wainberg ZA, Silver MR, Xiong H, Hong J, Taieb J, Bang YJ. Phase III Trial of Avelumab Maintenance After First-Line Induction Chemotherapy Versus Continuation of Chemotherapy in Patients With Gastric Cancers: Results From JAVELIN Gastric 100. J Clin Oncol. 2021 Mar 20;39(9):966-977. Epub 2020 Nov 16. link to original article dosing details in manuscript have been reviewed by our editors link to PMC article PubMed NCT02625610
- CheckMate 649: Janjigian YY, Shitara K, Moehler M, Garrido M, Salman P, Shen L, Wyrwicz L, Yamaguchi K, Skoczylas T, Campos Bragagnoli A, Liu T, Schenker M, Yanez P, Tehfe M, Kowalyszyn R, Karamouzis MV, Bruges R, Zander T, Pazo-Cid R, Hitre E, Feeney K, Cleary JM, Poulart V, Cullen D, Lei M, Xiao H, Kondo K, Li M, Ajani JA. First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial. Lancet. 2021 Jul 3;398(10294):27-40. Epub 2021 Jun 5. link to original article dosing details in manuscript have been reviewed by our editors link to PMC article PubMed NCT02872116
- Update: Shitara K, Ajani JA, Moehler M, Garrido M, Gallardo C, Shen L, Yamaguchi K, Wyrwicz L, Skoczylas T, Bragagnoli AC, Liu T, Tehfe M, Elimova E, Bruges R, Zander T, de Azevedo S, Kowalyszyn R, Pazo-Cid R, Schenker M, Cleary JM, Yanez P, Feeney K, Karamouzis MV, Poulart V, Lei M, Xiao H, Kondo K, Li M, Janjigian YY. Nivolumab plus chemotherapy or ipilimumab in gastro-oesophageal cancer. Nature. 2022 Mar;603(7903):942-948. Epub 2022 Mar 23. link to original article link to PMC article PubMed
- HRQoL analysis: Moehler M, Xiao H, Blum SI, Elimova E, Cella D, Shitara K, Ajani JA, Janjigian YY, Garrido M, Shen L, Yamaguchi K, Liu T, Schenker M, Kowalyszyn R, Bragagnoli AC, Bruges R, Montesarchio V, Pazo-Cid R, Hunter S, Davenport E, Wang J, Kondo K, Li M, Wyrwicz L. Health-Related Quality of Life With Nivolumab Plus Chemotherapy Versus Chemotherapy in Patients With Advanced Gastric/Gastroesophageal Junction Cancer or Esophageal Adenocarcinoma From CheckMate 649. J Clin Oncol. 2023 Dec 10;41(35):5388-5399. Epub 2023 Sep 15. link to original article link to PMC article PubMed
- Update: Janjigian YY, Ajani JA, Moehler M, Shen L, Garrido M, Gallardo C, Wyrwicz L, Yamaguchi K, Cleary JM, Elimova E, Karamouzis M, Bruges R, Skoczylas T, Bragagnoli A, Liu T, Tehfe M, Zander T, Kowalyszyn R, Pazo-Cid R, Schenker M, Feeny K, Wang R, Lei M, Chen C, Nathani R, Shitara K. First-Line Nivolumab Plus Chemotherapy for Advanced Gastric, Gastroesophageal Junction, and Esophageal Adenocarcinoma: 3-Year Follow-Up of the Phase III CheckMate 649 Trial. J Clin Oncol. 2024 Jun 10;42(17):2012-2020. Epub 2024 Feb 21. link to original article link to PMC article PubMed
- GO2: Hall PS, Swinson D, Cairns DA, Waters JS, Petty R, Allmark C, Ruddock S, Falk S, Wadsley J, Roy R, Tillett T, Nicoll J, Cummins S, Mano J, Grumett S, Stokes Z, Kamposioras KV, Chatterjee A, Garcia A, Waddell T, Guptal K, Maisey N, Khan M, Dent J, Lord S, Crossley A, Katona E, Marshall H, Grabsch HI, Velikova G, Ow PL, Handforth C, Howard H, Seymour MT; GO2 Trial Investigators. Efficacy of Reduced-Intensity Chemotherapy With Oxaliplatin and Capecitabine on Quality of Life and Cancer Control Among Older and Frail Patients With Advanced Gastroesophageal Cancer: The GO2 Phase 3 Randomized Clinical Trial. JAMA Oncol. 2021 Jun 1;7(6):869-877. Erratum in: JAMA Oncol. 2021 Aug 1;7(8):1249. link to original article link to PMC article dosing details in manuscript have been reviewed by our editors PubMed ISRCTN44687907
- ATTRACTION-4: Kang YK, Chen LT, Ryu MH, Oh DY, Oh SC, Chung HC, Lee KW, Omori T, Shitara K, Sakuramoto S, Chung IJ, Yamaguchi K, Kato K, Sym SJ, Kadowaki S, Tsuji K, Chen JS, Bai LY, Oh SY, Choda Y, Yasui H, Takeuchi K, Hirashima Y, Hagihara S, Boku N. Nivolumab plus chemotherapy versus placebo plus chemotherapy in patients with HER2-negative, untreated, unresectable advanced or recurrent gastric or gastro-oesophageal junction cancer (ATTRACTION-4): a randomised, multicentre, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2022 Feb;23(2):234-247. Epub 2022 Jan 11. link to original article dosing details in abstract have been reviewed by our editors PubMed NCT02746796
- EXELOX: Zhu XD, Huang MZ, Wang YS, Feng WJ, Chen ZY, He YF, Zhang XW, Liu X, Wang CC, Zhang W, Ying JE, Wu J, Yang L, Qin YR, Luo JF, Zhao XY, Li WH, Zhang Z, Qiu LX, Geng QR, Zou JL, Zhang JY, Zheng H, Song XF, Wu SS, Zhang CY, Gong Z, Liu QQ, Wang XF, Xu Q, Wang Q, Ji JM, Zhao J, Guo WJ. XELOX doublet regimen versus EOX triplet regimen as first-line treatment for advanced gastric cancer: An open-labeled, multicenter, randomized, prospective phase III trial (EXELOX). Cancer Commun (Lond). 2022 Apr;42(4):314-326. Epub 2022 Feb 25. link to original article link to PMC article dosing details in manuscript have been reviewed by our editors PubMed NCT02395640
- GLOWgastric: Shah MA, Shitara K, Ajani JA, Bang YJ, Enzinger P, Ilson D, Lordick F, Van Cutsem E, Gallego Plazas J, Huang J, Shen L, Oh SC, Sunpaweravong P, Soo Hoo HF, Turk HM, Oh M, Park JW, Moran D, Bhattacharya P, Arozullah A, Xu RH. Zolbetuximab plus CAPOX in CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma: the randomized, phase 3 GLOW trial. Nat Med. 2023 Aug;29(8):2133-2141. Epub 2023 Jul 31. link to original article link to PMC article dosing details in manuscript have been reviewed by our editors PubMed NCT03653507
- KEYNOTE-859: Rha SY, Oh DY, Yañez P, Bai Y, Ryu MH, Lee J, Rivera F, Alves GV, Garrido M, Shiu KK, Fernández MG, Li J, Lowery MA, Çil T, Cruz FM, Qin S, Luo S, Pan H, Wainberg ZA, Yin L, Bordia S, Bhagia P, Wyrwicz LS; KEYNOTE-859 investigators. Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): a multicentre, randomised, double-blind, phase 3 trial. Lancet Oncol. 2023 Nov;24(11):1181-1195. Epub 2023 Oct 21. link to original article dosing details in abstract have been reviewed by our editors PubMed NCT03675737
- RATIONALE-305: Qiu MZ, Oh DY, Kato K, Arkenau T, Tabernero J, Correa MC, Zimina AV, Bai Y, Shi J, Lee KW, Wang J, Poddubskaya E, Pan H, Rha SY, Zhang R, Hirano H, Spigel D, Yamaguchi K, Chao Y, Wyrwicz L, Disel U, Cid RP, Fornaro L, Evesque L, Wang H, Xu Y, Li J, Sheng T, Yang S, Li L, Moehler M, Xu RH; RATIONALE-305 Investigators. Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first line treatment for advanced gastric or gastro-oesophageal junction adenocarcinoma: RATIONALE-305 randomised, double blind, phase 3 trial. BMJ. 2024 May 28;385:e078876. link to original article contains dosing details on CT.gov PubMed NCT03777657
- ARMANI: NCT02934464
- ORIENT-16: NCT03745170
CapeOx & Nivolumab
CapeOx & Nivolumab: Capecitabine, OXaliplatin, Nivolumab
Regimen
Study | Dates of enrollment | Evidence | Comparator | Comparative Efficacy |
---|---|---|---|---|
Kang et al. 2022 (ATTRACTION-4) | 2017-03-23 to 2018-05-10 | Phase 3 (E-esc) | 1a. CapeOx 1b. SOX |
Superior PFS (co-primary endpoint) Median PFS: 10.45 vs 8.3 mo (HR 0.68, 98.51% CI 0.51-0.90) Did not meet co-primary endpoint of OS Median OS: 17.45 vs 17.15 mo (HR 0.90, 95% CI 0.75-1.08) |
Janjigian et al. 2021 (CheckMate 649) | 2017-03 to 2019-04 | Phase 3 (E-RT-esc) | 1a. CapeOx 1b. mFOLFOX6 |
Superior OS1 (co-primary endpoint) Median OS: 14.4 vs 11.1 mo (HR 0.70, 95% CI 0.61-0.81) |
2. Ipilimumab & Nivolumab | Not reported |
1Reported efficacy and MCBS score are for the group with PD-L1 CPS of 5 or more; reported efficacy is based on the 2022 update.
Chemotherapy
- Capecitabine (Xeloda) 1000 mg/m2 PO twice per day on days 1 to 14
- Oxaliplatin (Eloxatin) 130 mg/m2 IV once on day 1
Immunotherapy
- Nivolumab (Opdivo) 360 mg IV once on day 1
21-day cycles
References
- CheckMate 649: Janjigian YY, Shitara K, Moehler M, Garrido M, Salman P, Shen L, Wyrwicz L, Yamaguchi K, Skoczylas T, Campos Bragagnoli A, Liu T, Schenker M, Yanez P, Tehfe M, Kowalyszyn R, Karamouzis MV, Bruges R, Zander T, Pazo-Cid R, Hitre E, Feeney K, Cleary JM, Poulart V, Cullen D, Lei M, Xiao H, Kondo K, Li M, Ajani JA. First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial. Lancet. 2021 Jul 3;398(10294):27-40. Epub 2021 Jun 5. link to original article dosing details in manuscript have been reviewed by our editors link to PMC article PubMed NCT02872116
- Update: Shitara K, Ajani JA, Moehler M, Garrido M, Gallardo C, Shen L, Yamaguchi K, Wyrwicz L, Skoczylas T, Bragagnoli AC, Liu T, Tehfe M, Elimova E, Bruges R, Zander T, de Azevedo S, Kowalyszyn R, Pazo-Cid R, Schenker M, Cleary JM, Yanez P, Feeney K, Karamouzis MV, Poulart V, Lei M, Xiao H, Kondo K, Li M, Janjigian YY. Nivolumab plus chemotherapy or ipilimumab in gastro-oesophageal cancer. Nature. 2022 Mar;603(7903):942-948. Epub 2022 Mar 23. link to original article link to PMC article PubMed
- HRQoL analysis: Moehler M, Xiao H, Blum SI, Elimova E, Cella D, Shitara K, Ajani JA, Janjigian YY, Garrido M, Shen L, Yamaguchi K, Liu T, Schenker M, Kowalyszyn R, Bragagnoli AC, Bruges R, Montesarchio V, Pazo-Cid R, Hunter S, Davenport E, Wang J, Kondo K, Li M, Wyrwicz L. Health-Related Quality of Life With Nivolumab Plus Chemotherapy Versus Chemotherapy in Patients With Advanced Gastric/Gastroesophageal Junction Cancer or Esophageal Adenocarcinoma From CheckMate 649. J Clin Oncol. 2023 Dec 10;41(35):5388-5399. Epub 2023 Sep 15. link to original article link to PMC article PubMed
- Update: Janjigian YY, Ajani JA, Moehler M, Shen L, Garrido M, Gallardo C, Wyrwicz L, Yamaguchi K, Cleary JM, Elimova E, Karamouzis M, Bruges R, Skoczylas T, Bragagnoli A, Liu T, Tehfe M, Zander T, Kowalyszyn R, Pazo-Cid R, Schenker M, Feeny K, Wang R, Lei M, Chen C, Nathani R, Shitara K. First-Line Nivolumab Plus Chemotherapy for Advanced Gastric, Gastroesophageal Junction, and Esophageal Adenocarcinoma: 3-Year Follow-Up of the Phase III CheckMate 649 Trial. J Clin Oncol. 2024 Jun 10;42(17):2012-2020. Epub 2024 Feb 21. link to original article link to PMC article PubMed
- ATTRACTION-4: Kang YK, Chen LT, Ryu MH, Oh DY, Oh SC, Chung HC, Lee KW, Omori T, Shitara K, Sakuramoto S, Chung IJ, Yamaguchi K, Kato K, Sym SJ, Kadowaki S, Tsuji K, Chen JS, Bai LY, Oh SY, Choda Y, Yasui H, Takeuchi K, Hirashima Y, Hagihara S, Boku N. Nivolumab plus chemotherapy versus placebo plus chemotherapy in patients with HER2-negative, untreated, unresectable advanced or recurrent gastric or gastro-oesophageal junction cancer (ATTRACTION-4): a randomised, multicentre, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2022 Feb;23(2):234-247. Epub 2022 Jan 11. link to original article dosing details in abstract have been reviewed by our editors PubMed NCT02746796
CapeOx & Pembrolizumab
CapeOx & Pembrolizumab: Capecitabine, OXaliplatin, Pembrolizumab
Regimen
Study | Dates of enrollment | Evidence | Comparator | Comparative Efficacy |
---|---|---|---|---|
Rha et al. 2023 (KEYNOTE-859) | 2018-11-08 to 2021-06-11 | Phase 3 (E-RT-esc) | 1a. CF 1b. CapeOx |
Superior OS (primary endpoint) Median OS: 12.9 vs 11.5 mo (HR 0.78, 95% CI 0.70-0.87) |
KEYNOTE-859 included patients with GEJ malignancy
Biomarker eligibility criteria
- PD-L1 Combined Positive Score (CPS) of 1 or more as determined by an FDA-approved test
Chemotherapy
- Capecitabine (Xeloda) 1000 mg/m2 PO twice per day on days 1 to 14
- Oxaliplatin (Eloxatin) 130 mg/m2 IV once on day 1
Immunotherapy
- Pembrolizumab (Keytruda) 200 mg IV once on day 1
21-day cycle for up to 35 cycles
References
- KEYNOTE-859: Rha SY, Oh DY, Yañez P, Bai Y, Ryu MH, Lee J, Rivera F, Alves GV, Garrido M, Shiu KK, Fernández MG, Li J, Lowery MA, Çil T, Cruz FM, Qin S, Luo S, Pan H, Wainberg ZA, Yin L, Bordia S, Bhagia P, Wyrwicz LS; KEYNOTE-859 investigators. Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): a multicentre, randomised, double-blind, phase 3 trial. Lancet Oncol. 2023 Nov;24(11):1181-1195. Epub 2023 Oct 21. link to original article dosing details in abstract have been reviewed by our editors PubMed NCT03675737
CapeOx & Tislelizumab
CapeOX & Tislelizumab: Capecitabine, OXaliplatin, Tislelizumab
Regimen
Study | Dates of enrollment | Evidence | Comparator | Comparative Efficacy |
---|---|---|---|---|
Qiu et al. 2024 (RATIONALE-305) | 2018-12-13 to 2021-02-09 | Phase 3 (E-esc) | 1a. CapeOx 1b. CF |
Superior OS (primary endpoint) Median OS: 15 vs 12.9 mo (HR 0.80, 95% CI 0.70-0.92) |
Chemotherapy
- Capecitabine (Xeloda) 1000 mg/m2 PO twice per day on days 1 to 14
- Oxaliplatin (Eloxatin) 130 mg/m2 IV once on day 1
Immunotherapy
- Tislelizumab (Baizean) 200 mg IV once on day 1
21-day cycles
References
- RATIONALE-305: Qiu MZ, Oh DY, Kato K, Arkenau T, Tabernero J, Correa MC, Zimina AV, Bai Y, Shi J, Lee KW, Wang J, Poddubskaya E, Pan H, Rha SY, Zhang R, Hirano H, Spigel D, Yamaguchi K, Chao Y, Wyrwicz L, Disel U, Cid RP, Fornaro L, Evesque L, Wang H, Xu Y, Li J, Sheng T, Yang S, Li L, Moehler M, Xu RH; RATIONALE-305 Investigators. Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first line treatment for advanced gastric or gastro-oesophageal junction adenocarcinoma: RATIONALE-305 randomised, double blind, phase 3 trial. BMJ. 2024 May 28;385:e078876. link to original article contains dosing details on CT.gov PubMed NCT03777657
Carboplatin & Paclitaxel (CP)
Regimen
Study | Dates of enrollment | Evidence |
---|---|---|
Philip et al. 1997 | Not reported in abstract | Phase 2 |
Gadgeel et al. 2003 | 1996-2000 | Phase 2 |
Note: In contrast to the original reference, some guidelines list the dosage of carboplatin as AUC 6. Philip et al. included patients with locally advanced metastatic or recurrent esophageal or gastric cancer. Gadgeel et al. study showed an ORR of 35%.
Chemotherapy
- Carboplatin (Paraplatin) AUC 5 IV once on day 1, given second
- Paclitaxel (Taxol) 200 mg/m2 IV over 3 hours once on day 1, given first
21-day cycles
References
- Philip PA, Zalupski MM, Gadgeel S, Hussain M, Shields A. A phase II study of carboplatin and paclitaxel in the treatment of patients with advanced esophageal and gastric cancer. Semin Oncol. 1997 Dec;24(6 Suppl 19):S19-86-S19-88. dosing details in abstract have been reviewed by our editors PubMed
- Gadgeel SM, Shields AF, Heilbrun LK, Labadidi S, Zalupski M, Chaplen R, Philip PA. Phase II study of paclitaxel and carboplatin in patients with advanced gastric cancer. Am J Clin Oncol. 2003 Feb;26(1):37-41. link to original article dosing details in abstract have been reviewed by our editors PubMed
Cisplatin & Docetaxel (DC)
DC: Docetaxel, Cisplatin
TC: Taxotere (Docetaxel), Cisplatin
Regimen variant #1, 75/75
Study | Dates of enrollment | Evidence | Comparator | Comparative Efficacy |
---|---|---|---|---|
Roth et al. 2007 | 1999-2003 | Randomized Phase 2 (E-de-esc) | 1. ECF | Not reported |
2. TCF | Might have inferior ORR |
Note: the protocol was amended to change the original dose of docetaxel from 85 mg/m2 to 75 mg/m2 based on high incidence of febrile neutropenia.
Chemotherapy
- Cisplatin (Platinol) 75 mg/m2 IV over 4 hours once on day 1
- Docetaxel (Taxotere) 75 mg/m2 IV over 60 minutes once on day 1
Supportive therapy
- 3 liters per day "hyperhydration"
- Dexamethasone (Decadron) 8 mg PO given 12 hours & 6 hours prior to docetaxel, then 8 mg PO twice per day for 4 days after docetaxel
- 5-HT3 antagonist for emesis prophylaxis
- Growth factor support allowed, such as with Filgrastim (Neupogen)
21-day cycle for up to 8 cycles
Regimen variant #2, 75/85
Study | Dates of enrollment | Evidence | Comparator | Comparative Efficacy |
---|---|---|---|---|
Ajani et al. 2005 (V-325) | 1998-1999 | Randomized Phase 2 (C) | DCF | Seems to have inferior ORR |
Note: patients had 100% adenocarcinoma histology (32% esophagogastric junction/fundus and 68% gastric antrum/body). 95% were metastatic. 1% with Karnofsky PS score of 70.
Chemotherapy
- Cisplatin (Platinol) 75 mg/m2 IV over 1 to 3 hours once on day 1
- Docetaxel (Taxotere) 85 mg/m2 IV over 60 minutes once on day 1
Supportive therapy
- Dexamethasone (Decadron) 8 mg PO the night before chemotherapy, the morning of day 1, 1 hour before chemotherapy, the night of day 1, the morning of day 2, and the evening of day 2 (total dose per cycle: 48 mg)
- Dexamethasone (Decadron) 20 mg IV prior to cisplatin and 8 hours after cisplatin
- Ondansetron (Zofran) 8 mg IV prior to cisplatin, 4 hours after cisplatin, and 8 hours after cisplatin
- "Hydration was administered in a standard manner"
21-day cycles
References
- V-325: Ajani JA, Fodor MB, Tjulandin SA, Moiseyenko VM, Chao Y, Cabral Filho S, Majlis A, Assadourian S, Van Cutsem E. Phase II multi-institutional randomized trial of docetaxel plus cisplatin with or without fluorouracil in patients with untreated, advanced gastric, or gastroesophageal adenocarcinoma. J Clin Oncol. 2005 Aug 20;23(24):5660-7. link to original article dosing details in manuscript have been reviewed by our editors PubMed
- Roth AD, Fazio N, Stupp R, Falk S, Bernhard J, Saletti P, Köberle D, Borner MM, Rufibach K, Maibach R, Wernli M, Leslie M, Glynne-Jones R, Widmer L, Seymour M, de Braud F; Swiss Group for Clinical Cancer Research. Docetaxel, cisplatin, and fluorouracil; docetaxel and cisplatin; and epirubicin, cisplatin, and fluorouracil as systemic treatment for advanced gastric carcinoma: a randomized phase II trial of the Swiss Group for Clinical Cancer Research. J Clin Oncol. 2007 Aug 1;25(22):3217-23. link to original article dosing details in manuscript have been reviewed by our editors PubMed
Cisplatin & Fluorouracil (CF)
CF: Cisplatin, Fluorouracil
FP: Fluorouracil, Platinol (Cisplatin)
Regimen variant #1, 60/5000
Study | Dates of enrollment | Evidence | Comparator | Comparative Efficacy |
---|---|---|---|---|
Lee et al. 2009a | 2000-2004 | Phase 3 (C) | Fluorouracil & Heptaplatin (FH) | Equivalent OS |
Note: this is reported to be an equivalence study but the statistical analysis does not provide details on the definition of equivalence.
Chemotherapy
- Cisplatin (Platinol) 60 mg/m2 IV over 60 minutes once on day 1, given first
- Fluorouracil (5-FU) 1000 mg/m2 IV over 12 hours once per day on days 1 to 5, given second
28-day cycles
Regimen variant #2, 80/4000 x 8
Study | Dates of enrollment | Evidence | Comparator | Comparative Efficacy |
---|---|---|---|---|
Ajani et al. 2017 (DIGEST) | 2011-2014 | Phase 3 (C) | CS | Did not meet primary endpoint of OS |
Chemotherapy
- Cisplatin (Platinol) 80 mg/m2 IV over 1 to 3 hours once on day 1, given first
- Fluorouracil (5-FU) 800 mg/m2/day IV continuous infusion over 120 hours, started on day 1, given second (total dose per cycle: 4000 mg/m2)
Supportive therapy
- Some protocols: "Hyperhydration" for cisplatin
21-day cycle for 8 cycles
Regimen variant #3, 80/4000, indefinite
Study | Dates of enrollment | Evidence | Comparator | Comparative Efficacy |
---|---|---|---|---|
Kang et al. 2009 (ML17032) | 2003-2005 | Phase 3 (C) | CX | Non-inferior PFS |
Shitara et al. 2020 (KEYNOTE-062) | 2015-2017 | Phase 3 (C) | 1a. CF & Pembrolizumab 1b. CX & Pembrolizumab |
Might have inferior OS |
2. Pembrolizumab | Non-inferior OS | |||
Qiu et al. 2024 (RATIONALE-305) | 2018-12-13 to 2021-02-09 | Phase 3 (C) | 1a. CapeOx & Tislelizumab 1b. CF & Tislelizumab |
Inferior OS |
Rha et al. 2023 (KEYNOTE-859) | 2018-11-08 to 2021-06-11 | Phase 3 (C) | 1a. CapeOx & Pembrolizumab 1b. CF & Pembrolizumab |
Inferior OS |
Chemotherapy
- Cisplatin (Platinol) 80 mg/m2 IV over 1 to 3 hours once on day 1, given first
- Fluorouracil (5-FU) 800 mg/m2/day IV continuous infusion over 120 hours, started on day 1, given second (total dose per cycle: 4000 mg/m2)
Supportive therapy
- Some protocols: "Hyperhydration" for cisplatin
21-day cycles
Regimen variant #4, 100/4000
Study | Dates of enrollment | Evidence | Comparator | Comparative Efficacy |
---|---|---|---|---|
Duffour et al. 2006 (FFCD 9404) | 1995-1998 | Phase 3 (C) | FLP | Inconclusive whether non-inferior ORR |
Chemotherapy
- Cisplatin (Platinol) 100 mg/m2 IV over 60 minutes once on either day 1 or 2
- Fluorouracil (5-FU) 800 mg/m2/day IV continuous infusion over 120 hours, started on day 1 (total dose per cycle: 4000 mg/m2)
28-day cycles
Regimen variant #5, 100/4000, split-dose cisplatin
Study | Dates of enrollment | Evidence | Comparator | Comparative Efficacy |
---|---|---|---|---|
Ohtsu et al. 2003 (JCOG 9205) | 1992-1997 | Phase 3 (E-esc) | 1. Fluorouracil | Did not meet primary endpoint of OS |
2. UFTM | Did not meet primary endpoint of OS |
Note: this study included patients with ECOG PS of 2 (9.6%)
Chemotherapy
- Cisplatin (Platinol) 20 mg/m2 IV over 30 minutes once per day on days 1 to 5
- Fluorouracil (5-FU) 800 mg/m2/day IV continuous infusion over 120 hours, started on day 1 (total dose per cycle: 4000 mg/m2)
28-day cycle for up to 6 cycles
Regimen variant #6, 100/5000
Study | Dates of enrollment | Evidence | Comparator | Comparative Efficacy |
---|---|---|---|---|
Van Cutsem et al. 2006 (TAX 325) | 1999-2003 | Phase 3 (C) | DCF | Seems to have inferior OS |
Dank et al. 2008 | 2000-2002 | Phase 3 (C) | IF | Might have inferior TTP |
Ajani et al. 2010 (FLAGS) | 2005-2007 | Phase 3 (C) | CS | Did not meet primary endpoint of OS |
Note: TAX 325 patients had 100% adenocarcinoma histology (22% Esophagogastric junction, 88% gastric origin). 97% with metastatic disease. 1% with Karnosky PS of 70. Dank et al patients had 100% adenocarcinoma histology (20% Esophagogastric junction, 80% gastric origin). 96% with metastatic disease. 1% with Karnofsky PS of 70.
Chemotherapy
- Cisplatin (Platinol) 100 mg/m2 IV over 1 to 3 hours once on day 1, given first
- Fluorouracil (5-FU) 1000 mg/m2/day IV continuous infusion over 120 hours, started on day 1, given second (total dose per cycle: 5000 mg/m2)
Supportive therapy
- As described in Dank et al. 2008:
- "Hyperhydration" for 2 to 3 days with each infusion
- Ondansetron (Zofran) IV for antiemetic prophylaxis
- Dexamethasone (Decadron) IV for antiemetic prophylaxis, then PO for 2 to 3 days
- Metoclopramide (Reglan) for antiemetic prophylaxis
- Filgrastim (Neupogen) (dose not specified) SC once per day, starting on day 4, to be continued until ANC greater than 1000/μL for grade 3 to 4 neutropenia, febrile neutropenia, or neutropenic infection
- Atropine (Atropen) prn cholinergic symptoms
- Loperamide (Imodium) prn delayed diarrhea
28-day cycles
References
- JCOG 9205: Ohtsu A, Shimada Y, Shirao K, Boku N, Hyodo I, Saito H, Yamamichi N, Miyata Y, Ikeda N, Yamamoto S, Fukuda H, Yoshida S; JCOG. Randomized phase III trial of fluorouracil alone versus fluorouracil plus cisplatin versus uracil and tegafur plus mitomycin in patients with unresectable, advanced gastric cancer: the Japan Clinical Oncology Group study (JCOG9205). J Clin Oncol. 2003 Jan 1;21(1):54-9. link to original article dosing details in manuscript have been reviewed by our editors PubMed
- FFCD 9404: Duffour J, Bouché O, Rougier P, Milan C, Bedenne L, Seitz JF, Buecher B, Legoux JL, Ducreux M, Vetter D, Raoul JL, François E, Ychou M. Safety of cisplatin combined with continuous 5-FU versus bolus 5-FU and leucovorin, in metastatic gastrointestinal cancer (FFCD 9404 randomised trial). Anticancer Res. 2006 Sep-Oct;26(5B):3877-83. link to original article dosing details in manuscript have been reviewed by our editors PubMed
- TAX 325: Van Cutsem E, Moiseyenko VM, Tjulandin S, Majlis A, Constenla M, Boni C, Rodrigues A, Fodor M, Chao Y, Voznyi E, Risse ML, Ajani JA; V325 Study Group. Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group. J Clin Oncol. 2006 Nov 1;24(31):4991-7. link to original article dosing details in manuscript have been reviewed by our editors PubMed
- Dank M, Zaluski J, Barone C, Valvere V, Yalcin S, Peschel C, Wenczl M, Goker E, Cisar L, Wang K, Bugat R. Randomized phase III study comparing irinotecan combined with 5-fluorouracil and folinic acid to cisplatin combined with 5-fluorouracil in chemotherapy naive patients with advanced adenocarcinoma of the stomach or esophagogastric junction. Ann Oncol. 2008 Aug;19(8):1450-7. Epub 2008 Jun 16. link to original article dosing details in manuscript have been reviewed by our editors PubMed
- ML17032: Kang YK, Kang WK, Shin DB, Chen J, Xiong J, Wang J, Lichinitser M, Guan Z, Khasanov R, Zheng L, Philco-Salas M, Suarez T, Santamaria J, Forster G, McCloud PI. Capecitabine/cisplatin versus 5-fluorouracil/cisplatin as first-line therapy in patients with advanced gastric cancer: a randomised phase III noninferiority trial. Ann Oncol. 2009 Apr;20(4):666-73. Epub 2009 Jan 19. link to original article dosing details in manuscript have been reviewed by our editors PubMed NCT02563054
- Lee KH, Hyun MS, Kim HK, Jin HM, Yang J, Song HS, Do YR, Ryoo HM, Chung JS, Zang DY, Lim HY, Jin JY, Yim CY, Park HS, Kim JS, Sohn CH, Lee SN. Randomized, multicenter, phase III trial of heptaplatin 1-hour infusion and 5-fluorouracil combination chemotherapy comparing with cisplatin and 5-fluorouracil combination chemotherapy in patients with advanced gastric cancer. Cancer Res Treat. 2009 Mar;41(1):12-8. Epub 2009 Mar 31. link to original article link to PMC article dosing details in manuscript have been reviewed by our editors PubMed
- FLAGS: Ajani JA, Rodriguez W, Bodoky G, Moiseyenko V, Lichinitser M, Gorbunova V, Vynnychenko I, Garin A, Lang I, Falcon S. Multicenter phase III comparison of cisplatin/S-1 with cisplatin/infusional fluorouracil in advanced gastric or gastroesophageal adenocarcinoma study: the FLAGS trial. J Clin Oncol. 2010 Mar 20;28(9):1547-53. Epub 2010 Feb 16. link to original article dosing details in abstract have been reviewed by our editors PubMed NCT00400179
- AVAGAST: Ohtsu A, Shah MA, Van Cutsem E, Rha SY, Sawaki A, Park SR, Lim HY, Yamada Y, Wu J, Langer B, Starnawski M, Kang YK. Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a randomized, double-blind, placebo-controlled phase III study. J Clin Oncol. 2011 Oct 20;29(30):3968-76. Epub 2011 Aug 15. link to original article dosing details in manuscript have been reviewed by our editors PubMed NCT00548548
- DIGEST: Ajani JA, Abramov M, Bondarenko I, Shparyk Y, Gorbunova V, Hontsa A, Otchenash N, Alsina M, Lazarev S, Feliu J, Elme A, Esko V, Abdalla K, Verma U, Benedetti F, Aoyama T, Mizuguchi H, Makris L, Rosati G; DIGEST Study Group. A phase III trial comparing oral S-1/cisplatin and intravenous 5-fluorouracil/cisplatin in patients with untreated diffuse gastric cancer. Ann Oncol. 2017 Sep 1;28(9):2142-2148. link to original article dosing details in manuscript have been reviewed by our editors PubMed NCT01285557
- KEYNOTE-062: Shitara K, Van Cutsem E, Bang YJ, Fuchs C, Wyrwicz L, Lee KW, Kudaba I, Garrido M, Chung HC, Lee J, Castro HR, Mansoor W, Braghiroli MI, Karaseva N, Caglevic C, Villanueva L, Goekkurt E, Satake H, Enzinger P, Alsina M, Benson A, Chao J, Ko AH, Wainberg ZA, Kher U, Shah S, Kang SP, Tabernero J. Efficacy and Safety of Pembrolizumab or Pembrolizumab Plus Chemotherapy vs Chemotherapy Alone for Patients With First-line, Advanced Gastric Cancer: The KEYNOTE-062 Phase 3 Randomized Clinical Trial. JAMA Oncol. 2020 Oct 1;6(10):1571-1580. Epub 2020 Sep 3. link to original article link to PMC article dosing details in manuscript have been reviewed by our editors PubMed NCT02494583
- KEYNOTE-859: Rha SY, Oh DY, Yañez P, Bai Y, Ryu MH, Lee J, Rivera F, Alves GV, Garrido M, Shiu KK, Fernández MG, Li J, Lowery MA, Çil T, Cruz FM, Qin S, Luo S, Pan H, Wainberg ZA, Yin L, Bordia S, Bhagia P, Wyrwicz LS; KEYNOTE-859 investigators. Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): a multicentre, randomised, double-blind, phase 3 trial. Lancet Oncol. 2023 Nov;24(11):1181-1195. Epub 2023 Oct 21. link to original article dosing details in abstract have been reviewed by our editors PubMed NCT03675737
- RATIONALE-305: Qiu MZ, Oh DY, Kato K, Arkenau T, Tabernero J, Correa MC, Zimina AV, Bai Y, Shi J, Lee KW, Wang J, Poddubskaya E, Pan H, Rha SY, Zhang R, Hirano H, Spigel D, Yamaguchi K, Chao Y, Wyrwicz L, Disel U, Cid RP, Fornaro L, Evesque L, Wang H, Xu Y, Li J, Sheng T, Yang S, Li L, Moehler M, Xu RH; RATIONALE-305 Investigators. Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first line treatment for advanced gastric or gastro-oesophageal junction adenocarcinoma: RATIONALE-305 randomised, double blind, phase 3 trial. BMJ. 2024 May 28;385:e078876. link to original article contains dosing details on CT.gov PubMed NCT03777657
Cisplatin & Fluorouracil (CF) & Pembrolizumab
CF & Pembrolizumab: Cisplatin, Fluorouracil, Pembrolizumab
Regimen
Study | Dates of enrollment | Evidence | Comparator | Comparative Efficacy |
---|---|---|---|---|
Shitara et al. 2020 (KEYNOTE-062) | 2015-2017 | Phase 3 (E-esc) | 1a. CF 1b. CX |
Might have superior OS (co-primary endpoint) Median OS: 12.5 vs 11.1 mo (HR 0.85, 95% CI 0.70-1.03) |
2. Pembrolizumab | Not reported | |||
Rha et al. 2023 (KEYNOTE-859) | 2018-11-08 to 2021-06-11 | Phase 3 (E-RT-esc) | 1a. CF 1b. CapeOx |
Superior OS (primary endpoint) Median OS: 12.9 vs 11.5 mo (HR 0.78, 95% CI 0.70-0.87) |
KEYNOTE-062 & KEYNOTE-859 included patients with GEJ malignancy
Biomarker eligibility criteria
PD-L1 Combined Positive Score (CPS) of 1 or more as determined by an FDA-approved test
Chemotherapy
- Cisplatin (Platinol) 80 mg/m2 IV once on day 1
- Fluorouracil (5-FU) 800 mg/m2/day IV continuous infusion over 120 hours, started on day 1 (total dose per cycle: 4000 mg/m2)
Immunotherapy
- Pembrolizumab (Keytruda) 200 mg IV once on day 1
21-day cycle for up to 35 cycles
References
- KEYNOTE-062: Shitara K, Van Cutsem E, Bang YJ, Fuchs C, Wyrwicz L, Lee KW, Kudaba I, Garrido M, Chung HC, Lee J, Castro HR, Mansoor W, Braghiroli MI, Karaseva N, Caglevic C, Villanueva L, Goekkurt E, Satake H, Enzinger P, Alsina M, Benson A, Chao J, Ko AH, Wainberg ZA, Kher U, Shah S, Kang SP, Tabernero J. Efficacy and Safety of Pembrolizumab or Pembrolizumab Plus Chemotherapy vs Chemotherapy Alone for Patients With First-line, Advanced Gastric Cancer: The KEYNOTE-062 Phase 3 Randomized Clinical Trial. JAMA Oncol. 2020 Oct 1;6(10):1571-1580. Epub 2020 Sep 3. link to original article link to PMC article dosing details in manuscript have been reviewed by our editors PubMed NCT02494583
- KEYNOTE-859: Rha SY, Oh DY, Yañez P, Bai Y, Ryu MH, Lee J, Rivera F, Alves GV, Garrido M, Shiu KK, Fernández MG, Li J, Lowery MA, Çil T, Cruz FM, Qin S, Luo S, Pan H, Wainberg ZA, Yin L, Bordia S, Bhagia P, Wyrwicz LS; KEYNOTE-859 investigators. Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): a multicentre, randomised, double-blind, phase 3 trial. Lancet Oncol. 2023 Nov;24(11):1181-1195. Epub 2023 Oct 21. link to original article dosing details in abstract have been reviewed by our editors PubMed NCT03675737
Cisplatin & Fluorouracil (CF) & Tislelizumab
CF & Tislelizumab: Cisplatin, Fluorouracil, Tislelizumab
Regimen
Study | Dates of enrollment | Evidence | Comparator | Comparative Efficacy |
---|---|---|---|---|
Qiu et al. 2024 (RATIONALE-305) | 2018-12-13 to 2021-02-09 | Phase 3 (E-esc) | 1a. CapeOx 1b. CF |
Superior OS (primary endpoint) Median OS: 15 vs 12.9 mo (HR 0.80, 95% CI 0.70-0.92) |
Chemotherapy
- Cisplatin (Platinol) 80 mg/m2 IV once on day 1
- Fluorouracil (5-FU) 800 mg/m2/day IV continuous infusion over 120 hours, started on day 1 (total dose per cycle: 4000 mg/m2)
Immunotherapy
- Tislelizumab (Baizean) 200 mg IV once on day 1
21-day cycles
References
- RATIONALE-305: Qiu MZ, Oh DY, Kato K, Arkenau T, Tabernero J, Correa MC, Zimina AV, Bai Y, Shi J, Lee KW, Wang J, Poddubskaya E, Pan H, Rha SY, Zhang R, Hirano H, Spigel D, Yamaguchi K, Chao Y, Wyrwicz L, Disel U, Cid RP, Fornaro L, Evesque L, Wang H, Xu Y, Li J, Sheng T, Yang S, Li L, Moehler M, Xu RH; RATIONALE-305 Investigators. Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first line treatment for advanced gastric or gastro-oesophageal junction adenocarcinoma: RATIONALE-305 randomised, double blind, phase 3 trial. BMJ. 2024 May 28;385:e078876. link to original article contains dosing details on CT.gov PubMed NCT03777657
Cisplatin & S-1
CS: Cisplatin & S-1
SP: S-1 & Platinol (Cisplatin)
Regimen variant #1, q3wk ("SP3")
Study | Dates of enrollment | Evidence | Comparator | Comparative Efficacy |
---|---|---|---|---|
Ryu et al. 2015 (SOS) | 2009-2012 | Phase 3 (E-switch-ic) | Cisplatin & S-1; SP5 | Seems to have superior PFS (primary endpoint) Median PFS: 5.5 vs 4.9 mo (HR 0.82, 95% CI 0.68-0.99) |
Lee et al. 2020 (SOPP) | 2012-2014 | Phase 3 (C) | SOX | Non-inferior PFS |
Chemotherapy
- Cisplatin (Platinol) 60 mg/m2 IV once on day 1
- Tegafur, gimeracil, oteracil (S-1) 40 mg/m2 PO twice per day on days 1 to 14
21-day cycles
Regimen variant #2, q4wk
Study | Dates of enrollment | Evidence | Comparator | Comparative Efficacy |
---|---|---|---|---|
Ajani et al. 2010 (FLAGS) | 2005-2007 | Phase 3 (E-switch-ic) | CF | Did not meet primary endpoint of OS |
Ajani et al. 2017 (DIGEST) | 2011-2014 | Phase 3 (E-switch-ic) | CF | Did not meet primary endpoint of OS |
Note: This was an experimental arm of a study where the primary endpoint was not met. Included because CS has been shown to be superior in comparison to other regimens (see above).
Chemotherapy
- Cisplatin (Platinol) 75 mg/m2 IV over 1 to 3 hours once on day 1
- Tegafur, gimeracil, oteracil (S-1) 25 mg/m2 PO twice per day on days 1 to 21
28-day cycles
Regimen variant #3, q5wk ("SP5")
Study | Dates of enrollment | Evidence | Comparator | Comparative Efficacy |
---|---|---|---|---|
Koizumi et al. 2008 (SPIRITS) | 2002-2004 | Phase 3 (E-esc) | S-1 | Seems to have superior OS (primary endpoint) Median OS: 13 vs 11 mo (HR 0.77, 95% CI 0.61-0.98) |
Fujitani et al. 2016 (REGATTA) | 2008-2013 | Non-randomized part of phase 3 RCT | ||
Ryu et al. 2015 (SOS) | 2009-2012 | Phase 3 (C) | Cisplatin & S-1; SP3 | Seems to have inferior PFS |
Yamada et al. 2014 (G-SOX) | 2010-01 to 2011-10 | Phase 3 (C) | SOX | Non-inferior PFS |
Ishigami et al. 2018 (PHOENIX-GC) | 2011-2013 | Phase 3 (C) | IV/IP Paclitaxel & S-1 | Might have inferior OS |
Yamada et al. 2019 (JCOG1013) | 2012-2016 | Phase 3 (C) | Cisplatin, Docetaxel, S-1 | Did not meet primary endpoint of OS |
Kang et al. 2020 (SOLAR) | 2015-01-28 to 2016-12-05 | Phase 3 (C) | Oxaliplatin & TAS-118 | Seems to have inferior PFS |
Note: in REGATTA, there was no difference in outcome amongst patients who did or did not undergo surgery. SPIRITS trial included patients with ECOG PS of 2 (3% of patients).
Eligibility criteria
- REGATTA: presence of a single non-curable factor (ex: hepatic, peritoneal, and para-aortic mets), see link for further details
- PHEONIX-GC: patients with peritoneal metastasis who had received less than or equal to 2 months of prior chemotherapy without disease progression, see link for further details
Preceding treatment
- REGATTA: Non-laparoscopic gastrectomy with D1 lymphadenectomy versus no surgery; chemotherapy began within 8 weeks of surgery
Chemotherapy
- Cisplatin (Platinol) 60 mg/m2 IV once on day 8
- Tegafur, gimeracil, oteracil (S-1) by the following BSA-based criteria:
- Less than 1.25 m2: 40 mg PO twice per day on days 1 to 21
- Between 1.25 m2 and 1.5 m2: 50 mg PO twice per day on days 1 to 21
- 1.5 m2 or more: 60 mg PO twice per day on days 1 to 21
35-day cycles
References
- SPIRITS: Koizumi W, Narahara H, Hara T, Takagane A, Akiya T, Takagi M, Miyashita K, Nishizaki T, Kobayashi O, Takiyama W, Toh Y, Nagaie T, Takagi S, Yamamura Y, Yanaoka K, Orita H, Takeuchi M. S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial. Lancet Oncol. 2008 Mar;9(3):215-21. Epub 2008 Feb 20. link to original article dosing details in manuscript have been reviewed by our editors PubMed NCT00150670
- FLAGS: Ajani JA, Rodriguez W, Bodoky G, Moiseyenko V, Lichinitser M, Gorbunova V, Vynnychenko I, Garin A, Lang I, Falcon S. Multicenter phase III comparison of cisplatin/S-1 with cisplatin/infusional fluorouracil in advanced gastric or gastroesophageal adenocarcinoma study: the FLAGS trial. J Clin Oncol. 2010 Mar 20;28(9):1547-53. Epub 2010 Feb 16. link to original article dosing details in abstract have been reviewed by our editors PubMed NCT00400179
- G-SOX: Yamada Y, Higuchi K, Nishikawa K, Gotoh M, Fuse N, Sugimoto N, Nishina T, Amagai K, Chin K, Niwa Y, Tsuji A, Imamura H, Tsuda M, Yasui H, Fujii H, Yamaguchi K, Yasui H, Hironaka S, Shimada K, Miwa H, Hamada C, Hyodo I. Phase III study comparing oxaliplatin plus S-1 with cisplatin plus S-1 in chemotherapy-naïve patients with advanced gastric cancer. Ann Oncol. 2015 Jan;26(1):141-8. Epub 2014 Oct 14. link to original article dosing details in abstract have been reviewed by our editors PubMed JapicCTI-101021
- SOS: Ryu MH, Baba E, Lee KH, Park YI, Boku N, Hyodo I, Nam BH, Esaki T, Yoo C, Ryoo BY, Song EK, Cho SH, Kang WK, Yang SH, Zang DY, Shin DB, Park SR, Shinozaki K, Takano T, Kang YK; SOS study investigators. Comparison of two different S-1 plus cisplatin dosing schedules as first-line chemotherapy for metastatic and/or recurrent gastric cancer: a multicenter, randomized phase III trial (SOS). Ann Oncol. 2015 Oct;26(10):2097-101. Epub 2015 Jul 27. link to original article dosing details in abstract have been reviewed by our editors PubMed NCT00915382
- REGATTA: Fujitani K, Yang HK, Mizusawa J, Kim YW, Terashima M, Han SU, Iwasaki Y, Hyung WJ, Takagane A, Park DJ, Yoshikawa T, Hahn S, Nakamura K, Park CH, Kurokawa Y, Bang YJ, Park BJ, Sasako M, Tsujinaka T; REGATTA study investigators. Gastrectomy plus chemotherapy versus chemotherapy alone for advanced gastric cancer with a single non-curable factor (REGATTA): a phase 3, randomised controlled trial. Lancet Oncol. 2016 Mar;17(3):309-18. Epub 2016 Jan 26. link to original article dosing details in manuscript have been reviewed by our editors PubMed UMIN000001012
- DIGEST: Ajani JA, Abramov M, Bondarenko I, Shparyk Y, Gorbunova V, Hontsa A, Otchenash N, Alsina M, Lazarev S, Feliu J, Elme A, Esko V, Abdalla K, Verma U, Benedetti F, Aoyama T, Mizuguchi H, Makris L, Rosati G; DIGEST Study Group. A phase III trial comparing oral S-1/cisplatin and intravenous 5-fluorouracil/cisplatin in patients with untreated diffuse gastric cancer. Ann Oncol. 2017 Sep 1;28(9):2142-2148. link to original article dosing details in manuscript have been reviewed by our editors PubMed NCT01285557
- PHOENIX-GC: Ishigami H, Fujiwara Y, Fukushima R, Nashimoto A, Yabusaki H, Imano M, Imamoto H, Kodera Y, Uenosono Y, Amagai K, Kadowaki S, Miwa H, Yamaguchi H, Yamaguchi T, Miyaji T, Kitayama J. Phase III trial comparing intraperitoneal and intravenous paclitaxel plus S-1 versus cisplatin plus S-1 in patients with gastric cancer with peritoneal metastasis: PHOENIX-GC trial. J Clin Oncol. 2018 Jul 1;36(19):1922-1929. Epub 2018 May 10. link to original article dosing details in manuscript have been reviewed by our editors PubMed UMIN000005930
- JCOG1013: Yamada Y, Boku N, Mizusawa J, Iwasa S, Kadowaki S, Nakayama N, Azuma M, Sakamoto T, Shitara K, Tamura T, Chin K, Hata H, Nakamori M, Hara H, Yasui H, Katayama H, Fukuda H, Yoshikawa T, Sasako M, Terashima M. Docetaxel plus cisplatin and S-1 versus cisplatin and S-1 in patients with advanced gastric cancer (JCOG1013): an open-label, phase 3, randomised controlled trial. Lancet Gastroenterol Hepatol. 2019 Jul;4(7):501-510. Epub 2019 May 14. link to original article dosing details in abstract have been reviewed by our editors PubMed UMIN000007652
- SOPP: Lee KW, Chung IJ, Ryu MH, Park YI, Nam BH, Oh HS, Lee KH, Han HS, Seo BG, Jo JC, Lee HR, Kim JW, Park SR, Cho SH, Kang YK; SOPP study investigators. Multicenter phase III trial of S-1 and cisplatin versus S-1 and oxaliplatin combination chemotherapy for first-line treatment of advanced gastric cancer (SOPP trial). Gastric Cancer. 2021 Jan;24(1):156-167. Epub 2020 Jun 28. link to original article dosing details in abstract have been reviewed by our editors PubMed NCT01671449
- SOLAR: Kang YK, Chin K, Chung HC, Kadowaki S, Oh SC, Nakayama N, Lee KW, Hara H, Chung IJ, Tsuda M, Park SH, Hosaka H, Hironaka S, Miyata Y, Ryu MH, Baba H, Hyodo I, Bang YJ, Boku N. S-1 plus leucovorin and oxaliplatin versus S-1 plus cisplatin as first-line therapy in patients with advanced gastric cancer (SOLAR): a randomised, open-label, phase 3 trial. Lancet Oncol. 2020 Aug;21(8):1045-1056. Epub 2020 Jul 16. link to original article dosing details in abstract have been reviewed by our editors PubMed NCT02322593
CLF
CLF: Cisplatin, Leucovorin, Fluorouracil
FLP: Fluorouracil, Leucovorin, Platinol (Cisplatin)
Regimen variant #1
Study | Dates of enrollment | Evidence | Comparator | Comparative Efficacy |
---|---|---|---|---|
Al-Batran et al. 2008 | 2003-2006 | Phase 3 (C) | FLO | Might have inferior PFS |
Note: In contrast to the original reference, some guidelines list 5-FU as being given every 2 weeks rather than the schedule below. Patients had 100% adenocarcinoma histology (20% gastroesophageal junction, 80% gastric).
Chemotherapy
- Cisplatin (Platinol) 50 mg/m2 IV over 2 hours once per day on days 1, 15, 29, 43
- Leucovorin (Folinic acid) 200 mg/m2 IV over 2 hours once per day on days 1, 15, 29, 43
- Fluorouracil (5-FU) 2000 mg/m2 IV continuous infusion over 24 hours, started on days 1, 8, 15, 22, 29, 36 (total dose per cycle: 12,000 mg/m2)
Supportive therapy
- Up to 3 liters normal saline as hydration with cisplatin
- Antiemetic medications per "local protocols"
8-week cycles
Regimen variant #2
Study | Dates of enrollment | Evidence | Comparator | Comparative Efficacy |
---|---|---|---|---|
Bouché et al. 2004 (FFCD 9803) | 1999-2001 | Randomized Phase 2 (E-esc) | 1. LV5FU2 2. LV5FU2 & Irinotecan |
Not powered to draw conclusions |
Note: the primary reference said every cycle was 15 days, but also said that medications were given every 14 days, so the assumption was made that this more regular schedule was used.
Chemotherapy
- Cisplatin (Platinol) 50 mg/m2 IV over 60 minutes once on either day 1 or 2
- Leucovorin (Folinic acid) 200 mg/m2 IV over 2 hours once on day 1
- Fluorouracil (5-FU) 400 mg/m2 IV bolus once on day 1, then 1200 mg/m2 IV continuous infusion over 22 hours (total dose per cycle: 1600 mg/m2)
Supportive therapy
- 1 liter hydration over 3 hours before and after cisplatin
- 5-HT3 antagonist IV prior to cisplatin
- Methylprednisolone (Solumedrol) 120 mg IV 10 minutes prior to cisplatin
- Oral antiemetics and corticosteroids from days 2 to 5
14-day cycle for at least 4 cycles
References
- FFCD 9803: Bouché O, Raoul JL, Bonnetain F, Giovannini M, Etienne PL, Lledo G, Arsène D, Paitel JF, Guérin-Meyer V, Mitry E, Buecher B, Kaminsky MC, Seitz JF, Rougier P, Bedenne L, Milan C; Fédération Francophone de Cancérologie Digestive. Randomized multicenter phase II trial of a biweekly regimen of fluorouracil and leucovorin (LV5FU2), LV5FU2 plus cisplatin, or LV5FU2 plus irinotecan in patients with previously untreated metastatic gastric cancer: a Federation Francophone de Cancerologie Digestive Group Study--FFCD 9803. J Clin Oncol. 2004 Nov 1;22(21):4319-28. link to original article dosing details in manuscript have been reviewed by our editors PubMed
- Al-Batran SE, Hartmann JT, Probst S, Schmalenberg H, Hollerbach S, Hofheinz R, Rethwisch V, Seipelt G, Homann N, Wilhelm G, Schuch G, Stoehlmacher J, Derigs HG, Hegewisch-Becker S, Grossmann J, Pauligk C, Atmaca A, Bokemeyer C, Knuth A, Jäger E; Arbeitsgemeinschaft Internistische Onkologie. Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie. J Clin Oncol. 2008 Mar 20;26(9):1435-42. link to original article dosing details in manuscript have been reviewed by our editors PubMed
DCF
DCF: Docetaxel, Cisplatin, Fluorouracil
TCF: Taxotere (Docetaxel), Cisplatin, Fluorouracil
Regimen variant #1
Study | Dates of enrollment | Evidence | Comparator | Comparative Efficacy |
---|---|---|---|---|
Ajani et al. 2005 (V-325) | 1998-1999 | Randomized Phase 2 (E-esc) | DC | Seems to have superior ORR |
Van Cutsem et al. 2006 (TAX 325) | 1999-2003 | Phase 3 (E-RT-esc) | CF | Seems to have superior OS (secondary endpoint) Superior TTP (primary endpoint) |
Note: In contrast to the original references, some guidelines list each cycle as lasting 28 days. V-325 patients had 100% adenocarcinoma histology (32% gastroesophageal junction/fundus and 68% gastric antrum/body). 95% were metastatic. 1% with Karnofsky PS score of 70. TAX 325 patients had 100% adenocarcinoma histology (22% gastroesophageal junction, 88% gastric origin). 97% with metastatic disease. 1% with Karnosky PS score of 70.
Chemotherapy
- Docetaxel (Taxotere) 75 mg/m2 IV over 60 minutes once on day 1
- Cisplatin (Platinol) 75 mg/m2 IV over 1 to 3 hours once on day 1
- Fluorouracil (5-FU) 750 mg/m2/day IV continuous infusion over 120 hours, started on day 1 (total dose per cycle: 3750 mg/m2)
Supportive therapy
- (varied depending on reference):
- Dexamethasone (Decadron) 8 mg PO once the night before chemotherapy, then 8 mg PO once on day 1; 1 hour prior to chemotherapy, then 8 mg PO twice per day until day 2 (total dose per cycle: 48 mg)
- Dexamethasone (Decadron) 20 mg IV prior to cisplatin and 8 hours after cisplatin
- Ondansetron (Zofran) 8 mg IV prior to cisplatin, 4 hours after cisplatin, and 8 hours after cisplatin
- "Hydration (was) administered in a standard manner"
21-day cycles
Regimen variant #2
Study | Dates of enrollment | Evidence | Comparator | Comparative Efficacy |
---|---|---|---|---|
Roth et al. 2007 | 1999-2003 | Randomized Phase 2 (E-esc) | 1. ECF | Not reported |
2. TC | Might have superior ORR (primary endpoint) |
Note: the protocol was amended to change the original dose of docetaxel from 85 mg/m2 to 75 mg/m2 based on high incidence of febrile neutropenia.
Chemotherapy
- Docetaxel (Taxotere) 75 mg/m2 IV over 60 minutes once on day 1
- Cisplatin (Platinol) 75 mg/m2 IV over 4 hours once on day 1
- Fluorouracil (5-FU) 300 mg/m2/day IV continuous infusion over 14 days, started on day 1 (total dose per cycle: 4200 mg/m2)
Supportive therapy
- 3 liters per day "hyperhydration"
- Dexamethasone (Decadron) 8 mg PO given 12 hours & 6 hours prior to docetaxel, then 8 mg PO twice per day for 4 days after docetaxel
- 5-HT3 antagonist for emesis prophylaxis
- Growth factor support allowed, such as with Filgrastim (Neupogen)
21-day cycle for up to 8 cycles
References
- V-325: Ajani JA, Fodor MB, Tjulandin SA, Moiseyenko VM, Chao Y, Cabral Filho S, Majlis A, Assadourian S, Van Cutsem E. Phase II multi-institutional randomized trial of docetaxel plus cisplatin with or without fluorouracil in patients with untreated, advanced gastric, or gastroesophageal adenocarcinoma. J Clin Oncol. 2005 Aug 20;23(24):5660-7. link to original article dosing details in manuscript have been reviewed by our editors PubMed
- TAX 325: Van Cutsem E, Moiseyenko VM, Tjulandin S, Majlis A, Constenla M, Boni C, Rodrigues A, Fodor M, Chao Y, Voznyi E, Risse ML, Ajani JA; V325 Study Group. Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group. J Clin Oncol. 2006 Nov 1;24(31):4991-7. link to original article dosing details in manuscript have been reviewed by our editors PubMed
- Roth AD, Fazio N, Stupp R, Falk S, Bernhard J, Saletti P, Köberle D, Borner MM, Rufibach K, Maibach R, Wernli M, Leslie M, Glynne-Jones R, Widmer L, Seymour M, de Braud F; Swiss Group for Clinical Cancer Research. Docetaxel, cisplatin, and fluorouracil; docetaxel and cisplatin; and epirubicin, cisplatin, and fluorouracil as systemic treatment for advanced gastric carcinoma: a randomized phase II trial of the Swiss Group for Clinical Cancer Research. J Clin Oncol. 2007 Aug 1;25(22):3217-23. link to original article dosing details in manuscript have been reviewed by our editors PubMed
mDCF
mDCF: modified Docetaxel, Cisplatin, Fluorouracil
Regimen variant #1, 60/60/3000, 4-day 5-FU infusion
Study | Dates of enrollment | Evidence | Comparator | Comparative Efficacy |
---|---|---|---|---|
Wang et al. 2015 (DOCET L 02195) | 2008-2010 | Phase 3 (E-esc) | CF | Seems to have superior OS (secondary endpoint) Median OS: 10.2 vs 8.5 mo (HR 0.71, 95% CI 0.52-0.97) |
Chemotherapy
- Docetaxel (Taxotere) 60 mg/m2 IV once on day 1
- Cisplatin (Platinol) 60 mg/m2 IV once on day 1
- Fluorouracil (5-FU) 750 mg/m2/day IV continuous infusion over 96 hours, started on day 1 (total dose per cycle: 3000 mg/m2)
21-day cycles
Regimen variant #2, 60/60/3000, 5-day 5-FU infusion
Study | Dates of enrollment | Evidence | Comparator | Comparative Efficacy |
---|---|---|---|---|
Wang et al. 2015 (DOCET L 02195) | 2008-2010 | Phase 3 (E-esc) | CF | Seems to have superior OS (secondary endpoint) Median OS: 10.2 vs 8.5 mo (HR 0.71, 95% CI 0.52-0.97) |
Chemotherapy
- Docetaxel (Taxotere) 60 mg/m2 IV once on day 1
- Cisplatin (Platinol) 60 mg/m2 IV once on day 1
- Fluorouracil (5-FU) 600 mg/m2/day IV continuous infusion over 120 hours, started on day 1 (total dose per cycle: 3000 mg/m2)
21-day cycles
References
- DOCET L 02195: Wang J, Xu R, Li J, Bai Y, Liu T, Jiao S, Dai G, Xu J, Liu Y, Fan N, Shu Y, Ba Y, Ma D, Qin S, Zheng L, Chen W, Shen L. Randomized multicenter phase III study of a modified docetaxel and cisplatin plus fluorouracil regimen compared with cisplatin and fluorouracil as first-line therapy for advanced or locally recurrent gastric cancer. Gastric Cancer. 2016 Jan;19(1):234-44. Epub 2015 Jan 21. link to original article link to PMC article dosing details in manuscript have been reviewed by our editors PubMed NCT00811447
mDCF & Bevacizumab
mDCF & Bevacizumab: modified Docetaxel, Cisplatin, Fluorouracil & Bevacizumab
Regimen
Study | Dates of enrollment | Evidence |
---|---|---|
Shah et al. 2010 (MSK 06-096) | 2006-2008 | Phase 2 |
Note: patients had 100% adenocarcinoma (50% gastric, 45% gastroesophageal junction, 5% esophagus). 93% received no prior therapy. Unlike most DCF regimens that we are aware of, this one includes leucovorin.
Chemotherapy
- Docetaxel (Taxotere) 40 mg/m2 IV over 60 minutes once on day 1
- Cisplatin (Platinol) 40 mg/m2 IV over 1 to 3 hours once on day 3
- Leucovorin (Folinic acid) 400 mg/m2 IV once on day 1
- Fluorouracil (5-FU) 400 mg/m2 IV bolus once on day 1, then 1200 mg/m2/day IV continuous infusion over 48 hours (total dose per cycle: 2800 mg/m2)
Targeted therapy
- Bevacizumab (Avastin) 10 mg/kg IV once on day 1
Supportive therapy
- "Standard premedication and delayed emesis regimens"
14-day cycles
References
- MSK 06-096: Shah MA, Jhawer M, Ilson DH, Lefkowitz RA, Robinson E, Capanu M, Kelsen DP. Phase II study of modified docetaxel, cisplatin, and fluorouracil with bevacizumab in patients with metastatic gastroesophageal adenocarcinoma. J Clin Oncol. 2011 Mar 1;29(7):868-74. Epub 2010 Dec 28. link to original article dosing details in manuscript have been reviewed by our editors link to PMC article PubMed NCT00390416
Docetaxel & S-1
Regimen
Study | Dates of enrollment | Evidence | Comparator | Comparative Efficacy |
---|---|---|---|---|
Koizumi et al. 2013 (STARTgastric) | 2005-2008 | Phase 3 (E-esc) | S-1 | Seems to have superior OS (primary endpoint) Median OS: 12.5 vs 10.8 mo (HR 0.84, 95% CI 0.71-0.99) |
Chemotherapy
- Docetaxel (Taxotere) 40 mg/m2 IV once on day 1
- Tegafur, gimeracil, oteracil (S-1) by the following BSA-based criteria:
- Less than 1.25 m2: 40 mg PO twice per day on days 1 to 14
- Between 1.25 m2 and 1.5 m2: 50 mg PO twice per day on days 1 to 14
- 1.5 m2 or more: 60 mg PO twice per day on days 1 to 14
21-day cycles
References
- START: Koizumi W, Kim YH, Fujii M, Kim HK, Imamura H, Lee KH, Hara T, Chung HC, Satoh T, Cho JY, Hosaka H, Tsuji A, Takagane A, Inokuchi M, Tanabe K, Okuno T, Ogura M, Yoshida K, Takeuchi M, Nakajima T; JACCRO; KCSG. Addition of docetaxel to S-1 without platinum prolongs survival of patients with advanced gastric cancer: a randomized study (START). J Cancer Res Clin Oncol. 2014 Feb;140(2):319-28. Epub 2013 Dec 24. link to original article link to PMC article dosing details in manuscript have been reviewed by our editors PubMed NCT00287768
ECF
ECF: Epirubicin, Cisplatin, Fluorouracil
Regimen
Study | Dates of enrollment | Evidence | Comparator | Comparative Efficacy |
---|---|---|---|---|
Findlay et al. 1994 | 1988-1992 | Phase 2 | ||
Webb et al. 1997 | 1992-1995 | Randomized (E-switch-ic) | FAMTX | Superior OS |
Ross et al. 2002 | 1995-1998 | Phase 3 (C) | MCF | Seems to have non-inferior OS |
Roth et al. 2007 | 1999-2003 | Randomized Phase 2 (C) | 1. TC 2. TCF |
Not reported |
Cunningham et al. 2008 (REAL-2) | 2000-2005 | Phase 3 (C) | 1. ECX | Non-inferior OS |
2. EOF | Non-inferior OS | |||
3. EOX | Seems to have inferior OS |
Note: Findlay et al. patients all had metastatic gastric cancer. Ross et al. patients had adenocarcinoma, squamous carcinoma, or undifferentiated carcinoma histology, all advanced esophagogastric cancer. Roth et al. patients all had metastatic gastric cancer. REAL-2 patients had 35% esophageal, 25% gastroesophageal junction, 40% gastric. 11% ECOG PS of 2.
Chemotherapy
- Epirubicin (Ellence) 50 mg/m2 IV bolus once on day 1
- Cisplatin (Platinol) 60 mg/m2 IV over 4 hours once on day 1
- Fluorouracil (5-FU) 200 mg/m2/day IV continuous infusion over 21 days, started on day 1 (total dose per cycle: 4200 mg/m2)
Supportive therapy
- (varied depending on reference):
- 3 liters per day "hyperhydration"
- 5-HT3 antagonist for emesis prophylaxis
- Growth factor support allowed, such as with Filgrastim (Neupogen)
- Ross et al. 2002 & Cunningham et al. 2008 used Warfarin (Coumadin) 1 mg PO once per day for catheter thrombosis prophylaxis
21-day cycle for up to 8 cycles
References
- Findlay M, Cunningham D, Norman A, Mansi J, Nicolson M, Hickish T, Nicolson V, Nash A, Sacks N, Ford H, Carter R, Hill A. A phase II study in advanced gastro-esophageal cancer using epirubicin and cisplatin in combination with continuous infusion 5-fluorouracil (ECF). Ann Oncol. 1994 Sep;5(7):609-16. link to original article dosing details in manuscript have been reviewed by our editors PubMed
- Webb A, Cunningham D, Scarffe JH, Harper P, Norman A, Joffe JK, Hughes M, Mansi J, Findlay M, Hill A, Oates J, Nicolson M, Hickish T, O'Brien M, Iveson T, Watson M, Underhill C, Wardley A, Meehan M. Randomized trial comparing epirubicin, cisplatin, and fluorouracil versus fluorouracil, doxorubicin, and methotrexate in advanced esophagogastric cancer. J Clin Oncol. 1997 Jan;15(1):261-7. link to original article dosing details in manuscript have been reviewed by our editors PubMed
- Update: Waters JS, Norman A, Cunningham D, Scarffe JH, Webb A, Harper P, Joffe JK, Mackean M, Mansi J, Leahy M, Hill A, Oates J, Rao S, Nicolson M, Hickish T. Long-term survival after epirubicin, cisplatin and fluorouracil for gastric cancer: results of a randomized trial. Br J Cancer. 1999 Apr;80(1-2):269-72. link to original article link to PMC article PubMed
- Ross P, Nicolson M, Cunningham D, Valle J, Seymour M, Harper P, Price T, Anderson H, Iveson T, Hickish T, Lofts F, Norman A. Prospective randomized trial comparing mitomycin, cisplatin, and protracted venous-infusion fluorouracil (PVI 5-FU) With epirubicin, cisplatin, and PVI 5-FU in advanced esophagogastric cancer. J Clin Oncol. 2002 Apr 15;20(8):1996-2004. link to original article dosing details in manuscript have been reviewed by our editors PubMed
- Roth AD, Fazio N, Stupp R, Falk S, Bernhard J, Saletti P, Köberle D, Borner MM, Rufibach K, Maibach R, Wernli M, Leslie M, Glynne-Jones R, Widmer L, Seymour M, de Braud F; Swiss Group for Clinical Cancer Research. Docetaxel, cisplatin, and fluorouracil; docetaxel and cisplatin; and epirubicin, cisplatin, and fluorouracil as systemic treatment for advanced gastric carcinoma: a randomized phase II trial of the Swiss Group for Clinical Cancer Research. J Clin Oncol. 2007 Aug 1;25(22):3217-23. link to original article dosing details in manuscript have been reviewed by our editors PubMed
- REAL-2: Cunningham D, Starling N, Rao S, Iveson T, Nicolson M, Coxon F, Middleton G, Daniel F, Oates J, Norman AR; Upper Gastrointestinal Clinical Studies Group of the National Cancer Research Institute of the United Kingdom. Capecitabine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med. 2008 Jan 3;358(1):36-46. link to original article dosing details in manuscript have been reviewed by our editors PubMed ISRCTN51678883
ECX
ECX: Epirubicin, Cisplatin, Xeloda (Capecitabine)
ECC: Epirubicin, Cisplatin, Capecitabine
Regimen variant #1, continuous capecitabine
Study | Dates of enrollment | Evidence | Comparator | Comparative Efficacy |
---|---|---|---|---|
Cunningham et al. 2008 (REAL-2) | 2000-2005 | Phase 3 (E-RT-switch-ic) | 1. ECF | Non-inferior OS (primary endpoint) |
2. EOF 3. EOX |
Non-inferior OS (primary endpoint) | |||
Catenacci et al. 2017 (RILOMET-1) | 2012-2014 | Randomized Phase 2 (C) | ECX & Rilotumumab | Superior OS (primary endpoint) Median OS: 10.7 vs 8.8 mo (HR 0.75, 95% CI 0.61-0.91) |
Note: REAL-2 patients had 35% esophageal, 25% gastroesophageal junction, 40% gastric. 11% ECOG PS of 2. RILOMET-1 patients had unresectable or metastatic MET-positive gastric or gastro-esophageal junction cancer. ~80% gastric, 20% GE junction and 10% distal esophageal.
Chemotherapy
- Epirubicin (Ellence) 50 mg/m2 IV once on day 1
- Cisplatin (Platinol) 60 mg/m2 IV once on day 1
- Capecitabine (Xeloda) 625 mg/m2 PO twice per day
21-day cycle for up to 8 cycles (REAL-2) or 10 cycles (RILOMET-1)
Regimen variant #2, intermittent capecitabine
Study | Dates of enrollment | Evidence | Comparator | Comparative Efficacy |
---|---|---|---|---|
Konings et al. 2010 | 2005-2009 | Randomized Phase 2 (C) | ECC & Pravastatin | Did not meet primary endpoint of PFS6 |
Note: 6.6% of patients had an ECOG PS of 2
Chemotherapy
- Epirubicin (Ellence) 50 mg/m2 IV bolus once on day 1, given first
- Cisplatin (Platinol) 60 mg/m2 IV over 3 hours once on day 1, given second
- Capecitabine (Xeloda) 1000 mg/m2 PO twice per day on days 1 to 14
21-day cycle for up to 6 cycles
References
- REAL-2: Cunningham D, Starling N, Rao S, Iveson T, Nicolson M, Coxon F, Middleton G, Daniel F, Oates J, Norman AR; Upper Gastrointestinal Clinical Studies Group of the National Cancer Research Institute of the United Kingdom. Capecitabine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med. 2008 Jan 3;358(1):36-46. link to original article dosing details in manuscript have been reviewed by our editors PubMed ISRCTN51678883
- Konings IR, van der Gaast A, van der Wijk LJ, de Jongh FE, Eskens FA, Sleijfer S. The addition of pravastatin to chemotherapy in advanced gastric carcinoma: a randomised phase II trial. Eur J Cancer. 2010 Dec;46(18):3200-4. Epub 2010 Aug 18. link to original article dosing details in manuscript have been reviewed by our editors PubMed
- RILOMET-1: Catenacci DVT, Tebbutt NC, Davidenko I, Murad AM, Al-Batran SE, Ilson DH, Tjulandin S, Gotovkin E, Karaszewska B, Bondarenko I, Tejani MA, Udrea AA, Tehfe M, De Vita F, Turkington C, Tang R, Ang A, Zhang Y, Hoang T, Sidhu R, Cunningham D. Rilotumumab plus epirubicin, cisplatin, and capecitabine as first-line therapy in advanced MET-positive gastric or gastro-oesophageal junction cancer (RILOMET-1): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2017 Nov;18(11):1467-1482. Epub 2017 Sep 25. link to original article dosing details in manuscript have been reviewed by our editors link to PMC article PubMed NCT01697072
EOF
EOF: Epirubicin, Oxaliplatin, Fluorouracil
Regimen
Study | Dates of enrollment | Evidence | Comparator | Comparative Efficacy |
---|---|---|---|---|
Cunningham et al. 2008 (REAL-2) | 2000-2005 | Phase 3 (E-switch-ic) | 1. ECF 2. ECX |
Non-inferior OS (primary endpoint) |
3. EOX | Non-inferior OS (primary endpoint) |
Note: patients had 35% esophageal, 25% gastroesophageal junction, 40% gastric. 11% ECOG PS of 2.
Chemotherapy
- Epirubicin (Ellence) 50 mg/m2 IV bolus once on day 1
- Oxaliplatin (Eloxatin) 130 mg/m2 IV over 2 hours once on day 1
- Fluorouracil (5-FU) 200 mg/m2/day IV continuous infusion, started on day 1 (total dose per cycle: 4200 mg/m2)
Supportive therapy
- Warfarin (Coumadin) 1 mg PO once per day for catheter thrombosis prophylaxis
21-day cycle for up to 8 cycles
References
- REAL-2: Cunningham D, Starling N, Rao S, Iveson T, Nicolson M, Coxon F, Middleton G, Daniel F, Oates J, Norman AR; Upper Gastrointestinal Clinical Studies Group of the National Cancer Research Institute of the United Kingdom. Capecitabine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med. 2008 Jan 3;358(1):36-46. link to original article dosing details in manuscript have been reviewed by our editors PubMed ISRCTN51678883
EOX
EOX: Epirubicin, Oxaliplatin, Xeloda (Capecitabine)
EOC: Epirubicin, Oxaliplatin, Capecitabine
Regimen variant #1
Study | Dates of enrollment | Evidence | Comparator | Comparative Efficacy |
---|---|---|---|---|
Cunningham et al. 2008 (REAL-2) | 2000-2005 | Phase 3 (E-RT-switch-ic) | 1. ECF | Seems to have superior OS (secondary endpoint) Median OS: 11.2 vs 9.9 mo (HR 0.80, 95% CI 0.66-0.97) |
2. ECX | Non-inferior OS (primary endpoint) | |||
3. EOF | Non-inferior OS (primary endpoint) | |||
Waddell et al. 2013 (REAL3) | 2008-2011 | Phase 3 (C) | mEOC+P | Superior OS Median OS: 11.3 vs 8.3 mo (HR 0.73, 95% CI 0.57-0.93) |
Note: REAL-2 patients had 35% esophageal, 25% gastroesophageal junction, 40% gastric. 11% ECOG PS of 2. REAL3 patients had 99% adenocarcinoma, 1% undifferentiated histology. 39% esophagus, 31% gastroesophageal junction, 30% gastric. 6% ECOF PS of 2. 89% metastatic disease.
Chemotherapy
- Epirubicin (Ellence) 50 mg/m2 IV once on day 1
- Oxaliplatin (Eloxatin) 130 mg/m2 IV over 2 hours once on day 1
- Capecitabine (Xeloda) 625 mg/m2 PO twice per day on days 1 to 21
21-day cycle for up to 8 cycles
Regimen variant #2, with maintenance capecitabine
Study | Dates of enrollment | Evidence | Comparator | Comparative Efficacy |
---|---|---|---|---|
Zhu et al. 2022 (EXELOX) | 2015-2020 | Phase 3 (C) | CapeOx | Non-inferior PFS |
Chemotherapy
- Epirubicin (Ellence) as follows:
- Cycles 1 up to 8: 50 mg/m2 IV once on day 1
- Oxaliplatin (Eloxatin) as follows:
- Cycles 1 up to 8: 130 mg/m2 IV over 2 hours once on day 1
- Capecitabine (Xeloda) 1000 mg/m2 PO twice per day on days 1 to 14
21-day cycles
References
- REAL-2: Cunningham D, Starling N, Rao S, Iveson T, Nicolson M, Coxon F, Middleton G, Daniel F, Oates J, Norman AR; Upper Gastrointestinal Clinical Studies Group of the National Cancer Research Institute of the United Kingdom. Capecitabine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med. 2008 Jan 3;358(1):36-46. link to original article dosing details in manuscript have been reviewed by our editors PubMed content property of HemOnc.org ISRCTN51678883
- REAL3: Waddell T, Chau I, Cunningham D, Gonzalez D, Okines AF, Okines C, Wotherspoon A, Saffery C, Middleton G, Wadsley J, Ferry D, Mansoor W, Crosby T, Coxon F, Smith D, Waters J, Iveson T, Falk S, Slater S, Peckitt C, Barbachano Y. Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for patients with previously untreated advanced oesophagogastric cancer (REAL3): a randomised, open-label phase 3 trial. Lancet Oncol. 2013 May;14(6):481-9. Epub 2013 Apr 15. link to original article dosing details in manuscript have been reviewed by our editors link to PMC article PubMed NCT00824785
- EXELOX: Zhu XD, Huang MZ, Wang YS, Feng WJ, Chen ZY, He YF, Zhang XW, Liu X, Wang CC, Zhang W, Ying JE, Wu J, Yang L, Qin YR, Luo JF, Zhao XY, Li WH, Zhang Z, Qiu LX, Geng QR, Zou JL, Zhang JY, Zheng H, Song XF, Wu SS, Zhang CY, Gong Z, Liu QQ, Wang XF, Xu Q, Wang Q, Ji JM, Zhao J, Guo WJ. XELOX doublet regimen versus EOX triplet regimen as first-line treatment for advanced gastric cancer: An open-labeled, multicenter, randomized, prospective phase III trial (EXELOX). Cancer Commun (Lond). 2022 Apr;42(4):314-326. Epub 2022 Feb 25. link to original article link to PMC article dosing details in manuscript have been reviewed by our editors PubMed NCT02395640
Fluorouracil monotherapy
Regimen variant #1, CI
Study | Dates of enrollment | Evidence | Comparator | Comparative Efficacy |
---|---|---|---|---|
Ohtsu et al. 2003 (JCOG 9205) | 1992-1997 | Phase 3 (C) | 1. FP | Did not meet primary endpoint of OS |
2. UFTM | Did not meet primary endpoint of OS | |||
Boku et al. 2009 (JCOG 9912) | 2000-2006 | Phase 3 (C) | 1. Cisplatin & Irinotecan | Might have inferior OS |
2. S-1 | Non-inferior OS | |||
Shirao et al. 2013 (JCOG 0106) | 2002-2007 | Phase 3 (C) | MF | Did not meet primary endpoint of OS50% |
Note: JCOG 9205 included patients with PFS of 2 (9.6%)
Chemotherapy
- Fluorouracil (5-FU) 800 mg/m2/day IV continuous infusion over 120 hours, started on day 1 (total dose per cycle: 4000 mg/m2)
28-day cycles
Regimen variant #2, intermittent, BSA-based
Study | Dates of enrollment | Evidence | Comparator | Comparative Efficacy |
---|---|---|---|---|
Cullinan et al. 1985 | Not reported | Phase 3 (E-de-esc) | 1. FA 2. FAM |
Did not meet primary endpoint of OS |
Note: This was an experimental arm that did not meet its primary endpoint; included here because it represents a de-escalation strategy.
Chemotherapy
- Fluorouracil (5-FU) 500 mg/m2 IV once per day on days 1 to 5
28-day cycle for 2 cycles, then 35-day cycles
Regimen variant #3, intermittent, weight-based
Study | Dates of enrollment | Evidence | Comparator | Comparative Efficacy |
---|---|---|---|---|
Kolarić et al. 1986 | Not reported | Phase 3 (C) | Epirubicin & Fluorouracil | Seems to have inferior DOR |
Regimen variant #4, PVI
Study | Dates of enrollment | Evidence | Comparator | Comparative Efficacy |
---|---|---|---|---|
Tebbutt et al. 2002 | 1994-2001 | Phase 3 (C) | 5-FU & Mitomycin | Did not meet primary endpoint of ORR |
References
- Cullinan SA, Moertel CG, Fleming TR, Rubin JR, Krook JE, Everson LK, Windschitl HE, Twito DI, Marschke RF, Foley JF, Pfeifle DM, Barlow JF. A comparison of three chemotherapeutic regimens in the treatment of advanced pancreatic and gastric carcinoma: fluorouracil vs fluorouracil and doxorubicin vs fluorouracil, doxorubicin, and mitomycin. JAMA. 1985 Apr 12;253(14):2061-7. link to original article PubMed
- Kolarić K, Potrebica V, Stanovnik M. Controlled phase III clinical study of 4-epi-doxorubicin + 5-fluorouracil versus 5-fluorouracil alone in metastatic gastric and rectosigmoid cancer. Oncology. 1986;43(2):73-7. link to original article dosing details in abstract have been reviewed by our editors PubMed
- Tebbutt NC, Norman A, Cunningham D, Iveson T, Seymour M, Hickish T, Harper P, Maisey N, Mochlinski K, Prior Y, Hill M. A multicentre, randomised phase III trial comparing protracted venous infusion (PVI) 5-fluorouracil (5-FU) with PVI 5-FU plus mitomycin C in patients with inoperable oesophago-gastric cancer. Ann Oncol. 2002 Oct;13(10):1568-75. link to original article dosing details in manuscript have been reviewed by our editors PubMed
- JCOG 9205: Ohtsu A, Shimada Y, Shirao K, Boku N, Hyodo I, Saito H, Yamamichi N, Miyata Y, Ikeda N, Yamamoto S, Fukuda H, Yoshida S; JCOG. Randomized phase III trial of fluorouracil alone versus fluorouracil plus cisplatin versus uracil and tegafur plus mitomycin in patients with unresectable, advanced gastric cancer: the Japan Clinical Oncology Group study (JCOG9205). J Clin Oncol. 2003 Jan 1;21(1):54-9. link to original article dosing details in manuscript have been reviewed by our editors PubMed
- JCOG 9912: Boku N, Yamamoto S, Fukuda H, Shirao K, Doi T, Sawaki A, Koizumi W, Saito H, Yamaguchi K, Takiuchi H, Nasu J, Ohtsu A; Gastrointestinal Oncology Study Group of the Japan Clinical Oncology Group. Fluorouracil versus combination of irinotecan plus cisplatin versus S-1 in metastatic gastric cancer: a randomised phase 3 study. Lancet Oncol. 2009 Nov;10(11):1063-9. Epub 2009 Oct 7. link to original article dosing details in abstract have been reviewed by our editors PubMed NCT00142350
- JCOG 0106: Shirao K, Boku N, Yamada Y, Yamaguchi K, Doi T, Goto M, Nasu J, Denda T, Hamamoto Y, Takashima A, Fukuda H, Ohtsu A; Gastrointestinal Oncology Study Group of the Japan Clinical Oncology Group. Randomized Phase III study of 5-fluorouracil continuous infusion vs sequential methotrexate and 5-fluorouracil therapy in far advanced gastric cancer with peritoneal metastasis (JCOG0106). Jpn J Clin Oncol. 2013 Oct;43(10):972-80. Epub 2013 Sep 7. link to original article dosing details in manuscript have been reviewed by our editors PubMed NCT00149201
Fluorouracil & Heptaplatin (FH)
FH: Fluorouracil & Heptaplatin
Regimen
Study | Dates of enrollment | Evidence | Comparator | Comparative Efficacy |
---|---|---|---|---|
Lee et al. 2009a | 2000-2004 | Phase 3 (E-switch-ic) | CF | Equivalent OS (primary endpoint) Median OS: 7.3 vs 7.9 mo |
Note: this is reported to be an equivalence study but the statistical analysis does not provide details on the definition of equivalence.
Chemotherapy
- Fluorouracil (5-FU) 1000 mg/m2 IV over 12 hours once per day on days 1 to 5, given second
- Heptaplatin (SunPla) 400 mg/m2 IV over 60 minutes once on day 1, given first
28-day cycles
References
- Lee KH, Hyun MS, Kim HK, Jin HM, Yang J, Song HS, Do YR, Ryoo HM, Chung JS, Zang DY, Lim HY, Jin JY, Yim CY, Park HS, Kim JS, Sohn CH, Lee SN. Randomized, multicenter, phase III trial of heptaplatin 1-hour infusion and 5-fluorouracil combination chemotherapy comparing with cisplatin and 5-fluorouracil combination chemotherapy in patients with advanced gastric cancer. Cancer Res Treat. 2009 Mar;41(1):12-8. Epub 2009 Mar 31. link to original article link to PMC article dosing details in manuscript have been reviewed by our editors PubMed
Fluorouracil, Folinic acid, Mitomycin
Regimen
Study | Dates of enrollment | Evidence |
---|---|---|
Hofheinz et al. 2002 | 1998-2000 | Phase 2, fewer than 20 pts in this subgroup |
Chemotherapy
- Fluorouracil (5-FU) 2600 mg/m2 IV continuous infusion over 24 hours, started on days 1, 8, 15, 22, 29, 36 (total dose per cycle: 15,600 mg/m2)
- Leucovorin (Folinic acid) 500 mg/m2 IV over 2 hours once per day on days 1, 8, 15, 22, 29, 36
- Mitomycin (Mutamycin) 10 mg/m2 IV once per day on days 1 & 22
56-day cycle for 2 cycles
References
- Hofheinz RD, Hartung G, Samel S, Hochhaus A, Pichlmeier U, Post S, Hehlmann R, Queisser W. High-dose 5-fluorouracil / folinic acid in combination with three-weekly mitomycin C in the treatment of advanced gastric cancer: a phase II study. Onkologie. 2002 Jun;25(3):255-60. link to original article dosing details in abstract have been reviewed by our editors PubMed
FOLFIRI
FOLFIRI: FOLinic acid (Leucovorin), Fluorouracil, IRInotecan
IF: Irinotecan & 5-Fluorouracil
Regimen variant #1, 6 out of 7 weeks ("AIO regimen")
Study | Dates of enrollment | Evidence | Comparator | Comparative Efficacy |
---|---|---|---|---|
Dank et al. 2008 | 2000-2002 | Phase 3 (E-switch-ic) | CF | Might have superior TTP (primary endpoint) |
Note: patients had 100% adenocarcinoma histology (20% gastroesophageal junction, 80% gastric origin). 96% with metastatic disease.
Chemotherapy
- Fluorouracil (5-FU) 2000 mg/m2 IV continuous infusion over 22 hours, started on days 1, 8, 15, 22, 29, 36, given third (total dose per cycle: 12,000 mg/m2)
- Leucovorin (Folinic acid) 500 mg/m2 IV over 2 hours once per day on days 1, 8, 15, 22, 29, 36, given second
- Irinotecan (Camptosar) 80 mg/m2 IV over 30 minutes once per day on days 1, 8, 15, 22, 29, 36, given first
Supportive therapy
- Ondansetron (Zofran) for antiemetic prophylaxis
- Dexamethasone (Decadron) for antiemetic prophylaxis
- Filgrastim (Neupogen) (dose not specified) SC once per day, starting on day 4, to be continued until ANC greater than 1000/μL for grade 3 to 4 neutropenia, febrile neutropenia, or neutropenic infection
- Atropine (Atropen) prn cholinergic symptoms
- Loperamide (Imodium) prn delayed diarrhea
7-week cycles
Regimen variant #2, LV5FU2 & Irinotecan (200/1600/180)
Study | Dates of enrollment | Evidence | Comparator | Comparative Efficacy |
---|---|---|---|---|
Bouché et al. 2004 (FFCD 9803) | 1999-2001 | Randomized Phase 2 (E-esc) | 1. LV5FU2 2. LV5FU2 & Cisplatin |
Not powered to draw conclusions |
Note: patients had 100% adenocarcinoma (70% gastric origin, 30% cardia). The primary reference said every cycle was 15 days, but also said that medications were given every 14 days, so the assumption was made that this more typical schedule was used.
Chemotherapy
- Leucovorin (Folinic acid) 200 mg/m2 IV over 2 hours once on day 1
- Fluorouracil (5-FU) 400 mg/m2 IV bolus once on day 1, then 1200 mg/m2 IV continuous infusion over 22 hours (total dose per cycle: 1600 mg/m2)
- Irinotecan (Camptosar) 180 mg/m2 IV over 90 minutes once on day 1
14-day cycle for at least 4 cycles
Regimen variant #3, 400/2800/180
Study | Dates of enrollment | Evidence | Comparator | Comparative Efficacy |
---|---|---|---|---|
Guimbaud et al. 2014 (FFCD 03-07) | 2005-2008 | Phase 3 (E-switch-ic) | ECX | Superior TTF (primary endpoint) Median TTF: 5.08 vs 4.24 mo (HR 0.77, 95% CI 0.63-0.93) |
Chemotherapy
- Leucovorin (Folinic acid) 400 mg/m2 IV over 2 hours once on day 1
- Fluorouracil (5-FU) 400 mg/m2 IV bolus once on day 1, then 2400 mg/m2 IV continuous infusion over 46 hours, given third (total dose per cycle: 2800 mg/m2)
- Irinotecan (Camptosar) 180 mg/m2 IV over 90 minutes once on day 1
14-day cycles
References
- FFCD 9803: Bouché O, Raoul JL, Bonnetain F, Giovannini M, Etienne PL, Lledo G, Arsène D, Paitel JF, Guérin-Meyer V, Mitry E, Buecher B, Kaminsky MC, Seitz JF, Rougier P, Bedenne L, Milan C; Fédération Francophone de Cancérologie Digestive. Randomized multicenter phase II trial of a biweekly regimen of fluorouracil and leucovorin (LV5FU2), LV5FU2 plus cisplatin, or LV5FU2 plus irinotecan in patients with previously untreated metastatic gastric cancer: a Federation Francophone de Cancerologie Digestive Group Study--FFCD 9803. J Clin Oncol. 2004 Nov 1;22(21):4319-28. link to original article dosing details in manuscript have been reviewed by our editors PubMed
- Dank M, Zaluski J, Barone C, Valvere V, Yalcin S, Peschel C, Wenczl M, Goker E, Cisar L, Wang K, Bugat R. Randomized phase III study comparing irinotecan combined with 5-fluorouracil and folinic acid to cisplatin combined with 5-fluorouracil in chemotherapy naive patients with advanced adenocarcinoma of the stomach or esophagogastric junction. Ann Oncol. 2008 Aug;19(8):1450-7. Epub 2008 Jun 16. link to original article dosing details in manuscript have been reviewed by our editors PubMed
- FFCD 03-07: Guimbaud R, Louvet C, Ries P, Ychou M, Maillard E, André T, Gornet JM, Aparicio T, Nguyen S, Azzedine A, Etienne PL, Boucher E, Rebischung C, Hammel P, Rougier P, Bedenne L, Bouché O. Prospective, randomized, multicenter, phase III study of fluorouracil, leucovorin, and irinotecan versus epirubicin, cisplatin, and capecitabine in advanced gastric adenocarcinoma: a French intergroup (Fédération Francophone de Cancérologie Digestive, Fédération Nationale des Centres de Lutte Contre le Cancer, and Groupe Coopérateur Multidisciplinaire en Oncologie) study. J Clin Oncol. 2014 Nov 1;32(31):3520-6. Epub 2014 Oct 6. Erratum in: J Clin Oncol. 2015 Apr 20;33(12):1416. link to original article dosing details in manuscript have been reviewed by our editors PubMed NCT00374036
mFOLFOX6
mFOLFOX6: modified FOLinic acid (Leucovorin), Fluorouracil, OXaliplatin
Regimen variant #1, limited duration
Study | Dates of enrollment | Evidence | Comparator | Comparative Efficacy |
---|---|---|---|---|
Shah et al. 2021 (GAMMA-1) | 2015-2019 | Phase 3 (C) | mFOLFOX6 & Andecaliximab | Did not meet primary endpoint of OS |
Note: to our knowledge, this regimen was not tested as an experimental arm in an RCT in this context, prior to becoming a standard comparator arm.
Chemotherapy
- Fluorouracil (5-FU) 400 mg/m2 IV bolus once on day 1, then 2400 mg/m2 IV continuous infusion over 46 hours (total dose per cycle: 2800 mg/m2)
- Leucovorin (Folinic acid) 400 mg/m2 IV once on day 1
- Oxaliplatin (Eloxatin) 85 mg/m2 IV once on day 1
14-day cycle for 12 cycles
Subsequent treatment
- FULV maintenance
Regimen variant #2, indefinite
Study | Dates of enrollment | Evidence | Comparator | Comparative Efficacy |
---|---|---|---|---|
Janjigian et al. 2021 (CheckMate 649) | 2017-03 to 2019-04 | Phase 3 (C) | 1a. CapeOx & Nivolumab 1b. mFOLFOX6 & Nivolumab |
Inferior OS |
2. Ipilimumab & Nivolumab | Not reported | |||
Shitara et al. 2023 (SPOTLIGHT) | 2018-06-21 to 2022-04-01 | Phase 3 (C) | mFOLFOX6 & Zolbetuximab | Inferior PFS (primary endpoint) Inferior OS (secondary endpoint) |
Note: to our knowledge, this regimen was not tested as an experimental arm in an RCT in this context, prior to becoming a standard comparator arm.
Biomarker eligibility criteria
- SPOTLIGHT: CLDN18.2 positive
Chemotherapy
- Fluorouracil (5-FU) 400 mg/m2 IV bolus once on day 1, then 2400 mg/m2 IV continuous infusion over 46 hours (total dose per cycle: 2800 mg/m2)
- Leucovorin (Folinic acid) 400 mg/m2 IV once on day 1
- Oxaliplatin (Eloxatin) 85 mg/m2 IV once on day 1
14-day cycles
References
- GAMMA-1: Shah MA, Bodoky G, Starodub A, Cunningham D, Yip D, Wainberg ZA, Bendell J, Thai D, He J, Bhargava P, Ajani JA. Phase III Study to Evaluate Efficacy and Safety of Andecaliximab With mFOLFOX6 as First-Line Treatment in Patients With Advanced Gastric or GEJ Adenocarcinoma (GAMMA-1). J Clin Oncol. 2021 Mar 20;39(9):990-1000. Epub 2021 Feb 12. link to original article dosing details in manuscript have been reviewed by our editors link to PMC article PubMed NCT02545504
- CheckMate 649: Janjigian YY, Shitara K, Moehler M, Garrido M, Salman P, Shen L, Wyrwicz L, Yamaguchi K, Skoczylas T, Campos Bragagnoli A, Liu T, Schenker M, Yanez P, Tehfe M, Kowalyszyn R, Karamouzis MV, Bruges R, Zander T, Pazo-Cid R, Hitre E, Feeney K, Cleary JM, Poulart V, Cullen D, Lei M, Xiao H, Kondo K, Li M, Ajani JA. First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial. Lancet. 2021 Jul 3;398(10294):27-40. Epub 2021 Jun 5. link to original article dosing details in manuscript have been reviewed by our editors link to PMC article PubMed NCT02872116
- Update: Shitara K, Ajani JA, Moehler M, Garrido M, Gallardo C, Shen L, Yamaguchi K, Wyrwicz L, Skoczylas T, Bragagnoli AC, Liu T, Tehfe M, Elimova E, Bruges R, Zander T, de Azevedo S, Kowalyszyn R, Pazo-Cid R, Schenker M, Cleary JM, Yanez P, Feeney K, Karamouzis MV, Poulart V, Lei M, Xiao H, Kondo K, Li M, Janjigian YY. Nivolumab plus chemotherapy or ipilimumab in gastro-oesophageal cancer. Nature. 2022 Mar;603(7903):942-948. Epub 2022 Mar 23. link to original article link to PMC article PubMed
- HRQoL analysis: Moehler M, Xiao H, Blum SI, Elimova E, Cella D, Shitara K, Ajani JA, Janjigian YY, Garrido M, Shen L, Yamaguchi K, Liu T, Schenker M, Kowalyszyn R, Bragagnoli AC, Bruges R, Montesarchio V, Pazo-Cid R, Hunter S, Davenport E, Wang J, Kondo K, Li M, Wyrwicz L. Health-Related Quality of Life With Nivolumab Plus Chemotherapy Versus Chemotherapy in Patients With Advanced Gastric/Gastroesophageal Junction Cancer or Esophageal Adenocarcinoma From CheckMate 649. J Clin Oncol. 2023 Dec 10;41(35):5388-5399. Epub 2023 Sep 15. link to original article link to PMC article PubMed
- Update: Janjigian YY, Ajani JA, Moehler M, Shen L, Garrido M, Gallardo C, Wyrwicz L, Yamaguchi K, Cleary JM, Elimova E, Karamouzis M, Bruges R, Skoczylas T, Bragagnoli A, Liu T, Tehfe M, Zander T, Kowalyszyn R, Pazo-Cid R, Schenker M, Feeny K, Wang R, Lei M, Chen C, Nathani R, Shitara K. First-Line Nivolumab Plus Chemotherapy for Advanced Gastric, Gastroesophageal Junction, and Esophageal Adenocarcinoma: 3-Year Follow-Up of the Phase III CheckMate 649 Trial. J Clin Oncol. 2024 Jun 10;42(17):2012-2020. Epub 2024 Feb 21. link to original article link to PMC article PubMed
- SPOTLIGHT: Shitara K, Lordick F, Bang YJ, Enzinger P, Ilson D, Shah MA, Van Cutsem E, Xu RH, Aprile G, Xu J, Chao J, Pazo-Cid R, Kang YK, Yang J, Moran D, Bhattacharya P, Arozullah A, Park JW, Oh M, Ajani JA. Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): a multicentre, randomised, double-blind, phase 3 trial. Lancet. 2023 May 20;401(10389):1655-1668. Epub 2023 Apr 15. Erratum in: Lancet. 2023 Jul 22;402(10398):290. link to original article PubMed NCT03504397
mFOLFOX6 (L-Leucovorin)
mFOLFOX6: modified L-FOLinic acid (Leucovorin), Fluorouracil, OXaliplatin
Regimen
Study | Dates of enrollment | Evidence | Comparator | Comparative Efficacy |
---|---|---|---|---|
Shah et al. 2021 (GAMMA-1) | 2015-2019 | Phase 3 (C) | mFOLFOX6 & Andecaliximab | Did not meet primary endpoint of OS |
Note: to our knowledge, this regimen was not tested as an experimental arm in an RCT in this context, prior to becoming a standard comparator arm.
Chemotherapy
- Fluorouracil (5-FU) 400 mg/m2 IV bolus once on day 1, then 2400 mg/m2 IV continuous infusion over 46 hours (total dose per cycle: 2800 mg/m2)
- Levoleucovorin (Fusilev) 200 mg/m2 IV once on day 1
- Oxaliplatin (Eloxatin) 85 mg/m2 IV once on day 1
14-day cycle for 12 cycles
Subsequent treatment
- FULV maintenance
References
- GAMMA-1: Shah MA, Bodoky G, Starodub A, Cunningham D, Yip D, Wainberg ZA, Bendell J, Thai D, He J, Bhargava P, Ajani JA. Phase III Study to Evaluate Efficacy and Safety of Andecaliximab With mFOLFOX6 as First-Line Treatment in Patients With Advanced Gastric or GEJ Adenocarcinoma (GAMMA-1). J Clin Oncol. 2021 Mar 20;39(9):990-1000. Epub 2021 Feb 12. link to original article dosing details in manuscript have been reviewed by our editors link to PMC article PubMed NCT02545504
- ARMANI: NCT02934464
mFOLFOX6 & Nivolumab
mFOLFOX6 & Nivolumab: modified FOLinic acid (Leucovorin), Fluorouracil, OXaliplatin, Nivolumab
Regimen
Study | Dates of enrollment | Evidence | Comparator | Comparative Efficacy |
---|---|---|---|---|
Janjigian et al. 2021 (CheckMate 649) | 2017-03 to 2019-04 | Phase 3 (E-RT-esc) | 1a. CapeOx 1b. mFOLFOX6 |
Superior OS1 (co-primary endpoint) Median OS: 14.4 vs 11.1 mo (HR 0.70, 95% CI 0.61-0.81) |
2. Ipilimumab & Nivolumab | Not reported |
1Reported efficacy and MCBS score are for the group with PD-L1 CPS of 5 or more; reported efficacy is based on the 2022 update.
Chemotherapy
- Fluorouracil (5-FU) 400 mg/m2 IV bolus once on day 1, then 2400 mg/m2 IV continuous infusion over 46 hours (total dose per cycle: 2800 mg/m2)
- Leucovorin (Folinic acid) 400 mg/m2 IV once on day 1
- Oxaliplatin (Eloxatin) 85 mg/m2 IV once on day 1
Immunotherapy
- Nivolumab (Opdivo) 240 mg IV once on day 1
14-day cycles
References
- CheckMate 649: Janjigian YY, Shitara K, Moehler M, Garrido M, Salman P, Shen L, Wyrwicz L, Yamaguchi K, Skoczylas T, Campos Bragagnoli A, Liu T, Schenker M, Yanez P, Tehfe M, Kowalyszyn R, Karamouzis MV, Bruges R, Zander T, Pazo-Cid R, Hitre E, Feeney K, Cleary JM, Poulart V, Cullen D, Lei M, Xiao H, Kondo K, Li M, Ajani JA. First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial. Lancet. 2021 Jul 3;398(10294):27-40. Epub 2021 Jun 5. link to original article dosing details in manuscript have been reviewed by our editors link to PMC article PubMed NCT02872116
- Update: Shitara K, Ajani JA, Moehler M, Garrido M, Gallardo C, Shen L, Yamaguchi K, Wyrwicz L, Skoczylas T, Bragagnoli AC, Liu T, Tehfe M, Elimova E, Bruges R, Zander T, de Azevedo S, Kowalyszyn R, Pazo-Cid R, Schenker M, Cleary JM, Yanez P, Feeney K, Karamouzis MV, Poulart V, Lei M, Xiao H, Kondo K, Li M, Janjigian YY. Nivolumab plus chemotherapy or ipilimumab in gastro-oesophageal cancer. Nature. 2022 Mar;603(7903):942-948. Epub 2022 Mar 23. link to original article link to PMC article PubMed
- HRQoL analysis: Moehler M, Xiao H, Blum SI, Elimova E, Cella D, Shitara K, Ajani JA, Janjigian YY, Garrido M, Shen L, Yamaguchi K, Liu T, Schenker M, Kowalyszyn R, Bragagnoli AC, Bruges R, Montesarchio V, Pazo-Cid R, Hunter S, Davenport E, Wang J, Kondo K, Li M, Wyrwicz L. Health-Related Quality of Life With Nivolumab Plus Chemotherapy Versus Chemotherapy in Patients With Advanced Gastric/Gastroesophageal Junction Cancer or Esophageal Adenocarcinoma From CheckMate 649. J Clin Oncol. 2023 Dec 10;41(35):5388-5399. Epub 2023 Sep 15. link to original article link to PMC article PubMed
- Update: Janjigian YY, Ajani JA, Moehler M, Shen L, Garrido M, Gallardo C, Wyrwicz L, Yamaguchi K, Cleary JM, Elimova E, Karamouzis M, Bruges R, Skoczylas T, Bragagnoli A, Liu T, Tehfe M, Zander T, Kowalyszyn R, Pazo-Cid R, Schenker M, Feeny K, Wang R, Lei M, Chen C, Nathani R, Shitara K. First-Line Nivolumab Plus Chemotherapy for Advanced Gastric, Gastroesophageal Junction, and Esophageal Adenocarcinoma: 3-Year Follow-Up of the Phase III CheckMate 649 Trial. J Clin Oncol. 2024 Jun 10;42(17):2012-2020. Epub 2024 Feb 21. link to original article link to PMC article PubMed
FULV
FULV: 5-FU & LeucoVorin
Regimen variant #1
Study | Dates of enrollment | Evidence | Comparator | Comparative Efficacy |
---|---|---|---|---|
Bouché et al. 2004 (FFCD 9803) | 1999-2001 | Randomized Phase 2 (E-de-esc) | 1. LV5FU2 & Cisplatin 2. LV5FU2 & Irinotecan |
Not powered to draw conclusions |
Note: the primary reference said every cycle was 15 days, but also said that medications were given every 14 days, so the assumption was made that this more typical schedule was used. Patients had 100% adenocarcinoma histology (70% gastric origin, 30% cardia).
Chemotherapy
- Fluorouracil (5-FU) 400 mg/m2 IV bolus once on day 1, then 1200 mg/m2 IV continuous infusion over 22 hours (total dose per cycle: 1600 mg/m2)
- Leucovorin (Folinic acid) 200 mg/m2 IV over 2 hours once on day 1
14-day cycle for at least 4 cycles
Regimen variant #2
Study | Dates of enrollment | Evidence | Comparator | Comparative Efficacy |
---|---|---|---|---|
Lee et al. 2023 (KCSG ST13-10) | 2014-02 to 2019-01 | Phase 3 (C) | 1a. mFOLFOX6 1b. CapeOx 1c. Cisplatin & S-1 1d. CX |
Did not meet primary endpoint of OS Median OS: 7.5 vs 11.5 mo (HR 1.16, 95% CI 0.77-1.79) |
Note: to our knowledge, this regimen variant was not tested as an experimental arm in an RCT in this context, prior to becoming a standard comparator arm.
Chemotherapy
- Fluorouracil (5-FU) 2400 mg/m2 IV continuous infusion over 46 hours, started on day 1
- Leucovorin (Folinic acid) 100 mg/m2 IV once on day 1
14-day cycles
References
- FFCD 9803: Bouché O, Raoul JL, Bonnetain F, Giovannini M, Etienne PL, Lledo G, Arsène D, Paitel JF, Guérin-Meyer V, Mitry E, Buecher B, Kaminsky MC, Seitz JF, Rougier P, Bedenne L, Milan C; Fédération Francophone de Cancérologie Digestive. Randomized multicenter phase II trial of a biweekly regimen of fluorouracil and leucovorin (LV5FU2), LV5FU2 plus cisplatin, or LV5FU2 plus irinotecan in patients with previously untreated metastatic gastric cancer: a Federation Francophone de Cancerologie Digestive Group Study--FFCD 9803. J Clin Oncol. 2004 Nov 1;22(21):4319-28. link to original article dosing details in manuscript have been reviewed by our editors PubMed
- KCSG ST13-10: Lee KW, Zang DY, Ryu MH, Han HS, Kim KH, Kim MJ, Koh SA, Lee SS, Koo DH, Ko YH, Sohn BS, Kim JW, Park JH, Nam BH, Choi IS. A Phase 3 Randomized Clinical Trial to Compare Efficacy and Safety between Combination Therapy and Monotherapy in Elderly Patients with Advanced Gastric Cancer (KCSG ST13-10). Cancer Res Treat. 2022 Oct;55(4):1250-1260. Epub 2023 May 25. link to original article dosing details in manuscript have been reviewed by our editors link to PMC article PubMed NCT02114359
FULV (L-Leucovorin)
FULV: 5-FU & Levo-LeucoVorin
Regimen
Study | Dates of enrollment | Evidence | Comparator | Comparative Efficacy |
---|---|---|---|---|
Nakajima et al. 2020 (JCOG1108) | 2013-2017 | Phase 2/3 (C) | FLTAX | Did not meet primary endpoint of OS |
Chemotherapy
- Fluorouracil (5-FU) 600 mg/m2 IV bolus once per day on days 1, 8, 15, 22, 29, 36, given second, 60 minutes after levoleucovorin
- Levoleucovorin (Fusilev) 250 mg/m2 IV over 2 hours once per day on days 1, 8, 15, 22, 29, 36, given first
8-week cycles
References
- JCOG1108: Nakajima TE, Yamaguchi K, Boku N, Hyodo I, Mizusawa J, Hara H, Nishina T, Sakamoto T, Shitara K, Shinozaki K, Katayama H, Nakamura S, Muro K, Terashima M. Randomized phase II/III study of 5-fluorouracil/l-leucovorin versus 5-fluorouracil/l-leucovorin plus paclitaxel administered to patients with severe peritoneal metastases of gastric cancer (JCOG1108/WJOG7312G). Gastric Cancer. 2020 Jul;23(4):677-688. Epub 2020 Feb 8. link to original article dosing details in manuscript have been reviewed by our editors PubMed UMIN000010949
Irinotecan monotherapy
Regimen
Study | Dates of enrollment | Evidence |
---|---|---|
Enzinger et al. 2005 | 1997-12 to 2000-08 | Phase 2 |
Note: In contrast to the primary references, some guidelines list a dosing schedule of 125 mg/m2 IV once per day on days 1 & 8, with 21-day cycles. Enzinger et al. 2005 comment that "when irinotecan is used as a single-agent, a tri-weekly schedule may be preferable." This study included patients with GE junction and distal esophageal malignancy as well (~59% gastric, 9% GEJ and 33% distal esophagus). The results showed a 14% response rate and 53% disease control rate.
Chemotherapy
- Irinotecan (Camptosar) 125 mg/m2 IV over 90 minutes once per day on days 1, 8, 15, 22
42-day cycles
References
- Enzinger PC, Kulke MH, Clark JW, Ryan DP, Kim H, Earle CC, Vincitore MM, Michelini AL, Mayer RJ, Fuchs CS. A phase II trial of irinotecan in patients with previously untreated advanced esophageal and gastric adenocarcinoma. Dig Dis Sci. 2005 Dec;50(12):2218-23. link to original article PubMed
OLF
OLF: Oxaliplatin, Leucovorin, Fluorouracil
FLO: Fluorouracil, Leucovorin, Oxaliplatin
Regimen
Study | Dates of enrollment | Evidence | Comparator | Comparative Efficacy |
---|---|---|---|---|
Al-Batran et al. 2008 | 2003-2006 | Phase 3 (E-switch-ic) | FLP | Might have superior PFS (primary endpoint) Median PFS: 5.8 vs 3.9 mo |
Note: Patients had 100% adenocarcinoma histology (20% esophagogastric junction, 80% gastric).
Chemotherapy
- Oxaliplatin (Eloxatin) 85 mg/m2 IV over 2 hours once per day on days 1, 15, 29, 43
- Leucovorin (Folinic acid) 200 mg/m2 IV over 2 hours once per day on days 1, 15, 29, 43
- Fluorouracil (5-FU) 2600 mg/m2 IV continuous infusion over 24 hours, started on days 1, 15, 29, 43 (total dose per cycle: 10,400 mg/m2)
Supportive therapy
- Antiemetic medications per "local protocols"
8-week cycles
References
- Al-Batran SE, Hartmann JT, Probst S, Schmalenberg H, Hollerbach S, Hofheinz R, Rethwisch V, Seipelt G, Homann N, Wilhelm G, Schuch G, Stoehlmacher J, Derigs HG, Hegewisch-Becker S, Grossmann J, Pauligk C, Atmaca A, Bokemeyer C, Knuth A, Jäger E; Arbeitsgemeinschaft Internistische Onkologie. Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie. J Clin Oncol. 2008 Mar 20;26(9):1435-42. link to original article dosing details in manuscript have been reviewed by our editors PubMed
Paclitaxel & S-1
Regimen
Study | Dates of enrollment | Evidence | Comparator | Comparative Efficacy |
---|---|---|---|---|
Ishigami et al. 2018 (PHOENIX-GC) | 2011-2013 | Phase 3 (E-switch-ooc) | Cisplatin & S-1 | Might have superior OS Median OS: 17.7 vs 15.2 mo (HR 0.72, 95% CI 0.49-1.04) |
Note: Inclusion criteria for PHOENIX-GC included patients with peritoneal metastasis who had received less than or equal to 2 months of prior chemotherapy without disease progression, see link for further details
Chemotherapy
- Paclitaxel (Taxol) 50 mg/m2 IV once per day on days 1 and 8
- Tegafur, gimeracil, oteracil (S-1) by the following BSA-based criteria:
- Less than 1.25 m2: 40 mg PO twice per day on days 1 to 14
- Between 1.25 to 1.5 m2: 50 mg PO twice per day on days 1 to 14
- More than 1.5 m2: 60 mg PO twice per day on days 1 to 14
- Paclitaxel (Taxol) 20 mg/m2 IP once per day over 1 hour on days 1 and 8
Supportive therapy
- 500 mL of normal saline was given prior to intraperitoneal paclitaxel
35-day cycles
References
- PHOENIX-GC: Ishigami H, Fujiwara Y, Fukushima R, Nashimoto A, Yabusaki H, Imano M, Imamoto H, Kodera Y, Uenosono Y, Amagai K, Kadowaki S, Miwa H, Yamaguchi H, Yamaguchi T, Miyaji T, Kitayama J. Phase III trial comparing intraperitoneal and intravenous paclitaxel plus S-1 versus cisplatin plus S-1 in patients with gastric cancer with peritoneal metastasis: PHOENIX-GC trial. J Clin Oncol. 2018 Jul 1;36(19):1922-1929. Epub 2018 May 10. link to original article dosing details in manuscript have been reviewed by our editors PubMed UMIN000005930
Pembrolizumab monotherapy
Regimen
Study | Dates of enrollment | Evidence | Comparator | Comparative Efficacy |
---|---|---|---|---|
Shitara et al. 2020 (KEYNOTE-062) | 2015-2017 | Phase 3 (E-switch-ooc) | 1a. CF 1b. CX |
Non-inferior OS1 (co-primary endpoint) |
2a. CF & Pembrolizumab 2b. CX & Pembrolizumab |
Not reported |
1Reported efficacy is for patients with PD-L1 CPS score of 1 or more. Improved OS was seen in patients with PD-L1 CPS score of 10 or more (HR: 0.62) but was not tested per analysis plan.
KEYNOTE-062 included patients with GEJ malignancy.
Biomarker eligibility criteria
- PD-L1 CPS score of 1 or more
References
- KEYNOTE-062: Shitara K, Van Cutsem E, Bang YJ, Fuchs C, Wyrwicz L, Lee KW, Kudaba I, Garrido M, Chung HC, Lee J, Castro HR, Mansoor W, Braghiroli MI, Karaseva N, Caglevic C, Villanueva L, Goekkurt E, Satake H, Enzinger P, Alsina M, Benson A, Chao J, Ko AH, Wainberg ZA, Kher U, Shah S, Kang SP, Tabernero J. Efficacy and Safety of Pembrolizumab or Pembrolizumab Plus Chemotherapy vs Chemotherapy Alone for Patients With First-line, Advanced Gastric Cancer: The KEYNOTE-062 Phase 3 Randomized Clinical Trial. JAMA Oncol. 2020 Oct 1;6(10):1571-1580. Epub 2020 Sep 3. link to original article link to PMC article dosing details in manuscript have been reviewed by our editors PubMed NCT02494583
S-1 monotherapy
Regimen variant #1, BSA-based
Study | Dates of enrollment | Evidence | Comparator | Comparative Efficacy |
---|---|---|---|---|
Boku et al. 2009 (JCOG 9912) | 2000-2006 | Phase 3 (E-switch-ic) | 1. Cisplatin & Irinotecan | Not reported |
2. 5-FU | Non-inferior OS (primary endpoint) |
Chemotherapy
- Tegafur, gimeracil, oteracil (S-1) 40 mg/m2 PO twice per day on days 1 to 28
42-day cycles
Regimen variant #2, weight-based
Study | Dates of enrollment | Evidence | Comparator | Comparative Efficacy |
---|---|---|---|---|
Koizumi et al. 2008 (SPIRITS) | 2002-2004 | Phase 3 (C) | Cisplatin & S-1 | Seems to have inferior OS |
Narahara et al. 2011 (TOP-002) | 2004-06 to 2005-11 | Phase 3 (C) | IRIS | Did not meet primary endpoint of OS |
Koizumi et al. 2013 (STARTgastric) | 2005-2008 | Phase 3 (C) | Docetaxel & S-1 | Seems to have inferior OS |
Yoshino et al. 2016 (JFMC36-0701) | 2007-2010 | Phase 3 (C) | Lentinan & S-1 | Did not meet primary endpoint of OS |
Note: there is another trial named START in NSCLC.
Chemotherapy
- Tegafur, gimeracil, oteracil (S-1) by the following BSA-based criteria:
- Less than 1.25 m2: 40 mg PO twice per day on days 1 to 28
- Between 1.25 and 1.5 m2: 50 mg PO twice per day on days 1 to 28
- 1.5 m2 or more: 60 mg PO twice per day on days 1 to 28
42-day cycles
Regimen variant #3, 14 of 21 days
Study | Dates of enrollment | Evidence | Comparator | Comparative Efficacy |
---|---|---|---|---|
Lee et al. 2023 (KCSG ST13-10) | 2014-02 to 2019-01 | Phase 3 (C) | 1a. mFOLFOX6 1b. CapeOx 1c. Cisplatin & S-1 1d. CX |
Did not meet primary endpoint of OS Median OS: 7.5 vs 11.5 mo (HR 1.16, 95% CI 0.77-1.79) |
Note: to our knowledge, this regimen variant was not tested as an experimental arm in an RCT in this context, prior to becoming a standard comparator arm.
Chemotherapy
- Tegafur, gimeracil, oteracil (S-1) by the following renal function-based criteria:
- CrCl 60 mL/min or more: 40 mg/m2 PO twice per day on days 1 to 14
- CrCl less than 60 mL/min: 30 mg/m2 PO twice per day on days 1 to 14
21-day cycles
References
- SPIRITS: Koizumi W, Narahara H, Hara T, Takagane A, Akiya T, Takagi M, Miyashita K, Nishizaki T, Kobayashi O, Takiyama W, Toh Y, Nagaie T, Takagi S, Yamamura Y, Yanaoka K, Orita H, Takeuchi M. S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial. Lancet Oncol. 2008 Mar;9(3):215-21. Epub 2008 Feb 20. link to original article dosing details in manuscript have been reviewed by our editors PubMed NCT00150670
- JCOG 9912: Boku N, Yamamoto S, Fukuda H, Shirao K, Doi T, Sawaki A, Koizumi W, Saito H, Yamaguchi K, Takiuchi H, Nasu J, Ohtsu A; Gastrointestinal Oncology Study Group of the Japan Clinical Oncology Group. Fluorouracil versus combination of irinotecan plus cisplatin versus S-1 in metastatic gastric cancer: a randomised phase 3 study. Lancet Oncol. 2009 Nov;10(11):1063-9. Epub 2009 Oct 7. link to original article dosing details in abstract have been reviewed by our editors PubMed NCT00142350
- TOP-002: Narahara H, Iishi H, Imamura H, Tsuburaya A, Chin K, Imamoto H, Esaki T, Furukawa H, Hamada C, Sakata Y. Randomized phase III study comparing the efficacy and safety of irinotecan plus S-1 with S-1 alone as first-line treatment for advanced gastric cancer (study GC0301/TOP-002). Gastric Cancer. 2011 Mar;14(1):72-80. Epub 2011 Feb 23. link to original article link to PMC article dosing details in manuscript have been reviewed by our editors PubMed JapicCTI-050083
- START: Koizumi W, Kim YH, Fujii M, Kim HK, Imamura H, Lee KH, Hara T, Chung HC, Satoh T, Cho JY, Hosaka H, Tsuji A, Takagane A, Inokuchi M, Tanabe K, Okuno T, Ogura M, Yoshida K, Takeuchi M, Nakajima T; JACCRO; KCSG. Addition of docetaxel to S-1 without platinum prolongs survival of patients with advanced gastric cancer: a randomized study (START). J Cancer Res Clin Oncol. 2014 Feb;140(2):319-28. Epub 2013 Dec 24. link to original article link to PMC article dosing details in manuscript have been reviewed by our editors PubMed NCT00287768
- JFMC36-0701: Yoshino S, Nishikawa K, Morita S, Takahashi T, Sakata K, Nagao J, Nemoto H, Murakami N, Matsuda T, Hasegawa H, Shimizu R, Yoshikawa T, Osanai H, Imano M, Naitoh H, Tanaka A, Tajiri T, Gochi A, Suzuki M, Sakamoto J, Saji S, Oka M. Randomised phase III study of S-1 alone versus S-1 plus lentinan for unresectable or recurrent gastric cancer (JFMC36-0701). Eur J Cancer. 2016 Sep;65:164-71. Epub 2016 Aug 5. link to original article PubMed UMIN000000574
- KCSG ST13-10: Lee KW, Zang DY, Ryu MH, Han HS, Kim KH, Kim MJ, Koh SA, Lee SS, Koo DH, Ko YH, Sohn BS, Kim JW, Park JH, Nam BH, Choi IS. A Phase 3 Randomized Clinical Trial to Compare Efficacy and Safety between Combination Therapy and Monotherapy in Elderly Patients with Advanced Gastric Cancer (KCSG ST13-10). Cancer Res Treat. 2022 Oct;55(4):1250-1260. Epub 2023 May 25. link to original article dosing details in manuscript have been reviewed by our editors link to PMC article PubMed NCT02114359
- RESCUE-GC: NCT02867839
UFTM
UFTM: UFT (Tegafur and uracil) & Mitomycin
Regimen
Study | Dates of enrollment | Evidence | Comparator | Comparative Efficacy |
---|---|---|---|---|
Ohtsu et al. 2003 (JCOG 9205) | 1992-1997 | Phase 3 (E-esc) | 1. Fluorouracil | Did not meet primary endpoint of OS |
2. FP | Did not meet primary endpoint of OS |
Note: this arm of the study was terminated early, in 1995. Study included patients with PFS of 2 (9.6%). Mitomycin was interrupted for 1 month after patients received a total cumulative dose of 60 mg.
Chemotherapy
- Tegafur and uracil (UFT) 187.5 mg/m2 PO twice per day
- Mitomycin (Mutamycin) 5 mg/m2 IV once on day 1
7-day cycles (see note)
References
- JCOG 9205: Ohtsu A, Shimada Y, Shirao K, Boku N, Hyodo I, Saito H, Yamamichi N, Miyata Y, Ikeda N, Yamamoto S, Fukuda H, Yoshida S; JCOG. Randomized phase III trial of fluorouracil alone versus fluorouracil plus cisplatin versus uracil and tegafur plus mitomycin in patients with unresectable, advanced gastric cancer: the Japan Clinical Oncology Group study (JCOG9205). J Clin Oncol. 2003 Jan 1;21(1):54-9. link to original article dosing details in manuscript have been reviewed by our editors PubMed
Maintenance after first-line therapy
Capecitabine monotherapy
Regimen
Study | Dates of enrollment | Evidence |
---|---|---|
Ohtsu et al. 2011 (AVAGAST) | 2007-09 to 2008-12 | Non-randomized part of phase 3 RCT |
Kim et al. 2014 (SMC 2008-12-019) | 2009-2012 | Non-randomized part of phase 3 RCT |
Note: AVAGAST patients had 86% gastric and 14% GEJ. 5.4% of patients had an ECOG PS of 2. SMC 2008-12-019 patients had 79% gastric, 5% GEJ, and 16% unknown. 2% of patients had an ECOG PS of 2.
References
- AVAGAST: Ohtsu A, Shah MA, Van Cutsem E, Rha SY, Sawaki A, Park SR, Lim HY, Yamada Y, Wu J, Langer B, Starnawski M, Kang YK. Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a randomized, double-blind, placebo-controlled phase III study. J Clin Oncol. 2011 Oct 20;29(30):3968-76. Epub 2011 Aug 15. link to original article dosing details in manuscript have been reviewed by our editors PubMed NCT00548548
- SMC 2008-12-019: Kim ST, Kang JH, Lee J, Park SH, Park JO, Park YS, Lim HY, Hwang IG, Lee SC, Park KW, Lee HR, Kang WK. Simvastatin plus capecitabine-cisplatin versus placebo plus capecitabine-cisplatin in patients with previously untreated advanced gastric cancer: a double-blind randomised phase 3 study. Eur J Cancer. 2014 Nov;50(16):2822-30. Epub 2014 Sep 15. link to original article dosing details in manuscript have been reviewed by our editors PubMed NCT01099085
Metastatic or locally advanced disease, subsequent lines of therapy
Docetaxel monotherapy
Regimen variant #1, 60 mg/m2
Study | Dates of enrollment | Evidence | Comparator | Comparative Efficacy |
---|---|---|---|---|
Kang et al. 2012 (SMC 2008-08-055) | 2008-2010 | Phase 3 (E-esc) | Best supportive care | Superior OS (primary endpoint) Median OS: 5.3 vs 3.8 mo (HR 0.66, 95% CI 0.485-0.89) |
Regimen variant #2, 75 mg/m2 x 6
Study | Dates of enrollment | Evidence | Comparator | Comparative Efficacy |
---|---|---|---|---|
Ford et al. 2013 (COUGAR-02) | 2008-2012 | Phase 3 (E-esc) | Best supportive care | Superior OS (primary endpoint) Median OS: 5.2 vs 3.6 mo (HR 0.67, 95% CI 0.49-0.92) |
Chemotherapy
- Docetaxel (Taxotere) 75 mg/m2 IV over 60 minutes once on day 1
21-day cycle for up to 6 cycles
References
- SMC 2008-08-055: Kang JH, Lee SI, Lim DH, Park KW, Oh SY, Kwon HC, Hwang IG, Lee SC, Nam E, Shin DB, Lee J, Park JO, Park YS, Lim HY, Kang WK, Park SH. Salvage chemotherapy for pretreated gastric cancer: a randomized phase III trial comparing chemotherapy plus best supportive care with best supportive care alone. J Clin Oncol. 2012 May 1;30(13):1513-8. Epub 2012 Mar 12. Erratum in: J Clin Oncol. 2012 Aug 20;30(24):3035. link to original article dosing details in abstract have been reviewed by our editors PubMed NCT00821990
- PEP0206: Roy AC, Park SR, Cunningham D, Kang YK, Chao Y, Chen LT, Rees C, Lim HY, Tabernero J, Ramos FJ, Kujundzic M, Cardic MB, Yeh CG, de Gramont A. A randomized phase II study of PEP02 (MM-398), irinotecan or docetaxel as a second-line therapy in patients with locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma. Ann Oncol. 2013 Jun;24(6):1567-73. Epub 2013 Feb 13. link to original article PubMed NCT00813072
- COUGAR-02: Ford HE, Marshall A, Bridgewater JA, Janowitz T, Coxon FY, Wadsley J, Mansoor W, Fyfe D, Madhusudan S, Middleton GW, Swinson D, Falk S, Chau I, Cunningham D, Kareclas P, Cook N, Blazeby JM, Dunn JA; COUGAR-02 Investigators. Docetaxel versus active symptom control for refractory oesophagogastric adenocarcinoma (COUGAR-02): an open-label, phase 3 randomised controlled trial. Lancet Oncol. 2014 Jan;15(1):78-86. Epub 2013 Dec 10. link to original article dosing details in abstract have been reviewed by our editors PubMed NCT00978549
- INTEGRATEIIb: NCT04879368
Fluorouracil, Folinic acid, Mitomycin
Regimen
Study | Dates of enrollment | Evidence |
---|---|---|
Hofheinz et al. 2002 | 1998-2000 | Phase 2, fewer than 20 pts in this subgroup |
Chemotherapy
- Fluorouracil (5-FU) 2600 mg/m2 IV continuous infusion over 24 hours, started on days 1, 8, 15, 22, 29, 36 (total dose per cycle: 15,600 mg/m2)
- Leucovorin (Folinic acid) 500 mg/m2 IV over 2 hours once per day on days 1, 8, 15, 22, 29, 36
- Mitomycin (Mutamycin) 10 mg/m2 IV once per day on days 1 & 22
56-day cycle for 2 cycles
References
- Hofheinz RD, Hartung G, Samel S, Hochhaus A, Pichlmeier U, Post S, Hehlmann R, Queisser W. High-dose 5-fluorouracil / folinic acid in combination with three-weekly mitomycin C in the treatment of advanced gastric cancer: a phase II study. Onkologie. 2002 Jun;25(3):255-60. link to original article dosing details in abstract have been reviewed by our editors PubMed
Irinotecan monotherapy
Regimen variant #1, 125 mg/m2, 4 weeks out of 6
Study | Dates of enrollment | Evidence |
---|---|---|
Enzinger et al. 2005 | 1997-12 to 2000-08 | Phase 2 |
Note: In contrast to the primary references, some guidelines list a dosing schedule of 125 mg/m2 IV once per day on days 1 & 8, with 21-day cycles. Enzinger et al. 2005 comment that "when irinotecan is used as a single-agent, a tri-weekly schedule may be preferable." This study included patients with GE junction and distal esophageal malignancy as well (~59% gastric, 9% GE junction and 33% distal esophagus), and showed a 14% response rate and 53% disease control rate.
Chemotherapy
- Irinotecan (Camptosar) 125 mg/m2 IV over 90 minutes once per day on days 1, 8, 15, 22
42-day cycles
Regimen variant #2, 150 mg/m2 q2wk
Study | Dates of enrollment | Evidence | Comparator | Comparative Efficacy |
---|---|---|---|---|
Hironaka et al. 2013 (WJOG 4007) | 2007-2010 | Phase 3 (E-switch-ic) | Paclitaxel | Did not meet primary endpoint of OS |
Nishikawa et al. 2015 (TRICS) | 2007-2011 | Phase 3 (C) | Cisplatin & Irinotecan | Did not meet primary endpoint of OS |
Kang et al. 2012 (SMC 2008-08-055) | 2008-2010 | Phase 3 (E-esc) | Best supportive care | Superior OS (primary endpoint) Median OS: 5.3 vs 3.8 mo (HR 0.66, 95% CI 0.485-0.89) |
Higuchi et al. 2014 (BIRIP) | 2008-2011 | Phase 3 (C) | Cisplatin & Irinotecan | Seems to have inferior PFS |
Tanabe et al. 2015 (JACCRO GC-05) | 2008-2011 | Phase 3 (C) | Irinotecan & S-1 | Did not meet primary endpoint of OS |
Bang et al. 2018 (JAVELIN Gastric 300) | 2015-2017 | Phase 3 (C) | Avelumab | Did not meet primary endpoint of OS |
Note: WJOG 4007 had 3.7% patients with an ECOG PS of 2
Regimen variant #3, 300 mg/m2 q3wk
Study | Dates of enrollment | Evidence | Comparator | Comparative Efficacy |
---|---|---|---|---|
Roy et al. 2013 (PEP0206) | 2008-2010 | Randomized Phase 2 (C) | 1. Docetaxel 2. Irinotecan liposomal |
Did not meet primary endpoint of ORR |
Note: this study included patients with GE junction malignancy (77% gastric, 23% GE junction) and included patients with ECOG PS of 2
Regimen variant #4, 350 mg/m2 q3wk
Study | Dates of enrollment | Evidence | Comparator | Comparative Efficacy |
---|---|---|---|---|
Thuss-Patience et al. 2011 | 2002-2006 | Phase 3 (E-esc) | Best supportive care | Seems to have superior OS Median OS: 4 vs 2.4 mo (HR 0.48, 95% CI 0.25-0.92) |
Note: Thuss-Patience et al. 2011 included patients with GE junction malignancy (~58% gastric, 43% GE junction) and included patients with ECOG PS of 2.
Chemotherapy
- Irinotecan (Camptosar) as follows:
- Cycle 1: 250 mg/m2 (maximum dose of 500 mg) IV over 30 minutes once on day 1
- Cycles 2 to 10 (depending on toxicity): 350 mg/m2 IV over 30 minutes once on day 1
Supportive therapy
- Atropine (Atropen) 0.25 mg SC once on day 1, given prior to irinotecan
- 5-HT3 antagonist
- Dexamethasone (Decadron)
21-day cycle for up to 10 cycles
References
- Enzinger PC, Kulke MH, Clark JW, Ryan DP, Kim H, Earle CC, Vincitore MM, Michelini AL, Mayer RJ, Fuchs CS. A phase II trial of irinotecan in patients with previously untreated advanced esophageal and gastric adenocarcinoma. Dig Dis Sci. 2005 Dec;50(12):2218-23. link to original article PubMed
- Thuss-Patience PC, Kretzschmar A, Bichev D, Deist T, Hinke A, Breithaupt K, Dogan Y, Gebauer B, Schumacher G, Reichardt P. Survival advantage for irinotecan versus best supportive care as second-line chemotherapy in gastric cancer--a randomised phase III study of the Arbeitsgemeinschaft Internistische Onkologie (AIO). Eur J Cancer. 2011 Oct;47(15):2306-14. link to original article dosing details in manuscript have been reviewed by our editors PubMed NCT00144378
- SMC 2008-08-055: Kang JH, Lee SI, Lim DH, Park KW, Oh SY, Kwon HC, Hwang IG, Lee SC, Nam E, Shin DB, Lee J, Park JO, Park YS, Lim HY, Kang WK, Park SH. Salvage chemotherapy for pretreated gastric cancer: a randomized phase III trial comparing chemotherapy plus best supportive care with best supportive care alone. J Clin Oncol. 2012 May 1;30(13):1513-8. Epub 2012 Mar 12. Erratum in: J Clin Oncol. 2012 Aug 20;30(24):3035. link to original article PubMed NCT00821990
- PEP0206: Roy AC, Park SR, Cunningham D, Kang YK, Chao Y, Chen LT, Rees C, Lim HY, Tabernero J, Ramos FJ, Kujundzic M, Cardic MB, Yeh CG, de Gramont A. A randomized phase II study of PEP02 (MM-398), irinotecan or docetaxel as a second-line therapy in patients with locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma. Ann Oncol. 2013 Jun;24(6):1567-73. Epub 2013 Feb 13. link to original article PubMed NCT00813072
- WJOG 4007: Hironaka S, Ueda S, Yasui H, Nishina T, Tsuda M, Tsumura T, Sugimoto N, Shimodaira H, Tokunaga S, Moriwaki T, Esaki T, Nagase M, Fujitani K, Yamaguchi K, Ura T, Hamamoto Y, Morita S, Okamoto I, Boku N, Hyodo I. Randomized, open-label, phase III study comparing irinotecan with paclitaxel in patients with advanced gastric cancer without severe peritoneal metastasis after failure of prior combination chemotherapy using fluoropyrimidine plus platinum: WJOG 4007 trial. J Clin Oncol. 2013 Dec 10;31(35):4438-44. Epub 2013 Nov 4. link to original artile dosing details in abstract have been reviewed by our editors PubMed UMIN000001252
- BIRIP: Higuchi K, Tanabe S, Shimada K, Hosaka H, Sasaki E, Nakayama N, Takeda Y, Moriwaki T, Amagai K, Sekikawa T, Sakuyama T, Kanda T, Sasaki T, Azuma M, Takahashi F, Takeuchi M, Koizumi W; Tokyo Cooperative Oncology Group. Biweekly irinotecan plus cisplatin versus irinotecan alone as second-line treatment for advanced gastric cancer: a randomised phase III trial (TCOG GI-0801/BIRIP trial). Eur J Cancer. 2014 May;50(8):1437-45. Epub 2014 Feb 20. link to original article dosing details in abstract have been reviewed by our editors PubMed UMIN000001028
- TRICS: Nishikawa K, Fujitani K, Inagaki H, Akamaru Y, Tokunaga S, Takagi M, Tamura S, Sugimoto N, Shigematsu T, Yoshikawa T, Ishiguro T, Nakamura M, Morita S, Miyashita Y, Tsuburaya A, Sakamoto J, Tsujinaka T. Randomised phase III trial of second-line irinotecan plus cisplatin versus irinotecan alone in patients with advanced gastric cancer refractory to S-1 monotherapy: TRICS trial. Eur J Cancer. 2015 May;51(7):808-16. Epub 2015 Mar 18. link to original article dosing details in abstract have been reviewed by our editors PubMed UMIN000002571
- JACCRO GC-05: Tanabe K, Fujii M, Nishikawa K, Kunisaki C, Tsuji A, Matsuhashi N, Takagane A, Ohno T, Kawase T, Kochi M, Yoshida K, Kakeji Y, Ichikawa W, Chin K, Terashima M, Takeuchi M, Nakajima T; JACCRO. Phase II/III study of second-line chemotherapy comparing irinotecan-alone with S-1 plus irinotecan in advanced gastric cancer refractory to first-line treatment with S-1 (JACCRO GC-05). Ann Oncol. 2015 Sep;26(9):1916-22. Epub 2015 Jun 24. link to original article PubMed NCT00639327
- JAVELIN Gastric 300: Bang YJ, Yanez Ruiz E, Van Cutsem E, Lee KW, Wyrwicz L, Schenker M, Alsina M, Ryu MH, Chung HC, Evesque L, Al-Batran SE, Park SH, Lichinitser M, Boku N, Moehler MH, Hong J, Xiong H, Hallwachs R, Conti I, Taieb J. Phase III, randomised trial of avelumab versus physician's choice of chemotherapy as third-line treatment of patients with advanced gastric or gastro-oesophageal junction cancer: primary analysis of JAVELIN Gastric 300. Ann Oncol. 2018 Oct 1;29(10):2052-2060. link to original article link to PMC article dosing details in abstract have been reviewed by our editors PubMed NCT02625623
- INTEGRATEIIb: NCT04879368
Irinotecan liposomal monotherapy
Regimen
Study | Dates of enrollment | Evidence | Comparator | Comparative Efficacy |
---|---|---|---|---|
Roy et al. 2013 (PEP0206) | 2008-2010 | Randomized Phase 2 (E-switch-ic) | 1. Docetaxel 2. Irinotecan |
Did not meet primary endpoint of ORR |
References
- PEP0206: Roy AC, Park SR, Cunningham D, Kang YK, Chao Y, Chen LT, Rees C, Lim HY, Tabernero J, Ramos FJ, Kujundzic M, Cardic MB, Yeh CG, de Gramont A. A randomized phase II study of PEP02 (MM-398), irinotecan or docetaxel as a second-line therapy in patients with locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma. Ann Oncol. 2013 Jun;24(6):1567-73. Epub 2013 Feb 13. link to original article dosing details in manuscript have been reviewed by our editors PubMed NCT00813072
Irinotecan & Mitomycin
Regimen
Study | Dates of enrollment | Evidence |
---|---|---|
Bamias et al. 2003a | 1999-07 to 2001-02 | Phase 2 |
Note: Patients had advanced gastric and colorectal cancers.
Prior treatment criteria
- 5-fluorouracil-based chemotherapy
Chemotherapy
- Irinotecan (Camptosar) 125 mg/m2 IV once on day 1
- Mitomycin (Mutamycin) 5 mg/m2 IV once on day 1
14-day cycles
References
- Bamias A, Papamichael D, Syrigos K, Pavlidis N. Phase II study of irinotecan and mitomycin C in 5-fluorouracil-pretreated patients with advanced colorectal and gastric cancer. J Chemother. 2003 Jun;15(3):275-81. link to original article dosing details in abstract have been reviewed by our editors PubMed
Nivolumab monotherapy
Regimen
Study | Dates of enrollment | Evidence | Comparator | Comparative Efficacy |
---|---|---|---|---|
Janjigian et al. 2018 (CheckMate 032UGI) | 2013-2015 | Phase 1/2 | ||
Kang et al. 2017 (ATTRACTION-2) | 2014-2016 | Phase 3 (E-esc) | Placebo | Superior OS1 (primary endpoint) Median OS: 5.3 vs 4.1 mo (HR 0.62, 95% CI 0.50-0.75) |
1Reported efficacy for ATTRACTION-2 is based on the 2021 update.
Note: ATTRACTION-2 included patients with GE junction malignancy (82.6% gastric, 8.5% GE junction) and 12.3% of patients had a PD-L1 CPS score of at least 1
References
- ATTRACTION-2: Kang YK, Boku N, Satoh T, Ryu MH, Chao Y, Kato K, Chung HC, Chen JS, Muro K, Kang WK, Yeh KH, Yoshikawa T, Oh SC, Bai LY, Tamura T, Lee KW, Hamamoto Y, Kim JG, Chin K, Oh DY, Minashi K, Cho JY, Tsuda M, Chen LT. Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2017 Dec 2;390(10111):2461-2471. Epub 2017 Oct 6. link to original article dosing details in manuscript have been reviewed by our editors PubMed NCT02267343
- Subgroup analysis: Kato K, Satoh T, Muro K, Yoshikawa T, Tamura T, Hamamoto Y, Chin K, Minashi K, Tsuda M, Yamaguchi K, Machida N, Esaki T, Goto M, Komatsu Y, Nakajima TE, Sugimoto N, Yoshida K, Oki E, Nishina T, Tsuji A, Fujii H, Kunieda K, Saitoh S, Omuro Y, Azuma M, Iwamoto Y, Taku K, Fushida S, Chen LT, Kang YK, Boku N. A subanalysis of Japanese patients in a randomized, double-blind, placebo-controlled, phase 3 trial of nivolumab for patients with advanced gastric or gastro-esophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2). Gastric Cancer. 2019 Mar;22(2):344-354. Epub 2018 Dec 1. link to original article link to original article PubMed
- Update: Chen LT, Satoh T, Ryu MH, Chao Y, Kato K, Chung HC, Chen JS, Muro K, Kang WK, Yeh KH, Yoshikawa T, Oh SC, Bai LY, Tamura T, Lee KW, Hamamoto Y, Kim JG, Chin K, Oh DY, Minashi K, Cho JY, Tsuda M, Sameshima H, Kang YK, Boku N. A phase 3 study of nivolumab in previously treated advanced gastric or gastroesophageal junction cancer (ATTRACTION-2): 2-year update data. Gastric Cancer. 2020 May;23(3):510-519. Epub 2019 Dec 20. link to original article link to PMC article PubMed
- Update: Boku N, Satoh T, Ryu MH, Chao Y, Kato K, Chung HC, Chen JS, Muro K, Kang WK, Yeh KH, Yoshikawa T, Oh SC, Bai LY, Tamura T, Lee KW, Hamamoto Y, Kim JG, Chin K, Oh DY, Minashi K, Cho JY, Tsuda M, Nishiyama T, Chen LT, Kang YK. Nivolumab in previously treated advanced gastric cancer (ATTRACTION-2): 3-year update and outcome of treatment beyond progression with nivolumab. Gastric Cancer. 2021 Jul;24(4):946-958. Epub 2021 Mar 20. link to original article link to PMC article PubMed
- CheckMate 032UGI: Janjigian YY, Bendell J, Calvo E, Kim JW, Ascierto PA, Sharma P, Ott PA, Peltola K, Jaeger D, Evans J, de Braud F, Chau I, Harbison CT, Dorange C, Tschaika M, Le DT. CheckMate 032 Study: Efficacy and Safety of Nivolumab and Nivolumab Plus Ipilimumab in Patients With Metastatic Esophagogastric Cancer. J Clin Oncol. 2018 Oct 1;36(28):2836-2844. Epub 2018 Aug 15. link to original article link to PMC article dosing details in manuscript have been reviewed by our editors PubMed NCT01928394
Paclitaxel monotherapy
Regimen variant #1, 70 mg/m2, 3 out of 4 weeks
Study | Dates of enrollment | Evidence | Comparator | Comparative Efficacy |
---|---|---|---|---|
Lee et al. 2018 (KCSG ST10-01) | 2011-2015 | Phase 3 (C) | Irinotecan | Inconclusive whether non-inferior PFS |
Regimen variant #2, 80 mg/m2 weekly
Study | Dates of enrollment | Evidence |
---|---|---|
Kodera et al. 2007 (CCOG0302) | 2003-2006 | Phase 2 |
Regimen variant #3, 80 mg/m2, 3 out of 4 weeks
Study | Dates of enrollment | Evidence | Comparator | Comparative Efficacy |
---|---|---|---|---|
Hironaka et al. 2006 | 2002-2004 | Non-randomized | ||
Hironaka et al. 2013 (WJOG 4007) | 2007-2010 | Phase 3 (E-switch-ic) | Irinotecan | Did not meet primary endpoint of OS Median OS: 9.5 vs 8.4 mo (HR 0.88, 95% CI 0.67-1.16) |
Wilke et al. 2014 (RAINBOW) | 2010-2012 | Phase 3 (C) | Paclitaxel & Ramucirumab | Seems to have inferior OS |
Lorenzen et al. 2020 (RADPAC) | 2011-2015 | Phase 3 (C) | Everolimus & Paclitaxel | Did not meet primary endpoint of OS |
Shitara et al. 2017 (ABSOLUTE) | 2013-2015 | Phase 3 (C) | 1. nab-Paclitaxel weekly | Non-inferior OS |
2. nab-Paclitaxel q3wk | Might have superior OS | |||
Bang et al. 2017 (GOLD) | 2013-2016 | Phase 3 (C) | Olaparib & Paclitaxel | Might have inferior OS |
Shah et al. 2022 (BRIGHTER) | 2014-10-02 to 2016-12-12 | Phase 3 (C) | Napabucasin & Paclitaxel | Did not meet primary endpoint of OS |
Shitara et al. 2018 (KEYNOTE-061) | 2015-06-04 to 2016-07-26 | Phase 3 (C) | Pembrolizumab | Seems to have inferior OS1 |
Bang et al. 2018 (JAVELIN Gastric 300) | 2015-2017 | Phase 3 (C) | Avelumab | Did not meet primary endpoint of OS |
Chung et al. 2021 (KEYNOTE-063) | 2017-02-16 to 2018-03-12 | Phase 3 (C) | Pembrolizumab | Seems to have superior PFS (co-primary endpoint) Median PFS: 4 vs 2 mo (HR 0.62, 95% CI 0.40-0.96) Did not meet co-primary endpoint of OS |
Xu et al. 2021 (RAINBOW-Asia) | 2017-2020 | Phase 3 (C) | Paclitaxel & Ramucirumab | Seems to have inferior PFS |
1Reported efficacy is based on the 2021 update, for the CPS at least 1 group.
Note: RAINBOW included patients with GE junction malignancy (79% gastric, 21% GE junction). Satoh et al. patients had 98.5% gastric, 1.5% other. WJOG 4007 had 3.7% patients with a PFS of 2.
Prior treatment criteria
- RAINBOW: documented objective radiological or clinical disease progression during or within 4 months of the last dose of first-line platinum and fluoropyrimidine doublet with or without anthracycline
Chemotherapy
- Paclitaxel (Taxol) 80 mg/m2 IV over 60 minutes once per day on days 1, 8, 15
28-day cycles
Regimen variant #4, 175 mg/m2 q3wk
Study | Dates of enrollment | Evidence | Comparator | Comparative Efficacy |
---|---|---|---|---|
Kang et al. 2018 (DREAM) | 2013-2015 | Phase 3 (C) | DHP-107 | Non-inferior PFS |
References
- Hironaka S, Zenda S, Boku N, Fukutomi A, Yoshino T, Onozawa Y. Weekly paclitaxel as second-line chemotherapy for advanced or recurrent gastric cancer. Gastric Cancer. 2006;9(1):14-8. link to original article dosing details in manuscript have been reviewed by our editors PubMed
- CCOG0302: Kodera Y, Ito S, Mochizuki Y, Fujitake S, Koshikawa K, Kanyama Y, Matsui T, Kojima H, Takase T, Ohashi N, Fujiwara M, Sakamoto J, Akimasa N; Chubu Clinical Cancer Group. A phase II study of weekly paclitaxel as second-line chemotherapy for advanced gastric cancer (CCOG0302 study). Anticancer Res. 2007 Jul-Aug;27(4C):2667-71. link to original article dosing details in abstract have been reviewed by our editors PubMed
- WJOG 4007: Hironaka S, Ueda S, Yasui H, Nishina T, Tsuda M, Tsumura T, Sugimoto N, Shimodaira H, Tokunaga S, Moriwaki T, Esaki T, Nagase M, Fujitani K, Yamaguchi K, Ura T, Hamamoto Y, Morita S, Okamoto I, Boku N, Hyodo I. Randomized, open-label, phase III study comparing irinotecan with paclitaxel in patients with advanced gastric cancer without severe peritoneal metastasis after failure of prior combination chemotherapy using fluoropyrimidine plus platinum: WJOG 4007 trial. J Clin Oncol. 2013 Dec 10;31(35):4438-44. Epub 2013 Nov 4. link to original artile dosing details in abstract have been reviewed by our editors PubMed UMIN000001252
- RAINBOW: Wilke H, Muro K, Van Cutsem E, Oh SC, Bodoky G, Shimada Y, Hironaka S, Sugimoto N, Lipatov O, Kim TY, Cunningham D, Rougier P, Komatsu Y, Ajani J, Emig M, Carlesi R, Ferry D, Chandrawansa K, Schwartz JD, Ohtsu A; RAINBOW Study Group. Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial. Lancet Oncol. 2014 Oct;15(11):1224-35. Epub 2014 Sep 17. link to original article dosing details in manuscript have been reviewed by our editors PubMed NCT01170663
- PRO analysis: Al-Batran SE, Van Cutsem E, Oh SC, Bodoky G, Shimada Y, Hironaka S, Sugimoto N, Lipatov ON, Kim TY, Cunningham D, Rougier P, Muro K, Liepa AM, Chandrawansa K, Emig M, Ohtsu A, Wilke H. Quality-of-life and performance status results from the phase III RAINBOW study of ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated gastric or gastroesophageal junction adenocarcinoma. Ann Oncol. 2016 Apr;27(4):673-9. Epub 2016 Jan 7. link to original article link to PMC article PubMed
- ABSOLUTE: Shitara K, Takashima A, Fujitani K, Koeda K, Hara H, Nakayama N, Hironaka S, Nishikawa K, Makari Y, Amagai K, Ueda S, Yoshida K, Shimodaira H, Nishina T, Tsuda M, Kurokawa Y, Tamura T, Sasaki Y, Morita S, Koizumi W. Nab-paclitaxel versus solvent-based paclitaxel in patients with previously treated advanced gastric cancer (ABSOLUTE): an open-label, randomised, non-inferiority, phase 3 trial. Lancet Gastroenterol Hepatol. 2017 Apr;2(4):277-287. Epub 2017 Jan 19. link to original article dosing details in abstract have been reviewed by our editors PubMed JapicCTI-132059
- GOLD: Bang YJ, Xu RH, Chin K, Lee KW, Park SH, Rha SY, Shen L, Qin S, Xu N, Im SA, Locker G, Rowe P, Shi X, Hodgson D, Liu YZ, Boku N. Olaparib in combination with paclitaxel in patients with advanced gastric cancer who have progressed following first-line therapy (GOLD): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncol. 2017 Dec;18(12):1637-1651. Epub 2017 Nov 2. link to original article PubMed NCT01924533
- DREAM: Kang YK, Ryu MH, Park SH, Kim JG, Kim JW, Cho SH, Park YI, Park SR, Rha SY, Kang MJ, Cho JY, Kang SY, Roh SY, Ryoo BY, Nam BH, Jo YW, Yoon KE, Oh SC. Efficacy and safety findings from DREAM: a phase III study of DHP107 (oral paclitaxel) versus IV paclitaxel in patients with advanced gastric cancer after failure of first-line chemotherapy. Ann Oncol. 2018 May 1;29(5):1220-1226. link to original article dosing details in abstract have been reviewed by our editors PubMed NCT01839773
- KEYNOTE-061: Shitara K, Özgüroğlu M, Bang YJ, Di Bartolomeo MD, Mandalà M, Ryu MH, Fornaro L, Olesiński T, Caglevic C, Chung HC, Muro K, Goekkurt E, Mansoor W, McDermott RS, Shacham-Shmueli E, Chen X, Mayo C, Kang SP, Ohtsu A, Fuchs CS; KEYNOTE-061 investigators. Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial. Lancet. 2018 Jul 14;392(10142):123-133. Epub 2018 Jun 4. link to original article dosing details in manuscript have been reviewed by our editors PubMed NCT02370498
- Update: Fuchs CS, Özgüroğlu M, Bang YJ, Di Bartolomeo M, Mandala M, Ryu MH, Fornaro L, Olesinski T, Caglevic C, Chung HC, Muro K, Van Cutsem E, Elme A, Thuss-Patience P, Chau I, Ohtsu A, Bhagia P, Wang A, Shih CS, Shitara K. Pembrolizumab versus paclitaxel for previously treated PD-L1-positive advanced gastric or gastroesophageal junction cancer: 2-year update of the randomized phase 3 KEYNOTE-061 trial. Gastric Cancer. 2022 Jan;25(1):197-206. Epub 2021 Sep 1. link to original article link to PMC article PubMed
- KCSG ST10-01: Lee KW, Maeng CH, Kim TY, Zang DY, Kim YH, Hwang IG, Oh SC, Chung JS, Song HS, Kim JW, Jeong SJ, Cho JY. A phase III study to compare the efficacy and safety of paclitaxel versus irinotecan in patients with metastatic or recurrent gastric cancer who failed in first-line therapy (KCSG ST10-01). Oncologist. 2019 Jan;24(1):18-e24. Epub 2018 Aug 20. link to original article dosing details in abstract have been reviewed by our editors link to PMC article PubMed NCT01224652
- JAVELIN Gastric 300: Bang YJ, Yanez Ruiz E, Van Cutsem E, Lee KW, Wyrwicz L, Schenker M, Alsina M, Ryu MH, Chung HC, Evesque L, Al-Batran SE, Park SH, Lichinitser M, Boku N, Moehler MH, Hong J, Xiong H, Hallwachs R, Conti I, Taieb J. Phase III, randomised trial of avelumab versus physician's choice of chemotherapy as third-line treatment of patients with advanced gastric or gastro-oesophageal junction cancer: primary analysis of JAVELIN Gastric 300. Ann Oncol. 2018 Oct 1;29(10):2052-2060. link to original article link to PMC article dosing details in abstract have been reviewed by our editors PubMed NCT02625623
- RADPAC: Lorenzen S, Knorrenschild JR, Pauligk C, Hegewisch-Becker S, Seraphin J, Thuss-Patience P, Kopp HG, Dechow T, Vogel A, Luley KB, Pink D, Stahl M, Kullmann F, Hebart H, Siveke J, Egger M, Homann N, Probst S, Goetze TO, Al-Batran SE. Phase III randomized, double-blind study of paclitaxel with and without everolimus in patients with advanced gastric or esophagogastric junction carcinoma who have progressed after therapy with a fluoropyrimidine/platinum-containing regimen (RADPAC). Int J Cancer. 2020 Nov 1;147(9):2493-2502. Epub 2020 May 7. link to original article dosing details in abstract have been reviewed by our editors PubMed NCT01248403
- RAINBOW-Asia: Xu RH, Zhang Y, Pan H, Feng J, Zhang T, Liu T, Qin Y, Qin S, Yin X, Liu B, Ba Y, Yang N, Voon PJ, Tanasanvimon S, Zhou C, Zhang WL, Shen L. Efficacy and safety of weekly paclitaxel with or without ramucirumab as second-line therapy for the treatment of advanced gastric or gastroesophageal junction adenocarcinoma (RAINBOW-Asia): a randomised, multicentre, double-blind, phase 3 trial. Lancet Gastroenterol Hepatol. 2021 Dec;6(12):1015-1024. Epub 2021 Oct 6. link to original article dosing details in abstract have been reviewed by our editors PubMed NCT02898077
- KEYNOTE-063: Chung HC, Kang YK, Chen Z, Bai Y, Wan Ishak WZ, Shim BY, Park YL, Koo DH, Lu J, Xu J, Chon HJ, Bai LY, Zeng S, Yuan Y, Chen YY, Gu K, Zhong WY, Kuang S, Shih CS, Qin SK. Pembrolizumab versus paclitaxel for previously treated advanced gastric or gastroesophageal junction cancer (KEYNOTE-063): A randomized, open-label, phase 3 trial in Asian patients. Cancer. 2022 Mar 1;128(5):995-1003. Epub 2021 Dec 8. link to original article dosing details in manuscript have been reviewed by our editors link to PMC article PubMed NCT03019588
- BRIGHTER: Shah MA, Shitara K, Lordick F, Bang YJ, Tebbutt NC, Metges JP, Muro K, Lee KW, Shen L, Tjulandin S, Hays JL, Starling N, Xu RH, Sturtz K, Fontaine M, Oh C, Brooks EM, Xu B, Li W, Li CJ, Borodyansky L, Van Cutsem E. Randomized, Double-Blind, Placebo-Controlled Phase III Study of Paclitaxel ± Napabucasin in Pretreated Advanced Gastric or Gastroesophageal Junction Adenocarcinoma. Clin Cancer Res. 2022 Sep 2;28(17):3686–3694. Epub 2022 Jul 14. link to original article link to PMC article PubMed NCT02178956
- INTEGRATEIIb: NCT04879368
nab-Paclitaxel monotherapy
Regimen
Study | Dates of enrollment | Evidence | Comparator | Comparative Efficacy |
---|---|---|---|---|
Shitara et al. 2017 (ABSOLUTE) | 2013-2015 | Phase 3 (E-switch-ic) | 1. Paclitaxel; weekly | Non-inferior OS (primary endpoint) Median OS: 11.1 vs 10.9 mo (HR 0.97, 97.5% CI 0.76-1.23) |
2. nab-Paclitaxel; q3wk | Not reported |
Chemotherapy
- Paclitaxel, nanoparticle albumin-bound (Abraxane) 100 mg/m2 IV once per day on days 1, 8, 15
28-day cycles
References
- ABSOLUTE: Shitara K, Takashima A, Fujitani K, Koeda K, Hara H, Nakayama N, Hironaka S, Nishikawa K, Makari Y, Amagai K, Ueda S, Yoshida K, Shimodaira H, Nishina T, Tsuda M, Kurokawa Y, Tamura T, Sasaki Y, Morita S, Koizumi W. Nab-paclitaxel versus solvent-based paclitaxel in patients with previously treated advanced gastric cancer (ABSOLUTE): an open-label, randomised, non-inferiority, phase 3 trial. Lancet Gastroenterol Hepatol. 2017 Apr;2(4):277-287. Epub 2017 Jan 19. link to original article dosing details in abstract have been reviewed by our editors PubMed JapicCTI-132059
Paclitaxel & Ramucirumab
Regimen
FDA-recommended dose |
Study | Dates of enrollment | Evidence | Comparator | Comparative Efficacy |
---|---|---|---|---|
Wilke et al. 2014 (RAINBOW) | 2010-2012 | Phase 3 (E-RT-esc) | Paclitaxel | Seems to have superior OS (primary endpoint) Median OS: 9.6 vs 7.4 mo (HR 0.81, 95% CI 0.68-0.96) |
Xu et al. 2021 (RAINBOW-Asia) | 2017-2020 | Phase 3 (E-esc) | Paclitaxel | Seems to have superior PFS (co-primary endpoint) Median PFS: 4.1 vs 3.15 mo (HR 0.77, 95% CI 0.61-0.955) |
Note: RAINBOW included patients with GE junction malignancy (79% gastric, 21% GE junction).
Prior treatment criteria
- RAINBOW: documented objective radiological or clinical disease progression during or within 4 months of the last dose of first-line platinum and fluoropyrimidine doublet with or without anthracycline
Targeted therapy
- Ramucirumab (Cyramza) 8 mg/kg IV over 60 minutes once per day on days 1 & 15, given first
Chemotherapy
- Paclitaxel (Taxol) 80 mg/m2 IV once per day on days 1, 8, 15, given second
28-day cycles
References
- RAINBOW: Wilke H, Muro K, Van Cutsem E, Oh SC, Bodoky G, Shimada Y, Hironaka S, Sugimoto N, Lipatov O, Kim TY, Cunningham D, Rougier P, Komatsu Y, Ajani J, Emig M, Carlesi R, Ferry D, Chandrawansa K, Schwartz JD, Ohtsu A; RAINBOW Study Group. Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial. Lancet Oncol. 2014 Oct;15(11):1224-35. Epub 2014 Sep 17. link to original article dosing details in manuscript have been reviewed by our editors PubMed NCT01170663
- PRO analysis: Al-Batran SE, Van Cutsem E, Oh SC, Bodoky G, Shimada Y, Hironaka S, Sugimoto N, Lipatov ON, Kim TY, Cunningham D, Rougier P, Muro K, Liepa AM, Chandrawansa K, Emig M, Ohtsu A, Wilke H. Quality-of-life and performance status results from the phase III RAINBOW study of ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated gastric or gastroesophageal junction adenocarcinoma. Ann Oncol. 2016 Apr;27(4):673-9. Epub 2016 Jan 7. link to original article link to PMC article PubMed
- RAINBOW-Asia: Xu RH, Zhang Y, Pan H, Feng J, Zhang T, Liu T, Qin Y, Qin S, Yin X, Liu B, Ba Y, Yang N, Voon PJ, Tanasanvimon S, Zhou C, Zhang WL, Shen L. Efficacy and safety of weekly paclitaxel with or without ramucirumab as second-line therapy for the treatment of advanced gastric or gastroesophageal junction adenocarcinoma (RAINBOW-Asia): a randomised, multicentre, double-blind, phase 3 trial. Lancet Gastroenterol Hepatol. 2021 Dec;6(12):1015-1024. Epub 2021 Oct 6. link to original article dosing details in abstract have been reviewed by our editors PubMed NCT02898077
- RAMIRIS: NCT03081143
Pembrolizumab monotherapy
Regimen
Study | Dates of enrollment | Evidence | Comparator | Comparative Efficacy |
---|---|---|---|---|
Fuchs et al. 2018 (KEYNOTE-059) | 2015-03-02 to 2016-05-26 | Phase 2 (RT) | ORR: 12% (95% CI 8-16) | |
Shitara et al. 2018 (KEYNOTE-061) | 2015-06-04 to 2016-07-26 | Phase 3 (E-switch-ooc) | Paclitaxel | Seems to have superior OS1 (co-primary endpoint) Median OS: 9.1 vs 8.3 mo (HR 0.81, 95% CI 0.66-1.00) |
1Reported efficacy is based on the 2021 update, for the CPS at least 1 group.
Note: Both studies included patients with GE junction malignancy:
- KEYNOTE-059: 48.3% gastric, 51.4% GE junction and 57.1% of patients had a PD-L1 CPS score of at least 1
- KEYNOTE-061: 68.8% gastric, 31.2% GE junction and 66% of all patients receiving pembrolizumab had a PD-L1 CPS score of at least 1
Biomarker eligibility criteria
PD-L1 (combined positive score > 1%) as determined by an FDA-approved test.
Immunotherapy
- Pembrolizumab (Keytruda) 200 mg IV once on day 1
21-day cycle for up to 35 cycles (2 years)
References
- KEYNOTE-059: Fuchs CS, Doi T, Jang RW, Muro K, Satoh T, Machado M, Sun W, Jalal SI, Shah MA, Metges JP, Garrido M, Golan T, Mandala M, Wainberg ZA, Catenacci DV, Ohtsu A, Shitara K, Geva R, Bleeker J, Ko AH, Ku G, Philip P, Enzinger PC, Bang YJ, Levitan D, Wang J, Rosales M, Dalal RP, Yoon HH. Safety and efficacy of pembrolizumab monotherapy in patients with previously treated advanced gastric and gastroesophageal junction cancer: phase 2 clinical KEYNOTE-059 trial. JAMA Oncol. 2018 May 10;4(5):e180013. Epub 2018 May 10. link to original article link to PMC article dosing details in manuscript have been reviewed by our editors PubMed NCT02335411
- KEYNOTE-061: Shitara K, Özgüroğlu M, Bang YJ, Di Bartolomeo MD, Mandalà M, Ryu MH, Fornaro L, Olesiński T, Caglevic C, Chung HC, Muro K, Goekkurt E, Mansoor W, McDermott RS, Shacham-Shmueli E, Chen X, Mayo C, Kang SP, Ohtsu A, Fuchs CS; KEYNOTE-061 investigators. Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial. Lancet. 2018 Jul 14;392(10142):123-133. Epub 2018 Jun 4. link to original article dosing details in manuscript have been reviewed by our editors PubMed NCT02370498
- Update: Fuchs CS, Özgüroğlu M, Bang YJ, Di Bartolomeo M, Mandala M, Ryu MH, Fornaro L, Olesinski T, Caglevic C, Chung HC, Muro K, Van Cutsem E, Elme A, Thuss-Patience P, Chau I, Ohtsu A, Bhagia P, Wang A, Shih CS, Shitara K. Pembrolizumab versus paclitaxel for previously treated PD-L1-positive advanced gastric or gastroesophageal junction cancer: 2-year update of the randomized phase 3 KEYNOTE-061 trial. Gastric Cancer. 2022 Jan;25(1):197-206. Epub 2021 Sep 1. link to original article link to PMC article PubMed
Ramucirumab monotherapy
Regimen
FDA-recommended dose |
Study | Dates of enrollment | Evidence | Comparator | Comparative Efficacy |
---|---|---|---|---|
Fuchs et al. 2013 (REGARD) | 2009-2012 | Phase 3 (E-RT-esc) | Placebo | Seems to have superior OS (primary endpoint) Median OS: 5.2 vs 3.8 mo (HR 0.78, 95% CI 0.60-0.998) |
Note: this study included patients with GE junction malignancy (75% gastric, 25% GE junction).
Prior treatment criteria
- REGARD: Disease progression within 4 months of the last dose of first-line platinum-containing or fluoropyrimidine-containing chemotherapy for metastatic disease, or within 6 months of the last dose of platinum-containing or fluoropyrimidine-containing adjuvant treatment
References
- REGARD: Fuchs CS, Tomasek J, Yong CJ, Dumitru F, Passalacqua R, Goswami C, Safran H, dos Santos LV, Aprile G, Ferry DR, Melichar B, Tehfe M, Topuzov E, Zalcberg JR, Chau I, Campbell W, Sivanandan C, Pikiel J, Koshiji M, Hsu Y, Liepa AM, Gao L, Schwartz JD, Tabernero J; REGARD Trial Investigators. Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet. 2014 Jan 4;383(9911):31-9. Epub 2013 Oct 3. link to original article dosing details in manuscript have been reviewed by our editors PubMed NCT00917384
Regorafenib monotherapy
Regimen
Study | Dates of enrollment | Evidence | Comparator | Comparative Efficacy |
---|---|---|---|---|
Pavlakis et al. 2016 (INTEGRATE) | 2012-2014 | Randomized Phase 2 (E-esc) | Placebo | Superior PFS (primary endpoint) Median PFS: 2.6 vs 0.9 mo (HR 0.40, 95% CI 0.28-0.59) |
Note: INTEGRATE included patients with GEJ malignancy: 62% stomach or other, 38% GEJ
References
- INTEGRATE: Pavlakis N, Sjoquist KM, Martin AJ, Tsobanis E, Yip S, Kang YK, Bang YJ, Alcindor T, O'Callaghan CJ, Burnell MJ, Tebbutt NC, Rha SY, Lee J, Cho JY, Lipton LR, Wong M, Strickland A, Kim JW, Zalcberg JR, Simes J, Goldstein D. Regorafenib for the treatment of advanced gastric cancer (INTEGRATE): A multinational placebo-controlled phase II trial. J Clin Oncol. 2016 Aug 10;34(23):2728-35. Epub 2016 Jun 20. link to original article dosing details in manuscript have been reviewed by our editors link to PMC article PubMed ANZCTR12612000239864
Trifluridine and tipiracil monotherapy
Regimen
Study | Dates of enrollment | Evidence | Comparator | Comparative Efficacy |
---|---|---|---|---|
Shitara et al. 2018 (TAGS) | 2016-2018 | Phase 3 (E-RT-esc) | Placebo | Superior OS (primary endpoint) Median OS: 5.7 vs 3.6 mo (HR 0.69, 95% CI 0.56-0.85) |
Chemotherapy
- Trifluridine and tipiracil (Lonsurf) 35 mg/m2 PO twice per day on days 1 to 5, 8 to 12
28-day cycles
References
- TAGS: Shitara K, Doi T, Dvorkin M, Mansoor W, Arkenau HT, Prokharau A, Alsina M, Ghidini M, Faustino C, Gorbunova V, Zhavrid E, Nishikawa K, Hosokawa A, Yalçın Ş, Fujitani K, Beretta GD, Van Cutsem E, Winkler RE, Makris L, Ilson DH, Tabernero J. Trifluridine/tipiracil versus placebo in patients with heavily pretreated metastatic gastric cancer (TAGS): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2018 Nov 1;19(11):1437-48. Epub 2018 Oct 18. link to original article dosing details in abstract have been reviewed by our editors PubMed NCT02500043
- INTEGRATEIIb: NCT04879368